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The enclosed papers have been classified into five
major sections whose content is as follows:
Section A - The eosinophil leucocyte
The first works are studies on the mechanisms of
eosinophil accumulation following antigen-antibody
(1 2 )
reactions in guinea pig skin. ' y These were extended
to observations on eosinophil chemotaxis in vitro in
(3 4)
relation to the complement system. '
The eosinophil chemotactic factor of anaphylaxis
(ECF-A) was first described in 1971.Interactions
between ECF-A and complement-derived eosinophilotactic
(7)
factors were reported later as were investigations on
(8 )
the chemical characterisation of ECF-A. Inhibition
of eosinophil chemotaxis by an agent related to disodium
(9)
cromoglycate is also described. Other eosinophil
*>
chemotactic agents thought to participate in eosinophil
accumulation in vivo include material derived from
Hodgkin's lymph node cells,histamine and one of its
major catabolites, imidazole acetic acid.The inter¬
actions of these agents both in vitro and in vivo were
(12 13)
extensively studiedv » ' and extended to investigations
on the response of eosinophils to an ECF-A tetrapeptide
(14)
and histamine in various disease states as well as
the capacity of these agents to mobilise eosinophils in
(15)
the skin of atopic and non-atopic human volunteers.
Evidence was provided that one of the functions of
the eosinophil in allergic tissue reactions may be its
(16 )
capacity to inhibit mast cell 'regranulation'.
Membrane receptors for IgG and complement (C4, C3b
and C3d) on human eosinophils and neutrophils and their
(17)
relation to eosinophilia were described and this work
led to the observation that the ECF-A tetrapeptides and
histamine both selectively enhance human eosinophil
complement receptors.
This work, and those of others, was reviewed in
several articles.
Section B - Mediators of hypersensitivity
In 1974 it was shown that both slow reacting substance
of anaphylaxis (SRS-A) and ECF-A were released from
passively sensitized skin following interaction with
(27)
specific antigen. ' The inactivation of SRS-A by the
arylsulphatase contained in various tissues was
(28 )describedv y and later it was shown that appreciable
amounts of human SRS-A were present in lung as a pre¬
formed mediator.
A number of miscellaneous papers relating to
mediators are contained in this section: these include
an observation on complement activation by Corynebacterium
parvum; ^ some chemical and physical properties of
(31)
synthetic human fibrinopeptides and the description of
(32)
a primate macrophage-cytophilic antibody.
A review of the various biological pathways associated
with the inflammatory response as they relate to complica¬
tions of blood transfusion were described in a review
article.^33^
Section C - Studies on chemotaxis
This section contains papers on chemotaxis of
(34)
neutrophils, monocytes and basophils. Particular
attention was given to the identification of chemotactic
agents associated with Hageman factor-dependent path¬
ways, fibrin, formation and fibrinolysis.
There is a study on the relation between neutrophil
accumulation in vivo and agents that are chemotactic
.+ (40)in vitro.
Alterations in monocyte chemotaxis in bronchial
carcinoma were described.
Much of this work, especially the relation between
chemotaxis and haemostasis, was reviewed in 1975.'^2)
Section D - Clinical studies
This section contains reports on alterations in the
(43_45)
complement systems in bronchial asthma and the
significance of immunoglobulins and complement in pleural%
effusions associated with bronchial carcinoma.
Studies on mediators of hypersensitivity in chronic
bronchitis and asthma and their modulation by pharmaco-
(47 48)
logical agents are also described. '
Detailed immunological investigations of two clinical
(49)
cases, one of chronic benign neutropenia and the other
on the effect of transfer factor in chronic mucocutaneous
candidiasis,are described.
A consideration of how coagulation and other
biological systems may interrelate in the context of
(51)
'Stroke' was discussed in a review article.
Section E - Methodology
This section contains two articles on methodology*
( 52)
one on the preparation of transfer factor and the
(53 )
other on tests of immune function.
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STUDIES ON EOSINOPHIL LEUCOCYTE MIGRATION
I. EOSINOPHIL AND NEUTROPHIL ACCUMULATION
FOLLOWING ANTIGEN-ANTIBODY REACTIONS IN
GUINEA-PIG SKIN
A. B. KAY
Department of Pathology, University of Cambridge
(Received 1 July 1969)
SUMMARY
Eosinophil leucocytes migrated into the site of PCA reactions mediated by those
fractions of 7S guinea-pig IgG containing IgG,; neutrophils were associated with
IgG, and IgG2. Maximal eosinophil infiltration is seen at 12 hr and was associated
with degranulation.
Intradermal histamine was not eosinophilotactic in guinea-pigs.
Preformed antigen-antibody complexes of IgG, and IgG2 both promoted eosino¬
phil and neutrophil migration in guinea-pig skin but slightly more eosinophils
were seen following injections of complexes containing IgG,. Local eosinophilia
and PCA activity were mediated by a relatively heat-stable element since these
effects were demonstrable even after prolonged heating of fractions containing
IgG,. Eosinophils were seen following injections of Compound 48/80 and this
was accompanied by low mast cell counts; however, there was also some associ¬
ated tissue destruction.
INTRODUCTION
Eosinophils are associated with certain 'allergic' tissue reactions particularly immediate-
type (Type 1) hypersensitivity. Various mediators of an eosinophilia have been proposed
including histamine (Kline, Cohen & Rudolph, 1932; Archer, 1963), antigen-antibody
complexes (Litt, 1964) and sensitized tissue treated with antigen (Samter, Kofoed & Piper,
1953; Parish & Coombs, 1968).
Experiments in vitro using Boyden's millipore technique indicate that the eosinophil and
neutrophil chemotaxis generated by antigen-antibody complexes require the presence of
fresh serum and that the chemotactic activity is probably mediated by intermediate comple¬
ment components or their fragments (Keller & Sorkin, 1969; Ward, 1969).
In the present study an initial experiment showed that following passive cutaneous
anaphylaxis (PCA) reactions in the guinea-pig eosinophils and neutrophils accumulated
Correspondence: Dr A. B. Kay, Robert Brigham Hospital, Parker Hill Avenue, Boston, Massachusetts
02120, U.S.A.
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in large numbers around the reaction site 24 hr following challenge with antigen. Investiga¬
tions were, therefore, carried out to determine the relationship of eosinophil to neutrophil
migration following PCA reactions using fractions of 7S guinea-pig immunoglobulins.
In further experiments the eosinophilia was specifically studied in order to determine more
precisely the mechanism of eosinophilotaxis.
MATERIALS AND METHODS
Animals
Male albino guinea-pigs weighing between 200 and 400 g were used throughout this
study.
Guinea-pig antisera
Antisera to ferritin (Koch-Light) and bovine serum albumin (BSA, Armour Laboratories)
were raised separately in two sets of eight guinea-pigs according to the following schedule:
Day 1. One hundred micrograms of the antigen was given in Freund's complete adjuvant
to each hind footpad.
Day 14. One hundred micrograms of antigen in Freund's incomplete adjuvant was given
in two subcutaneous areas in the neck.
Day 28. One hundred micrograms of antigen was introduced intradermally into two areas
of the back. This process was repeated at weekly intervals until the development of a strong
Fr Fr 2
Fr 3
Exclusion peak 0 01 m P04 buffer, pH 8 0
Remainder eluted with a second step with
0 3m P04 buffer, pH 8 0
Fractionation of the 0 3m DE 32 peak
on Sephadex G-200
Fr 4
A Buffer: 01 m Tris
0-5m Na CI,
pH 7-2
Fig. 1. Chromatographic fractionation of guinea-pig anti-ferritin. Virtually identical patterns
were obtained with antiserum to BSA.
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Arthus reaction. The course was usually complete within 6-8 weeks. The animals were bled
1 week after the last injection and the anti-ferritin and anti-BSA antisera were pooled separ¬
ately.
Preparation of guinea-pig IgGx and IgG2 immunoglobulins
The procedures followed were essentially those of Forsgren (1968). Sixty millilitres of
guinea-pig anti-ferritin was precipitated with 33% saturated ammonium sulphate and the
precipitate was redissolved in distilled water. The process was repeated four times and the
final precipitate was redissolved in 10 ml of water and dialysed against 0-01 m phosphate
buffer at pH 8-0. The sample was applied to a column of DEAE-cellulose (DE 32—Whatman)
3-5 x 26-5 cm, which had been previously equilibrated with 0-01 m phosphate buffer, pH 8.
A second small peak followed the main exclusion peak (Fig. 1). The rest of the sample was
eluted with a 0-3 m phosphate buffer, pH 8. The fractions were pooled as indicated in Fig. 1
and concentrated using a UM 1 Amicon-Diaflow membrane. The 0-3 m peak was then
applied to a column of Sephadex G-200 (3-5 x 95 cm) in order to eliminate IgM and to further
purify IgG,. The purity of the fractions was tested using gel-diffusion and Immuno¬
electrophoresis as described below. The guinea-pig anti-BSA sera gave virtually similar
chromatographic patterns as the anti-ferritin sera (Fig. 1).
Preparation of anti-sera to guinea-pig immunoglobulins
(1) Rabbit anti-guinea-pig IS IgG. The second Sephadex G-200 peak [Fraction (Fr) 4]
of the guinea-pig anti-BSA was precipitated at equivalence with the antigen and the precipit¬
ate was washed eight times in 0-01 m EDTA-saline at +4°C. Half a milligram of the washed
Fig. 2. Gel-dilTusion studies using fractions of guinea-pig anti-ferritin. 1,2,3 and 4 correspond
to Fr 1, 2, 3 and 4, respectively. The R5094 (abs IgG2) gives an antisera specific for IgGi.
Similar results were obtained with R5095.
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precipitate was suspended in 1 ml of saline and emulsified with 1 ml of FCA and injected
intramuscularly into rabbits (R5048 and R5049). The injections were repeated 14 days
later and the animals were subsequently given 0-25 mg of the precipitate intravenously in
saline at weekly intervals for 2 weeks following the second injection. The animals were bled
1 week following the last injection.
(2) Specific anti-guinea-pig IgGj. The ascending part of the DEAE exclusion peak of the
guinea-pig anti-BSA (Fr 1) which gave a single line on gel diffusion and a single y2 line on
immunoelectrophoresis was polymerized with ethyl chloroformate for use as an immuno-
absorbent as described by Avrameas & Ternynck (1967). The rabbit anti-IgG,, also
containing IgG2 (R5048 and R5049), was absorbed with the polymerized IgG2 (Fr 1) to
give an antisera specific for IgG,. The results of the gel-diffusion studies are shown in
Fig. 2. Fr 1 contains only IgG2 and gives a line of identity with the other fractions. Fr 4,
therefore, contains some IgG2 in addition to the spuring IgG,. The late peak of IgG2 (Fr 3)
shows bending of the IgG, line and therefore contains a little IgG,.
Preparation of antigen-antibody complexes
Samples of anti-ferritin Fr 1 and Fr 4 (IgG2 and IgG,) were precipitated at equivalence
with ferritin following a standard optimal proportions titration. The complexes were
washed four times in 0-01 m EDTA-saline and resuspended in saline. The protein content of
the final suspension was measured by the Folin method.
Passive cutaneous anaphylaxis
The recommendations of Brocklehurst (1967) were observed in all PCA reactions with the
exception that 0-1 -ml volumes of fractions were injected intradermally under sterile con¬
ditions. Following sensitization 1 ml of 0-25% Evans Blue containing 1 mg of ferritin was
injected intravenously.
Quantitation of eosinophil and neutrophil infiltration following PCA reactions
At intervals following challenge with antigen and dye the animals were killed and the
injection sites, previously marked, were immediately biopsied using a circular punch of
1 cm diameter. The biopsy included all layers of the skin including the panniculus carnosus
muscle. Following fixation in formal saline, or Susa's medium in the case of mast cell
experiments, sections were taken from the site and approximately 2 mm either side of the
intradermal injection. The sections were wax embedded, cut and stained in the usual way
using haematoxylin and chromotrope 2R. Chromotrope 2R was found to be a satisfactory
stain for eosinophils as background staining was minimized. For mast cell experiments
aqueous toluidine blue was used. From each section a total of fifteen random high power
fields were counted in 0-3-mm strips between the junction of the epidermis and dermis and
the upper limit of the panniculus carnosus using a previously calibrated graticule and the
high power (x 40) objective (Fig. 5). The cell count is expressed as a total of fifteen strips
which represents the mean of the three sections counted, i.e. forty-five strips. Preliminary
experiments showed that sections from the anterior abdominal wall were unsatisfactory due
to difficulties in obtaining complete sections of the entire skin thickness. The biopsy studies
reported below were prepared from multiple, well spaced sites on the back which reached
laterally to the mid axillary line. Biopsies from these areas gave the most satisfactory
results.
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RESULTS
The association of eosinophil and neutrophil infiltration with passive cutaneous anaphylaxis
An initial experiment showed that large numbers of eosinophils and neutrophils infiltrated
into the site of PCA reactions when the skin was passively sensitized with a dilution of
1:50 of the unfractionated guinea-pig antiserum to ferritin. Skin injected with saline or dye
alone and the uninjected sites all showed minimal cellular infiltration.
Isolated fractions of 7S IgG showed that PCA reactions were only associated with those
fractions containing IgG! (Fr 3 and 4), but not with Fr 1 and 2 which by gel diffusion and
immunoelectrophoresis had been shown to contain lgG2 only. Biopsies of PCA reactions
using isolated fractions of IgG (Fr 1, 3 and 4) taken 24 hr after antigen challenge showed
that eosinophil infiltration is only associated with those fractions containing IgG, and
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Fig. 3. Eosinophil (•) and neutrophil (o) accumulation into guinea-pig skin following passive
cutaneous anaphylaxis with isolated fractions of guinea-pig IgG anti-ferritin. IgG2 (a), IgG2
(late peak) (b) and IgG, (c) are fractions 1, 3 and 4, respectively. Four hours sensitization
period. Biopsies taken 24 hr following antigen challenge. N, Normal skin; S, saline.
dose as low as 9 pg of antibody protein. A few eosinophils were seen in normal skin but
neutrophils were almost always entirely absent. Neutrophils appear in large numbers
following treatment with IgG, or IgG2 in doses as low as 9 pg of antibody protein. The
results in Fig. 3 represent the counts from one animal given randomly spaced injections of
the various dilutions of antibody protein. Normal skin and saline injections represent
controls in the same animal implying that the migration of eosinophils and neutrophils is
directional to the reactive sites. The experiment in this form was repeated once and gave
essentially similar results. In further investigations a dose of 27 pg of antibody protein was
chosen for fractions 1 and 4, respectively, and as seen from Figs. 4 and 7 and Table 1, the
F
4 8 12 24 48 4 8 12 24 48
Time (hr) following antigen challenge
Fig. 4. The time course of eosinophil (•) and neutrophil (o) accumulation into guinea-pig skin
following passive cutaneous anaphylaxis and intradermal histamine. Four hours sensitization,
(a) IgG2, (b) IgGt, (c) saline, (d) uninjected sites, (e) 1 pg histamine, (f) 10 pg histamine.
eosinophil infiltration was associated with IgGj containing fractions and not with IgG2 and
so in effect the main observation of this first experiment was confirmed several times.
The time course of eosinophil and neutrophil in filtration into the skin
In initial experiments a time of 24 hr following antigen challenge was arbitrarily chosen
for measuring cellular infiltration. Using a dose of 27 pg of antibody protein pairs of
animals were treated with Fr 1, Fr 4 and histamine (Fig. 4). Each pair of animals was killed
Table 1. Eosinophil and mast cell counts following PCA reactions and intradermal injections of Compound
48/80
Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5
E M E M E M E M E M
IgG! (Fr 4) 909 0 557 5 258 4 157 0 350 0
IgG2 (Fr 1) 9 46 2 51 ND ND ND ND ND ND
Normal skin 0 39 0 75 24 171 5 99 1 89
Compound 48/80 18 57 75 51 199 2 133 27 40 103
E, Eosinophils; M, mast cells; ND, not done.
Compound 48/80, 10 pg, Experiments 1 and 2; 100 pg, Experiments 3, 4 and 5.
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at 4, 8, 12, 24 and 48 hr and the injection sites biopsied as previously described. With
IgG2 (Fr 1) minimal neutrophil infiltration was seen at 8 hr but at this time very few
eosinophils were noted. Treatment with IgGt (Fr 4) showed that substantial eosinophilia
was seen at 8 hr and a considerable eosinophil count was noted at 12 hr. The eosinophil
count with IgGi roughly paralleled the neutrophil count with the exception that neutrophils
appeared earlier than eosinophils. At 48 hr eosinophils were still plentiful but few neutro¬
phils were seen. Areas injected with saline and the uninjected sites were virtually free from
eosinophils or neutrophils.
The effect of histamine
Fig. 4 shows that in addition to the study of the cellular events following PCA reactions
with IgGj and IgG2 the effect of intradermal histamine was also investigated. The doses of
4 hr 8 hr 12 hr 24 hr 48 hr
Epidermis
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Degree of eosinophil
degronulation
Fig. 5. A diagrammatic representationof thedistributionof neutrophils (•) and eosinophils(o)
following passive cutaneous anaphylaxis with IgG, (Fr 4).
histamine acid phosphate (British Drug blouses) was expressed as the weight of hista¬
mine base and was injected in saline at neutral pH. With 1 pg a slight neutrophilia was
seen at 8 hr and similarly at 8 and 12 hr when 10 /<g of histamine was injected. The
number of eosinophils observed following the injection of 1 pg and 10 ng of histamine
at intervals over 48 hr was no more than that seen when normal skin was biopsied. The area
of blueing noted with \0 pg of histamine was slightly greater than that given by 27 pg of IgG,.
The morphology and distribution of eosinophils and neutrophils following PCA reactions with
IgG,
At 4 hr a few eosinophils were seen in and around the small blood vessels immediately
above the panniculus carnosus (Fig. 5). Considerably more were seen in this area at 8 hr, at
which time some had migrated into the loose connective tissue below the dermis. At 12 hr
eosinophils were seen in large numbers throughout all layers of the skin. Some were seen
gathered in clusters around small vessels or randomly scattered in tissue spaces. Many of
the eosinophils, especially those in large accumulations of the cell, showed degranulation
with scattering of the granules for some distance around the intact nucleus. The significance
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of this observation is discussed later. By 48 hr the eosinophils were confined to the dermis
and upper part of the loose connective tissue whilst the remaining neutrophils were seen
only in the lower layers of the skin. Neutrophils were seen in fairly large numbers through¬
out all layers at 4 hr although they were observed in greater numbers in the lower layers of
the skin (Fig. 5). At 8 hr the number of neutrophils appeared slightly fewer than at 4 hr
but the maximum number were noted at 12 hr when they were observed throughout the area
of the skin counted. The neutrophils were more difficult to count, especially when present in
large numbers. They often appeared in 'seams' or 'clusters' and many had pyknotic nuclei.
It should be noted that the most numerous 'loose' cells were the tissue macrophages or
histiocytes. These cells were far too numerous to count but it appeared that they were
more plentiful when the skin was infiltrated with eosinophils and neutrophils.
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Fig. 6. Eosinophil and neutrophil accumulation into guinea-pig skin 12 hr following intradermal
injections of preformed antigen-antibody complexes.
Eosinophil and neutrophil accumulation following the intradermal injection of antigen-
antibody complexes
The previous experiments have shown that eosinophilia is associated with PCA reactions
mediated by fractions containing IgG,. Since histamine alone did not appear to generate
this eosinophilia other possible mechanisms of eosinophilotaxis were investigated. The
products ofmast cell degranulation other than histamine may be chemotactic for eosinophils
or alternatively IgG, and its antigen in a tissue bound or free form may generate such a
chemotactic agent. In order to test the latter hypothesis preformed complexes of IgG, or
IgG2 and antigen were injected intradermally in amounts indicated in Fig. 6. Biopsies taken
12 hr later showed that with all doses of complexes the amount of neutrophil infiltration
was too numerous to count, and has been scored on a plus ( + ) basis. Eosinophils appeared
following treatment with both types of complexes although the numbers were about three
times higher with IgG,-antigen complexes than with IgG2-antigen complexes. On a weight
basis there were far fewer eosinophils with IgG,-antigen complexes than with PCA re¬
actions with IgG,. Very few neutrophils were seen following injections of antibody alone,
even in a dose of 400 pg. This experiment was repeated and gave a virtually similar result.
The effect of heat on the IgGl containing immunoglobulin fraction (Fr 4) which mediated PCA
reactions and eosinophila
It is known that the ability of IgG, to elicit a homologous PCA reaction depends on a
heat stable portion of the antibody molecule. It is conceivable, however, that the eosinophilia
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associated with PCA reactions depends on a heat labile part of the molecule or that the
eosinophilia is the result of interaction by an as yet unidentified heat labile immunoglobulin
residing in the region. It is shown in Fig. 7 that the ability of IgGj to elicit PCA reactions
is partly retained even after prolonged heating and that the associated eosinophilia is
proportionately reduced suggesting that the eosinophilia does not in fact depend on a heat
labile moeity. Instead of a 4-hr sensitization period between intradermal antibody and
antigen challenge the experiment was repeated using a 48-hr sensitization time. This was to
confirm that the PCA reaction and associated eosinophilia did in fact depend on tissue bound
antibody since presumably non-bound antibody would have diffused away. This experiment
gave similar results to the 4 hr sensitization period experiment. Although not recorded in
Fig. 7 the neutrophilia associated with IgG2 is still apparent after a 48-hr sensitization
period. There were, however, only about half as many neutrophils as when a 4-hr sensitiza¬
tion period was used.
Fig. 7. The effect of heat onPCA reactions and subsequent eosinophilia mediated by IgGj (Fr 4).
(a) Four hours sensitization, (b)48 hr sensitization. Figures at end of lines indicate eosinophil
counts.
Eosinophil accumulation following injections of Compound 48/80
Since histamine did not appear to be chemotactic for eosinophils and preformed antigen-
antibody complexes generated comparatively less eosinophil migration than PCA reactions
with IgG, the possibility was investigated that a mast cell component other than histamine
released eosinophilotactic agents.
Experiments were designed to compare the eosinophil migration following PCA reactions
with IgGj and injections of Compound 48/80. Preliminary studies showed that it was not
possible to get comparative areas of blueing with Compound 48/80 and PCA reactions due
to the flat dose-response curve for 48/80. Doses of 10 pg and 100 pg of 48/80 were chosen.
In order to show that the effect of 48/80 was in part due to histamine release following mast
cell degranulation it was demonstrated that 25 mg of mepyramine maleate inhibited the
blueing reaction of 48/80 up to doses of 75 pg. Above this dose the area of blueing was only
partially inhibited. Mast cell counts were performed by staining alternate sections with
aqueous toluidine blue. It will be seen in Table 1 that with 10 pg of 48/80 eosinophil migra¬
tion was small (Table 1, Experiments 1 and 2). The fact that there was little alteration in the
mast cell count is in agreement with previous observations (Mota & Vugman, 1956a, b) on
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the peculiarity of guinea-pigs to treatment with 48/80. In two of the experiments using
higher doses of 48/80 eosinophil migration was seen and this was accompanied by low
mast cell counts. There was, however, considerable distortion and destruction of the
tissue. In one experiment (Experiment 5, Table 1) a small eosinophilia was noted even
with 100 fig of 48/80. These experiments do suggest, however, that treatment leading to low
mast cell counts, presumably by degranulation, is followed by eosinophil infiltration.
DISCUSSION
Eosinophil infiltration has been observed following PCA reactions mediated by fractions
containing IgG,. This agrees with the work of Parish (1969).
Recent reports have suggested that several classes or subclasses of immunoglobulins may
exist in the electrophoretically fast y, region and that PCA reactions may represent an activity
in an immunoglobulin as yet unidentified by standard immunoelectrophoretic techniques
(Pondman & Van Es, 1969; Van Es & Pondman, personal communication, 1969). In the
present study, however, the comparison is made between IgG, and the electrophoretically
slow IgG2, the latter being unassociated with PCA activity or eosinophil migration.
Since the eosinophilia is not associated with lgG2 it would seem unlikely that all antigen-
antibody reactions prepare the tissue for a local eosinophilia as implied by Litt (1964).
It is improbable that all the IgG2 would have diffused away during the 4 hr sensitization
period since it has been shown that homologous IgG2 is absorbed onto guinea-pig tissue
(Brocklehurst & Colquhoun, 1965) and that IgG2 contains those antibodies cytophilic for
macrophages (Jonas et a/., 1965). The neutrophilia associated with IgG2 could be a result
of bacterial contamination or the liberation of complement chemotactic factors (Ward,
Cochrane & Muller-Eberhard, 1965). The neutrophil migration observed with IgG, (Fr 4)
may be the result of contamination with IgG2 or alternatively substances attracting eosino¬
phils are also chemotactic for neutrophils. The eosinophil degranulation noted when the
cells are gathered in large numbers could be artifactual resulting from the fixation process.
The eosinophil membrane is, however, fairly resistant and can survive osmotic shock and
acetone treatment. The fact that other cells surrounding degranulated eosinophils usually
appeared normal indicates that the observation may be significant. Morphological changes
accompanying eosinophil chemotaxis in vitro have also been noted (Kay, unpublished
observations).
Various reports have concluded that histamine has eosinophilotactic properties. The
evidence has recently been reviewed (Archer, 1968a). Other studies have been unable to
support this view (Cohen & Sapp, 1963; Felarca & Lowell, 1968) and it could be that the
situation in horses is exceptional (Archer, 1963). The argument that large local concentrations
of histamine are required for eosinophilotaxis is invalid (Archer, 1968b) since in the present
study the area of blueing with 10 fig of histamine was greater than that observed following
PCA reactions with 27 fig of IgG,. Both reactions were inhibited by mepyramine maleate
but only IgG, PCA reactions were associated with an eosinophilia. The failure to produce
eosinophil chemotaxis with histamine using the in vitro millipore technique (Keller &
Sorkin, 1968; Kay, 1969) provides more convincing evidence that histamine is not eosino¬
philotactic. One explanation of the eosinophilia associated with PCA reactions involving
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IgG, is that the IgG,-antigen complex activates a serum or tissue factor, possibly comple¬
ment, in a differentmanner to the IgG2-antigen complexes although earlier reports suggested
that IgG, was incapable of completing the complement haemolytic sequence (Bloch et at.,
1963). This has been recently challenged with the report that preformed IgG,-antigen
complexes can consume certain complement intermediates (Osier et at., 1969). If IgG, and
its antigen generate eosinophilotactic products intradermal injection of the complex should
promote a substantial eosinophila. Both IgG, and IgG2 produce eosinophil migration when
injected with antigen as the preformed complex but more eosinophils were noted with IgG,.
However, the numbers on a weight basis were far less than when IgG, was introduced as
for PCA reactions. Although this makes it unlikely that IgG, and its antigen react uniquely
with complement to produce eosinophilotactic products it could be that this reaction is
only possible when configurational changes have taken place in the antibody molecule as a
result of tissue sensitization. Injection of the preformed complex may be an unsatisfactory
method of obtaining adequate tissue fixation since the success of this procedure (using
human IgE) requires a critical antigen-antibody ratio (Ishizaka & Ishizaka, 1968).
The slight eosinophilia noted with high doses of the IgG2-antigen complex could be a
result of IgG, contamination which was not detected by gel-diffusion. However, it has been
observed that in in vitro studies using the millipore technique of Boyden chemotactic
substances for eosinophils and neutrophils have been observed when fresh serum is incubated
with IgG, and IgG2 antigen complexes (Kay, unpublished observations). The substantial
neutrophilia observed following the injection of preformed complexes may have prevented
the recognition of the eosinophilotactic effects.
Although Compound 48/80 is said to be one of the least toxic of the agents affecting mast
cells in rats, dogs, cats and man its action in the guinea-pig is thought to be atypical in
that it had little effect on mast cell morphology and its toxic action was not prevented by
antihistamines (Feinberg & Sternberger, 1955; Mota & Vugman, 1956a, b). It was concluded
by Miles & Miles (1952), however, that 48/80 injected intradermally liberates local histamine
and that the effect could be blocked by an antihistaminic agent. The present study confirms
the findings of Miles and reports an association of a local eosinophilia especially with
large doses of 48/80 injected intradermally. These experiments give some support to the view
that a mast cell product may be eosinophilotactic but the superadded toxic effects of Com¬
pound 48/80 limits the interpretations of these in vivo studies. The eosinophilia following
PCA reactions, antigen-antibody complexes and Compound 48/80 could represent the
effect of several different eosinophilotactic agents generated by distinct mechanisms.
Experiments are in progress using the Boyden millipore technique as amethod of quantitat-
ing eosinophil chemotaxis in vitro. The difficulties of in vivo studies have been largely over¬
come since individual components free from other tissue or serum factors can now be
tested directly.
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SUMMARY
Decomplementation with cobra venom factor had no effect on eosinophil accumu¬
lation into the site of IgGj-mediated PCA reactions in the guinea-pig. Eosinophil
and neutrophil accumulation also followed PCA reactions in animals partially
or totally deficient in C4.
The effect of intradermal injections of pre-formed antigen-antibody complexes
prepared from guinea-pig IgGt or IgG2 were not affected by decomplementation
with cobra venom. The lesions produced with either immunoglobulin complex
were similar in appearance in decomplemented and normal animals and were
followed by comparable tissue accumulation of eosinophils and neutrophils.
INTRODUCTION
Purified guinea-pig 7S IgG immunoglobulins have been found to mediate the formation
of two chemotactic factors, in vitro, which selectively attract eosinophils from a mixed cell
population. One factor, having similar physicochemical properties to C5a, was generated
from whole serum by pre-formed antigen-antibody complexes prepared from either IgGj
or IgG2, required the presence of the complement system (Kay, 1970a) and has been
designated an eosinophil chemotactic factor derived from complement (ECF-C). The
other factor, an eosinophil chemotactic factor of anaphylaxis (ECF-A), was released by
antigen challenge of lung fragments passively sensitized with IgG1; but not IgG2 (Kay,
Stechschulte and Austen, 1971). Complement was not required for the release of ECF-A
and on the basis of a molecular size of 500 to 1000 and a different formation mechanism,
ECF-A was distinguished from ECF-C which had a molecular weight of approximately
15,000.
An earlier report using cell counts in guinea-pig skin, had shown that both IgGj and
IgG2, as pre-formed complexes, prepared the tissue for a subsequent local eosinophilia 12
hr after injection. However, if antibody was first placed in the skin and after a variable
Correspondence: Dr A. B. Kay, Department of Respiratory Diseases, City Hospital, Greenbank Drive,
Edinburgh 10, Scotland.
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latent period the animal was challenged with antigen and Evans' blue dye intravenously
(as in a usual passive cutaneous anaphylactic reaction), IgGi but not IgG2 elicited a local
eosinophil response 8-12 hr after the initial blueing reaction (Kay, 1970b). It was the
purpose of the present report to determine the effect of a deficient complement system on
the eosinophilia following PCA reactions or intradermal injection of pre-formed com¬
plexes.
MATERIALS AND METHODS
Partially purified cobra venom factor was prepared according to a previous report (Ballow
& Cochrane, 1969). Guinea-pig serum was obtained by cardiac puncture before and after
the intravenous injection of 1 ml of cobra venom factor orTyrode's solution. The titre of'late
acting' components was measured using EAC l8P4hu cells and purified guinea-pig C2 (Kay
et al., 1971). Guinea-pig 7S IgGt and IgG2 anti-ferritin (Kay, 1970a) and anti-ovalbumin
(Kay et al., 1971) were the DEAE-cellulose chromatographic fractions previously des¬
cribed. Pre-formed antigen-antibody complexes were prepared as described (Kay, 1970b).
Guinea-pigs, partially or totally deficient in the fourth component of complement (C4),
having comparable age and weight were from a strain of animals reported by Ellman el al.
(1971). The haemolytic titres of C4 were performed by the method of Opferkuch et al.
(1971).
The preparation of histological sections and the method for counting cells in guinea-pig
skin was previously reported (Kay, 1970b). Twelve hours following passive cutaneous
anaphylaxis (PCA) reactions or injections of pre-formed complexes, the areas were biopsied
to include all layers of the skin including the panniculus carnosus muscle. The specimens
were fixed in Susa's medium and following wax embedding and sectioning, were stained
with haemotoxylin and chromotrope 2R. Sections were taken to include the injection site
and approximately 2 mm on either side. Eosinophils were counted in a total of fifteen
random high power fields in each section between the junction of the epidermis and dermis
and the upper limit of the panniculus carnosus muscle. The mean cell counts represent
the summation of the average count from the three areas examined.
In normal animals and animals decomplemented with cobra venom factor, 0-1 ml of
antibody was injected intradermally and after a 4-hr latent period, antigen, 1 mg in 1 ml
of 0-25% Evans' blue dye was given intravenously. The diameter of blueing reactions were
measured 30 min later. In the C4 deficient animals antibody was administered intra¬
dermally and after a 4-hr latent period 0T ml of antigen was injected into the same site
in order to minimize the hazards of intravenous injection. Fifteen minutes later the area
of induration and surrounding erythema were measured.
Pre-formed antigen-antibody complexes and Tyrode's diluent control were injected
intradermally immediately following the intravenous administration of 0-25% Evans' blue
dye in 1 ml of Tyrode's solution. The lesions were assessed 1 hr later by examining both the
diameter and the intensity of the blueing reaction. The lesions were biopsied 12 hr later.
RESULTS
Passive cutaneous anaphylaxis
Animals were injected intradermally with antibody 10 hr after the intravenous adminis¬
tration of 2 units of purified cobra venom factor. At this time less than 5/ of the cir-
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culating level of terminal complement components was detectable. As shown in Table 1,
there was no appreciable difference in the skin eosinophil count between the cobra venom
treated animals and those pretreated with intravenous injections of Tyrode's solution. The
diameters of the blueing reactions were the same in both groups of animals. Large numbers
of neutrophils were also seen in the site of PCA reactions from both groups of animals,
but were too numerous to count.
Animals from the C4 deficient strain were comprised of a homozygote, totally deficient
in C4, a heterozygote and an animal from the same strain reared under the same laboratory
conditions, having a normal C4 level. In the three animals there was no appreciable dif¬
ference either in the area of induration or erythema following PCA reactions or in the
numbers of eosinophils which accumulated in the reaction sites 12 hr after antigen chal¬
lenge (Table 2). Neutrophil accumulation accompanied the local eosinophilia in numbers
too numerous to count accurately.
Table i. The effect of decomplementation by cobra venom factor on eosinophil infiltration following PCA
reactions
Change in haemolytic Eosinophil
Animal No. Treatment titre of terminal infiltration Diameter of
complement components (Mean Cell count) blueing reaction
1 Cobra venom factor 5120-+20 125 25
2 Cobra venom factor 5120->20 120 25
3 Cobra venom factor 5120-+20 90 25
4 Tyrode's solution 5120-^5120 130 25
5 Tyrode's solution 5120-»5120 ■ 88 25
6 Tyrode's solution 5120->5120 82 25
Normal skin, and skin injected with Tyrode's buffer alone, had eosinophil counts of less than 5. The
antibody was a purified 7S IgG, (fraction 6) anti-ferritin (Kay, 1970a) which contained 200//g of total
protein per ml.
Intradermal antigen-antibody complexes
Animals injected with pre-formed antigen-antibody complexes were treated with cobra
venom factor in the same manner as described above. The results are shown in Table 3.
Animals treated with cobra venom factor showed no appreciable difference in either the
diameter or intensity of the blueing reactions from those treated with Tyrode's solution.
With IgGt or TgG2 complexes, in both groups of animals the lesions were discrete, in¬
tensely blue and all showed small central areas of haemorrhage. The histological reactions
were similar in that both groups had eosinophil infiltration in comparable quantities and
had vast infiltrations of neutrophils.
DISCUSSION
The capacity of C4 deficient guinea-pigs or guinea-pigs decomplemented with cobra venom
factor to react fully in PCA reactions has been previously reported (Maillard & Zarco,
1968; Cochrane, Miiller-Eberhard & Aikin, 1970; Ellman et al., 1971). The present study
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confirms these observations and demonstrates that this procedure does not affect the
subsequent infiltration of eosinophils and neutrophils into the reaction site (Table 1).
The experiment with C4 deficient animals (Table 2) indicates that the participation of
this early acting complement component is not an essential prerequisite for subsequent
eosinophil and neutrophil infiltration following passive cutaneous anaphylaxis. These
results are in agreement with in vitro data that complement is not a requirement for the
antigen-induced release of ECF-A from lung tissue passively sensitized with IgGj (Kay et
at., 1971). Furthermore, it has been found that there was no difference in the capacity of
C4 deficient and normal guinea-pig lung tissue to be passively sensitized for the antigen-
induced release of ECF-A (Kay, Stechschulte and Austen, unpublished observations).
The generation of eosinophil chemotactic factors, in vitro, by pre-formed complexes
prepared from IgGj or IgG2 requires complement (Kay, 1970a) yet when introduced into
the skin of decomplemented animals both complexes elicited a subsequent local eosino¬
phils (Table 3). In the case of IgGi this discrepancy could be attributed to the capacity
Table 2. Eosinophil accumulation into the site of PCA reactions in guinea-pigs partially or totally deficient
in C4




Homozygote less than 5 97 12 25
Heterozygote 286,000 110 12 20
Normal 777,000 81 10 25
* Mean of two sites in each animal.
Skin injected with antigen or antibody or with Tyrode's solution showed no induration or erythema
and had eosinophil counts of less than 5. The antibody was a purified IgG, (fraction 5) anti-ovalbumin
(Kay et al., 1971) containing 150 mg of total protein per ml. The ovalbumin was administered at a
concentration of 300 /ig/ml.
of the IgG: to release chemical mediators from target cells without prior fixation and in
the absence of complement. In this situation the IgG[ complex may be analogous to rat
IgGa complexes which can release histamine from rat mast cells in vitro without prior
fixation (Bach, Bloch and Austen, 1971). Since IgG2 is unable to sensitize skin for passive
cutaneous anaphylaxis (Ovary, Benacerraf and Bloch, 1963) or lung fragments for hista¬
mine (Baker, Bloch and Austen, 1964) and SRS-A release (Stechschulte, Austen and
Bloch, 1967) but can fix complement, it was expected that complement may play a part
in the cellular infiltration following intradermal injection of IgG2 complexes. It was found,
however, that IgG2 as a pre-formed complex evoked both a blueing reaction and sub¬
sequent eosinophil and neutrophil infiltration as great as the IgGj complexes in both normal
and cobra venom treated animals. These findings are similar to those of Broder (1969)
who demonstrated that soluble complexes prepared from guinea-pig IgGi or IgG2 both
have the capacity to liberate histamine from perfused guinea-pig lung. It should be noted,
that on a weight basis, IgGt is far more efficient in preparing tissue for an eosinophilia
when administered in PCA reactions than when injected as pre-formed complexes.
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Recent preliminary experiments have shown that partially purified ECF-A can elicit a
local eosinophilia following intraperitoneal injection. These results, and the data presented
herein are consistent with the view that ECF-A may play a role in cutaneous eosinophil
accumulation in vivo.
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Chemotactic activity for eosinophils and neutrophils has been studied using guinea-
pig serum activated by preformed antigen-antibody complexes.
Rabbit complexes or complexes prepared either with guinea-pig IgG2 or IgGj
were equally capable of generating a heat stable activity from guinea-pig serum that
was chemotactic for guinea-pig eosinophils and for neutrophils of both the guinea-
pig and the rabbit. This was distinguished from a relatively heat-labile chemotactic
activity present in untreated guinea-pig serum.
The heat-stable complex-mediated chemotactic activity was thought to be
complement dependent since chemotaxis for eosinophils or neutrophils could not
be generated from heated serum, ammonia treated serum or from serum treated
with complexes in the presence of 0-01 m EDTA.
Guinea-pig sera, activated either with rabbit, guinea-pig IgG, or IgG2
complexes, was fractionated by sucrose-density gradient ultracentrifugation and
by Sephadex chromatography. In all experiments two peaks of cell specific
chemotactic activity could be separated. The peak of activity for guinea-pig
neutrophils was approximately 4-5S and in the fractionation range of proteins
having a molecular weight of between 65,000 and 85,000. The peak of guinea-pig
eosinophil chemotactic activity was 1-5S-2S and in the molecular weight range
of between 15,000 and 20,000. Those fractions which were chemotactic for guinea-
pig neutrophils did not attract rabbit neutrophils. Rabbit neutrophils migrated
towards those fractions of guinea-pig serum chemotactic for guinea-pig eosinophils;
therefore, the properties associated with guinea-pig eosinophil chemotactic
activity were similar to previously published data for a fragment cleaved from the
5th component of complement.
INTRODUCTION
It has been previously demonstrated that eosinophil leucocytes migrate into the site of
Correspondence: Dr A. B. Kay, Department of Medicine, Harvard Medical School at the Robert B.
Brigham Hospital, Boston, Massachusetts 02120, U.S.A.
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passive cutaneous anaphylactic (PCA) reactions mediated by those fractions of 7S guinea-
pig IgG containing IgG, whereas passive sensitization with IgG2 did not evoke a local
eosinophil response. Preformed antigen-antibody complexes however, prepared either from
IgG, or IgG2 both promoted a local eosinophil and neutrophil migration following injec¬
tions into guinea-pig skin (Kay, 1970).
Although it is yet to be ascertained that these two methods of treating guinea-pig skin
represent more than one mechanism for preparing the tissue for a local eosinophilia the
possibility exists that in the case of preformed complexes 'complement mediated' chemotaxis
is involved. Furthermore, it has been shown that chemotactic activity for eosinophils is
demonstrable in vitro following incubation of unheated serum with antigen-antibody com¬
plexes (Keller and Sorkin, 1969; Ward, 1969a).
It is the purpose of this report to determine whether, in the guinea-pig, a complement
mediated chemotactic activity for eosinophils and neutrophils could be generated in vitro
and to compare the chemotactic-generating properties of guinea-pig IgG, and IgG2. In
addition, guinea-pig serum activated by antigen-antibody complexes prepared from
various immunoglobulins has been fractionated in order to determine whether specific
chemotactic activity for eosinophils and neutrophils could be separated.
MATERIALS AND METHODS
Preparation ofguinea-pig IgG ^ and IgG2 immunoglobulins
Antiserum to Ferritin (Koch-Light) was raised in guinea-pigs as previously described
(Kay, 1970). Guinea-pig anti-sheep red cell serum was prepared according to the schedule
described by Jonas et al. (1965). 35 ml of guinea-pig anti-ferritin and 5 ml of guinea-pig
anti-sheep red cell sera were pooled and precipitated at room temperature with 12-5%
sodium sulphate. The precipitate was redissolved in 10 ml of distilled water and dialysed
against 0-01 m phosphate buffer at pH 8-0. The sample was applied to a column of DEAE-
cellulose (DE 32-Whatman) 3-22 x 35 cm, which had been previously equilibrated with
0-01 m phosphate buffer at pH 8-0. Following the exclusion peak a gradient of increas¬
ing phosphate buffer concentrations was applied and the fractions were collected, pooled as
shown in Fig. 1, and concentrated to 10 ml volumes using a UM I Amicon-Diaflow
Membrane.
Rabbit anti-ovalbumin serum
Antiserum to ovalbumin (Koch-Light) was prepared in rabbits following an injection
schedule previously described for preparing rabbit anti-guinea-pig 7S IgG (Kay, 1970).
Preparation of antigen-antibody complexes
Antigen-antibody complexes from unfractionated rabbit anti-ovalbumin or guinea-pig
IgG, or IgG2 anti-ferritin were prepared as previously described (Kay, 1970).
Guinea-pig complement reagents
Pooled guinea-pig serum was used as a source of complement (C) and was stored
at — 20°C for no longer than 12 weeks. Ammonia-treated guinea-pig serum (R4) was
prepared as described by Mayer (1961).
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Methods used to test the purity of guinea-pig IgG1 and IgG2
(a) Gel-diffusion and Immunoelectrophoresis
Gel-diffusion was performed using a rabbit (R5094) anti-guinea-pig 7S IgG and a rabbit
(R5094 absorbed with IgG2) anti-guinea-pig IgG,. These reagents were prepared as pre¬
viously described (Kay, 1970). Immunoelectrophoresis was performed using both the
rabbit (R5094) anti-guinea-pig 7S IgG and a rabbit (R1814) antiserum (kindly supplied by
Professor R. R. A. Coombs) which had been prepared following a prolonged course of
alum-precipitated whole guinea-pig serum.
(b) Passive cutaneous anaphylaxis (PCA)
This was performed as previously described (Kay, 1970). The PCA titre of anti-ferritin in
each fraction was expressed as the reciprocal of the final dilution which gave a mean lesion
diameter of 10 mm.
(c) Whole complement litre (CH50) following incubation ofguinea-pig serum with preformed
antigen-antibody complexes
Samples from fractions 1, 2, 5 and 6 (Fig. 1) were precipitated with ferritin following a
standard optimal proportion titration. The precipitates were washed four times with
0-01 m EDTA/saline and finally resuspended in CFT veronal buffer. The protein content
of the resuspended precipitate was measured using the Folin method.
0-25 ml volumes of guinea-pig complement were incubated with the precipitates at a
concentration of 5 mg of the antigen-antibody complex per 1 ml of complement.
Following incubation for 30 min at 37°C the samples were centrifuged to remove the
antigen-antibody precipitates and then titrated in doubling dilutions on microagglutination
trays in 0-025 ml volume. 0-025 ml of 1 % sensitized sheep cells were added and the mixture
was incubated at 37°C for 30 min when the 50% lytic end point was determined visually.
(d) Haemolysin titre of guinea-pig anti-sheep RBC Serum
Dilutions of the fractions (Fig. 1) in 0 025 ml volumes were incubated with 0-025 ml of a
suspension of 1% sheep red blood cells. A 1 in 10 dilution of guinea-pig complement in
0-025 ml volumes was added and following incubating at 37°C for 30 min the 50% lytic end
point was determined visually.
(e) Macrophage-cytophilic antibody
The monolayer test as described by Jonas et al. (1965) was used to detect macrophage-
cytophilic antibody directed against sheep red blood cells. Dilutions of fractions of antisera
were applied to monolayers of guinea-pig peritoneal macrophages. After 1 hr sensitization
the monolayers were washed three times and a 0-25% suspension of sheep red blood cells
was added and allowed to react for 3 hr. Rosette formation was scored on the +(plus) basis.
All dilutions and washings were performed using Hanks's (Oxoid) solution adjusted to
pH 7-2.
Chemotactic chambers
Chemotaxis was measured using a modification of the Millipore technique of Boyden
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(1962). Millipore filters of 13 mm diameter were attached to sawn-off disposable 2 ml
syringe barrels (Johnson and Co., Ltd) using millipore cement (Millipore Corp., Bedford,
Mass.). This served as the upper compartment into which was placed 1 ml of the cell
suspension containing approximately 1 x 106 cells. The potency of the cell compartment was
checked before placing it into a 30 mmx 16 mm plastic pill pack (Camlab (Glass) Ltd)
containing 1 ml of the test solution. The syringe barrel was sawn off at the point where the
fluid in the cell compartment and the test compartment was level when each contained 1 ml.
The chemotactic chambers were placed in a moist box and incubated in air for 3 hr at
37°C. Following cell fixation, of between 1 and 18 hr using a mixture of 50% ethanol and
50% saturated mercuric chloride, the filters were removed and stained as follows: Carazzi's
haematoxylin 5 min, running tap water 2 min, 1% HCL in 70% alcohol 5 sec, running tap
water 10 min, 0-5% chromotrope 2R in 1% phenol 30 sec, running tap water 2 min, 20 dips
in two changes of 95% absolute alcohol, propanol 2 min, propanol/xylol (equal parts)
2 min, xylol 20 min and mounted in DPX.
Cell counts from five fields taken at random were performed using the high power (x 40)
objective and a counting grid. Only those cells which had migrated through the thickness of
the millipore were counted. The result of each treatment is expressed as the mean cell count.
Five high power field counts was considered to be a satisfactory sampling since, although not
recorded, the standard deviation was calculated in all experiments (except the fractionation
studies) and found, in every treatment, to be less than 15% of the mean cell count.
Rabbit and guinea-pig neutrophils were obtained by the method described by Hirsch &
Church (1960). Guinea-pig eosinophils were obtained from the peritoneal cavity following
weekly intraperitoneal injections of 2 ml of horse serum. Peritoneal cells were harvested 4-12
weeks following the initial injection and 7 days following the last injection ofhorse serum and
contained between 10% and 40% of eosinophils.
The optimal pore size for each cell type was determined by preliminary experiments
using filters of various pore sizes. The pore size selected was that which allowed only
minimal background migration when the suspending medium alone was used in the test
compartment. For rabbit and guinea-pig neutrophils a 1-2 fi pore size was used whereas
guinea-pig eosinophil migration was measured using an 8-0 fi pore size. Hanks's solution
containing 0-5% ovalbumin (Koch-Light) and 50 units of penicillin and 5 fig of strepto¬
mycin per ml (adjusted to pH 7-2) was used as the suspending medium in both the cell and
the test compartments.
Sucrose density-gradient ultracentrifugation
A 5 ml linear density gradient was prepared between 8 and 36% sucrose in Flanks's
solution with added penicillin and streptomycin but omitting phenol red. Haemoglobin
and [125I]thryoglobulin were used as markers. Following application of 0-25 ml of
activated serum or normal serum control, the gradients were centrifuged at 35,000 rev/min
using a SW39 head in a model L-2 Spinco Ultracentrifuge for 20 hr at 4°C.
Approximately thirty samples of 0-16 ml were collected. Even numbered fractions were
tested for guinea-pig neutrophil chemotaxis and odd numbered fractions for guinea-pig
eosinophil chemotaxis. The position of the [125I]thyroglobulin marker (19S) was deter¬
mined using a sodium iodide crystal, well-type scintillation counter. The position of the
haemoglobin marker (4-5S) was determined using a Unicam (SP-600) spectrophotometer
at 415 m/u
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Gel filtration on Sephadex G-100 and G-50
The columns were equilibrated using phosphate buffered saline (PBS). The Sephadex
G-100 column (T77 cm2 x 85 cm) and the Sephadex G-50 column (1-77 cm2 x 75 cm) were
standardized by a preliminary fractionation of the molecular markers. With each column a
1 ml sample was applied and 2-5 ml fractions were collected. Odd numbered fractions were
tested for guinea-pig eosinophil chemotaxis and even numbered fractions were tested for
guinea-pig neutrophil chemotaxis. In some experiments even numbered fractions were also
tested against rabbit neutrophils. Volumes of 0-9 ml of the fractions were placed in the
chemotaxis chambers to which were added 0-1 ml of 5% ovalbumin in order to give a final
concentration of 0-5% ovalbumin in isotonic Hanks's balanced salt solution.
RESULTS
The purity offractions ofguinea-pig IgGl and IgG2
The purity of the fractions obtained by DEAE-cellulose chromatography (Fig. 1) was
assessed both by gel-diffusion and immunoelectrophoresis in addition to the estimation of
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Fraction number
Fig. I. The separation of guinea-pig IgG! and IgG2 by DEAE(DE-32)-cellulose chroma¬
tography of a pooled anti-ferritin and anti-sheep red-blood cell serum.
Table 1. The purity of fractions of guinea-pig IgGt and IgG2 determined by estimations of their known
biological activities
Fraction number 1 2 3 4 5 6 7 8
PCA titre <10 <10 <10 40 640 1280 80 40
Haemolysin titre 48 48 4 2 4 0 0 4
Macrophage-cytophilic antibody w + + + + w w w w
CH50 following incubationwith <1 <1 NT NT >256 >256 NT NT
preformed complexes
Protein concentration
in mg (Folin) 1-5 1-4 0-3 0-32 10 10 0'75 0-55
w = Weak, NT = not tested.
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By gel-diffusion it was shown that IgG, was detectable only in fractions 5 and 6 (Fig. 2).
Similar results were obtained using immunoelectrophoresis since the precipitation arcs
produced byfractions 5 and 6 corresponded to the IgG, spur noted with the unfractionated
antiserum (Fig. 3).
Fig. 2. The location of the fractions containing IgG, and IgG2 as shown by gel-diffusion.
The fractions obtained by DEAE-cellulose chromatography were placed in the outer wells
as indicated and correspond to the fractions shown in Fig. 1. The centre well in the lower
pattern contains a rabbit (R5094) anti-guinea-pig 7S IgG. A specific anti-IgGi (R5094 absorbed
with IgG2) was placed in the centre well illustrated in the upper pattern.
High PCA titres were obtained only with the IgG, containing fraction but not with
IgG2 eluted with the lower molarity buffer (Table !).
The relative inefficiency of IgG, to fix complement has been confirmed. This was demon¬
strated both by estimation of the haemolysin titre and also by measuring whole complement
(CH50) following incubation of guinea-pig serum with preformed complexes prepared from
either IgG, or IgG2 containing fractions (Table 1). Only IgG2 containing fractions showed
fixation of whole guinea-pig complement.
The fractionation of pooled, anti-ferritin and anti-sheep RBC sera was convenient for
identifying macrophage-cytophilic antibody in addition to the measurement of the haemo¬
lysin titre. A previous report (Jonas et al., 1965) that macrophage-cytophilic antibody
resided in the electrophoretically fasterlgG2 containing region was confirmed (Table 1)
since only fraction 2 showed a significant rosette-forming reaction.





















Fig. 3. The purity of the fractions obtained by DEAE-cellulose chromatography (Fig. 1) as
shown by immunoelectrophoresis. The fractions and the unfractioned whole serum (ws) were
placed in the wells as indicated on the left and antisera was applied to the troughs as shown on
the right.
As a result of the gel-diffusion and immunoelectrophoretic studies Fractions 1 and 6 were
chosen as the most pure fractions of IgG2 and IgGi respectively.
Chemotaxis generated from guinea-pig serum by preformed antigen-antibody complexes
In initial experiments it was found that normal, untreated guinea-pig serum had chemo-
tactic activity (Table 2). Using guinea-pig eosinophils and neutrophils from the guinea-pig
and rabbit it was shown that this chemotactic activity was partially destroyed by heating the
serum at 56°C for 30 min.
Following activation of normal guinea-pig serum by preformed antigen-antibody com¬
plexes prepared from rabbit antiserum and then subsequently heating at 56°C for 30 min
chemotactic activity could be demonstrated (Table 3). Therefore, by heating activated
serum in addition to the normal serum controls the chemotactic activity of normal unheated
serum could be distinguished from the chemotactic activity generated by antigen-antibody
complexes. Consequently, following incubation of guinea-pig serum with the antigen-
antibody complexes for 15 min at 37°C, the complexes were removed by centrifugation and
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Table 2. The effect of heat on the chemotactic activity of
normal guinea-pig serum. The figures are mean cell counts and
represent the pooled results of three experiments
Neutrophils Eosinophils
Guinea-pig Rabbit Guinea-pig
Serum, unheated 29-2 27-2 12 6
Serum, heated 11-4 8-7 2-9
(56°C for 30 min)
Each test compartment contained 01 ml of serum (heated or
unheated) and 0-9 ml of 0-5% ovalbum in inHanks's solution.
Table 3. The property of rabbit antigen-antibody complexes
to generate chemotactic activity from guinea-pig serum. The




1. Serum 3-5 5-8 0-7
2. Serum+ rabbit
complexes 23-6 37-4 36-2
3. Diluent alone 0 0 0
1. Serum, 01 ml (incubated 37°C for 15 min, 56°C for 30
min)+ 0-9 ml of 0-5% ovalbumin in Hanks's solution.
2. Serum, 01 ml (incubated at 37°C for 15 min, with 5mg of
complex per ml of serum, complexes removed by centrifuga-
tion, 56°C for 30 min)+ 0-9 ml of 0-5% ovalbumin in Hanks's
solution.
3. Diluent, 1 ml of 0-5% ovalbumin in Hanks's solution.
Table 4. The property of antigen-antibody complexes prepared from
guinea-pig IgGj or IgG2 to generate chemotactic activity from guinea-
pig serum. The figures are mean cell counts and represent the pooled
results of three experiments
Neutrophils Eosinophils
Guinea-pig Rabbit Guinea-pig
Serum 8-6 5-9 0-5
Serum+ IgG2 (Fr 1) 49-2 30 1 160
Serum -t-IgG] (Fr 6) 62-3 43-3 17-2
Diluent alone 0 0 0
Test compartments prepared as in Table 3.
Eosinophil and neutrophil specific chemotaxis 731
the sera, including the unheated controls, were heated for 30 min at 56°C and 0-1 ml
volumes tested for chemotactic activity.
The chemotactic generating ability of complexes prepared either from guinea-pig IGg,
or IgG2 is shown in Table 4. It was established in preliminary experiments that the various
antigen-antibody complexes were not chemotactic per se but both IgG, or IgG2, as pre¬
formed complexes, were equally capable of generating chemotactic activity for guinea-pig
neutrophils, rabbit neutrophils and guinea-pig eosinophils following incubation with guinea-
pig serum.
Although little difference was observed in the chemotactic generating properties of
guinea-pig IgG, and IgG2 complexes, measurements of the CH50 levels following activation
of serum but prior to heating at 56°C was < 1 for complexes prepared from Fr 1 (IgG2)
and Fr 2 (IgG2) and >256 for complexes prepared from Fr 5 (IgG,), Fr 6 (IgG,) and for
untreated guinea-pig serum, as shown in Table 1.
Antigen-antibody complexes prepared from guinea-pig IgG, and IgG2 and from un-
fractioned rabbit antiserum were unable to generate chemotactic activity for guinea-pig
eosinophils and neutrophils and for rabbit neutrophils in the presence of 0-01 m EDTA
(Table 5). The serum was incubated with antigen-antibody complexes in the presence of
Table 5. The inability of antigen-antibody complexes to generate chemotactic
activity from guinea-pig serum in the presence of 0-01 EDTA
Neutrophils Eosinophils
Guinea-pig Rabbit Guinea-pig
Serum 8 4-6 4-4
Serum+ IgG, (Fr 6) 21-5 46-4 15-8
EDTA Serum+ IgG, (Fr 6) 0 8 2-6
Serum+ IgG2 (Fr 1) 19 5 36-1 111
EDTA Serum + IgG 2 (Fr 1) 0 4 4-2
Serum + Rabbit complexes 14-7 37-7 21-4
EDTA Serum +Rabbit complexes 1 11-4 3-7
The figures are mean cell counts and represent the pooled results of two ex¬
periments.
Test compartments prepared as in Table 3. Treatment with 0-01 EDTA pre¬
pared as described in text.
0-01 m EDTA and dialysed overnight at 4°C. Serum incubated with antigen-antibody
complexes in the absence of EDTA and subsequently dialysed served as a control. The
experiments were repeated omitting dialysis but by replacing the divalent cations before
testing for chemotaxis. Essentially similar results were obtained.
It was also shown that neither guinea-pig nor rabbit antigen-antibody complexes could
release chemotactic activity for neutrophils or eosinophils from ammonia-treated (R4)
serum or from serum previously treated at 56°C for 30 min.
Fractionation ofguinea-pig serum activated by antigen-antibody complexes
(A) Sucrose density-gradient ultracentrifugation. Since antigen-antibody complexes
generated chemotactic activity for guinea-pig neutrophils and eosinophils, attempts were
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made, using fractionation procedures, to determine whether the same chemotactic factors
were active for both cell types.
Using sucrose density-gradient ultracentrifugation, it was determined in preliminary
experiments that neither high concentrations of sucrose nor the [125l]thyroglobulin or
haemoglobin markers had any chemotactic effect per se or that they influenced the chemo¬
tactic properties of serum activated by antigen-antibody complexes.
Following ultracentrifugation of guinea-pig serum activated by rabbit antigen-antibody
complexes, the chemotactic activity for both cell types was observed in the slowly sediment-
ing region (Fig. 4). The peak activity for guinea-pig eosinophils was in the range of proteins
Tube number
Fig. 4. The ultracentrifugal analysis of guinea-pig serum activated by rabbit antigen-antibody
complexes. The position of the two molecular markers [125I]thyroglobulin (19S), measured as
counts per 4 sec, and haemoglobulin (4-5S), measured at OD 415 mn is illustrated and from
this was drawn a linear relationship for S valves.
The peak of eosinophil and neutrophil chemotactic activity was found in the slowly sedi-
menting region. Eosinophil chemotactic activity was between l -5Sand 2S whereas the peak of
neutrophil chemotactic activity was less well defined but sedimented slightly faster and was
approximately 4-5S.
having a sedimentation constant (SW2()) of approximately 1-5S-2-0S whilst the peak acti¬
vity for guinea-pig neutrophils, although less well defined, was slightly faster sedimenting
and was approximately 4-5S. Rabbit neutrophil chemotaxis was not determined in the
ultracentrifugation fractionation procedures.
Following fractionation of serum incubated with guinea-pig IgGj and IgG2 virtually
identical results were obtained as with incubation with rabbit antigen-antibody complexes
except that the mean cell counts for chemotaxis were slightly less.
(B) Gel-filtration on Sephadex <17-100 and G-50. In an attempt to differentiate further the
eosinophil and neutrophil chemotactic activity demonstrated on sucrose density-gradient
ultracentrifugation and to obtain preliminary data on the molecular weight of the chemo¬
tactic factors, the activated serum was fractionated using gel-filtration.
Guinea-pig serum activated with rabbit antigen-antibody complexes was passed through
a column of Sephadex G-100, the void volume of the molecular markers blue dextran,
haemoglobin and cytochrome C having been previously determined. Two peaks of cell-
specific chemotactic activity were noted (Fig. 5). The guinea-pig eosinophil chemotactic
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Fig. 5. The fractionation on Sephadex G-100 of guinea-pig serum activated by rabbit antigen-
antibody complexes. Alternate fractions were tested for guinea-pig eosinophil or neutrophil
chemotactic activity and could be separated and were found to correspond to the cytochrome
C and the haemoglobulin markers respectively.
peak was in the fractionation range for molecules having a range of molecular weight of
between 15,000 and 20,000 whilst guinea-pig neutrophil chemotactic activity was in the range
of 65,000-85,000 molecular weight. In a separate experiment no chemotactic activity for
guinea-pig eosinophils and neutrophils (and rabbit neutrophils) was found when heated
serum, without prior activation, was fractionated on Sephadex G-100.
Two further fractionation studies were performed using serum activated with guinea-pig
IgG, and IgG2 and their antigens respectively. Essentially similar results were obtained as
with serum activated with rabbit antigen-antibody complexes with the exception that, as
with the ultracentrifugation studies, the values of the mean cell counts for eosinophils and
neutrophils were less than half that shown in Fig. 4 although the peaks of activity were
virtually identical.
In order to determine more precisely the molecular weight range of the more slowly
sedimenting eosinophil chemotactic activity, fractionation of serum activated with rabbit
antigen-antibody complexes was performed on Sephadex G-50, since it was considered that
the fractionation range of G-50 was such that a more accurate determination could be made
of this molecular weight. In addition, alternate fractions were also examined for rabbit
neutrophil chemotactic activity since a low molecular weight factor chemotactic for rabbit
neutrophils generated from guinea-pig serum has also been described (Snyderman, Gewurz
& Mergenhagen, 1968). The results are shown in Fig. 6. Similar findings were obtained with
guinea-pig neutrophils and eosinophils as in the fractionation with Sephadex G-100,
although the peaks of activity were not so widely separated. The eosinophil chemotactic
activity was again in the range of molecular weight between 10,000 and 15,000 whilst the
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Fig. 6. Sephadex G-50 fraction of guinea-pig serum activated rabbit antigen-antibody
complexes. In addition to guinea-pig neutrophils and eosinophils rabbit neutrophils were
also tested for chemotaxis and found to migrate towards those fractions chemotactic for
guinea-pig eosinophils.
guinea-pig neutrophil peak was in the position of the haemoglobin marker. The peak of
activity for rabbit neutrophils' chemotaxis was similar to that for guinea-pig eosinophils,
an observation that was repeated by fractionation on Sephadex G-100 and on Sephadex
G-50 using serum activated by guinea-pig IgGj and IgG2 antigen-antibody complexes.
Fractionation on Sephadex G-50, therefore, did not allow a more precise determination
of the molecular weights of the specific guinea-pig and neutrophil chemotactic factors
but confirmed the observations obtained with Sephadex G-100 and showed that guinea-
pig and rabbit neutrophils migrated towards separate fractions whilst guinea-pig
eosinophil and rabbit neutrophil chemotaxis had a virtually identical chromatographic
pattern.
The eosinophil and neutrophil chemotactic activity was specific as indicated in Figs 5 and
6. When the neutrophil rich suspension (which normally contained about 5% of eosinophils)
was tested with the fraction having peak chemotactic activity for eosinophils, migration of
eosinophils alone was observed although the pore size was only 1 -2 /.i. Most of the neutrophils,
on the other hand, remained on the upper surface of the millipore, very little migration
having occurred.
DISCUSSION
The main findings of this report are that eosinophils and neutrophlis migrate towards serum
activated with antigen-antibody complexes prepared either with guinea-pig IgGt or with
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IgG2 and that, irrespective of the manner in which the serum was activated, chemotactic
activity for these two cell types could be separated by fractionation procedures.
The technique used to separate guinea-pig IgG, and IgG2 has enabled these immuno¬
globulins to be obtained in a reasonably pure state. This was demonstrated both by gel
diffusion and immuno-electrophoresis and also by the confirmation of previous reports that
haemolysin and macrophage-cytophilic antibody are detectable only in the IgG2 region
(Bloch et al., 1963; Jonas et at., 1965) and that PCA activity is confined to the IgG, con¬
taining fractions (Ovary, Benacerraf & Bloch, 1963).
The ability of IgG, and its antigen to generate a heat labile chemotactic agent from guinea-
pig serum contrasts with the findings of Keller, Nussenzweig & Sorkin (1968). Using an
IgG, preparation containing approximately 10'% IgG2, an experiment was reported in
which the cell counts per field were 93 and 288 for IgG, and IgG2 respectively compared
with a count of 39 for the untreated serum control. They concluded that the moderate
count with IgG, was a reflection of contaminating IgG2. In the present study, however, the
purified IgG, preparation gave, in some cases, a slightly higher count than treatment with
complexes prepared from IgG2 (Table 2).
It has been claimed recently that preformed antigen-antibody complexes prepared from
IgG, can fix total complement (Osier et al., 1969). The present report was unable to confirm
these observations (Table 1). It would appear, however, that the chemotactic activity
generated either by IgG2 or IgG, is in fact complement mediated since it was shown that
activity could not be generated in the presence of 0-01 m EDTA or from ammonia-treated
serum or from serum previously heated at 56°C for 30 min. A possible explanation as to why
antigen-antibody complexes prepared from IgG, liberated chemotactic activity but did not
affect total complement levels as measured by the CH50 was that in the experiments des¬
cribed here a 'limited' complement system was employed. For instance, it can be shown
that under certain conditions of testing, sheep IgG2, like guinea-pig IgG,, is also 'non-
complement fixing' but when increasing amounts of complement are used, sheep IgG, and
IgG2 were shown to have equal haemolytic activity (Feinstein & Hobart, 1969). Furthermore,
both immunoglobulins as preformed complexes could generate chemotactic activity from
rabbit serum (Kay & Hobart, unpublished observation).
It has been shown that specific chemotactic activity for rabbit neutrophils and rabbit
macrophages can be separated when rabbit serum, heated at 56°C for 30 min, is fractionated
on Sephadex G-200 (Wilkinson, Borel, Stecher-Fevin & Sorkin, 1969). The present study is
another example of how chemotactic activity for more than one cell type can be separated
following chromatography, but here the activities were generated by antigen-antibody
complexes and were specific for eosinophils and neutrophils. In contrast to the findings of
Wilkinson et al. (1969), no chemotaxis was noted following fractionation of heated guinea-
pig serum, although unheated serum had a relatively heat labile chemotactic activity.
The small molecular weight factor reported in this study which had chemotactic activity
for guinea-pig eosinophils was similar in molecular weight and sedimentation constant to a
factor previously described which had chemotactic activity for rabbit neutrophils but was
generated from guinea-pig serum by endotoxic lipopolysaccharide and cobra factor (Snyder-
man et al., 1968; Shin, Gewurz & Snyderman, 1969) and from purified guinea-pig C5 by
EAC1423 (Shin et al., 1968). The present experiments showed that there was a different
profile of chemotactic activity for rabbit and guinea-pig neutrophils when activated guinea-
pig serum was fractionated. The use of rabbit neutrophils, therefore, to detect activity
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generated in guinea-pig serum must limit the in vivo significance of such experiments. It
would seem likely, however, that the factor described here which was chemotactic for guinea-
pig eosinophils is similar in molecular weight and sedimentation constant to the small
molecular weight factor described by Shin et al. (1968). These workers concluded this to be a
fragment cleaved from the 5th component of complement and showed that the factor also
had anaphylatoxic properties (Shin et al., 1968).
The factor chemotactic for guinea-pig neutrophils which was observed in the molecular
weight range of 68,000 has not been further investigated but it would seem unlikely that this
represents the chemotactic C 567 macromolecular complex described by Ward, Cochrane &
Miiller-Eberhard (1966). It has been confirmed, nevertheless, that human C 567 generated
in free solution is chemotactic for human neutrophils and eosinophils (Lachmann, Kay &
Thompson, 1970) suggesting that for eosinophils, as neutrophils, there is also a heterogeneity
of chemotactic factors generated from the complement system (Ward, 1969b). It is em¬
phasized that in the present study a macromolecular chemotactic factor was not detectable
when whole guinea-pig serum was activated with preformed complexes. Either there is a
species difference in the ability to form chemotactic C567 or the conditions required for its
generation from whole serum need to be more clearly defined.
A specific eosinophilotactic factor, therefore, has been generated from guinea-pig serum
in vitro but the in vivo significance of this observation is yet to be determined. Experiments
currently in progress are attempting to ascertain whether this factor is associated with the
moderate accumulation of eosinophils observed in Arthus (Type III) reactions.
It was previously shown that in guinea-pig skin a local eosinophilia followed PCA
reactions with IgGt, but not after the passive administration of IgG2 and subsequent
antigen challenge. Injections of compound 48/80 also evoked a local eosinophil response
(Kay, 1970); therefore, the possibility exists that the eosinophilia associated with Type I
reactions is produced independently of the complement system. This possibility is also being
investigated.
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Summary. C567, prepared by the interaction of purified C56 with purified
C7 in solution, has been shown to be chemotactic for neutrophils and eosinophils.
This activity was not significantly affected by the presence of C8 and C9, even in
substantial excess. However, if the interaction of C56 with C7 took place in the
presence of an excess of erythrocytes, these cells bound the C567 and were con¬
verted to EC567; and no chemotactic factor was found.
INTRODUCTION
In human acute phase sera treated witli zymosan it is possible to generate a stable,
activated complex of the fifth and sixth components of complement—C56. C56 has been
substantially purified and on interaction with purified C7 gives arise to an evanescent
complex, C567*f, which briefly has the capacity to attach to red cell membranes, con¬
verting them to EC567 and enabling them to be lysed by C8 and C9 (Reactive Lysis).
If binding is not achieved the binding site decays and the resulting complex, C567, while
haemolytically inactive, retains its capacity to react with C8 and C9 (Thompson and Lach¬
mann, 1970; Lachmann and Thompson, 1970). The chemotactic activity of this G567
prepared in free solution from functionally purified C56 and G7 is reported in this
communication.
The chemotactic activity of the C567 complex of human or rabbit complement liberated
during the conventional complement fixation reaction was described by Ward, Cochrane
and Miiller-Eberhard (1966). Their findings have however been disputed by Steelier and
Sorkin (1969) on the grounds that they were unable to detect any difference between the
chemotactic activity of normal and C6-deficient rabbit serum after treatment with antigen-
antibody complexes.
MATERIALS AND METHODS
C56 was purified from acute phase serum activated with zymosan as described by
Lachmann and Thompson (1970). The preparation used had a protein concentration of
I The overbar refers to activation of the site allowing reaction with subsequent complement components; the
asterisk to activation of the binding site for the cell membrane.
895
896 P. J. Lachmann, A. B. Kay and R. A. Thompson
600 /ig/ml and its titre for giving reactive lysis of sheep erythrocytes was 512. 0-1 ml of
1/10 dilution was used in the chemotactic test. A less purified preparation, still containing
C9—referred to as 'C56+9'—was used at an approximately equivalent titre.
C7 was purified from normal human serum as described by Thompson and Lachmann
(1970). The preparation used had a protein concentration of 240 /(g/ml and a haemolytic
titre of 1000. 0-1 ml of 1/5 dilution was used in the chemotactic system to ensure C7
excess. A less purified preparation still containing C8—referred to as 'C7+8'—was used
at an approximately equivalent titre.
C8+9 was prepared from a rivanol precipitate of normal human serum by C-M
cellulose chromatography as described by Manni and Miiller-Eberhard (1969). The
haemolytic titre for sheep EG567 was in the region of 5000 and the protein concentration
around 17 mg/ml.
Activated serum was prepared by absorbing normal human serum with zymosan (2
mg/ml) for 30 minutes at 37°. In some experiments unactivated normal serum was used.
The technique used for testing for chemotactic activity was modified from that originally
described by Boyden (1962) and is to be described more fully elsewhere (Kay, 1970.)
Human leucocytes were obtained from a single donor and extracted by dextran sedi¬
mentation. Counts of migrating leucocytes were made in the body of a millipore filter
0-65 /< pore size (Millipore filter Corporation, Bedford, Mass.) after 3 hours incubation at
37°. The diluent in both compartments was a 0-5 per cent solution of crystalline ovalbumin
(Koch Light & Co. Ltd., Colnbrook, Bucks.) in Hanks's buffered salt solution, pH 7-2,
containing 50 units penicillin and 5 jig streptomycin/ml.
RESULTS
Six separate experiments were performed and in three of these eosinophils were counted
separately. The data are set out in Table 1. The data pooled into suitable groups and their
statistical analysis are shown in Table 2.
THE GHEMOTACTIC ACTIVITY OF C567
In Table 2 the data have been pooled in the first place, into three groups: normal,
unactivated complement components; C56 in the absence of C7; and C567 (89) except
those where the C567 was made in the presence of E.
It is clear that C567 shows strong and highly significant chemotactic activity for both
neutrophils and eosinophils. The effect is substantially larger for neutrophils, this being
true also for activated serum.
C56 shows a minor degree of chemotactic activity for polymorphs which is not significant
at the 5 per cent level. This is not seen with the eosinophils.
THE EFFECT OF C8 AND C9 ON THE CHEMOTACTIC ACTIVITY OF C567
In one experiment (D) a sharp fall in chemotactic activity was observed in the presence
of C8 and C9. However, more extensive testing with a number of dilutions of C8 and C9
failed to repeat this one observation and taking all the observations together there is no
statistically significant effect for either neutrophils or eosinophils.
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(ii) With C8 but without C9
C56^C7 + 8
(iii) With C8 + C9
C56 + 9->C7 + 8
C56->C7->-C8 + 9 1/20
C56^C7-»C8 + 9 1/40
C56->C7->C8+ 9 1/50
C56->-C7->-C8 + 9 1/100
C56->-C7->C8 + 9 1/1000



































Activated serum 22-8 20-6 >30 41-6 34-8 >60 8-4 1-2 6-6
Each figure in this table is based on the mean of five readings taken on one chamber. The 95 per cent confidence
limits for these means are ±5-8 for the neutrophils and +1*9 for the eosinophils.
The figures for the ovalbumin controls are given as counted. In all other cases the ovalbumin blank for that
experiment has been subtracted from the count. The substantial variation in the blank appears to depend on the
particular batch of millipore membranes used.
THE EFFECT OF MAKING C567 IN THE PRESENCE OF EXCESS ERYTHROCYTES
There were four paired observations for neutrophils where in one, C56 was mixed with
excess E before the addition of the C7-containing reagent, thereby allowing the C567*
to bind to red cell membranes. The mean chemotactic activity of the G56-E-C7 was not
significantly different from that of the normal complement components. The formation of
C567 in the presence of E thus abolishes its chemotactic effect.
The single paired observation for eosinophils shows the same result.
The red cells taken from the chambers could be lysed by C8+9, showing that they had
been converted to EG567.
DISCUSSION
The data confirm the findings of Ward et al. (1966) that the trimolecular complex
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Comparison between groups A Means Significance A Means Significance
C567(89) v. C7, etc. 28-9 P<g0-001 5-1 P< 0-01
C567(89) v. C56 21-6 PcO-OOl 4-8 P<0-01
C567(89) v. C56 and C7, etc. 26-1 P-4 0-001 5-0 PcO-001
C56 v. C7, etc. 7-3 0-05<P<0-l 0-3 0-8<P<0-9
C56->7 v. C5fT-s-C7-*C8 + 9 0-3 0-8<P<0-9 0
C56-^C7 v. C56->-E-s-C7
(paired variates) 31-5 T^O-001 5-2 (One result only)
C56-s-E-*-C7 v. C7, etc. 3-6 0-4<P<0-5 1-3 (One result only)
C567 is chemotactic for neutrophils. A similar effect has been found for eosinophils.
The complex used was generated from two reagents—C56 and C7.
The C56 was fractionated from serum initially treated with zymosan and therefore pre¬
sumably highly chemotactic. The C56 preparations themselves, however, showed only
trivial—and dubiously significant—chemotactic activity. While this activity may rep¬
resent a property of C56 itself there are at least two other possible explanations. Firstly, it
is possible that the preparation is contaminated with other chemotactic factors. The
fractionation procedure which involves euglobulin precipitation, ion-exchange chromato¬
graphy and G-200 sephadex filtration makes it most unlikely that any low molecular
weight factors (e.g. C5a) are present but a trivial contamination with preformed C567 (89)
is difficult to exclude. Secondly it is possible that a little C567 is generated in the
diffusion chambers from C7 present in the leucocyte preparation. This is thought unlikely
since the effect is much the same if the leucocytes are washed twice or three times.
The C7 preparation, and the C8 and 9 preparations subsequently used, were free of
chemotactic activity.
The chemotactic activity generated by mixing C56 with C7 is not found if the C56 is
first mixed with excess sheep cells; thus allowing fixation of C567* to the cell membrane.
This control provides good evidence that the chemotactic activity is indeed a property of
the material that can be bound to cells (i.e. the C567 itself) and not of some factor pro-
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duced in the interaction. The availability of cell membranes or other hydrophobic surfaces
to bind G567* as it is formed may thus be important in determining the amount of C567
that appears free in solution to act as a chemotactic factor; and may help to explain the
discrepancy between the findings ofWard et al. (1966) on the one hand and of Sorkin and
his colleagues (Stecher and Sorkin, 1969; Wilkinson, Borel, Stecher-Levin and Sorkin,
1969) and of Snyderman, Shin, Phillips, Gewurz and Mergenhagen (1969) on the other
as to the role of C567 in the chemotactic activity generated in serum by complement
activation.
G8+9 even in great excess were without significant effect on the chemotactic activity
of C567 although it is known that these components do react with C567 in solution
(Lachmann and Thompson, 1970). This lack of effect is at variance with a result of Ward
et al. (1966) who found that the terminal components reduced chemotactic activity. Such
inhibition also occurred in just one ofour experiments but could not be repeated even with
the same reagents.
Although the data presented all deal with an entirely human system, one experiment
using rabbit peritoneal leucocytes gave essentially similar results.
Since a number of chemotactic factors are now known to be generated by antigen-
antibody interaction in serum, there would seem to be no essential contradiction between
finding chemotactic activity both in C567 and in C6-deficient rabbit serum.
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AN EOSINOPHIL LEUKOCYTE CHEMOTACTIC FACTOR OF
ANAPHYLAXIS*
By A. B. KAY,| Ph.D., DANIEL J. STECHSCHULTE,§ M.D., and
K. FRANK AUSTEN, M.D.
(From the Department of Medicine, Harvard Medical School, and the Robert B. Brigham
Hospital, Boston, Massachusetts 02120)
(Received for publication 26 October 1970)
The mechanism by which eosinophil leukocytes migrate into the site of immediate-
type hypersensitivity reactions has been difficult to study in vivo because of the
large numbers of variables in any experimental design. Certain of these difficulties
have been overcome by the use of a modification of the in vitro Millipore technique
of Boyden by which the eosinophilotactic properties of substances can be directly
measured. Using this technique, it was shown that guinea pig IgGi or IgG2, as pre¬
formed antigen-antibody complexes, could both generate from whole serum a factor
which was specifically chemotactic for eosinophils (ECF-C)1 and was apparently
identical to C5a (1).
An earlier report (2), using cell counts in guinea pig skin, had shown that both
IgGi and IgG2, as preformed complexes, also prepared the tissue for a subsequent
local eosinophilia 12 hr after injection. However, if antibody was first placed in the
skin and after a variable latent period the animal was challenged with antigen and
Evans blue dye intravenously (as in a usual passive cutaneous anaphylactic reaction),
IgGi but not IgG2 elicited a local eosinophil response 8-12 hr after the initial blueing
reaction (2).
It was the purpose of the present study to determine whether tissue, actively
sensitized or passively sensitized with IgGi, but in the absence of serum, can
* Supported by grant AI-07722 from the National Institutes of Health and a grant from
the John A. Hartford Foundation, Inc.
t T. K. Stubbins Research Fellow, Royal College of Physicians of London; recipient of a
Wellcome Research Travel Grant and a McCunn (Medical Research Traveling) Scholarship.
§ Postdoctoral Fellow of The Arthritis Foundation.
1 In this presentation, an eosinophil chemotactic factor (ECF) derived from whole guinea
pig serum by treatment either with antigen-antibody complexes (1) or with zymosan,2
which appears to be identical with C5a and therefore a product of the interaction of comple¬
ment proteins, is termed ECF-C. Material selectively attracting neutrophils, also of comple¬
ment origin (1) but having a larger molecular size, is termed NCF-C. A factor with eosino¬
philotactic activity appearing in association with immediate:type hypersensitivity reactions
and generated in the apparent absence of a complement requirement is designated ECF-A.
Other abbreviations used in this paper: DNP-BGG, dinitrophenol conjugates of bovine gamma
globulin; DNP-BSA, dinitrophenol conjugates of bovine serum albumin; SRS-A, slow react¬
ing substance of anaphylaxis; zym G/P, zymosan-treated guinea pig.
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release an eosinophilotactic agent after the addition of specific antigen and
whether such an agent" is the same or different from that produced from the
interaction of serum with preformed antigen-antibody complexes (1) or
zymosan.2 For this purpose, an in vitro model involving the release of chemi¬
cal mediators from guinea pig lung was used, which has been employed by
numerous workers as a model of immediate-type hypersensitivity in the guinea
pig (4-7). It has enabled the definition of an immunoglobulin mediating the
release of pharmacological agents (6, 7) and allowed the mediators themselves
to be quantitated (4, 7). This report, therefore, combines two in vitro systems,
namely the Millipore technique for measuring chemotaxis and an in vitro
model of anaphylaxis.
Materials and Methods
Materials were obtained as follows: histamine acid phosphate, zymosan, serotonin creat¬
inine sulphate, and succinic acid (Mann Research Labs. Inc., New York); bradykinin triace¬
tate (Sandoz Pharmaceuticals, Basel, Switzerland); prostaglandins PGEi, PGE2, and PGF2a
(generously supplied by Dr. John Pike of the Upjohn Co., Kalamazoo, Mich.); maleic acid
(Hopkin & Williams, Ltd., Chadwell Heath, Essex, England); blue dextran (Pharmacia
Fine Chemicals Inc., New Market, N. J.); glucagon (Nutritional Biochemicals Corporation,
Cleveland, Ohio); vitamin B12 (Wyeth Laboratories, Philadelphia, Pa.); glycogen (J. T. Baker
Chemical Co., Phillipsburg, N. J.); horse serum (Grand Island Biological Co., Grand Island,
N. Y.); ovalbumin, five times crystallized (Pentex Biochemical, Kankakee, 111.); and guinea
pig serum (Pel-Freez Biologicals, Inc., Rogers, Ark.).
Dinitrophenol conjugates of bovine gamma globulin (DNP-BGG) and bovine serum
albumin (DNP-BSA) were prepared according to the method of Benacerraf and Levine (8)
and contained 40 and 20 haptenic groups per molecule, respectively. Partially purified cobra
venom was prepared as previously described (9). The titer of "late acting" complement com¬
ponents was estimated in microliter plates using equal volumes of 1 X 108 sensitized sheep
erythrocytes prepared with the first component of guinea pig complement and the fourth
component of human complement (EAClBp4lm), SO effective molecules of guinea pig second
component (C2), and doubling dilutions of guinea pig serum as a source of terminal compo¬
nents. The plates were incubated for 30 min each at 30° and 37°C and centrifuged at 100
rpm for 5 min at 4°C. The 50% lytic endpoint was determined by inspection. The guinea
pig serum was obtained by cardiac puncture before and after the intravenous injection of 1
ml of cobra venom factor or Tyrode's solution.
Guinea pig IgGi and IgG2 7S immunoglobulin fractions were prepared as follows. Antisera
to ovalbumin were prepared in guinea pigs following the same injection schedule as previously
described for raising guinea pig antiserum to ferritin (2). The antiserum was fractionated by
diethylaminoethyl (DEAE)-cellulose chromatography (1). The functional purity of the IgGi-
and IgG2-containing fractions was tested by passive cutaneous anaphylaxis and by passive
hemolysis as described by Bloch et al. (10) and by immunoelectrophoresis and gel diffusion
using rabbit anti-7S IgG and specific anti-guinea pig IgGi (2). Passive hemagglutination was
performed as previously described (10).
Preparation of Lung Tissue for the In Vitro Release of Mediators.—Whole lung: The heart
and lungs from guinea pigs were excised and perfused free of visible blood with Tyrode's
solution as previously described (4). Animals were actively sensitized with DNP-BSA by the
2 A. B. Kay. Unpublished observations.
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method of Benacerraf et al. (11), or with ovalbumin in phenol (5), or by a single injection of
200 fxg of ovalbumin in complete Freund's adjuvant into each hind footpad. The lungs of ac¬
tively sensitized animals were challenged with 4 mg of antigen (ovalbumin or DNP-BGG)
via the pulmonary artery and the perfusate was collected for 30 min after antigen challenge.
The perfusates were placed on ice and assayed the same day for histamine and slow react¬
ing substance of anaphylaxis (SRS-A) according to the method of Brocklehurst (4), and for
chemotaxis as described below. Some perfusates were tested after a single freezing at — 70°C
and rapid thawing.
Lung fragments: In experiments using lung fragments the perfused tissue was sliced with
fine scissors, washed in Tyrode's solution, and divided into 300 mg portions using an overhead
weighing balance. With actively sensitized lung, the portions were suspended in 2.5 ml of
Tyrode's solution to which was added the antigen suspended in 0.5 ml of Tyrode's solution.
The samples were gently agitated in a water bath at 37°C. For passive sensitization, the lung
fragments were suspended in 1.8 ml volumes of fractions containing antibody at 37°C. After
the incubation period the fragments were washed twice and resuspended in 2.5 ml of Tyrode's
solution. Antigen was then added as for the actively sensitized lung. After incubation with
antigen the diffusates were removed with a Pasteur pipette and assayed for histamine, SRS-A,
and chemotaxis. In all studies using lung fragments the values for chemotaxis, histamine re¬
lease, and SRS-A release represent the mean of duplicate samples. For all three measurements
the values obtained with duplicate samples varied by less than 15%.
Some experiments with lung fragments were modified as follows. In experiments with
ethylenediaminetetraacetate (EDTA), the samples were washed once either with Ca++- and
Mg++-free Tyrode's, containing 5 mM EDTA, or in the case of the control samples, with
Ca++- and Mg^-free Tyrode's containing EDTA in which Ca++ and Mg++ had been re¬
placed before the addition of antigen. The reconstituted Tyrode's solutions were adjusted by
adding 6.8 mM of Ca++ and 1 mM of Mg+% The effect of succinate or maleate was studied
using 5 mM concentrations in Tyrode's solution adjusted to pH 7.4 with 0.1 N NaOH. Antigen
was added to actively or passively sensitized fragments 1 min after incubation of the lung
samples with maleate or succinate. The diffusate from the samples challenged with antigen
alone was tested for chemotaxis in the presence of 5 mM of succinate or maleate.
Measurement and Fractionation of Eosinophil Chemotactic Activity of the Anaphylactic Re¬
action Mixture.—
Measurement of chemotaxis: A modification of the Millipore technique of Boyden was used
as previously described (1). Guinea pig eosinophils were obtained by peritoneal lavage from
animals which had received multiple injections of horse serum (1). Neutrophils were harvested
from the peritoneal cavity of animals injected with glycogen 3-6 hr previously. For measuring
eosinophil migration an 8.0 fx pore size was used and for neutrophils 1.2 fx, 3.0 yu, and 8.0 fx
pore sizes were employed.
In the assay for chemotaxis, Tyrode's solution containing 0.5% ovalbumin was used in
both the cell and the test compartments. Zymosan-treated guinea pig (zym G/P) serum served
as a reference pool of material having both eosinophil and neutrophil chemotactic activity.
Zymosan which had been boiled and washed twice in distilled water was incubated for 30
min at 37°C with guinea pig serum using 20 mg of zymosan/ml of serum. The zymosan was
removed by centrifugation and the serum subsequently heated at 56°C for 30 min. Samples
were stored at — 70°C until used.
In experiments using the perfusate from whole lung, a value for the total chemotactic ac¬
tivity of the perfusate was expressed as V X C. V represented the volume of the perfusate
and C the percentage chemotaxis of 1 ml of perfusate as compared with 0.1 ml of a zymosan-
treated reference serum when both were tested against the same suspension of eosinophils.
The chemotactic activity of the diffusate from lung fragments was usually determined using
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0.6 ml volumes to which were added 0.1 ml of 5% ovalbumin and 0.3 ml of Tyrode's solution.
When the release of SRS-A and histamine was low, 0.9 ml volumes of the diffusate was used.
The chemotactic counts were expressed as the mean cell count of five high power fields (1).
Fractionation of chemotactic activity by gel filtration chromatography: A Sephadex G-2S col¬
umn (40 X 1 cm) was equilibrated using Tyrode's solution as a buffer. In each experiment,
1 ml of lung supernate was applied and 1 ml fractions were collected. The column was stand¬
ardized by preliminary fractionation of various substances of known molecular weight. The
tubes containing the highest concentration of blue dextran and vitamin B12 were read visually.
The peak of glucagon was recorded at 280 mg using a DU-2 Beckman spectrophotometer
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Fig. 1. Relation between the total amount of lung histamine released and the total chemo¬
tactic activity, V X C (see Methods), of the perfusate from sensitized lung following chal¬
lenge with antigen. The animals were killed at various time intervals following an initial
sensitizing injection. The data on individual animals sensitized with ovalbumin either in
complete Freund's adjuvant or phenol are depicted. Correlation coefficient = 0.48; number
of samples = 27; 0.02 > P > 0.01.
RESULTS
The Antigen-Induced, Release In Vitro of an Eosinophil Chemotactic Factor
from Actively Sensitized Guinea Pig Lung.—When guinea pig lungs from actively
sensitized animals were perfused free of visible blood via the pulmonary artery
and subsequently challenged with specific antigen, the perfusate contained, in
addition to histamine and SRS-A, a factor specifically chemotactic for guinea
pig eosinophil leukocytes. This eosinophil chemotactic factor of anaphylaxis has
been designated ECF-A. ECF-A was measured in the perfusate from animals
sensitized with either ovalbumin or DNP-BGG and challenged with oval¬
bumin or DNP-BSA, respectively. A single injection of ovalbumin given in
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complete Freund's adjuvant was slightly better than ovalbumin in phenol for
preparing guinea pigs for the specific antigen-induced release of histamine,
SRS-A, and ECF-A. Sensitization for the release of all these mediators was
observed 10 days after the administration of ovalbumin in phenol or complete
Freund's adjuvant but was not pronounced until 3 wk or later and was satisfac¬
tory up to 8 wk, at which time the study was terminated. The relationship
between the total quantity of specific antigen-induced release of histamine and
ECF-A from the lungs of each animal is shown in Fig. 1. A similar direct rela¬
tionship was also demonstrated between the total amount of SRS-A released
and the total ECF-A activity.
Studies were next carried out to determine whether ECF-A could be released
from fragments of actively sensitized lung, and the results are shown in Table I.
Addition of specific antigen to the lung fragments induced the release of hista¬
mine, SRS-A, and ECF-A, whereas no activities were detected in the absence
of antigen. A linear dose-response curve was obtained when dilutions of the
TABLE I
Antigen-Induced Release of ECF-A, Histamine, and SRS-A from Fragments of Actively
Sensitized Guinea Pig Lung
Eosinophil chemotaxis Histamine release SRS-A
mean cell counl MS/8 units/g
Lung + antigen 21.5 4 450
Lung + diluent 1.6 0 0
Zym G/P serum 18.6
anaphylactic diffusate were tested for chemotaxis (Fig. 2). Replicate samples of
sensitized lung fragments therefore provided a convenient test system for
investigating both the antibody involved and the mechanism of release of
ECF-A.
Selective Chemotactic Activity of the Anaphylactic Diffusate for Eosinophils.—
Anaphylactic diffusates were examined for eosinophil and neutrophil chemo¬
tactic activity using a suspension of cells rich in neutrophils but containing
12% eosinophils. Guinea pig serum treated with zymosan has both neutrophil
and eosinophil chemotactic activity (2) but attracted only neutrophils when
millipores with a 1.2 /j. or 3.0 pore size were used. With an 8.0 fj, pore size both
eosinophils and neutrophils migrate towards zym G/P serum, the ratio of
migrating eosinophils to neutrophils being almost the same as in the cell com¬
partment before migration commenced. Chemotactic activity of the lung dif¬
fusate was detectable only with an 8.0 ju pore size; 84% of the cells migrating
were eosinophils although only 12% were present in the cell compartment
(Table II). The experiment was repeated using diffusates from actively or pas¬
sively sensitized lung challenged with antigen. On these occasions, using a
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neutrophil-rich suspension and an 8.0 pt millipore size, 100% of the cells migrat¬
ing towards the anaphylactic diffusate were eosinophils. Taken together these
experiments demonstrated a selective chemotactic property for eosinophils of
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Fig. 2. Chemotactic dose-response curve following dilutions of lung diffusate containing
ECF-A.
TABLE II
Selective Chemotactic Property of an Anaphylactic Lung Diffusale Jor Eosinophil Leukocytes
Millipore size
Eosinophil and neutrophil chemotaxis
(mean cell count)*
1.2 u 3.0 u 8.0 u
Anaphylactic lung diffusate









Diluent 0 0 0
* Mean cell counts are expressed as (E + N)/T where E is the eosinophil count, N the
neutrophil count, and T the total mean cell count. The cell suspension contained 80% neutro¬
phils, 12% eosinophils, and 8% mononuclear cells.
Identification of the Antibody Mediating the Release of ECF-A from Guinea
Pig Lung.—Analysis of the sera obtained from the actively sensitized animals
shown in Fig. 1 revealed a relationship between the passive cutaneous anaphy¬
laxis (PCA) titer of the sera and the histamine release from the donor animals
after antigen challenge. The sera of animals whose lungs released large amounts
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of histamine and ECF-A had circulating antibody characteristic of IgGj. The
antibody was heat stable and gave a high 4 hr PCA titer which at 48 hr showed
a falling titer of one or two doubling dilutions. No evidence was found of an
IgE-type antibody.
Direct evidence that IgCh mediated the release of ECF-A was sought by
experiments in which lung fragments were passively sensitized with fractions
o. D.
(254mv)
0.01 M Phosphate Buffer
| ( pH 8.0)
Gradient Applied
(0.2 M Phosphate Buffer)
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(mhos x !03)
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0 0 0 330 1 50 1 50
Fig. 3. Ability of fractions of guinea pig IgGi and IgG2, obtained by DEAE-cellulose
chromatography, to passively sensitize lung fragments for the antigen-induced release of
ECF-A, histamine, and SRS-A. Antibody fractions 1-5 were diluted 1:50, fraction 6 was
diluted 1:5.
(Fr) of guinea pig 7S IgG. Biologic evidence for separation of IgGi and IgG2 is
shown in F:g. 3. Fractions 1-5 all agglutinated red cells which were passively
sensitized with ovalbumin, but only those cells sensitized with the IgG2 con¬
taining fractions (Fr 1, 2, and 3) hemolyzed on the addition of guinea pig com¬
plement. PCA titers were given only with the IgGi containing fractions (Fr 4,
5, and 6). Immunoelectrophoretic and gel diffusion studies with specific antisera
to guinea pig 7S IgGi demonstrated IgGi only in fractions 4, 5, and 6. Only
those fractions which contained IgGi (Fr 4, 5, and 6) prepared lung fragments
for the antigen-induced release of ECF-A, histamine, and SRS-A (Fig. 3). In
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these experiments, the dose of antigen, the time of sensitization with antibody,
and the time of incubation with antigen were arbitrarily chosen on the basis of a
previous study (6).
The heat stability of the antibody mediating the release of ECF-A was also
determined and provided further evidence that IgGi and not an IgE-type anti¬
body mediated its release. Fractions 4 and 5 were heated for 4 hr at 56°C and
when compared with the unheated fractions showed no difference in their
ability to mediate the release of histamine, SRS-A or ECF-A (Table III).
The Mechanism of Release of ECF-A.—
Optimal conditions for the release of ECF-A after passive sensitization of lung
fragments: The optimal conditions required for the release of ECF-A after
TABLE III
Kjfect of Heat on the Ability of IgGi to Prepare Guinea Pig Lung Fragments for the
Antigen-Induced Release of ECF-A, Histamine, and SRS-A*
Sensitization Eosinophil chemotaxis Histamine release SRS-A
mean cell count MS/S units/g
Fraction 4
Unheated 12.7 1.5 50
Heated 14.7 1.5 80
Fraction 5
Unheated 14.1 1.3 80
Heated 14.4 1.3 70
* Fractions were heated for 4 hr at 56°C and diluted 1:50. 0.9 ml volumes of lung effluents
were tested for chemotaxis to which was added 0.1 ml of 5% ovalbumin. Control samples
sensitized with fraction 4 or 5 but not challenged with antigen gave a background chemotactic
count of less than 1.5.
passive sensitization of normal lung were determined as follows. Using a
hr sensitization period and 200 gtg of ovalbumin/300 mg of lung tissue, a 1:50
dilution of an IgGi-containing fraction (Fr 4) was found to release more ECF-A
than a 1:5 or a 1:500 dilution. The time course of sensitization of tissue with
antibody is shown in Fig. 4. The release of ECF-A, histamine, and SRS-A was
detectable after 10 min of sensitization, reached a peak at 1 hr, and was main¬
tained for at least 2j>^ hr. In further experiments either a 1 hr or a 2j/£ hr
sensitization time was used. With regard to the time course of release, incuba¬
tion with antigen beyond 15 min did not result in greater release of ECF-A.
With a 1 hr sensitization period and a 1:50 dilution of fraction 4 (IgGi) 20 and
200 /ig of ovalbumin yielded greater release of ECF-A, histamine, and SRS-A
than 2 or 2,000 jug of ovalbumin/300 mg of lung (Fig. 5).
The effect of decomplementation with cobra venom factor: Animals were depleted
of circulating complement by an intravenous injection of a purified factor from
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cobra venom. Less than 5 % of the circulating complement level was detectable
10 hr after the administration of 2 units of purified cobra venom factor. Accord¬
ingly, actively sensitized animals were sacrificed 10 hr after injection, their
lungs removed, perfused, and sliced as described above and portions challenged
HOURS OF PASSIVE SENSITIZATION
Fig. 4. Time course of passive sensitization of lung fragments by an IgGi-containing frac¬













ANTIGEN DOSE, OVALBUMIN !gjg/300mg lung)
Fig. 5. Effect of antigen concentration on the release of ECF-A, SRS-A, and histamine from
guinea pig lung passively sensitized with IgGi (fraction 4 diluted 1:50).
with specific antigen. Table IV shows that there was no difference in the
amounts of ECF-A released from lungs of cobra venom-treated animals and
untreated animals. Although absolute histamine release in the actively sensi¬
tized animals appeared to be somewhat affected by venom treatment, the per
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cent release was similar in the two groups, being in animals one to six 31.0,
37.5, 31.0, 43.2, 36.2, and 35.2 respectively.
An experiment was also performed using normal animals whose circulating
complement levels were depleted with cobra venom factor and whose lungs in
the same manner as described were then passively sensitized with a 1:50
dilution of fraction 4 (IgGi). Virtually identical results were obtained as with
lungs from actively sensitized animals (Table IV).
TABLE IV
Effect of Complement Depletion In Vivo on the In Vitro Release of ECF-A, Histamine, and



























































































* With animals 1-6, 0.9 ml volumes of lung effluent were tested for chemotaxis and with
animals 7-11, 0.6 ml volumes were used. Lung fragments suspended in Tyrode's alone gave
background counts of less than 3.4 and 0 in the two experiments, respectively. Lungs were
passively sensitized for hr with a 1:50 dilution of fraction 4.
Inhibition and enhancement: A requirement of divalent cations for the release
of ECF-A was determined by experiments in which actively sensitized lung
was challenged with antigen in the presence of 5 mM of EDTA (Table V). In
the absence of calcium and magnesium ions, there was no release of ECF-A,
histamine, or SRS-A. Before testing for chemotaxis, calcium and magnesium
ions were added to the diffusates containing EDTA. Tyrode's EDTA in which
the divalent cations had been replaced served as a control in that this solution,
together with antigen, was used to challenge sensitized lung for ECF-A release
and the same solution was used in the chemotactic chamber. Replacement of
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cations fully restored antigen-induced release of ECF-A, histamine, and SRS-A.
The experiment was repeated with passively sensitized lung and gave the same
result.
The capacity of succinate and maleate to enhance the release of histamine and
SRS-A (12) was also sought in terms of ECF-A release. When actively sensi¬
tized lung was used, the enhancement of ECF-A release in the presence of 5
TABLE V
Effect of EI)TA on the Antigen-Induced, Release of ECF-A, Histamine, and SRS-A from
Actively Sensitized Guinea Pig Lung Fragments
Suspending medium for lung fragments Challenge che'motaxis "reSe"6 SRS-A
mean cell
count MS/S units/g
5 mM EDTA in Tyrode's Antigen 0.4 0 0
5 mM EDTA in Tyrode's with Ca++, Mg++ Antigen 20.4 9 100
replaced
Normal Tyrode's solution Antigen 24.6 8 110
Normal Tyrode's solution Tyrode's 3.6 0 0
TABLE VI
Effect of Succinate and Maleate on the Antigen-Induced Release of ECF-A and Histamine from
Actively Sensitized Guinea Pig Lung Fragments
Eosinophil chemotaxis (mean cell count)
Suspending medium for lung fragments Volume of lung diffusate assayed ^release16
0.6 ml 0.3 ml 0.15 ml
V>g/g
Antigen with 5 mM succinate in Tyrode's 30.8 30.2 16.2 3.0
Antigen with 5 mM maleate in Tyrode's 31.8 26.2 18.2 3.5
Antigen in Tyrode's (succinate)* 26.2 17.0 7.8 1.6
Antigen in Tyrode's (maleate) { 25.0 16.2 8.0 1.6
Tyrode's solution 1.2 0.0 0.0 0.0
* Succinate (5 him) added to chemotactic chamber.
t Maleate (5 mm) added to chemotactic chamber.
mM of succinate or maleate approximated the augmentation of histamine re¬
lease (Table VI). When the usual volume of 0.6 ml of lung diffusate was used,
the enhancement was less apparent than when smaller volumes were employed.
The experiment was repeated using lung fragments passively sensitized for
2)>"2 hr with a 1:50 dilution of IgGi (Fr 4); 5 mM succinate or maleate again
strikingly enhanced the release of ECF-A and histamine. SRS-A was not
measured in these enhancement experiments.
Differentiation of ECF-A from the Other Pharmacological Mediators of Ana-
TABLE VII
Experiments to Show that Histamine, Bradykinin, Serotonin, Prostaglandins E\ , E'i , and





Lung + antigen 27.1
Lung + Tyrode's 2.6
Lung + histamine (0.5 /xg/ml) 3.0
Lung + histamine (5 /xg/ml) 4.4
Histamine (0.5 jug/ml) 0.0
Histamine (5 fig/ml) 0.0
Experiment 2
Lung -f antigen 20.4
Lung + Tyrode's 0.0
Lung + bradykinin (0.01 /xg/ml) 0.0
Lung -|- bradykinin (0.1 /xg/ml) 0.0
Lung + bradykinin (1-0 /xg/ml) 0.0
Bradykinin (1.0 /xg/ml) 0.0
Lung + serotonin (0.01 /xg/ml) 0.0
Lung + serotonin (0.1 /xg/ml) 0.0
Lung + serotonin (1.0 p.g/ml) 0.0
Serotonin (1.0 /jg/ml) 0.0
Experiment 3
Lung + antigen 17.0
Lung + Tyrode's 3.2
Lung + PGEi (0.01 /xg/ml) 1.0
Lung + PGEi (0.1 /xg/ml) 2.0
Lung + PGEj (1.0 jL*g/ml) 0.6
PGEj (1.0 pg/m\) 0.0
Lung + PGE2 (0.01 jug/ml) 1.0
Lung + PGE2 (0.1 jug/ml) 1.0
Lung + PGE2 (1.0 /xg/ml) 1.4
PGE2 (1.0 /xg/ml) 0.0
Lung + PGF&, (0.01 /xg/ml) 1.0
Lung + PGF2« (0.1 /xg/ml) 1.0
Lung + PGF2a (1.0 /xg/ml) 3.4
PGF2« (1.0 /xg/ml) 0.0
Experiment 4
Lung + antigen 16.6
Lung + Tyrode's 0.0
Lung + SRS-A* (15 units/ml) 2.0
Lung + SRS-A (30 units/ml) 0.6
SRS-A (50 units/ml) 4.0
* The SRS-A was prepared by boiling an SRS-A ethanol extracted preparation in 0.05
N NaOH for 10 min. Before boiling in alkali the preparation had 50 units of SRS-A/ml and
an eosinophil chemotactic count of 61.0.
The histamine release in micrograms per milliliter of lung diffusate was 0.5, 0.25, 0.35,
and 0.13 in experiments 1, 2, 3, and 4, respectively.
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phylaxis.—In order to determine whether ECF-A was in fact an already recog¬
nized pharmacological agent, various chemical mediators of anaphylaxis were
tested directly for their ability to evoke the migration of eosinophils (Table
VII). It was found that histamine, bradykinin, serotonin, and prostaglandins
PGEi, PGE2, and PGF»a were not chemotactic for eosinophils per se; and,
furthermore, when incubated with sensitized lung in the absence of antigen,
these agents did not secondarily affect the release of ECF-A. The 0.5 /ug dose
of histamine used in experiment 1 was comparable to the amount of histamine
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Pig. 6. Effect on ECF-A and SRS-A activity of boiling in acid or alkaline solutions.
Some crude preparations of SRS-A were chemotactic for eosinophils. These
were obtained by extraction of lung diffusates in 80% ethanol, removal of the
precipitate by centrifugation, and evaporation to dryness of the supernate
under vacuum using a rotary evaporator. The extracted material was reconsti¬
tuted in distilled water. It was possible, however, to differentiate ECF-A and
SRS-A activity by boiling the crude material in alkaline solution. Since it had
been previously reported that SRS-A survives boiling in 0.05 n NaOH but not
in 0.05 n HCI (13), the behavior of ECF-A under these conditions was investi¬
gated. As seen in Fig. 6, ECF-A activity rapidly disappeared after boiling in
acid or neutral solution and even more rapidly when boiled in alkali. In these
experiments, the preparations were immediately adjusted to neutral pH before
testing for SRS-A and chemotaxis. Thus by boiling in alkali, it was possible to
destroy all ECF-A without influencing SRS-A activity (Table VII). It was also
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possible to separate ECF-A from SRS-A by Sephadex G-25 chromatography
(Fig. 7, vide infra). The peak of SRS-A activity was usually ill defined but ap¬
peared after ECF-A.
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Fig. 7. Sephadex G-25 chromatography of anaphylactic lung diffusate and zymosan-
treated guinea pig serum. Even numbered fractions from tubes 10-48 were tested for chemo-
taxis.
traction suggesting that its biological activity is not associated with a large
molecule; for this reason, a lung diffusate having high chemotactic activity was
applied to a column of Sephadex G-25. In each of six experiments, five using
material from actively sensitized lung and one from a passively sensitized lung,
the peak of eosinophil chemotactic activity eluted after the fractions containing
the molecular marker glucagon (mol. wt. 3485) and vitamin B12 (mol. wt. 1357)
but before histamine acid phosphate (mol. wt. 310) (Fig. 7). Thus, the molecu¬
lar weight of ECF-A is thought to be approximately 500-1000.
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In order to calculate the per cent recovery of ECF-A following passage
through a Sephadex column, advantage was taken of the linear dose response
for chemotaxis when dilutions are made of material containing ECF-A activity
(Fig. 2). In this way, it was possible to obtain an arbitrary chemotactic value
for an ECF-A preparation in relation to one preparation of target cells. When
the same cells were tested against fractions of the ECF-A preparation, it was
possible to demonstrate a 100% recovery of ECF-A activity after passage
through a column of Sephadex G-25.
It has been shown that ECF-C, produced either by treating whole serum with
antigen-antibody complexes (1) or with zymosan,2 has a molecular weight of
approximately 15,000. As shown in Fig. 7, ECF-C activity from zymosan-
treated serum was excluded by Sephadex G-25.
DISCUSSION
The capacity of actively (Table I) or passively (Fig. 3) sensitized guinea pig
lung to react with antigen to release a factor chemotactic for eosinophil leuko¬
cytes (ECF-A) has been demonstrated. In all experiments, the release of ECF-A
was also accompanied by the release of both histamine and SRS-A. Indeed, the
release of all these mediators exhibited a similar reponse in terms of the time
course of passive sensitization (Fig. 4), the effect of antigen dose (Fig. 5), and
the time course of release. Furthermore, the release of ECF-A was dependent
on divalent cations (Table V) and was strikingly enhanced by the presence of
succinate or maleate (Table VI). These features are again characteristic of the
release of histamine and SRS-A (12, 14).
It has previously been demonstrated that guinea pig IgGi can passively
sensitize guinea pig lung slices for the antigen-induced release of histamine (6)
and SRS-A (7), and this same immunoglobulin has been shown to mediate the
release of ECF-A (Fig. 3). The fractions which prepared tissue for ECF-A re¬
lease (Fr 4 and 5) lost no activity after heating at 56°C for 4 hr (Table III), a
property characteristic of IgGi but not of an IgE-like immunoglobulin. The
IgG2-containing fractions, having hemagglutinating activity virtually equal to
that of IgGi fractions, failed to prepare lung fragments for the antigen-induced
release of histamine, SRS-A, or ECF-A (Fig. 3).
Since guinea pig IgGi appears capable of mediating the release of several
pharmacologic agents, it was necessary to exclude the possibility that ECF-A
was an already recognized chemical mediator or was released secondary to the
presence of other reaction products recognized herein. Histamine, SRS-A, and
the prostaglandins PGEi, PGE2, and PGF2„ were not eosinophilotactic per se;
neither was ECF-A detected after the incubation of these agents with sensitized
lung in the absence of antigen (Table VII). Studies with sensitized guinea pig
lung (15, 16) have shown the release of kallikrein after antigen challenge; this
enzyme was not studied herein, but it was demonstrated that the product of its
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reaction with kininogen, namely bradykinin, was not itself chemotactic for
eosinophils and did not secondarily affect the release of ECF-A (Table VII).
Similar findings were observed with serotonin (Table VII).
Since eosinophilotactic activity could still be detected after extraction of
anaphylactic lung diffusate in 80% ethanol and evaporation to dryness, the
possibility was considered that SRS-A contained chemotactic activity. Reasons
for considering ECF-A as separate from SRS-A are that SRS-A survived boiling
in alkaline solution for 20 min whereas ECF-A activity was abolished by this
procedure (Fig. 6); and in addition SRS-A and ECF-A could be separated by
gel filtration (Fig. 7).
The finding that ECF-A generation is a consequence of antigen-antibody
interaction and dependent upon the presence of divalent cations raises the ques¬
tion of whether it is identical with the eosinophilotactic factor formed in guinea
pig serum following treatment with immune complexes (1) or zymosan.2
ECF-C produced in vitro by antigen-antibody complexes, prepared either with
IgGx or IgG2 and antigen, requires the participation of complement since ECF-C
is not generated from serum heated at 56°C for 30 min or from ammonia-
treated serum or from serum activated in the presence of 0.01 m EDTA (1). No
evidence was found, however, that ECF-A generation was dependent on an
intact complement system. Guinea pig lung, perfused free of visible blood and
then cut in slices and thoroughly washed was capable of being passively sensi¬
tized with an IgGi-containing fraction (even after heating for 4 hr at 56°C) for
the subsequent antigen-induced release of ECF-A (Table III, Fig. 3). Further¬
more, depleting the donor animals of 95 % of the circulating complement level
had no effect on the capacity of their isolated lung fragments to yield ECF-A
after passve sensitization and antigen challenge (Table IV). Decomplementa-
tion was accomplished by the administration of purified cobra venom factor, a
procedure which depletes C3 and to a lesser extent the complement components
acting thereafter (17, 18). This maneuver also had no effect on the antigen-in¬
duced release of ECF-A from lung fragments from actively sensitized animals
(Table IV).
ECF-A and ECF-C can be distinguished not only in terms of the complement
requirement for their generation but also by their apparent size differences as
determined by gel filtration. On Sephadex G-25, ECF-C is excluded as shown
by the molecular marker blue dextran (Fig. 7), consistent with its previously
reported molecular weight of approximately 15,000 (1). In contrast, ECF-A ap¬
peared after the molecular marker vitamin Bi2 (mol. wt. 1357) but before hista¬
mine acid phosphate (mol. wt. 310), suggesting a molecular weight of approxi¬
mately 500 -1000 (Fig. 7). It should further be noted that the complete recovery
of ECF-A in the diffusate introduced onto the Sephadex column indicated that
the eosinophilotactic activity of the lung diffusate is unlikely to be a mixture of
molecules having appreciable size differences.
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In a cell suspension containing predominantly neutrophils, only eosinophils
migrated towards ECF-A whereas zymosan-treated serum, which contains both
ECF-C and NCF-C (l),2 attracted both neutrophils and eosinophils in the
same proportion as was present in the original cell suspension (Table II). Thus,
ECF-A represents a hitherto undescribed agent which, like ECF-C, selectively
attracts eosinophil leukocytes.
SUMMARY
The capacity of actively or passively sensitized guinea pig lung to react with
antigen to release a factor specifically chemotactic for eosinophil leukocytes
(ECF-A) has been demonstrated. The release of ECF-A was also accompanied
by the elaboration of both histamine and SRS-A and the appearance of all these
mediators exhibited a similar response in terms of the time course of passve
sensitization, the effect of antigen dose, the time course of release, divalent ca¬
tion dependence and enhancement by the presence of succinate or maleate.
Decomplementation by the administration of purified cobra venom factor had
no effect on the antigen-induced release of ECF-A from actively or passively
sensitized lung fragments.
When fragments of guinea pig lung were passively sensitized with fractions of
guinea pig 7S IgG, only the IgGi-containing fractions prepared tissue for the
antigen-induced release of ECF-A. Histamine, SRS-A, bradykinin, serotonin,
and the prostaglandins PGEi, PGE2, and PGF2„ were not eosinophilotactic
per se; neither was ECF-A detected following the incubation of these agents
with sensitized lung in the absence of antigen.
Both eosinophilotactic activity and SRS-A survived extraction in 80%
ethanol and evaporation to dryness. SRS-A, however, withstood boiling in alka¬
line solution for 20 min, whereas ECF-A activity was abolished by this pro¬
cedure. SRS-A and ECF-A could also be separated by gel filtration. ECF-A ac¬
tivity was completely recovered following its passage through a column of
Sephadex G-25 and had an estimated molecular weight of between 500 and 1000.
On the basis of size and a formation mechanism independent of the complement
system, ECF-A is distinguishable from a previously described complement-de¬
pendent eosinophilotactic factor (ECF-C). Thus, ECF-A represents a hitherto
undescribed agent which selectively attracts eosinophil leukocytes.
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The IgE-Mediated Release of an Eosinophil Leukocyte Chemotactic Factor from
Human Lung1
A. B. KAY2 AND K. FRANK AUSTEN
From the Departments of Medicine, Harvard Medical School, and the Robert B. Brigham Hospital,
Boston, Massachusetts
We have recently demonstrated the capacity of
actively or passively sensitized guinea-pig lung
to react with antigen to release a factor specifi¬
cally ehemotactic for guinea-pig eosinophil
leukocytes (ECF-A) (1). The antibody mediating
the release of ECF-A was shown by fractionation
studies to be of the immunoglobulin class IgGi,
which also prepares guinea-pig tissue for passive
cutaneous anaphylaxis (PCA) and the release of
histamine and slow reacting substance of anaphy¬
laxis (SRS-A) from lung fragments. Histamine,
SRS-A and other chemical mediators of anaphy¬
laxis failed to attract eosinophils. ECF-A was
released from lung tissue by a mechanism in¬
dependent of the complement system, had an
estimated molecular weight of between 500 and
1000, and therefore differed from a previously
described complement-dependent eosinophilo-
tactic factor (ECF-C) (2).
The present report describes the recognition of
a comparable material from human lung, the
release of which is shown to be mediated by IgE.
MATERIALS AND METHODS
Histamine acid phosphate, serotonin creatinine
sulphate, bradykinin triacetate, prostaglandins
PGEi, PGE2 and PGF2a and ovalbumin were
obtained as previously described (1), as was the
source of ragweed antigen E and the serum from
the ragweed-sensitive patient EW (3). Heparin
(1000 units/ml) was purchased from Organon,
Inc., West Orange, N. J. Serum from a ragweed-
sensitive individual AR, serum AR absorbed with
rabbit anti-IgE and monospecific rabbit anti-
IgE and anti-IgG were generously supplied by Dr.
K. Ishizaka. Serum AR was absorbed with the
y globulin fraction of monospecific rabbit anti-
1 This work was supported by Grant Al-07722
from the National Institutes of Health and a grant
from the John A. Hartford Foundation, Inc.
2 T. K. Stubbins Research Fellow, Royal College
of Physicians of London, and recipient of a
Wellcome Research Travel Grant and a McCunn
(Medical Research Traveling) Scholarship.
IgE coupled to Sepharose 2B (Mann Research
Laboratories, New York, N. Y.) according to a
previous report (4). PCA reactions in monkey skin
and the measurement of IgE were carried out as
previously described (5, 6). Human plasma
kallikrein was prepared by diethylaminoethyl
(DEAE) cellulose chromatography (7).
Human lung, obtained at pneumonectomy, was
dissected free of pleura, bronchi and large blood
vessels, sliced into 50- to 100-mg fragments by
hand, and washed with Tyrode's solution until
the surrounding fluid was free of blood. Frag¬
ments were divided into 300-mg portions using
an overhead balance, suspended in 2-ml volumes
of diluted serum or Tyrode's buffer, and passively
sensitized for 18 hr at room temperature. The
sera from the ragweed-sensitive individuals EW
and AR were diluted 1:4 and 1:5, respectively.
A 1:4.5 dilution of serum AR absorbed with
anti-IgE was used to approximate the equivalent
IgG concentration of the unabsorbed serum.
Following the sensitization period, the lung frag¬
ments were washed three times with Tyrode's
solution and resuspended in 3.0 ml Tyrode's
buffer containing 0.2 jug ragweed antigen E/ml.
Lung diffusates were harvested 45 min after
antigen challenge, placed on ice, and assayed the
same day for histamine and SRS-A as previously
described (8) and for chemotaxis as indicated
below. Some diffusates were tested after a single
freezing at —70°C and rapid thawing. Sephadex
G-25 chromatography of anaphylactic diffusate
was performed as described (1).
Chemotaxis was measured by a modification
of the Millipore technique of Boyden (2). Human
peripheral blood, rich in eosinophils, was drawn
into a syringe containing 50 units of heparin/ml
and transferred to plastic test tubes. Red blood
cells were allowed to settle for 90 min at 37°C,
after which the leukocyte-rich supernatant was
removed and centrifuged for 5 min at 100 X G.
The cells were washed once, resuspended in
Tyrode's solution containing 0.5% ovalbumin,
and adjusted to a final concentration of 1.5 X 10°
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TABLE I












Eosinophils Neutrophils Eosinophils Neutrophils Eosinophils Neutrophils
G. It. Rheumatoid arthritis 73 19 28 1 2 38
A. K. Hay fever 8 40 23 10 0 35
J. N. Drug hypersensitivity 20 52 20 2 2 >50
F. F. Carcinomatosis and pos¬ 14 08 31 2 2 36
sible drug hypersensi¬
tivity
D. P. Extrinsic asthma 14 48 20 17 0 >50
K. T. Extrinsic asthma 11 52 10 2 0 >50
leukocytes/ml. Chemotactic experiments were
performed using a 3.0 p Millipore filter. In most
experiments cells from the patient G.R. were
used (Table I). Unless stated otherwise, 0.9 ml
volumes of lung diffusate to which were added 0.1
ml of 5% ovalbumin were tested for chemotaxis.
Three-tenths-milliliter volumes of the kallikrein
preparation were used to which were added 0.6
ml of Tyrode's solution and 0.1 ml of 5% oval¬
bumin. The chemotactic counts were expressed
as the mean cell count of five high-power fields
(1, 2).
RESULTS
The anaphylactic diffusate from human lung,
passively sensitized with sera from ragweed-
sensitive individuals and subsequently challenged
with ragweed antigen E, contained histamine,
SRS-A and a factor that selectively attracted
eosinophil leukocytes (ECF-A). Peak release of
ECF-A was observed 15 to 45 min after antigen
challenge. A linear dose response curve was ob¬
tained when dilutions of the anaphylactic diffu¬
sate were tested for chemotaxis (Fig. 1). No
chemotactic activity was detected in the diffu-
sates of passively sensitized lung challenged with
Tyrode's solution or of unsensitized lung in¬
cubated with ragweed antigen E.
The selectivity of ECF-A for peripheral
blood eosinophils obtained from patients with
an eosinophilia due to a variety of causes is shown
in Table I. In all of the cases investigated the
cells migrating towards the anaphylactic diffusate
were predominantly eosinophils, whereas when
the same cell suspensions were tested against




VOLUME OF LUNG DIFFUSATE, ml
Figure 1. The specific antigen-induced release
of an eosinophil chemotactic factor from passively
sensitized human lung. The lung diffusate showed
a chemotactic dose-response curve. The perfusate
from lung sensitized with antibody and challenged
with antigen (•) also contained 000 ng/ml of
histamine and 200 units/ml of SRS-A. No mediator
release was detected with unsensitized lung
incubated with antigen (O) or sensitized lung
incubated with Tyrode's solution (A).
ECF-A was distinguished from histamine,
serotonin, bradykinin and the prostaglandins
PGEi, PGE2 and PGF2a since these agents
alone, in concentrations of 0.01, 0.1 and 1.00
pg/ml, were unable to affect eosinophil migration
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in vitro. Because of their similar size, human
ECF-A and SRS-A could not be fully separated
by passage through a column of Sephadex G-25.
The stability of ECF-A and SRS-A differed
(Table II). ECF-A was preserved following lyo-
philization and boiling in acid solution, whereas
50% of SRS-A activity was lost. In contrast,
ECF-A did not survive boiling in alkaline solu¬
tion whereas SRS-A activity was fully retained.
The evidence that IgE was the immuno¬
globulin class which prepared human lung for
the antigen-induced release of ECF-A included
heat lability, loss of effect with specific absorp¬
tion and response of the lung tissue to anti-IgE.
Serum EW, heated for 4 hr at 56°C, was com¬
pared with unheated serum for its ability to
prepare lung fragments for antigen-induced
mediator release. Unheated serum gave an
eosinophil chemotactic count of 38 and released
3.5 ftg/g of histamine and 500 units/g of SRS-A.
The corresponding figures for heated serum were
3, 0.03 and 0, respectively. When serum AR was
selectively absorbed with a rabbit antiserum to
IgE, it no longer passively sensitized lung frag¬
ments for the subsequent antigen-induced release
of ECF-A, histamine and SRS-A (Table III).
Absorption removed more than 99% of the total
TABLE 11
The effect of ECF-A and SRS-A in human lung
anaphylactic lung diffusate of lyophilization
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IgE and the serum no longer sensitized monkey
skin for passive cutaneous anaphylaxis; the
levels of IgG and IgA were virtually unchanged.
The release of ECF-A, histamine and SRS-A
was also affected by the reverscd-type reaction
employing a specific antibody to IgE prepared in
the rabbit. When lung was incubated with anti-
IgE at a concentration of 0.1 /ug protein/ml, the
diffusate gave an eosinophil chemotactic count
of 13.8 and contained 1.85 fig of histamine/g of
lung and 800 units/g of SRS-A. Anti-IgE alone
was not chemotactic. Lung incubated with a
specific anti-IgG, even at a protein concentration
10 times that of anti-IgE, did not affect mediator
release. With human lung the release of chemical
mediators by anti-IgE did not require prior
passive sensitization of tissue with reaginic
serum, presumably because IgE was present on
the tissue.
DISCUSSION
The ability of passively sensitized human lung
to release a factor specifically chemotactic for
human eosinophils (ECF-A) has been demon¬
strated following challenge with specific antigen
(Fig. 1.). A linear dose-response curve was ob¬
tained when dilutions of the anaphylactic
diffusate were tested for chemotaxis. Peripheral
blood eosinophilia in relation to a variety of
clinical problems reacted similarly to human
lung anaphylactic diffusates (Table I). In con¬
trast, only the neutrophils from these patients
migrated towards a partially purified plasma
kallikrein preparation, as previously described
(9).
Human ECF-A was distinguished from hista¬
mine, bradykinin, serotonin and the prosta¬
glandins PGEi , PGE2 and PGF2a since these
agents were not chemotactic per se. After treat¬
ment of the lung diffusate with 80% ethanol and
evaporation to dryness, the reconstituted ma¬
terial contained SRS-A and ECF-A activity
TABLE 11T
The capacity of IgE to mediate the release of ECF -A. histamine and Sh'S-A from human lung
Serum Used Immunoglobulin Concentration PCA Titer EosinophilChemotaxis Histamine SRS-A
for Sensitization (Monkey Skin) (Mean Cell Release Release
IgG IgA IgE Count t
mg/tnl mg/ml US/ml MS/« units/g
Unabsorbed 15.50 2.12 7.40 128 15.2 3.25 750
Absorbed 13.50 1.80 0.05 0 0 0 0
None 0 0 0
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which chrornatographed together on Sephadex
G-25 in the same region as guinea-pig SRS-A
(1). Human SRS-A and ECF-A could, however,
be separated functionally since the former was
partially destroyed by lyophilization and boiling
in acid solution and the latter by boiling for 10
min in alkaline solution (Table II).
The antigen-induced release of ECF-A from
human lung was mediated by IgE. Serum ab¬
sorbed with anti-IgE no longer passively sensi¬
tized lung for the antigen-induced release of
ECF-A, histamine or SRS-A (Table III), and
anti-IgE but not anti-IgG released ECF-A,
histamine and SRS-A from normal lung.
SUMMARY
Following antigenic challenge of human lung
passively sensitized with serum from a ragweed-
sensitive donor, the anaphylactic diffusate con¬
tained, in addition to histamine and slow reacting
substance of anaphylaxis (SRS-A), a factor
selectively chemotactic for human eosinophils
(ECF-A). ECF-A evoked the migration of
eosinophils obtained from the blood of a number
of donors with eosinophilia. ECF-A was distin¬
guished from histamine, bradykinin, serotonin,
the prostaglandins PGEi , 15GE2 and PGF2„ and
from SRS-A. The immunoglobulin mediating the
release of ECF-A was IgE. Heating or absorp¬
tion of ragweed-sensitive serum with a rabbit
antibody specific for IgE removed its ability to
passively sensitize lung for mediator release, and
anti-IgE released ECF-A from normal lung.
ECF-A, a unique mediator of the anaphylactic
reaction, has been identified in human lung tissue.
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Summary. ECF-A and C5a were chemotactic both for eosinophils and neutro¬
phils. However, when eosinophils comprised approximately 10 per cent or more
of a mixed leucocyte population, they were preferentially attracted by both of these
agents.
Marked synergism was observed between ECF-A and C5a in their ability to
attract eosinophil leucocytes.
INTRODUCTION
In previous reports, two chemotactic factors have been described which selectively
attract eosinophil leucocytes from a mixed cell population. The first factor (ECF-C)
required the presence of an intact complement system and was generated by incubating
fresh guinea-pig serum with antigen-antibody complexes prepared from homologous
IgGt or IgG2 (Kay, 1970). By Sephadex G-100 chromatography, it was shown that
ECF-C had an estimated molecular size of approximately 15,000 and was thought
therefore to be identical to a fragment cleaved from the fifth component of complement
(C5a). The second factor, an eosinophil chemotactic factor of anaphylaxis (ECF-A)
was released by antigen challenge of actively sensitized lung or lung passively sensitized
with IgGx (Kay, Stechschulte and Austen, 1971). The release of ECF-A did not require
the presence of complement and, on the basis of a molecular size of between 500 to 1000,
it was shown to be distinct from ECF-C.
C5a is also known to attract neutrophils (Shin, Snyderman, Friedman, Mellors and
Mayer, 1968; Ward and Newman, 1969) and monocytes (Snyderman, Shin and Hausman,
1971; Hausman, Snyderman and Mergenhagen, 1972), and a purpose of the present
report is to extend studies on the chemotaxis of eosinophils using C5a derived from
highly purified C5 and to examine further selective chemotaxis of eosinophils by ECF-A.
In addition, studies have been conducted on the relationship between ECF-A and C5a
in terms of their ability to act synergistically in eosinophil chemotaxis.
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MATERIALS AND METHODS
Materials were obtained as follows. Histamine acid phosphate, cytochrome C (BDH
Chemicals Ltd, Poole, England); blue dextran (Pharmacia Fine Chemicals, Uppsala,
Sweden); vitamin B12 (Glaxo Laboratories, Ltd, Greenford, England); glycogen, oval¬
bumin five times crystallized (Koch-Light Laboratories, Colnbrook, England); and horse
serum (Wellcome Reagents Ltd, Beckenham, England).
Preparation ofECF-A
Guinea-pig anaphylactic lung diffusate was obtained from actively sensitized guinea-pig
lung perfused free of blood and challenged with ovalbumin as previously described (Kay
et al., 1971). The cell free diffusate was extracted in 80 per cent ethanol, freed ofprecipitate
by centrifugation, evaporated to dryness under vacuum using a rotary evaporator,
reconstituted to one-tenth of the volume of the starting material in distilled water and
centrifuged again at 15,000 g for 30 minutes. One millilitre of the concentrated lung
diffusate was applied to a column of Sephadex G-25 (95x3-5 cm) and alternate 2-ml
fractions tested for eosinophil and neutrophil chemotaxis using 0-2-ml volumes. For
calibrating the column, the tubes containing the highest concentration of blue dextran
and vitamin B12 were read visually. Histamine and slow reacting substance of anaphylaxis
(SRS-A) were assayed as previously described (Kay et al., 1971).
Preparation of C5a
Guinea-pig C5 was prepared by isoelectric precipitation, diethylaminoethyl (DEAE)
and carboxylmethyl (CM)—cellulose chromatography and hydroxylapatite chromato¬
graphy as previously described (Cook, Shin, Mayer and Laudenslayer, 1971). The C5
preparation contained approximately 400 gg of protein per ml and was treated with 4 ng
of trypsin for 30 minutes at 25°. The reaction was stopped with 8 gg of soybean trypsin
inhibitor (SBTI). The total volume of trypsin and SBTI added was 1/50 of the volume of
C5. This mixture was used as the source of C5a. In experiments designed to show that
C5a was chemotactic for both eosinophils and neutrophils, 0-3 ml of trypsinized C5 was
applied to a column of Sephadex G-100 (40 x 1-0 cm) and 1-ml fractions collected.
Measurement of chemotaxis
A modification of the Millipore technique of Boyden was used as previously described
(Kay, 1970). Guinea-pig eosinophils were obtained by peritoneal lavage from animals
which had received multiple injections of horse serum. Neutrophils were harvested from
peritoneal cavity of animals injected with glycogen 3-6 hours previously. Eosinophil
and neutrophil migration were both measured using an 8-0-ji pore size, since previous
studies with guinea-pig peritoneal cells had shown that this pore size gave full expression
of eosinophil and neutrophil chemotaxis towards ECF-A and 'activated guinea-pig
serum'. Under these conditions background counts with diluent alone were zero. Neutro¬
phils or eosinophils were used at a concentration of 2 x 106 cells/ml. Tyrode solution
containing 0-5 per cent ovalbumin was used as the diluent throughout.
RESULTS
EOSINOPHIL AND NEUTROPHIL CHEMOTACTIG ACTIVITY OF EGF-A AND C5a
In previous studies we have shown that compared with eosinophils, there was minimal
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chemotaxis of neutrophils towards an anaphylactic lung diffusate (Kay et al., 1971).
When the concentrated anaphylactic diffusate was applied to a column of Sephadex G-25,
neutrophil and eosinophil chemotactic activity eluted in the same position thus providing
some evidence that both activities were a function of ECF-A (Fig. 1).
When trypsinized C5 was applied to a column of Sephadex G-100, eosinophil and
neutrophil chemotactic activity eluted together (Fig. 2). The peak of activity for both
cell types eluted at approximately the same position as the cytochrome C marker (mol. wt
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Fig. 1. Sephadex G-25 chromatography ofan anaphylactic diffusate. Even numbered tubes were tested
for (o) neutrophil chemotaxis and odd numbered tubes tested for (•) eosinophil chemotaxis. Although
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Fig. 2. Sephadex G-100 chromatography of trypsinized Co showing the chemotactic response of fractions
towards ( ) eosinophils and ( ) neutrophils.
ECF-A free of antigen, histamine, and SRS-A after Sephadex G-25 gel-filtration and
C5a derived from highly purified C5 were then tested for their ability to attract eosinophils
and neutrophils. The neutrophil suspension contained less than 1 per cent of eosinophils.
The eosinophil preparation contained 52 per cent eosinophils, the remainder being
only mononuclear cells. The cell counts were adjusted so that each preparation had the
same number of eosinophils and neutrophils respectively. The total white cell count of the
eosinophil preparation was therefore approximately twice that of the neutrophil suspen¬
sion. The ability of these two cell preparations to migrate towards C5a is shown in Fig. 3.
About ten times as many neutrophils migrated compared to eosinophils. With ECF-A,
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however, eosinophil chemotaxis was predominant; very little neutrophil chemotaxis
being noted even with the highest concentration of ECF-A (Fig. 3).
100
Fig. 3. The capacity of (o) neutrophils and (•) eosinophils to respond in chemotaxis to increasing
doses of C5a and ECF-A. No chemotaxis was observed with untreated C5 or with the trypsin/SBTI




E 52 42 32 22 12 4
NO 18 36 54 72 90
Cells in test comportment (%) prior to migration
Fig. 4. The effect of alterations in the percentage of (■) eosinophils (E) and (□) neutrophils (N) in the
test compartment on the chemotactic response to 0-8 ml of ECF-A.
THE EFFECT OF VARIATIONS IN PERCENTAGE OF EOSINOPHILS AND NEUTROPHILS
An eosinophil preparation containing no neutrophils was mixed in varying proportions
with a suspension of neutrophils having only 4 per cent of eosinophils. When these cell
preparations and their mixtures were tested against ECF-A, it was found that as the per¬
centage of eosinophils increased this cell type was selectively attracted (Fig. 4). The







E 45 36 27 18 9 I
NO 19 38 57 76 95
Cells in test comportment (%) prior to migration
Fig. 5. The effect ofalterations in the percentage of (■) eosinophils (E) and (□) neutrophils (N) in the
test compartment on the chemotactic response to C5a derived from 40 fjg of C5.
Fig. 6. Synergism between (a) EGF-A and C5a. A dose response for (•) C5a, (o) EGF-A and a
mixture of the two. The concentration of C5a is defined as in Fig. 3.
threshold for predominant eosinophil attraction was as low as 12 per cent. A similar
effect was found with C5a (Fig. 5) with the threshold being 9 per cent in the experiment
depicted. When there was no competition from eosinophils, neutrophils migrated toward
both C5a and ECF-A.
SYNERGISM BETWEEN EGF-A AND C5a
Since ECF-A and C5a are distinct both in their molecular size and formation mechan¬
ism, it was of interest to determine the effect of combining the two agents in eosinophilo-
taxis. As seen in Fig. 6, the cell counts obtained after mixing were three times or greater
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than that which would have been expected by summation of counts when the agents
were assayed alone. This suggested that ECF-A and C5a acted synergistically in their
ability to attract eosinophils.
More evidence of synergism was obtained in the experimental designs shown in Fig. 7.
Chemotaxis towards ECF-A was examined in a dose-response fashion with and without
the presence of a dose of C5a which gave a low chemotactic count. The counts obtained
with the mixtures were far higher than would have been expected by summation (Fig. 7a).
A dose-response study of C5a with a low concentration ofECF-A again revealed an increase
in chemotactic counts far greater than would have been expected by addition. Since the
preparation of C5a contained a trace of trypsin and SBTI, it was necessary to determine
that this enzyme and inhibitor were not contributing to the synergism observed with
ECF-A. Trypsin and SBTI in equivalent concentrations had no effect on the dose-















A 1 r r





Fig. 7. Synergism between ECF-A and C5a. (a) Dose response for ECF-A (o) is compared with the
same volumes of ECF-A to which 5 /ig of C5a (A) giving a chemotactic count of 8 was added, (b) A
dose response of C5a (•) is compared with the same volumes of C5a to which 0-125 ml of ECF-A (a)
giving a chemotactic count of 2, was added. The concentrations of C5a are defined as in Fig. 3.
DISCUSSION
Chromatographic separation of ECF-A and C5a (Figs 1 and 2) demonstrated that both
eosinophil and neutrophil chemotactic activity eluted at the same bed volume character¬
istic for the size of these molecules (mol. wt approximately 1000 and 15,000 respectively).
When ECF-A and C5a were examined in a dose-response fashion against a suspension
of cells which contained greater than 95 per cent of neutrophils this cell type migrated
towards C5a whereas neutrophils migrated only in small numbers to ECF-A (Fig. 3).
When eosinophils were examined in the same manner using a suspension of cells contain¬
ing 52 per cent eosinophils and 48 per cent mononuclear cells, migration was demon¬
strated in a dose-response fashion towards both factors (Fig. 3). Under these conditions
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the neutrophil was attracted in larger numbers, however, attraction of eosinophils to C5a
may have been impaired, in part, by the presence of the mononuclear cells.
The highest doses of C5a and EGF-A shown in Fig. 3 were then examined for their
effect on various mixtures of eosinophils and neutrophils. When eosinophils comprised
only about 10 per cent of the target-cell population they were selectively attracted by
either ECF-A (Fig. 4) or C5a (Fig. 5). The preferential attraction of eosinophils by EGF-A
and C5a was particularly striking when eosinophils and neutrophils were present in
the cell compartment in approximately equal numbers. In both situations there was
marked eosinophil migration whereas neutrophil chemotaxis was virtually absent. The
experimental design illustrated in these studies involved dilution of either eosinophils or
neutrophils by the other cell types. Dilution is not considered to account for the selective
eosinophil migration since previous studies (Kay, unpublished observations), have shown
that each cell type would respond maximally at the lowest concentration used in these
studies. It should be noted that the summation of eosinophil and neutrophil responses is
less for mixtures than for the original suspensions in which one or the other of the cell types
predominates.
A broad specificity of chemotactic factors can be demonstrated when conditions for
migration are optimal and when other cells which may be preferentially attracted are
absent. Thus, in unusual cases of basophilia in association with chronic leukaemia, baso¬
phils migrated in small numbers towards C5a and an anaphylactic diffusate containing
EGF-A (Kay and Austen, 1972). In this situation, the conditions for basophil chemotaxis
were optimal since there was little competition from other cell types. In addition, mono¬
nuclear cell chemotaxis has been demonstrated with C5a when this cell type predominated
in the cell chamber (Snyderman et al., 1971; Hausman etal., 1972). The present studies
confirm the report of Shin et al. (1968) and Ward and Newman (1969), who described
neutrophil chemotaxis to C5a. In addition, conditions have been demonstrated under
which eosinophil chemotaxis can predominate.
Synergism between ECF-A and C5a was shown in three sets of experiments. When
C5a and ECF-A, which when tested alone gave low cell counts, were mixed together, the
resultant chemotactic counts were three times or more than would have been expected by
summation alone (Fig. 6). When a low dose of C5a was added to increasing doses of
ECF-A, the resultant increase in chemotaxis was also three times or more than would have
been expected by addition of the counts (Fig. 7a). Virtually identical results were obtained
when ECF-A was added to increasing doses of C5a (Fig. 7b). It is possible that eosinophils
have more than one receptor for chemotaxis and that, if different types of receptors are
stimulated at a low threshold, this produces an increased chemotactic response. These
observations on synergism may be of significance in parasitic infestations, many of which
are associated with a pronounced eosinophilia. Homocytotropic antibody and comple¬
ment-fixing antibody occur together in a variety of parasitic diseases, situations in which
ECF-A and C5a might act together.
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Summary. Preparations of ECF-A derived from anaphylactic guinea-pig lung
diffusates were subjected to a variety of enzymatic degradations. The enzymes
employed had specificity only for their appropriate substrates. No effect was
found following treatment with relatively high doses of trypsin, cc-chymotrypsin,
pronase, alkaline phosphatase and sialidase. In contrast a loss ofactivity was demon¬
strated in a dose-dependent fashion following incubation with tyrosinase, aryl
sulphatase and leucine aminopeptidase, suggesting that ECF-A contains a
phenolic hydroxyl group, a sulphate ester and a peptide linkage with a free
a-amino group.
INTRODUCTION
The antigen challenge of sensitized lung leads to the release of histamine, slow-reacting
substance of anaphylaxis and an eosinophil chemotactic factor of anaphylaxis (ECF-A)
(Kay, Stechschulte and Austen, 1971). ECF-A selectively attracts eosinophils from a
mixed leucocyte population and has an estimated molecular size of between 500 and 1000
(Kay, Shin and Austen, 1973). Preliminary data suggested that ECF-A has the charac¬
teristics of a peptide (Kay, Stechschulte, Kaplan and Austen, 1971). In the present
study we have attempted to gain further insight into the chemical nature of ECF-A by
incubating a partially purified preparation with a variety of enzymes of known specificity.
With each enzyme preparation particular care was taken to estimate the presence of
other enzymatic activities.
MATERIALS AND METHODS
Materials for the chemotactic assays were obtained as previously described (Kay,
Shin and Austen, 1973). The source of enzymes is shown in Table 1. The enzyme sub¬
strates were obtained from Sigma Chemical Company (St Louis, Missouri), with the
exception of 7V-acetyl-neuraminyl-lactose which was obtained from Calbiochem, (La
Jolla, California), as was the buffer 2-(7V,-morpholino)-ethanesulphonic acid (MES).
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Chemical preparations
Tyrosine-O-sulphate was prepared as described by Tallan, Bella, Stein and Moore
(1955). Sialidase was isolated from Clostridium perfringens and purified by affinity chroma¬
tography as described by Cuatrecasas and Illiano (1971). The purified enzyme had no
demonstrable phospholipase C activity (Bach and Brashler, 1973).
Preparation of ECF-A
Partially purified guinea-pig ECF-A was prepared from anaphylactic lung diffusates
by ethanol extraction as described (Kay et al., 1973). A control preparation was prepared
by subjecting an equivalent amount of ovalbumin antigen and histamine to the same
isolation procedure. In experiments testing for the production of inhibitory substances
by enzymatic digestion the control preparation was an ethanol-extracted diffusate from
normal lung in the presence of antigen. Tyrode's buffer was used throughout.
Measurement of chemotaxis
Guinea-pig eosinophils were obtained by peritoneal lavage from animals which had
received multiple injections of horse serum. Chemotaxis was measured by a modification
of the Millipore technique of Boyden using a pore size of 8 0 ^m as previously described
(Kay, 1970). For purposes of comparison, the migration induced by untreated ECF-A
preparations was normalized to 100 per cent, and migration induced by treated samples
was expressed relative to this value.
Enzyme incubations
Aliquots of 0-9 ml of ECF-A-containing pools were incubated in quadruplicate at
37° for 30 minutes with 01-ml additions containing the enzymes to be tested. At the end
of this incubation, the samples were heated to 56° for 1 hour to inactivate those enzymes
which are heat-sensitive. Control incubations of ECF-A with heat-inactivated enzymes
were included wherever appropriate. In addition, enzymes were incubated with control
preparations to exclude chemotactic activity in the enzyme preparations themselves or
the generation of chemotactic activity from contaminants in the ECF-A preparation.
Aryl sulphatase has a pH optimum which is more acidic than the pH of Tyrode's
solution. To study the effects of this enzyme 40 ^1 of 1 m MES was added to the incubations
prior to addition of the enzymes. After incubation and before heat inactivation, 40 /A
of 1 m NaOH were then added to restore the original pH. Controls had shown that these
modifications did not affect the chemotactic activity of ECF-A, nor did they evoke
chemotactic activity in the control preparations.
Enzyme calibrations
The enzyme and the methods used for estimating their activity under the conditions of
incubations are shown in Table 1.
RESULTS
enzyme calibrations
The activities of the enzymes used on their usual assay substrates are shown in Table 2.
In addition, an estimate of the levels of contaminating activities in the enzyme prepara¬
tions is also recorded. Values denoted as '<' indicate that there was no detectable activity
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EFFECT OF ENZYME TREATMENTS ON THE CHEMOTACTIC ACTIVITY OF ECF-A
Enzymes causing inhibition of chemotactic activity are shown in Fig. 1. Aryl sulphatase,
tyrosinase and leucine aminopeptidase each produced a dose-dependent loss of activity.
The heated preparations of the thermolabile enzymes (aryl sulphatase and tyrosinase)
had no effect, suggesting that the loss of activity was not a result of non-specific binding or
adsorption of ECF-A. No chemotactic activity was generated in control preparations
incubated with these enzymes. Mixtures of control preparations which were incubated
with tyrosinase and aryl sulphatase and subsequently heat inactivated did not reduce the







Dose of enzyme (units/ml) in chemotactic chamber
T 0 3 30 30 0
LAP 0 0001 0001 0 01
AS 0006 0 06 0-6
Fig. 1. Inhibition of the chemotactic activity of ECF-A following treatment with tyrosinase (T) (•),
leucine aminopeptidase (LAP) (o) and aryl sulphatase (AS) (a). The points represent the pooled
results from three experiments. The standard error of the assay was < + 15 per cent.
Trypsin, a-chymotrypsin, pronase, alkaline phosphatase and sialidase did not inhibit
ECF-A activity in doses of 1000, 3700, 375, 100 and T7 x 10 ~2 units respectively.
Preparations of carboxypeptidase A and B inhibited ECF-A activity but these pre¬
parations contained amounts of aryl sulphatase activity which could account for the
observed effect (Table 2, Fig. 1).
DISCUSSION
For the purposes of this study enzymes that inactivated the preparation of ECF-A
were defined as those which caused a dose-dependent loss of activity with the maximum
inhibition being at least 75 per cent.
Although these experiments indicate that ECF-A is susceptible to treatment by several
enzymes, there are a number of aspects to be considered in the interpretation of the results.
Thus the enzymes employed may have had a direct effect on target cells. This possibility
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was largely excluded with heat-sensitive enzymes, since preheating did not affect ECF-A
activity. The same control was not possible with leucine aminopeptidase; the only enzyme
that affected ECF-A activity but was heat stable. Further, enzymes that had an apparent
effect on ECF-A may have generated inhibitors of chemotaxis. This was largely excluded
by taking control preparations and incubating in the presence of enzymes, subsequently
heating, and adding the mixture to ECF-A and demonstrating no loss in activity. How¬
ever, the generation of heat-sensitive inhibitors remains a possibility.
It should be stated that leucine aminopeptidase was activated by preincubation with
manganese chloride and that the incubation with aryl sulphatase was in the presence of
MES. Control experiments have shown that neither manganese chloride nor MES alone,
at the maximal concentration used, influenced ECF-A activity.
A number of enzymes had no effect on ECF-A activity, even at doses greater than
twice those at which the same enzymes are active in other biological systems (Coding¬
ton, Sanford and Jeanloz, 1970; Bach, Brashler, Bloch and Austen, 1971; Bach and Brash-
ler, 1973).
The failure of pronase to inactivate ECF-A in these studies is at variance with the work
of Wasserman, Goetzl, Ellman and Austen (1974) using ECF-A of human origin. This
discrepancy may be due to a difference in species or in the preparation of the enzyme.
Contaminating enzymatic activities could not account for the loss of chemotactic
activity in preparation treated with leucine aminopeptidase, tyrosinase and aryl sul¬
phatase (Table 2). Assuming that the loss of activity with these enzymes was due to their
recognized biochemical activity the following conclusions can be drawn. The effect of
leucine aminopeptidase suggests that ECF-A contains a free a-amino group belonging to a
relatively hydrophobic amino acid in peptide linkage. Inactivation by tyrosinase indicates
the presence of a phenolic hydroxyl group which is not necessarily present as tyrosine.
The action of aryl sulphatase suggests the presence of a sulphate ester. Model experiments
have excluded tyrosine-O-sulphate as a substrate of the aryl sulphatase employed in these
experiments (Dodgson and Rose, 1970). Therefore the presence of a sulphate residue
indicates that ECF-A contains in its structure a component which is not usually found in
peptides.
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Inhibition of eosinophil chemotaxis by the antagonist of
slow reacting substance of anaphylaxis — compound
FPL 55712*
The antigen challenge of sensitized lung and skin leads to the release of a number of
pharmacological mediators which include histamine, a slow reacting substance of
anaphylaxis (SRS-A) and an eosinophil chemotactic factor of anaphylaxis (ECF-A)
(Brocklehurst, 1960; Kay, Stechschulte & Austen, 1971; Jones &Kay, 1974). ECF-A
selectively attracts eosinophils from amixed leucocyte population (Kay, Shin & Austen,
1973) has an estimated molecular size of between 500 and 1000 and probably has a
peptide-like structure (Kay, Stechschulte & others, 1971).
In a recent report it was shown that the compound FPL 55712* is a potent inhibitor
of SRS-A whereas it had relatively little antagonistic effect on the ileum-contracting
activity of histamine and other pharmacological agents (Augstein, Farmer & others,
1973). In the present study we have tested the capacity of FPL 55712 to inhibit
ECF-A activity. In addition the antiallergic compounds hydrocortisone and di-
sodium cromoglycate have been tested for inhibition of ECF-A-induced eosinophil
chemotaxis, since both these agents are associated with a reduction in the number of
circulating eosinophils when administered in vivo (Thorn, Forsham & others, 1948;
Easton, 1973).
A partially purified preparation of guinea-pig ECF-A was prepared as previously
described (Kay & others, 1973). Chemotaxis was measured by a modification of the
Millipore technique of Boyden using guinea-pig eosinophils prepared from the
peritoneal cavity of animals which had received multiple injections of horse serum
(Kay, 1970).
Solutions of FPL 55712, disodium cromoglycate and hydrocortisone were freshly
prepared by dissolving the compounds in distilled water. One part of increasing
Fig. 1. The graph shows the percent inhibition of the chemotactic response of guinea-pig
eosinophils towards partially purified guinea-pig ECF-A by increasing concentrations of FPL
55712 (A— A), disodium cromoglycate (O — O), and hydrocortisone (# — Q).
* Sodium 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyI-
4/f-chromene-2-carboxylate.
918 communications, J. Pharm. Pharmac., 1974, 26, 918
dilutions of the compound were added to nine parts of ECF-A in Tyrode solution.
The results were expressed as the percent inhibition of eosinophil chemotaxis as
compared with the same volume of ECF-A containing one part of distilled water.
As shown in Fig. 1, FPL 55712 inhibited ECF-A in a dose-dependent fashion and
had an IC50 of 0-2 pg ml-1 (3-8 x 10_7m). Neither hydrocortisone nor disodium
cromoglycate inhibited the activity of ECF-A at concentrations of up to 100 pg ml-1
(2-8 x 10-4 and 1-9 x 10~4m respectively). These experiments were performed
three times and gave similar results.
We were also able to confirm both the antagonistic effect of FPL 55712 on the
ileum-contracting activity of guinea-pig SRS-A, and its negligible effect on histamine.
Thus the present report suggests that the reduction in the number of circulating
eosinophils in vivo associated with the administration of corticosteroids and disodium
cromoglycate is unlikely to be due to their direct effect on this cell. The inhibitory
effect of FPL 55712 on ECF-A-induced chemotaxis of eosinophils could be a result
of an alteration of the ECF-A molecule itself or on the recognition by the eosinophil
of the chemotactic stimulus. Thus the unique action of FPL 55712 may serve as a
useful adjunct for further study on the mechanism of ECF-A-induced chemotaxis
of eosinophils.
Hydrocortisone sodium succinate was obtained from Organon Laboratories Ltd.,
Morden, Surrey. FPL 55712 and disodium cromoglycate were a gift from Fisons
Research Laboratories. We are grateful to Miss Doreen Spence for her technical
assistance. This work was supported by the Medical Research Council.
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synopsis Cultured lymph node cell supernatants from five out of six cases of Hodgkin's disease
were relatively more chemotactic for peripheral blood eosinophils than neutrophils. In contrast,
supernatants from two cases of lymphocytic lymphoma and four nodes showing reactive hyper¬
plasia were chemotactic for neutrophils but had little eosinophil chemotactic activity. In most
instances the degree of eosinophil infiltration observed histologically in the Hodgkin's lymph node
correlated with elaboration of eosinophil chemotactic activity from the cultured cells. Following
gel-filtration of three of the Hodgkin's lymph node supernatants, four peaks of eosinophil chemo¬
tactic activity were demonstrated in each case. One of these corresponded in molecular size to the
previously described eosinophil chemotactic factor of anaphylaxis (ECF-A). It is suggested that the
eosinophil chemotactic activity of cultured lymph node cell supernatants may be of value in the
diagnosis and classification of Hodgkin's disease.
The histological diagnosis of Hodgkin's disease is
made by the recognition of the characteristic Reed-
Sternberg cell which is a large multinucleate cell
containing two or more nuclei with prominent
nucleoli (Butler, 1970). Other morphological features
of the lymph nodes are variable, and this has led to
several attempts at classification with the object of
relating the histology to clinical staging and prog¬
nosis (Jackson and Parker, 1944a; Jackson and
Parker, 1944b; Lukes and Butler, 1966; Smithers,
1967; Smithers, 1970; Dorfman, 1972). One of the
characteristics of the Hodgkin's lymph node is the
presence of eosinophil leucocytes (Dreschfeld, 1892),
and it has been suggested that this may represent
part of the inflammatory infiltrate (Stuart, 1970),
the eosinophil accumulation in the nodes being a
result of chemotaxis (Vianna et al, 1971). In the
present study we provide evidence to support this
concept by showing that supernatants from cultured
Hodgkin's lymph nodes attract a greater propor¬
tion of eosinophils from mixed leucocyte popula¬
tions than do supernatants from cultures of non-
Hodgkin's lymph nodes.
Received for publication 15 January 1975.
Material and Methods
PREPARATION OF LYMPH NODE CELL
CULTURE SUPERNATANTS
Lymph nodes obtained at surgery were bisected.
One-half was taken for routine histology and the
other for cell culture as described (Habeshaw, 1972).
Cells for culture were obtained by carefully dividing
the tissue into small fragments with scalpel blades,
gently homogenizing and passing through a sieve
to remove fibrous debris. Cell counts were adjusted
to 5 x 106 cells/ml and the viability was assessed by
Trypan blue exclusion and phase contrast micro¬
scopy. Only those preparations which contained
greater than 90% of viable cells were subsequently
cultured. Cultures were set up in 'flying cover slips'
in glass test tubes, and the cells were contained in
1 ml volumes of medium 199 with 0-5% lact-
albumin, 50 units of penicillin, and 5 jug of strepto¬
mycin. The tubes were incubated at 37°C and the
supernatants removed at day 3, replaced with
culture medium, and removed again at day 5.
Supernatants thus obtained were centrifuged to
remove particulate material, pooled and dialysed
for 24 hours against phosphate buffered saline (PBS),
and lyophilized. Before chemotaxis the material
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was reconstituted in distilled water and the protein
concentrations were measured by the Folin-
Ciolcalteau method.
MEASUREMENT OF CHEMOTAXIS
Chemotaxis of human peripheral blood eosinophils
and neutrophils was assayed by a modification of the
Millipore technique of Boyden as previously de¬
scribed (Kay, 1970). Cell counts were performed in
duplicate or triplicate. A chemotactic index to show
the relative proportion of eosinophils migrating was
calculated from the equation:
Eosinophil chemotactic count/
Neutrophil chemotactic count
% eosinophils in cell suspension before migration/
% neutrophils in cell suspension before migration
GEL FILTRATION
Hodgkin's lymph node cell supernatants were
concentrated by rotary evaporation at 37°C under
vacuum. Samples of 1 ml containing approximately
11-5 mg/ml of protein were applied to a column of
Sephadex G-50 (104 x 2-5 cm) in PBS. From alter¬
nate 2 ml fractions 0-5 ml volumes were taken and
tested in duplicate for neutrophil and eosinophil
chemotaxis.
Results
Chemotactic activity from cultured lymph node cell
supernatants was demonstrable in a dose-dependent
fashion as shown in fig 1 for cultures from a Hodg¬
kin's and a reactive lymph node cell supernatant.
The chemotactic activity of lymph node cell
supernatants from six patients with Hodgkin's
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Fig 1 Neutrophil and eosinophil chemotactic activity
ofa Hodgkin's and reactive hyperplasia cultured lymph
node cell supernatant.
nodes showing reactive hyperplasia are shown (fig
2). Neutrophil and eosinophil chemotaxis was
demonstrable with all supernatants but five out of
the six Hodgkin's supernatants gave greater eosino¬
phil chemotactic indices than the highest index
obtained with non-Hodgkin's supernatants.
The degree of eosinophil infiltration in the lymph
nodes, arbitrarily assessed 0 to + +, to some extent
correlated with the eosinophil chemotactic activity
from the cell culture supernatants (fig 2). However,
one Hodgkin's node had no eosinophils, and eosino¬
phil infiltration was present in one of the non-
Hodgkin's nodes.
When the chemotactic gradient was eliminated by
placing supernatants from either Hodgkin's or non-
Hodgkin's lymph nodes in both the test and cell
compartments of the chemotactic chambers little or
no migration was observed for either cell type.
This suggests that the leucotaxis was a result of
directional, rather than random, migration.
When concentrated cell supernatants from three
Hodgkin's lymph nodes were applied to a column of






















Diagnosis H H H H H H
Lymph node ♦♦ o ♦ ♦ ♦ ♦♦
Eosinophils
ll ll r r r r
0 0 0 * 0 0
□ neutrophils £1 eosinophils
Fig 2 Neutrophil and eosinophil chemotaxis and the
eosinophil chemotactic index from Hodgkin's and non-
Hodgkin's cultured lymph node cell supernatants.
The degree of lymph node eosinophil infiltration is
also indicated: H = Hodgkin's disease, LL =
lymphocytic lymphoma, R = reactive hyperplasia.
The measurements represent the pooled results from
three experiments except in (1) and (2) where there
was sufficient sample for only one and two estimations
respectively. All samples were tested at a protein
concentration of 0-6 mglml.
504 A. B. Kay, J. G. McVie, A. E. Stuart, A. Krajewski, and Lindsay W. Turnbull
BLUE DEXTRAN
| M.W.200,000)












i i i i i i i i i i i i i i i i
12 16 20 2U 28 32 36 « U Ut 52 56 60 6U 68 72 76
TRACTION NUMBER
Fig 3 Sephadex G-50 chromatography of a cultured lymph node eelI supernatant from Hodgkin's disease.
The column was previously calibrated with markers having the molecular sizes indicated.
activity were consistently demonstrable (fig 3). The
molecular markers indicated that these four activi¬
ties were associated with molecules having an
approximate molecular size of 30 000, 6000, 2000,
and 500 daltons respectively (fig 3).
Discussion
The capacity of human peripheral blood lympho¬
cytes to release chemotactic factors for neutrophils
and monocytes following stimulation by mitogens
and specific antigen has been reported by a number
of workers (Ward et al, 1969; Altman et al, 1973).
In addition, an eosinophil chemotactic factor from
lymphocyte supernatants has also been reported,
but in this system there was an additional require¬
ment for antigen-antibody complexes (Cohen and
Ward, 1971). In the present study we have demon¬
strated the elaboration of neutrophil and eosinophil
chemotactic agents from cultured lymph node cell
supernatants but in addition have shown that
Hodgkin's lymph node preparations attract relatively
more eosinophils than the non-Hodgkin's super¬
natants (figs 1 and 2).
Care was taken to use the same protein con¬
centrations when making comparisons between the
activity of the cell supernatants. A dose-response
effect was obtained with each supernatant as well as
the ones depicted in figure 1.
Although relatively more eosinophil than neutro¬
phil chemotactic activity was observed in a node
in which histologically there were no demonstrable
eosinophils, there was in general an association
between lymph node eosinophilia and the elabora¬
tion of eosinophil chemotactic activity. More
direct evidence would be possible by performing
these measurements on several nodes from individual
patients.
Several peaks of activity were obtained following
chromatography on Sephadex G-50, suggesting that
there is a heterogeneity of eosinophil chemotactic
factors from Hodgkin's lymph node cell super¬
natants (fig 3). One peak corresponded to a molecular
size of the eosinophil chemotactic factor of anaphy¬
laxis (ECF-A) (Kay and Austen, 1971; Kay et al,
1971). In a previous report a substance of compatible
molecular size was extracted from an undifferen¬
tiated carcinoma of lung associated with a peripheral
blood eosinophilia (Wasserman et al, 1974).
The finding that Hodgkin's lymph node cell
supernatants attract relatively more eosinophils
than non-Hodgkin's cultures suggests that this may
be of value both in diagnosis and in the classification
of various forms of the disease.
This work was supported by a grant from the
Melville Trust, the Medical Research Council, the
Cancer Campaign, and an anonymous gift to the
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Edinburgh. We are very grateful to Dr R. A. A.
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Eosinophils and mediators of anaphylaxis
HISTAMINE AND IMIDAZOLE ACETIC ACID AS CHEMOTACTIC AGENTS FOR
HUMAN EOSINOPHIL LEUCOCYTES
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Summary. Histamine and one of its major catabo-
lites, imidazole acetic acid (ImAA), were selectively
chemotactic for human eosinophils, whereas L-histi-
dine and other histamine catabolites including
1,4-methylhistamine, l-methyl-4-imidazole acetic
acid and A-acetyl histamine were inactive in eosino-
philotaxis over a large dose range. The dose response
for histamine was dependent on the chemotaxis
incubation time and the source of eosinophils,
although the latter was not clearly associated with
particular disease states. When histamine and ImAA
were combined the chemotactic response was similar
to that obtained when one agent was assayed alone,
no additive or synergistic effects being observed.
There was cross-deactivation between histamine and
ImAA. These experiments suggest that histamine
and ImAA activate the same chemotactic recognition
mechanism for eosinophils. Thus ImAA joins hista¬
mine and the tetrapeptides (ECF-A) as anaphylaxis-
associated selective chemoattractants for human
eosinophils.
INTRODUCTION
Human lung can be passively sensitized by IgE for
the antigen-induced release of a number of pharma-
Correspondence: Dr A. B. Kay, South-East Scotland
Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh EH3 9HB.
cological mediators of anaphylaxis. These include
histamine, a slow reacting substance (SRS-A) and an
eosinophil chemotactic factor (ECF-A). ECF-A is
now recognized as two associated acidic tetra¬
peptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu
(Goetzl & Austen, 1975). An analogue Val-Gly-
Asp-Glu also selectively attracts human eosinophils
from a mixed cell population (Kay, 1976).
The role of histamine in the recruitment of
eosinophils to the site of allergic tissue reactions has
been the subject of some controversy (Parish, 1974).
Whereas subcutaneous injections of histamine into
the horse resulted in eosinophil accumulation
(Archer, 1956) these observations have not been
confirmed in the guinea-pig (Kay, 1970a) or man
(Felarca & Lowell, 1968). Similarly in vitro experi¬
ments failed to show chemoattractant properties for
histamine when eosinophils from guinea-pig and
man were used as target cells (Kay, Stechschulte &
Austen, 1971; Kay & Austen, 1971). However,
Clark, Gallin & Kaplan (1975) were able to show
human eosinophilotaxis by histamine although the
activity was only demonstrable at concentrations of
approximately 5 x 10"5 mol/l, there being inhibition
with higher doses. It now appears that these appar¬
ent discrepancies in the chemotactic property of
histamine can be explained largely on the type of
micropore filters used in the assays. Thus with the
more traditional Millipore filter, chemotaxis by
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histamine cannot be demonstrated whereas these
membranes were suitable for the identification and
characterisation of ECF-A (Kay & Austen, 1971).
In contrast, cellulose nitrate filters were satisfactory
for the assay of both the ECF-A peptides and hista¬
mine (Kay, 1976).
In the present report we have confirmed and
extended the observation on eosinophil chemotaxis
by histamine and in addition describe a similar
eosinophilotactic property for a major histamine
metabolite, imidazole acetic acid (ImAA). The inter¬
actions between histamine and ImAA in terms of




The materials were obtained as follows. Histamine
acid phosphate (BDH Chemicals Ltd, Poole);
imidazole acetic acid hydrochloride (ImAA) chro-
matographically free of histidine, histamine and iso-
propylester, 98-8 per cent pure; l-methyl-4-imidazole
acetic acid hydrochloride (1,4-MeImAA), L-histidine,
free base, 1,4-methylhistamine dihydrochloride (1,4-
MeHm), A-acetylhistamine (N-AcHm), all chroma-
tographically homogeneous (Calbiochem Ltd, San
Diego, California); ovalbumin five times crystallised
(Koch-Light Laboratories, Colnbrook, Bucks.);
cellulose nitrate filters, 8 0 //m (Sartorius-membrane
filters, 34 Gottingen, W. Germany).
Eosinophil chemotaxis
Peripheral blood was withdrawn from patients with
an eosinophilia of between 10 and 25 percent. Leuco¬
cyte rich plasma, obtained by dextran sedimentation
of heparinised blood (Kay, 1970b) was applied to a
density gradient of 9 per cent Ficoll solution and
sodium diatrizoate (density 1 140) in the proportions
2-4:1 (English & Andersen, 1974). Following centri-
fugation, at 400 8 for 40 min at 20°, the eosinophil-
rich pellet was retained, washed in Tyrode's buffer
and resuspended in Tyrode's containing 0-5 per cent
ovalbumin. This procedure increased the eosinophil
concentration two- to three-fold, the contaminating
cells being mostly neutrophils. The cell counts were
then adjusted to 2 x 106 cells/ml, with a final eosino¬
phil concentration of 20-30 per cent. Blood with an
initial eosinophil concentration in this range was
prepared by dextran sedimentation alone. The
chemotactic assay procedure was as previously
described (Kay, 1970b) but using 8 0 pm Sartorius
micropores. All agents tested for chemotaxis were
dissolved in Tyrode's solution and the pH adjusted
to 7-24.
Statistics
Measurements from duplicate filters from three
separate experiments were pooled, the mean and
standard error determined and observations com¬
pared using the Student's r-test. Such pooling was
considered to be statistically valid since in the present
study the variation between duplicate filters was
similar to variations between individual experiments
as previously observed (Clark et al., 1975).
RESULTS
(1) Eosinophil chemotactic activity of histamine and
histamine metabolites
Histamine, L-histidine, ImAA, 1,4-MeHm, 1,4-
MelmAA and A-AcHm were assayed for chemo¬
tactic activity at the concentrations shown in Fig. 1.
With a 135-min incubation period eosinophil
chemotaxis by histamine was demonstrable at con¬
centrations of 10"5 and 10"6 mol/1 with apparent
inhibition of migration at 10~4 mol/l. In contrast,
chemotaxis by ImAA gave a linear-dose response
from 10~3 to 10~5 mol/1. No chemotactic activity
was found with histidine or the other histamine
catabolites. Within the dose-ranges tested in Fig. 1,
Figure 1. Chemotaxis for human eosinophils by histamine
(O), ImAA (•), 1,4-MeImAA (A), 1,4-MeHm (A), N-AcHm
(■) and L-histidine (□). Incubation period 135 min. The bars
for Figs 1-5 represent ±s.e.m. The P values refer to the
points immediately above or below.
Eosinophil chemotaxis
Table 1. Pattern of chemotactic response to histamine by human eosinophils from various patients
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No. of
Patient Associated disease experiments
H.W. Microfilariasis (D. perstans) 4
J.P. Microfilariasis (D. perstans) 1
G.M. Drug reaction 2
E.S. Allergic asthma 1
R.G. Drug reaction 2
F.F. Hypereosinophilic syndrome 2
Pattern of response
Linear dose-response with maximal density at 10~3 mol/1
Linear dose-response with maximal density at 10~3 mol/1
Linear dose-response with maximal density at 10~3 mol/1
Peak activity at 5 xlO"6 mol/1 with inhibition at higher
dose
Peak activity at 5 xlO"6 mol/1 with inhibition at higher
dose
Peak activity at 5 xlO"6 mol/1 with inhibition at higher
dose
neutrophil migration was not observed with hista¬
mine, ImAA or the other compounds.
(2) Time-course studies
Using a 180-min incubation time eosinophil chemo¬
tactic activity by histamine was found to give a
linear-dose response between 10"3 and 10~7 mol/1
(Fig. 2). However at 135 min there was an inhibition
of chemotaxis with a dose of 10" 3 mol/1. Negligible
activity was found at all doses with a 90-min incuba¬
tion time. Therefore by increasing the incubation
period the apparent inhibition of migration by
higher concentrations of histamine could be
abolished. However eosinophils from certain indivi¬
duals gave a peak of activity at approximately
5 x 10"6 mol/1 with inhibition at higher doses even
with a 180-min incubation period (Table 1). The two
types of chemotactic profile, i.e. maximal activity at
10"3 or at 5 x 10"6 mol/1 were not clearly associated
with the disease state. In subsequent studies only the
eosinophils from patients giving the linear dose-
response pattern of activity shown in Fig. 2 (180
min) were used.
Similar experiments were carried out with ImAA.
The latter was selectively chemotactic for human
eosinophils between 10"3 and 10"4 mol/1 using
either 135- or 180-min incubations and invariably
gave a linear-dose response irrespective of the source
of eosinophils. As with histamine little activity was
seen at 90 min. In all further experiments a 180-min




Figure 2. The effect of varying incubation times on eosinophil
chemotaxis by histamine.
(3) The effect of combining histamine and ImAA
When histamine was combined with ImAA (10"3
mol/1) there was virtually no difference in the eosino¬
phil chemotactic response when compared to hista-
Histamine+10 3m ImAA
Histamine




Figure 3. Eosinophil chemotaxis by combination of histamine
and ImAA.
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mine alone, with the exception of the lowest dose
of histamine (10~7 mol/1) which when added to
ImAA resulted in higher counts (Fig. 3). However
histamine (10~5 mol/1) and ImAA (10"7 mol/1) in
combination gave less chemotaxis than histamine
alone at 10"5 mol/1. Thus although there was some
augmentation or depression of the chemotactic
response when these agents were combined at various
concentrations there were, in general, no marked
additive or synergistic effects.
(4) Deactivation of eosinophil chemotaxis by histamine
and ImAA
Cells preincubated with histamine (5xl0~6 mol/1)






















Figure 4. Eosinophil chemotactic deactivation for histamine
by histamine and ImAA.
I0~5
ImAA (mol/t)




| |CH2CH2NHCOCH5 | |CH;C00H
At-acetylhislamine l-methyl- 4-imidazole
acetic acid
Figure 6. Metabolites of histamine found in the urine of man (after Schayer, 1959).
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Tyrode's solution and resuspended in buffered
ovalbumin/Tyrode's solution, pH 7-24, were set up in
chemotaxis against increasing doses of histamine
(Fig. 4). When compared to preincubation in
Tyrode's there was a significant inhibition of eosino¬
phil migration in both cases. Similar experiments
performed using ImAA as the chemoattractant (Fig.
5) gave comparable results indicating a cross-
deactivation between histamine and ImAA. Histidine
and the histamine catabolites, 1,4-MeHm, 1,4-
MelmAA and A-AcHm did not deactivate eosino¬
phils in chemotaxis to either histamine or ImAA.
DISCUSSION
A number of agents associated with the anaphylactic
response have been shown to attract selectively
human eosinophils in vitro. These include the
eosinophil chemotactic factor of anaphylaxis (ECF-
A) (Kay & Austen, 1971), now recognized as two
related acidic tetrapeptides, Val-Gly-Ser-Glu and
Ala-Gly-Ser-Glu (Goetzl & Austen, 1975), an
analogue Val-Gly-Asp-Glu (Kay, 1976) and hista¬
mine (Clark et a!., 1975). The recognition of hista¬
mine as an eosinophilotactic agent was not possible
using the traditional Millipore filters and was only
apparent using cellulose-nitrate filters. This may be
related to variations in thickness and charge between
micropores from various commercial sources. We
have extended this observation on human eosinophil
chemotaxis by histamine, to include its precursor
histidine, and its major metabolites.
ImAA was found to give a linear dose-response,
irrespective of incubation times. In contrast the
apparent inhibition of chemotaxis by higher dose of
histamine was abrogated using increased incubation
times in three subjects. However, other individuals
gave peak activity at 5 x 10"6 mol/1 with inhibition
at high doses even with the longer period of incuba¬
tion (Table 1). This was not clearly related to the
associated clinical conditions and the reason for the
altered response is yet to be determined. It may be
related to the content of leucocyte histaminase, and
this possibility is being explored.
The ImAA used in these experiments was free of
histamine and histidine as assessed by gas chromato¬
graphy and had 10,000 times less ileal-contracting
activity than histamine (Turnbull, L.W., unpublished
observation).
The major metabolites of histamine found in the
urine of man are shown in Fig. 6. These include
ImAA, 1,4-MeHm, 1,4-MeImAA and A-AcHm and
account for 25, 8, 60 and < 1 per cent respectively of
the urinary histamine breakdown products following
a loading dose of labelled histamine (Nilsson, Lindell,
Schayer & Westling, 1959). It is not known which
metabolic pathway predominates following various
types of anaphylactic response but it should be noted
that ImAA can also be formed directly from histidine
so raising the possibility that there is a relationship
between eosinophil recruitment and this histidine-
independent pathway.
There is no obvious explanation, from the chemical
structures of these agents, as to why histamine and
ImAA but not histidine and the other histamine
catabolites are chemotactic for eosinophils. There is
presumably some form of steric hindrance by the
compounds inactive in eosinophil chemotaxis.
When ImAA was added to histamine the resultant
chemotaxis was in general no more than found with
each agent alone. There was however some augmen¬
tation or depression depending on the relative doses
of the two agents. These observations suggest
therefore that both compounds are competing for
the same recognition mechanism. Further evidence
was provided by the cross-deactivation exhibited
between the two substances (Figs 4 and 5).
These experiments provide further evidence that
a breakdown product of histamine is not inert but
has biological activity. Other activities for ImAA
have been reported and include effects on the central
nervous system such as a depressant action on the
neurons of the cerebral cortex of the cat (Hosli and
Haas, 1971). In these experiments ImAA was more
active than histamine but in the present study using
a 180-min incubation period both agents had com¬
parable activities at 10"3 mol/1. However histamine,
under the experimental conditions cited (Figs 1 and
2) was far more active at lower doses.
Thus ImAA joins histamine and the acidic tetra¬
peptides (ECF-A) as selective anaphylaxis-associated
chemotactic agents for eosinophils.
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Chemotactic Activity of Guinea Pig Eosinophils for the ECF-A
Acidic Tetrapeptides, Histamine, Histamine Metabolites, and the
Effect ofHI- and H2-Receptor Antagonists
D. G. Jones and A. B. Kay
South-East Scotland Regional Blood Transfusion Service, Royal Infirmary, Edinburgh, and
the University Department of Respiratory Diseases, Edinburgh
Abstract. Histamine and one of its major metabolites, imidazoleacetic acid, were select¬
ively chemotactic for guinea pig eosinophils, whereas L-histidine, 1,4-methylimidazoleacetic
acid, 1,4-methylhistamine and N-acetylhistamine were inactive. The response to histamine
was unaffected by concentrations of eosinophils of between 30 and > 90% but it was
abrogated by preincubation of the cells with histamine prior to assay (self-deactivation).
Eosinophilotaxis was also inhibited by Hl-(mepyramine-) and H2-(burimamide-)receptor
antagonists at high doses (10-3M), although at lower concentrations (10~5M) inhibition
was principally associated with burimamide. The human tetrapeptide, alanine-glycine-serine-
glutamic acid, and the analogue, valine-glycine-aspartic acid-glutamic acid, were inactive
whereas alanine-glycine-serine-glutamic acid was chemotactic for the guinea pig eosinophil.
These results support the concept that the tissue accumulation of eosinophils following
anaphylaxis depends on a complex interaction of factors, which in part may be mediated
by H2 receptors on the target cells. There may be species differences in the composition of
ECF-A.
Introduction
The accumulation of eosinophil leuco¬
cytes in the tissues is a feature of immedi¬
ate-type 'allergic' hypersensitivity reactions
in several species including guinea pig and
man [8]. In both species, eosinophil recruit¬
ment was initially attributed to the release
of a preformed mast-cell-associated media¬
tor released following anaphylaxis in vitro
[5, 6, 9]. This principle was designated the
eosinophil chemotactic factor of anaphylax¬
is (ECF-A) and in man has now been identi¬
fied as a family of closely related acidic
tetrapeptides including valine-glycine-
serine-glutamic acid (VGSG) and alan-
ine-glycine-serine-glutamic acid (AGSG)
[4], The presence of other amino acids, par¬
ticularly aspartic acid, in purified ECF-A
preparations raised the possibility of other
affiliated peptides contributing towards its
activity and it has recently been shown that
an analogue, valine-glycine-aspartic acid-
glutamic acid (VGAGa), inaddition to syn-
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thetic VGSG and AGSG, possessed selec¬
tive chemotactic activity for human eosino¬
phils [12].
Histamine has been variously ascribed
roles in anaphylaxis-associated eosinophil
accumulation [11]. However, two recent
reports [2, 13] have confirmed that hista¬
mine selectively attracts eosinophils from
mixed human leucocyte populations in vitro.
In the latter study, eosinophilotactic activity
was also shown to be a property of a major
histamine catabolite - imidazoleacetic acid
(ImAA).
In the present study, we have assessed
the ability of histamine and its major meta¬
bolites including L-histidine, 1,4-methylhis-
tamine (1,4-MeHm), l-methyl-4-imidazole-
acetic acid (1,4-MeImAA) and N-acetyl-
histamine (N-AcHm) to induce the migra¬
tion of guinea pig peritoneal eosinophils
and the modulation of this response by
HI- and H2-receptor antagonists and by
self-deactivation. In addition, we have simi¬
larly tested synthetic VGSG, AGSG and




Dunkin-Hartley strain guinea pigs, weighing
300-400 g, of either sex, were used as a source of
target leucocytes throughout.
Materials were obtained as follows: histamine
acid phosphate (BDH Chemicals Ltd, Poole,
England); imidazoleacetic acid hydrochloride,
chromatographically free of histidine, histamine
and isopropyl ester 98.8°/o pure; L-histidine, free
base, 1,4-methylhistamine dihydrochloride,
l-methyl-4-imidazoleacetic acid hydrochloride,
N-acetylhistamine, all chromatographically homo¬
geneous (Calbiochem Ltd, San Diego, Calif.,
USA); mepyramine maleate (May & Baker Ltd,
Dagenham, England); ovalbumin, 5 times crystal¬
lised (Koch-Light Laboratories, Colnbrook,
England); horse serum (Wellcome Research Labo¬
ratories, Beckenham, England); sodium diatrizoate
(Winthrop Laboratories, Surbiton-on-Thames, Eng¬
land); cellulose nitrate filters, 8.0 um pore size
(Sartorius-Membrane Filters, 34 Gottingen, FRG).
(HCl)-VGSG (molec. wt 427), (HCl)-AGSG (molec.
wt 497) and (HCl)-VGAGa (molec. wt 455) were a
generous gift from Dr. R. Camble, ICI Ltd, Phar¬
maceuticals Division, Alderley Park, Macclesfield,
England, and burimamide was kindly donated by
S. K. & F. Laboratories Ltd, Welwyn Garden City,
England.
Eosinophil Chemotaxis
Eosinophils were obtained from the peritoneal
cavities of animals which had received 4-6 weekly
intraperitoneal injections of horse serum [7].
Where necessary, these preparations were further
purified by centrifugation on cushions of sodium
diatrizoate (d = 1.140 at 20 °C) [3], Neutrophils
were similarly obtained from guinea pigs 3-4 h af¬
ter the administration of glycogen suspensions [7].
Eosinophil chemotactic assays were performed in
modified Boyden micropore chambers [7] using
8.0-jMin pore size cellulose nitrate filters and a fi¬
nal total cell concentration of 2X106 ml"1 in Ty-
rode's buffer 0.5%> ovalbumin, pH 7.2. Following
a 3-hour incubation period at 37 °C, the filters
were removed, fixed and stained as previously de¬
scribed [7], Cell counts were expressed as the
mean total of 5 high-power (X 40) fields in dupli¬
cate filters. Neutrophil chemotaxis was similarly
evaluated but using a 90-min incubation period.
All agents tested were freshly prepared in Ty-
rode's buffer, pH 7.2-7.6. For inhibition studies
with the Hl-(mepyramine-) and H2-(burimamide-)
antagonists, the drugs were either mixed through¬
out the assay with the test agents or preincubated
with the leucocyte suspensions. In the latter in¬
stance, the cells were incubated for 30 min at 37 °C
and the drugs removed by washing twice in Ty-
rode's buffer. The washed cells were then resus-
pended to a concentration of 2X106ml~1 in Ty-
rode's buffer/0.5%> ovalbumin. In deactivation
studies, cells were similarly treated but with his¬
tamine in place of the drugs. Leucocytes from the
same starting populations preincubated with Ty-
rode's buffer alone served as controls. Cell viabili¬
ty, as judged by trypan blue dye exclusion, was
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unaffected by pretreatment with any of these
agents.
Results
Chemotactic Activity of Histamine and
its Metabolites
Histamine was selectively eosinophilo-
tactic over a limited dose range, maximum
ur3 icr4
Concentration, M
Fig. 1. Chemotaxis (per 5 high-power fields)
of guinea pig eosinophils towards histamine (•; n
= 8), ImAA (O; n = 4), L-histidine (■; n = 3),
1,4-MeHm (□; n = 3), 1.4-MeImAA (A; n = 3)
and N-AcHm (f\\ n = 3). Each point represents




Fig. 2. Chemotaxis (per 5 high-power fields)
of guinea pig eosinophils towards the ECF-A tetra-
peptides AGSG (•), VGSG (O) and the analogue
VGAGa (■). Each point represents the mean of 3
experiments.
activity being observed at 5 X10"° M; there
was an apparent inhibition of response at
higher doses (fig. 1), ImAA was also chemo¬
tactic for eosinophils but at relatively high¬
er doses, peak activity being at 10~3M.
L-Histidine, 1,4-MeHm, 1,4-MeImAA and
N-AcHm were inactive at doses between
10~3 and 10~7 M. None of the compounds
tested possessed any activity for neutrophil-
rich (> 94%) leucocyte suspensions.
Chemotactic Activity of AGSG, VGSG
and VGAG&
Chemotaxis was observed with AGSG at
a concentration of 10~5 M (fig. 2). As with
histamine the activity was selective, no re¬
sponse being observed with neutrophils, and
it was apparently inhibited at high doses.
Over a range of concentrations from 10"3 to
10~8 M, VGSG and VGAGa were chemo-
tactically inactive.
Effect of Cell Purity on Histamine-
Induced Chemotaxis
The pattern and magnitude of the eosi¬


















Fig. 3. Chemotactic response (per 5 high-
power fields) to histamine of leucocyte suspen¬
sions containing 92°/o (•), 64% (O) and 30% (■)
eosinophils. The cell counts and percent purity
were pooled from 3 essentially similar experi¬
ments.
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Table I. Chemotaxis of eosinophils, from initial
populations of varying purity, towards a fixed (0.1 ml)
dose of inulin-activated homologous serum; eosino¬
phil chemotaxis is expressed as total cell counts per 5
high-power (x 40) fields











from 10~4 to 10~8 M were unaffected by the
concentration of eosinophils in the leuco¬
cyte preparation (fig. 3). Thus the observed
chemotaxis was similar whether the starting
population contained 30, 64 or 92% eosino¬
phils.
In contrast, the numbers of cells migrat¬
ing towards an inulin-activated normal
guinea pig serum were directly proportional
to the eosinophil concentration (table I).
This observation was not attributed to an
increase in random migration since the pres¬
ence of the same dose of histamine in both
compartments of the Boyden chamber com¬
pletely abrogated the eosinophil response.
Self-Deactivation of Histamine
Chemotactic Activity
When cells were preincubated with his¬
tamine (5 X10"5 M) prior to assay with var¬
ious doses of the same agent as the chemo-
attractant, the number of migrating eosi¬
nophils was always markedly reduced
(fig. 4). The dose-response pattern of the
control preparations pretreated with Ty-
Fig. 4. Chemotactic response of eosinophils
(per 5 high-power fields) to histamine following
preincubation with Tyrode's buffer (#) or
5X 1(T5 M histamine (O). Each point represents
the mean of 3 experiments.
Fig. 5. Chemotactic response of eosinophils to
histamine following preincubation with burimamide
(#-#) and mepyramine (O-O), or with burim¬
amide (•—•) and mepyramine (O—O) present
in the stimulus compartment throughout.
rode's buffer to histamine was similar but




At high doses (ICC3 M), both mepyramine
and burimamide abrogated the eosino¬
phil response to histamine (fig. 5). At lower
concentrations (10~5 M), however, chemo-
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taxis was selectively inhibited by burimam-
ide. The effect of both drugs was similar ir¬
respective of whether they were mixed with
the chemoattractant throughout the assay or
preincubated with the eosinophil suspen¬
sions and removed by washing before the
introduction of the cells into Boyden cham¬
bers.
Discussion
Histamine was shown to be chemotactic
for guinea pig peritoneal eosinophils over a
narrow dose range with peak activity at
5 X10~6 M and inhibition at higher concen¬
trations (fig. 1). These results are compara¬
ble with those obtained using human peri¬
pheral blood eosinophils as target cells [2,
13]. Guinea pig eosinophils also migrated
towards ImAA, showing a similarity in both
the pattern of dose-response and magnitude
to the response observed with human cells
[13]. As in the latter study, no activity was
demonstrable with several other histamine
metabolites, including L-histidine, 1,4-
MeHm, 1,4-MeImAA and N-AcHm.
In man, the eosinophil response to his¬
tamine was dependent on the absolute num¬
bers of this cell in the starting population
[2]. In the present study, there was no ap¬
parent correlation between the numbers of
migrating cells and their starting concentra¬
tion (fig. 3). This may be a species differ¬
ence, but it is unlikely to be due to an in¬
crease in random mobility since the pres¬
ence of identical doses of histamine in both
compartments of the Boyden chamber abro¬
gated eosinophil migration. In addition, it
was shown that preincubation with histam¬
ine deactivated their migration towards the
same agent (fig. 4), a property of chemotac¬
tic stimuli but not those which promote only
random mobility [1]. Unlike histamine,
eosinophilotactic response of the guinea pig
cells towards an activated homologous se¬
rum was directly proportional to their initial
concentration (table I).
Thus, eosinophil chemotactic activity
joins the traditionally recognised pharma¬
cological actions of histamine such as in¬
creasing vascular permeability, contraction
of smooth muscle, bronchoconstriction, and
the secretion of gastric HC1. The effects on
both the vasculature and smooth muscle are
blocked by classical (HI) antihistamines,
whereas HC1 secretion is abrogated in the
presence of H2-receptor antagonists. The
latter also blocks the self-inhibition of his¬
tamine release from anaphylactic mast cells
[10]. It was of interest, therefore, to deter¬
mine whether eosinophilotaxis was under
the influence of HI or H2 receptors. It was
found that both mepyramine (HI) and burim-
amide (H2) were inhibitory at high con¬
centrations (10-3 M) but that at lower doses
(10~5 M) this effect was principally associat¬
ed with burimamide (fig. 5). In man, how¬
ever, neither pyrilamine (HI) or metiamide
(H2) at a dose of 10~5 M had a direct block¬
ing effect on chemotaxis, although the pres¬
ence of metiamide did reduce the inhibition
of cell migration observed with high doses
of histamine [2].
The characterisation of human lung
ECF-A as two related acidic tetrapeptides
[4] has facilitated its synthesis in the labora¬
tory. Synthetic 'ECF-A' (VGSG and
AGSG) and an analogue, VGAGa, were
shown to possess selective chemotactic ac¬
tivity for human eosinophils [12], In the
present study, AGSG was shown to possess
activity for guinea pig cells, but VGSG and
VGAGa were without effect (fig. 2). The
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chemotactic activity of histamine, ImAA
and the ECF-A tetrapeptide, AGSG, was
selective for eosinophils as judged by their
total inability to attract neutrophils from
pure (> 94%) suspensions.
Several conclusions may be drawn from
the data presented. These may be summa¬
rised as follows: (a) in guinea pig, as in man,
the accumulation of eosinophils at anaphy¬
lactic tissue sites involves the complex inter¬
action of several components of the reac¬
tion, including histamine, ECF-A and pos¬
sibly ImAA, in a manner not yet under¬
stood; (b) this interaction may be, in part,
mediated through H2 receptors present on
the target cells, although there is a differ¬
ence between the human and guinea pig ob¬
servations in this respect, and (c) guinea pig
ECF-A may differ from its human counter¬
part, although it remains likely that both are
families of closely related tetrapeptides.
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Summary. The ECF-A acidic tetrapeptides Val-Gly-
Ser-Glu, Ala-Gly-Ser-Glu and the analogue Val-
Gly-Asp-Glu were selectively chemotactic for
human eosinophils over a narrow dose range
although eosinophils from different individuals
varied in their dose-response pattern. Histamine
abrogated the chemotactic properties of the indi¬
vidual tetrapeptides. When Val-Gly-Ser-Glu and
Ala-Gly-Ser-Glu were combined in various con¬
centrations the resultant chemotaxis was either
negligible or no greater than that produced when
each peptide was tested separately.
Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu both pro¬
moted eosinophil accumulation when applied to the
abraded skin of man or i.d. to the marmoset.
Biopsies of marmoset skin revealed that peptide-
induced eosinophilia was not associated with mast-
cell degranulation.
Histamine, which was chemotactic in vitro, did not
lead to appreciable eosinophil accumulation in vivo,
and combinations of histamine and the acidic
tetrapeptides evoked little or no cutaneous eosino¬
phil infiltration either in man or the marmoset.
These studies suggest that there is a complex
interaction between histamine and the ECF-A
tetrapeptides; however, the tetrapeptides alone can
Correspondence: Dr A. B. Kay, South-East Scotland
Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh EH3 9HB.
promote the recruitment and localization of eosino¬
phils by a mechanism apparently independent of
mast-cell degranulation.
INTRODUCTION
It is now recognized that a number of chemical
mediators associated with immediate-type (type 1)
hypersensitivity reactions can attract selectively
human eosinophils in vitro. These include the
eosinophil chemotactic factor of anaphylaxis (ECF-
A) (Kay, 1969; Kay & Austen, 1971), now identi¬
fied as at least two acidic tetrapeptides, Val-Gly-
Ser-Glu and Ala-Gly-Ser-Glu (Goetzl & Austen,
1975), an analogue, Val-Gly-Asp-Glu (Kay, 1976),
histamine (Clark, Gallin & Kaplan, 1975) and one
of its major catabolites, imidazole acetic acid
(Turnbull & Kay, 1976). In the present report we
describe the effect of combining these peptides
with histamine in terms of their capacity both to
attract selectively the eosinophil in chemotaxis and
to evoke eosinophil accumulation following admin¬




Materials were obtained as follows: (HCl)-Val-Gly-
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Ser-Glu (mol. wt 427), (HCl)-Ala-Gly-Ser-Glu (mol.
wt 497) and (HCl)-Val-Gly-Asp-Glu (mol. wt 455)
(a gift from Dr R. Camble, ICI Ltd, Pharmaceuticals
Division, AlderleyPark, Macclesfield); histamine acid
phosphate (BDH Chemicals Ltd., Poole); cellulose
nitrate filters 8 0 p (Sartorius-Membrane Filters,
34 Gottingen, W. Germany), Millipore filters 0-2 p
(Millipore Corp., Bedford, Massachusetts); Timothy
grass pollen (TGP), lyophilized and defatted (a gift
from Beecham Research Laboratories, Betchworth).
Eosinophil chemotaxis
Peripheral blood was obtained from individuals
with an eosinophilia of between 10 and 25%. The
preparation of eosinophil leucocytes and the chemo-
tactic assay were performed as previously described
(Turnbull & Kay, 1976).
Marmoset skin studies
Marmosets (Callithrix jacchus) of either sex, with
an average weight of 350 g, were maintained on a
balanced vegetable diet with added vitamins and
salts. Six marmosets received i.d. injections of 0 05
ml of serum from an individual (R.B.) sensitive
to TGP. Following a 48-h sensitization period the
same sites were challenged i.d. with 1 pg of TGP
contained in 0 05 ml of saline. At the same time other
sites, all on the abdomen, received 0 05 ml of the
following: histamine; Val-Gly-Ser-Glu (valyl-pep-
tide); Ala-Gly-Ser-Glu (alanyl-peptide); valyl-pep-
tide and histamine; alanyl-peptide and histamine;
valyl-peptide, alanyl-peptide and histamine; TGP;
or saline—all at a final concentration of 10"3
mol/1 whether given alone or in combination; and
TGP (1 mg/ml). Immediately after the injections,
0-5 ml of 10% Evans blue in saline was administered
i.v. These procedures were carried out on six animals
of which three were killed at 12 h and three at 24 h
following injection of Evans blue. Immediately
after the animals were killed, the full thickness of
the skin sites were excised and fixed and stained for
eosinophils and mast cells. This was performed on the
same sections using a modification of the method of
Lendrum (1944) in which Alcian blue and chromo-
trope 2R were used to identify mast cells and eosino¬
phils respectively (Hogg, R.M. & Banks, D.,
manuscript in preparation). Cell counts were
performed as described (Kay, 1970a). Neutrophil
counts were expressed semi-quantitatively on a
'plus' basis.
Human skin studies
'Skin window' studies were performed on four atopic
volunteers who had seasonal, allergic rhinitis and
an immediate-type skin weal and flare reaction
to TGP. The method used was slightly modified
from that described by Felarca & Lowell (1968).
Skin sites on the forearm were thoroughly cleaned
with 70% alcohol, and minimally abraded with a
high-speed drill. The penetration of skin was
insufficient to cause bleeding. Skin sites were approxi¬
mately 0-3 cm in diameter and 5 cm apart. Plastic
'hats' (10 mm diameter and 5 mm high) were packed
with sterile cotton wool and sealed with a Millipore
filter (0-2 p) using a thermoplastic glue. The cotton
wool acted as a reservoir for the test solutions.
Between the abrasion and the plastic 'hat' a second
0-2 p filter was introduced which was removed and
replaced with a new filter at time intervals of 2,
4, 6, 8, 12, 16, 20 and 24 h. Fresh filters were damp¬
ened with the appropriate test solution and at
each change the interior of the plastic 'hats' was
moistened by injection of the same solution into
the cotton-wool reservoir. The plastic 'hats' were
securely attached to the skin with adhesive tape
and crepe bandages. The solutions were as follows:
Tyrode's diluent; histamine; valyl-peptide; alanyl-
peptide; valyl-peptide and histamine; alanyl-peptide
and histamine; valyl- and alanyl-peptide; valyl-
peptide, alanyl-peptide and histamine—all at a
concentration of 10"3 mol/1 whether given alone
or in combination; and TGP (1 mg/ml). The filters,
removed at the time intervals described above,
were fixed and stained as previously described (Kay,
1970b). Counts were expressed as the total of 10
random high-power fields (x 90), per filter.
RESULTS
Eosinophil chemotaxis
The valyl- and alanyl-tetrapeptides, and the analogue
Val-Gly-Asp-Glu, were tested for eosinophil chemo¬
taxis over a wide dose range (Fig. 1). Eosinophils
from six subjects gave two types of dose-response
pattern with the valyl- and alanyl-peptides. Of these,
four individuals gave peak activity to the valyl-
peptide at 10"8 mol/1, with inhibition at higher
doses, whereas two patients gave two peaks of
activity, one at 10~4 mol/1 and one at 10"7 mol/1.
Eosinophils from individuals giving a double peak of
activity with the valyl-peptide gave a similar pattern
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of response to the alanyl-peptide; however the
response at 10"4 mol/1 was less marked. Similarly
the four individuals whose eosinophils gave a single
peak at 10~8 mol/1 with the valyl-peptide gave a
comparable response to Ala-Gly-Ser-Glu. Only
those subjects who gave two peaks of activity with
the valyl- and alanyl-peptides were tested against
Val-Gly-Asp-Glu. The eosinophils from these
individuals gave a single peak with this analogue
which was maximal at 10"7 mol/1. The patterns of
activity, in terms of the shape of the dose-response
curve, remained constant for eosinophils from the
same person tested against any of the individual
peptides on three or more separate occasions.
Eosinophils from the four individuals who gave
a single peak of activity to the valyl- or alanyl-
peptides, were tested in chemotaxisagainst histamine,
either alone or in combination with the peptides.
With histamine alone these subjects gave a linear
dose response with peak activity at the highest
concentration. When the valyl- (Fig. 2) or alanyl-
(Fig. 3) peptides were tested in combination with
histamine at either 10" 3, 10"5 or 10"7 mol/1 the
resultant chemotaxis was negligible.
When the two peptides were mixed the resultant
eosinophil chemotaxis was dependent on their
relative concentrations (Fig. 4). Increasing con¬
centrations of the alanyl-peptide were combined
with the valyl-peptide at either 10~4, 10~6 or 10"8
mol/1. Chemotaxis was only observed when the
alanyl-peptide, at concentrations from 10"5 to
10"9 mol/1, was combined with the valyl-peptide at
10"8 mol/1.
Further experiments (not shown in the figures)
using a variety of dose combinations of both the
peptides and histamine again resulted in negative
chemotaxis. A similar effect was observed when the
analogue Val-Gly-Asp-Glu was combined with
histamine.
In all studies neutrophil chemotaxis paralleled
the eosinophil response although the counts for the
former were considerably lower. Thus the pattern
of the various dose responses was virtually identical
for both cell types, there being neither neutrophil
nor eosinophil chemotaxis using combinations of
the peptides and histamine.
Marmoset skin studies
In preliminary experiments it was shown that
following passive cutaneous anaphylactic (PCA)
reactions in the marmoset a peak of eosinophil
accumulation was seen at 12 h, whereas untreated
skin examined at 4, 8, 12 and 24 h from animals
given Evans blue dye i.v. contained neither eosino¬
phils nor neutrophils. With increasing concentra¬
tions of serum from the TGP-sensitive individual
(R.B.) there was a concomitant increase in both the
'blueing' reaction and the subsequent infiltration
of eosinophils. The PCA reactions therefore served
as a positive control enabling a comparison of the
eosinophil promoting effects of histamine and the
valyl- and alanyl-peptides. Following i.d. injection
of these agents either alone or in combination, the
resultant eosinophil and neutrophil accumulation
was determined at 12 and 24 h (Fig. 5). At 12 h
neutrophil infiltration was observed with the controls
[antigen alone, antibody alone (not shown in Fig. 5)
and saline] but considerably more was seen at the
treatment sites and following the PCA reaction.
At 24 h, few neutrophils were seen with saline,
antigen, antibody or histamine alone but with the
other treatments large numbers of neutrophils
were still present. Few eosinophils were found at
12 or 24 h with antigen, antibody, saline or histamine
alone; however, when these treatments were com¬
pared to the alanyl- and valyl-peptides the eosinophil
accumulation at 24 h was significantly greater
(P <0 02). At 12 h there was relatively little eosino-
philia with the peptides. At 24 h, when the valyl-
peptide was combined with histamine, the resultant
eosinophil infiltration was significantly less than
that obtained when the peptide was injected separ¬
ately (P<002). When the alanyl-peptide was
combined with histamine the infiltration although
much less than the peptide alone was not significantly
different. Similarly when all three agents were
administered simultaneously inhibition of eosinophil
accumulation was observed when this mixture was
compared to the alanyl- (P < 0 02) or valyl-peptide
(P<005) alone. None of the differences was
significant at 12 h. In the control PCA sites there
were more eosinophils at 12 h than at 24 h, whereas
the individual peptides gave a greater eosinophil
response at 24 h.
In general there was little difference in the number
of mast cells present in the test and control sites at
12 h. However at 24 h, there were fewer mast cells
in the PCA site, compared to the control and treat¬
ment areas of skin. These studies indicate that
the marmoset PCA reactions are associated with
mast-cell depletion (presumably as a result of
60 Lindsay W. Turnbull, D. P. Evans & A. B. Kay
degranulation) but that the acidic tetrapeptides
administered either alone, or in combination with
histamine, did not affect mast cells as assessed by
light microscopy of paraffin sections. The 'blueing'
reactions evoked by the peptides in the marmoset
skin were usually diffuse and ill-defined and there¬
fore it was not possible to quantify them with
accuracy.
Human skin studies
The valyl- and alanyl-peptides and TGP all evoked
eosinophil infiltration following application to the
abraded skin of atopic individuals (Fig. 6), the TGP
positive control giving the greatest response. The
pattern of eosinophil infiltration to TGP was
biphasic with peaks at 8 h and 20-24 h. A similar,
but less marked, response was observed when
either the valyl- or alanyl-peptides were administered
separately. At 24 h the counts with these peptides
were significantly greater than the Tyrode's control
(P<005). However, even at the concentrations
used (10" 3 mol/1) the resultant eosinophilia was only
approximately one-third that of the TGP control.
When the two peptides were applied together there
was an apparent inhibition of eosinophil accumula¬
tion when the values from this combination were
compared to the agents administered separately
(P <0-02). Applications of histamine led to minimal
eosinophil infiltration but this was not significantly
different to the Tyrode's control at any of the time
intervals studied.
The response to Val-Gly-Ser-Glu or Ala-Gly-
Ser-Glu administered in combination with histamine
was significantly less (P<0 05 and P<0 05, res¬
pectively) than with the peptides alone. A mixture of
either of the two peptides and histamine gave a
smaller response than the combination of both
peptides and histamine although this difference
was not significant. Whatever the nature, or com¬
bination, of the agents giving a positive eosinophil
response the patterns tended to be biphasic. The
first peak was between 6 and 8 h and the second,
which was always the more marked, between 20 and
24 h. Neither of the peptides, nor combinations of
the peptides with histamine, gave an eosinophil
response comparable in magnitude to the TGP
control. With all treatments, excluding TGP, the
predominant cell type was the neutrophil but the
numbers were too numerous for accurate quanti¬
fication.
DISCUSSION
A product of the anaphylactic reaction which selec¬
tively attracted eosinophils from a mixed leucocyte
population (Kay, 1969) was later identified as the
eosinophil chemotactic factor of anaphylaxis (ECF-
A) and shown to be a unique mediator of type I
hypersensitivity (Kay & Austen, 1971). It now ap¬
pears that this activity is the property of a family
of closely related acidic peptides, two of which
were identified as Ala-Gly-Ser-Glu and Val-Gly-
Ser-Glu (Goetzl & Austen, 1975). A certain amount
of aspartic acid was also present in highly purified
ECF-A and it has subsequently been shown that the
analogue Val-Gly-Asp-Glu possessed comparable
eosinophilotactic activity (Kay, 1976). The observa¬
tion that histamine (Clark, Gallin & Kaplan, 1975)
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Figure 1. Eosinophil chemotaxis by Val-Gly-Ser-Glu (a),
Ala-Gly-Ser-Glu (b) and the analogue Val-Gly-Asp-Glu (c).
The two patterns of dose-response were from four indivi¬
duals (•) with eosinophilia in association with non-Hodgkin's
lymphoma, microfilariasis, carcinoma of colon and loa-loa,
and two (O) in association with hypersensitivity to mefen-
amic acid and the 'hypereosinophilic syndrome'. Bars
represent +s.e.m.
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Figure 2. Eosinophil chemotaxis to Ala-Gly-Ser-Glu (•), or
histamine (O), or the two agents in combination (■) Ala-
Gly-Ser-Glu+ histamine 10~3 mol/l; (□) Ala-Gly-Ser-Glu+
Histamine 10~5 mol/l; (A) Ala-Gly-Ser-Glu +histamine
I0~7 mol/l.
Figure 3. Eosinophil chemotaxis to Val-Gly-Ser-Glu (•), or
histamine (O), or the two agents in combination. (■) Val-
Gly-Ser-Glu+histamine 10~3 mol/l; (□) Val-Gly-Ser-Glu +
histamine 10~5 moi/1; (A) Val-Gly-Ser-Glu+histamine
I0"7 mol/l.
acid (Turnbull & Kay, 1976) are also preferentially
chemotactic for eosinophils points to the com¬
plexity of anaphylaxis-associated eosinophil chemo¬
tactic agents. In previous studies anaphylactic
diffusates, in general, gave a linear dose response
in chemotaxis, maximal activity being observed with
the highest concentrations. In contrast, the peptides,
or histamine, gave varying patterns of dose-response
activities. Furthermore, different sources of target
cells also gave differing chemotactic profiles to
these agents. In general the peptides gave a peak of
activity between 10"6 and 10"8 mol/l with apparent
inhibition at higher doses (Fig. 1). Eosinophils
from some individuals gave an additional peak
with the valyl- and alanyl-peptides at 10"4 mol/l.
In this report various combinations of the peptides
or histamine were tested in chemotaxis in order to
ascertain whether the pattern of response was
comparable to that of previously published studies
employing anaphylactic diffusates. It was found that
when histamine was combined with either the valyl-
or alanyl-peptides the resultant chemotaxis was
negligible (Figs 2 and 3). Thus not only did histamine
and the peptides fail to act additively or synergistic-
ally but their combination abrogated the chemotactic
response suggesting that there may be cross-
deactivation between these agents. However we
have recently shown that prior incubation of cells
with histamine did not affect their response to the
peptides and similarly incubation with the peptides
did not abrogate the response to histamine (Turnbull
& Kay, unpublished observations). In contrast
prior incubation with histamine deactivated the cells
for chemotaxis towards histamine or imidazole
acetic acid (Turnbull & Kay, 1976) and prior
incubation with the individual peptides deactivated
to the same peptides (Goetzl & Austen, 1975). At the
present time we are unable to explain these clearly
complex interactions but suggest that in vivo there
are possibly two processes which may require
different relative concentrations and combinations
of the various agents. Such events may be, firstly,
directional migration of the cells and secondly,
stabilization of the eosinophil at the site of allergic
reactions. A possible role for histamine in localizing
the eosinophil at the site of anaphylactic reactions
has previously been suggested (Parish, 1974). It
may be that there are also other, as yet unrecognized,
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Figure 4. Chemotaxis of eosinophils to varying combinations
of Ala-Gly-Ser-Glu and Val-Gly-Ser-Glu. (•) Alanyl+
Val-Gly-Ser-Glu 10"4 mol/l; (O) analyl+ Val-Gly-Ser-Glu
chemotactic agents in the anaphylactic diffusate
which also contribute to directional migration and/
or localization. In addition there may be, in vivo,
differing pharmacokinetics in terms of histamine
and ECF-A diffusion and/or inactivation, all of
which may be critical for the observed eosinophil
accumulation and localization. Many of these
problems will not be solved until the relative
Figure 5. Eosinophil (solid columns) and neutrophil accumu¬
lation, and mast-cell counts (open columns) in the skin of
marmosets at 12 h (a) and 24 h (b) following the i.d. injection
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Figure 6. Eosinophil accumulation in human 'skin windows'
following the application of the valyl-, the alanyl-, or
histamine or these agents in various combinations. Timothy
grass pollens (TGP) and Tyrode's (TYR) solution served
as the positive and negative controls respectively.
amounts of the acidic peptides, histamine and
possibly imidazole acetic acid present in anaphy¬
lactic diffusates are known. For this purpose the
development of a quantitative assay for the peptides
in biological fluids is required.
When the valyl- and alanyl-peptides were com¬
bined at low doses in the absence of histamine the
resultant chemotaxis was similar to that of each
peptide tested alone (Fig. 4). The apparent inhibition
of chemotaxis by higher doses of the alanyl-peptide
alone could be abrogated when this peptide was
mixed with the valyl-peptide at 10"8 mol/l.
The studies in vivo using the skin of marmosets
and humans had essential differences in their
experimental design. Experiments in marmoset
skin involved full thickness skin biopsies following
a single injection of the agents either alone or in
combination (Fig. 5). The human skin window
studies, however, involved repeated applications
of the agents to the skin site at 2- or 4-h intervals
over the 24 h study period. These probably explain
the major differences between the results obtained
in humans and the non-human primate. In
marmosets and man both the alanyl- or valyl-
peptide could promote infiltration of eosinophils
(Fig. 5). Combinations of the peptides with histamine
gave lower eosinophil counts in both experimental
situations. The exception was when histamine and
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the valyl- and alanyl-peptides were combined
together in human skin (Fig. 6). In this situation the
resultant eosinophilia was comparable to the valyl-
or alanyl-peptide alone and only slightly more than
histamine alone. These, however, were the observa¬
tions at 24 h. At 12 h, in human skin, histamine
promoted very little eosinophil response whereas
the peptides alone showed some activity. It was the
impression both with the peptides and the positive
control (Timothy grass pollen) that there was a
biphasic response with a peak at 8 h, a slightly
lower count at 12 h and then rising to a greater peak
at 24 h. This dual response was not particularly
marked but was a comparable finding to that of
Hirashima & Hayashi (1976). These workers found
a biphasic response in terms of eosinophil infiltration
in active anaphylaxis in the guinea-pig. The first
peak was associated with ECF-A-like material
whereas the second was related to an eosinophilo-
tactic protein ofmolecular size approximately 70,000,
the nature of which was undetermined. The studies
described in this report may be indicative of a
comparable phenomenon in humans.
There have been a number of studies relating to
capacity of histamine to promote a local eosinophilia
in the skin ofman. Both Eidinger,Wilkinson & Rose
(1964) and Feinberg, Feinberg & Lee (1967)
reported that histamine could induce a modest
eosinophilia in atopic individuals but this response
was far less than that produced by specific antigen.
In contrast Felarca & Lowell (1968) found no such
eosinophil promoting effect with histamine alone.
In general, these studies, and those described in
the present report suggest that in man histamine
has slight eosinophil-attracting activities in vivo
although we were unable to show that the response,
by this agent, was significantly different from the
Tyrode's control. In any event the response to
histamine was far less than that of the individual
tetrapeptides and these, in turn, evoked less eosino¬
phil infiltration than the specific antigen.
Our demonstration of eosinophil recruitment in
the skin of man by acidic tetrapeptides may possibly
have clinical significance in terms of an individual's
capacity to mobilize this cell type in various disease
states associated with an eosinophilia.
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Eosinophil chemotaxis to an ECF-A tetrapeptide
and histamine: the response in various disease states
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Summary
Using the micropore filter technique of Boyden, the eosinophil chemotactic responses
to an ECF-A tetrapeptide (Val-Gly-Ser-Glu) and histamine were studied in thirty-two
patients with a peripheral blood eosinophilia. The eosinophilia was associated with
extrinsic asthma (twelve patients), neoplasia (seven), helminth disease (five) and a
miscellaneous group (eight) which included three patients with pulmonary eosino¬
philia, one of whom also had asthma. Both the tetrapeptide and histamine gave two
types of dose-response. With Val-Gly-Ser-Glu this was either a single peak at 10-8, or
two peaks at 10~4 and 10-7 mol/1, respectively. Histamine gave either a linear dose-
response with maximal chemotaxis at the highest concentration or a peak response at
10-5 mol/1 with inhibition at higher doses. The two types of response given by the
peptide were not related to the disease state and were reproducible when tested on
more than one occasion. However, with histamine, linear dose-responses were
observed in ten out of twelve patients with asthma, four out of five with helminth
disease and two of the three with pulmonary eosinophilia. This was also reproducible
when tested on subsequent occasions. Therefore, in these diseases, which are known
to be associated with exogenous antigens and raised IgE levels, eosinophils from 80%
of the patients studied (sixteen out of twenty) gave a linear rather than a 'bell-shaped'
response to histamine. In contrast, only four of twelve patients (33%)with eosinophilia
in association with other diseases (which included seven with neoplasia) gave this type
of response. If this observation can be confirmed with larger numbers of patients it
may be useful diagnostically in eosinophilia of unknown origin.
Introduction
It has now been established that, using the appropriate micropore filter, both the
ECF-A peptides (Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu) and histamine selectively
attract eosinophils from a mixed leucocyte population (Kay & Austen, 1971; Goetzl &
Austen, 1975; Clark, Gallin & Kaplan, 1975). In previous reports the authors have
shown that cells obtained from six individuals with an eosinophilia gave two patterns
of dose-response curve to histamine and two to the peptides (Turnbull & Kay, 1976;
Correspondence: Dr A. B. Kay, Department of Pathology (Experimental Pathology), The Medical
School, Teviot Place, Edinburgh.
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Turnbull, Evans & Kay, 1977). The purpose of the present study was to determine
whether, in thirty-two individuals with an eosinophilia, the different patterns of
chemotactic response could be related to the subjects' disease state.
Materials and methods
Materials
Materials were obtained as follows: (HCI)-Val-Gly-Ser-Glu, mol. wt. 427 (a gift from
Dr R. Camble, I.C.I. Ltd, England); histamine acid phosphate (BDH Chemicals,
Poole, England); ovalbumin five times crystallized (Koch-Light Laboratories, Coin-
brook, Bucks., England); cellulose nitrate filters, 8-0 ;im (Sartorius-Membrane
Filters, 34 Gottingen, W. Germany).
Patients
Peripheral blood was obtained from thirty-two individuals with an eosinophilia of
between 9 and 37%. Twelve of the patients had extrinsic bronchial asthma with
positive prick test reactions to a variety of extracts of common inhalant allergens.
None of these patients was taking corticosteroids or antihistamines. Seven patients
had neoplasms. These were Hodgkin's disease (three), non-Hodgkin's lymphoma
(one), bronchogenic carcinoma (two), acute lymphatic leukaemia (one) and carcinoma
of the colon (one); none had received any chemotherapy. Five of the patients had
helminth infestation. Three had filariasis, one had Loa-Loa and one had recently
returned from central Africa and the nature of his helminth had not been precisely
defined. Another group of eight patients had a miscellaneous group of disorders
which included pulmonary eosinophilia (three), one of whom also had asthma, and
rheumatoid arthritis (two) (Table 1).
Eosinophil chemotaxis
The preparation of eosinophil leucocytes for the chemotactic assay was performed as
previously described (Turnbull & Kay, 1976). Leucocyte-rich plasma, obtained by
dextran sedimentation of heparinized blood (Kay, 1970), was applied to a density
gradient of 9% Ficoll solution and sodium diatrizoate (density IT40) in the propor¬
tions of 2-4:1 (English & Anderson, 1974). Following centrifugation at 400 g for 40
min at 20°C the eosinophil-rich pellet was retained, washed in Tyrode's solution and
resuspended in Tyrode's solution containing 0-5% ovalbumin. The cell counts were
then adjusted to between 2 and 3 x 106 cells/ml, with a final eosinophil concentration
of 20-30%. Histamine or the valyl-peptide were dissolved in Tyrode's solution and
the pH adjusted to 7-24. All concentrations of each of these agents were assayed in
duplicate. Following a 3 hr incubation, filters were removed, fixed and stained as
previously described (Kay, 1970). The number of eosinophils which had migrated
through each filter was then counted and the results expressed as the total number of
cells in five random high power fields (x 40) per filter. The mean from each pair of
duplicate readings was used in the subsequent statistical analysis as previously
described (Turnbull & Kay, 1976).
Results
The peripheral blood eosinophil count (mean + 1 s.d.) for the groups of patients were:
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asthma, 11-9 + 2-7%; neoplasia, 13-4+ 3-2%; helminth infestation, 13-4 + 3-2%;
pulmonary eosinophilia and miscellaneous conditions (Table 1), 17-5±9-0%. The
differences between these groups were not statistically significant (Wilcoxon test).
Similarly there were no significant differences in the concentration of eosinophils,
after partial separation, and purification between the different groups of subjects
studied.
The results of the eosinophil chemotaxis experiments in the groups of patients with
asthma (Fig. 1), helminth infestation (Fig. 2), neoplasia (Fig. 3), pulmonary eosino¬
philia and the miscellaneous group (Table 1) indicate that there were two types of
dose-response with each chemoattractant. In the majority of patients with asthma,
helminth disease and pulmonary eosinophilia the shape of the dose-response to
histamine was linear while in others a 'bell-shaped' curve was obtained, maximum
eosinophil chemotaxis being observed at a histamine concentration of 10~5 mol/1
with apparent inhibition at higher concentrations (Table 2). Neither the numbers of
eosinophils migrating or the shape of the dose-response curves were related to the
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Fig. 1. Mean (± 1 s.e.m.) eosinophil chemotactic response of twelve patients with extrinsic asthma.











When the asthma, helminth and pulmonary eosinophilia group were considered
together, sixteen of the twenty patients (80%) gave a linear dose-response to histamine.
Only 33% (four of the twelve) in the other groups, which included four patients with
neoplasms, gave a straight line response.
Two patterns of eosinophil response were also seen when the valyl-peptide was
used as the chemotactic agent. In some of the patients there was a single peak of
eosinophil response at 10" 8 mol/1 whereas in others there were two peaks of activity,
one at 10-4 mol/1 the other at 10~7 mol/1. These two patterns of response were
observed with similar frequency (Table 2) and could not be related to the disease state
or the patients' peripheral blood eosinophil count (Fig. 4). Like histamine, the number






Fig. 2. Mean (+1 s.e.m.) eosinophil chemotactic response of five patients with helminth disease. The
numbers of patients giving each pattern of response are shown in parentheses, (a) Histamine; (b) Val-
Gly-Ser-Glu.
Chemotactic agent (mol/l)
Fig. 3. Mean (± 1 s.e.m.) eosinophil chemotactic response of seven patients with neoplastic disease.
The numbers of patients giving each pattern of response are shown in parentheses, (a) Histamine;
(b) Val-Gly-Ser-Glu.
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Table 2. Patterns of the eosinophil chemotaxis dose-response to histamine or
the ECF-A valyl-peptide in patients with diseases associated with exogenous
antigens (extrinsic asthma, helminth disease and pulmonary eosinophilia) and
others with eosinophilia (neoplasia and a miscellaneous group)
Shape of dose-response curve
No. of to histamine
patients
'Bell-shaped' Straight line
Extrinsic asthma 12 2 10
Helminth disease 5 1 4
Pulmonary eosinophilia 3 1 2
Total 20 4 16
Neoplasia 7 3 4
Miscellaneous 5 5 0
Total 12 8 4
Shape of dose-response curve
to valyl-peptide
One peak of Two peaks of
chemotactic chemotactic
activity activity
Extrinsic asthma 12 6 6
Helminth disease 5 2 3
Pulmonary eosinophilia 3 0 3
Total 20 8 12
Neoplasia 7 4 3
Miscellaneous 5 2 3




Bell-shaped' Straight line One peak of Two peaks of
dose-response response chemotactic chemotactic
curve activity activity
Histamine Valyl-peptide
Fig. 4. Peripheral blood eosinophil counts of patients with different patterns of dose-response curve
to histamine and the valyl-peptide.
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of eosinophils migrating to this peptide were virtually identical irrespective of the
disease state or the peripheral blood eosinophil count.
The individual results for eight of the thirty-two patients are shown in Table 1,
but in the others mean values are given (Figs 1, 2 and 3). However, there was no
apparent relationship between the pattern of response to histamine and the ECF-A
peptide. For example, of the twenty patients in all who gave a straight line response to
histamine, ten gave one peak and ten gave a two peak response to peptide.
The patterns of dose-response to both the peptide and histamine were identical
when repeated on one or more occasions in eleven patients. These were helminth
disease (three times with three patients, and twice with one patient), pulmonary
eosinophilia (three times with two patients), asthma (twice with three patients),
miscellaneous (twice with two patients).
Discussion
Under the conditions of these in vitro studies, using a modified Boyden chemotactic
assay, we have observed two patterns of dose-response to histamine so confirming the
observations in a previous report (Turnbull et ah, 1977). In that study, employing
eosinophils from only six subjects, the linear dose-response with highest activity at
the greatest concentration and the response giving a single peak of activity with
inhibition at higher doses were equally divided among these numbers. Tn the present
investigation, in which thirty-two patients were studied, the linear dose-response to
histamine was far more frequent in those who had diseases associated with exogenous
antigens (Figs 1 and 3, Tables I and 2). Although we did not measure IgE levels it is
reasonable to assume that in this respect extrinsic asthma, helminth disease and pul¬
monary eosinophilia represent a homogenous group in terms of our present under¬
standing of the mechanism of eosinophilia. That sixteen out of twenty (80%) gave a
straight line response to histamine suggests that this observation may be useful
diagnostically in the investigation of eosinophilia of unknown cause. Clearly larger
numbers are required to substantiate this finding. However, the observation is
supported by the fact that only four out of twelve (33%) of the remainder gave a
straight line pattern.
Of the two recognized ECF-A tetrapeptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu
(Goetzl & Austen, 1975), only one, the valyl-peptide, was employed in the present
study since from previous work, and other unpublished observations, the pattern of
response in a particular individual is the same for each peptide (Turnbull et al., 1977).
These two shapes of dose-response to the peptides, unlike histamine, did not appear
to be related to the disease associated with the eosinophilia. Moreover, none of the
responses appears to be related to the percentage of eosinophils in the cell population
before migration (Fig. 4). The reasons for these different dose-response curves are
unclear. However, the apparent inability of pharmacological or biological agents to
exert their effects at high, but non-cytotoxic, concentrations is well documented. An
example is the inhibition, by disodium cromoglycate, of histamine release from
passively sensitized human lung fragments challenged with specific antigen (Orange &
Austen, 1971). In this situation the pharmacological effect was only apparent at doses
of 10 jug/ml or less, no effect being observed at higher doses. In the present study inhi¬
bition at high doses of the chemoattractant was unlikely to be a cytotoxic effect, since
the migration of eosinophils into the micropore was unaffected by the higher doses of
either histamine or ECF-A peptide.
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In the accompanying paper differences between atopic and non-atopic individuals
were described in terms of their 'skin window' responses to histamine and the valyl-
peptide. Of considerable interest will be the relationship between the in vivo and in
vitro response to these agents in the variety of eosinophilia-associated diseases and
this is the subject of an ongoing study.
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Cutaneous eosinophil accumulation in atopic and
non-atopic individuals: the effect of an ECF-A
tetrapeptide and histamine
D. H. BRYANT and A. B. KAY
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Scotland Regional Blood Transfusion Service, Royal Infirmary, Edinburgh
Summary
The numbers of eosinophils recruited locally to abraded human skin were measured
in eight atopic and eight non-atopic volunteers, at time intervals over 24 hr, following
the application of an ECF-A tetrapeptide (Val-Gly-Ser-Glu) or histamine. In all
subjects the higher doses of the peptide (10~4 and 10~6 mol/1) or histamine (10~3 and
10"5 mol/1) produced significantly greater counts than the Tyrode's diluent alone. The
counts produced with the lowest dose of peptide (10~8 mol/1) or histamine (10~7
mol/1) were not significantly different from the control. The peptide or histamine
evoked a greater local eosinophilia in the atopics than the non-atopics. This effect was
probably independent of the peripheral blood eosinophil counts since at the time of
study the numbers of circulating eosinophils between the two groups were not signifi¬
cantly different. In the atopics, histamine in doses of 10~3 and 10~5 mol/1 were required
to give the same eosinophil response as that obtained with 10~4 and 10" 6 mol/1 of the
peptide, respectively.
It is suggested that the relative paucity of eosinophils recruited by locally applied
ECF-A peptide or histamine, when compared to antigen-induced eosinophilia, is due
either to an inability to mimic the events associated with the release of these mediators
from mast-cells or the involvement of other pharmacological agents.
Introduction
Various human tissues can be sensitized passively by IgE for the antigen-induced
release of a number of pharmacological mediators. These include histamine, a slow
reacting substance of anaphylaxis and the eosinophil chemotactic factor of anaphylaxis
(ECF-A) (Kay & Austen, 1971). ECF-A selectively attracts eosinophils from a mixed
leucocyte population and has been chemically characterized as two related acidic
tetrapeptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu (Goetzl & Austen, 1975).
Recently it has been shown that, with certain types of micropore filter, histamine will
also selectively attract human eosinophils (Clark, Gallin & Kaplan, 1975) as will one
of its major catabolites, imidazole acetic acid (Turnbull & Kay, 1976).
We have also reported that the individual ECF-A tetrapeptides and, to a lesser
Correspondence: Dr A. B. Kay, Department of Pathology (Experimental Pathology), The Medical
School, Teviot Place, Edinburgh.
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extent, histamine evoked eosinophil accumulation in vivo when applied to the abraded
skin of four atopic subjects (Turnbull, Evans & Kay, 1977). In the present investigation
this study has been expanded to include greater numbers of subjects and to compare
atopic with non-atopic individuals.
Materials and methods
Human volunteers
Eight healthy individuals who had no history of eczema, asthma, allergic rhinitis or
any other allergic disorder and who had negative skin prick test reactions to extracts
of five common inhalant allergens (house dust, the mite Dermatophagoides pteronys-
sinus, mixed grass pollens, A. fumigatus and cat fur—Bencard, Brentford, England)
and eight subjects with perennial allergic rhinitis were studied. All of the subjects with
rhinitis gave positive skin prick test reactions to two or more of the allergen extracts,
one of which was the house dust mite D. pteronyssinus. The symptoms in all of these
subjects were very mild and none had required any form of medication in the four
weeks prior to the study.
Materials were obtained as follows: (HCl)-Val-Gly-Ser-Glu, mol. wt. 427 (a gift from
Dr R. Camble, I.C.I. Ltd, England); histamine acid phosphate (B.D.H. Chemicals
Ltd, England); millipore filters 0-2 pm (Millipore Corporation, U.S.A.); and lyophi-
lized house dust mite extract (a gift from Beecham Research Laboratories, England).
'Skin window'' studies
The 'skin window' technique used in this study has been described in detail elsewhere
(Turnbull et al., 1977). All of the studies were begun at noon and the subjects were
not permitted any alcoholic beverages in the 24 hr prior to the study. Skin sites on the
forearm were thoroughly cleaned with 70% ethanol, and minimally abraded with a
high speed drill, insufficient to cause bleeding. The skin sites were approximately 0-3
cm in diameter and at least 5-0 cm apart. Plastic 'hats' (10 mm in diameter and 5 mm
high) were packed with sterile cotton wool and sealed with a millipore filter (0-2 pm)
using a thermoplastic glue. A second 0-2 pm filter was placed between the abrasion
and the plastic 'hats' (Fig. 1). These filters were soaked with the appropriate test
solution and were changed at intervals of 4,8, 12,20 and 24 hr after the initial abrasion.
At the same time the appropriate test solution was injected into the plastic 'hats' which










Fig. 1. Diagrammatic representation of the 'skin window' technique. Cell counts were performed on
the second Millipore filter on the side in contact with the abraded skin.
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tested in each subject were: Tyrode's diluent; Val-Gly-Ser-Glu (valyl-tetrapeptide) at
concentrations of 10~4, 10-6 and 10~8 mol/1; histamine at 10~3, 10~5 and 10~7
mol/1; and 0-025 mg/ml solution of house dust mite extract. All of the agents were
dissolved in Tyrode's diluent which had been prepared using sterile pyrogen-free
distilled water. All solutions were then passed through a sterile bacterial filter (0-22 pm,
Millipore Corp., U.S.A.) prior to use. The 'skin window' filters were removed at the
time intervals described above and fixed and stained as previously described (Kay,
1970). The counts were expressed as the total number of eosinophils present in ten
random high power fields (x 90) per filter.
Logarithmic rather than linear values were used in the statistical analysis as this
made the variance of the different groups comparable and enabled the Student's
r-test to be used.
Results
The mean peripheral blood eosinophil count of the atopic subjects was higher than
that of the non-atopic subjects but the difference between the groups was not statis¬
tically significant (Table 1). However the 'skin window' eosinophil response to house
dust mite extract between these two groups was markedly different. In atopic subjects
the response rose to a peak at 12 hr and then fell with a secondary rise being observed
Table 1. Peripheral blood eosinophil count and eosinophil response to house
dust mite extract at 'skin window' sites in eight atopic and eight non-atopic
subjects
Subject Eosinophil count 'Skin window' Eosinophil count
(per n\) 4 hr 8 hr 12 hr 20 hr 24 hr
Atopic subjects
D.B. 310 377 562 630 208 267
A.K. 550 180 132 139 22 47
S.M. 120 220 520 310 109 167
J.B. 280 71 153 140 53 88
T.B. 300 13 48 79 64 99
S.C. 240 16 38 70 56 115
D.R. 290 33 58 144 109 172
D.J. 170 67 85 102 52 155
Geometric mean 230 51-4 123-2 153-4 69-3 124-0
± 1 s.e.m. 5 1-6 1-4 1-3 1-3 1-2
Non-atopic subjects
D.P. 150 0 3 0 2 0
C.D. 250 13 6 2 2 2
R.B. 130 6 0 8 0 2
M.M. 340 2 4 0 0 3
J.S. 110 5 5 0 2 0
C.A. 100 2 0 3 4 0
D.H. 310 0 0 0 2 0
J.B. 110 0 3 0 0 0
Geometric mean 170 2-5 2-2 1-6 1-6 1-4
± 1 s.e.m. 3 1-3 1-2 1-3 1-2 1-2
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at 24 hr. The eosinophil response in the non-atopic subjects was negligible and not
even different from that obtained with the Tyrode's diluent (Fig. 2). Although only
eosinophils were counted these cells were far less numerous than neutrophils and
monocytes. In the first 12-20 hr neutrophils predominated while towards the end of
the 24 hr study period mononuclear cells became more frequent. In general these
other cell types were far too numerous to count and this pattern of cellular accumula¬
tion was the same in response to allergen, peptide or histamine.
Time(hr) Time (hr)
Fig. 2. Geometric mean (± 1 s.e.m.) of the eosinophil response to valyl-tetrapeptide at 'skin window'
sites of eight atopic (a) and eight non-atopic subjects (b).
The eosinophil response of the atopic and non-atopic subjects to the valyl-tetra-
peptide is shown in Fig. 2. In the atopic subjects the mean eosinophil counts obtained
with both the 10~4 and 10~6 mol/1 solutions were significantly different (/3<0-0005)
from the number obtained with the Tyrode's diluent at all of the time intervals studied.
With the 10~8 mol/1 solution only the counts obtained at the 12 and 20 hr intervals
were significantly different (PcO-Ol) from those obtained with the Tyrode's diluent.
In the non-atopic subjects the mean number of counts obtained at the 8 and 12. hr
intervals with the 10~4 mol/1 and 10~6 mol/1 solutions were significantly greater than
the values obtained with the Tyrode's diluent (/5<0 05) but none of the mean values
obtained with these two concentrations of valyl-tetrapeptide at the other times nor
any of the mean values obtained with the 10"8 mol/1 solution was significantly greater
than that of the Tyrode's diluent.
The mean eosinophil counts obtained in the atopic subjects with 10~4 and 10~6
mol/1 peptide solutions were significantly higher (P <0-005) between 8 and 24 hr, than
the mean counts in the non-atopic subjects at these times. The atopic group gave
significantly higher counts at 12 hr and after with the 10~8 mol/1 solutions. In both
groups of subjects the counts rose to a maximum between 8 and 12 hr. With atopic
subjects the eosinophil counts were maintained at this level for the 24 hr while in the
non-atopics the eosinophil counts fell after 12 hr and by 20 hr the mean values obtained
with all of the concentrations of valyl-tetrapeptide used were not significantly different
from those obtained with the Tyrode's diluent.
The eosinophil responses of the atopic and non-atopic subjects to the histamine
solutions are shown in Fig. 3 (and should be compared with the Tyrode's control
shown in Fig. 2). The mean eosinophil counts obtained in the atopic subjects with the
10~7 mol/1 solution were not significantly different from those obtained with the
Tyrode's diluent at any of the time intervals studied while all of the values obtained
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mol/L
Fig. 3. Geometric mean (+1 s.e.m.) of the eosinophil response to histamine at 'skin window' sites of
eight atopic (a) and eight non-atopic subjects (b). The Tyrode's diluent control is shown in Fig. 2.
with the 10""3 and 10"5 mol/1 solutions were significantly higher from 8 hr and after.
In the non-atopics the values between 4 and 20 hr, with the 10"3 mol/1 solution, and
those between 4 and 12 hr with the 10~5 mol/1 solution were significantly greater
(P<0-005) than the control. The values with 10"7 mol/1 in the non-atopics were not
significantly greater than control.
In Table 2 the eosinophil responses (of the two groups) to the valyl-peptide and
histamine are compared in terms of the maximal response regardless of the time at
which this occurred. The maximal eosinophil response in the non-atopic subjects to
the valyl-peptide was significantly less (P <0-005) than that obtained in the atopic
subjects. Moreover the maximal response in the non-atopic subjects occurred in the
first 12 hr of the study while, in the atopic subjects, the eosinophil counts tended to
increase with time. A similar pattern of results was obtained with histamine.
Although histamine and the valyl-peptide were not compared at identical molar
concentrations in the two groups, doses of histamine at 10"3 and 10"5 mol/1 were
required to evoke the same eosinophil response as that obtained with 10~4 and 10"6
mol/1 of the peptide respectively. This suggested that the eosinophil mobilizing capacity
of the peptide was about ten times greater than that of histamine.
Table 2. Maximal eosinophil response to valyl-tetrapeptide and histamine at 'skin window' sites of
eight atopic and eight non-atopic subjects





of chemotactic agent giving
peak response
Median time of peak
response (hr)
Val-Gly-Ser-Glu Histamine
Atopic Non-atopic Atopic Non-atopic
subjects subjects subjects subjects
390 13 1 25-6 16-5
1-8 3-2 1-3 1-4
10"4 10-4 10"3 io-3
22 6 22 10
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Discussion
The main purpose of this study was to compare the eosinophil responses of atopic and
non-atopic individuals. The results suggest that the valyl-tetrapeptide (Fig. 2) or
histamine (Fig. 3) evoked a greater eosinophil response in atopic compared to non-
atopic subjects. Thus the atopic individuals appear to have a greater eosinophil
mobilizing capacity than 'normal' subjects (Table 2). The reasons remain unclear at
present but are not explicable solely on differences in the peripheral blood eosinophil
count as these were not significantly different between the two groups (Table 1).
In a previous study, with only four atopic subjects, it was reported that histamine
had only slight eosinophil-attracting activity in vivo (Turnbull et al., 1977). However,
in this report, in which sixteen subjects were investigated, histamine clearly had a
significant eosinophil-attracting effect even in non-atopics. Significant eosinophil
accumulation in human skin, especially in that of atopics, was described in previous
studies (Eiginger, Wilkinson & Rose, 1964; Cole & Roberts, 1966; Feinberg, Feinberg
& Lee, 1967) while other workers have failed to demonstrate that this amine is capable
of evoking eosinophil accumulation in human skin (Fowler & Lowell, 1966; Felarca &
Lowell, 1968). However, in contrast to these other investigators, we have studied
sixteen individuals and made measurements at 4, 8, 12, 20 and 24 hr following the
application of three different concentrations of histamine. Therefore it is not possible
to compare directly our results with these previous reports.
In view of the marked disparity between the number of eosinophils which accu¬
mulated in the abraded skin sites treated with allergen, and those treated with tetra-
peptide or histamine, it is evident that it is not possible to explain fully the eosinophil
accumulation which occurs at the site of immediate allergic reactions. A requirement
for both histamine and peptide in promoting eosinophil accumulation seems unlikely
as mixtures of these agents had a negative rather than additive effect both in vivo and
in vitro. It was for this reason also that one only of the ECF-A peptides was used since
mixing the valyl- and alanyl-peptide also had a negative effect under these same
conditions (Turnbull et al., 1977).
It is reasonable to suppose that eosinophilotactic anaphylaxis-associated mediators
play a role in eosinophil accumulation in vivo. However, in the present study eosinophil
counts obtained in atopics by the mite allergen were far greater than those in which
exogenous histamine had been applied to the skin (Table 1). There was no evidence,
from the appearance of the various skin sites, that there was more histamine release by
antigen than the amount applied externally. The inability to mimic the antigen-
induced eosinophil response by chemical mediators alone may be explained as follows.
Subtle mixtures of histamine and peptides may be required although this is unlikely
for the reasons explained above. The time course of release, the rate of diffusion and/or
inactivation may be critical factors, or alternatively other mediators are involved
which have yet to be defined.
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Summary. Depletion of eosinophils by an anti-
eosinophil serum resulted in the inhibition of hista¬
mine reaccumulation into guinea-pig skin sites fol¬
lowing IgGl-mediated passive cutaneous anaphy¬
laxis. This suggests that eosinophils may have
a regulatory role in the repair mechanism which
follows immediate-type hypersensitivity reactions.
INTRODUCTION
Following IgG 1 -mediated passive cutaneous anaphy¬
laxis (PCA) in the guinea-pig, eosinophils accumu¬
lated in large numbers 8-12 h following antigen
challenge (Kay, 1970a). We have suggested that
eosinophils may play a role in repair following local
anaphylaxis (Jones & Kay, 1975). In the present
report evidence is provided to support this concept
by showing that eosinophil depletion by a mono¬
specific anti-eosinophil serum accelerates the re¬




Albino Dunkin-Hartley guinea-pigs of either sex
Correspondence: Dr A. B. Kay, South-East Scotland
Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh, Scotland.
weighing 300-400 g were used throughout this study
Preparation ofpurified guinea-pig IgGl
Guinea-pig antiserum to ovalbumin was prepared
and fractionated as previously described (Kay,
1970a, b). The functional purity of the IgGl-con-
taining fractions was tested by PCA, passive
haemolysis and passive haemagglutination (Bloch,
Kourilsky, Ovary & Benacerraf, 1963) and by
immunoelectrophoresis and gel diffusion using
rabbit anti-7S IgG and specific anti-guinea-pig IgGl
(Kay, 1970a).
Preparation of rabbit anti-guinea-pig eosinophil
serum {AES)
Eosinophils were recovered by peritoneal lavage of
animals which had received weekly intraperitoneal
injections of horse serum for a 4-6-week period (Kay,
1970b). Eosinophils were purified by density
centrifugation on sodium diatrizoate (d = 1140 at
20") (Gleich & Loegering, 1973). Cell populations
containing more than 95 per cent eosinophils were
used for raising AES.
AES was prepared in the rabbit by three weekly
injections of purified eosinophils in Freund's com¬
plete adjuvant. Each preparation, containing ap¬
proximately 10s cells in a total volume of 2 ml of
Tyrode's solution was administered to two sub¬
cutaneous areas of the neck. Animals were bled by
cardiac puncture 1 week after the final injection, the
serum inactivated by heating at 56° for 60 min and
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stored in 1-ml aliquots at —85°. Normal rabbit
serum (NRS) was similarly inactivated as a control
for assessing the specificity of AES.
Measurement of histamine depletion following PCA
The shaved dorsa of guinea-pigs were divided into
six equal areas of three pairs. One site of each pair
was injected intradermally with 01 ml of IgGl, and
a contralateral control site with 01 ml of Tyrode's
solution. Following an 18-h sensitization period the
animals were challenged intravenously with 0-75 ml
of 2 per cent Evan's blue in Tyrode's solution con¬
taining 1 mg/ml of ovalbumin. Blueing reactions were
measured and marked with indelible ink after 30-45
min. The dilution of IgGl was adjusted to give
blueing areas of approximately 15 mm in diameter
(1:100 for the preparation used). At varying time
intervals following challenge animals were killed, the
IgGl-treated and equivalent control sites removed,
dissected free of subcutaneous adipose tissue,
weighed, chopped into small fragments, washed in
Tyrode's solution, resuspended in 3 ml of the same
buffer and placed in a boiling water bath for 15 min.
The supernatants were then removed and assayed for
histamine using the isolated, perfused guinea-pig
ileum (Brocklehurst, 1960).
Changes in tissue histamine content (H) were de¬
fined as a percentage depletion (per cent D). The
latter was computed as the mean value of
H control - H test
G 1 x 100H control
for the three pairs where H was expressed as uglg
wet weight of skin. At least three animals were used
for each measurement.
RESULTS
Cell specificity of AES
AES was shown to agglutinate suspensions of puri¬
fied guinea-pig eosinophils to a dilution of 1 in 80
and to lyse these cells following the addition of fresh
guinea-pig serum as a source of complement. At
a dilution of 1 in 5 AES did not agglutinate, or
'complement-Iyse', guinea-pig neutrophils, macro¬
phages, lymphocytes or red cells.
Following PCA reactions, in which antigen and
Evan's blue was administered with Tyrode's solu¬
tions, NRS or AES, the number of eosinophils
migrating to the reaction sites at 18 h is shown in
Table 1. Depletion of eosinophils from the sites of
IgGl-mediated PCA reactions by anti-eosinophil
serum
Animal no. Treatment (ml) Eosinophils/5 h.p.f.
1 AES (0-25) 9
2 AES (0-25) 7
3 AES (0.5) 1
4 AES (0-5) 2
5 AES (0-5) 12
6 NRS (0-25) 50
7 NRS (0 5) 24




Table 1. With AES the number of eosinophils was
markedly less than in animals pretreated with NRS.
The numbers of cells in NRS or Tyrode's pretreated
animals were virtually identical. With all treatments
the numbers of infiltrating neutrophils and mono¬
nuclear cells were too numerous to count.
Effect of AES on skin histamine levels following
PCA
The depletion and replenishment of tissue histamine
levels following PCA reactions is shown in Table 2.
Irrespective of the treatment, the histamine content
of the control sites (1-14) showed no significant
differences. This indicated that AES had no effect
on normal skin histamine content. There were also
no significant differences in histamine content
between contralateral sites in untreated animals (1);
the same sites in animals challenged with antigen
(2) and control and test sites pretreated with anti¬
body in unchallenged animals (3). In those sets of
animals in which a PCA reaction was evoked (4—14),
there was considerable depletion of histamine at 1 h
(4, 8 and 12). Those animals having Tyrode's (4-7) or
0-25 ml of NRS (8-11), injected intravenously with
antigen, had comparable patterns of histamine
replenishment and levels were not restored to con¬
trol values until 48 h. In contrast, those animals
receiving 0-25 ml of AES with antigen had recovered
their histamine skin content by 9 h (13) and this was
maintained at 24 h (14). Thus there was no signifi¬
cant difference between the Tyrode's and NRS 9-
and 24-h points (5 and 9, 6 and 10 respectively)
whereas there was a highly significant difference
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Table 2. The effect of anti-eosinophil serum on skin histamine replenishment following passive cutaneous anaphy¬
laxis
Prior
preparation Time (h) after Histamine content* Percentage
antigen No. of (+ s.e.mean) of depletion (+s.e.mean)
No. Treatment IgGl Ag challenge animals control sites of test sites
1 Tyrode's None None 6 3-7 (±0-4) + 6-0 (±4-4)
2 Tyrode's — + 6 3-1 (±0-7) + 4-0 (±4-7)
3 Tyrode's + — 6 3-9 (±0-3) + 0-4 (±5-3)
4 Tyrode's + + 1 6 3-3 (+0-6) -56-2 (± 3-9)
5 Tyrode's + + 9 4 3-6 (+0-4) -34-0 (±1-0)
6 Tyrode's + + 24 6 3-9 (±0-5) -33-0 (+4-3)
7 Tyrode's + + 48 6 3-3 (±0-2) -10-5 (±3-4)
8 NRS + + 1 3 3 0 (+0-6) -49-0 (±2-6)
9 NRS + + 9 4 3-0 (±0-6) -34-0 (±14-4)
10 NRS + + 24 4 3-6 (±0-4) -23-0 (±4-7)
11 NRS + + 48 4 2-9 (+0-5) -1-7 (±2-2)
12 AES + + 1 3 3-4 (±1-4) -47-3 (±2-0)
13 AES + + 9 3 3-3 (±0-2) + 6-0 (+5-9)
14 AES + + 24 11 3-1 (±0-4) + 6-4 (±14-4)
* pg/g wet weight of skin.
when the Tyrode's or NRS 9-h points (5 or 9) were
compared with the AES 9-h point (13) (PcO-OOl).
Similarly, the Tyrode's or NRS 24-h points (6 or 10)
were significantly different when compared to AES
at 24 h (14) (P<005).
DISCUSSION
In this report we suggest that the eosinophil may
prevent replenishment of tissue histamine levels
following cutaneous anaphylaxis (Table 2). The
basis of this claim depends largely on the specificity
of the anti-eosinophil serum. The AES used in these
experiments was not absorbed with other cell types
as this resulted in considerable loss in AES activity.
However, cells used for immunoabsorption in¬
variably contained eosinophils which could not be
removed entirely even by separation procedures
such as density centrifugation on sodium diatrizoate.
Nevertheless, we feel that the AES used in this study
was highly specific as shown by selective agglutina¬
tion and lysis of eosinophils in vitro and selective
depletion of this cell type in vivo following passive
cutaneous anaphylaxis (Table 1). It was very un¬
likely that AES had a direct effect on mast cells in
terms of their histamine content since the levels of
this amine in the control sites of AES-treated animals
were virtually identical to those in other control sites
(Table 2). We were unable to ascertain conclusively
the effect of local AES treatments since normal rabbit
serum from a variety of sources evoked local dye
extravasation (Kay, unpublished observation).
A rabbit anti-guinea-pig eosinophil serum has also
been described by Gleich, Loegering & Olsen (1975).
These workers and ourselves have found that AES
activity, as analysed by in vitro cytotoxicity tests,
was removed by adsorption with neutrophils. How¬
ever, whereas the intraperitoneal injection of AES
resulted in a complete absence of eosinophils from
the peripheral blood and peritoneal cavity, there was
only transient, or no, reduction in circulating
neutrophils. However the effect of antisera directed
against the neutrophil, monocyte or lymphocyte on
mediator replenishment following anaphylaxis is yet
to be ascertained but these studies are in progress.
The work described here, together with other
reports on the role of the eosinophil in immediate-
type hypersensitivity, suggest that this cell has
a number of functions in allergic tissue reactions.
Thus eosinophil-derived prostaglandins may in¬
hibit further histamine release (Hubscher, 1975a, b),
and eosinophil histaminase (Zeiger & Colten, 1974)
and arylsulphatase (Wasserman, Goetzl & Austen,
1975) inactivate histamine and slow reacting sub¬
stance of anaphylaxis respectively. Therefore the
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eosinophil may have a regulatory role at all stages
of the allergic response, namely mediator release,
mediator inactivation and, as suggested here, media¬
tor replenishment. The regulatory role of the eosino¬
phil in the events following anaphylaxis may provide
a homeostatic mechanism whereby the antigen-
induced release of histamine and possibly other
mediators is not perpetuated in situations where
there is continuous antigenic stimulation.
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MEMBRANE RECEPTORS FOR IgG AND COMPLEMENT (C4, C3b AND
C3d) ON HUMAN EOSINOPHILS AND NEUTROPHILS AND THEIR
RELATION TO EOSINOPHILS
A. R. E. ANWAR1 AND A. B. KAY
From the South-East Scotland Regional Blood Transfusion Service, Royal Infirmary, Edinburgh, and Department ofPathology,
University ofEdinburgh
Receptors have been shown, on human eosinophils and
neutrophils, for rabbit IgG, human IgG, and human C4, C3b
and C3d. Both types of granulocyte formed rosettes with
EAcf11. This was directly related to the amount of sensitizing
antibody. No rosettes were formed with E alone or EAN',:ih
Receptors for human IgG were also demonstrated by using
heat-aggregated IgG and fluorescent-labeled anti-human
IgG. In addition, aggregated human IgG inhibited both eosi¬
nophil and neutrophil rosettes with EA<fh.
Red cell intermediates were prepared with EAMb (EA) and
functionally pure human complement components. Eosino¬
phil and neutrophil rosette formation was demonstrable
with EAC14 and EAC1423b, prepared with limited amounts
of C4 (EAC3b), and was related directly to the input of
either C4 or C3. No granulocyte rosettes were formed with
EAC1 or EAC142. By decay experiments it was shown that
C2, in addition to forming the classical pathway C3 conver-
tase with CI and C4, also inhibited eosinophil and neutro¬
phil EAC14 rosettes. EAC3d intermediates (prepared by
treating EAC3b cells with the C3b inactivator and so render¬
ing them immune adherence negative, unsusceptible to lysis
with C5-C9 and more agglutinable with anti-C3d) formed
rosettes with eosinophils and neutrophils in comparable
numbers to EAC3b cells. In general, the percentage of neu¬
trophils bearing receptors for rabbit IgG, human IgG, or
human C4, C3b, and C3d was approximately two and one-
half times greater than eosinophils.
There was a significantly reduced percentage of eosino¬
phils forming rosettes with EAC14 or EAC3b when patients
with eosinophilia of various etiology were compared to con¬
trols; however, no differences were found with EA';ah- When
neutrophils from patients with eosinophilia were compared
to controls in terms of percentage of EA<fb, EAC14, or
EAC3b rosettes, there were no significant differences. These
results, taken together with previously published findings
on the monocyte, suggest that all circulating phagocytic
cells have similar membrane receptors for promoting adher¬
ence of opsonized particles and that with eosinophils the
numbers of complement receptors may be altered in disease.
Membrane surface receptors for immunoglobulin and com¬
plement components have been demonstrated on a number of
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hemopoietic cells. Most of the studies relate to cells of the
lymphoid series and mononuclear phagocytes; however, the
presence of surface receptors for IgG and complement on hu¬
man or animal granulocytes has also been described. For
example, the presence of receptors for human IgG (1), C3b (2)
and C4 (3, 4) on human neutrophils has been described. Simi¬
larly, the presence of IgG (5) and C3 receptors on human
eosinophils (5, 6) has been reported. It was also claimed that
eosinophils have lymphocyte-like properties in that they bind
sheep red blood cells (E)3 alone (i.e., unsensitized) (6).
The need to define the presence of immunoglobulin and
complement receptors on human eosinophils more precisely
has been prompted largely by the work of Butterworth et al.
(7) who showed that human eosinophils from normal individ¬
uals were the principal effector cells in antibody-dependent
killing of schistosomula in vitro.
In the present study we report on the presence of IgG, C4,
C3b, and C3d receptors on human eosinophils and neutrophils
and their apparent alteration in individuals with blood eosino¬
philia.
MATERIALS AND METHODS
Buffers. Dextrose-gelatin-Veronal buffer (DGVB++), pH 7.4,
was prepared by mixing equal volumes of isotonic Veronal -
buffered saline (containing 0.0015 M Ca++, 0.0005 M Mg++,
and 0.1% gelatin Veronal buffer (GVB++)) with 5% dextrose in
water containing the same concentration of Ca++ and Mg++, as
previously described (8). GVB= was prepared as for GVB++ but
without the addition of divalent cations.
A stock solution of 0.086 M EDTA, pH 7.4, was prepared and
diluted in GVB=, to prepare 0.04 M EDTA GVB=, or 0.01 M
EDTA GVB-.
Sheep red blood cells. Sheep blood was drawn aseptically
into sterile Alsever's solution and kept at 4°C. Immediately
before use the E were washed twice in cold saline, once in 0.01
M EDTA GVB=, and adjusted to the required concentration in
the same buffer.
Rabbit anti-sheep red blood cells (A). Multiple injections of
E stroma were administered to rabbits as described by Rapp
and Borsos (9). The IgG and IgM fractions were obtained by
gel filtration on Sephadex G-200 (10).
Sensitization ofE. Either rabbit IgG or IgM was added to E.
Sensitization was achieved by selecting an antibody concen¬
tration which caused optimal sensitization but no agglutina-
2 Please address all correspondence to Dr. A. B. Kay, Department
of Pathology, University Medical School, Teviot Place, Edinburgh,
EH8 9AG.
3 Abbreviations used in this paper: E, sheep red blood cells;
DGVB, dextrose-gelatin-Veronal buffer; GVB, gelatin Veronal
buffer; A, anti-sheep red blood cells.
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tion (9). The mixture was incubated at 37°C for 30 min in a
shaking water bath, and 0°C for 30min with frequent shaking.
The cells were then washed once in 0.01 M EDTA GVB= and
twice in DGVB++.
Human IgG and complement components. Human IgG was
prepared by diethylaminoethyl (DEAE)-cellulose chromatog¬
raphy and aggregated by the method of Dickler and Kunkel
(11). The control, bovine serum albumin (BSA) (Miles Labora¬
tories Inc., Kankakee, 111.) was aggregated as described (12).
All aggregated proteins were adjusted to a concentration of 1.2
mg/ml.
Human CI was prepared by euglobulin precipitation accord¬
ing to the method described by Vroon et al. (13). Human C4
was prepared by sequential precipitation and ion-exchange
chromatography on DEAE-Sephadex and carboxymethyl
(CM)-Sephadex as previously described (13). Human C2, C5,
C6, C7, C8, and C9 were purchased from Cordis Laboratories
(Miami, Fla.) and purified human C3 was a generous gift from
Dr. D. K. Peters. Purified C3b inactivator was kindly supplied
by Dr. P. J. Lachmann, but in some experiments Cordis C3b
inactivator was used. All complement components were func¬
tionally pure and free of other hemolytically active compo¬
nents as assayed by effective molecular titrations (9). Mono¬
specific anti-C3d was purchased from the Netherlands Red
Cross Blood Transfusion Service, Amsterdam.
Preparation ofcomplement-coated intermediates. EAj?b was
prepared as for EAfcab\ For EA)|bClhu, EA was mixed with 400
effective molecules of human CI per red cell. The mixture was
incubated for 90 min at 0°C and then washed once in DGVB++.
EAjJbClhu4hu cells described in Table I, Table II, and Figure 4
were prepared by the addition of 4000 effective molecules of
human C4 per EAC1 cell. The mixture was incubated for 30
min at 37°C. The cells were then washed four times in
DGVB++.
EA(fbClhu4hu2hu cells used in the C2 decay experiments were
prepared by adding 50 effective molecules of human C2 per
EAC14 cell and the mixture was incubated at 30°C for 10 min
without washing.
EAC1423b (EAC3b) cells were prepared as follows: 400 effec¬
tive molecules of human C4 were added to EAC1 and incu¬
bated and washed as described. To this EAC14 intermediate
(which had insufficient C4 to form rosettes with either neutro¬
phils or eosinophils) were added 50 effective molecules of hu¬
man C2 and the mixture was incubated at 30°C for 10 min
without washing. In the experiments described in Table I,
Table II, Figure 3, and Figure 4, 2500 effective molecules of
purified human C3 were added to these EAC142 cells. The
mixture was incubated at 37°C for 30 min and the cells were
washed twice in DGVB++.
EAC1423d intermediates were prepared by treating 0.5 ml of
EAC3b cells containing 1 x 108 cells/ml with 0.5 ml of the C3b
inactivator. The mixture was incubated for 1 hr at 37°C. The
cells were then washed twice with cold DGVB++. The quantity
of C3b inactivator added was calculated by determining the
amount required to cause 95% inhibition of immune adherence
by using EAC3b cells and human group O, Rh-positive eryth¬
rocytes (14).
Eosinophils and neutrophils. Blood from patients with eo¬
sinophils (Table III and Fig. 4) and from healthy controls was
drawn into plastic tubes containing 10 units of preservative-
free heparin (Evans Medical, Liverpool, England) per ml. The
red cells were sedimented with 70% dextran (Lomodex 70,
Fisons Pharmaceuticals, Loughborough, England); one part
dextran to four parts blood v/v, for 60 min at room tempera¬
ture. The leukocyte-rich plasma was then layered over sodium
metrizoate (Nyegaard & Co., As, Oslo, Norway), specific grav¬
ity 1.148 at 4°C, in 15-ml plastic conical centrifuge tubes and
centrifuged at 4°C for 40 min at 400 x G.
The pellet, containing red blood cells and granulocytes, was
resuspended in 0.82% ammonium chloride solution as de¬
scribed by Boyle to lyse the red cells (15).
The cells were then washed twice in medium 199 (Flow
Laboratories, Irvine, Scotland, U.K.), pH 7.4, and the cell
count was finally adjusted to 2 x 106/ml in the same medium.
These suspensions contained both eosinophils and neutrophils
but were virtually free of mononuclear cells.
EA and EAC rosette formation. One-tenth milliliter of E,
EA, or EAC containing 1 x 108 cells/ml in DGVB++ was added
to equal volumes of granulocyte suspension in medium 199.
The mixture was centrifuged at 100 x G for 10 min at 4°C.
These mixtures, with the undisturbed pellet, were then incu¬
bated at 0°C (for EA rosettes) or 37°C (for EAC rosettes) for 30
min. The pellet was gently resuspended and smears were
prepared on clean glass slides in duplicate. These were dried
quickly in air, fixed in 95% methanol, and stained with May
Grunwald/Giemsa. Only granulocytes with three or more ad¬
herent E were termed rosettes. In each slide 200 granulocytes
were counted and the number of rosetting cells was expressed
as a percentage of the total number of eosinophils or neutro¬
phils counted.
Immunofluorescence. Granulocyte concentrations were ad¬
justed to 5 x 106/ml in medium 199. Before use the cells were
washed once in "FA buffer" (Difco Laboratories, Detroit,
Mich.) and 0.5 ml of the granulocyte suspension was mixed
with an equal volume of heat-aggregated human IgG, native
IgG, or the control-aggregated bovine serum albumin. The
mixture was incubated at 0°C for 30 min. The cells were then
washed three times in FA buffer at 4°C. The fluorescent-
labeled rabbit anti-human IgG (Miles Laboratories, Slough,
England) was added to the cell suspension and the mixture
incubated for a further 30 min at 0°C. The cells were washed
three times in cold FA buffer and then resuspended in 2 drops
of the "FA mounting medium" (Difco Laboratories). One drop
of the cell suspension was mounted in a clean glass slide under
a coverslip. The slides were prepared in duplicate, viewed
under ultraviolet light, and the number of fluorescing cells
counted. Cells with two or more peripheral fluorescing sites
(i.e., nongranular fluorescence) were deemed positive. In each
slide 200 cells were counted and the granulocytes showing
positive fluorescence were expressed as a percentage of the
total number of granulocytes counted.
RESULTS
E sensitized with rabbit IgG (EA<rab) formed rosettes with
human neutrophils and eosinophils in a dose-response fashion
by using increasing amounts of antibody (Fig. 1). The percent¬
age of rosetting neutrophils was approximately two and one-
half times the number of eosinophil rosettes. Heat-aggregated
human IgG inhibited rosette formation of neutrophils and
eosinophils with EA^ab. No rosette formation was observed
with E or with EAjfb prepared with a comparable agglutinat¬
ing titer to rabbit IgG.
When these experiments were performed at higher tempera¬
tures, (18° and 37°C), the number of rosetting cells was consid¬
erably less and was associated with phagocytosis of sensitized
red cells by both neutrophils and eosinophils.
Surface receptors for human IgG were demonstrable by
treating the granulocyte suspensions with heat-aggregated
human IgG and counting the number of fluorescing cells after
the addition of fluorescein-labeled monospecific rabbit anti-












Figure 1. The effects of increasing concentra¬
tions of rabbit IgG on human neutrophil and
eosinophil rosette formation by EA<Jab and their
inhibition by aggregated human IgG. The points
represent the mean (± 1 S.D.) of five experi¬
ments. The degree of significnce of inhibition
with aggregated IgG1"1 is expressed as p value as
calculated by the Student t-test.
human IgG (Fig. 2). The number of fluorescing cells with heat-
aggregated IgG was significantly greater (p < 0.001) than with
native IgG or with the aggregated bovine serum albumin
control. As with the EAoab rosettes (Fig. 1), the percentage of
fluorescing neutrophils was approximately two and one-half
times that of eosinophils.
The rosette-forming capacity of E coated with various hu¬
man complement components with human neutrophils and
eosinophils is shown in Table I. E, EAm", EA-;?bClhu, and
EA(?bClhu4hu2hu were virtually unreactive at 0°C and 37°C. the
apparent ability of EAMabC142 to form rosettes at 37°C was
attributable to C2 decay (Table II). In contrast, EAC14 (pre¬
pared with 4000 effective molecules per cell), EAC1423b, and
EAC1423d (prepared with limited amounts of C4) formed ro¬
settes with neutrophils and eosinophils.
Rosette formation by EAC14 and EAC 1423 was related to
the input of C3 or C4 as shown in Figure 3. Increasing amounts
of these complement components gave rise to increased num¬
bers of eosinophil rosettes which paralleled the percentage of
lysis as determined by the addition of the appropriate late
components required to complete the hemolytic sequence.
Similar results were found with the neutrophils although the
number of resetting cells was two to three times greater. The
ability of eosinophils and neutrophils to recognize activated
cell-bound human C4 or C3 was demonstrable in a dose-de¬
pendent fashion.
The capacity ofC2 to inhibit the binding ofEAC 14 to eosino¬
phils and neutrophils is shown in Table II. Binding of EAC14
to these granulocytes was restored by allowing C2 decay from
EAC142 cells after incubation of this intermediate at 37°C for
30 min. The C2 preparation was free of the C3b reactivator.
Therefore the addition of C2 to EAC14 promotes both the
formation of the classical pathway C3 convertase and the
inhibition of binding of C4 to these granulocytes.
Evidence for binding of red cell intermediates coated with
C3d was achieved by treating the EAC1423b with purified C3b
reactivator for 1 hr at 37°C. These C3d-coated cells, in contrast
to untreated C3b cells, were no longer immune adherence
positive and could not be lysed by the addition of C5-C9.










Figure 2. The percentage of fluorescing eosinophils and neutro¬
phils after treatment with heat-aggregated IgG, or controls, and
fluorescent anti-human IgG. The bars represent the mean (± 1 S.D.)
of seven experiments.
did C3b cells, but to a greater extent. Both EAC3b and EAC3d
formed rosettes with neutrophils and eosinophils as shown in
Table III but only the numbers of EAC3d eosinophil rosettes
were significantly less than that for EAC3b (p < 0.05).
The numbers of eosinophils and neutrophils from normal
individuals, or those with eosinophilia, giving rosettes with
EA{fb, EAC14, or EAC1423 are shown in Figure 4. With
EAg" there was no difference in the numbers of rosetting
eosinophils between the two groups. However, the number of
eosinophils rosetting with EAC14 or EAC 1423 was signifi¬
cantly lower (p < 0.05) in the eosinophilia group. When the
neutrophils from individuals with eosinophilia were compared
with those having eosinophil counts of less than 4%, there was
no significant difference in the percentage of rosetting cells
with EAg"' i EAC14, or EAC1423. The percentage of blood
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TABLE I
Eosinophil and neutrophil rosettes with E coated with rabbit antibody and various human complement intermediates"
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Indicator Cells
Eosinophil Rosettes Neutrophil Rosettes










EA[?b 25.3 ± 3.6 16.3 ± 2.8 76.8 ± 7.6 58.3 ± 8.0
EA{?b 2.4 ± 1.2 3.3 ± 1.3 5.6 ± 2.2 4.5 ± 1.4
EA(?bClbu 4.0 ± 1.5 6.0 ± 1.6 3.5 ± 1.0 4.6 ± 1.3
EA(?bClbu4hub 10.0 ± 2.7 20.5 ± 1.8 54.8 ± 4.9 63.0 ± 7.5
EA(?bClhu4hu2bu<' 5.2 ± 1.6 (15.5 ± 3.6) 7.0 ± 1.8 (42.5 ± 6.9)
EArabCllm4hu2lm3bhuc ND" 33.9 ± 2.4 ND 62.6 ± 2.6
EA£fbClhu4hu2hu3dhu<" ND 23.9 ± 1.6 ND 55.8 ± 4.4
" The figures represent the mean values of 15 experiments (± 1 S.D.) with the exception of the EAC3d experiments which were performed
eight times. Rosette formation by EAC142 at 37°C was thought to represent EAC14 as a result of C2 decay and is therefore recorded in
parenthesis.
b Prepared with 4000 effective molecules of C4 per cell.
c Prepared with 400 effective molecules of C4 per cell.
d ND, not done.
TABLE II
The effect ofC2 decay on the binding ofEAC142 cells (prepared with
4000 molecules of C4 and 50 molecules of C2 per cell) to human
eosinophils and neutrophils"
Eosinophil Rosettes Neutrophil Rosettes











J. A. 8.0 27.0 8.5 53.0
M. B. 5.0 26.0 6.5 61.0
A. M. 4.0 22.0 6.0 55.0
J. N. 5.0 26.5 9.0 51.0
" EAC14 cells were incubated with C2 as described. Before decay,
EAC 142 cells were hemolytically active as shown by total lysis after
the addition of C3-C9. The C3b inactivator (as assayed by the
method of Lachmann and Mtiller-Eberhard (1968)) was undetectable
in the C2 preparation. All the rosette experiments were performed at
0°C.
eosinophilia and the percentage of rosetting neutrophils and
eosinophils using EAcab, EAC14, or EAC1423 in 15 patients
were unrelated to the various disease states although the
majority of patients had an eosinophilia in association with an
exogenous antigen, i.e., bronchial asthma, pulmonary eosino¬
philia, or helminth disease. In addition, there was no associa¬
tion between the percentage of eosinophilia and the percent¬
age of rosetting cells irrespective of the indicator erythrocytes.
The number of eosinophils and neutrophils from patients
with eosinophilia-forming rosettes with EAC3d when com¬
pared to normal individuals were similar (Table III), but the
numbers were smaller than with EAC14 or EAC3b.
DISCUSSION
The evidence for receptors for human IgG on human eosino¬
phils and neutrophils is provided by both the capacity of heat-
aggregated human IgG to inhibit EA<?b rosettes and its ability
to adsorb directly on to these cells, as shown by immunofluo¬
rescence (Fig. 2). This binding is probably through the Fc
portion of the IgG, but this is yet to be ascertained with
certainty. Also, the subclass of the IgG which binds to granu¬
locytes, and the possibility that these cells have receptors for
other immunoglobulins also remains to be determined. How¬
ever, the demonstration of IgG receptors on human eosino¬
phils is consistent with the findings of Butterworth et al. (7)
who have shown that the eosinophil is the principal effector
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Figure 3. The effect of increasing concentrations of C3 or C4, with
their appropriate red cell intermediate, on eosinophil rosette forma¬
tion and lysis with terminal complement components. The EAC3b
intermediate was prepared by using 400 effective molecules of C4 per
cell. The points represent the mean (± 1 S.D.) offive experiments.
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ula. The antibody, in this system, was identified as IgG (16)
and the adherence of eosinophils to IgG-sensitized schistosom-
ula may be dependent on the presence of freely available
immunoglobulin receptors.
EAcab rosettes were consistently shown both in healthy
controls and patients with eosinophilia (Figs. 1 and 4). This
contrasts with the report of Tai and Spry (5) who were unable
to demonstrate appreciable numbers of EAcab rosettes with
human eosinophils from healthy donors. This apparent dis¬
crepancy could be due to differences in the preparation of
TABLE III
Eosinophil and neutrophil rosettes with EAC3b and EAC3d"
Eosinophil Rosettes Neutrophil Rosettes
Patient Diagnosis
EAC3b EAC3d EAC3b EAC3d
% % % %
J. c. Unknown 33 25 60 63
E. B. Pulmonary eosino¬ 33 23 62 62
philia
M. H. Lymphoma 37 24 59 56
D. F. Atopic eczema 32 22 65 51
S. L. Bronchial asthma 36 25 64 54
J. S. Hypersensitivity to 33 24 68 53
sulfonamides
A. M. Bronchial asthma 35 20 63 54
A. W. Atopic eczema 34 22 64 53
D. B. Normal 43 26 62 58
P. D. Normal 41 27 64 54
J. N. Normal 38 24 65 52
G. R. Normal 37 25 67 50
" These intermediates were prepared with 400 effective molecules
of C4 per cell.
EA cab, and the time of incubation for rosette formation. Tai
and Spry (5) reported on six normal individuals by using a 4-
min incubation time, whereas in the present report 15 normal
individuals were studied by using a total incubation time of 40
min (Fig. 4).
Unlike Sher and Glover (6) we were unable to demonstrate
eosinophil rosettes with E alone (Table I). Furthermore when
E were treated with 2-aminoethylisothiouronium bromide hy-
drobromide (AET), which is believed to enhance their T cell
binding property (17), this did not evoke eosinophil rosetting
(A.R.E. Anwar, unpublished observation).
Cell-bound C4 and C3 form rosettes with eosinophils and
neutrophils (Table I and Fig. 3). Since increasing amounts of
these components were associated with increased rosette for¬
mation and lysis, this suggests that the number of adherent
cells was directly proportional to the input of C4 and C3. The
relation between C4 and C3 receptors has yet to be ascer¬
tained, although appropriate inhibitory studies are in prog¬
ress. C4 receptors on human neutrophils have been previously
described (3, 4). Eosinophils have also been shown to have C4
receptors although details of the methodology and how the
findings related to eosinophilia were not given (18). It should
be emphasized that the amount of C4 (400 effective molecules)
used to prepare the EAC3 intermediates gave the same num¬
ber of rosettes as E alone. Therefore the rosettes observed with
EAC3b and EAC3d in all the experiments cited are not due to
C4 and thought to be entirely C3 dependent.
Rosette formation by neutrophils and eosinophils with
EAC14 could be inhibited by functionally pure human C2
which was free of C3b inactivator (Table II). Although it was
previously reported that C2 did not inhibit immune adherence
by EAC14 cells (19), it should be noted that in our present
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Figure 4. The percentage eosinophil or neutrophil
rosettes with EA, EAC14, or EAC3b as compared be¬
tween healthy normal controls (C) and patients with
eosinophilia (E). The EAC14 cells contained 4000 ef¬
fective molecules of C4 and the EAC3b were pre¬
pared with 400 effective molecules of C4 per cell.
The bars represent the mean (± 1 S.D.). The p
values were calculated by the Student t-test. (N.S.
= not significant.)
n.s. N.S. P 0.05 N.S. P<0.05
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decay. Binding capacity could be restored by allowing C2
decay. This suggests that C4 hemolytic- and granulocyte-bind-
ing sites are likely to be closely related.
The apparent inability of C3d cells to bind to human neutro¬
phils had been previously reported (2, 20). However, in the
present study, EAC3d cells prepared by treating EAC3b cells
with C3b inactivator gave comparable rosette formation, with
both neutrophils and eosinophils, to the untreated EAC3b cells
(Table III). Nevertheless, unlike EAC3b, EAC3d cells were
immune adherence negative, resistant to lysis by C5-C9 and
gave stronger agglutination with anti-C3d than did the
EAC3b cells. Differences in technology probably explain these
discrepancies, particularly in the report by Ross et al. (20)
where indicator and target cells were incubated for only 5 min.
We have found that this incubation time is insufficient for
rosette formation.
The relationship between granulocyte markers and eosino-
philia was also studied. We found a decrease in rosetting
eosinophils with EAC14 and EAC3b in patients with eosino-
philia which was possibly due to smaller numbers of comple¬
ment receptors on immature eosinophils (Fig. 4). Rabellino
and Metcalf (21) were unable to demonstrate C3 receptors on
mouse eosinophil colony cells grown in vitro, whereas in the
same study IgG receptors were present. This is in agreement
with the present study in which there was no difference be¬
tween rosetting eosinophils with EA)ilb in patients with eosin¬
ophils compared to controls. Neutrophils from patients with
eosinophilia had similar numbers of complement and IgG
rosettes when compared to controls, providing further evi¬
dence that the stimulus for eosinophil production may be
independent from the stimulus for neutrophil production.
We have considered the possibility that the granulocyte
separation procedure may have yielded only a subpopulation
of neutrophils and eosinophils. However, the recovery of gran¬
ulocytes was always more than 80%. Moreover, in early exper¬
iments with unseparated leukocyte suspensions, similar ratios
of eosinophil to neutrophil rosettes were observed.
There was no apparent association between the percentage
of eosinophil and neutrophil rosettes and the degree of eosino¬
phil with either EAgb EAC14, or EAC3b. There was also
no association between the degree of rosette formation and the
disease states; however, the majority of individuals studied
had either atopic disease or hypersensitivity reactions (Table
III).
Our results are consistent with previous findings on surface
markers on human monocytes (22, 23) in that, like monocytes,
the eosinophil and neutrophil also have receptors for IgG, C3b,
and C3d. Therefore, there would appear to be similarities in
terms of recognition of opsonized particles by all circulating
phagocytic cells. Phagocytosis by eosinophils is generally con¬
sidered to be slower than the neutrophils in terms of the rate of
ingestion (reviewed by Kay) (24). The relative paucity of re¬
ceptors on human eosinophils as compared to the neutrophils
may explain its relatively poor phagocytic response. There¬
fore, it is unlikely that the eosinophil plays a major role as a
phagocytic cell. However, the presently recognized functions
of eosinophils are that it acts as a cytotoxic-killer cell in
helminth disease (7) and has a homeostatic or "dampening"
effect in immediate hypersensitivity (25). These processes pre¬
sumably involve a recognition mechanism enabling contact
between eosinophils and target cells which in turn may de¬
pend on immunoglobulin and/or complement receptors.
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The ECF-A tetrapeptides and
histamine selectively enhance
human eosinophil complement receptors
Various products of the anaphylactic reaction such as the ECF-A
tetrapeptides1 (Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu)2 and his¬
tamine3-4 preferentially attract the human eosinophil in chemotaxis
in vitro. We have designed experiments to show whether these
chemical mediators have a direct effect on the eosinophil cell
membrane, as assessed by their capacity to alter receptors for
either IgG or complement (C). We have established here that these
two ECF-A peptides and histamine both enhance markedly the
expression of eosinophil receptors for C3 but not for IgG,
Neutrophil and monocyte receptors seemed to be unaltered and a
number of other chemical mediators of hypersensitivity had no
effect on these membrane markers when tested at comparable
concentrations. Our demonstration of eosinophil membrane
receptor enhancement by chemotactic factors may have more
general biological significance in terms of how surface recognition
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Fig. 1 The effect of increasing concentrations of the valyl-(#) and
alanyl-(O) ECF-A peptides and histamine (A) on a, EAC3b and b.
EAG rosettes by human eosinophils and neutrophils. The lines
represent the percentage rosettes of untreated eosinophils and
neutrophils. Each point represents the mean of five experiments
± ls.d. Dextrose-gelatin-veronal buffer(DGVB2+ />H 7.4) was used
for washing sheep RBC during sensitisation and coating with various
complement components. This was prepared by mixing equal
volumes of isotonic veronal-buffered saline (containing 0.0015 M
Ca2 + . 0.0005 M Mg2+ and 0.1% gelatin-veronal buffer (GVB2 + )
with 5% dextrose in water containing the same concentration ofCa2 +
and Mg2+ (ref. 10). The lgG and IgM fractions of rabbit antisera to
sheep red cells were prepared by Sephadex G-200 gel filtration. Sheep
cells were sensitised with either the IgG fraction for preparing EAG
(EAG) or IgM (EAMri,b) for EACT423b rosettes. Functionally pure
human complement components were added sequentially to EAM'ab
to prepare C3b-coated cells as described11. The amounts were as
follows: 400 effective molecules ofC1.400 ofC4. 50 ofC2 and 2,500 of
C3. This amount of C4 was insufficient to give EAC14 rosettes with
neutrophils, eosinophils or monocytes'1. The valyl-((HCl)-Va!-Gly-
Scr-Glu, molecular weight 427) and alanylpeptides ((HCl)-Ala-Gly-
Ser-Glu, molecular weight 497) were a gift from Dr R. Camble (ICI
Limited, Pharmaceuticals Division, Alderley Park, Macclesfield);





Fig. 2 The effect of time on enhancement of EAC3b rosettes by
eosinophils and neutrophils following incubation with the valyl-(#)
and alanyl-(O) ECF-A peptides and histamine (A)- Each mediator
was tested at a concentration of 10 - 4 mol 1 -1. The lines represent the
percentage rosettes of untreated eosinophils and neutrophils. Each
point represents the mean of five experiments +1 s.d.
Receptors were measured by the 'rosette technique' using sheep
red blood cells (RBC) sensitised with either IgG or C3b (Fig. 1).
Human eosinophils, neutrophils5 and monocytes6 were prepared
from venous blood from patients with eosinophilia of various
aetiology and adjusted to a concentration of 4x 106 ml 1 in
medium 199 (pH 7.4). Equal volumes of leukocyte suspensions
and various concentrations of the pharmacological agents under
study, or control medium alone, were mixed and incubated in a
shaking water-bath at 37 ' C for varying intervals. The cells were
then washed twice in medium 199 and the numbers adjusted to
2x 106 ml 1 in the same medium. An aliquot (0.1 ml) of IgG-
(EAG) or complement-coated (EAC3b) red cells containing
1 x 108 mP was then added to 0.1 ml of the cell suspension. The
mixtures werecentrifugedat lOOgfor 10 minat4 °Cand thepellets
incubated at 0 °C (for EAG rosettes) or 37 °C (for EAC3b rosettes)
for 30 min as described. The pellets were gently resuspended and
smears were prepared in duplicate. The slides were dried in air,
fixed in methanol and stained; Cells with three or more adherent
erythrocytes were counted as rosettes. Two hundred cells were
counted on each slide and the number of rosettes expressed as a
percentage of the total number counted.
With no treatment the percentages of neutrophil, IgG or
complement receptors were usually more than twice that of the
eosinophil (Fig. 1). With increasing concentrations of the valyl- or
alanyl-peptide, or histamine there was a dose-dependent enhance¬
ment of the numbers of eosinophils, but not of neutrophils, which
formed rosettes with EAC3b. There was no increase in the
numbers ofeosinophils or neutrophils forming rosettes with EAG.
When other pharmacological mediators, which included brady-
kinin and the prostaglandins PGEi, E2 and F2„ were incubated at
comparable concentrations (10~4-10-6 mol 1 1) to that of the
ECF-A peptides or histamine, there was no appreciable increase in
Table 1 Percentage increase in the numbers of resetting eosinophils, neutrophils and monocytes with EAC3b cells following incubation w ith increasing
concentrations of various chemical mediators of hypersensitivity
10" 6 (mol 1 ~ ') 10" 5 (mol 1 " ') 10~J (mol 1
Neutro¬ Neutro¬ Neutro¬
Eosinophils phils Monocytes Eosinophils phils Monocytes Eosinophils phils Monocytes
Valyl-
peptide 43.3 5.6 (6.8) 55.6 0.5 (0.3) 77.8 8.1 (4.5)
Alanyl-
peptide 37.0 1.0 5.3 60.6 8.1 (1.8) 87.8 (3.1) (7.0)
Histamine 25.1 (1.1) (3.3) 48.8 7.8 (3.3) 83.4 1.3 3.0
Bradykinin 0.5 7.8 0.5 (4.9) 3.0 2.3 —
pge, 5.6 4.2 — (2.0) (8.5) — 14.7 1.3 —
pge, (0.9) (3.9) — 6.5 2.9 — 6.8 (7.7) —
pgf2, 5.6 (3.1) — 13.3 1.3 — (3.3) 2.1 —
5-HT 3.0 (5.2) — 17.8 (3.4) — 25.0 6.7 —
The figures represent the mean of five experiments, with the exception of bradykinin (three experiments). Decreases in rosette formation are shown in
parentheses. Prostaglandins E2 and F2* were supplied by Dr John Pike. Upjohn Company, Kalamazoo, USA; bradykinin triacetate and 5-
hydroxytryptamine were obtained from Sigma. Kingston-upon-Thames, UK.
the numbers of eosinophil- or neutrophil-EAC3b rosettes (Table
1). An increase of 25% was observed with 5-hydroxytryptamine,
but only at the highest concentration (10~4 mol l"1). The en¬
hancement with the ECF-A peptides or histamine, with this dose
was almost three times this value, thus achieving virtually the same
percentage of rosetting eosinophils as neutrophils (Figs 1 and 2).
The monocyte was also tested with the valyl- and alanyl-peptide
and histamine but, unlike the eosinophil, there was no apparent
alteration in the numbers of rosetting cells (Table 1). The
enhancement of EAC3b eosinophil rosettes by the ECF-A pep¬
tides or histamine also increased with incubation time (Fig. 2).
With the peptides, however, most of the increase in rosette
formation was apparent at 40 min. In contrast, most of the
histamine-induced rosette enhancement took place between 40
and 80 min.
These experiments suggest that the ECF-A peptides and
histamine not only attract eosinophils selectively in chemotaxis
but also have a direct effect on the eosinophil membrane as shown
by the apparent increase in the numbers ofcomplement receptors.
It is not known whether this enhancement is caused by the
generation of new receptors or whether receptors, previously
'hidden', are revealed as a result of membrane changes. The
inability of these pharmacological agents to increase neutrophil
and monocyte complement receptors emphasises further the
unique, intimate relationship between the human eosinophil and
these anaphylaxis-associated agents. We also explored the possi¬
bility that neutrophil and monocyte complement receptor en¬
hancement may be revealed when the amount of C3 on the
indicator cell was limited. In experiments in which the quantity of
C3 used was adjusted to give approximately half the number of
rosetting cells (that is, 1,000 effective molecules) however, there
was no apparent increase in rosette formation following in¬
cubation with these agents. Similar negative results were found
with neutrophils and monocytes when the amounts of IgG were
decreased to give lower numbers ofEAG rosettes. The reason why
complement, and not IgG, receptors were altered by the ECF-A
peptides and histamine is unknown. It was previously shown that
IgG and C3b receptors act together to aid macrophage phago¬
cytosis7. A similar mechanism may exist for eosinophils; optimal
receptor ratio being determined by the presence of pharmacologi¬
cal mediators such as ECF-A and histamine.
The role of the eosinophil in immediate-type hypersensitivity is
thought to be that ofa homoeostaticcell affectingmediator release,
mediator inactivation and mediator replenishment by mast cells8.
Their function in helminth disease may be that of a cytotoxic cell
requiring the participation of IgG, in an analogous fashion to
lymphocyte-antibody-dependent cell-mediated cytotoxicity9. Al¬
though complement does not seem to be required in this system, it
is nevertheless possible that adherence by way of the C3 receptor
may amplify the parasiticidal properties of eosinophils. Our
observations may therefore, be of relevance in helminth disease
where the IgE-mediated release of chemical mediators is well
recognised. In any event, our finding ofa new biological activity for
both the ECF-A peptides and histamine may provide further
insight into both the essential biochemical differences between
human eosinophils and other blood leukocytes, and the way in
which chemical mediators modulate recognition mechanisms by
cell membranes.
A.R E.A. is a British Council Fellow.
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SPECIAL ARTICLE
The Eosinophil in Infectious Diseases
A. B. Kay
Although the role of the eosinophil leukocyte re¬
mains unknown, experimental situations have re¬
cently been described in which the cell has been
shown to have characteristics distinct from those
of other leukocytes. Thus the eosinophil migrates
preferentially towards certain chemical stimuli and
is dependent on various essential prerequisites for
its maturation in the bone marrow and appearance
in the peripheral blood.
Generally speaking, there are two situations in
which eosinophils are associated with infection.
In many parasitic diseases there is an increase in
the number of eosinophils both in the tissues and
in the circulation, whereas in a number of acute
pyogenic processes the cell disappears from the
peripheral blood. The eosinophilia which accom¬
panies certain types of hypersensitivity reactions
to drugs used to treat infectious diseases is a more
indirect association, but one of considerable clin¬
ical importance.
In the present article morphologic and histo-
chemical features of the eosinophil are described,
and mechanisms by which the number of eosino¬
phils fluctuates in the situations cited are discussed.
In addition, the capacity of the eosinophil to in¬
gest and kill microorganisms will be compared
with that of the neutrophil. Finally, some specu¬
lations as to a possible role of the cell in the in¬
flammatory response will be presented.
Morphology and Histochemistry
The eosinophil is characterized by the presence of
large intracytoplasmic granules that have an af¬
finity for acid or analine dyes [1], The number of
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granules ranges from 25-50 in the horse to 200-
400 in the rat [2], The size and shape of human
eosinophil granules are intermediate between those
of the two species cited. The granules are biconvex
disks bounded by a double-layer membrane and
consist of a central crystalline core surrounded by
a less electron-dense matrix [3, 4].
Miller et al. concluded that the crystalline "in¬
ternum" that appears as parallel lines with regular
spacing is a cubic lattice, the sides of the cube
measuring approximately 30 A in rodents and ap¬
proximately 40 A in man [5]. The core probably
forms the basic material of Charcot-Leyden crys¬
tals, which are observed when wet eosinophil
preparations undergo degeneration [6], It was
noted by Ghadially and Parry that in some elec¬
tron-microscopic preparations the eosinophil gran¬
ules have an electron-dense matrix that surrounds
a less dense core, and that this reversal of electron
density can be seen in cells from the same bone
marrow preparation in a number of species exam¬
ined [7]. This observation may indicate a func¬
tional heterogeneity of the eosinophil population.
The double-layer membrane surrounding the
outer cortex of the granule contains lipid [8]. The
cortex coiftains an abundance of the enzyme pe¬
roxidase [9], which differs from neutrophil myelo¬
peroxidase (see below). The central crystalline
core is rich in arginine, as shown by the Saka-
guchi reaction. Recent studies by Gleich et al.
have shown that this material has an isoelectric
point of 10 and a molecular weight of 6,000-
12,000 daltons [10], Histochemical techniques re¬
vealed that the granules are Feulgen and pyronin
negative [11] and contain only a small amount of
material that stains with the periodic acid-Schiff
reagent [12].
A number of enzymes are released following
disruption of eosinophil granules [13]. They in¬
clude cathepsin, ribonuclease, arylsulfatase, and
(^-glucuronidase. Peroxidase remains bound to the
insoluble residue, from which it can be extracted
by treatment with weak acid. Acid phosphatase
has been located in the matrix, but not in the
crystalline core. Since eosinophil granules are col-
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lections of enzymes contained within limited mem¬
branes, they have been considered as lysosomelike
structures.
Peroxidase catalyzes the oxidation of a wide
range of substrates. Many histochemical tech¬
niques depend on the capacity of peroxidase to
cleave oxygen from H202, thereby oxidizing a suit¬
able leuko-dye to a colored product. Kelsall sug¬
gested that eosinophils produce, store, and trans¬
port peroxidase to catalyze oxidation reactions in
a number of tissues [14]. Rytomaa and Teir
showed that tissues rich in eosinophils, such as
lung, spleen, uterus, and the gastrointestinal tract,
had a high peroxidase content [15]. Peroxidase
has been shown to be discharged into phagosomes
after phagocytosis by eosinophils [16]. The bio¬
logical significance of eosinophil peroxidase is un¬
known. Unlike myeloperoxidase from the neutro¬
phil, it is apparently unable to react in the bacte¬
ricidal system involving H202 and a halide [17].
In most species the nucleus of the eosinophil is
similar in appearance to that of the neutrophil
[18], and the cell has mitochondria, golgi appa¬
ratus [19], ribosomes, and an endoplasmic retic¬
ulum [2]. Many of these intracellular organelles
are more numerous and better developed than
those of the neutrophil [18].
Compared with neutrophils, eosinophils con¬
tain a large amount of copper as well as other
trace metals such as zinc, magnesium, manganese,
and cobalt [20],
No lysozyme has been identified in eosinophils
[11], However, like neutrophils, human eosino¬
phils also release leukocyte pyrogen [21],
The Eosinophil and Parasitic Infection
An increase in the number of eosinophils both in
the tissues and in the circulation is a feature of
parasitic disease in both man and experimental
animals. In North America and continental Eu¬
rope, the parasites that usually cause clinical eosin-
ophilia are the nematodes, of which Ascaris lum-
bricodes, Toxocara canis, and Trichuris trichura
are common examples; to a lesser extent, the ces-
todes such as Taenia solium and Taenia saginata
are associated with eosinophilia. The parasitic
causes of eosinophilia most commonly encountered
in Europeans returning from Central Africa are
filariasis and helminthiasis [22]. Loa-Loa, Oncho¬
cerca volvulus, Dipetalonema perstans, and lym¬
phatic filariasis due to Wuchereria bancrofti ac¬
count for the majority of cases of filarial
eosinophila.
Helminthic infections [5], especially bilharzia,
are also common forms of eosinophilia acquired
in the tropics. The significance of the association
of eosinophils with parasitic infection is unknown,
although the mechanism of eosinophilia, in terms
of both bone marrow turnover and acccumulation
at tissue reaction sites, is becoming clearer from
work with experimental animals.
Most studies on eosinophil turnover in normal
and infected animals have been performed in the
rat. These investigations have shown that, before
birth, eosinophil production can be observed in
both the thymus and the lymph nodes [23], In
adults the majority of the cells are produced in
the bone marrow [24], The precursor of the
eosinophil in the bone marrow has not been iden¬
tified, but it is known that the cell proceeds
through several divisions before maturing and
entering the bloodstream [25-30]. A stimulus for
increased eosinophil production, such as the iv
injection of larvae from Trichinella spiralis, ap¬
pears to act at all stages of eosinophil maturation,
with a resultant shortening of the phases of the
cell cycle before final maturation. [29],
In the normal rat, labeled eosinophils appeared
in the circulating blood 36-40 hr after a single
pulse of tritiated thymidine. After a stimulus to
increased production of eosinophils, this interval
was reduced to about 18 hr. The same stimulus
did not affect the time required for neutrophil
emergence. There is evidence to suggest that after
emergence from the bone marrow, the eosinophil
matures further in the spleen. Peripheral blood
eosinophils were found to be removed exponen¬
tially with a half-life of 6.7 hr, the same as the
half-life of neutrophils in normal rats [30],
Recent studies have indicated that the lympho¬
cyte may play a central role in the mechanism
whereby injections of parasitic larvae lead to in¬
creased turnover of eosinophils in bone marrow
of the rat [31, 32], The eosinophil response could
be depressed by chronic thoracic duct drainage,
X irradiation, and thymectomy [33]. Furthermore,
the lymphocytes from animals with an eosino¬
philia, when transferred to an irradiated recipient,
led to an increase in the numbers of circulating
eosinophils. Transfer of serum had no effect. An
increase in the number of circulating eosinophils
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could also be produced by placing the lympho¬
cytes in diffusion chambers and implanting them
ip. These experiments suggested that a soluble
factor or factors, released from the lymphocytes
of parasitized rats, can initiate increased turnover
of eosinophils in bone marrow.
It has been found that a reproducible method
of evoking an eosinophilia in the rat with T.
spiralis is to inject iv living or dead muscle-stage
larvae [31]. The larvae become arrested in the
pulmonary vasculature. When the larvae are
homogenized and thus pass through the pulmonary
circulation, a subsequent blood eosinophilia is not
observed. The larvae apparently have to be ar¬
rested in the lung in order to initiate the mech¬
anisms leading to selective bone marrow turnover
of eosinophil leukocytes. Even Sephadex beads
trapped in the lung after iv injection give rise to
a modest eosinophilia [34], It has been suggested
that in this experimental model, Sephadex is re¬
acting with natural antibody directed against poly¬
saccharide antigens, thereby producing an eosino¬
philia in a similar fashion to that observed with
parasitic larvae.
The local cellular reaction to parasites depends
on a number of factors such as the type of or¬
ganism, the route of administration, and the spe¬
cies involved. Thus, the local accumulation of cells
around muscle-stage Trichinella larvae takes place
relatively quickly after iv administration [35]. The
12-24-hr lesion is essentially granulomatous, the
parasite being encased by large mononuclear cells.
Eosinophils are seen in large numbers but at a
distance from the parasite, as are lymphocytes and
a few neutrophils.
The majority of eosinophils reside within the
tissues. It has been estimated that for every circu¬
lating cell there are 300-500 cells within the
tissues [36]. The fate of eosinophils depends
largely on the stimulus to their production. In
acute allergic reactions the cell undergoes exten¬
sive degranulation at the site of mast cell disrup¬
tion [37]. Normally, eosinophils find their way to
mucosal surfaces where they shed their contents
into the lumen [24],
A feature of parasitic infection in both man
and experimental animals is the production of
circulating IgE antibody. Thus, elevations in cir¬
culating IgE have been demonstrated in Ethiopian
school children with ascariasis [38], and in pa¬
tients with visceral larva migrans [39]. In Nippo-
strongylus brasiliensis infection in the rat, IgE
production has an apparent protective effect, as
shown by massive expulsion of worms between the
10th and 18th days after administration of the
worm (the so-called "self-cure" phenomenon)
[40-42]. This effect can be transferred by tissue-
sensitizing antibody, which adsorbs onto mast cells
of the gastrointestinal tract, thus leading to hista¬
mine release by the worm antigen. The release of
this amine apparently leads to expulsion of the
worms. The production of IgE and the associated
eosinophilia suggests that there is an allergic ele¬
ment in the host reaction to many parasitic dis¬
eases. For example, rats injected with Trichinella
larvae developed systemic anaphylaxis when chal¬
lenged with trichinella extract, and the survivors
subsequently developed a blood eosinophilia [43].
These observations suggest that a product of the
anaphylactic reaction, possibly the eosinophil
chemotactic factor of anaphylaxis (ECF-A),
participates in parasite-mediated eosinophilia [44-
46],
In addition to IgE, antibodies capable of acti¬
vating the complement system are produced in a
number of parasitic infections; advantage is taken
of this fact in serodiagnosis. A fragment cleaved
from the fifth component of complement (C5a)
has been shown to attract the eosinophil selec¬
tively under defined experimental conditions [47].
When ECF-A and C5a were combined, marked
synergism was observed in their ability to attract
eosinophils. Possibly this mechanism is operative
in the local accumulation of eosinophils in certain
parasitic states [46],
It is not possible to give a unifying hypothesis
to explain the continued eosinophil response found
in association with parasitic disease. Present evi¬
dence suggests that the lymphocyte plays a role
in production of eosinophils by the bone marrow
and that continued local infiltration of eosinophils
may be accentuated by allergic responses to the
parasite involving both IgE and complement. A
possible role for the eosinophil in parasitic and
other states is discussed below.
Eosinophils and Acute Infective Processes
It has long been recognized that a peripheral blood
eosinopenia accompanies acute infection. It was
shown by Spink that the eosinophilia evoked by
trichinosis in the guinea pig could be obliterated
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by a superimposed staphylococcal, trypanozomal,
or tuberculous infection [48], Until recently the
eosinopenia of infection was regarded as a re¬
sponse to stress and thus a reflection of increased
production of adrenal glucocorticosteroids.
Bass has shown recently that the eosinopenia
of various types of acute inflammation are medi¬
ated by a mechanism independent of adrenal
glucocorticosteroids [49]. Using mice infected
with T. spiralis, he showed that the resultant
eosinophilia could be depressed by the super-
imposition of a pneumococcal abscess, staphylo¬
coccal infection, Escherichia coli pyelonephritis,
Coxsackie B4 pancreatitis, or acute sc inflamma¬
tion due to turpentine. The eosinophils that disap¬
peared from the peripheral blood appeared to
accumulate at the site of inflammation. Splenec¬
tomy caused an even greater fall in peripheral
eosinophil counts. When the acute inflammatory
procedures were terminated at an early stage,
eosinophil production was restored to normal.
The theory that the eosinopenia of an acute
inflammation was the result of the adrenal re¬
sponse was tested directly by assay of cortisone
in serum. Increased levels of serum cortisone were
found after bacterial, viral, and rickettsial infec¬
tions. However, these were smaller than the in¬
crease in serum cortisone observed after the
response to trichinosis during the early infective
period. It was thus concluded that the eosinopenia
of acute inflammation could not be ascribed to
stimulation of the adrenal glands.
Bass then showed that material present in the
exudate from the pneumococcal abscess produced
a decrease in the number of circulating eosino¬
phils 4—24 hr after injection. The material respon¬
sible for this effect was referred to as an "eosino-
penic factor" (EF), although it is not certain
whether this is the property of one or several
molecules. The eosinopenic effect could not be
transferred by heat-killed pneumococci, pneumo-
coccal-culture filtrate, or normal serum. Adre-
nalectomized mice responded to EF in a way simi¬
lar to that of normal animals. EF had no effect
on the number of circulating neutrophils but
caused a reduction of about 30% in the number
of circulating lymphocytes. The significance of
this shift in the eosinophil population is unknown.
Further studies on EF may help to explain this
effect.
Other Associations of the Eosinophil
with Infective Agents
Although a blood eosinopenia is a feature of the
acute stage of many infections, the number of
white blood cells returns to normal when the in¬
flammatory process resolves [50]. Some infections,
notably scarlatina [51], pneumococcal pneumonia,
and tuberculosis [52], are occasionally asso¬
ciated with a blood eosinophilia during the con¬
valescent phase of the illness. These situations are
probably a reflection of some form of hypersensi¬
tivity reaction to bacterial products.
Adverse reactions to drugs used in the treat¬
ment of infectious diseases are often associated
with a blood eosinophilia. This is invariably a
manifestation of a hypersensitivity state. The
mechanisms by which this occurs are poorly
understood, but such reactions are probably me¬
diated by a number of factors including IgE, com¬
plement, and possibly a delayed-type hypersensi¬
tivity component [53].
Some of the types of "pulmonary eosinophilia,"
which include simple pulmonary (Loffler's syn¬
drome), asthmatic, and tropical eosinophilia, are
associated with what is presumed to be an alveolar
hypersensitivity to parasites [54, 55], A. lumbri-
coides, Ancylostomum braziliense, T. trichura,
T. saginata, and Fasciola hepaticum have all been
implicated in simple pulmonary eosinophilia.
Evidence of hypersensitivity to Aspergillus fumi-
gatus can be demonstrated in about 50% of cases
of asthmatic pulmonary eosinophilia. Convincing
evidence exists that tropical pulmonary eosino¬
philia is associated with a filaria that is unable to
mature further in the human host.
The Phagocytic and Bactericidal Properties
of the Eosinophil
The morphology of eosinophil and neutrophil
phagocytosis is similar. The granules coalesce
with the phagosomes following membrane fusion
[16].
A number of recent studies have compared the
capacity of eosinophils and neutrophils to ingest
and kill various microorganisms. The events lead¬
ing to phagocytosis and destruction of particles
are often considered in terms of chemotaxis, ad¬
herence, engulfment, and digestion. Agents capa¬
ble of selectively attracting the eosinophil include
ECF-A [44], C5a [47], and a lymphocyte-medi-
610 Kay
ated chemotactic factor [56], The eosinophil has
a receptor for immune adherence [57], but not
for the Fc portion of IgG [58].
Studies comparing the capacity of eosinophils
and neutrophils to phagocytose microorganisms
and inert particles have all concluded that the
eosinophil is less efficient than the neutrophil [21,
59, 60], Similarly, the bactericidal activity of
eosinophils is less than that of the neutrophil in
terms of intracellular killing of E. coli, Staphylo¬
coccus aureus, Staphylococcus cdbus, and Listeria
monocytogenes [17, 21, 60].
In contrast, the metabolic activity of the rest¬
ing, unstimulated eosinophil is greater than that
of the neutrophil [21], Oxidation of 1-14C glucose,
6-14C glucose, and 14C formate, which reflect
activity of the hexosemonophosphate shunt,
Kreb's cycle, and formation of H202, respectively,
are greater in the resting eosinophil than in the
resting neutrophil. Similarly, following stimulation
of eosinophils, either by contact with a particle or
by engulfment, a greater increase in the hexose¬
monophosphate shunt and production of intra¬
cellular H202 can be demonstrated [21, 59, 61],
The oxidative response of the eosinophil is thought
to be due to increased nicotinamide-adenine
dinucleatide phosphate-H oxidase of granular ori¬
gin rather than soluble nicotinamide-adenine dinu-
cleotide phosphate-H oxidase, which is apparently
operative in the neutrophil [60],
Despite the availability of H202 and peroxidase,
the eosinophil is apparently unable to utilize effi¬
ciently the peroxidase-H202 bactericidal system
that is thought to play an important role in the
killing of microorganisms by the neutrophil [62],
This relatively poor bactericidal response by the
eosinophil may be related to the nature of its
peroxidase, which differs in several respects from
myeloperoxidase of the neutrophil. Thus it was
found that the optical spectra of the reduced form
of eosinophil peroxidase differed from that of the
reduced form of neutrophil myeloperoxidase [63],
The two peroxidases are also antigenically dis¬
tinct [64], and unlike neutrophil myeloperoxidase,
eosinophil peroxidase is not inhibited by cyanide
[65].
It should be noted that many of the studies on
the capacity of eosinophils and neutrophils to in¬
gest and kill microorganisms have used popula¬
tions of cells that have ranged between 50% and
90% in purity. These are essentially mixed cell
populations, and a possible influence of one cell
type on another, in terms of phagocytosis and
killing of microorganisms, cannot be excluded.
Concluding Comments
The eosinophil has distinct morphologic and his-
tochemical features, but these have yet to be
equated with a unique function. The material
which comprises the central core of the eosinophil
granule is a major histochemical feature of the
cell, and therefore it will be of interest to see
whether the isolated protein can modulate inflam¬
matory processes associated with eosinophilia.
Why the eosinophil is unable to take up and in¬
gest common pathogens efficiently is unknown,
but this deficiency may indicate that engulfment
is a property the cell has maintained during evo¬
lution and is therefore incidental to its main
functions(s) [66].
The association of eosinophils with parasitic
infections has been discussed, and it was suggested
that this association is due in part to an allergic
response to parasitic antigens, which are able
regularly to produce IgE-type antibodies in man
and a number of experimental animals [41, 67].
When IgE becomes adsorbed to cell membranes
of the mast cell-basophil series and reacts with
specific antigen, chemical mediators are released,
with subsequent accumulation of eosinophils.
It has been suggested that a role of the eosino¬
phil is to inactivate pharmacologic agents [68].
However, we have been unable to show that
eosinophils inactivate histamine. Purified suspen¬
sions of eosinophils from humans, guinea pigs,
and horses, when incubated with histamine, did
not affect the capacity of the amine to contract
the isolated perfused guinea pig ileum [69]. We
have shown, furthermore, that histamine is inac¬
tivated very rapidly after local release in the skin,
which is several hours before the infiltration of
eosinophils [70],
We regard the eosinophil more as a repair cell
which restores the status quo of tissues that have
undergone an allergic response. Thus, in studies
in the rat, eosinophil leukocytes were seen to
accumulate around degranulated mast cells and
to ingest their granules [71], These observations
have been confirmed by Mann, who further
showed that after the accumulation of eosinophils
around mast cells and phagocytosis of the gran-
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ules there was phagosome formation followed by
intracellular breakdown of the phagosome mem¬
brane [72]. These observations are consistent with
the view that the eosinophil acts as a repair cell
in immediate-type hypersensitivity reactions. The
repair mechanism may be restricted to phagocyto¬
sis of mast cell contents, although the eosinophil
may also participate in the restoration of mast cell
contents, thus enabling the cell to react again in
immediate-type hypersensitivity.
A previous study has shown that eosinophils
can adhere directly to certain parasites in vitro
[73]. Possibly eosinophils have the capacity to
destroy parasites or inactivate their products.
However, the association of eosinophils and para¬
sitic diseases is usually long-term, suggesting that
whereas the eosinophil may contain the spread of
parasites, it probably does not have a profound
elfect of the viability of the organisms. The recent
description of an antiserum specific for the eosino¬
phil cell membrane may help to answer these
questions [74].
Another possibility is that the eosinophil in¬
fluences the synthesis and assembly of the IgE
molecule. It would, however, be of interest to
have details of correlations of fluctuations in
eosinophil levels with the amount of circulating
IgE and to determine the effect of antiserum to
eosinophils or exogenous administration of eosino¬
phils on the IgE response.
In conclusion, it is unlikely that the eosinophil
plays a major role in the phagocytosis and destruc¬
tion of common microorganisms or that it inac¬
tivates chemical mediators such as histamine.
Some investigations are mentioned that have sug¬
gested possible roles of the cell; these include the
capacity of the eosinophil to repair those cells
participating in immediate-type hypersensitivity,
the direct influence of this leukocyte on parasites
and their products, the ability of the eosinophil
to modulate the production of IgE-type antibodies,
and the biochemical properties of the granular
material.
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Introduction
An increase in the number of eosinophils in the tissues and the circula¬
tion is a feature of various clinical conditions. These include diseases associ¬
ated with high levels of IgE, such as extrinsic (or allergic) asthma, hay fever
and parasitic infections [1-4], and disorders in which there is direct or
circumstantial evidence of the presence of circulating, or fixed antigen anti¬
body complexes capable of activating the complement system. The latter
group of diseases includes polyarteritis nodosa with lung involvement,
pulmonary aspergillosis and rheumatoid arthritis [5-8].
In experimental animals, an eosinophilia can be evoked following in¬
jection of specific antigen into a sensitised animal. Thus, an eosinophilia can
occur following general or local anaphylaxis [9-11] or following the im¬
plantation of anaphylactic tissue into normal animals [12, 13]. Injections of
antigen-antibody complexes into the peritoneal cavity of normal animals
also results in a local eosinophilia [14],
In order to study the relationship between immediate-type (anaphylactic)
hypersensitivity, the complement system and the accumulation of eosino¬
phils, initial experiments were performed in guinea-pig skin [15]. It was
shown that IgGi and IgG2, as preformed complexes, prepared skin for a
subsequent local eosinophilia 12 h after injection. However, if antibody was
1 Supported by the Medical Research Council, the Royal College of Physicians of
London (T.K. Stubbins Fellow) and an anonymous gift to the Department of Respiratory
Diseases.
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first placed in the skin and after a variant latent period the animal was
challenged by antigen and Evans blue dye intravenously (as in a usual
passive cutaneous anaphylactic reaction) IgG1: but not IgG2, elicited a
local eosinophil response 8-12 h after the initial blueing reaction. Intra¬
dermal histamine given at different skin sites in the same animals in doses
which gave a comparable blueing reaction to the IgGj-mediated response
did not lead to an accumulation of eosinophils. Eosinophils also accumulated
around the sites of injections of compound 48/80, an agent which depletes
mast cell granules. Low mast cell counts also accompanied the infiltration
of eosinophils observed with IgG^mediated passive cutaneous anaphylaxis
(PCA) reactions. It was suggested at this time that the accumulation of
eosinophils following PCA reactions was by a complement-independent
mechanism subsequent to the release from mast cells of an agent other than
histamine. The participation of the complement system was suggested in
antigen-antibody complex mediated eosinophilia.
When animals were decomplemented with cobra venom factor this had
no effect on eosinophil accumulation into the site of IgG1-mediated PCA
reactions in the guinea-pig [16]. Furthermore, eosinophil accumulation also
followed PCA reactions in animals partially or totally deficient in the fourth
component of complement. Surprisingly, intradermal injections of pre¬
formed antigen-antibody complexes prepared from guinea-pig IgGx or IgG2
were also unaffected by decomplementation with purified cobra venom
factor. The lesions produced with either immunoglobulin complex were
similar in appearance in decomplemented and normal animals and were
followed by comparable tissue accumulation of eosinophils. Since IgG2 is
tunable to sensitise skin for PCA reactions [17] or lung fragments for his-
amine [18] and slow-reacting substance of anaphylaxis (SRS-A) release [19],
but can fix complement by the classical pathway, it was expected that com¬
plement may play a part in the cellular infiltration following intradermal
injections of IgG2 complexes. These apparent discrepancies could be
explained on a weight basis since IgGj^ is far more efficient in preparing
tissue for an eosinophilia when administered in PCA reactions than when
injected as preformed complexes. It was previously demonstrated that
soluble complexes prepared from guinea-pig IgGj or IgG2 both have the
capacity to liberate histamine from perfused guinea-pig lung [20]. This
suggests that IgG2 may have similar properties to IgGx, in terms of its
effect on mast cells, when presented to tissue as a complex.
These observations in vivo prompted studies on the identification of
chemotactic agents for eosinophils released during the anaphylactic reaction
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or following complement activation. A modification of theMillipore techni¬
que of Boyden was used for these experiments [21]. Eosinophils were ob¬
tained from the peritoneal cavity of the guinea-pig following multiple
injections of horse serum. In the human studies peripheral blood leucocytes
from patients with eosinophilia were used as a source of target cells.
An Eosinophil Chemotactic Factor of Anaphylaxis (ECF-A)
As an experimental model of anaphylaxis, sensitised guinea-pig lung was
chosen since this has been employed by numerous workers as a model of
immediate-type hypersensitivity and the organ can be perfused free of blood
thereby providing a serum-free system. Similarly, human lung fragments
taken at pneumonectomy can be thoroughly washed before and after
sensitisation with serum from an allergic individual. When sensitised lung
was challenged with specific antigen there appeared in the diffusate, along
with histamine and SRS-A, an agent which selectively attracted eosinophils.
Thiseosinophil chemotactic factorofanaphylaxis has been termedECF-A [22],
Formation Mechanism
The release of ECF-A was accompanied by the release of histamine and
SRS-A, but differed in its time course of release. In the experiment depicted
in figure 1 guinea-pig lung was perfused free of blood by cannulating
the pulmonary artery. Specific antigen was injected via the same route.
Approximately 10 ml volumes of perfusate were collected every 15 min for
1 h. Virtually all the histamine and SRS-A was released during the first
15 min, whereas ECF-A continued to be released for the duration of the
experiment. A similar time-course of release was observed with human lung
fragments passively sensitised with serum from a ragweed-sensitive individual
and challenged with ragweed antigen E [23]. Histamine, SRS-A and ECF-A
were similar in terms of the time-course of passive sensitisation and the
amount of antigen required for optimal release. ECF-A release was dependent
on the presence of divalent cations and was strikingly enhanced by the
presence of succinate or maleate; features characteristic of the release of
histamine and SRS-A [24],
In the guinea-pig, decomplementation by the administration of purified
cobra venom factor had no effect on the antigen-induced release of ECF-A
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Fig. 1. Time-course of release of chemical mediators of anaphylaxis following antigen
challenge of perfused, actively sensitised guinea-pig lung. The measurements represent
the mean values from 16 animals. The experimental technique and the expression of
results are described in ref. No. 22. SRS-A= slow-reacting substance of anaphylaxis,
ECF-A = eosinophil chemotactic factor of anaphylaxis.
from actively or passively sensitised lung fragments. Since the lungs were
then perfused free of blood and the fragments thoroughly washed this
strongly suggests that ECF-A release is complement-independent [22].
There is evidence that increase in the level of intracellular 3'-5' cyclic
adenosine monophosphate (cyclic AMP) inhibits the release of ECF-A since
the antigen-induced release of ECF-A was inhibited from passively sensitised
human lung fragments by either isoprenaline, in doses ranging from 10~5
to 10~8 M, or with dibutyryl cyclic AMP in a concentration of 5 x 10~4 M
[25].
Antibody Requirement
ECF-A from the guinea-pig can be released from normal lung passively
sensitised with IgG^ The same immunoglobulin has been shown to sensitise
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guinea-pig lung slices for the antigen-induced release of histamine and SRS-
A. The fractions of IgGi were prepared by ion exchange chromatography
and lost no activity after heating at 56 °C for 4 h, a property characteristic
of IgGx but not of an IgE-like immunoglobulin. Comparable amounts of
IgG2-containing fractions failed to sensitise lung fragments for the antigen-
induced release of histamine, SRS-A or ECF-A. The capacity of guinea-pig
IgE to sensitise tissue for ECF-A release is yet to be ascertained due to
difficulties in raising antibodies of this class and in obtaining guinea-pig
IgE free from IgGj.
In the human, the release of ECF-A was shown to be mediated by
IgE [23]. This was demonstrated by absorption of ragweed-sensitive serum
with a rabbit antibody specific for IgE. Absorbed antibody could no
longer passively sensitise lung for the release of ECF-A, histamine or SRS-A.
ECF-A could also be released from normal lung by the reversed-type reac¬
tion employing a specific anti-IgE prepared in the rabbit.
The Identification of ECF-A as a Distinct Pharmacological Agent
Various chemical mediators of anaphylaxis were tested directly for their
ability to evoke the migration ofeosinophils [22], It was found that histamine,
bradykinin, serotonin and prostaglandins (PGE) PGE1; PGE2 and PGF2a
over a wide dose range, were not chemotactic for eosinophils per se; and,
furthermore, when incubated with sensitised lung in the absence of antigen
these agents did not secondarily affect the release of ECF-A. Although
SRS-A is yet to be chemically characterised there were several reasons for
considering ECF-A to be distinct from this agent. SRS-A survived boiling
in alkaline solution for 20 min, whereas ECF-A activity was abolished by
this procedure and, in addition, SRS-A and ECF-A in the guinea-pig could
be separated by gel-filtration. Human ECF-A appears to be more closely
associated with human SRS-A, but they could be separated functionally
since the latter was partially destroyed by lyophilisation and boiling in acid
solution, whereas ECF-A was inactivated by boiling for 10 min in
alkaline solution. Further evidence that ECF-A is distinct from SRS-A
and histamine was apparent from measurements of mediators in the per¬
fusates described for figure 1. In 4 of the 16 lungs no SRS-A or histamine
was detected in the 15- to 30-min perfusate, although this contained large
quantities of ECF-A. Histamine and SRS-A were released during the first
15 min only.
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Physico-Chemical Properties of ECF-A
Guinea-pig and human ECF-A were relatively resistant to heat, only
about 25% of the activity being lost following boiling for 10 min or heating
at 56 °C for 1 h. Both human and guinea-pig ECF-A activity was totally
recovered following lyophilisation and multiple freezing and thawing. About
30% of their activity was destroyed by extraction in 80% ethanol, evapora¬
tion to dryness and re-suspension of the residue to the original volume.
Some preliminary evidence suggested that ECF-A may be a small peptide
[26]. It is fully recovered from a column of Sephadex G-25 and had an
estimated molecular weight of between 500 and 1,000. The peak of ECF-A
activity contained materials which had free amino groups (ninhydrin
reaction) and peptide bonds (starch-iodide reaction). Recent experiments
have shown, however, that guinea-pig ECF-A activity is not destroyed by
relatively large doses of pronase, chymotrypsin and trypsin [27]. In these
experiments advantage was taken of the relative heat stability of ECF-A.
Partially purified guinea-pig ECF-A, prepared by G-25 Sephadex chromato¬
graphy, and a control Tyrode's buffer with antigen subjected to the same
procedure, were incubated with enzymes for 1 h at 30 °C and then heated
at 56 °C for 30 min. Both chymotrypsin and trypsin completely lost activity
by this heat treatment although pronase was unaffected. However, the heated
enzymes were inactive in chemotaxis when tested alone, and when mixed
with ECF-A did not affect its activity. The proteolytic activity of the enzymes
was monitored by following the release of trichloroacetic acid insoluble
material from casein using the same buffer and identical incubation condi¬
tions to those used for the samples.
Selectivity of ECF-A for Eosinophil Leucocytes
ECF-A selectively attracts eosinophils from a mixed leucocyte popula¬
tion. Guinea-pig neutrophils from a pure population (>96% purity) will
migrate towards ECF-A, although when eosinophils are introduced into
the suspension they are selectively attracted when they comprise 10% or more
of the mixed cell population [28]. Human ECF-A also selectively attracts
eosinophils but neutrophils and basophils will migrate when eosinophils are
present in very small numbers. Thus, a broad specificity for ECF-A, as of
other chemotactic factors can be shown when conditions for migration are
optimal and when other cells which may be preferentially attracted are absent.
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Table I. Tissue eosinophil counts at the sites of intrapulmonary injections of guinea-
pig anaphylactic lung diffusates














Volumes of 0.2 ml were injected into each lung, and tissue eosinophil counts were
performed 12 h later using the technique previously described [39]. The anaphylactic
diffusate contained 1.0 |Ug/ml of histamine, 60 U/ml of slow-reacting substance of
anaphylaxis (SRS-A) and 50 /ig/ml of ovalbumin. An equivalent amount of histamine
and antigen was injected into the control lung.
Other Features of ECF-A
The source of lung ECF-A is not known; however, a comparable
material has been identified from highly purified sensitised human peripheral
blood basophils challenged with antigen [29], There is evidence that ECF-A
exists in a pre-formed state in highly sensitised human basophils [30] or
guinea-pig lung [31], i.e. cells or tissue which will release relatively large
amount of mediators following antigen challenge. In these situations slight
mechanical manipulation, in the absence of antigen challenge, results in the
elaboration of an eosinophil-attracting substance.
When a guinea-pig anaphylactic diffusate was injected into one lung
of an animal and the appropriate control administered into the other lung,
a 3-fold increase in local eosinophil accumulation could be demonstrated
(table I) [32], A similar local eosinophilia could be seen in the guinea-pig
peritoneal cavity following injection of partially purified ECF-A (table II).
A summary of the features of ECF-A is depicted in table III.
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Table II. Eosinophilia following intraperitoneal injections ofpartially purifiedECF-A
Animal No. Treatment Eosinophil count per millilitre


















ECF-A = eosinophil chemotactic factor of anaphylaxis.
Volumes of 5 ml were injected and eosinophil counts were performed 12 h later.
Partially purified ECF-A, giving a chemotactic count of 45 cells/ml [22], was prepared
by Sephadex G-25 chromatography and was free of histamine and SRS-A.
Table III. Some properties of human and guinea-pig ECF-A
Released by antigen challenge of actively or passively sensitised lung.
Passive sensitisation mediated by IgE in human lung and IgGx in the guinea-pig.
Release of ECF-A accompanied by histamine and SRS-A.
Release of ECF-A from perfused whole guinea-pig lung slower than histamine and
SRS-A.
Optimal conditions for ECF-A release, in terms of antigen and antibody dose,
similar to histamine and SRS-A.
Requirement for divalent cations.
Enhanced by succinate and maleate.
Complement not required.
Probably modulated by levels of intracellular cyclic AMP.
Distinct from histamine, bradykinin, serotonin, SRS-A, prostaglandins (PGE) PGEj,
PGE2, PGF2a and C5a.
Labile in alkaline solution.
Resistant to heat, lyophilisation and multiple freezing and thawing.
Molecular weight 500-1,000.
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Factors Generated from Serum by Antigen-Antibody Complexes
Although the in vivo significance of complement-dependent chemotactic
factors is unknown, an eosinophil specific chemo-attractant can be generated
from serum [21]. Preformed antigen-antibody complexes prepared either from
guinea-pig IgG2 or IgGx were equally capable of generating, from normal
serum, heat-stable activities that were chemotactic for guinea-pig eosinophils
and neutrophils. The generation of this activity was apparently dependent on
the presence of an intact complement system. When serum, activated by
complexes prepared from either of these sub-classes, was passed over a
column of Sephadex G-100, two peaks of chemotactic activity could be
demonstrated. The peak of activity for guinea-pig neutrophils had a molecu¬
lar weight of approximately 75,000. The eosinophil chemotactic activity
eluted with molecules having a molecular weight of between 15,000 and
20,000. The nature of the neutrophil chemotactic activity is unknown but a
comparable activity has been generated from rat serum and is thought to be
a cleavage product of the 5th component of complement [33]. The smaller
fragment which was predominately chemotactic for eosinophils had a
similar molecular size and sedimentation constant to that of C5a. It was sub¬
sequently confirmed that C5a prepared from highly purified C5 did, in fact,
preferentially attract eosinophils from a mixed leucocyte population [28].
Although C5a, like ECF-A, is chemotactic for neutrophils, when eosinophils
comprised approximately 10% or more of a mixed population they were
preferentially attracted by this complement fragment.
Interaction of ECF-A with C5a
Since ECF-A and C5a are distinct both in their molecular weight and
formation mechanism, it was of interest to determine the effect of combining
the two agents in eosinophilotaxis [28]. When these agents were mixed
together in the test compartment of the chemotactic chamber the resultant
counts were three times or more greater than would have been expected by
summation of counts when the agents were assayed alone. This suggested
that ECF-A and C5a act synergistically in their ability to attract eosinophils.
It is possible that eosinophils have more than one receptor for chemotaxis
and that, if different types of receptors are stimulated at a low threshold,
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this produces an increased chemotactic response. These observations
on synergism may be of significance in parasitic infestations, many of
which are associated with a pronounced eosinophilia. Homocytotropic
antibody and complement-fixing antibody can occur together in a variety
of parasitic diseases, situations in which ECF-A and C5a might act to¬
gether.
Other Complement-Derived Eosinophil Chemotactic Factors
A fragment from the third component of complement (C3a) [34] and the
trimolecular complex of C567 [35] have also been shown to attract eosino¬
phils. When purified C56 and C7 were prepared as in the 'reactive-lysis'
procedure their combination resulted in attraction of neutrophils, eosino¬
phils [36] and basophils [37], There was no evidence that C567 was pref¬
erentially chemotactic for any of these cell types.
Cell-specific attraction for eosinophils or neutrophils has recently been
demonstrated by activating serum from the hog, rat or guinea-pig with
antigen-antibody complexes, yeast or dextran [38], Following progressive
purification of the activated serum, two peptides have been isolated which
have been termed 'classical anaphylatoxin' and 'cocytotaxin'. By themselves
these peptides have little chemotactic activity but on re-combination and
depending on their molar ratio, cell-specific chemotactic activity for eosino¬
phils or neutrophils can be demonstrated. These interesting observations
suggest that low molecular weight anaphylatoxins are distinct from chemo¬
tactic agents although closely related in molecular size, and that the ratio
in which they are combined determines the expression of various biological
activities. Although the peptides are probably products of complement
activation this has yet to be demonstrated conclusively.
Conclusion
Two chemotactic factors have been described which selectively attract
eosinophil leucocytes. They differ both in molecular size and in formation
mechanism. ECF-A is a product of the anaphylactic reaction and is distinct
from previously described pharmacological mediators. The complement-
derived factor, C5a, can show preferential attraction of eosinophils under
certain experimental conditions. Marked synergism was observed between
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ECF-A and C5a in their ability to attract eosinophil leucocytes. The elabora¬
tion of these agents in various hypersensitivity states may in part account for
the infiltration of eosinophils.
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THE ROLE OF EOSINOPHILS
Chairman: S.G. Cohen











Discussing the nature of eosinophil structure, G. Gleich reported
that the major basic protein recovered from a pool of isolated
cytoplasmic granules in the guinea-pig is a more potent sulphydryl
agent than mercaptoethanol. In several biologic systems the protein
was found to be devoid of enzymatic activity, inflammatory or anti¬
inflammatory effects.
Regarding the kinetics of eosinophil development, G. Hudson raised
many unresolved problems particularly the importance of cell death
as a regulator of eosinopoesis.
D.G. Colley offered preliminary evidence that lymphocyte culture
fluid containing eosinophil stimulating promotor (ESP) also contains
in vitro colony stimulating activity in bone marrow cultures.
R.S. Speirs reported, in the mouse, that the secondary eosinophil
response can be transferred by T-cells primed with tetanus toxoid.
In neonatally thymectomized mouse models, D.A. Cohn's observation
supports this finding. In contrast, Colley in a non-tras ;fer system
in T-cell depleted Schistosoma mansonl infected mice stated that
these animals were still capable of mounting an intermittent periph¬
eral blood eosinophilia. Rosette formation of eosinophils around
macrophages induced by the injection of Trichnella larvae was re¬
ported by R.S. Walls. Other investigators (Speirs, Cohn) agree with
this observation; Speirs suggesting that the development of this
phenomenon leads to the killing of macrophage target cells by eosino¬
phils participating in the inflammatory response. The biologic sig¬
nificance of this observation is not known.
A number of experimental animal models of eosinophilia were dis¬
cussed. D.L. Boros found a fall in circulating eosinophils in mice
following the administration of a monospecific anti-eosinophil serum
(AES); the effect on other cell types in vivo was not reported.
This same AES also prevented the appearance of eosinophils within
382 Workshop reports
granulomatous cells responses engendered around schistosome ova.
D.G. Jones and A.B. Kay also reported on the inhibition of eosinophil
accumulations by AES in vivo following PCA reactions in the guinea-pig.
In another experiment model D. Zucker-Franklin reported on an
association between eosinophilia in rats induced by intravenous in¬
jections of protein antigen-coated latex particles and in vitro
stimulation of lymphocytes by corresponding antigen on the particles.
Ul'trastuctural study of the lesions surrounding the particles showed
a characteristic delayed type reaction with blast cell transformation
of lymphocytes. In this regard W.E. Parish showed that "naked" part¬
icles can also induce a reaction with some of these histological
characteristics; this phenomenon was attributed to surface absorption
and possible aggregation of autologous serum proteins.
Parish stated that eosinophil chemotactic factor of anaphylaxis
(ECF-A) while promoting a local eosinophilia does not provide the
stimulus for engendering systemic eosinophilia reflected in the
peripheral blood. By contrast, a distinct mediator having an approx¬
imate molecular weight of 30,000 which was also derived from anaphy¬
lactic lung diffusates elicited a blood eosinophilia but this agent
was not chemotactic for eosinophils in vitro. M. Samter and Kay's
observation on the infiltration of eosinophils into lung and perit¬
oneal cavity following the administration of ECF-A is relevant to a
consideration of an in vivo physiologic role for this mediator.
Attempts have been made to characterise ECF-A by the susceptibility
of this mediator to treatment by a variety of enzymes. M.K. Bach,
Jones and Kay reported on guinea-pig studies in which no demonstrable
loss of activity resulted from treatment with trypsin, chymotrypsin,
pronase, alkaline phosphatase and sialidase. In contrast loss of
activity in a dose-dependent fashion was shown with tyrosinase,
leucine aminopeptidase and aryl sulfatase; thus suggesting that ECF-A
contains a phenolic hydroxyl group, a sulfate ester and a peptide
linkage with a free 0C- amino group. The enzymes employed had speci¬
ficity only for their appropriate substrates. Thus, although carbo-
xypeptidase A and B inactivated ECF-A the arylsulfatase present in
these preparations was sufficient to account for the loss of chemo¬
tactic activity. E. Goetzl, S. Wasserman and K.F. Austen reported
that human ECF-A is inactivated by aminopeptidases, carbo-
xypeptidase A, subtilisin, pronase and possibly the arylsulphatase
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derived from eosinophils but not trypsin or chymotrypsin; thus
confirming its suspected peptide nature.
Goetzl and his co-workers also reported that pre-incubation of
human eosinophils with corticosteroids inhibit random migration and
chemotaxis but this effect was not seen with the cells of guinea-pig
origin. This observation was confirmed by Jones and Kay with respect
to non-inhibition of migration of hydrocortisone in the guinea-pig
system. These same workers were also unable to demonstrate inhib¬
ition by disodium chromoglycate but did find that an anti-SRS-A
compound, FLP 55712, inhibited chemotaxis at a considerably lower
dosage than that required for the selective inhibition of SRS-A.
Studying eosinophil infiltrations into skin sites subsequently
biopsied, B. Zweiman noted that one week of moderage dosages of short
acting corticosteroids in either daily or alternate day regimes is
followed by significantly less eosinophil accumlLations than that
resulting from intradermal injections of compound 48/80 or of antigen
in specifically sensitized individuals. The whealing response how¬
ever was not significantly affected.
Comments by S.G. Cohen were directed to difficulties in his
experience, in reconciling putative eosinophil functions visualised by
the induction of animal models of eosinoh lilia and in vitro experi¬
ments with known patholophysologic alterations in eosinophil-related
syndromes and disorders. Specifically mentioned in the discussion were
eosinophil properties of phagocytosis of antigen-antibody complexes,
relationships to basophil and mononuclear leukocytes and lymphocytes,
and the association with tissue sensitising antibody.
A number of multi-systemic diseases of unknown aetiology associated
with hypereosinophilia were reported (Zucker-Franklin) D.M. Geunther).
Thus an eosinophilia occurs in association with a number of clin¬
ical states and is evoked by injection of antigen using a variety of
animal models. It is clear that under certain circumstances the
cell is associated with the antigen induction phase. The role of the
cell is associated with the antigen ineuction phase. The role of the
cell in the modulation of the humoral and/or cellular response is un¬
known. This aspect of eosinophil study is possibly the most confusing
due partly to the variety of experimental models used. A number of
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issues were raised in regard to the participation of the cell in the
inflammatory response. Does the eosinophil have a primary function
in inactivating chemical mediators or is it a repair cell? The
kinetics of eosinophil infiltration following local anaphylaxis
would suggest the latter. Therefore it was not felt possible at this
time to interpret the role of eosinophil granuolcytes in either
physiologic states or human disorders On the basis of our present
knowledge of eosinophil function.
A.B. Kay and S.G. Cohen
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were further purified by density centrifugation
on sodium metrizoate (Hypaque) gradients12'13.
Eosinophil chemotactic factor of anaphylaxis
(ECF-A)
ECF-A like histamine is a preformed mediator
and preferentially attracts eosinophils from a
mixed leucocyte population (Fig. 2). The agent
was first identified in anaphylactic diffusates
derived from actively or passively sensitised
guinea-pig lung challenged with specific anti¬
gen 1J. The factor was shown to be distinct
from previously recognised chemical mediators
of anaphylaxis. A comparable agent was sub¬
sequently recognised in human lung tissue15.
The antibody mediating the release of ECF-A
was shown to be IgE in man and IgGt in the
guinea-pig. In the guinea-pig it has recently
been shown that other tissues including skin,
Fig. 2: Millipore filter showing the chemotaxis of
guinea-pig eosinophils towards ECF-A. (Flaema-
toxylin and Chromotrope 2 R x 40 magnification).
uterus, heart and intestine in addition to the
lung can be passively sensitised with IgGj for
the subsequent antigen induced release of a
factor with similar biological and chemical pro¬
perties to ECF-A16'17. In contrast this mediator
was not released in detectable amounts from
sensitised kidney, liver, brain and skeletal
muscle. In vivo the injection of guinea-pig
anaphylactic diffusate into normal lung or
partially purified ECF-A into the guinea-pig
peritoneal cavity provoked the local accumula¬
tion of eosinophils1. The release of ECF-A
from human lung apparently required an intact
glycolytic pathway, a DFP inhibitable esterase
and interaction with the cyclic AMP path¬
way18- 19.
Biologically ECF-A shows considerable cellular
specificity. Thus guinea-pig eosinophils were
preferentially attracted when they comprised
10% or more of mixed leucocyte populations20.
However ECF-A would attract neutrophils
from pure (>96%) populations. Similarly
human ECF-A selectively attracted human
eosinophils, but neutrophils and basophils
would migrate when eosinophils were present
in low numbers21. Recent work in this labora¬
tory has shown that ECF-A has a functional
similarity between species22. Thus, human
ECF-A selectively attracted guinea-pig eosino¬
phils and ECF-A of human origin was chemo¬
tactic for guinea-pig cells. In addition rat mast
cell ECF-A preferentially attracted guinea-pig
eosinophils.
The chemical structure of ECF-A is unknown
but it is likely to be, in part, a peptide-like
molecule. Human and guinea-pig ECF-A were
fully recovered as a single peak of activity
from Sephadex G-25 and had an estimated
molecular size of between 500 and 1,000 dal-
tons14'15. ECF-A was relatively heat stable,
retaining 75% of its activity following boiling
for 10 minutes or heating at 56° C for an hour.
Chemotactic activity was fully recovered fol¬
lowing lyophilisation and multiple freeze-
thawing, and about 70% of the original
activity remained following extraction in 80%
ethanol.
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An inhibitor of eosinophil migration
Compound FPL 55712 has been shown to anta¬
gonise the contractile effect of SRS-A on the
isolated guinea-pig ileum30. In a recent study
we have shown that the same agent potently
inhibits (IC50 2 x 10"7 g/ml"1; 3.8 x 10"7 M) the
migration of eosinophils towards partially
purified guinea-pig ECF-A37. The agent did
not affect the IgGj-mediated release of ECF-A
or histamine from guinea-pig lung in vitro.
High doses of FPL 55712 had a selective cyto¬
toxic effect on the eosinophil as shown by
Trypan blue exclusion. However lower doses
which still markedly inhibited eosinophil chemo-
taxis did not exhibit cytotoxicity38.
Studies on the role of the eosinophil
A number of reports have suggested that the
eosinophil inactivates chemical mediators of
anaphylaxis30'40. However we were unable to
confirm previous studies on the capacity of the
eosinophil to inactivate histamine using cells
from the horse, guinea-pig and human1. Aryl-
sulphatases of various origin including the
mollusc41, human eosinophils40, guinea-pig and
human lung tissue42 have been shown to in¬
activate SRS-A. This group of enzymes has a
wide biological distribution43. Thus although
the eosinophil contains appreciably more aryl-
sulphatase than other granulocytes44 it is un¬
likely that the content of this enzyme in
eosinophils points to a unique function. Further¬
more maximal eosinophil infiltration in vivo
did not occur until several hours after mediator
release8.
This laboratory has developed a model for
studying the repair mechanism following PCA
reactions in the guinea-pig by measuring the
restoration of histamine in depleted skin sites45.
Preliminary evidence suggests that eosinophil
infiltration correlates with the restoration of
histamine following the local anaphylactic
reaction suggesting that the cell may play a
part in the repair mechanism by which the
functional integrity of the mast cell is resorted.
Attempts to modulate the "repair time" in
terms of histamine depletion following PCA
reactions are being undertaken employing a
monospecific anti-eosinophil serum and injec¬
tions of viable eosinophils.
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Annotation
FUNCTIONS OF THE EOSINOPHIL LEUCOCYTE
An increase in the number ofeosinophils both in the tissues and the circulation is a feature of
many clinical conditions. They include diseases associated with high serum levels of IgE, such
as extrinsic (or allergic) bronchial asthma, allergic rhinitis and certain parasitic infections, and
disorders in which there is evidence of circulating antigen-antibody complexes capable of
activating the complement system. The latter group of diseases include polyarteritis nodosa
with lung involvement, pulmonary aspergillosis and rheumatoid arthritis. Until recently,
little was known about the function of these cells but now several laboratories have sug¬
gested possible functions for the eosinophil both in parasitic disease and immediate-type
hypersensitivity.
The main obstacle in attributing a unique role to the eosinophil had been the difficulty in
demonstrating a biological activity for the cell distinct from those of other leucocytes. For
example, eosinophils and neutrophils are both motile, respond in chemotaxis to a variety of
agents, engulf particles, undergo degranulation and kill micro-organisms (reviewed by
Kay, 1974a; Clark & Kaplan, 1975). Certain agents such as eosinophil chemotactic factor of
anaphylaxis (ECF-A) preferentially attract the eosinophil from a mixed leucocyte population
but there is no marked difference between neutrophils and eosinophils in terms of the type of
particles these cells ingest, their rates of engulfment, the mode of degranulation or the types
ofmicro-organism they kill. If anything the eosinophil is more sluggish than the neutrophil
in its rate of ingestion (Cline et at, 1968) and bacterial killing but paradoxically has a higher
metabolic activity in terms ofH202 production, oxidative response and iodination (Baehner
& Johnston, 1971; Mickenberg et al, 1972).
It was hoped that the special structural features of the eosinophil might offer an insight into
its specific function(s). The granules, with their affinity for acid or analine dyes, are the
central feature of the cell. Contained in the granular core is a major basic protein, rich in
arginine, having a molecular size of about 11 000 daltons (Gleich et al, 1973). This material
has been isolated in a highly purified form but in a variety of test systems no biological
activity or anti-inflammatory properties could be shown (Gleich et al, 1974). The granule is
also characterized by its high content of a peroxidase which is present mainly in the cortex.
This enzyme is clearly different both chemically and antigenically from the myeloperoxidase
of the neutrophil and does not appear to participate in the peroxidase-H2 02-halide bacteri¬
cidal system (Bujak & Root, 1974).
The clear association between eosinophils and parasites has encouraged many investigators
to examine both the mechanisms ofparasite-induced eosinophilia and the possibility that the
eosinophil is an effector cell in parasite destruction. Following administration of homo¬
genized larvae from trichinella, bone marrow turnover of eosinophils was shown to be
dependent on viable (probably T-dependent) lymphocytes (Basten et al, 1970; Basten &
Beeson, 1970). When lymphocytes from animals with an eosinophilia were transferred to




irradiated recipients this evoked an increase in the number of circulating eosinophils. Further
studies indicated that a soluble mediator from lymphocytes sensitized to trichinella antigen
evoked selective eosinophil production by the bone marrow. Raised serum levels of IgE and
complement-fixing antibodies are a feature of many parasitic infections associated with an
eosinophilia. The mobilization of eosinophils around the parasite in tissues may be a result
of eosinophil chemotactic factor of anaphylaxis and complement-dependent chemotactic
factors acting synergistically since in vitro there is marked synergism between ECF-A and
a fragment cleaved from the fifth component of complement (Kay et al, 1973).
A role for the eosinophil in the destruction ofparasites has been suggested (Kay, 1974a) and
recently there have been a number of studies to support this concept. It is known that normal
leucocytes (normal in the sense of being unsensitized) have the capacity to lyse antibody-
coated target cells (reviewed by Perlmann et al, 1972). In most systems the effector cell has
been shown to be a subpopulation oflymphocytes and this reaction is usually termed lympho¬
cyte-dependent antibody mediated cytotoxicity (LDAC) or K (killer)-cell cytolysis. In some
systems the neutrophil (Dean et al, 1974) or macrophage (Holm & Hammarstrom, 1973) have
been identified as effector cells but all require antibody on target cells with an intact Fc region.
Using an in vitro assay normal human peripheral blood leucocytes were shown to release
51 chromium from labelled immature schistosomes (schistosomula) (Butterworth et al, 1974).
When the leucocytes were separated into eosinophil, neutrophil or mononuclear cell rich
preparations K-cell activity was associated with the eosinophil (Butterworth et al, 1975). It is
of particular interest that, in contrast to eosinophils from normal subjects, eosinophils from
patients with high numbers ofcirculating eosinophils are apparently ineffective in this system,
suggesting that in eosinophilia the cells may be altered possibly by interference with cell
surface receptors by circulating antigen-antibody complexes.
Further evidence for the eosinophil as an effector cell in antibody dependent damage to
schistosomula has been demonstrated in an in vivo system (Mahmoud et al, 1975). In Schisto¬
soma mansoni infection in mice partial immunity can be transferred by immune serum which
contains specific antibody directed against the schistosomula. The protective effect of serum
was abrogated by prior treatment of the mice with anti-eosinophil serum but not with anti-
sera directed against the lymphocyte, monocyte or neutrophil. Therefore the partial im¬
munity transferred by serum would also appear to require the participation of the eosinophil.
Although these findings on the relationship between the eosinophil and parasitic infection
will need to be substantiated (particularly in other parasitic states where an eosinophil
response is more marked) they strongly support previous suggestions that eosinophils have
parasiticidal properties. There would also appear to be a role for complement in the destruc¬
tion of sensitized schistosomula (Dean et al, 1974) and therefore it is probable that both
humoral and cellular effector systems play a part in parasite destruction (Fig 1).
The functions of the eosinophil in immediate-type (allergic or anaphylactic) hypersensi¬
tivity reactions are probably diverse and therefore point to the versatility of the cell in various
inflammatory states. It may have a regulatory role at all stages of the allergic response,
namely mediator release, mediator inactivation and mediator replenishment. This is depicted
diagramatically in Fig 2. Tissue containing mast cells can be sensitized by IgE (or equivalent
tissue sensitizing antibody) for the antigen-induced release of chemical mediators of ana¬
phylaxis. These pharmacological agents include histamine, slow reacting substance of
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anaphylaxis (SRS-A) and an eosinophil chemotactic factor of anaphylaxis (ECF-A). ECF-A
selectively attracts eosinophils from a mixed leucocyte population in vitro (Kay, 1969; Kay
et al, 1971) and following administration in vivo also leads to eosinophil recruitment at the site
of injection (Kay, 1974b). Histamine itselfmay also contribute to the infdtration and localiza¬
tion of eosinophils (Clark et al, 1975). Following mediator release an eosinophil derived
inhibitor of histamine release (EDI)—probably a prostaglandin—-may then inhibit further
histamine release (Hubscher, 1975a, b). Eosinophil histaminase (Zeiger & Colten, 1974) and
arylsulphatase (Wasserman et al, 1975) are then available for histamine and SRS-A inactiva-








? Participation of complement
Immobilization
or death
Fig 1. Diagrammatic representation of the possible participation of the eosinophil in the destruction
of schistosomula.
tissue stores of these enzymes in mediator inactivation. Many tissues including the lung, skin,
ileum, spleen and liver are rich in both arylsulphatase II B (Kay et al, 1976) and histaminase
(Buffoni, 1966). Furthermore in kinetic studies in which the infdtration of eosinophils has
been observed following a local anaphylactic response, appreciable eosinophil infiltration
does not occur until several hours after antigen challenge at a time when mediator release has
almost certainly terminated and the repair process initiated (Kay, 1970). In addition it should
be emphasized that although the eosinophil contains about eight times more arylsulphatase
II B than the neutrophil (Tanaka et al, 1962), the neutrophil is initially the predominant cell
following an anaphylactic tissue response (Kay, 1970). However, the role of eosinophil
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arylsulphatase in SRS-A inactivation in the subacute or chronic statewhere eosinophilia ismore
pronounced is yet to be ascertained. Eosinophil derived histaminase can be markedly induced
by parasitic infestations but there was no difference in the cell content ofthis enzyme between
normal and allergic individuals (R. S. Zeiger and H. R. Colten, personal communication).
This raises the possibility that eosinophil arylsulphatase may also be an inducable enzyme.
Following mediator release and inactivation a repair process is initiated which leads to
mediator replenishment. A role for the eosinophil is also suggested in repair in which it may
have a 'negative' or 'dampening' effect as with mediator release and inactivation. Depletion
ofeosinophils by anti-eosinophil serum (AES) resulted in more rapid histamine accumulation
following cutaneous anaphylaxis when compared to controls (Jones & Kay, 1976). In
these experiments AES or control rabbit serum (CRS) was injected intravenously along
MEDIATOR RELEASE MEDIATOR INACTIVATION MEDIATOR REPLENISHMENT
Specific antigen
lines.
with specific antigen into guinea-pigs previously sensitized with homocytotropic antibody.
These were then excised, histamine extracted, and the levels compared with those in unsensi-
tized contralateral skin sites. At 1 h, with control rabbit serum, there was approximately
55% depletion and histamine stores were not fully replenished until 48 h. With anti-
eosinophil serum there was a comparable histamine depletion at 1 h but levels were fully
restored by 9 h. Therefore eosinophils may also have a regulatory role in repair following
anaphylaxis and so provide a homeostatic mechanism whereby the antigen-induced release
of mediators, presumably derived from mast cells, is not perpetuated in situations where
there is continuous antigenic stimulation.
In conclusion, whereas the functions of the eosinophil in parasitic disease and immediate-
type hypersensitivity are becoming clearer, these observations do not explain its association
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with other disease states such as malignancies, connective tissue disorders and the hyper-
eosinophilic syndrome. Possibly in these conditions, other biochemical features of the cell are
operative which are unconnected with mechanisms pertinent to parasitic and allergic states.
Notwithstanding, the cell can no longer be regarded as an innocent bystander in inflammatory
responses, but rather an active participant, and probably a very effective one.
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Eosinophil Leucocytes:
Recruitment, Localization and Lunction in
Immediate-Type Hypersensitivity1
A.B. Kay
South-East Scotland Regional Blood Transfusion Service, Royal Infirmary, and the
University Department of Respiratory Diseases, Edinburgh
Over the years, a number of laboratories have addressed themselves to the
following series of closely related questions regarding the eosinophil and immedi¬
ate-type hypersensitivity. What is the mechanism by which eosinophils accumu¬
late at the site of allergic tissue reactions? What is the relationship of eosinophils
to recognised chemical mediators of anaphylaxis? What role does the eosinophil
play in immediate-type reactions?
In a variety of models of experimental anaphylaxis in vivo, the eosinophil
appears at the site of allergic tissue reactions following antigen challenge (Samter
et al, 1953; Parish and Coombs, 1968). When antibody was injected into the
skin of the guinea-pig and after a variable latent period the animal challenged
with specific antigen and Evan's blue dye intravenously (as in a usual passive
cutaneous anaphylactic [PCA] reaction), IgG! but not IgG2 elicited a local eo¬
sinophil response which was maximal 8—12 h following the initial blueing reac¬
tion (Kay, 1970). Therefore, IgGi which prepares guinea-pig skin in vivo for
PCA (Ovary et al., 1963) and in vitro for the antigen-induced release of chemical
mediators of anaphylaxis (Jones and Kay, 1974) could also evoke a local eosino¬
phil response. In the same species, intradermal injections of histamine, in doses
which gave a comparable blueing reaction to the IgG!-mediated response, did
not lead to the accumulation of eosinophils (Kay, 1970). Eosinophils did ac¬
cumulate, however, at the site of injections of compound 48/80, an agent which
depletes mast cell granules. It was suggested therefore that the accumulation of
eosinophils following PCA reactions in the guinea-pig was subsequent to the
release from mast cells of an agent other than histamine.
1 Part of this work was supported by a grant from the Medical Research Council.
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Identification and Characterization ofEosinophil Chemotactic Factor of
Anaphylaxis (ECF-A)
The in vivo observations prompted a search for chemotactic agents for
eosinophils possibly released during the anaphylactic reaction. For this purpose,
a modification of the micropore technique of Boyden (1962) was used. It was
shown that an agent, released by specific antigen from sensitized guinea-pig lung,
selectively attracted eosinophil leucocytes from a mixed cell population {Kay,
1969). This factor was later shown to be distinct from other chemical mediators
such as histamine, slow reacting substance (SRS-A), bradykinin, 5-hydroxytrypt-
amine and the prostaglandins PGE], PGE2 and PGF2a and termed an 'eosinophil
chemotactic factor of anaphylaxis' (ECF-A) {Kay et al., 1971). Material released
from human lung sensitized with IgE, and challenged with specific antigen was
comparable to guinea-pig ECF-A in terms of its capacity to attract selectively
this cell from a mixed population, its molecular size and its identification as a
previously unrecognized mediator of anaphylaxis {Kay and Austen, 1971).
Human ECF-A could also be released from lung by antibody to IgE as in the
'reverse-type' reaction.
ECF-A, like histamine, resides in tissues in a preformed state from which it
can readily be extracted by multiple freezing and thawing or homogenization
{Wasserman et al, 1974). Using isolated cell preparations from the rat, ECF-A
was shown to be localized in mast cells probably in association with the granules.
When cell free homogenates from human lung were applied to a column of
Sephadex G-25, several peaks of eosinophilotactic activity were found including
one in the molecular size range 500—1,000, corresponding to 'anaphylactic ECF-
A'. Following desalting and further purification of this peak by QAE-Sephadex
chromatography and high voltage paper electrophoresis, several acidic peptide-
like components could be eluted which possessed ECF-A activity {Kay, 1976 a).
Using similar procedures Goetzl and Austen (1975) have purified human ECF-A
and synthesized two acidic tetrapeptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu.
These workers and ourselves also recognized the presence of aspartic acid in the
purified peptide preparations. We have found that the analogue, Val-Gly-Asp-
Glu, also had chemotactic activity for human eosinophils which was comparable
to the other tetrapeptides {Kay, 1976 a). The evidence therefore seems to point
to ECF-A being a family of closely related peptides, but there may be species
difference in their chemical structure.
The ECF-A acidic tetrapeptides Val-Gly-Ser-Glu, Ala-Gly-Ser-Glu and the
analogue Val-Gly-Asp-Glu were selectively chemotactic for human eosinophils
over a narrow dose range, although eosinophils from different individuals varied
in their dose response pattern {Turnbull et al., 1977). For instance, eosino¬
phils from some patients gave two peaks of activity, one at 10"4 M and one at
10-1 M.
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When the valyl- and alanyl-peptides were combined at low doses in the
absence of histamine, resultant chemotaxis was similar to that of each peptide
tested alone. The apparent inhibition of chemotaxis by higher doses of the
alanyl-peptide alone could be abrogated when this peptide was mixed with the
valyl-peptide at low concentrations (10~8 M).
Guinea-pig ECF-A may have chemical dissimilarities with its human counter¬
part. Val-Gly-Ser-Glu and the analogue Val-Gly-Asp-Glu had no appreciable
activity for guinea-pig eosinophils over a wide dose range, although some activity
was seen with Ala-Gly-Ser-Glu {Jones and Kay, 1976). In previous studies on the
effect of enzyme digestions on the activity of ECF-A from the guinea-pig, it was
shown that partially purified material lost activity following incubation with
tyrosinase, arylsulphatase and leucine aminopeptidase (Bach et al., 1975). This
suggested that guinea-pig ECF-A contained a phenolic hydroxyl group, a sul¬
phate ester and a peptide linkage with a free a-amino group. It could be that in
the guinea-pig, the full expression of eosinophil chemotactic activity requires
traces of SRS-A and this possibility is being explored.
Histamine and Imidazole Acetic Acid as Eosinophil Chemotactic Factors
The role of histamine in the recruitment of eosinophils to the site of allergic
tissue reactions has been the subject of some controversy (Parish, 1974).
Whereas subcutaneous injections of histamine into the horse resulted in eosino¬
phil accumulation, these observations have not been confirmed in the guinea-pig
(Kay, 1970) or man (Felarca and Lowell, 1968). Similarly as described above, in
vitro experiments failed to show chemo-attractant properties for histamine when
eosinophils from the guinea-pig and man were used as target cells. However,Clark
et al. (1975) were able to show human eosinophilotaxis by histamine with peak
activity of concentrations of approximately 5 X 10"5 M, there being inhibition
with higher doses. It now appears that these discrepancies on the chemotactic
property of histamine can be explained largely on the type of micropore filter
used in the assays. Thus, with the more traditional 'Millipore' filter chemotaxis
by histamine cannot be demonstrated, whereas these membranes were suitable
for the identification and characterization of ECF-A (Kay and Austen,
1971). In contrast, cellulose nitrate filters were satisfactory for the assay of both
ECF-A peptides and histamine (Kay, 1976a). Our laboratory has confirmed and
extended these observations to show that in addition to histamine, one of its
major catabolites, imidazole acetic acid, is also selectively chemotactic for the
human eosinophil (Turnbull and Kay, 1976). 7,-histidine and other histamine
catabolites including 1,4-methylhistamine, l-methyl-4-imidazole acetic acid and
Af-acetylhistamine were inactive in eosinophilotaxis over a large dose range. The
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dose response for histamine was dependent on the chemotaxis incubation time
and the source of eosinophils, although the latter was not clearly associated with
particular disease states. When histamine and imidazole acetic acid were com¬
bined, the chemotactic response was similar to that obtained when one agent
was assayed alone, no additive or synergistic effects being observed. There was
also cross-deactivation between histamine and imidazole acetic acid. These
experiments seem to suggest that histamine and imidazole acetic acid may ac¬
tivate the same chemotactic recognition mechanism for eosinophils and, there¬
fore, it was of considerable interest to determine how histamine and the acidic
tetrapeptides reacted both in vivo and in vitro following combination at various
doses.
Histamine and imidazole acetic acid were also chemotactic for the guinea-
pig eosinophil, the dose-response patterns being similar to those obtained with
human cells (Jones and Kay, 1977). Similarly, histidine and the major histamine
catabolites were inactive in guinea-pig eosinophilotaxis. Chemotaxis of
guinea-pig eosinophils to histamine could be inhibited by both Hr and H2-recep-
tor antagonists at high concentrations (10~3 M), but the effect was more pro¬
nounced with the H2-receptor antagonist, burimamide at lower doses (10"5 M).
A similar but more complex dependence on H2-receptors by human eosinophils
in terms of their migration to histamine has been reported by Clark et al. (1975).
Eosinophil Chemotaxis by Combinations of the ECF-A Peptides and
Histamine
In previous studies, anaphylactic diffusates, in general, gave a linear dose
response in eosinophil chemotaxis, maximal activity being observed with the
highest concentrations {Kay and Austen, 1971). We therefore tested various
combinations of the ECF-A peptides and histamine in order to ascertain whether
the pattern of response was comparable to that of anaphylactic diffusates. It was
found that when histamine was combined with either the valyl- or alanyl-pep-
tides, the resultant chemotaxis was negligible {Turnbull et al., 1977). Thus, not
only did histamine and the peptides fail to act additively or synergistically, but
their combination abrogated the chemotactic response, suggesting that there
may be cross-deactivaton between these agents. However, prior incubation of
cells with histamine did not affect their response to the peptides and similarly
incubation with the peptides did not abrogate the response to histamine. In
contrast, as stated above, prior incubation with histamine deactivated the cells
for chemotaxis towards histamine or imidazole acetic acid and similarly prior
incubation with the individual peptides deactivated to the same peptides. At the
present time, we are unable to explain these clearly complex interactions, but
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suggest that in vivo there are possibly two processes which may require different
relative concentrations and combinations of the various agents. Such events may
be, firstly, directional migration of cells and secondly, stabilization of the eo¬
sinophil at the site of allergic reactions. A possible role for histamine in local¬
izing the eosinophil at the site of anaphylactic reactions has previously been
suggested (Parish, 1974). It may be that there are also other, as yet un¬
recognized, chemotactic agents in the anaphylactic diffusate which also con¬
tribute to directional migration and/or localization. In addition, there may be, in
vivo, differing pharmokinetics in terms of histamine and ECF-A diffusion and/or
inactivation, all of which may be critical for the observed eosinophil accumula¬
tion and localization. Many of these problems will not be solved until the rela¬
tive amounts of the acidic peptides, histamine and possibly imidazole acetic acid
present in the anaphylactic diffusates are known. For this purpose, the develop¬
ment of a quantitative assay for the peptides in biological fluids is required.
EosinophilAccumulation following the Administration of the ECF-A
Peptides and Histamine to Human and Non-Human Primate Skin
The acidic tetrapeptides both promoted eosinophil accumulation when
introduced into the skin of man and a non-human primate (marmoset) (Turnbull
et al., 1977). Experiments in marmoset skin involved full thickness skin biopsies
following a single intradermal injection of the agent either alone, or in combina¬
tion. Human studies were performed in timothy grass pollen (TGP) sensitive
individuals using the 'skin window' technique. In these experiments, there were
repeated applications of the agents to the skin sites at 2- or 4-hour intervals over
a 24-hour study period. In marmosets and man, both the alanyl- and valyl-
peptide evoked infiltration of eosinophils. Combinations of the peptides with
histamine gave lower eosinophil counts in both experimental situations. The
exception was when histamine and the valyl- and alanyl-peptides were combined
together in human skin. In this situation, the resultant eosinophilia was com¬
parable to the valyl- or alanyl-peptide alone and only slightly more than hista¬
mine alone. These were the observations at 24 h; however, at 12 h, in human
skin, histamine promoted little eosinophil response whereas the peptides alone
showed some activity. It was the impression both with the peptides and the
positive control (TGP) that there was a biphasic response with a peak at 8 h, a
slightly lower count at 12 h and then rising to a greater peak at 24 h. A more
striking dual response has recently been reported by Hiroshima and Hayashi
(1976) in terms of eosinophil infiltration in active anaphylaxis in the guinea-pig.
In this study, the initial peak was associated with ECF-A-like material, whereas
the second was related to an eosinophilotactic protein of molecular size approxi-
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mately 70,000, the nature of which was undetermined. Our studies may be
indicative of a comparable phenomenon in humans.
In general, histamine did not evoke eosinophil accumulation in the skin of
marmosets or humans, although with the latter, using repeated applications,
some cells were seen at 20—24 h (Turnbull et al, 1977). These observations are
in agreement with other studies on eosinophil accumulation by histamine in man
(Felarca and Lowell, 1968) and the guinea-pig {Kay, 1970). In contrast, the
individual peptides had considerable activity both in vivo and in vitro. It was
unlikely that the peptides exerted their effect by releasing other mediators, as in
the marmoset mast cell disruption by these agents was not apparent {Turnbull et
al, 1977).
Eosinophil Function in Immediate-Type Hypersensitivity
The role of the eosinophil in immediate-type (allergic or anaphylactic)
hypersensitivity reactions is probably diverse and therefore points to the versatil¬
ity of the cell in various inflammatory states (reviewed by Kay, 1976b). It may
have a regulatory role at all stages of the allergic response, namely mediator
release, mediator inactivation and mediator replenishment. Thus, following
mediator release, an eosinophil-derived inhibitor of histamine release (EDI) —
probably a prostaglandin — may inhibit the further liberation of histamine
{Hubscher, 1975 a, b). Eosinophil histaminase {Zeiger and Colten, 1974) and
arylsulphatase {Wasserman et al, 1975) are then available for histamine and
SRS-A inactivation — SRS-A having a free sulphate group. It is difficult to
ascertain the relative importance of tissue stores of these enzymes in mediator
inactivation. Many tissues, including the lung, skin, ileum, spleen and liver are
rich in both arylsulphatase IIB {Kay et al, 1976) and histaminase {Buffoni,
1966). Furthermore, in kinetic studies in which the infiltration of eosinophils
has been observed following a local anaphylactic response, appreciable eosino¬
phil infiltration does not occur until several hours after antigen challenge at a
time when mediator release has almost certainly terminated and the repair
process initiated {Kay, 1970). In addition, it should be emphasized that although
the eosinophil contains about eight times more arylsulphatase IIB than the
neutrophil {Tanaka et al, 1962), the neutrophil is initially the predominant
cell following an anaphylactic tissue response {Kay, 1970). However, the role of
eosinophil arylsulphatase in SRS-A inactivation in the subacute or chronic state
where eosinophilia is more pronounced is yet to be ascertained. Eosinophil-
derived histaminase can be markedly induced by parasitic infestations, but there
was no difference in the cell content of this enzyme between normal and allergic
individuals {Zeiger and Colten, 1976). It is therefore possible that eosinophil
arylsulphatase is also an inducible enzyme.
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Following mediator release and inactivation, a repair process is initiated
which leads to mediator replenishment. A role for the eosinophil is also sug¬
gested in repair in which it may have a 'negative' or 'dampening' effect, as with
mediator release and inactivation. Depletion of eosinophils by anti-eosinophil
serum (AES) resulted in more rapid histamine accumulation following cutaneous
anaphylaxis when compared to controls {Jones and Kay, 1976). In these ex¬
periments, AES or control rabbit serum (CRS) was injected i.v. along with
specific antigen into guinea-pigs previously sensitized with homocytotropic anti¬
body. These were then excised, histamine extracted, and the levels compared
with those in unsensitized contralateral skin sites. At 1 h, with CRS, there was
approximately 55% depletion and histamine stores were not fully replenished until
48 h. With AES, there was a comparable histamine depletion at 1 h, but levels
were fully restored by 9 h. Therefore, eosinophils may provide a homeostatic
mechanism whereby the antigen-induced release of mediators, presumably
derived from mast cells, is not perpetuated in situations where there is con¬
tinuous antigenic stimulation.
Concluding Comments
It seems probable that recruitment and localization of eosinophils to the site
of allergic reactions is dependent on the interaction between the acidic tetrapep-
tides (ECF-A), histamine and possibly other anaphylaxis-associated mediators.
The functions of the eosinophil in immediate-type hypersensitivity (and
helminth disease) are becoming clearer, although this does not explain the associ¬
ation of this cell with other disease states such as malignancies, connective tissue
disorders and the hypereosinophilic syndrome. Possibly in these conditions,
other biochemical features of the cell are operative which are unconnected with
mechanisms pertinent to parasitic and allergic states. Notwithstanding, the cell
can no longer be regarded as an innocent bystander in inflammatory responses,
but rather an active participant, and probably a very effective one.
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An increase in the number of eosinophils both in the
tissues and the blood is a feature of many clinical
conditions. They include the allergic diseases such as
extrinsic bronchial asthma, atopic dermatitis and allergic
rhinitis; hypersensitivity to numerous drugs; pulmonary
eosinophilia; certain neoplasms including Hodgkin's
disease; a number of connective tissue disorders and the
hypereosinophilic syndrome. In terms of world population
the commonest association with eosinophilia are almost
certainly helminth diseases, the more prevalent being
intestinal infestation with nematodes (e.g. Ascaris
lumbricoides, Toxocara canis and Trichuris trichura),
filariasis (e.g. Loa-Loa, Onchocerca volvulus, Dipetalonema
perstans and Wuchereria bancrofti), schistosomiasis, and
infestation with trematodes and, less commonly, the
cestodes (1).
Recently, several functional properties of the
eosinophil have been described which are quite distinct
from that of the neutrophil and other leucocytes and may
help to explain the role of this cell both in helminth
disease and allergic tissue reactions. The main emphasis
in this chapter will be on the formation, function and
fate of eosinophils in relation to helminth disease.
Formation of the eosinophil
It was shown in the rat that, before birth, eosinophil
production occurs in both the thymus and the lymph
nodes (2); whereas in adults the majority of cells are
produced in the bone marrow (3). The precursor of the
eosinophil in the bone marrow has not been identified with
certainty, but it is known that the cell proceeds through
several divisions before maturing and entering the blood¬
stream (4). During early stages of development protein
synthesis is apparently very active as shown by a highly
developed endoplasmic reticulum and the presence of up to
four nucleoli. With maturation and the appearance of
granules, morphological signs of protein synthesis
disappear (5).
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Structural features and enzyme content
The hallmark of the mature eosinophil is its content
of large intracytoplasmic granules which have an affinity
for acid or aniline dyes. Contained in the granular core
is a major basic protein, rich in arginine, having a
molecular size of about 11,000 daltons (6). This material
has been isolated in a highly purified form but in a variety
of test systems no biological activity or anti-inflammatory
properties could be shown (7). The granule is also
characterised by its high content of a peroxidase which is
present mainly in the cortex. This enzyme is different
both chemically and antigenically from the myeloperoxidase
of the neutrophil and does not appear to participate in the
peroxidase-H^jj-halide bactericidal system (8). "Late"
eosinophils contain a second type of smaller granule which
has no crystalline core and stains intensely for acid
phosphatase and arylsulphatase (9). There is evidence
that these granules are derived from the Golgi apparatus.
A number of eosinophil-derived lysosomal enzymes are
thought to be located primarily in the large granules,
although this is yet to be shown conclusively. Compared
to the neutrophil, the human eosinophil contains eight
times as much arylsulphatase (10), two and a half times as
much ^-glucuronidase and twice the amount of /3-glycero-
phosphatase (11). Phospholipase D, previously recognised
only in plants has also been shown to be present in human
eosinophils (12).
Function of the eosinophil
(i) General properties
The main obstacle in attributing a unique role to the
eosinophil has been the difficulty in demonstrating
biological activity for the cell distinct from those of
other leucocytes. For example, eosinophils and neutrophils
are both motile, respond in chemotaxis to a variety of
agents, engulf particles, undergo degranulation and kill
micro-organisms. Certain agents such as the eosinophil
chemotactic factor of anaphylaxis (ECF-A) (13), histamine
(14, 15) and imidazole acetic acid (15) preferentially
attract the human eosinophil from human peripheral blood
leucocytes but there is no marked difference between
neutrophils and eosinophils in terms of the nature of the
particle these cells ingest (whether these are micro¬
organisms or inert substances), their rate of engulfment,
the mode of degranulation or the variety of micro-organisms
they kill. If anything, the eosinophil is less efficient
than the neutrophil in terms of its rate of ingestion (16)
and bacterial killing although, perhaps paradoxically, it
has a higher metabolic activity as determined by ^2^2
production, oxidative response and iodination (17, 18).
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Human eosinophils contain receptors for rabbit and
human IgG and the human complement components C4, C3b and
C3d (19). There are about two and a half times more
detectable receptors for immunoglobulin and complement on
neutrophils when compared to the eosinophil. In eosino¬
phil ia of various aetiology the number of eosinophil C4 and
C3b receptors was reduced when compared to the eosinophil
from the blood of normal individuals.
Both human (20, 21) and mouse (22) eosinophils bear
cell surface specific antigens which has enabled the
production of monospecific anti-eosinophil serum. Mono¬
specific antisera against guinea pig eosinophils have been
more difficult to prepare (23, 24). However, all these
various anti-eosinophil sera have proved useful reagents
for studying the function of the cell in helminth disease
and immediate-type hypersensitivity.



















Fig. 1. Diagrammatic representation of the possible
mechanisms involved in helminth destruction by eosinophils.
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(ii) Helminths
In figure 1 a scheme is presented which attempts to
explain, diagrammatically, some of the events which may
follow the introduction of a helminth into the mammalian
host. Data are taken from various sources, some from work
with in vitro models and others with iri vivo systems.
Investigators concerned with the events leading to
eosinopoiesis by the bone marrow have often used the
administration of trichinella to the rat, whereas studies
on eosinophil-killing have, in general, focussed on the
larval stages of Schistosoma mansoni.
Following administration of homogenised larvae from
trichinella, bone marrow turnover of eosinophils was shown
to be dependent on viable (probably T dependent)
lymphocytes (25, 26). When lymphocytes from animals with
an eosinophilia were transferred to irradiated recipients
this evoked an increase in the number of circulating
eosinophils. Further studies indicated that a soluble
mediator (diffusible factor) from lymphocytes sensitised
to trichinella antigen evoked selective eosinophil
production by the bone marrow. Exactly how helminths
induce a T-cell dependent eosinophilia is unknown although
it is probably determined by unique structural configura¬
tions of the parasite antigen.
Helminths also evoke an antibody response, particularly
IgE but also IgG and probably other immunoglobulin classes.
The way in which eosinophils are recruited to the site of
tissue parasites is probably complex but the results of
in vitro experiments suggest a number of possible
mechanisms. For instance, parasite antigens may release,
from IgE-sensitised mast cells, various chemical mediators
of anaphylaxis which increase selectively human eosinophil
locomotion. These include the ECF-A tetrapeptides (now
characterised as Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu) (27),
histamine, and one of its major catabolites, imidazole
acetic acid (15). The ECF-A tetrapeptides and, to a much
lesser extent, histamine elicit a local eosinophilia when
applied to the abraded skin of man (28, 29) suggesting that
they have both iji vivo as well as in vitro activity.
Various components of the complement system are also known
to be chemotactic for the eosinophil and are possibly
generated in vivo as a result of IgG interaction with the
appropriate helminth antigen. The components include
human C5a (30) and the trimolecular complex C567 (31).
In general these agents have no particular preferential
eosinophil attracting properties in vitro, with the
exception of the guinea pig in which C5a evokes selective
eosinophil migration (32). ' Furthermore, synergism was
reported in JLn vitro chemotaxis between guinea pig C5a and
ECF-A suggesting that in some circumstances these agents
may act together (33). Other chemotactic factors for the
eosinophil include a product which is released by the inter¬
action of a T-lymphocyte product and immune complexes (34).
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Another lymphocyte mediator of considerable interest
enhances the migration of eosinophils out of agarose
■ droplets in vitro. This has been referred to as the
eosinophil stimulation promoter (ESP) and was first
. observed in supernatants of mouse lymphocytes stimulated
with phytohaemagglutinin or specific antigen (35). It is
derived from T-cells and is dependent on protein
synthesis (36). Secretion of ESP could be demonstrated
by isolated schistosome egg granulomas cultured ill vitro (37).
It has yet to be determined what biological property this
agent confers on the eosinophil leucocyte and what its
relationship is to the diffusible factor (25, 26).
Recent work suggests that eosinophils act as cytotoxic
"killer" cells for helminths sensitised by IgG. Using an
in vitro assay normal human peripheral blood leucocytes
were shown to release 51cr from labelled immature
schistosomes (schistosomula) (38). When the leucocytes
were separated into eosinophil, neutrophil or mononuclear
cell rich preparations cytotoxic activity was only
associated with the eosinophil (39). Eosinophils from
patients with schistosomiasis and other helminths were,
however, ineffective in this system and there is evidence
to suggest that eosinophil receptors may be blocked by
circulating antigen-antibody complexes in certain parasitic
diseases.
Although this system requires human IgG and the
eosinophil as the effector cell, a similar system has been
described using rat cells and serum in which killing is
mediated by the macrophage sensitised with IgE (40).
However, in general, (see below), in vivo experiments in
mice support iri vitro findings in humans in that the
eosinophil appears to be the principal effector cell in
schistosomula killing. Antibody-dependent killing of
schistosomula by eosinophils does not apparently require
the participation of other cells, such as neutrophils and
mononuclear cells (41), and the release of ®^Cr correlates
well with damage to parasites as judged by phase contrast
and electron microscopy (42). The association between
eosinophils and schistosomula is one of tight adherence
accompanied by eosinophil degranulation and the appearance
of electron dense material on the surface of the parasite.
The biochemical mechanisms by which human eosinophils
kill schistosomula in the presence of antibody has been
studied using metabolic inhibitors and other agents which
alter cell function (43). There would appear to be no
requirement for oxidative phosphorylation, protein
synthesis, intact microtubules, DNA and mRNA synthesis or
prostaglandin synthesis; parasite killing was not
inhibited with prednisolone. In contrast, agents which
act on microfilaments such as cytochalasin B rendered
eosinophils ineffective in this system and inhibitors of
glycolysis decreased markedly eosinophil parasiticidal
activity. There was also a dependence for agents which
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modulate the levels of intracellular cyclic AMP. In
addition inhibition of certain cell membrane-associated
esterases also rendered eosinophils ineffective in this
system. It would appear, therefore, that the killing of
antibody coated schistosomula by eosinophils is a complex
phenomenon requiring the integrity of certain metabolic
pathways, tight adherence of eosinophils to target cells
and presumably an intact Fc receptor.
Schistosome eggs are also destroyed by eosinophils in
an antigen specific system (44). Only eosinophils from
schistosome infected mice were active whereas those from
normal mice or those infected with T. spiralis were
ineffective. These experiments suggest that eosinophils
from infected animals become "armed" by a cytophilic anti¬
body directed against the appropriate antigen.
Eosinophils have also been shown to be the effector
cells in the killing of the epimastigotes from Trypanosoma
cruzii (45). Using a technique which depends on the
release of RNA from T. cruzii. eosinophils, in the presence
of specific antibody, mediated killing whereas lymphoid
cells had insignificant activity.
Although these various in_ vitro systems do not have
the requirement for complement the possibility that
complement enhances this reaction has not been excluded.
In other systems, where cells of the lymphoid series are
antibody-dependent killer cells, the sensitised target
cell (usually erythrocytes) can be rendered more susceptible
to lysis if they are coated with the early complement
components up to C3 (46).
Recent experiments suggest that it may be possible to
explain the association between helminths, eosinophils, the
IgE response and complement. Receptors for C3b (but not
IgG) were enhanced by incubating eosinophils with either
the ECF-A tetrapeptides, or histamine, and this enhancement
was demonstrable in a time- and dose-dependent fashion (47).
Other mediators of anaphylaxis such as bradykinin, the
prostaglandins PGE^, E2 and F2o< as well as serotonin were
ineffective in this system. Neutrophils and monocyte
receptors were unaffected by any of these treatments.
Whether the enhanced eosinophils are more effective in the
various other systems described is currently under
investigation but as is shown in figure 1 it is suggested
that the increase in receptors may represent an amplifica¬
tion mechanism whereby eosinophils are rendered more
efficient in killing parasites.
There are a number of in vivo studies which support
the contention that there is a requirement for eosinophils
and specific antibody in the killing of certain helminths
especially schistosomula. In Schistosoma mansoni infection
in mice partial immunity can be transferred by immune serum
which contains specific antibody directed against the
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schistosomula (48). The protective effect of serum was
abrogated by prior treatment of mice with anti-eosinophil
"
serum but not with antisera directed against the lymphocyte,
monocyte or neutrophil. Therefore, the partial immunity
■ transferred by serum would also appear to require the
participation of the eosinophil. Not only was immunity
to reinfection abolished but treatment with anti-eosinophil
serum also reduced the size and numbers of eosinophils in
granulomas formed after intravenous injection of schistosome
eggs.
The participation of eosinophils in damage to other
helminths has been suggested and of particular interest is
the apparent requirement for this cell in containing the
number of muscle stage larvae in T. spiralis infection in
mice (49).
In view of these findings it will not be surprising
if a number of helminths, associated with eosinophilia, are
shown to be destroyed by this cell under the appropriate
experimental conditions. One of the many questions which
arises is at what stage in the life cycle, or development of
a parasite, is destruction by eosinophils most effective and
how does this relate to eosinophil-independent mechanisms
which are also thought to have significance in immunity to
parasites.
(iii) Allergic disease
The functions of the eosinophil in allergic tissue
reactions are also becoming clearer from recent experimental
work. Many consider that the cell has a negative or
"dampening" effect in type I or immediate-type hypersensiti¬
vity reactions (50). Thus an eosinophil derived product
(EDI), possibly prostaglandin in nature, apparently inhibits
further histamine release from sensitised basophils
challenged with antigen (51, 52). The eosinophil also
contains a number of enzymes which inactivate various
chemical mediators associated with hypersensitivity. These
include an arylsulphatase (53) which destroys the biological
activity of slow reacting substance of anaphylaxis and
histaminase (54). The eosinophil may also have a preferen¬
tial phagocytic capacity for mast cell granules although it
has yet to be shown with certainty that this cell is any
more effective than other phagocytes in this respect (55).
Eosinophils may also play a part in the regeneration of mast
cells following type I reactions (23). Depletion of guinea
pig eosinophils by anti-eosinophil serum greatly accelerated
the restoration of local skin histamine levels following an
IgG-^ mediated passive cutaneous anaphylactic reaction.
Possibly this is a way in which the organism regulates the
perpetuation of immediate-type reactions in situations where
there is continuous antigenic stimulation. These possible
functions of the cell in allergic reactions are depicted
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Fig. 2. Diagrammatic representation of the functions
of the eosinophil during immediate-type (anaphylactic)
hypersensitivity. The "inhibitory" effects of the
eosinophil are represented by the interrupted lines.
Conclusion
The function of the eosinophil is becoming clearer
both in helminth disease and allergic tissue reactions.
Currently, the role of the eosinophil as antibody-
dependent killer cell is receiving much attention and
there are many experiments to suggest that in immediate-
type hypersensitivity eosinophils have a "homeostatic"
role. However, much is to be learnt as to the exact
biochemical pathways by which these cells exert their
various effects.
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Fate of the eosinophil
The fate of human eosinophils from a patient with
the hypereosinophilic syndrome was studied by reinjection
of the cells labelled with 51-chromium (56). Following
infusion, radioactivity attributed to the eosinophil
declined rapidly within the first 3 hours but was
followed by an increase after 6-24 hours. Thereafter
the radiolabelled cells were removed from the circulation
in an exponential fashion, with a half-life of
approximately 45 hours. One explanation of these
findings was the existence of a recirculating pool of,
or marginal compartment for, eosinophils although surface
counting data did not indicate specific tissue localisa¬
tion of these cells. These findings are yet to be
substantiated in eosinophilia in association with the
more common diseases.
Eosinophils comprise between 1 and 5% of the total
circulating leucocytes in normal healthy individuals.
However, for every circulating eosinophil there are
approximately 200 mature cells in the bone marrow reserve
and 500 in loose submucosal connective tissue. There is,
therefore, a dynamic turnover of eosinophils, with
production and maintenance of a reserve pool in the marrow,
and transport via the blood to certain tissue sites. The
fate of these cells is not fully appreciated either in
health or disease. However, "damaged" eosinophils may be
engulfed by macrophages or may pass through the intestinal
and respiratory mucosae and be excreted. This would be
similar to neutrophil elimination where the bulk of cells
are probably excreted or removed by tissue macrophages.
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Eosinophiles et reponses immunitaires.
Une augmentation du nombre des eosinophiles est caracteristique d'un*
grand nombre de parasitoses. L'augmentation du "turn over" des
eosinophiles dans la moelle des os a la suite d'une agression parasitaire
depend vraisemblablement de la liberation de facteurs solubles par une
sous-population de lymphocytes T. Plusieurs laboratoires ont suggere que
les eosinophiles agiraient en tant que cellule cytotoxique sous 1'action
d'anticorps (IgG). Le role des IgE est mal defini quoique 1'action de
produits de la reaction anaphylactiques : histamine et tetrapeptides ECF-A
(Val-Gly-Ser-Glu et Ala-Gly-Ser-Glu) se traduise par une augmentation des
recepteurs de membrane des eosinophiles. Ceci peut representer une etape
d'amplification par laquelle les eosinophiles accomplissent leur effet
cytotoxique. Les mecanismes d'activite des eosinophiles en tant que
cellules effectrices dans la destruction des parasites sont discutes au
niveau des reponses immunitaires humorales et cellulaires.
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It has been appreciated for many years that there is a clear
association between eosinophil leukocytes and immediate-type hyper-
■ sensitivity reactions. In a variety of models of experimental anaphy¬
laxis in vivo the eosinophil appears at the site of allergic tissue
reactions following antigen challenge (1,2). When antibody was placed
in the skin of the guinea-pig and after variable latent period the
animal challenged by specific antigen and Evan's blue dye intravenously
(as in a usual passive cutaneous anaphylactic reaction), IgGj but not
IgG2 elicited a local eosinophil response which was maximal 8-12 hr
following the initial bluing reaction (3). Therefore IgCj, which pre¬
pares guinea-pig skin in vivo for passive cutaneous anaphylaxis (PCA)
(4) and in vitro for the antigen-induced release of chemical mediators
of anaphylaxis (5), could also evoke a local eosinophil response. In
the same species intradermal injections of histamine in doses which
gave a comparable bluing reaction to the IgGj-mediated response did
not lead to the accumulation of eosinophils (3). Eosinophils did
accumulate, however, at the sites of injection of Compound 48/80, an
agent which depletes mast cell granules. It was suggested therefore
that the accumulation of eosinophils following PCA reactions in the
guinea-pig was subsequent to the release from mast cells of an agent
other than histamine.
These in vivo'observations prompted studies on the identification
of chemotactic agents for eosinophils released during the anaphylactic
reaction and for this purpose a modification of the micropore tcchni-
|ue of Boyden was used (6,7). The Boyden chambers consist essentially
>f two compartments divided by a micropore filter. A suspension of
■osinophi1-rich leukocytes is placed in the upper compartment and the
hemotactic agent is introduced into the lower part of the chamber,
ollowing an incubation period the filter is removed, fixed and stained
nd chemotaxis is measured by counting the number of cells which have
raversed the entire thickness of the micropore or by measuring the
istance the "leading front" of cells has migrated from the origin (8).
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Other refinements to the technique include a method in which leuko¬
cytes are labelled with ^chromium and chemotaxis is expressed in
terms of radioactivity of a membrane placed between the filter and
the chemo-attractant (9). Suspensions of eosinophil-rich leukocytes
from the guinea-pig are obtained by twice weekly intraperitoneal in¬
jections of horse serum for 3-6 weeks. Human eosinophils were taken
from the peripheral blood from patients with eosinophilia in associa¬
tion with a variety of conditions. Eosinophils can be further puri¬
fied following centrifugation on sodium metrizoate cushions (10).
II. EOSINOPHIL CHEMOTACTIC FACTOR OF ANAPHYLAXIS
A. Identification
An agent released by specific antigen from sensitized guinea-
pig lung which selectively attracted eosinophil leukocytes from a
mixed cell population was first described in 1969 (11). This factor
was later shown to be distinct from other chemical mediators such as
histamine, slow-reacting substance (SRS-A), bradykinin, 5-hydroxytrypt-
amine and the prostaglandins PGEj, PGE2 and and was termed an
"eosinophil chemotactic factor of anaphylaxis" (ECF-A) (12). ECF-A
(or ECF-A-like material), was then shown to be present in a number of
tissues including human lung (13) and nasal polyps (14), basophil-
rich human leukocytes (15), isolated rat mast cells (16), guinea-pig
skin (5), uterus, heart and intestine (17).
ECF-A was shown to be distinct from a fragment cleaved from the
fifth component of complement (C5a; 12), which also, under certain
conditions, selectively attracts the eosinophil in vitro (18).
Furthermore, prior decomplementation in vivo by purified cobra venom
factor did not affect the antigen-induced release of ECF-A (12).
It was shown that guinea-pig ECF-A had a molecular size of
approximately 500 (12) and probably had a peptiile-1 ike structure (19).
Material released from human lung sensitized with IgE and chal¬
lenged with specific antigen was comparable to guinea-pig ECF-A in
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terms of its capacity to attract selectively this cell from a mixed
.population, its molecular size and its identification as a previously
unrecognized mediator of anaphylaxis (13). Human ECF-A could also be
released from lung by antibody to IgE as in the "reversed type"
reaction.
B. Biochemistry of ECF-A Release
Generally speaking the biochemical variables for the release of
ECF-A are similar to those for histamine and SRS-A release. These
include a requirement for calcium ions (12), an intact glycolytic
pathway, and prior activation of a DFP-inhibitable serine esterase
(20). Similarly the release of ECF-A, like histamine and SRS-A, can
be modulated by alterations in the intracellular levels of the cyclic
nucleotides, adenosine monophosphate (cyclic-AMP) and guanosine mono-
ahosphate (cyclic-GMP) (20). As in other systems, levels of these
luclcotides have opposing effects; increased levels of cyclic AMP
leading to inhibition of ECF-A release and enhancement of release
iy raised concentration of cyclic CMP.
C. ECF-A Release in Relation to Histamine and SRS-A
Studies on the time course of mediator release from tissue
ragments are difficult to interpret since ECF-A, like histamine and
1S-A, is highly charged (see below). However when sensitized whole
tinea-pig lung was perfused with specific antigen through the pul-
>nary artery and mediators measured in the perfusate there was a
ire protracted release of ECF-A, compared to histamine and SRS-A
1). This is not surprising if ECF-A does indeed play a role in
c recruitment of eosinophils to the site of allergic tissue re-
tions in vivo.
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D. Selectivity of Action of ECF-A for the Eosinophil
The remarkable property of ECF-A is its capacity to attract selec¬
tively eosinophils from a mixed leukocyte population. In general
this is more striking with a homologous guniea-pig system than when
studying human ECF-A with.human eosinophils as target cells. Thus,
although guinea-pig ECF-A will attract the neutrophil from pure (>96%)
preparations it selectively attracted the eosinophils when the com¬
prised 10% or more of mixed cell suspension (18). Selective attraction
of human eosinophils by homologous human ECF-A was less striking.
Guinea-pig ECF-A was also shown to act synergistically with C5a
(18). The capacity of ECF-A and the complement-derived fragment to
act together in chemotaxis may be of significance in parasitic in¬
fections associated with a pronounced eosinophilia in which homocyto-
tropic and complement-fixing antibodies occur together.
Further evidence for the selective effect of ECF-A on the eosino¬
phil was provided by studies on diminished eosinophil chemotactic
responsiveness (deactivation). Thus, eosinophils pretreated, and
then washed free of ECF-A showed a marked inhibition of chemotaxis
when subsequently tested against ECF-A in micropore chambers (22).
These observations point to a special recognition process between
ECF-A and the eosinophil, the nature of which is yet to be ascertained.
E. Chemical Characterization of ECF-A
It is now appreciated that ECF-A, like histamine, resides in
tissues in a preformed state from which it can be readily extracted
by multiple freezing and thawing or homogenization (16). Using iso¬
lated cell preparations from the rat, ECF-A was shown to be localized
in mast cells probably in association with the granules. Khen cell-
free homogenates from human lung were applied to a column of Sephadex
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G-25 several peaks of eosinophilotactic activity were found including
one in the molecular size range 500-1000 corresponding to "anaphy¬
lactic ECF-A". Following desalting and further purification of this
peak by QAE-Sephadex chromatography and high voltage paper electro¬
phoresis, several acidic peptide-like components could be eluted
which possessed ECF-A activity (L.W. Turnbull, D.G. Jones and A.B.
Kay - unpublished). Using similar procedures Goetzl and Austen have
purified human ECF-A and synthesized two acidic tetrapcptides, Val-
Gly-Ser-Glu and Ala-Gly-Ser-Glu (23) possessing ECF-A-like activity.
Both groups have also recognized the presence of aspartic acid in
the purified peptide preparations. We have found that Val-Gly-Asp-Glu
also has chcmotactic activity for human eosinophils comparable to the
other tetrapeptides (24). The evidence therefore seems to point to
ECF-A being a family of closely related peptides. Furthermore there
may be species differences in ECF-A. Thus, the three tetrapeptides
mentioned above had little or no activity for guinea-pig eosinophils
(D.G. Jones and A.B. Kay - unpublished) and there is evidence that
amongst guinea-pig ECF-A(s) there may be phenolic hydroxyl groups,
sulfate esters and groups susceptible to the effects of leucine
aminopeptidase (25).
It is now recognized that other pharmacological mediators associ¬
ated with anaphylaxis have selective chcmotactic activity for human
eosinophils. These include histamine (26) and one of its major meta¬
bolites, imidazole acetic acid (24). Histidinc and other histamine
catabolites including N-acetylhistamine, 1,4-mcthylhistamine and
1,4-methyl imidazole acetic acid had no eosinophil or neutrophil chem-
otactic activity over the dose range 10"^ to lO'^M.
Because of their quite different dose-response patterns it is
difficult to compare the relative eosinophil chemotactic activities
of the tetrapeptides with that of histamine and imidazole acetic
acid (Fig. 1). With Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu there were
two peaks of eosinophil chcmotactic activity, one at lO'^M and one
at 10"6M. Between these doses there was apparent inhibition of
chemotaxis. These two peptides also evoked some neutrophil chemotaxis
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Fig. 1. Chemotaxis for human eosinophils by acidic tetrapeptides,
histamine and imidazole acetic acid. (The synthetic peptides wore
kindly supplied by Dr. R. Camble, I.C.I. Pharmaceuticals, Aldcrley
Park, England.)
but only at 10~-*M. The pattern of eosinophil chemotaxis with Val-Gly-
Asp-Glu was similar except that there was little activity for either
the eosinophil or the neutrophil at high doses (10'^M). Maximal
activity with histamine was at lO'^M with some apparent inhibition
at 10"^M. With imidazole acetic acid there was a linear dose-response
at concentrations higher than 10"^M. In the study depicted, the re¬
sults represent the pooled values from three different preparations
of target cells, i.e. each agent, at seven concentrations, was set
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up in chemotaxis against three different preparations of eosinophils.
We have observed, in both these and other experiments, that the pep¬
tides and imidazole acetic acid give similar patterns (or shape) of
dose-response irrespective of the source of target cells. With hista¬
mine, however, the concentration giving maximal chemotaxis can vary
between sources of eosinophils although for a particular patient the
pattern remains constant. Thus, the concentration of histamine giv¬
ing maximal activity may be 10"?, lO"4 or 10~6M, with inhibition at
higher doses. The reasons for these variations in eosinophil response
to histamine are unclear but may be related to the concentrations of
leukocyte histaminase. The complex dose response patterns for both
the tetrapeptides and histamine are difficult to explain but may be
related to optimal in vivo concentrations required for cell accumu¬
lation. Furthermore it is likely that these agents act in combination
in the events leading to local eosinophilia in allergic tissue
reactions.
F. Tumor-associated ECF-A-like Material
Eosinophilia is found in association with a number of neoplastic
conditions including various carcinomas and llodgkin's disease. An
eosinophilotactic agent extracted from a large-cell anaplastic carci¬
noma of the lung from a patient with eosinophilia has been described
(27). The active, material was shown to be peptide-like and had many
of the characteristics of ECF-A.
Selective eosinophilotactic activity was also demonstrable from
cultured llodgkin's lymph node supernatants (28). Control supernatants
prepared from lymphocytic lymphoma and reactive hypoplasia nodes were
chemotactic for neutrophils but had little eosinophil chemotactic
activity. In most instances the degree of eosinophil infiltration
observed histologically in the Hodgkin's lymph node correlated with
elaboration of eosinophil chemotactic activity from the cultured
cells. Following gel filtration of the Hodgkin's lymph node super¬
natants, several peaks of eosinophil chemotactic activity were ob¬
served, one of which corresponded in molecular size to ECF-A.
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Wliether tumor-derived ECF-A is chemically identical to the
tetrapeptides is yot to be determined.
III. CONCLUSION
Despite the identification of ECF-A and the appreciation that
histamine and imidazole acetic acid are also selectively chcmotactic
for eosinophils, the precise contributions of these agents to the re¬
cruitment and accumulation of the cell in vivo are not known. Follow¬
ing administration of partially purified ECF-A to the lung and perito¬
neal cavity of the guinea-pig, there was a subsequent eosinophil
infiltration (21). However these studies will have to be corroborated
using the synthetic peptides and other eosinophilotactic agents,
either alone, or in combination. Furthermore, the events leading to
eosinophil infiltration in the anaphylactic situation are clearly
complex and chemotaxis may only contribute to a limited extent in
cellular localization. "Stickiness" of the vasculature, passage
through the endothelium and entrapment of eosinophils at the reaction
site are other prerequisites for cell recruitment and may be depen¬
dent on agents other than chemotactic factors. In the subacute and
chronic situation there is, in addition to cell recruitment, a signal
for turnover of eosinophils by the bone marrow.
Despite the uncertainty of the exact in vivo role for ECF-A the
agent(s) have the potential for providing considerable information on
the biology and biochemistry of eosinophils due to their unique
selective action on this cell.
The central issue is the role of the eosinophil. In anaphylaxis
it has been proposed that eosinophils play a part both in mediator
release, mediator inactivation and mediator replenishment. At all
stages this is thought to be a "negative" or "dampening" effect.
Thus an eosinophi1-derived inhibitor (EDI) - probably a prostaglandin
can inhibit the anaphylactic release of histamine (29,30); eosinophil
histaminase and arylsulfatase inactivate histamine (31) and SRS-A
respectively (32); histamine replenishment by tissue which has
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undergone an immediate hypersensitivity response, is more rapid in
the absence of eosinophils (33). It would seem therefore that eosino¬
phils are more than colorful onlookers in the anaphylactic response
but rather active participants (see also Zucker-Franklin, Chapter 15
this volume).
IV. RECENT DEVELOPMENTS
Since this chapter was written there have been a number of fur¬
ther studies on the biology of ECF-A and its association with disease.
The variation in the in vitro dose-response pattern by eosinophils
to ECF-A and histamine from different individuals, referred to above,
has been investigated further. The eosinophil chemotactic response
to Val-Gly-Ser-Glu and histamine was studied in 32 patients with a
peripheral blood eosinophilia (34). Their eosinophilia was associated
with extrinsic asthma (12 patients), neoplasia (7), helminths (5) and
a miscellaneous group (8) which included three patients with pulmonary
eosinophilia, one of whom had asthma. Both the tetrapeptide and hista¬
mine gave two types of dose-response with Val-Gly-Scr-Glu. This was
either a single peak at 10'^M, or two peaks at 10~4 and 10"^M, respec¬
tively. ilistamine gave either a linear dose-response with maximal
chemotaxis at the highest concentration or a peak response at 10"SM
with inhibition at higher doses. The two types of response given by
the peptide were not related to the disease state and were reproducible
when tested on more than one occasion. However, with histamine,
linear dose-responses were observed in ten out of twelve patients
with asthma, four out of five with helminth disease and two of the
three with pulmonary eosinophilia. This was also reproducible when
tested on subsequent occasions. Therefore in these diseases, which
are known to be associated with exogenous antigens and raised IgE
levels, eosinophils from 80% of the patients (16 out of 20) gave a
linear rather than a "bell-shaped" response to histamine. In con¬
trast only four of twelve (33%) with eosinophilia in association
rfith other diseases (which included seven with neoplasia) gave this
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type of response. If this observation can be confirmed with a larger
number of patients it may be useful diagnostically in eosinophilia
of unknown origin. Although the differences with histamine in terms
of their association with disease were more apparent than with Val-
Gly-Ser-Glu, the association of the dose-response curve with disease
states may be apparent with the peptide response when greater numbers
of patients are studied.
We have also found that when Val-Gly-Ser-Glu or Ala-Gly-Ser-Glu
were combined in various concentrations the resultant chemotaxis was
either negligible or no greater than that produced when each peptide
was tested separately. (35). Thus not only did histamine and the
peptides fail to act additively or synergistically but their combi¬
nation abrogated the chemotactic response suggesting that there may
be cross-deactivation between these agents. However prior incubation
of cells with histamine did not affect their response to the peptides
and similarly incubation with the peptides did not abrogate the re¬
sponse to histamine. In contrast, prior incubation with histamine
deactivated the cells for chemotaxis towards histamine or imidazole
acetic acid, (24) and prior incubation with the individual peptides
deactivated to the same peptide. (23) At the present time we arc
unable to explain these clearly complex interactions but suggest that
in vivo there are possibly two processes which may require different
relative concentrations and combinations of the various agents. Such
events may be, firstly, directional migration of the cells and sec¬
ondly, stabilization of the eosinophil at the site of allergic re¬
actions. It may be that there are also, as yet unrecognized, chemo¬
tactic agents in the anaphylactic diffusate which also contribute to
directional migration and/or localization. In addition there may be,
in vivo, differing pharmacokinetics in terms of histamine and EFC-A
diffusion and/or inactivation, all of which may be critical for the
observed eosinophil accumulation and localization. Many of these
problems will not be solved until the relative amounts of the acidic
peptides, histamine and possibly imidazole acetic acid present in the
anaphylactic diffusates are known. For this purpose, the development
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of a quantitative assay for the peptides in biological fluids is
required.
We were also able to show that Val-Gly-Ser-Glu and Ala-Gly-Ser-
Glu both promoted eosinophil accumulation when applied to the abraded
skin of man or intradermally to the marmoset. (35) Biopsies of marmo¬
set skin revealed that peptide-induccd cosinophilia was not a result
of mast cell degranulation. These experiments have been extended and
the number of eosinophils recruited locally to abraded human skin were
measured in eight atopic and eight non-atopic volunteers, at time
intervals over 24 hr, following the application of Val-Gly-Ser-Glu or
histamine. (36) In all subjects the higher doses of the peptide
(10"'' and 10~^M) or histamine (10"^ and 10~^M) produced significantly
greater counts than the Tyrode's diluent alone. The counts produced
with the lower dose of peptide (10"®M) or histamine (10~^M) were not
significantly different from the control. The peptide or histamine
evoked a greater local eosinophilia in the atopics than the non-
atopics. This effect was probably independent of the peripheral blood
eosinophil count since at the time of study the numbers of circulating
eosinophils between the two groups were not significantly different.
In the atopics, histamine in doses of 10"^ and 10~^M were required to
give the same eosinophil response as that obtained with 10~4 and 10"6M
of the peptide, respectively. It is suggested that the relative
paucity of eosinophils recruited by locally applied F.CF-A peptide or
histamine, when compared to antigen-induced eosinophilia, is due
either to an inability to mimic the events associated with the re¬
lease of these mediators from mast cells or the involvement of other
as yet undetermined pharmacological agents. For instance, we have
also found that histamine, when combined with the acidic tetrapep-
tides, evoked little or no cutaneous eosinophil infiltration either
in man or in the marmoset. Therefore, these recent studies suggest
that there is a complex interaction between histamine and the FiCF-A
tetrapeptides; however, the tetrapeptides alone can promote the re¬
cruitment and localization of eosinophils by a mechanism apparently
independent of mast cell degranulation. The dose-response pattern
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of the peptides and histamine in vitro has considerable individual
variation, which in the case of histamine may be related to the
disease state.
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SUMMARY
Guinea-pig skin fragments were passively sensitized for the antigen-induced release
of histamine, SRS-A and ECF-A. Skin histamine was chemically identified by fluor-
imetry; SRS-A gave a characteristic dose-dependent contraction of the guinea-pig
ileum; and ECF-A selectively attracted eosinophils. The antibody mediating the
release of these agents was shown to be IgG^ Following antigen challenge different
time courses of release were demonstrable for histamine, SRS-A and ECF-A. Skin
SRS-A was resistant to treatment with the enzyme pronase and skin ECF-A had an
estimated molecular size of between 500 and 1000. They were therefore comparable
to similar agents released from the lung. Thus SRS-A and ECF-A join histamine as
chemical mediators in cutaneous anaphylaxis.
INTRODUCTION
It has long been recognized that the skin is a target organ for immediate-type hypersensitivity
reactions in man and experimental animals. The antigen-induced release of a histamine-like
substance from sensitized skin in vitro has been described in a number of species (Mongar &
Schild, 1952; Greaves, Fairley & Yamamoto, 1971; Yeoh, Tay & Greaves, 1972; Greaves,
Yamamoto & Fairley, 1972). However, anti-histamines only partially suppress cutaneous
anaphylaxis (Fisher & Cooke, 1957) suggesting the possible participation of other chemical
mediators.
In this report it is shown that agents other than histamine are released when passively
sensitized skin fragments are challenged with specific antigen. These include a slow reacting
substance of anaphylaxis (SRS-A) and an eosinophil chemotactic factor of anaphylaxis
(ECF-A). Both are shown to have properties comparable with agents previously described
in the lung (Brocklehurst, 1962; Kay, Stechschulte & Austen, 1971). In addition, the optimal
conditions and the antibody mediating the release of these mediators from skin are described.
Correspondence: Dr D. G. Jones, University Department of Respiratory Diseases, City Hospital, Green-
bank Drive, Edinburgh.
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MATERIALS AND METHODS
Animals
Dunkin-Hartley strain guinea-pigs, of either sex, were used throughout the study.
Reagents
Histamine acid phosphate, Blue Dextran, vitamin B12, glycogen, ovalbumin five times
crystallized and horse serum were obtained as previously described (Kay, Shin & Austen,
1973). Other materials were obtained as follows. Amberlite IRC-50, n-butanol and orthoph-
thalaldehyde (BDH Chemicals Ltd, Poole, England); casein (Merck, Darmstadt, Germany);
mepyramine maleate (May & Baker Ltd, Dagenham, England); inulin (Schwarz-Mann,
Orangeburg, New York, U.S.A.); Ring-[2-14C]histamine dihydrochloride (Radiochemical
Centre, Amersham, England), and pronase P (Serva, Heidelburg, Germany).
Preparation ofguinea-pig IgG 1 and IgG2 immunoglobulins
Antiserum to ovalbumin was prepared in guinea-pigs following an injection schedule
previously described (Kay, 1970a), and fractionated by diethylaminoethyl (DEAE)-
cellulose chromatography (Kay, 1970b). All fractions were diluted in Tyrode's solution
before use. The functional purity of the IgGl- and IgG2-containing fractions was tested by
passive cutaneous anaphylaxis and passive haemolysis (Bloch et al., 1963); Immunoelectro¬
phoresis and gel diffusion using rabbit anti-7S IgG and specific anti-guinea-pig IgGl
(Kay, 1970a); and passive haemagglutination (Bloch et al., 1963).
Preparation of skin for the in vitro release ofmediators
Guinea-pigs were killed by stunning and exsanguination. Shaved abdominal and thoracic
skin was separated from subcutaneous tissue and cut into fragments of 10-20 mm2 in area.
Portions of skin (0-5-2-0 g) washed twice in Tyrode's solution and sensitized in 3-6 ml of
antibody per gram wet weight of skin, were challenged with ovalbumin in a total volume of
3 ml. The characteristics of the antibody solution are described in the results. The diffusate
was then removed and the residual histamine extracted by suspending the fragments in an
equal volume of Tyrode's solution and placing in a boiling water-bath for 15 min.
Assay of anaphylactic mediators
Histamine was measured fluorometrically or by bioassay using the guinea-pig ileum sus¬
pended in oxygenated atropinized Tyrode's solution (0-5 pmo\e atropine/litre) in a 2-ml
capacity organ bath maintained at 37°C by a continuous flow water-jacket (Brocklehurst,
1960). Fluorimetric assay was performed by a modification (Jones, 1973) of the method of
Oates, Marsh & Sjoerdsma (1962) in which [14C]histamine was used to estimate recovery.
Allowance was made for the contribution of non-histamine fluorescence by the addition of
the fluorometric reagents in reverse order (reverse-blank).
SRS-A was assayed by the method of Brocklehurst (1960).
Chemotaxis was measured using a previously described modification of the Millipore
technique of Boyden (Kay, 1970b), with the exception that a 4-hour incubation period was
used. Guinea-pig eosinophils were obtained by peritoneal lavage from animals which had
received multiple injections of horse serum. Neutrophils were harvested from the peritoneal
cavity of animals injected with glycogen 3-6 hr previously. Eosinophil and neutrophil
\
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migration were both estimated using an 8-0 it pore size and total cell counts adjusted to
0-5-2-0 x 106/ml.
Inulin-treated guinea-pig serum possessing both eosinophil and neutrophil chemotactic
activity was used as a positive control in all the experiments described. A pool of this
material was prepared by incubating fresh guinea-pig serum with inulin (20 mg/ml serum)
for 30 min at 37°C. The inulin was then removed by centrifugation and the serum subse¬
quently heated at 56°C for 30 min. Samples were stored at — 85°C until used. ECF-A
activity was expressed as the mean cell count of five high power fields from duplicate ana¬
lyses (Kay, 1970b). Counts were performed either in the body of the filter or on the surface
to which the cells had migrated.
Activity ofpronase
Pronase activity was tested using casein as a substrate. The enzyme was dissolved in
Tyrode's solution to a concentration of 100 PUK units/ml. (1 PUK unit = the amount of
enzyme required to give an optical density of 1-0 at 660 m/r, 40°C and pH 7-4 as determined
by the casein-Folin method.)
Gel filtration
A cell-free anaphylactic skin diffusate (20 ml) was evaporated to dryness under vacuum,
at 60°C, using a rotary evaporator. The residue was reconstituted in 2 ml of distilled water,
centrifuged free of particulate matter and the supernatant applied to a column of Sephadex
G-25 (90 x 2-0 cm). Alternate 2 ml fractions were tested for eosinophil chemotaxis using 1 ml
volumes. The column was calibrated as previously described using Blue Dextran, vitamin
B, 2 and histamine as molecular markers (Kay et al., 1973).
RESULTS
Histamine
Content in normal guinea-pig skin. The mean abdominal skin histamine content from
twenty-eight normal animals weighing between 200 and 600 g was 1-85 + 0-89 (yug/g wet






Fig. 1. The inverse relationship between total extractable abdominal skin histamine and body
weight. Correlation coefficient, -0-75. Number of samples, twenty-eight. P<0-001.
216 D. G. Jones and A. B. Kay
weight + S.E.M.). An inverse relationship was found between total body weight and the skin
histamine content (Fig. 1). The amount of extractable histamine in the skin of younger
animals (300 g or less) was significantly higher (2-43 ±0-73) and therefore smaller animals
were used in further studies.
In all experiments abdominal skin was chosen since in five animals the histamine content
of the dorsal region was approximately 20% lower than that of the abdomen. In addition,
abdominal skin was more easily dissected free of subcutaneous tissue.
Chemical identification in anaphylactic dijfusates. When passively sensitized guinea-pig
skin was challenged with specific antigen, there appeared in the diffusate an agent which gave
a characteristic histamine-like contraction of the isolated guinea-pig ileum. The identity of
this material was confirmed by its fluorimetric characteristics when complexed with orthoph-
thalaldehyde following extraction using Amberlite IRC-50 and w-butanol. The fluori¬
metric spectra obtained with synthetic histamine and the skin diffusate are illustrated in
Fig. 2. The spectra for synthetic histamine, a skin diffusate and a mixture of the two were
i '«» —»,«.»« »
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Fig. 2. Fluorometric spectra of synthetic histamine and skin diffusates. (a) Synthetic histamine
(0-2 /ig/ml). (b) Graphs (a) + (c). (c) Skin diffusate (0 06 //g/ml histamine by bioassay). (d) Skin
diffusate reverse-blank (see Materials and Methods section).
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Fig. 3. The capacity of fractions of guinea-pig IgGl and IgG2 passively to sensitize skin frag¬
ments for the antigen-induced release of histamine. All antibody fractions were diluted 1 in 20
identical, all having optimal excitation and fluorescent wavelengths of 360 and 450 m/t
respectively.
Since measurement of histamine by fluorimetry or bioassay gave similar values ( + 5%)
the bioassay was used for convenience in further experiments.
Optimal conditions for antigen-induced release
Antibody mediating release. Fractions of IgGI and IgG2 obtained from guinea-pig
antiserum to ovalbumin by DEAE-cellulose chromatography were tested for their ability to
prepare guinea-pig skin fragments for the antigen-induced release of histamine (Fig. 3).
Only skin sensitized with IgGl-containing fractions (possessing high PCA and low passive
haemolysis titres) evoked an appreciable release of histamine. An IgGl-containing fraction
Antigen ciose i/j.q)
Fig. 4. The effect of antigen concentration on the release of histamine from guinea-pig skin
sensitized with IgGj (fraction 4 diluted 1 in 20).
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Sensitization time (hr)
Fig. 5. Time and temperature course of passive sensitization of skin fragments by an IgGl-
containing fraction (fraction 4 diluted 1 in 20) for the antigen-induced release of histamine.
(fraction 4) was used in further experiments at a concentration of 1 in 20, since this gave
optimal release when this fraction was tested in doubling dilutions from 1 in 5 to 1 in 160.
Antigen dose. The effect of increasing doses of specific antigen on the release of histamine
from skin fragments passively sensitized with guinea-pig anti-ovalbumin (fraction 4) is
shown in Fig. 4. Maximal liberation of histamine was observed when 0-5 g of skin was
challenged with 200 pg of ovalbumin in a total volume of 3 ml. These conditions were used
in all further studies on histamine release. An inhibitory effect was observed with the higher
doses of antigen.
Temperature and time of sensitization. Skin fragments were sensitized at varying time
intervals at either 4°C, 18°C or 37°C and challenged with antigen for 15 min at 37°C.












Fig. 6. Time course of release of histamine, SRS-A and ECF-A following antigen challenge of
guinea-pig skin fragments passively sensitized with an IgGl-containing fraction (fraction 4 dilu¬
ted 1 in 20).
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Direction of trace
Fig. 7. Kymograph tracing showing the effect of a skin diffusate on the mepyramized guinea-
pig ileum: 1 and 5 = diffusate from IgGl-sensitized skin challenged with antigen, diluted 1 in
2; 2 = As above, undiluted; 3 = Tyrode's solution alone; 4 = Undiluted diffusate from IgGl-
sensitized skin incubated without antigen.
Time course of release. Skin, sensitized at 37°C for 4 hr, was challenged with ovalbumin
for periods of up to 90 min. Maximal release of histamine occurred following a 15-minute
incubation at 37°C (Fig. 6). Unlike SRS-A and ECF-A (see below) the percentage release
and the absolute release of histamine steadily declined following continued incubation with
antigen.
Quantitative release. In fourteen experiments using the optimal conditions defined above,
the mean+ S.E.M. percentage release of histamine was 14-3 + 4-8 (range 6-24-5) or, in terms
of /tg/g wet weight skin, 0-20 ±0 06 (range 0-10-0-33). In all experiments under the defined
conditions there was no release of histamine from untreated skin, or from skin incubated
with antigen or antibody alone.
Table 1. The capacity of fractions of guinea-pig IgGl and IgG2 (Fig. 3) to passively sensitize
skin fragments for the antigen-induced release of SRS-A and ECF-A. Fractions were
diluted 1 in 20
Histamine SRS-A activity Eosinophil chemotactic activity
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Volume of skin diffusate (ml)
Fig. 8. Chemotactic dose-response following increasing concentrations of skin diffusate. Cell
counts were adjusted so that both the (•) eosinophil and (O) neutrophil suspensions contained
l-6x 106 cells per ml. The mean cell counts of eosinophils and neutrophils migrating towards
01 ml of inulin-treated guinea-pig serum were both >50.
Slow reacting substance
Passively sensitized skin challenged with specific antigen under the conditions described
above for histamine release contained an agent which produced a contraction of the guinea-
pig ileum, in the presence of mepyramine maleate, which was similar in character to con¬
tractions produced by SRS-A from the lung. SRS-A from the skin was demonstrable in a
dose-response fashion (Fig. 7). No SRS-A activity was detected in samples incubated with
antigen or antibody alone. In order to obtain skin SRS-A in appreciable amounts it was
necessary to halve the reaction volume. Thus 2 g of sensitized skin was challenged in a total
volume of 6 ml.
As with histamine the antibody mediating the release of skin SRS-A was shown to be
IgGl. In the experiment depicted (Table 1) fractions containing IgG2 were unable passively
to sensitize skin for the antigen-induced release of SRS-A (or ECF-A—see below). The
experiment was repeated twice for all of the mediators and gave similar results.
In contrast to histamine maximal release of skin SRS-A was detected at 45 min and was
virtually maintained for at least 90 min (Fig. 6).
In six experiments the mean + S.E.M. release of SRS-A, expressed in units/g wet weight
skin, was 14+10 (range 3-32).
Skin SRS-A was unaffected by treatment with the enzyme pronase. In three experiments
diffusates were incubated at 37°C for 30 min with pronase at a concentration of 10 PUK
units per unit of SRS-A. The diffusates contained 15, 12 and 20 units per ml of SRS-A.
No loss of activity was observed following treatment with the enzyme.
Eosinophil chemotactic factor
In addition to histamine and SRS-A, diffusates from passively sensitized guinea-pig skin
challenged with antigen contained a factor specifically chemotactic for guinea-pig eosinophil
leucocytes (Fig. 8). Chemotactic activity was demonstrable in a dose-response fashion, no
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chemotaxis being observed when neutrophils were used as target cells. In all experiments skin
ECF-A was prepared under the same conditions as those described for SRS-A. Only
fractions containing IgGj prepared skin for the antigen-induced release of ECF-A (Table 1).
The time course of release of ECF-A is shown in Fig. 6. Maximal release was observed
after 15 min and was maintained for the duration of the experiment.
Following passage of a concentrated skin diffusate through a column of Sephadex G-25,
chemotactic activity eluted between a vitamin B12 marker (mol. wt 1357) and histamine
(mol. wt 310). The estimated molecular size ofECF-A from the skin was therefore 500-1000.
DISCUSSION
In previous reports (Mongar & Schild, 1952; Yeoh et at., 1972) the release of a histamine-like
substance from the skin of actively sensitized guinea-pigs, challenged with specific antigen,
was described. Active sensitization in the guinea-pig induces several types of cutaneous
hypersensitivity reactions. These include delayed-type reactions and cutaneous basophil
hypersensitivity (Dvorak et at., 1970). In order to study immediate-type hypersensitivity we
have eliminated these variables by passively sensitizing skin fragments in vitro with purified
antibody. In addition, we have found that passive sensitization was not associated with the
spontaneous release of histamine previously reported when actively sensitized guinea-pigs
were used (Yeoh et at., 1972).
Extractable histamine was inversely related to total body weight (Fig. 1). This may reflect
age-dependent changes in the synthesis and storage of this amine in the skin.
In a previous report (Yeoh et at., 1972) the histamine-like substance released from guinea-
pig skin was identified by its capacity to contract the guinea-pig ileum. In order to show that
this effect was not due to other ileum-contracting agents, we chemically defined the presence
of histamine by fluorimetry (Fig. 2).
In studies using guinea-pig lung, IgGl was shown to mediate the antigen-induced release
of histamine (Baker, Bloch & Austen, 1964), SRS-A (Stechschulte, Austen & Bloch, 1967)
and ECF-A (Kay et at., 1971). Using skin from the guinea-pig we have similarly shown that
IgGl mediates the antigen-induced release of these agents from passively sensitized frag¬
ments.
High doses of antigen inhibited the release of histamine from passively sensitized skin
fragments (Fig. 4). A similar effect was reported in the guinea-pig lung system (Kay et at.,
1971). It has been suggested that inhibition by high doses of antigen may be a result of an
inability to effect the necessary conformational changes on cell-bound immunoglobulins
which lead to mediator release (Osier, 1971).
Skin SRS-A was shown to be resistant to proteolytic activity and in this respect is similar
to SRS-A from the lung (Brocklehurst, 1962). This treatment also distinguishes SRS-A
from bradykinin, an agent which also contracts the guinea-pig ileum (Rocha e Silva, Beraldo
& Rosenfeld, 1949).
Skin ECF-A also has properties in common with ECF-A from the lung (Fig. 8). These
include its estimated molecular size and its capacity to attract guinea-pig eosinophils
selectively (Kay et at., 1971). The presence of ECF-A may partly explain the histology of
cutaneous anaphylaxis in terms of infiltration of eosinophils (Kay, 1970a).
Thus histamine, SRS-A and ECF-A have been identified from guinea-pig skin passively
sensitized in vitro and challenged with antigen.
F
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Summary. The release of slow reacting substance of
anaphylaxis (SRS-A) from sensitized guinea-pig
lung challenged with antigen was followed by a fall
in the activity of this mediator in the diffusate when
the incubations were continued for 3 h. The in¬
activating principle was also present in normal lung
in addition to other normal guinea-pig tissues such
as the liver, kidney, spleen, ileum and skin. No
activity was found in muscle. Evidence is provided
that some of this SRS-A-inactivating activity was
due to tissue arylsulphatases. These were measured
by hydrolysis of p-nitrophenyl sulphate (p-NPS)
and p-nitrocatechol sulphate (p-NCS), which reflect
activities of arylsulphatase II A and II B respec¬
tively. Hydrolytic activity for p-NCS was present
in all tissues with SRS-A-inactivating properties,
whereas only lung, liver and skin tissue hydrolysed
p-NCS and p-NPS. Following passage of a cell-free
lung homogenate through a column of Sephadex
G-200 the p-NCS hydrolysing and SRS-A-inactivat-
ing activities eluted together, with molecules having
a molecular size of approximately 150,000 Daltons,
p-NPS hydrolysing activity being destroyed during
the preparation of the homogenate. The release of
arylsulphatase from sensitized tissue was not
dependent on the presence of specific antigen. These
experiments suggest that inactivation of SRS-A is
Correspondence: Dr A. B. Kay, South-East Scotland
Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh EH3 9HB.
related to tissue arylsulphatase and that these
enzymes may play a role in the expression of the
effective levels of this mediator within the tissues.
INTRODUCTION
Slow reacting substance of anaphylaxis (SRS-A) is a
low molecular weight acidic lipid which gives a
characteristic contraction of guinea-pig ileal, and
human bronchial, smooth muscle (Brocklehurst,
1960, 1962). Unlike preformed anaphylactic media¬
tors such as histamine and eosinophil chemotactic
factor (ECF-A), the formation of SRS-A requires
the interaction of specific antigen with sensitized
tissue.
SRS-A is known to contain a free sulphate group
as shown by its inactivation by arylsulphatases of
various origins including the mollusc (Orange,
Murphy and Austen, 1974), human eosinophils
(Wasserman, Goetzl and Austen, 1975), guinea-pig
and human lung (Jones and Kay, 1975; Wasserman
and Austen, 1975). During experiments on the time
courses of mediator release from sensitized tissue we
observed that there was a fall in the amount of SRS-
A when the incubations were continued up to 3 h.
It is the purpose of the present report to show that
this inactivation of SRS-A by lung and other tissues
is probably related to their content of arylsulphatase
and that the enzyme is released non-specifically from
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Dunkin-Hartley strain guinea-pigs, of either sex,
were used throughout the study.
Reagents
Materials were obtained as follows. Ovalbumin five
times crystallized (Koch-Light Laboratories, Coin-
brook), Freund's complete adjuvant (Wellcome
Reagents Ltd, Beckenham, Kent), Amberlite XAD-2
(BDH Chemicals Ltd, Poole), p-nitrocatechol
sulphate, 4-nitrocatechol, p-nitrophenyl sulphate, 4-
nitrophenol and quinol (Sigma London Chemical
Company Ltd, Kingston-upon-Thames, Surrey).
Preparation ofSRS-A
Animals were actively sensitized with ovalbumin in
Freund's complete adjuvant and an anaphylactic
diffusate prepared by challenging sliced perfused
lung, with 670 gg of antigen per gram of tissue as
previously described (Kay, Stechschulte and Austen,
1971).
SRS-A inhibition assay
Inactivation of SRS-A was performed by incubating
increasing quantities of various tissue fragments,
washed free of visible blood, with 2 ml of purified
SRS-A in Tyrode's solution at 37° for 2 h. The re¬
maining activity was compared with the same vol¬
ume of SRS-A alone incubated under the same
conditions and subsequently extracted from the
tissues in 80 per cent ethanol prior to assay. For
inactivation of SRS-A by cell-free lung homogenates,
1 ml of purified SRS-A was incubated with 1 ml of
homogenate under the same conditions. The loss in
SRS-A activity was compared with 1 ml of SRS-A
and 1 ml of homogenate incubated separately and
then mixed prior to ethanol extraction and assay.
Homogenates were prepared from wet lung frag¬
ments on ice, using an M.S.E. tissue blender.
Resulting supernatants were centrifuged at 15,000 g
for 2 h to remove particulate matter.
Assay of arylsulphatases
Arylsulphatases were measured by their capacity to
hydrolyse either p-nitrocatechol sulphate (p-NCS)
or p-nitrophenyl sulphate (p-NPS) which reflect
activity of the type II B and II A enzymes respec¬
tively (Roy, 1960; Rammler, Grado and Fowler,
1964). Volumes of 0-4 ml of diffusate or 0-4 ml of 0-5
m sodium acetate containing 400 pg tissue frag¬
ments were incubated with 0-4 ml of the appropriate
substrate at a concentration of 6-25 x 10"3 m in 0-5 m
sodium acetate, pH 5-6. Following 60 min incuba¬
tion at 37° the reaction was stopped by the addition
of 2 ml of an 'alkaline-quinol' solution (20 ml of 5
per cent Na2S03. 7H20 in 0-5 n NaOH mixed with 1
ml of 4 per cent quinol in 01 n HC1 immediately
before use). The amount of4-nitrocatechol (4-NC) or
4-nitrophenoI (4-NP) liberated was measured at 515
nm or 410 nm respectively on a Gilford 300-N
microsampling spectrophotometer. A standard
curve of increasing concentrations of 4-NC or 4-NP,
in a mixture of 0-8 ml of 0-5 m sodium acetate and 2
ml of 'alkaline-quinol' solution, was used as a
reference. One unit of arylsulphatase activity is
defined as the amount which liberates 1 pmole of
4-NC or 4-NP per hour from the appropriate sub¬
strate under the conditions described above.
Gel filtration chromatography
A volume of 2 ml of lung homogenate was applied to
a column of Sephadex G-200 (95 x 3-5 cm) equilib¬
rated in 0-5 m sodium acetate buffer, pH 5.6. Frac¬
tions of 2 ml were collected and tested for aryl¬
sulphatase and SRS-A-inhibiting activity. The
column was calibrated by using guinea-pig serum
as a source of molecular markers. The serum gave
three distinct peaks which corresponded to V0 and
the elution volumes of IgG (molecular weight
150,000) and albumin (molecular weight 60,000).
RESULTS
SRS-A levels following antigen challenge
When actively sensitized lung fragments were in¬
cubated with specific antigen at time intervals up to
3 h, maximal SRS-A activity was found in the
diffusates sampled between 30 and 60 min (Figs 1
and 4). When the incubation was continued up to 3
h the activity was depleted by 40 per cent. If the
diffusate was removed at 30 min, centrifuged to
remove particulate matter, and the incubation con¬
tinued at 37° for up to 3 h there was only a 20 per
Inactivation ofSRS-A 85
Time (h)
Figure 1. The release and inactivation of SRS-A following
antigen challenge of sensitized lung.
cent loss in the amount of remaining SRS-A, sug¬
gesting that the majority of the SRS-A-inactivating
principle was associated with the lung fragments.
Both these experiments were performed three times
and gave essentially similar results.
The capacity of normal lung fragments to inacti¬
vate SRS-A in a dose-dependent fashion was deter¬
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Figure 2. Inactivation of SRS-A by increasing quantities of
normal lung fragments. The points represent the mean of
four experiments+ two standard errors.
the remaining SRS-A was extracted in 80 per cent
ethanol to exclude the non-specific adherence of
SRS-A to the increasing quantities of tissue.
Since arylsulphatases are known to inactivate
SRS-A, several tissues were tested for the presence
of arylsulphatases and SRS-A-inactivating proper¬
ties (Table 1). The lung, liver, kidney, spleen, ileum
Table 1. The arylsulphatase and SRS-A-in¬






Lung 55 0-61 0-70
Liver 58 0-34 0-43
Kidney 20 0-84 010
Spleen 37 0-81 000
Ileum 25 0-44 0-09
Skin 10 0-52 0-21
Muscle 4 004 003
These values represent the average results
from three experiments.
and skin had both SRS-A-inactivating activity and
sulphatase as assessed by hydrolysis ofp-NCS which
represents the activity of arylsulphatase type II B.
In contrast p-NPS which is used as a substrate for
type II A sulphatase was hydrolysed by lung, liver
and skin tissue only. Muscle contained little or no
SRS-A-inactivating or sulphatase activities. There
was no clear correlation between the amounts of
sulphatases in tissues and their SRS-A-inactivating
activities.
A cell-free homogenate of normal lung with SRS-
A-inactivating and sulphatase activity was applied
to a column of Sephadex G-200 (Fig. 3). During the
preparation of this cell-free lung homogenate the
p-NPS hydrolysing capacity was destroyed but
arylsulphatase as assessed by p-NCS hydrolysis was
unaffected. The latter eluted from the column in the
same position as the SRS-A-inactivating principle
and had a molecular size of approximately 150,000
Daltons. This was repeated twice with essentially the
same results.
Experiments were undertaken to determine
whether arylsulphatase was released following
antigen challenge of sensitized lung. Fig. 4 shows
that the release of this enzyme was not affected by
F






Figure 3. Sephadex G-200 chromatography of a cell-free lung homogenate showing the elution profiles of arylsulphate II B
and SRS-A-inactivating activities.
Figure 4. The diffusion of arylsulphatase from actively sensi¬
tized lung challenged with antigen (•), actively sensitized
lungs alone (O) and normal lung (■). The amount of SRS-A
appearing in the diffusate of the sensitized, challenged lung is
also shown (A).
the presence of specific antigen and that normal lung
also releases arylsulphatase following incubation in
Tyrode's balanced salt solution.
DISCUSSION
It is clear that a number of factors influence the
release of SRS-A into the diffusate when sensitized
tissue fragments are challenged with specific antigen.
SRS-A is an acidic lipid which combines non-
specifically with tissue and plasma proteins from
which it can be recovered by extraction in 80 per
cent ethanol (Brocklehurst, 1962). Furthermore it
has been shown that a proportion of SRS-A formed
during a type I (anaphylactic) reaction remains
within the cell from which it can be extracted by
organic solvents (Lewis, Wasserman, Goetzl and
Austen, 1974). There would now appear to be a
further influence on the amount of SRS-A activity
in the diffusate due to the presence of tissue derived
arylsulphatase. Thus our observation that the
amount of SRS-A appearing in the diffusate dimin¬
ished when the incubation time was prolonged to 3
hours, probably reflects the subsequent action of
sulphatases which have diffused from the tissue
(Figs 1 and 4). A recent report by Wasserman and
Austen (1975) has shown that arylsulphatases II A
and II B with estimated molecular sizes of 100,000
and 65,000 respectively can be extracted from human
lung tissue. In the present report we show that these
sulphatases are also present in guinea-pig lung (Table
1) but arylsulphatase II B had an estimated molecu¬
lar size of 150,000 Daltons (Fig. 3). In the present
study the apparent lability of arylsulphatase II A
prevented determination of its molecular size by gel
filtration.
Lung tissue contained both sulphatase II A and II
B activity and could inactivate SRS-A in a dose-
dependent fashion (Fig. 2, Table 1). Liver and skin
also contained both these activities but kidney,
spleen and ileum had only sulphatase II B activity.
Under the experimental conditions herein muscle
had no sulphatase activity and did not affect SRS-A.
In general tissues containing arylsulphatases had
the capacity to inactivate SRS-A but there was no
clear correlation between enzymatic content and the
ability to destroy SRS-A.
The enzyme cannot be regarded as a mediator of
anaphylaxis since the rate of diffusion from sensi¬
tized tissue was not affected by the presence of
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specific antigen (Fig. 4). Therefore although sulpha-
tases may have a regulatory role in the expression of
the pharmacological effects of SRS-A the release of
the enzyme(s) are presumably independent of the
biochemical pathways which lead to the elaboration
of pharmacological mediators of anaphylaxis.
Previous studies have shown that the infiltration
of the eosinophil into sensitized tissue is maximal
8-12 h following challenge with specific antigen
(Kay, 1970). Since arylsulphatases are widely dis¬
tributed throughout the tissues it is unlikely that the
high content of this enzyme in the eosinophil points
to a unique function of this cell (Wasserman et al.,
1975).
Whether tissue or circulating levels of arylsulpha-
tase have importance in clinical conditions mediated
by SRS-A, such as extrinsic (allergic) asthma, is yet
to be determined.
It should be emphasized that in these experiments
on tissue inactivation by SRS-A, the mediator was
extracted in 80 per cent ethanol prior to assay and
therefore it is unlikely that the observed loss of
activity was due to non-specific binding by this
acidic lipid to the tissues.
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Summary. Homogenates from human lung contained
a preformed slow reacting substance (pSRS). The
pattern of contraction on the guinea-pig ileum by
pSRS was indistinguishable from that of SRS-A.
The activity of pSRS could not be attributed to the
presence of K+, Na+, Ca2 + and Mg2 + ions, or any
prostaglandin including PGF2a or its 15-oxo deri¬
vative. As with SRS-A, pSRS could be adsorbed onto
Amberlite XAD-2 and silicic acid. Both were eluted
from the former with 80 per cent ethanol and from
the latter with a mixture of ethanol, ammonia and
water. Both pSRS and SRS-A were resistant to the
action of NaOH whereas their activities were de¬
stroyed by boiling in HC1. Arylsulphatase II B des¬
troyed the activities of both pSRS and SRS-A. An
antagonist of SRS-A, FPL 55712, inhibited the action
of pSRS at comparable concentrations to that of
SRS-A. These experiments suggest that pSRS and
SRS-A are identical. Thus SRS joins histamine and
ECF-A as a preformed mediator. Although SRS
was present in a preformed state the amount of
material extractable was more than doubled by the
anaphylactic reaction. The extraction of slow react¬
ing substance from human lung without apparent
requirement for antigen or antibody points to a
possible role of this mediator in inflammatory
reactions evoked by mechanisms independent of
IgE and other tissue-sensitizing antibodies.
Correspondence: Dr A. B. Kay, South-East Scotland
Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh EH3 9HB.
INTRODUCTION
The term 'slow reacting substance' was first used to
describe material released from guinea-pig or cat
lung perfused by cobra venom (Feldberg & Kell-
away, 1938). Subsequently an agent with similar
pharmacological properties was identified in vitro
from perfusates of sensitized guinea-pig lung chal¬
lenged with specific antigen (Brocklehurst, 1960).
This was designated 'slow reacting substance of
anaphylaxis' (SRS-A) to distinguish it from other
slow reacting substances released by non-immuno-
logical mechanisms.
A number of workers have since reported that
SRS-A, unlike histamine and eosinophil chemotactic
factor (ECF-A) which are recognized as preformed
mediators of anaphylaxis, is present in tissue only
in a precursor state from which the active form must
be generated either immunologically (Brocklehurst,
1962; Austen & Orange, 1975) or by a calcium
ionophore (Bach & Brashler, 1974).
Although SRS-A must await full chemical char¬
acterization, it can now be obtained in a highly
purified form by a combination of non-ionic chro¬
matography and differential solubility in a variety of
organic solvents (Orange, Murphy, Karnovsky &
Austen, 1973). Therefore SRS-A can be distin¬
guished from other slow reacting substances which
evoke a similar pattern of contraction of the
guinea-pig ileum.
We have found that fresh human lung obtained
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at surgery contains a preformed SRS (pSRS)
which can be extracted non-immunologically.
Since SRS-A is considered to be a primary mediator
in allergic (extrinsic) bronchial asthma (Brockle-
hurst, 1956), due largely to its capacity to produce
sustained contraction of bronchial smooth muscle,
it seemed important to determine the relationship
of pSRS to SRS released by anaphylaxis. In the
present report we show that pSRS and SRS-A are
identical, so raising the possibility that SRS may
participate in those forms of bronchial asthma in
which there is no evidence for the participation of
IgE and other tissue-sensitizing antibodies.
MATERIALS AND METHODS
Materials were obtained as follows: Amberlite
XAD-2 (BDH Chemicals Ltd, Poole), silicic acid
(SIL-R, Sigma Chemical Company, St. Louis),
arylsulphatase II B and N,N-bistrimethylsilyl-
trifluoroacetamide BSTFA, Sigma T.6381- (Sigma
Chemical Company, St. Louis), FPL 55712-sodium
7-((3-(4- acetyl - 3 -hydroxy - 2 -propylphenoxy) - 2 -
hydroxypropoxyl))-4-oxo-8-propyl-4H-chromene-2-
carboxylate—(a gift from Fisons Research Labora¬
tories, Loughborough), prostaglandins (PG) F2„
15-oxo F2« (a gift from Professor E. Horton,
Department of Pharmacology, University of Edin¬
burgh), Timothy grass pollen (a gift from Beecham
Research Laboratories, Betchworth).
Preparation ofSRS-A andpSRS
Macroscopically normal human lung obtained at
surgery, usually in association with bronchiogenic
carcinoma, was dissected free of pleura, bronchi and
large blood vessels, sliced into fragments of approx¬
imately 50 mg and washed thoroughly in Tyrode's
buffer. For SRS-A, each gram wet weight of sliced
lung fragment was incubated with 5-4 ml of a 1 in
8 dilution of serum (R.B.) from an individual sen¬
sitive to Timothy grass pollen. Following an 18 h
incubation period at room temperature the fragments
were washed twice in Tyrode's solution and chal¬
lenged in 9 ml of the same buffer, containing 0-2
,ug/ml of Timothy grass pollen antigen. Following
incubation for 15 min at 37° the diffusate was
removed and stored at —85° until use.
pSRS was prepared from thoroughly washed,
unsensitized, unchallenged lung by gentle homo-
genization on ice using an MSE tissue blender,
freezing and thawing twice and heating at 56° for
1 h in a water bath. The preparation was centrifuged
at 15,000 g for 30 min to remove particulate matter
and stored at —85° until use.
For experiments on the generation of SRS, 350 mg
of lung fragments were sensitized with 1-8 ml of
varying dilutions of serum (R.B.) and challenged
with 3 ml of the antigen/Tyrode's solution as
described above. After the removal of the diffusate,
residual SRS was extracted by resuspending the
fragments in a further 3 ml of Tyrode's solution
and boiling for 15 min in a water bath.
Measurement of SRS
SRS was measured by the method of Brocklehurst
(1960) using the isolated guinea-pig ileum in the
presence of atropine and mepyramine maleate as
previously described. One unit of SRS-A or pSRS
was defined as the concentration required to give a
contraction of the ileum of equal amplitude to 5
ng of histamine in that assay.
Progressive purification of SRS-A andpSRS
SRS-A and pSRS were purified in parallel by extrac¬
tion in 80 per cent ethanol, hydrolysis in 01 n NaOH
for 60 min at 37° and chromatography on Amberlite
XAD-2 (Orange et al., 1973). These partially purified
preparations were used in subsequent inactivation
and inhibition studies. Where necessary further
purification was achieved following the application
of the samples to activated silicic acid and sequential
elution with hexane, dichloromethane, acetone, n-
propanol and a mixture of ethanol, concentrated
ammonia and water (6:3:1 v/v) as described (Orange
et al., 1973). Eluates were evaporated to dryness
and resuspended in Tyrode's buffer for bioassay or
distilled H20 for prostaglandin analysis.
Inactivation by arylsulphatase
Arylsulphatase II B was partially purified by chro¬
matography on Sephadex G-200 in 0-5 m acetate
buffer, pH 5-5, as described (Kay, Roberts & Jones,
1976). One-millilitre volumes of partially purified
SRS-A and pSRS of equivalent ileal contracting
activity (approximately 55 u/ml) were adjusted to
pH 5-5 with 01 n HC1 and incubated for 1 h with 1
ml of increasing concentrations of arylsulphatase.
Following incubation the samples were readjusted
to pH 7-4-7-7 with 0-1 n NaOH and assayed
immediately for SRS activity.
SRS from human lung 815
Inhibition by FPL 55712
Dilutions of FPL 55712, freshly prepared in Tyrode's
solution, were applied to the perfused guinea-pig
ileum for 2 min. The organ bath was then refilled
with partially purified SRS-A, or pSRS, containing
the same concentration of drug and contractile
activity measured (Brocklehurst, 1960). Before the
addition of subsequent samples the ileum was
returned to its original sensitivity by repeated
washing with mepyramised Tyrode's.
Detection ofprostaglandins
Prostaglandins were measured using an LKB 9000
Gas Chromatograph Mass Spectrometer as described
(Green, 1969) with PGF2c, and 15-oxo F2tt as internal
standards. All samples contained in 1 to 2 ml
volumes were initially brought to pH 3, using n
HC1 and then extracted three times with 20 ml of
ether. A three-step derivativation procedure was
then carried out.
Methyl ester formation. 0-3-0-4 ml of diazo-
methane (nine parts diethyl ether, one partmethanol)
were incubated with the test samples for 5 min at
room temperature and then removed using a nitro¬
gen jet and vacuum desiccation.
O-alkyloxime formation. O-alkylhydroxylamine
hydrochloride (1 mg in 0-2 ml) in dry pyridine was
added to the desiccates. The samples were then
heated at 60° for 90 min. The pyridine was then
removed with a nitrogen jet and the samples vacuum
desiccated.
Trimethylsilyl ether formation. Finally, 25 p\ of
BSTFA were added to the samples, which were then
either heated for 15 min at 60° or left overnight at
room temperature. The BSTFA was then removed
with a nitrogen jet and the residues redissolved in
n-heptane, before analysis.
Measurement ofNa+, K+, Ca2+ and Mg2+ levels
Na+ and K+ levels were determined using a standard
flame photometry technique, using lithium as the
internal standard.
Ca2+ levels were measured by a modified Kessler
and Wolfman technique (1964) using cresophthalein
and 8-hydroxyquinoline. Blue colouration was
measured using a spectrophotometer, the readings
being made at 580 nm.
Mg2+ levels were determined by atomic ab¬
sorption.
RESULTS
Comparison of SRS-A and pSRS
Contraction of the guinea-pig ileum
The pattern of contraction of the guinea-pig ileum
of SRS-A and pSRS is shown in Fig. 1. Both
agents gave identical types of contraction which were
demonstrable in a dose-dependent fashion. These
effects could not be attributed to the presence of
potassium since the concentration of this ion in both
the SRS-A and pSRS preparations was invariably
less than that present in Tyrode's solution (3-0
mmol/litre). Furthermore the pattern of contraction
observed with high concentrations of K+ (20 mmol/
© ® © © .©© (D © ©
Figure 1. Contraction of the guinea-pig ileum for SRS-A,
pSRS and K+. (1, 2 and 3) SRS-A diluted 1 in 35, 20 and 10,
respectively. (4) Tyrode's buffer (5, 6 and 7) pSRS diluted 1
in 20, 10 and 5, respectively. (8 and 9) K+ at 3 0 and 20-0
mmol/1 in. Tyrode's, respectively. Direction of trace from
right to left.
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Table I. Progressive purification of SRS-A and pSRS
SRS-A pSRS
Procedure Percentage Percentage
Units/g recovery Units/g recovery
Starting material 380 240 —
Ethanol extraction 106 28 75 31-5
0-1 n NaOH (37° x 30 min) 76 20 56 23
Amberlite XAD-2 chromatography 67 18 48 20
Silicic acid chromatography—
Hexane 6-0 1-5 5-5 2-3
Dichloromethane 4-5 1-2 40 1-7
Acetone 4-5 1-2 3-5 1-5
n-Propanol 3-0 0-8 3-0 1-3
Ethanol/conc. NH3/H20 6:3:1 v/v 20-5 5-4 18-0 7-5
litre) was clearly different from that produced by
pSRS or SRS-A. The levels of other ions including
Na+, Ca2 + and Mg2 + were also lower in the test
preparations than in Tyrode's solution.
Progressive purification
SRS-A and pSRS were progressively purified as
shown in Table 1. Comparable amounts were
recovered following extraction in 80 per cent ethanol,
alkaline hydrolysis and adsorption and elution from
Amberlite XAD-2. Following further purification
by adsorption onto activated silicic acid, appreciable
amounts of SRS-A or pSRS were recovered in the
ethanol:ammonia:water eluate but considerably
less was present in the hexane, dichloromethane,
acetone and n-propanol fractions.
Effect of acid hydrolysis
Preparations of SRS-A and pSRS which had been
extracted in 80 per cent ethanol, hydrolysed with 01
n NaOH and subjected to adsorption and elution on
Amberlite XAD-2 as in Table 1, were rapidly
inactivated by boiling in 0 05 n HC1. Thus 75 and
60 per cent of activity, respectively, was lost within
5 min.
Effect of arylsulphatase
The effect of increasing concentrations of aryl¬
sulphatase II B on the ileal-contracting properties
of SRS-A and pSRS is shown in Fig. 2. The in-
activation profiles for both preparations were
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Figure 2. Inactivation of SRS-A (•) and pSRS (O) by in¬
creasing concentrations of arylsulphatase.
arylsulphatase is shown in Fig. 3. A similar pattern
of inactivation of both preparations was observed,
both SRS-A and pSRS being totally destroyed after
30 min.
Effect ofFPL 55712
When SRS-A and pSRS were applied to the ileum
in the presence of increasing concentrations of FPL
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Figure 3. Time course of inactivation of SRS-A (•) and
pSRS (o) by arylsulphatase. One-millilitre volumes of SRS
were incubated with 1 ml of arylsulphatase containing 1-2
units/ml.
55712 following a 2 min preincubation with the same
agent, there was a similar dose-dependent inhibition
of both activities, with an IC50 of approximately
lO"7 g/1 (1-9 xlO"7 M).
pSRS, SRS-A and prostaglandins
SRS-A and pSRS activities were not due to the
presence of the prostaglandins PGF2« and 15-oxo
F2« as shown in Table 2. One sample of pSRS before
extraction by solvents on silicic acid contained 100
ng/ml of PGF2„. However in a separate experiment
eluates obtained by the sequential elution from
silicic acid by various organic solvents possessing
SRS activity contained no detectable prostaglandin
as assessed by mass spectrometry, the smallest
amounts detectable being 50 ng of PGF2« and 15-oxo
F2« and 100 ng/ml of PGE and E2 per millilitre of
sample. The amounts of pure PGF2lt and 15-oxo
F2« required to give contraction of the ileum of equal
amplitude to that of SRS was far greater than the
actual amounts present.
Generation ofSRS
Although SRS was present in a preformed state, the
total amount of SRS recoverable from lung follow¬
ing in vitro sensitization and antigen challenge was
more than double that extractable from an untreated
sample of the same lung (Fig. 5). The amount of
antigen-induced SRS release decreased with in¬
creasing dilutions of tissue-sensitizing antibody.
However the amount of the residual SRS, in both
test and control samples, was relatively constant.
DISCUSSION
We have been able to show that material extracted
from human lung non-specifically by homogeniza-
Table 2. The prostaglandin content of pSRS and SRS-A
Amount of prostaglandin





Number SRS (u/ml) pgf2, 15-oxo F2j PGF2a 15-oxo F2„
1 SRS-A (28) 560 700 <50 <50
2 pSRS (15) 300 375 100 <50
3 pSRS (15) 300 375 <50 <50
4 pSRS (10) 200 250 <50 <50
5 pSRS (8) 160 200 <50 <50
6 pSRS (6) 120 150 <50 <50
7 pSRS (19) 380 475 <50 <50
All samples were extracted in 80 per cent ethanol, hydrolysed with 01 n NaOH and
adsorbed and eluted from Amberlite XAD-2. In addition samples 3-7 were adsorbed
onto activated silicic acid. Sample 3 was eluted with hexane, 4 with dichloromethane,
5 with acetone, 6 with n-propanol and 7 with a mixture of ethanol, concentrated
ammonia and water (v/v 6:3:1).
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tion and freezing and thawing (pSRS),had biological
and chemical properties identical to SRS-A. It has
been suggested that potassium ions may account
for the gut-contracting property ofmaterial extracted
from 'unshocked' tissue (Brocklehurst, 1962).
However, in the present investigations potassium
ion concentration in pSRS was less than that of the
Tyrode's buffer and the effect on the ileum of high
concentrations of potassium was an irregular
pattern of brisk, spontaneous-like contractions,
which did not dose-respond and usually led to
irreversible damage of the gut (Fig. 1). Similarly
the levels of Na+, Ca2+ and Mg2+ in pSRS were
always less than those present in Tyrode's solution.
When SRS-A and pSRS were purified progres¬
sively by a combination of non-ionic chromatography
and differential solubility in a variety of organic
solvents the recovery at each step was comparable
for the two preparations (Table 1). Thus both agents
could be extracted in 80 per cent ethanol, survived
alkaline hydrolysis and adsorbed onto Amberlite
XAD-2 from which they could be eluted with 80 per
cent ethanol. At the stage both preparations adsorbed
onto activated silicic acid from which they could not
be eluted in appreciable amounts by hexane, di-
chloromethane, acetone or n-propanol but could be
recovered in larger quantities by an ethanol: am¬
monia: water mixture.
A number of agents which are known to destroy
the activity of SRS-A, or inhibit its action on target
tissue, had a comparable effect on pSRS. Thus
SRS-A and pSRS were destroyed by acid hydrolysis
and the enzyme arylsulphatase (Figs 2 and 3). It is
known that SRS-A contains a free sulphate group
which is essential for its biological activity (Orange
et al., 1974) and which can be cleaved by aryl-
sulphatases derived from a variety of sources such
as normal lung, skin, liver and spleen (Kay et al.,
1976) and preparations of purified eosinophils
(Wasserman, Goetzl & Austen, 1975).
An antagonist of SRS-A, FPL 55712 (Augstein,
Farmer, Lee, Sheard & Tattersall, 1973), which
also inhibits the migration of guinea-pig eosinophils
towards ECF-A (Jones & Kay, 1974), was found to
inhibit pSRS activity at comparable concentrations
to those affecting SRS-A (Fig. 4).
Prostaglandins PGF2a and 15-oxo F2a are known
to contract the guinea-pig ileum and to be present in
human lung in a preformed state (Horton & Main,
1963). There was the possibility that activity of pSRS













Concentration of FPL 55712 (gH)
Figure 4. Inhibition of SRS-A (•) and pSRS(o) by increasing
concentrations of FPL 55712.
15-oxo F2. which were retained throughout the
extraction and purification steps. Although des¬
truction of pSRS activity by arylsulphatase and its
inhibition by FPL 55712 made it unlikely that
prostaglandins were accounting for the observed
effects, it was necessary to measure the amounts
present. This was achieved by applying samples of
preparations of pSRS and SRS-A to the mass
spectrometer after the appropriate extraction pro¬
cedures (Green, 1969). There was no detectable
prostaglandin material in any of the preparations
which had passed through the 'silicic acid step' and
had been extracted by various solvents (Table 2).
Although one 'pre-silicic acid' sample contained
100 ng/ml of PGF2», none of the preparations
contained sufficient prostaglandin material to
account for their ileal-contracting activity.
These experiments indicate that pSRS and SRS-A
were identical. However, it was necessary to deter¬
mine if all the SRS was present in a preformed state
or whether some was generated by the anaphylactic
mechanism. It was shown that more than twice the
amount of SRS could be generated from lungs
sensitized by IgE and challenged with specific
antigen than could be extracted from fragments
from the same lung by non-immunological means
(Fig. 5). Thus a large amount of SRS-A was formed
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Figure 5. The antigen-induced, and residual SRS, released from human lung fragments sensitized with dilutions of
serum from a Timothy grass pollen-sensitive individual and challenged with specific antigen. The results are the pooled
values from four experiments. For each experiment each point was performed in triplicate. The bars represent one





Figure 6. A diagramatic representation of the possible origins of SRS. In (a) two cell types, A and B, are proposed
and in (b) one cell type having both SRS and SRS is postulated.
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as a direct result of the anaphylactic reaction.
Two suggestions as to the origin of SRS are depicted
diagrammatically in Fig. 6. Since pSRS and SRS-A
are apparently identical it is proposed that, in its
precursor form, the agent should be referred to as
SRS and that SRS be used to describe the active
state. One possibility is that there are two distinct
intracellular pools of SRS contained in two different
cell types, one in the form of SRS and the other SRS
which is converted to SRS following anaphylaxis.
Alternatively the same cell may contain both SRS
and SRS, the anaphylactic reaction stimulating the
conversion of SRS to more SRS. The concept of two
pools is based on the finding that the amount of
extractable (or residual) SRS remained fairly con¬
stant whereas the amounts of SRS released immuno¬
logically decreased with dilutions ofantibody (Fig. 5).
The possibility exists that activation of SRS to
SRS occurred in the non-anaphylactic lung during
the initial preparatory stages by an artificial com¬
bination of, as yet undetermined, enzyme and
substrate. Flowever this is unlikely since the extrac¬
tion procedures were performed at 0° or 100°.
Finally, these observations may have considerable
implications in the mechanisms of bronchial smooth
muscle contraction in situations where IgE-mediated
release of SRS is probably not operative, for example,
chronic or intrinsic bronchial asthma. Since SRS
can now no longer be regarded as exclusive to the
anaphylactic reaction the possibility remains that it
is released from lung stores by acute or chronic
non-specific inflammatory reactions.
ACKNOWLEDGMENTS
The authors are indebted to Dr N. H. Wilson for the
prostaglandin assays, Professor E. W. Horton, Dr
W. E. Brocklehurst and Dr J. D. Cash for helpful
discussions and Mr R. J. M. McCormack and Mr
P. R. Walbaum for supplying lung specimens.
This work was supported by the Medical Research
Council and a grant from Beecham Pharmaceuticals.
REFERENCES
Augstein J. Farmer J.B., Lee T.B., Sheard P. & Tat-
tershall M.L. (1973) Selective inhibitor of slow
reacting substance of anaphylaxis. Nature: New Biol.
245, 215.
Austen K.F. & Orange R.P. (1975) Bronchial asthma: the
possible role of the chemical mediators of immediate
hypersensitivity in the pathogenesis of subacute chronic
disease. Amer. Rev. resp. Dis. 112, 423.
Bach M.K. & Brashler J.R. (1974) In vivo and in vitro
production of a slow reacting substance in the rat upon
treatment with calcium ionophores. J. Immunol. 113,
2040.
Brocklehurst W.E. (1956) A slow reacting substance in
anaphylaxis—'SRS-A'. Ciba Symposium on Histamine,
p. 175. Churchill, London.
Brocklehurst W.E. (1960) The release of histamine and
formation of a slow-reacting substance (SRS-A) during
anaphylactic shock. J. Physiol. (Lond.), 151, 416.
Brocklehurst W.E. (1962) Slow reacting substance and
related compounds. Progr. Allerg. 6, 539.
Feldberg W. & Kellaway C.H. (1938) Liberation of hista¬
mine and formation of lysolecithin-like substance by
cobra venom. J. Physiol. (Lond.), 94, 187.
Green K. (1969) Gas chromatography—mass spectrometry
of O-methyloxime derivatives of prostaglandins. Chem.
Phys. Lipids, 3, 254.
FIorton E.W. & Main I.H.M. (1963) A comparison of the
biological activities of four prostaglandins. Brit. J.
Pharmacol. 21, 182.
Jones D.G. & Kay A.B. (1974) Inhibition of eosinophil
chemotaxis by the antagonist of slow reacting substance
of anaphylaxis—compound FPL 55712. J. Pharm.
Pharmac. 26, 917.
Kay A.B., Roberts E.M. & Jones D.G. (1976) Tissue
inactivation of slow reacting substance of anaphylaxis.
Immunology, 30, 83.
Kessler G. & Wolfman M. (1964) An automated procedure
for the simultaneous determination of calcium and
phosphorus. Clin. Chem. 10, 686.
Orange R.P., Murphy R.C. & Austen K.F. (1974) In¬
activation of slow reacting substance of anaphylaxis
(SRS-A) by arylsulfatases. J. Immunol. 113, 316.
Orange R.P., Murphy C.R., Karnovsky M.L. & Austen
K.F. (1973) The physicochemical characteristics and
purification of slow reacting substance of anaphylaxis.
J. Immunol. 110, 760.
Wasserman S.I., Goetzl, E.J. & Austen K.F. (1975)
Inactivation of slow reacting substance of anaphylaxis by
human eosinophil arylsulfatase. J. Immunol. 114, 645.
Clin. exp. Immunol. (1975) 19, 143-147.
ACTIVATION OF THE CLASSICAL AND ALTERNATE
PATHWAYS OF COMPLEMENT BY
COR YNEBACTERIUM PARVUM
W. H. McBRIDE, D. M. WEIR, A. B. KAY,* D. PEARCEj and
J. R. CALDWELLf
Immunology Laboratory, Department of Bacteriology, Medical School,
University of Edinburgh, * South-East Scotland Regional Blood Transfusion Centre,
Royal Infirmary of Edinburgh and University Department of Respiratory Diseases,
City Hospital, Edinburgh, and f Division of Allergy and Rheumatology,
Division of Infectious Diseases and Immunology, The J. Hillis Miller Health Centre,
University of Florida, Gainesville, Florida 32610, U.S.A.
{Received 1 June 1974)
SUMMARY
The immunological adjuvant Corynebacterium parvum has been shown to activate
the alternate pathway of complement in human and guinea-pig serum. Human
serum in addition contains anti-C. parvum antibodies leading to activation of the
classical complement pathway.
The possible role of a C. parvum derived polysaccharide in this activation is con¬
sidered in relation to the biological effects of the micro-organism.
INTRODUCTION
A number of biological effects are associated with the administration of a killed vaccine of
Corynebacterium parvum to experimental animals. These include adjuvant effect for both
T cell- and B cell-dependent antigens (Howard, Scott & Christie, 1973) and the ability to
induce 'anti-self' red cell activity in CBA mice (McCracken, McBride & Weir, 1971). There
is also widespread proliferation of lymphoid cells, including macrophages, in response to
C. parvum injection which results in marked hypertrophy of lymphoid tissues (Halpern et al.,
1964). Of particular interest is the ability of C. parvum to inhibit tumour growth in mice
(Woodruff & Boak, 1966; Halpern et al., 1966), and the effectiveness of this agent to
influence dissemination of tumour in man is currently under investigation (New Scientist,
1973).
The mechanisms underlying these effects are still obscure as are the particular constituents
of the micro-organism responsible. Our recent observation that a polysaccharide moiety
extractable from a strain of C. parvum binds to tissue cells (McBride, Jones & Weir, 1974)
suggests the need to consider the possible involvement of this material in the biological
Correspondence: Dr W H. McBride, Immunology Laboratory, Department of Bacteriology, Medical
School, The University, Edinburgh.
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effects of the organism. Various polysaccharides such as inulin, zymosan and endotoxin
are known to activate complement. In addition various polysaccharides have anti-tumour
effects which are possibly a result of activation of complement components (Okuda et al.,
1972). In the present study we report a further biological activity of C. parvum, that is its
capacity to activate directly the complement system in both human and guinea-pig serum.
MATERIALS AND METHODS
Assay of complement components
Individual components were assayed by the effective molecular titration method described
by Rapp & Borsos (1970).
C3 proactivator was identified in immunoelectrophoresis using anti-C3 proactivator
antibody (Hoechst Pharmaceuticals) (Gotze & Muller-Eberhard, 1971).
Agglutination tests
Direct agglutination tests were performed in the presence of Difco latex 0-8 pm, 100 p\ of
latex suspension in 1 ml of suspension of C. parvum 3x 1011 organisms/ml. The stock
suspension is finally diluted 1/20 before use in the agglutination test (Woodruff, McBride &
Dunbar, 1974).
C. parvum strain 10390 was obtained from the National Collection of type cultures
(Colindale, England) and cultured as described previously (McBride et al., 1974).
RESULTS
When increasing concentrations of a washed suspension of killed C. parvum 10390 were
incubated with guinea-pig or human serum for 1 hr at 37°C and centrifuged, there was a
dose-dependent decrease in the total haemolytic complement (CH50) of the supernatant
(Fig. 1). The levels of the individual complement (C) components CI, C4, C2 and C3 were
then measured in pooled sera before and after treatment with a dose of 5 x109 organisms per
ml. Following treatment of human serum the level of C3 was greatly depleted as were the
components of the 'classical pathway' CI, C4 and C2. In contrast, whereas guinea-pig C3
was also depleted after treatment there was apparent sparing ofCI, C4 and C2 in this serum
indicating activation via the 'alternate pathway' of complement (Table 1).
Evidence that human, but not guinea-pig serum, contained 'natural antibodies' to
C. parvum was provided by direct agglutination tests. Agglutination of C. parvum was
observed at a 1 in 32 dilution of the human serum pool whereas no agglutination was
observed with the guinea-pig pool. Further evidence that antibodies to C. parvum were
present in human serum and could account for 'classical pathway' activation was obtained
by testing sera that had been repeatedly absorbed with the organisms in the presence of
0-04 M EDTA. The absorbed serum was dialysed against dextrose-gelatin veronal buffer
containing Ca+ + and Mg+ + and divided into two. One half was treated with C. parvum at a
concentration of 5 x 109 organisms per ml, while the other was left untreated. The C4 titres
of the treated and the untreated control sera were similar, being 7750 and 6940 respectively.
In contrast, the titres of the terminal components (C3-9) (Borsos & Rapp, 1967) were 41 and
194 respectively indicating activation of the 'alternate pathway' of complement. These
experiments therefore suggest 'that C. parvum has the capacity, in human serum, ofactivating
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Fig. 1. Depletion of the CH50 of human (a) and guinea-pig (•) serum by C. parvum. The CH50
was measured by the method of Mayer (1961). Each estimation was performed on a pool
prepared from equal volumes of fifty human and twenty guinea-pig sera.
both pathways of complement'. These observations were further substantiated by incubating
the human serum with the organisms in the presence of Mg++ EDTA, which permits
'alternate' (but not the Ca+"""-dependent 'classical') pathway activation. The C3-9 titre of
the serum that had been treated with C. parvum in the presence of Mg++ EDTA was <5
compared with the untreated control titre of 115, again indicating terminal component
activation. Following immunoelectrophoresis using an antibody against the C3 proactivator
(Hoechst Pharmaceuticals) the electrophoretic mobility of this protein had changed in the
serum treated with C. parvum from the ft to the y region; an observation compatible with
'alternate pathway' activation (Gotze & Muller-Eberhard, 1971). Thus the difference in the
pathways of complement activation between the sera of man and guinea-pig is most likely
due to the presence of 'natural antibodies' to C. parvum present in the human but not in the
guinea-pig serum.
Table 1. The effect of C. parvum on the titre of the individual complement components
CI, C4, C2 and C3 in human and guinea-pig serum
Human serum Guinea-pig serum
C. parvum treated Control C. parvum treated Control
CI 11700 208000 22261 19321
C4 <5000 17021 9142 10240
C2 <50 1143 30567 35310
C3 305 2250 <50 1650
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DISCUSSION
These results show that the immunological adjuvant C. parvum is capable of activating the
alternate pathway of complement in both human and guinea-pig serum. The activation of
the classical pathway in human serum is likely to be due to anti-C. parvum antibodies present
in such sera.
It has been suggested that receptors for C3 on lymphoid cells may play a role in the antigen
induction phase of the immune response (Pepys, 1972; Dukor et al., 1974). A C. parvum-
derived polysaccharide, bound to these cells (McBride et al., 1974), and activating C3 may
result in an amplification of the activity of these cells and also account for some of the
biological effects of this agent. Whether or not the observed anti-tumour effect referred to
above depends upon the presence of an intact complement system has yet to be determined.
This study raises a number of issues relating to the biological activities of corynebacteria,
some of which may be concerned in the initiation and amplification of cellular defence
mechanisms. In addition this report points to a possible hazard in the use of C. parvum as a
therapeutic agent, due to the formation of immune complexes with subsequent activation
of the complement system.
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Summary
Some properties of synthetic human fibrinopeptides were studied by thin-layer
chromatography, thin-layer electrophoresis and low voltage and high voltage paper
electrophoresis. The Rf values and electrophoretic mobilities of the peptides in these
systems were determined. In high voltage electrophoresis synthetic and natural
(fibrinogen-derived) peptides migrated in an identical fashion.
When gel filtration was performed in 0.05 M pyridine or 0.1 N ammonia, synthetic
fibrinopeptides A and B appeared to be aggregated. In contrast, when filtration was
performed in 1.3 M formic acid, the peptides eluted in positions corresponding to their
monomeric molecular weights.
In addition it was possible to quantitate synthetic fibrinopeptides by two colori-
metric assays, the Sakaguchi reaction and the Folin-Ciocalteu method. Ultraviolet
extinction coefficients for each peptide were also determined.
Introduction
In the final stages of blood coagulation, thrombin cleaves several small peptides
from the N-terminus of the a- and (3-chains of fibrinogen (Blomback and Vestermark
1958). These peptides have been designated fibrinopeptides A, AP, AY and B and
are recognised on the basis of their electrophoretic mobilities. These acidic peptides
are associated with a number of biological activities which include the potentiation
of bradykinin induced contraction of the oestrous rat uterus, prolonged rhythmic
vaso-constriction and chemotaxis of leucocytes (Gladner et al. 1968; Colman ct al.
1967; Kay et al. 1974).
Synthetic human fibrinopeptides have recently become available thereby providing
prepaiations of high purity suitable for investigation of their physical and chemical
properties. In the present study some chromatographic and electrophoretic properties
of these synthetic peptides are reported. In one system (high voltage electrophoresis)
their electrophoretic mobilities are compared with natural (fibrinogen-derived) pep¬
tides A and B.
Materials and Methods
Synthetic Fibrinopeptides
Synthetic fibrinopeptides A, B, and fibrinopeptide B (1-Glu), an analogue of fibrino-
peptide B in which glutamic acid was substituted for pyrrolidone carboxylic acid at the
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N-terminus, were obtained from Schwarz/Mann (Orangeburg, New York). Amino acid
analyses of the fibrinopeptides in g moles/mg were as follows: Fibrinopeptide A, Arg-0.72,
Asp-1.50, Glu—1.50, Ser-0.62, Gly-3.64, Ala-1.79, Yal-0.72, Leu—0.80, Phe-0.72; Fibrino¬
peptide B, Arg-0.53, Asp-1.50, Glu-1.67, Ser-0.50, Gly-1.03, Ala-0.53, Val-0.55, Phe-
0.94; (1-Glu) Fibrinopeptide B, Arg-0.61, Asp-1.68, Glu-1.70, Ser-0.53, Gly-1.14, Ala-
0.60, Val-0.59, Phe-1.11.
Human Fibrinogen-derived Fibrinopeptides
were prepared as previously described (Kay et al. 1974). Human fibrinogen, purified by
the method of Blomback and Blombaek (1956), was clotted with bovine thrombin (Parke-
Davis, Detroit, Michigan). Following centrifugation of the clot, the resulting supernatant
was precipitated with trichloroacetic acid. Fibrinopeptides A and B were then separated
from the TCA-soluble fraction of the clot supernatant by high voltage electrophoresis in
two dimensions (Kay et al. 1974).
Gel Filtration
Sephadex G-25 columns were prepared at 4° C with the following eluants: 0.05 M
pyridine, pH 8.0; 0.1 M ammonia, pH 9.0 and 1.3 M formic acid, pH 2.0. Mixtures of blue
dextran, vitamin B12 (M. W. 1357) and sodium chloride were first passed through the
columns as markers and subsequently detected by spectrophotometric absorption and
conductivity. Samples of 0.5 mg of each of the synthetic fibrinopeptides A and B were
then chromatographed individually. For gol filtration of the (1-Glu) analogue of fibrino¬
peptide B, a G-75 column was prepared at room temperature with 0.05 M pyridine as the
eluant. Following elution the peptides were detected in pyridine by the Folin-Ciocalteau
method, in ammonia solution by absorption at 215 nm, and in formic acid by the Folin-
Ciocalteau reaction of samples which had been evaporated to dryness and re-dissolved in
PBS (phosphate buffered saline, pH 7.2, containing 6.80 g sodium chloride, 1.48 g diso-
dium hydrogen orthophosphate and 0.43 g potassium dihydrogen orthophosphate per
litre of distilled water).
Fibrinopeptide Detection and Quantitation
For quantitation of fibrinopeptides in solution two techniques were used: the Folin-
Ciocalteau method (Legget-Bailey 1967) using human serum albumin for the standard
curve and the Sakaguchi reaction (Shainoff and Page 1960) with arginine for the standard
curve. Sakaguchi spray solutions were used to detect peptides following thin-layer chro¬
matography and thin-layer or paper electrophoresis (Leggett-Bailey 1967).
Thin-layer and Paper Chromatography
Silica gel pre-coated aluminium sheets (Merck), 0.25 mm thick, and Whatman No. 1
filter paper were cut into 20 cm x 2 cm strips. Fifty pg of synthetic fibrinopeptides A and B,
dissolved in 5 pi of 0.05 M pyridine, were applied at the origin. Arginine was also added
as a standard. The strips were chromatographed at room temperature in an airtight tank
saturated with one of the following solutions: n-propanol: water, 7:3 v/v (Blomback ot al.
1972): n-butanol:acetic acid:water, 2:2:1 or 2 — methoxyethanol:acetic acid: sec-
butanol:water, 2:1:8:3. After five hours the sheets were dried at 85° C and sprayed with
Sakaguchi reagents.
Thin-layer Electrophoresis
The peptides were applied to cellulose pre-coated TLC glass plates, 0.1 mm thick, 10 cm
X 20 cm (Merck), as described above. Electrophoresis was performed at 31 V/cm for 30
minutes in either 4% v/v acetic acid and 1% v/v formic acid, pH 2.0 (Herzig et al. 1972)
or pyridine: acetic acid: water, 1:30:89, pH 3.0.
Low Voltage Paper Electrophoresis
Samples were applied to Whatman No. 1 filter paper. A potential difference of 23 V/cm
was maintained for 85 minutes using the pH 2.0 buffer as described for thin-layer electro¬
phoresis.
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High Voltage Paper Electrophoresis
Electrophoresis was performed in vertical tanks using the following buffers: pH 6.5,
pyridine-acetic acid-water (25:1:225 by volume); pH 3.5, pyridine-acetic acid-water
(1:10:8); pH 2.1 acetic acid-formic acid-water (35:10:355) (Ambler 1963).
For electrophoresis at pH 2.1, 50 to 100 gg of synthetic fibrinopeptides A and B or the
natural (fibrinogen-derived) peptides, plus a mixture of ninhydrin-positive amino acid
markers (Milstein and Milstein, 1968) were applied to Whatman No. 1 paper (57 cm x
16 cm). For electrophoresis at pH 3.5 and 6.5 Whatman No. 3 paper was used. In each
tank a potential difference of approximately 60 V/cm was maintained for one hour, at
which time the paper strips were dried at 45° C and sprayed with Sakaguchi reagents. The
Sakaguchi-positive spots were marked with a lead pencil, and the paper was then immersed
in 0.2% ninhydrin in acetone and dried at 60° C. Migration was measured from the centre
of the taurine marker.
Results
Gel Filtration
When synthetic fibrinopeptides were chromatographed on G-25 Sephadex with
three different solvents, different elution patterns were observed (Fig. 1). The Kd
values of A and B respectively were 0 and 0 in 0.05 M pyridine, 0.09 and 0.18 in 0.1 M
ammonia, and 0.32 and 0.54 in 1.3 M formic acid.
Thin-layer and Pa-per Chromatography
After chromatography on silica gel or paper strips for 5*4-7 hours, the solvent front
had moved 12-16 cm and Rf values were calculated as described in Table 1.
Table 1. The Rf values of synthetic fibrinopeptides A and B obtained by thin layer




1. TLC n-propanol:water, 7 :3 0.20 0.16 -—
2. TLC n-butanol: acetic acid:
water, 2:2:1 0.30 0.31 0.23
3. Paper n-butanol: acetic acid:
chromatography water, 2:2:1 0.86 0.90 0.67
4. TLC 2-methoxyethanol: acetic
acid: sec-butanol:water,
2:1:8:3 0.14 0.14 0.08
Several techniques were investigated in attempting to improve the silica gel
separation. When strips were first heated at 85° C for four hours before application of
the sample, the determined Rf's of B and A in solvent 1 were 0.20 and 0.15. After a
five-hour separation, silica gel strips were dried and re-run a second, third or fourth
time, but this modification did not improve the separation.
Thin-layer Electrophoresis and Low Voltage Paper Electrophoresis
Electrophoretic migration of the peptides determined by these methods is shown in
Table 2. Of the three systems the greatest separation of the peptide was achieved by
paper electrophoresis at pH 2.0.
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Bl.Dex. vit B12 NaCI
0 05 M Pyridine
-.y .--a.-.g--g—g.—a -a- a-- Q---Q
0 4 0 5 10 KH
Fig. 1. Sephadex G-25 chromatography of synthetic fibrinopeptides A (O — O) and B
(A - A) using three solvents. The Ka is shown on the abscissa and on the ordinate the
optical density of the fractions measured either directly or after Folin-Ciocalteau assay.
Each column was first calibrated with three markers, blue dextran (Bl. Dex.), vitamin
B12 (Vit. B12), and sodium chloride (NaCI).
High Voltage Paper Electrophoresis
As shown in Fig. 2 synthetic fibrinopeptides A and B migrated together at pH 6.5
but separated at pH 3.5 and pH 2.1. The separation at the lower pH was slightly
greater. Natural (fibrinogen-derived) peptides migrated to identical positions as the
synthetic peptides in each system.
Quantitation of Fibrinopeptides in Solution
Since accurate weighing of small amounts of the hygroscopic fibrinopeptides was
difficult, three methods were used to determine the concentration of peptides in
solution. Solutions of peptides A and B were first quantitated by the Sakaguchi
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Table 2. The distance ofmigration of synthetic fibrinopeptides A and B by thin-layer and
paper electrophoresis using different solvent systems.
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Fig. 2. High voltage electrophoresis of fibrinopeptides A and B at pH 6.5, 3.5 and 2.1.
A, B, Cya, XCFF, Taur, e-DNP-Lys, Asp, Glu, Val, Ala-Gly, Gly, Hist, Arg, Lys indicate
respectively the positions reached by synthetic and natural fibrinopeptide A, synthetic
and natural fibrinopeptide B, cysteic acid, xylene cyanol FF, taurine, epsilon-dinitro-
phenol lysine, aspartic acid, glutamic acid, valine, alanine-glycine, glycine, histidine,
arginine, and lysine.
reaction using an arginine standard curve. Since one mole of each peptide contains
one mole of arginine, equimolar solutions produced the same colour yield.
By the Folin method 1 p.g of fibrinopeptide A or B, previously quantitated by the
Sakaguchi reaction, gave the same optical density as 1.00 fxg or 0.56 u.g of human
serum albumin respectively.
To determine the extinction coefficients, each peptide was dissolved in PBS and
quantitated by the Sakaguchi reaction. The optical density of the quantitated solution
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was then measured at 215 nm. From these measurements, El'/snm values of 100 and
125 were calculated for peptides A and B respectively.
Discussion
In a previous study, Johnson and May (1969) reported that in water synthetic
fibrinopeptide A eluted from Sephadex G-25 as the first major fraction. In the present
work synthetic fibrinopeptides were filtered on Sephadex G-25 using three solvents
each of which gave a different elution pattern. As shown in Fig. 1, fibrinopeptides A
and B were excluded by G-25 Sephadex in 0.05 M pyridine. Since the gel is reported
to exclude molecules of molecular weights greater than 5000 daltons, the peak at V0
may have resulted from aggregation of the peptides (molecular weights ca. 1500). In
0.1 N ammonia both peptides were retarded by the gel perhaps as dimeric aggregates.
In 1.3 M formic acid, however, peptides A and B eluted with the same Ka values
expected for the monomeric molecular weights of peptides which contain one (peptide
A) and two (peptide B) aromatic residues. According to Ambler (personal communi¬
cation) peptides may be retarded on Sephadex G-25 due to binding ofaromatic groups
by the gel. With pyridine, however, hydrophobic binding of aromatic groups to
Sephadex G-25 may either be averted by saturation of the sites on the gel by the
aromatic groups of the eluant, or possibly masked by aggregation of the peptides.
We have also shown that by gel filtration on Sephadex G-75 the [1-Glu] analogue
of fibrinopeptide B eluted with the same Ka as a "marker" ofmolecular weight 6000
(Trasylol, Bayer, Germany) when 0.05 M pyridine was used as the solvent. This
finding is consistent with tetramer aggregation under these conditions.
In the purification of fibrinopeptides this aggregating property can be exploited by
desalting on G-25 in 0.05 M pyridine followed by subsequent G-25 filtration in 1.2 M
formic acid.
Comparing a propanol solvent used by Blomback et al. (1972) with several other
thin-layer chromatography solvents, we found that the diluted propanol gave the
best separation of A and B. When a butanol-acetic acid solvent was used for both
silica gel and paper chromatography, a higher Rfvalue was found on paper chromatog¬
raphy, but the spots migrated less compactly showing some "tailing." In this latter
system Johnson and May (1969) reported an Rf value of 0.75 for synthetic fibrino¬
peptide A. Differences in our results may be due to differences in temperature or
chromatographic paper.
In the present study we obtained the best electrophoretic separation of fibrino¬
peptides A and B using a pH 2.0 solvent. This system proved more suitable for
qualitative identification of fibrinopeptides A and B than thin-layer chromatography
or thin-layer or paper electrophoresis. Natural (fibrinogen-derived) and synthetic
fibrinopeptides A and B gave identical migration on high voltage electrophoresis. As
described in a previous report, synthetic peptides can be used as markers in the
purification of fibrinogeu-derived peptides (Kay et al. 1974).
Three methods were standardized for the quantitation of fibrinopeptides in solution.
When the sensitivities of these assays were compared, the Folin reaction produced the
highest O.D. for peptide A whereas the absorbance of B was greatest when measured
directly at 215 nm.
Resume
On a etudie quelques proprietes des fibrinopeptides humains synthetiques par
chromatographic et electrophorese en couche mince, et par electrophorese sur papier
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a, bas et haut voltage. On a determine les valeurs de Rf et la mobilite electrophore-
tique des peptides dans les differents systemes. Au cours de Telectrophorese a baut
voltage les peptides synthetiques et naturels (derives du fibrinogene) migrent de
faijon identique.
Quand la filtration sur gel est faite dans la pyridine 0.005 M ou l'ammoniaque 0.1 N
les fibrinopeptides synthetiques semblent etre agreges. Au contraire avec l'acide
formique 1.3 M les peptides sont elues de faijon correspondante a leur poids mole-
culaire de monomere.
De plus il est possible de determiner quantitativement les fibrinopeptides syntheti-
ques par deux methodes eolorimetriques, la reaction de Sakaguchi et la methode de
Folin-Ciocalteu. On a egalement determine les coefficients d'extinction dans 1'ultra-
violet pour les deux peptides.
Zusammenfassung
Es wurden einige Eigenschaften der synthetischen Menschenfibrinopeptide mit
Hilfe der Dunnscliichtchromatograpbie, der Dunnschichtelektrophorese, der Tief-
und Hochspannungs-Papierelektrophorese studiert. Die Rf-Werte und die elektro-
plioretische Mobilitat wurden in diesen Systemen bestimmt. In der Hochspannungs-
elektrophorese bewegten sich die synthetischen und die naturlichen (aus Fibrinogen)
Peptide in identischer Weise.
Wenn die Gelfiltration entweder 0.05 M Pyridin oder in 0.1 M Ammoniaklosung
durchgefiihrt wurde, schienen die Fibrinopeptide A und B aggregiert zu sein.
Hingegen wurden sie in 1.3 Ameisensaure als Peptidmonomer eluiert.
Zusatzlich war es moglich, die synthetischen Fibrinopeptide mit zwei kolorimetri-
schen Methoden, mit der Sakaguchi-Reaktion und mit der Folin-Ciocalteu-Methode,
quantitativ zu messen. Der UV-Extinktionskoeffizient wurde fiir beide Peptide auch
bestimmt.
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Passive Sensitization of Tissue Cells
III. A Primate Macrophage-Cytophilic Antibody
A. B. Kay, B. W. Gurner and R. R. A. Coombs
Immunology Division, Department of Pathology, University of Cambridge, Cambridge
Introduction
As a result of the original studies of Boyden and Sorkin [1960], our
laboratory, and others, have devoted much effort to the study of
macrophage-cytophilic antibody in guinea pigs and mice [see Nelson
and Boyden ,1967; Jonas, Gurner, Nelson and Coombs, 1965; and
Tizard, 1969]. Our main interest lies in the still unknown role of this
antibody and the model it supplies for the phenomenon of passive
sensitisation (allergisation) of tissue cells in general.
Another special interest for us, is the selectivity of uptake by the
macrophage membrane of this type of antibody and the use of this
reaction to characterise macrophage-like properties. A recent report
by Coulson, Gurner and Coombs [1967] has suggested that a percent¬
age of guinea-pig lymphocytes undergoing 'transformation' may
acquire such macrophage-like properties, as demonstrated by the
ability of such cells to passively adsorb cytophilic antibody onto their
cell membrane.
For various reasons, not the least being the already existing knowl¬
edge on the human immunoglobulins and the interest in having the
fullest understanding of allergic reactions in man, we have attempted
to produce this type of antibody in a primate - namely the baboon.
Materials and Methods
Baboons. All baboons (Papio cynocephalus) were aged between 6 and 12 months and weighed
between 3 and 4 kg. They were maintained on a balanced vegetable diet with added
vitamins and salts.
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Preparation of cytophilic antisera. These were produced by injecting baboons with four-
times washed red cells of the rabbit in Freund's complete adjuvant under the experimental
schedules shown in table II and III. The animals were lightly sedated with 5 mg ofPheny-
cyclidine (Parke Davis) before injection. The antisera were stored at -20° C.
Fractionation of antisera. The conditions for Sephadex G 200 filtration and DEAE cellulose
chromatography are described under section 4 of Experimental Study.
Procurement and storage of baboon and human macrophages. Baboon peritoneal macrophages:
The peritoneal cavity of baboons which had had abdominal operations 7 days previously
were washed out with 200 ml of heparinised Hanks solution. The operation involved the
placing of various suturing material into the small bowel. A stimulus such as this was a
necessary step in the procurement of macrophages in a sufficient quantity. The peritoneal
cells were then centrifuged in siliconed glassware at 100 g for 5 min at 4° C and resuspended
in Hanks solution. To an equal volume of the cell suspension was added, dropwise, an equal
volume of 20% dimethyl sulphoxide at 4°C, the cell count having previously been adjusted
to give a final concentration of 5 X 10" cells per ml. The cells were then cooled at 1° C/min
using the Nagington cylinder [Nagington and Greaves, 1962] and stored at —180° C in
liquid nitrogen. For use in the tests the cells were thawed quickly at 37° C and slowly diluted
with Hanks solution to a final concentration of approximately 1,000 cells per mm3.
Human peritoneal macrophages were obtained from human peritoneal washings obtained
during the course of peritoneal dialysis in the treatment of renal failure. A balanced salt
solution is introduced into the peritoneal cavity and removed after 30 min. The process is
repeated hourly. Macrophages and neutrophils usually appear in the dialysate after the
third day. The cells were centrifuged at 100 g for 5 min and resuspended in Hanks solution.
The cells were stored in the same manner as described for baboon peritoneal cells.
Baboon alveolar macrophages were obtained by the method outlined byMyrvik, Leake and
Fariss [1961].
Baboon and human blood leucocyte monolayers were prepared in a similar manner to that
described by Jonas et al. [1965].
Papain-treated rabbit red cells for cytophilic tests. Rabbit red cells were papain treated in
essentially the same way as described by Hawes and Coombs [I960],
Special antiglobulin reagentsfor experiment 5. Anti-y (R4785), the two anti-a sera (R83 and
R179) and the anti-/i (R199) were prepared as described by Coombs, Jonas, Lachmann
and Feinstein [1965].
Sheep 198 anti-IgA was raised against colostral IgA, purified by ion exchange chromato¬
graphy and Sephadex G 200 filtration. It was made heavy chain specific by absorbing with
human cord serum. This serum was kindly given to us by Dr. A. Feinstein. The anti-
human albumin serum was raised in a rabbit injected with crystallized human serum
albumin (Mann Laboratories).
Procedure usedfor testing sera for antibodies cytophilic for macrophages and other cells. Both the
monolayer technique the more sensitive 'suspension-centrifugation method' and the
method of scoring the reaction were used as described by Jonas et al. [1965] in studies on
guinea-pig macrophage-cytophilic antibody. Essentially, dilutions of antiserum were added
to the macrophage suspension or monolayer. After incubation at room temperature the
cells were washed. The rabbit red cells next added were previously treated with papain to
render them less sticky to glass and to increase their agglutinability. In the monolayer test
the red cell suspension was allowed to sediment on the serum-treated monolayer, while in
the suspension-centrifugation method the red cells and serum-treated macrophage suspension
were mixed and centrifuged together and the deposited cells subsequently mounted on a
slide.
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Experimental Study
1. Attempted Production in the Baboon of Macrophage-Cytophilic
Antibody to Sheep Red Blood Cell Antigens
Attempts to stimulate and demonstrate cytophilic antibody directed
against sheep red blood cells were unsuccessful since peritoneal and
alveolar macrophages from three normal baboons without any treat¬
ment with serum, gathered sheep red cells in rosette formation around
them. We therefore tested the ability of various species of red blood
cells to form rosette reactions with baboon macrophages in the ab¬
sence of cytophilic antibody and, as may be seen from table I, only
sheep red cells acted in this way. This natural affinity reaction was
greatly reduced by pre-treatment of the sheep red cells with papain
but, even so, it was decided that this particular system was not a
satisfactory model for further study. The titres ofdirectly agglutinating
antibody and sensitizing antibody (detectable by the antiglobulin
test) in baboon sera against sheep red blood cells were only 5 and 10
respectively and since there were also rosettes around neutrophils it
was considered unlikely that this was a naturally occurring cytophilic
antibody.
It was subsequently found that sheep red cells had no natural
affinity for human macrophages.
2. Stimulation ofMacrophage Cytophilic Antibody in Baboons against
Rabbit Red Cells
Rabbit red cells in a saline suspension have the disadvantage of being
'sticky' on glass and have a tendency to non-specific aggregation, but
these difficulties are largely overcome by pretreatment of the washed
cells with papain.
A total of 5 baboons were injected at different times with washed
rabbit red cells emulsified in Freund's complete adjuvant according
to the schedules given in tables II and III. The schedule followed that
used successfully for the stimulation of macrophage-cytophilic anti¬
body in the guinea pig [Jonas et al., 1965]. The titre of cytophilic
antibody produced is also given in these tables. It may be seen that
very little cytophilic antibody was produced in these baboons without
the intradermal booster injections of red cells given at multiple sites.
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Table I. The reaction between red cells of various species and a monolayer of baboon
macrophages. Only red cells of the sheep form rosettes around untreated macrophages










Table II. Injection schedule and titre of macrophage-cytophilic antibody to rabbit red cells
produced in baboon (Willis)
Day Treatment Titre cytophilic antibody
5 20 100 500 dil
0 bled and 1st FGA injection1 _ _
9 bled NT
15 bled and booster i.d. injection2 NT
22 bled + + + 3 + + + + + + -
30 bled + + + + + + - -
68 bled and 2nd FCA injection1 + + + w - -
68 + 9 bled + + + + + + + -
68 + 28 bled + + + + + + + + + -
68 + 36 bled + + + + + + + + w -
1 2 ml 30% suspension rabbit red cells emulsified with equal volume of Freund's
Complete Adjuvant and injected intramuscularly.
2 0.2 ml of a 30% suspension of washed rabbit red cells in saline were injected intra-
dermally into 6 sites on the anterior abdominal wall.
3 + ++,++, +,w, strength of rosette formation, - negative, N.T. = not tested.
3. Selectivity as Regards Cell Type onto Which This Cytophilic Anti¬
body Is Passively Adsorbed
The preliminary tests with these antisera were done on monolayers of
macrophages obtained from the peritoneal cavity of baboons seven
days following laparotomy for other purposes. Fixation and staining
with Leishman's stain of the rosettes showed the involved cell to be the
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Table III. The effect of the 17th day intradermal booster injection on stimulation ofmacro-
phage-cytophilic antibody
Baboon Day Treatment Titre of cytophilic antibody













0 bled and 1st FCA injection
10 bled
17 bled and booster i.d.
injection2
25 bled
0 bled and 1st FCA injection
10 bled










+ + + + +
+
+
1 2 ml 30% suspension rabbit red cells emulsified with equal volume of Freund's
Complete Adjuvant and injected intramuscularly.
2 0.2 ml of a 30% suspension of washed rabbit red cells in saline were injected intra-
dermally in to 6 sites on the anterior abdominal wall.
3 + + +,++, +,w, strength of rosette formation, — negative.
macrophage. The cytophilic antibody was also adsorbed on to alveolar
macrophages. Using monolayers of blood leucocytes prepared by the
method described by Jonas et al. [1965] it was clear that although the
antibody was passively adsorbed by blood monocytes it was not taken
up by polymorphonuclear cells. Using the suspension-centrifugation
technique no reaction was obtained on lymphocytes or eosinophils or
polymorphonuclear leucocytes. These findings are similar to those
found in the guinea pig [Jonas et al., 1965] and in the mouse [Tizard,
1969] using macrophage-cytophilic antibody produced in the respec¬
tive species.
These baboon cytophilic antibodies had a similar pattern of
reactivity on human cells. Both polymorphonuclear leucocytes and
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Table IV. Distribution ofcytophilic activity following Sephadex G 200 filtration of antiserum
Sephadex G 200
I II III
Immuno-electrophoresis1 IgG + + + (+ )
IgA + -
IgM ■ - -
Micro-Ouchterlony2 IgG - + + + + +
IgA - + + -
IgM + + - -
Cytophilic antibody titre13 0 500 (5)
1 Using polyvalent anti-human serum in the troughs and an anti-a serum.
2 Using specific anti-human immunoglobulin sera (see Methods).
3 Titre of unfractionated serum 500.
macrophages were obtained from peritoneal washing during dialysis;
only the macrophages reacted. These macrophages were also found to
be adequate in 'monolayer' or 'suspension-centrifugation' tests after
storage at -180° C in 10% dimethyl sulphoxide.
4. Physical Characteristics of Baboon Macrophage-Cytophilic Anti¬
body
a) Filtration through Sephadex G 200. 2.5 ml of a baboon serum with a
cytophilic antibody titre of 500 was added to a Sephadex G 200
column (2.5x94 cm) which was equilibrated with 0.1 m Tris and 0.5
m NaCl pH 7.2. Two further peaks followed the exclusion peak. Cuts
were made to separate the material under each peak.
After concentration to the original volume fractions 1, 2 and 3
were tested by immuno-electrophoresis and in micro-Ouchterlony
plates. The location of IgG, IgA and IgM was as shown in table IV.
The cytophilic antibody was located in the second peak (table IV)
suggesting that cytophilic antibody resided in either IgG or IgA.
b) DEAE chromatography. 4.0 ml of the cytophilic antiserum was
dialysed against 0.0175 m phosphate buffer, pH 7.2, and added to an
equilibrated DEAE cellulose column (1.43x15 cm). Following the
exclusion peak a step elution followed with 0.2 m phosphate buffer.
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Table V. Distribution of cytophilic activity following DEAE chromatography of antiserum
DEAE cellulose
I II
Immuno-electrophoresis1 IgG + + + slow + + fast
IgA - +
IgM - +
Micro-Ouchterlony2 IgG ++ + + +
IgA - + +
IgM - + +
Cytophilic antibody titre3 500 100
1 Using polyvalent anti-human serum in the troughs and an anti-a serum.
2 Using specific anti-human immunoglobulin sera.
3 Titre of unfractionated serum 500.
The eluates under the two peaks were pooled and concentrated to the
original volume to give fractions I and II. Testing these fractions by
immuno-electrophoresis and in micro-Ouchterlony tests (table V)
showed the cytophilic activity to be fairly evenly divided between
fractions I and II the titre being 500 and 100 respectively. These
results taken in conjunction with those on the Sephadex fractions
suggest that macrophage-cytophilic antibody is to be associated with
the 7S IgG antibodies.
c) Treatment with 2-mercapto-ethanol. Treatment of the DEAE ex¬
clusion fraction with 0.1 m 2-mercapto-ethanol left the macrophage-
cytophilic antibody unaffected.
The antibody was also heat-stable to heating at 56° C for % h.
d) Digestion of Fc piece by pepsin. The DEAE '7S' fraction of cyto¬
philic baboon serum was digested with pepsin according to the
method ofNisonoff, Wissler and Woernley [1959].
After treatment the F(ab)2 antibody fraction agglutinated papain-
treated rabbit red cells to a titre of 1,280 ( > 2,560 by the antiglobulin
test on untreated rabbit red cells) as compared with 2,560 and > 2,560
respectively using the undigested antibody. This indicated very little
reduction in the agglutinating activity of the F (ab)2 antibody. How¬
ever the pepsin-treated antibody had no cytophilic activity in either
the monolayer or in the more sensitive 'suspension-centrifugation
technique' using dilutions of Vio and Vioo at which the untreated anti-
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Table VI. Attempt to inhibit uptake of baboon macrophage-cytophilic antibody by specific
anti-human immunoglobulin sera
Monolayer incubated with Subsequent rosette





Normal rabbit serum 1:40







Sheep 198 anti-a4 1:40
R199 anti-/i 1:40
R X 516 anti-(56 1:40
R anti-s6 1:40












1 Viiso represented 2 doses of cytophilic antibody, 1/E0 = 10 doses.
2 3 4 See 'Materials'.
5 Anti-<5 was a gift from Dr. D. Rowe.
6 Anti-e was a gift from Dr. S. G. O. Johansson.
body produced a strong reaction. It thus seems that as with guinea pig
macrophage-cytophilic antibody [Berken and Benacerraf, 1966]
and mouse cytophilic antibody (Tizard, 1969] the cytophilia depends
on an intact Fc piece.
5. Attempts to Identify the Immunoglobulin Class of Baboon Cyto¬
philic Antibody by Specific Inhibition Studies
After formation of monolayers of baboon peritoneal cavity macro¬
phages the cells were washed and specific antiglobulin sera added to
the chambers as shown in table VI. Diluted cytophilic antiserum was
then added and following incubation the cells washed and tested for
uptake of cytophilic antibody by the usual procedure. Table VI shows
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the pattern of reactivity which summarises the results of 5 experiments
each with differing doses of the various reagents.
Should cytophilic antibody be one of the common immunoglobulins
it is probable that the doses of antiglobulin used would not have been
sufficient to neutralize the activity. However a neutralizing effect was
produced consistently by one polyvalent serum and by two supposedly
class-specific anti-heavy chain reagents, both anti-a sera. Should these
inhibitory effects recorded reflect neutralization of the operative
immunoglobulin it would seem that the antibody is not 'common'
IgG not IgM, IgD or IgE.
The inhibitory results with the two anti-a reagents (R179 and R83)
pointed to IgA but no inhibition was produced by the sheep 198
anti-a reagent. This latter serum was raised against ion exchange and
sephadex purified colostral IgA while R179 was raised against whole
colostrum and R83 which was raised against myeloma protein in
urine. This could suggest that the inhibition was not due to anti-a
heavy chain but to some other minor immunoglobulin.
A further piece of evidence that cytophilic antibody is not IgA
came from an experiment in which normal human serum and human
colostrum (as a source of IgA) was added to a macrophage monolayer
to complete with cytophilic antibody for receptor sites on the macro¬
phages [see Jonas et al., 1965]. Colostrum inhibited very poorly while
normal human serum gave inhibition. A human serum (Ro) known to
be naturally free of IgA gave especially good inhibition.
No firm conclusions as to immunoglobulin class of primate macro-
phage-cytophilic antibody can be drawn from these experiments but
they rather indicate that baboon macrophage-cytophilic antibody is
not IgM IgD or IgE, but is a minor immunoglobulin residing within
the 7S IgG fraction. It must be remembered however the antibodies
were raised not in man, but in the baboon and the specific anti¬
globulin reagents were against human immunoglobulins.
Discussion
We have mentioned in the introduction that there are many reasons
to encourage a search for macrophage-cytophilic antibody in man.
There are however many difficulties, not the least being that Freund's
complete adjuvant may be needed to produce it experimentally. This
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made us use another primate, namely the baboon where this can be
done. Fortunately, as with reaginic antibody where human antibody
reacts in baboon skin, the baboon macrophage-cytophilic antibody
reacts on human macrophages. This interchangeability of cells and
reagents within the primate species has made the present investiga¬
tion possible. Even so the system is not an easy one to work with.
Neither human nor baboon macrophages are easy to obtain fresh or
on demand, but fortunately we found that a source may be preserved
frozen at -180° C in 10% dimethyl sulphoxide, but such cells have not
quite the 'viability' of freshly procured cells. Another difficulty of
course is that, despite this interchangeability, baboon immunoglobulins
may differ considerably and in many details from their human counter¬
parts.
We would now wish to see if man produced this type of cytophilic
antibody under natural conditions but the system to test is not obvious.
An antibody with such a distinctive property may well form a distinct
sub-class or even class of immunoglobulin and its study could make a
physico-chemical definition possible.
We have already made use of the antibody in an analytical sense to
reveal changes in the membrane of human lymphocytes undergoing
antigen-induced 'transformation'. A percentage of the cells acquire
macrophage-like properties in that they stick to glass, engage in phago¬
cytosis and passively take up baboon macrophage-cytophilic antibody
[Coombs, Gurner, Chalmers and Kay, 1969].
The observed natural affinity of sheep red cells to baboon macro¬
phages (but not to human macrophages as subsequently found) pre¬
cluded using sheep red cells and their membrane antigens in these
tests. Annoying as this was, this 'affinity' reaction is an interesting
phenomenon. Other examples of this type of reaction have been
discussed by Coombs and Franks [1969].
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Summary
1. Injection of rabbit red cells into baboons has been successful in stimulating macrophage-
cytophilic antibodies. These passively adsorb selectively on to both baboon and human cells
of the macrophage/monocyte series.
2. The macrophage-cytophilic antibody resists heating at 56° C for % h> resists the action
of 0.1 m 2-mercapto-ethanol, but loses its cytophilic activity on pepsin-treatment.
3. The immunoglobulin class of the antibody is not yet ascertained but, from prelimi¬
nary filtration, chromatographic and biological inhibition studies, there is a suggestion that
it may not belong to any of the existing classes although it is closely associated with '7S' IgG.
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Some Complications Associated with the
Administration of Blood and
Blood Products
A. B. KAY
Although it is difficult to assess the frequency of the complications of blood
transfusions the ever increasing demand for blood and blood products has
made associated adverse effects following administration of these agents one
of the more common clinical problems. The transmission of hepatitis B virus
remains the most serious complication, and this is dealt with elsewhere as are
the effects of massive transfusion. This chapter deals largely with immuno¬
logical aspects of blood transfusion with particular consideration of the
mechanisms leading to the clinical manifestations of adverse clinical effects.
The understanding of the various blood group systems in man and the
technology for grouping and matching compatible red cells for transfusion
have made erythrocyte associated transfusion reactions a relatively rare event.
During 1974 the Blood Transfusion Laboratories of the Royal Infirmary of
Edinburgh supplied 57 462 units of whole blood or red cell concentrates to
16 815 individuals (Table 1). Signs and symptoms which were probably a
Table 1. The incidence of transfusion reactions (Blood Transfusion Laboratories, Royal
Infirmary of Edinburgh, 1974)
Number
Patients receiving whole blood or red cell concentrates 16815
No. of units transfused 36 424
Transfusion reactions 114
Associated with red cell antibodies 1
Associated with leucocyte or plasma protein antibodies 27
No cause found 86
result of these infusions developed in 114 patients (0.68 per cent). Only one
recipient had a reaction which was clearly attributable to red cell incompati¬
bility. Apart from this patient, leucocyte or plasma protein antibodies were
found in 27 persons who had allegedly reacted, but in the remaining 86
individuals laboratory tests were unhelpful in the investigation of the cause
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Table 2. Antibodies to immunoglobulin determinants and leucocyte antigens found in
association with adverse transfusion reactions (Blood Transfusion Laboratories, Royal
Infirmary of Edinburgh, 1974)
Immunoglobulin Leucocyte
antibodies No. antibodies (anti HL-A) No.
Gm 1 2 HL-A 1 2
Gm 4 + 17 1 HL-A 2 3
Gm 4 1 HL-A 2 + 9 1
Gm 5 1 HL-A 7 1
Gm 25 1 HL-A 12 2
Inv 1 2 Polyspecific anti HL-A 4
Polyspecific anti-Gm 5 Polyspecific anti HL-A
+
Polyspecific anti-Gm 1
(Tables 1 and 2). A considerable degree of sophistication has been achieved by
the red cell serologists in the grouping and cross-matching of erythrocytes for
transfusion, but this technology is not yet available on a practical routine basis
for the detection of antibodies or specifically sensitised cells present in donor
or recipient blood which are directed against antigens on granulocytes, platelets
or plasma proteins. It should be emphasised that the evidence for attributing
reactions to the infusion ofblood or blood products is often largely conjectural.
Although it is reasonable to assume that features such as fever, rigors and
urticaria are a direct result of transfusion if they appear during or after the
administration of blood it is usually impossible to prove this beyond per-
adventure.
A number of factors determine the response of a particular individual to an
antigenic stimulus. These include the amount of antigen administered and the
activity of various regulatory systems which determine the degree of the
'immune response'. Thus the existence of specific immune response (IR) genes
to specific antigens or groups of antigens has been described and shown to be
linked to the major histocompatibility systems in several animal species (re¬
viewed by McDevitt and Bodmer, 1974). Also of relevance in this context is
the recognition of the suppressive effect of certain populations of T lympho¬
cytes in terms of their effect on the production of specific antibody or specific¬
ally sensitised cells. There are therefore many complex interactions which
finally determine the response of an individual to various antigens. These
various regulatory mechanisms are dynamic and so the contributions of the
biological systems to the final expression of the immune response will vary in
any one individual.
THE RED CELL AND TRANSFUSION REACTIONS
As stated the major obstacles to the successful transfusion of blood and its
products have been overcome by the pioneering work of the red cell serologists.
Indeed the situation is such that the majority of red cell associated transfusion
reactions are usually a result of technical or clerical errors. All blood trans¬
fusion centres, therefore, must have procedures which ensure that the correct
donor blood is delivered to the appropriate recipients. Physicians and surgeons
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have a special responsibility in ensuring that the samples of blood sent for
grouping and cross-matching are fully and correctly labelled.
The precise mechanism by which the administration of incompatible red
cells are destroyed in vivo and in turn evoke adverse reactions is not fully
appreciated. The participation of various enzyme cascades such as complement
(C) probably play a central role as does red cell destruction by mononuclear
cells both in the circulation and in organs such as the liver and spleen.
The term complement (or alexin) was introduced about 70 years ago to
describe an activity present in normal serum (normal in the sense of not being
'immunised') which led to the lysis of red cells or bacteria previously sensitised
with specific antibody. It soon became apparent that this 'activity' was not the
property of a single factor but of several components most of which are now
available in highly purified forms. A certain amount is now known about their
molecular structure. In many respects the complement system is similar to the
blood coagulation pathway in which components become activated and
depleted in turn. Like the coagulation pathway the complement system has a
number of inactivators and inhibitors which act at various stages during the
reaction sequence thereby maintaining homeostasis. The order in which com¬
ponents of the 'classical pathway' of complement act is different from the
order in which they were discovered. A red cell sensitised with the appropriate
antibody will activate CI and the order of reaction thereafter is C4, C2, C3,
C5, C6, C7 with lysis being brought about by the terminal components C8
and C9. When an antigen-antibody complex is incubated with a source of
complement the reaction sequence will proceed in a similar fashion with
activation and depletion of the components in turn (reviewed by Ruddy,
Gigli and Austen, 1972).
As a result of complement activation a number of factors are released which
have biological activity. These include chemotactic agents and peptides which
release histamine (and other pharmacological agents) directly from mast cells
(e.g., anaphylatoxins).
Most of our knowledge of the complement system in terms of the identifica¬
tion and chemical characterisation of the individual components, the nature
of the biological agents released during the reaction sequence and the nature
of the interactions of the components has been gained from a standard in vitro
model using sheep red blood cells, a source of sensitising antibody (haemolysin
usually prepared in the horse or rabbit) and complement from various species.
As discussed below extrapolation of this model using animal reagents to gain
insight into the human complement cascade has led to a number of erroneous
conclusions and a certain amount of confusion.
As stated, the classical pathway* of complement (C) activation involves the
* The term 'classical pathway' is used to distinguish this reaction sequence from the
'alternate pathway'. The alternate pathway of complement activation activates C3 and the
terminal components thereafter with apparent sparing of CI, C4 and C2. The components
of the alternate pathway include properdin, factor B (also termed the C3 proactivator or
glycine-rich (3-glycoprotein) and other activating enzymes. Their reaction sequence is not
fully defined and since there is no direct evidence at present that the alternate pathway parti¬
cipates in the transfusion reactions considered in this chapter it will not be discussed further.
Readers are referred to a review by Miiller-Eberhard (1974) for a full account of the patterns
of complement activation.
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sequential interaction of at least nine plasma proteins (Figure 1). An erythro¬
cyte (E) when coated with the appropriate antibody (A) activates the first
component (CI). In general antibodies capable of activating CI are IgGi, IgG3
and IgM. IgG2 is relatively inefficient in activating CI whereas IgG<i, IgA, IgD
and IgE do not 'fix' complement via the classical pathway. In the human
/I
CI inhibitor













Figure 1. The classical pathway of complement activation. Associated biological properties
are indicated by the interrupted lines.
situation there are exceptions to this general rule as discussed below. Follow¬
ing the action ofCI on its natural substrates C4 and C2 an EAC 142 enzymatic
intermediate is formed which then activates C3. Activated C3 acts on C5
leading to consumption of the terminal components C6, CI, C8 and C9. The
action of C8 and C9 on the red cell membrane leads to lysis and release of
intracellular constituents. Following the interaction of CI, C4 and C2 a small
'kinin-like vasoactive peptide' is released which evokes tissue swelling. The
agent is thought to be of importance in the pathogenesis of the hereditary form
of angio-oedema in which there is an absence of the natural inhibitor of CI
(CI inh). Similarly two peptides are released from C3 and C5 (C3a and C5a).
These are both chemotactic for leucocytes and are anaphylatoxins. C3 in its
activated form on the cell membrane is termed C3b and has the capacity of
adhering to various cells including B lymphocytes and macrophages. C3b also
renders cells highly susceptible to phagocytosis. Thus cells which escape
extravascularly in the form EAC 1423b presumably adhere to macrophages of
the reticuloendothelial (RE) system where they are engulfed and destroyed.
C3b is extremely sensitive to the action of the C3b inactivator and can cleave
this molecule into C3c (containing the A antigen) and C3d (containing the D
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antigen*, also termed a2d) (Figure 2). C3d remains on the cell and is inactive
both in adherence and in its action on C5 and subsequent completion of the
'haemolytic sequence'. Macrophages apparently have receptors for the A and
D antigens present on C3b but not for the D antigen alone. These mononuclear
cells also have receptors for IgGi and IgG3 but not for other IgG subclasses or
IgM. The interaction of antibody-coated erythrocyte with cells of the macro¬
phage/monocyte series apparently results in either phagocytosis or, where the
Activation step
(i.e. classical or alternate (A antigen)
Figure 2. The antigens and electrophoretic mobilities of C3 and its breakdown products.
During the conversion of C3 to C3b the B antigen is lost but this antigenic determinant is
apparently not on the C3a fragment cleaved during the reaction.
contact is more transient, the fragmentation of red cells with the appearance
of spherocytes and fragmentation of red cells. Spherocytes are particularly
sensitive to osmotic lysis which takes place either extravascularly or in the
circulation.
In general human red cell antibodies which are 'haemolytic' in vitro are
associated with immediate intravascular destruction of red cells in vivo. These
antibodies have the capacity to lyse human cells (containing the corresponding
antigen) in the presence of a source of human complement and therefore
presumably activate CI. Antibodies which do not 'fix complement' or are
only slowly haemolytic in vitro are associated with extravascular haemolysis
which occurs mainly in the spleen.
The rapid intravascular reactions associated with, for example, anti-A and
anti-B red cell antibodies are probably largely complement mediated. The
clinical features produced such as pain, fever and shock may be a result of
the liberation of vasoactive peptides ('C kinin', C3a and C5a) in addition to the
rapid release of haemoglobin. In these situations there is usually some degree
of extravascular destruction and it is assumed that EAC 1423b cells can be
removed by erythrophagocytosis before the C3b inactivator can act. A similar
mode of action may be operative in the extravascular destruction of cells
coated with anti-Lea and Le6 in which the antibody is usually IgM and
haemolysis in vitro is slow.
One molecule of IgM or two adjacent molecules of IgGi or IgG3 are
capable of activating the complement cascade. It has been stated that if the
* The terms A and D antigens are unfortunate for the red cell serologist since they are
terms used both for antigens on C3 and antigens of the ABO and Rhesus (Rh) blood group
systems.
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antigenic sites on the red cell are too sparse, such as in the Rh system where
the antibodies are IgGi or IgG3, CI binding cannot occur (Rosse, 1968). This
is unlikely to be the whole explanation for 'non-complement fixation' by
anti-Rh antibodies. A rare variant of the Rh system (Ripley antibody) is a
potent 'haemolytic' antibody. In practice destruction of cells coated with
anti-D, -E, -e, -C and -c takes place mainly in the spleen presumably by RE
macrophages containing IgG receptors.
There are obviously a number of factors that determine the rate and site of
destruction of antibody-coated red cells. These include the optimal tempera¬
ture of antibody binding, the class or subclass, the amount of incompatible
cells infused, the distribution of antigens and the relative amounts of circulat¬
ing complement components and their cofactors.
Another form of complement independent red cell lysis which may be of
importance in the destruction of sensitised human red cells is the phenomenon
of lymphoid cell-mediated antibody-dependent cytotoxicity (LDAC). This is
apparently distinct from thymus-dependent T lymphocyte-mediated cyto¬
toxicity with its requirement for specifically sensitised effector cells. In this
respect LDAC is 'nonspecific' and appears to be the property of an as yet
unidentified subpopulation of lymphocytes which recognise and destroy
target cells coated with IgG. Urbaniak, S. J. (personal communication) has
recently shown that human peripheral blood lymphoid cells have the capacity
to lyse CDe/CDe cells coated with anti-C plus anti-D. Thus LDAC (some¬
times called K-cell cytotoxicity) may play a role in human red cell destruction
in vivo. These various proposed mechanisms of red cell damage are dia-
gramatically summarised in Figure 3.
THE LEUCOCYTE AND TRANSFUSION REACTIONS
Following pregnancy or the administration of blood products containing
white cells many individuals will show evidence of sensitisation to allogeneic
leucocytes. Because of the complexity of the leucocyte antigen systems and
individual variations in the immune response (see above) the exact incidence
of sensitisation both quantitatively and qualitatively is extremely difficult to
assess. Chromosomes of leucocytes have an area referred to as the major
histocompatibility complex which is made up of at least four separate regions
(two defined serologically (SD) and two defined by mixed lymphocyte culture
(MLR) techniques (LD)). The SD system has been termed traditionally the
human leucocyte (HL-A) antigenic system and is an extremely polymorphic
genetic system controlled by two closely linked segregant series of genes. The
first (also called LA series) and second segregant series (also called Four) are
inherited by autosomal mendelian inheritance. HL-A antigens (or antibodies)
are usually detected by a simple cytotoxic technique which depends on the
capacity of separated human lymphocytes to undergo lysis by the appropriate
antibody in the presence of a source of rabbit complement. Following a
transfusion or pregnancy, individuals may produce HL-A antibodies (lympho-
cytotoxins and leucoagglutinins) not present on their own leucocytes (or
other cells such as platelets which also contain HL-A antigens). The original
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technique for detecting HL-A antibodies was by leucoagglutination. Some
authorities find leucoagglutination, as a method for detecting anti-leucocyte
antibodies following transfusion, to be more sensitive than the lymphocyto-
toxic test (McCullough et al, 1974).
A
f "X Antibody( E + C142356789 —► lysis
IgGj, (IgG2), IgGj, orlgM
s*—s. • C3b receptor
B (i) ( E j>— + C1423b — IgG (Fc) receptor
A l" ■ Erythro phagocytosis
/ A and/or red cell fragmentation
B (ii) \ E macrophage /monocyte
\^_-y'lgG1 or IgG3
^.lymphoid cell - IgG (Fc) recept0r
C
V E "J. ■ lysis
IgGj or IgGj
A - Complement mediated with completion of the haemolytic pathway
B (i) - C3b coated cells and macrophages
B (ii)- IgG coated cells and macrophages
C - Lymphoid cell dependent, antibody mediated cytotoxicity
(K-cell cytolysis)
Figure 3. Some immune mechanisms of red ceil (E) destruction.
It is now apparent that these leucocyte antigenic systems are even more
complex as it has come to be appreciated that some individuals can be
immunised to antigens specific for the neutrophil. Neutropenia in association
with isoimmune neonatal sensitisation or following transfusions has been
reported and the mode of inheritance and nomenclature of various neutrophil
antigens is described (Lalezari and Radel, 1974).
Whereas a mixed lymphocyte reaction can be used for determining the
genetics of the LD loci and for determining compatibility, or otherwise,
between donor and recipient prior to grafting, the technique cannot be used
retrospectively for identifying lymphocytes specifically sensitised against
leucocyte antigens. One approach to this problem is by the use of a cytotoxic
assay in which recipient lymphocytes are incubated for between four and 24
hours with 51Cr labelled allogeneic lymphocytes, lysis being assessed by
measuring chromium release.
Generally speaking transfusion reactions associated with granulocyte
incompatibilities are mild and can often be minimised or prevented either by
the use of corticosteroids and antihistamines or by giving washed or frozen
and thawed red cells. Whereas the presence of leucocyte antibodies in recipi¬
ents requiring red cells is usually of little clinical importance in the majority
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of patients it has serious implications in those individuals awaiting an organ
transplant, bone marrow transplant or granulocyte therapy. In order to
minimise sensitisation by leucocyte antigens it is common practice to give
thawed and frozen red cells to patients on chronic dialysis awaiting a kidney
graft. In these individuals the administration of frozen and thawed red cells
poor in leucocytes greatly minimises the risk of developing lymphocytotoxic
antibodies (Miller et al, 1975). However, white cell-poor blood usually con¬
tains an appreciable amount of leucocyte antigenic material (Engelfreit et al,
1975). When frozen and thawed red cells were injected into rabbits, they
produced both anti-lymphocyte and anti-granulocyte antibodies. However,
in the clinical situation there is apparently considerable variability in the
capacity of individual patients to form lymphocytotoxic antibodies against
various preparations of leucocyte-poor blood (Perkins et al, 1974). Methods
of rendering 'erythrocyte-rich' blood as free as possible from viable leucocytes
or their fragments by filtration procedures is discussed elsewhere (Chapter 3).
It has recently been stated that patients on chronic dialysis receiving frozen
and thawed red cells have a higher rate of subsequent graft rejection than those
receiving whole blood (Opelz and Terasaki, 1974). This was attributable to a
state of immunological tolerance to white cell antigens in those individuals
receiving whole blood. It has also been suggested that HL-A antigens present
in partially purified albumin solution may also produce tolerance (Pattison,
Hindman and Maynard, 1974). These observations will require long-term
ratification and substantiation before a unified policy is introduced in terms
of the most beneficial blood products for patients awaiting organ transplanta¬
tion. It does however raise a number of questions in regard to the efficacy and
economics of the use of special blood products in these patients. It must be
emphasised nevertheless that the use of frozen and thawed red cells greatly
reduces the risk of transmitting hepatitis B infection and therefore most
centres having these facilities will probably continue to use frozen and
thawed cells in patients receiving long-term immunosuppressive therapy.
In renal allograft recipients there is a marked variation in the production of
leucocyte cytotoxic antibodies. Presumably the response of the individual
patient is governed by the same general immunological principles as outlined
above.
A less common transfusion complication found in association with cir¬
culating leucoagglutinins is a syndrome characterised by pulmonary infiltrates
and the abrupt onset of fever, tachycardia, cough and dyspnoea (Ward,
Lipscomb and Cawley, 1968). This reaction is distinguished from the 'post-
perfusion lung' syndrome where hypoxia is the prominent feature and which
is recognised in patients undergoing cardiac bypass surgery and thought to
be a result of the occlusion of small pulmonary vessels by microaggregates
(Nahas et al, 1965a, b).
Particular care must be taken with the use of blood in immunosuppressed
individuals because of the potential hazard of a graft vs host reaction. Even
after 22 days of storage at 4°C viable dividing mononuclear cells have been
detected in whole blood (Petrakis and Politis, 1962). Blood which has been
washed and the red cells frozen and thawed still contains a number of lympho¬
cytes capable of responding in mitosis in the presence of phytohaemagglutinin
ADMINISTRATION OF BLOOD AND BLOOD PRODUCTS 173
(Crowley, Skrabut and Valeri, 1974). Transfusions of fresh blood to the
human fetus and newborn infant also carry the risk of evoking a graft vs host
reaction (Parkman et al, 1974). These problems can be minimised or alleviated
by prior irradiation of the blood. It has been reported that the administration
of whole blood to non-immunosuppressed adults leads to an increase in the
capacity of lymphocytes to undergo spontaneous DNA synthesis (Schechter,
Soehnlen and McFarland, 1972). This was assessed by incorporation of
3H-thymidine by lymphocytes and was maximal one week after transfusion.
This increased lymphocyte reactivity was not found with leucocyte-poor blood
suggesting that in routine whole blood transfusions there is a degree of
sensitisation to donor white cell antigens in the majority of patients.
The administration of granulocytes as therapy for the infected neutropenic
individual is considered elsewhere. Adverse reactions can usually be minimised
by giving cells from HL-A compatible donors, the majority of complications
of granulocyte transfusions being associated with the presence of leuco-
agglutinins or leucocytotoxins in the recipient's serum. Since many of the
patients requiring granulocyte transfusions are undergoing immunosuppres¬
sive therapy, graft vs host reaction is a particular hazard. Again this can be
minimised by irradiating cells prior to transfusion. Granulocytes for infusion
are usually prepared by continuous flow centrifugation using a cell separator
or by the less expensive and simpler method of filtration leucaphoresis in
which granulocytes are trapped on nylon filters from which they are sub¬
sequently eluted. Although filtration leucaphoresis gives high yields of
granulocytes and has the advantage of low cost, the survival of cells in vivo
is shorter and cells prepared in this fashion are more commonly associated
with febrile reactions.
The use of red cells, granulocytes or platelets in relation to bone marrow
transplantation requires special consideration. Generally speaking trans¬
fusions should be avoided if possible in patients in whom this treatment is
indicated. Cells given for supportive therapy following transplantation before
the graft is established should also be HL-A and MLC compatible. Ideally the
bone marrow donor should also supply the platelets and granulocytes for
supportive therapy after transplantation and in these situations it is essential
to have access to a continuous flow cell separator. Failure of the bone marrow
grafting is the rule in the previously multitransfused individual. Since bone
marrow transplantation is becoming an established line of treatment in a
number of conditions including selected cases of aplastic anaemia and certain
leukaemias every effort should be made to avoid prior sensitisation of potential
recipients to leucocyte antigens.
COMPLICATIONS OF PLATELET THERAPY
This has been discussed in detail in Chapter 5 and will only be summarised
here.
Since platelets contain the A and B blood group antigens they should
always, when possible, be given to ABO compatible individuals. Platelet rich
preparations also contain considerable amounts of contaminating red cells
174 A. B. KAY
and therefore should also be matched for the Rhesus D antigen. In addition
platelets carry HL-A antigens but in most cases it is impracticable to HL-A
type donor and recipient in the context of routine platelet therapy. There are
conditions, however, when this is highly desirable as discussed above in the
context of bone marrow transplantation. Individuals who require long-term
platelet therapy often become refractory to treatment due to the development
of leucocyte/platelet antibodies. HL-A compatible platelets will often survive
normally in these patients (McCredie et al, 1974). Some patients with aplastic
anaemia and thrombocytopenia seem at particular risk of developing anti¬
bodies. In all these situations an HL-A compatible individual, preferably a
sibling or another relative, is the most suitable donor (Herzig, Poplack and
Yankee, 1974).
A rare complication of platelet therapy is 'post-transfusion purpura'
(Shulman et al, 1964). In this condition an episode of thrombocytopenia
occurs approximately seven days after the administration of blood and occurs
almost exclusively in women who lack the PLA1 platelet antigen. The exact
mechanism of post-transfusion purpura is not understood but anti-PLA1
antibodies are often detected. It has been suggested that complexes of this
antigen and specific antibody become absorbed onto recipient platelets lead¬
ing to destruction possibly by complement or phagocytosis. The condition has
been successfully treated by repeated plasmapheresis, the antibody presum¬
ably being 'washed-out' (Abramson, Eisenberg and Aster, 1974).
PLASMA PROTEINS AND TRANSFUSION REACTIONS
The recognition of genetic polymorphism amongst a number of plasma
proteins has led to an appreciation of their possible role in various adverse
transfusion reactions. Antibodies against allotypic* determinants on immuno¬
globulins are often detectable in multitransfused individuals but usually have
to be present in high titre to be associated with adverse effects following
transfusion. Anti-Gm antibodies, directed solely against the Fc fragment of
IgG, are more commonly found after multiple transfusions than anti-Inv
antibodies, which recognise determinants on light chains (Table 2). Such
reactions are usually mild in contrast to reactions against purified gamma
globulin which occasionally occur in individuals receiving long-term gamma
globulin therapy. These patients, who are usually those with acquired or sex-
linked agammaglobulinaemia, develop anaphylactic-type reactions within
minutes following intramuscular gamma globulin. Although some of these
individuals have circulating anti-Gm and/or Inv antibodies their serum may
also contain antibodies against denatured gamma globulin (Ellis and Henney,
1969). It would appear that the preparation of gamma globulin for clinical
use results in a degree of denaturation which reveals antigenic sites not present
on native IgG. Individuals with persistent anaphylactoid reactions to gamma
globulin will often require infusions of fresh frozen plasma as a source of IgG.
* Allotypic specificities are those antigenic specificities on various plasma proteins which
are distinct between different groups of individuals within the same species.
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This has the attendant risk of transmitting hepatitis B virus not present with
fractionated gamma globulin and we have recently described a case in which
such a person acquired a dual infection as demonstrated by the presence of
both the ay and ad antigens on circulating virus particles (Lawton et al, 1975).
The anaphylactic reactions which follow union of the globulin antigen with
recipient antibody are possibly complement-mediated. Since the complement
cascade can also be activated by soluble antigen-antibody complexes in the
fluid phase (see above), vasoactive peptides such as anaphylatoxins may be
liberated. This concept is compatible with the work of Barandun et al (1975)
who were able to show that plasmin-treated gamma globulin was well toler¬
ated by immunodeficient patients highly sensitive to native IgG. Plasmin
treatment presumably removed the CI binding site on the Fc region of IgG
thus preventing complement activation.
The evidence that complement plays a major role in these types of reactions
and in the reactions involving anti-IgA (described below) is still circumstantial
and there is little data to support the concept. It is therefore worth considering
the possible participation of the kinin-forming system in immune-complex
induced anaphylactoid reactions since activation of the kinin system has been
demonstrated in vivo in monkeys following the infusion of anti-red cell anti¬
bodies (Lopas et al, 1973). Bradykinin and related peptides are cleaved from
circulating kininogen by the action of the enzyme kallikrein (kininogenase)
(Figure 4). Prekallikrein is converted to kallikrein by the action of fragments
Hageman Factor (F XII)
Contact activation (glass, collagen, antigen-antibody complexes)






Figure 4. The kinin-forming system in human plasma.
derived from activated Hageman factor (factor XII). Factor XII is activated
following contact with a variety of agents including glass, collagen, uric acid
crystals and antigen-antibody complexes. Thus kinin formation as a result
of immune complex activation ofHageman factor may account for some ofthe
clinical features of transfusion reactions found in association with antibodies
to plasma proteins. Bradykinin and the anaphylatoxins C3a and C5a all
contain a terminal arginine which is cleaved by circulating carboxypeptidase B
rendering them biologically inactive. The activity of this enzyme in the plasma
would presumably influence the contribution of these various peptides in an
acute anaphylactic-type response.
Anaphylactic transfusion reactions associated with anti-IgA antibodies
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have received particular attention (Schmidt, Taswell and Gleich, 1969; Vyas
et al, 1969). These can be either class-specific antibodies found exclusively in
individuals with IgA deficiency or allotype-specific (anti-Am) antibodies in
multitransfused patients with normal serum IgA levels (Nadorp et al, 1973).
The occurrence of total IgA deficiency has been estimated to be about one in
700 normal individuals. These people occasionally develop circulating anti-
IgA antibodies even though they have not received prior transfusions. The
associated reactions to plasma are usually mild but occasionally anaphylactic-
type reactions occur which can be life-threatening.
The term 'anaphylactic-like' has been used up to now to distinguish these
from classical anaphylactic reactions mediated by IgE. The exact significance
of tissue-sensitising antibody in blood transfusion reactions is not known but
the administration of plasma from 'allergic individuals' does carry the risk of
untoward reactions and was in fact one of the earliest recorded examples of
transfusion complications. In 1919 Ramirez described the case of a person who
developed acute bronchospasm whilst driving in an open horse-drawn
carriage several weeks after receiving a transfusion of blood. The donor was
subsequently found to be highly allergic to horse hair and thus had passively
transferred this sensitivity by his plasma to the previously 'non-allergic'
recipient. It is now appreciated that this antibody is of the IgE class and has
the capacity of binding firmly to cells of the mast cell/basophil series. Follow¬
ing the incubation of cell-bound IgE with specific antigen a biochemical
mechanism is initiated which leads to the release of a number of pharmaco¬
logical mediators including histamine, slow-reacting substance (SRS-A) and
eosinophil chemotactic factor of anaphylaxis (ECF-A) (Austen, 1974; Kay,
1974). Thus the administration of blood from an allergic donor can confer
IgE-mediated hypersensitivity to the recipient. This may have particular
significance following infusion of plasma from donors with certain forms of
drug hypersensitivity. Total levels of serum immunoglobulin E have been
measured in multitransfused patients and shown to be elevated. There is no
real evidence, however, that these recipients are at any particular risk in
developing anaphylactic reactions or other manifestations of hypersensitivity
(Cartron et al, 1973).
The occurrence of amyloidosis has been described in association with
multiple transfusions (Sharma and Geer, 1970; Prentice et al, 1971). It is
appreciated that persistent antigen stimulus in experimental animals leads to
amyloidosis and that a similar situation may occur in multitransfused humans.
Although the nature of amyloid is not known it has been suggested that it
may be derived from the light chains of immunoglobulins.
Purified albumin solution is usually a safe and effective form of therapy but
there have been some reports relating to adverse effects of this preparation on
the circulation (Torda et al, 1973; Izaka et al, 1974). This has been attributed
to the presence of a bradykinin-like activity in certain batches of albumin
preparation thought to have been formed during the manufacturing process.
This is of little clinical importance in individuals requiring a limited amount
of purified albumin since the bradykinin is presumably inactivated by circulat¬
ing carboxypeptidase B. Individuals requiring large amounts of this prepara¬
tion, especially those undergoing cardiac bypass surgery and other situations
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where the solution is given rapidly, may be at risk in developing hypotension
and other haemodynamic changes.
TRANSFER FACTOR
Transfer factor is a dialyzible extract from human leucocytes which has been
given to patients with a wide variety of disorders including immunodeficiency
states, chronic disseminated infections and certain neoplasms (reviewed by
Basten et al, 1975; Grob et al, 1975). Although there is very convincing
evidence of the usefulness of transfer factor in the treatment of certain well-
defined conditions such as chronic mucocutaneous candidiasis its efficacy still
awaits critical analysis by controlled clinical trials. The agent has an estimated
molecular size of approximately 5000 daltons and contains a polypeptide and
oligonucleotide. These consist of approximately 12 amino acids with three to
four RNA bases. Generally speaking transfer factor has proved to be remark¬
ably free from side-effects. There is occasionally pain and erythema at the site
of injection which can be accompanied by a transient pyrexia. The administra¬
tion of large amounts of transfer factor has not been associated with any
detectable biochemical abnormalities.
Two patients, one with combined immunodeficiency and the other with the
Wiskott-Aldrich syndrome, developed a polyclonal gammopathy following
the administration of transfer factor. These gammopathies may have been a
manifestation of the underlying disease and emphasise the need to subject the
use of transfer factor to a critical clinical appraisal.
PHARMACOLOGICAL AGENTS IN BLOOD PRODUCTS
The potential danger of transfusing plasma from individuals with drug hyper¬
sensitivity has been discussed above. The indications for refusing donors tends
to vary between blood transfusion centres. In addition to antibiotics it is prob¬
ably prudent to refuse donations for therapy from individuals taking regular
medication with agents such as hypotensive drugs. Aspirin is a difficult
problem since many individuals could be unaware that they are taking aspirin
contained in proprietary preparations. Therefore, whilst in theory a platelet
donation from an individual taking aspirin would be contraindicated due to
its capacity to aggregate the platelet, this does not seem in practice to represent
a major therapeutic problem since most patients receive pooled platelet
preparations from several donors.
It should be emphasised that although a blood donation may be unsuitable
for therapy the plasma may still be of use as a source of reagents and this must
be taken into account when refusing donors. Such reagents include anti-A and
anti-B red cell antigens for use in red cell serology and plasma or serum as a
source of tissue culture medium in tests of lymphocyte reactivity.
The practice of introducing drugs into the blood packs prior to transfusion
is to be strongly discouraged. For example, when ethacrynic acid was mixed
with whole blood this was shown to lead to haemolysis of red cells in vitro in
concentrations above 1 mg/ml (Da Costa andWhite, 1973). All pharmaceutical
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agents have the potential capacity of leading to permeability changes across
the red cell membrane and, furthermore, the introduction of any agent into
blood collection bags carries the risk of bacterial contamination.
The use of phthalic acid esters in the manufacture of plastics used for the
storage of blood has given concern in terms of its probably harmful long-term
effects. These compounds have been shown to be teratogenic in experimental
animals and manufacturers are attempting to provide disposable plastic blood
collection bags which do not contain these compounds.
Hypersensitivity to thimerosal, used as a preservative in gamma globulin
preparations, has also been described (Mackenzie and Vlahcevic, 1974).
THE INVESTIGATION OF TRANSFUSION REACTIONS
As discussed above transfusion reactions having an 'immunological mechan¬
ism' are most likely to occur in individuals who have been sensitised by pre¬
vious transfusions or pregnancies. In general severe reactions accompanied by
symptoms during, or immediately after, infusions are usually due to massive
red cell destruction or bacterial contamination. Infected fluids often cause
severe rigors with circulatory collapse. Rigor with loin pain, headache, renal
impairment and jaundice is suggestive of a haemolytic reaction. An acute
anaphylactic reaction (see above) can cause dyspnoea, chest pain, urticaria,
pruritus and circulatory collapse. A mild transient pyrexia is often the only
symptom of incompatibilities associated with leucocyte and plasma (anti-
allotype) antibodies.
It is important to check immediately that the correct blood or blood product
has been given to the recipient. The need for scrupulous checking by technicians
and doctors has already been stressed and it is also necessary to enquire
whether donor blood has been overheated, frozen, stored too long and to
determine if it is infected (see below). Such mishandlings of blood will often be
apparent by the appearance of free haemoglobin in the donor blood pack.
For a comprehensive investigation of a transfusion reaction the laboratory
will require a pre- and post-transfusion sample of the recipient's blood in
addition to the samples used for cross-matching. The remainder of the donor
blood will also be required even if only the fluid in the giving set is all that is
available.
All blood samples should be regrouped for ABO and D antigens and the
red cell compatibility tests, using simple agglutination tests, should be
repeated to exclude a laboratory error. If there is still no evidence of in¬
compatibility the more sensitive autoanalyser procedure can be employed to
detect 'immune' red cell antibodies* in recipient serum. The autoanalyser
* The term 'immune' antibody is red cell serology jargon hallowed by long usage. It is
used to describe those red cell antibodies produced as a result of previous transfusions,
pregnancy or the injection of foreign red cells and which are therefore apparently distinct
from 'naturally-occurring' antibodies for which the antigenic stimulus is unknown. Some
'naturally-occurring' antibodies, apart from those of the ABO blood group system, can give
positive reactions in ABO and D antigen compatibility testing as well as mediating red cell
transfusion reactions. A common example is 'naturally-occurring' antibodies of the Lewis
blood group system.
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system has approximately five to ten times the sensitivity of routine agglutina¬
tion tests. It is advisable to test for the presence of antibodies in both the
pre- and post-transfusion samples by the autoanalyser technique since with
relatively small amounts of antibody a positive reaction may be detectable only
in the pre-transfusion sample and absent in the post-transfusion specimen as
a result of adsorption by the transfused red cells. In these situations it is
advisable to have a further blood sample 10 to 14 days after the reaction in
order to determine whether the antibody has reappeared in the patient's
serum. The search for red cell incompatibility should be more strenuous if
there is evidence of red cell destruction as shown by haemoglobinaemia or
bilirubinaemia. The urine should also be examined for the presence of haemo¬
globin, urobilinogen and albumin. Serum haptoglobin binds free haemo¬
globin and so its level will fall following intravascular haemolysis. More
sophisticated investigations such as erythrocyte survival studies using 51Cr-
labelled red cells may be of value when serological tests are unhelpful but
where other clinical and laboratory evidence still points to a haemolytic
transfusion reaction.
Often more than one red cell antibody may be present in the serum of a
multitransfused individual or following pregnancies. These are often difficult
to identify with certainty but it is useful to perform a full red cell genotype on
recipient cells since this will exclude the presence of antibodies to the antigens
present. To this end it is necessary to use a panel of stock cells which ideally
should contain at least the following antigens: C, Cw, c, D, E, e, M, N, S, s,
P, Lua, K, k, Lea, Leb, Fya, Fyb, Jka, Jkb (Tovey and Gillespie, 1974). If a
transfusion reaction associated antibody is identified and confirmed the
appropriate genotyped blood will be required if further transfusions of red
cells are necessary.
It is essential that a full bacteriological examination be undertaken on the
donor blood or blood product and the attending medical personnel should be
asked specifically whether drugs or other agents were introduced into the
blood pack.
The investigation of reactions in association with white cell, platelet and
plasma protein antibodies is usually performed in specialised laboratories.
The presence of lymphocytotoxic and leucoagglutinating antibodies can be
detected by the methods outlined above. By and large, tests for platelet anti¬
bodies are difficult to perform due to the technical problems involved. An
antiglobulin consumption test is sometimes used as is direct aggregation of
platelets in the presence of platelet specific antibody using an aggregometer.
Such tests must be interpreted with caution since many agents are known to
aggregate platelets including immune complexes. Antibodies to plasma pro¬
teins, in particular allotypic determinants on IgG, require special reagents
and techniques for a comprehensive study. This is not usually required for
routine investigation of transfusion reactions but the reader is referred to
Natvig and Kunkel (1973) for a full account of the identification of human
immunoglobulin classes and subclasses and their genetic variants.
It should be emphasised that the technology and approach to the investiga¬
tions of blood transfusion reactions is a rapidly developing field and therefore
it is not possible to give a comprehensive list of investigations to be used as
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standard practice in transfusion centres. In practical terms the cause of the
more severe reactions, in contrast to milder adverse effects, is almost always
determined by the investigations outlined above.
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SUMMARY
Human peripheral blood basophils from two patients with unusually high baso¬
phil counts in association with chronic myelogenous leukaemia migrated in vitro
toward various chemotactic agents of human origin. These included supernatants
from sensitized lymphocytes challenged with specific antigen, diffusates from lung
fragments challenged with pollen antigen E, the enzyme plasma kallikrein, and
two complement derived agents, C5a and C567. Thus, chemotaxis in vitro, a
previously unreported property of human basophils, has been observed, although
none of the agents tested produced a selective chemotactic response.
INTRODUCTION
The ability of neutrophils, eosinophils and mononuclear cells to react in chemotaxis has
been reported by several workers (Boyden, 1962; Kay & Austen, 1971; Ward, 1968). The
capacity of basophil leucocytes to respond to a chemotactic stimulus has been difficult to
study since the cell is not readily available in high concentrations. We have had the oppor¬
tunity to study the chemotactic response of leucocytes of two patients with chronic myelo¬
genous leukaemia who both had an unusually high percentage ofcirculating basophils. Known
chemotactic agents of human origin, including supernatants from lymphocytes challenged
with specific antigen (Ward, Remold & David, 1970), diffusates from lung fragments
challenged with antigen E (Kay & Austen, 1971), the plasma enzyme kallikrein (Kaplan,
Kay & Austen, 1972), a fragment cleaved from the fifth component of complement (C5a)
(Ward & Newman, 1969) and the trimolecular complex of the fifth, sixth and seventh
components of complement (C567) (Lachmann, Kay & Thompson, 1970) were examined for
their ability to attract in vitro the cells of these two patients.
MATERIALS AND METHODS
Chemotactic factors
The preparation of supernatants from sensitized lymphocytes challenged with specific
Correspondence: Dr A. B. Kay, Department of Respiratory Diseases, City Hospital, Greenbank Drive,
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antigen, the source of streptokinase-streptodornase (SKSD) and purified protein derivative
of tuberculin (PPD) used as antigens, and the method of testing for macrophage migration
inhibitory factor (MIF) using guinea-pig macrophages as target cells have been described
(Rocklin, Meyers & David, 1970). The lymphocytes from two normal human donors, A
and B, were separated from 60 ml of peripheral blood and cultured for 3 days in the presence
or absence of antigen. The cell-free supernatants were removed each day, and fresh medium
was added. Each sample gave a final pooled volume of between 12 and 14 ml. After extensive
dialysis against saline and then water, the supernatants were lyophilized and reconstituted
in Hanks' solution. The supernatants from donor A and donor B were concentrated 2-5 and
seven times, respectively. The materials were tested for chemotaxis using 0-5-ml volumes.
A diffusate was prepared from human lung passively sensitized with serum from a
ragweed sensitive individual and challenged with ragweed antigen E in Tyrode's solution
(Kay & Austen, 1971). The 3-ml diffusate from 300 mg of lung fragments contained hista¬
mine, slow reacting substance of anaphylaxis (SRS-A) and eosinophil chemotactic factor
of anaphylaxis (ECF-A). Volumes of 0-8 ml were used in the chemotactic chambers.
Preparations of highly purified human prekallikrein and Hageman factor fragments were
incubated in phosphate buffered saline to yield kallikrein as described (Kaplan et al., 1972;
Kaplan & Austen, 1970), and assayed for chemotaxis in volumes of 0-25 ml.
Human C5 was prepared by the method of Nilsson & Miiller-Eberhard (1965). C5a was
generated by incubating 50 pg of C5, contained in potassium phosphate buffer with added
calcium at pH 7-8, with 10 ^g of trypsin (Mann Research Laboratories) for 10 min at
30°C, after which the reaction was terminated by adding 5 /rg of soybean trypsin inhibitor
(Mann Research Laboratories). The amount of soybean trypsin inhibitor (SBTI) used was
that which prevented the action of trypsin on benzoyl DL arginine p-nitroanilide at the same
ratio of enzyme to inhibitor under conditions previously described (Eriksson, 1965). For
chemotaxis, trypsinized or untreated C5 was tested in 0-15-ml volumes each containing
20 ng of protein. As a further control, equivalent amounts of trypsin and SBTI were used.
With the cells from patient 2 partially purified C5a was employed. Two millilitres of tryp¬
sinized C5, prepared as described above, were applied to a 3 x 85-cm column of Sephadex
G-100, using conditions previously described for the isolation of C3a (Bokisch, Muller-
Eberhard & Cochrane, 1969). Three millilitre-fractions were collected. When alternate
fractions were tested for chemotaxis of human peripheral blood leucocytes, activity appeared
as a single peak shortly after a cytochrome C marker. Two-tenths millilitre from the tube
containing the most chemotactic activity was used for basophil chemotaxis studies.
The trimolecular complex, C567 was made by incubating purified C56 with C7, as
described in the 'reactive lysis' procedure (Thompson & Lachmann, 1970; Goldman,
Ruddy & Austen, 1972). For the chemotactic experiments, 0-005 ml of C56 in veronal
buffered saline at pH 7-5 containing 4-7 haemolytic units per ml and 0 05 ml of a 1 in 500
dilution of C7 in 0-1 m acetate buffer at pH 6-0 containing 60,000 haemolytic units per ml
were employed (Goldman et al., 1972).
Chemotactic assay
Chemotaxis was measured by a modification of the Millipore technique previously
described (Kay, 1970). Blood was drawn into heparin and the red cells were sedimented
with 6% Dextran (Kay & Austen, 1971). The leucocyte-rich supernatant was centrifuged
to obtain the white cells which were washed twice in Hanks' solution and resuspended in
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Hanks' solution containing 0-5% ovalbumin at a final white cell concentration of 2x 106
per ml. The final volume in the test compartment was brought to 1 ml. After the incubation
period, the Millipores were removed, rinsed in Hanks' solution and immersed for 20
sec in a mixture of 1 part absolute ethanol and 1 part saturated mercuric chloride. After
washing for 3 min in running tap water, the Millipores were stained for 5 min in 1 % aqueous
toluidine blue. Following a further 3 min wash in tap water, the Millipores were dehydrated,
cleared and mounted as previously described. Basophils were counted using a high power
(x 90) oil immersion objective; the basophil chemotactic count was expressed as the total
count of ten fields.
Patients
Patient 1 is a 57-year-old white male. A diagnosis of chronic myelogenous leukaemia was
made in April, 1966. At the time of the investigation he was undergoing an acute blastogenic
crisis. His total white cell count was 62,000/mm3 of which 25% were mature basophils,
35% immature basophils, 10% promyelocytes and 30% mononuclear cells. Apart from
busulphan, 8 mg/day, he was receiving no other medication. Following venipuncture for
chemotactic studies, he was given, intravenously, cytosine arabinoside, daunomycin and
vincristine in doses of 2 mg, 1 mg and 1-5 mg/kg of body weight, respectively. Blood was
drawn for further chemotactic studies 18 hr later.
Patient 2 is a 68-year-old white female. A diagnosis of chronic myelogenous leukaemia
was made in April, 1969. At the time of the investigation her white cell count was 23,000/
mm3 of which 38% were basophils, 45% neutrophils, 12% blast cells, 1% metamyelocytes,
1% myelocytes, 2% lymphocytes and 1% eosinophils. She was receiving 6-mercaptopurine,
50 mg twice a week, and allopurinol, 100 mg twice a day.
RESULTS
The granulocytes from patient 1 consisted entirely of basophils or their precursors and thus
it was possible to study basophil chemotaxis using a filter of 3-/<m pore size since the only
migrating cells were mature or immature basophils. The circulating white cells in Patient 2
were predominantly neutrophils and using a filter of 3-jum pore size, neutrophils preferentially
migrated with no observable basophil chemotaxis. With a filter of 8-0-pm pore size basophil
chemotaxis could be demonstrated with the cells from patient 2, although there were
also high neutrophil counts.
The chemotactic response of human basophils to human lymphocyte supernatants is
shown in Table 1. Supernates from lymphocyte donors A and B were tested against the cells
from patients 1 and 2, respectively. Donors A and B both had strongly positive delayed-type
skin reactions to 5 units of SKSD but reacted weakly to 0-1 ml of intermediate strength
(0-001 mg) of PPD. Lymphocytes from donor B produced MIF following culture with
SKSD. No MIF activity was detected when cells from donor B were incubated with PPD.
MIF was not assayed with cells from donor A. When tested for chemotaxis, basophils from
both patients migrated towards the supernatants of lymphocytes of donors A and B follow¬
ing incubation with SKSD. Lymphocyte supernatants from the PPD culture gave little or
no chemotaxis. Samples of SKSD, PPD or medium alone or cells incubated with medium
alone did not evoke basophil chemotaxis with cells from either patient.
A human lung diffusate containing ECF-A (Kay & Austen, 1971), 600 ng of histamine and
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Table 1. Chemotactic activity of human lymphocyte supernatants
for human basophils
Lymphocytes Lymphocytes
+ SKSD + PPD
Patient 1*
Basophil chemotaxis 20 0
Patient 2*
Basophil chemotaxis 39 12
Macrophage migration (%)t 61 91
* Supernatants from the lymphocytes of donors A and B were
used to attract cells from patients 1 and 2, respectively.
t Average value from two populations of guinea-pig macro¬
phages.
200 units of SRS-A per ml was chemotactic for the basophils from both patients. The cells
from patients 1 and 2 gave chemotactic counts of 18 and 26 respectively, whereas no re¬
sponse was observed to antigen E alone or to diffusate from tissue not antigen challenged.
Neither the fragments derived from active Hageman factor or highly purified pre-
kallikrein were chemotactic for basophils when tested alone (Table 2). When these factors
were incubated together bradykinin was generated from heat-inactivated plasma, indicating
conversion of prekallikrein to kallikrein, and the mixture was chemotactic for basophils
from both patients 1 and 2.
Trypsinized C5, to which SBTI had been added, was chemotactic for basophils from
patient 1 whereas no migration was seen with untreated C5 or trypsin and SBTI alone. The
basophils of patient 2 migrated toward partially purified C5a but not toward untreated C5
(Table 3).
Table 2. Generation of chemotactic activity for human basophils by activation of
prekallikrein
Prekallikrein
Hageman factor and Hageman
Prekallikrein fragments factor fragments
Patient 1
Basophil chemotaxis 0 0 36
Total bradykinin generated
from heat inactivated
plasma Og) 0 0 2 10
Patient 2
Basophil chemotaxis N.D. N.D. 35
Total bradykinin generated
from heat-inactivated
plasma (//g) 0 0 118
N.D. = not done.
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Table 3. The chemotactic activity of trypsinized








Partially purified C5a 19
Untreated C5 2
Table 4. Generation of chemotactic activity
for human basophils following interaction of
C56 with C7
Basophil chemotaxis
C56 CI C56+ C7
Patient 1 10 0 20
Patient 2 4 0 20
Preparations of C56 and C7 had little chemotactic activity when tested alone. When these
factors were incubated together to form C567, the complex prepared unsensitized sheep red
blood cells for lysis by C8 and C9 (Thompson & Lachmann, 1970; Goldman et at., 1972)
and was chemotactic for the basophils from both patients (Table 4).
DISCUSSION
The capacity of basophils to respond chemotactically to supernatants from lymphocytes
incubated with specific antigen (Table 1), a diffusate from sensitized lung incubated with
ragweed antigen E, the plasma enzyme kallikrein (Table 2) and two complement-derived
factors, C5a (Table 3) and C567 (Table 4), has been demonstrated using cells from two
patients with unusually high basophil counts. Although directional basophil migration
through the entire thickness of the Millipore was observed, the overall chemotactic counts
were low. In previous studies (Kay & Austen, 1971; Kaplan et at., 1972), chemotaxis was
expressed as mean cell counts per high power field whereas in the present report the data are
presented as the total count of ten high power fields. Of interest is that a few hours after
blood was drawn from patient 1, therapy was commenced with several antimitotic agents;
the following day his cells did not respond in chemotaxis.
No evidence was found for a selective basophil chemotactic agent since these cells
responded to all the agents tested. The preparations of kallikrein, C5a and C567 were puri-
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fled whereas the lymphocyte supernatants and the lung diffusate contained multiple bio¬
logical agents which may have influenced the identification of a specific basophil chemo-
tactic agent.
When attempting to relate the in vitro observations described with clinical situations, it
may be noted that, apart from neoplastic disorders, there have been few reports of condi¬
tions associated with an increase in the number of tissue basophils. High basophil counts
have been observed in contact allergy (Dvorak & Mihm, 1972), the histological picture being
similar to cutaneous basophil hypersensitivity described earlier in the guinea-pig (Dvorak
et at., 1970). This phenomenon is thought to be a form of delayed-type hypersensitivity
produced under special conditions of immunization. The ability of basophils to migrate
towards an anaphylactic diffusate is of interest in view of the recent report that basophil
infiltration is a late event in immediate-type skin reactions in certain atopic individuals
(Felarca & Lowell, 1971).
The significance of the capacity of kallikrein, C5a and C567 to attract basophils is not
known. It should be noted that with the cells from both patients the in vitro conditions were
optimal for basophil migration since the basophil was only recognizable granulocyte in
patient 1 and in patient 2 a large pore size was used. Our recent data on cell selectivity with
the eosinophil suggest that ECF-A, present in a high concentration, will attract the neutro¬
phil when eosinophils are absent or comprise a very small percentage of the total cell popula¬
tion. Thus, it is suggested that a broad specificity of chemotactic factors can be shown when
conditions for migration are optimal and when other cells which may be preferentially
attracted are absent.
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A PREALBUMIN ACTIVATOR OF PREKALLIKREIN*
III. Appearance of Chemotactic Activity for Human Neutrophils
by the Conversion of Human Prekallikrein to Kallikrein
By ALLEN P. KAPLAN,! A. B. KAY,§ and K. FRANK AUSTEN
{From the Departments of Medicine, Harvard Medical School and
the Robert B. Brigham Hospital, Boston, Massachusetts 02120)
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The generation of bradykinin in human plasma is initiated by the activation
of Hageman factor (1-3). Activated Hageman factor and a series of fragments
derived from activated Hageman factor by digestion with the fibrinolytic
enzyme plasmin lead to the subsequent conversion of prekallikrein to kallikrein
(4, 5). The smallest of the Hageman factor fragments is stable, has a mol wt of
approximately 30,000-35,000, and appears to be the primary activator of
prekallikrein having six times greater prekallikrein-activating activity than
the parent Hageman factor molecule. Cleavage of the substrate kininogen by
kallikrein leads to the elaboration of the permeability factor bradykinin (6).
In order to explore further the potential participation of the kinin-generating
system in the inflammatory response, certain of the various components were
examined for chemotactic activity. The generation of chemotactic activity
specific for human neutrophils is shown to result from the conversion of pre¬
kallikrein to kallikrein. Evidence is also presented that both the chemotactic
activity and bradykinin-generating activity are dependent upon the integrity
of the active site of kallikrein.
Materials and Methods
Bradykinin triacetate (Sandoz Pharmaceuticals, Basel, Switzerland, or New England Nu¬
clear Corp., Cambridge, Mass.) was used as the standard for native bradykinin. Antisera to
IgG, IgA, IgM, /3-lipoprotein, transferrin, albumin, and whole human serum were purchased
from Behring Diagnostics Inc., Woodbury, N. Y. Antiserum to human k and X Bence Jones
proteins was obtained from Melpar Inc., Falls Church, Va. Hexadimethrine (polybrene) was
a gift of Dr. Floyd Mclntire of Abbott Laboratories, North Chicago, 111. Plasma throm¬
boplastin antecedent (PTA)'-deficient plasma containing less than 1% of normal PTA activ-
* Supported by grants AI-07722 and AM-12051 from the National Institutes of Health, and
a grant from The John A. Hartford Foundation, Inc.
! NIH Special Research Fellow (2 F03 AI 42810-03).
§ T. K. Stubbins Research Fellow, Royal College of Physicians of London; recipient of a
Wellcome Research Travel Grant and a McCunn (Medical Research Traveling) scholarship.
1 Abbreviations used in this paper: DFP, diisopropyl fluorophosphate; ECF-A, eosinophil
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ity was supplied by Dr. Anthony Britten (Boston, Mass.). Plasma thromboplastin component
(PTC)-deficient plasma containing 2% normal PTC activity was obtained from Sera-Tec Bio-
logicals, New Brunswick, N. J. Diisopropyl fluorophosphate (DFP) was a product of Aldrich
Chemical Co., Inc., Milwaukee, Wis. Tosyl-l-lysine chloromethvl ketone (TLCK) was ob¬
tained from Cyclo Chemical Division of Travenol Laboratory, Los Angeles, Calif. Ampholine
carrier ampholytes for use in isoelectric focusing were purchased from Microbiological Associ¬
ates Inc., Bethesda, Md. Ovalbumin 5X crystalized was a product of Pentex, Kankakee, 111.
Fractionation Procedures
Serum was drawn for the isolation of active enzymes of the kinin-generating system and was
processed as previously described (4). Diethylaminoethyl (DEAE)-cellulose chromatography,
carboxymethyl (CM)-cellulose chromatography, Sephadex G-100 gel filtration (Pharmacia
Fine Chemicals, Inc., Uppsala, Sweden), and disc gel electrophoresis at pH 9.3 were performed
as previously described (4, 5).
Plasma was prepared for the isolation of proenzymes of the kinin-generating system as
follows. 100 ml of blood were collected in plastic tubes containing 9 mg of disodium ethylene-
diaminetetraacetate (EDTA) and 3.6 mg of hexadimethrine in 0.1 ml of 0.15 m saline for each
10 ml of blood drawn. The tubes were immediately centrifuged at 900 g for 20 min at 4°C and
the plasma was separated using siliconized pipettes and dialyzed against 4 liters 0.01 m PO4
buffer, pH 7.8. The dialysis bag was opened hourly, the plasma centrifuged at 900 g for 10 min
at 4°C to remove any precipitated protein, and the supernatant plasma dialyzed for a total of
6 hr. Samples were concentrated by ultrafiltration using a UM-10 membrane (Amicon Corp.,
Lexington, Mass.) to 5-10 ml and then further concentrated by wall vacuum using Collodion
bags No. 100 (Schliecher and Schuell Inc., Keene, N. H.).
Gel Filtration.—A 2.5 X 150 cm column of Sephadex G-150 superfine was equilibrated with
0.02 m tris (hydroxymethyl) aminomethane (Tris) CI, pH 7.6. Samples of 2-3 ml were applied
and the column run by upward flow at 5 ml/hr. 2.5-ml fractions were collected.
A 5.0 X 100 cm column of Sephadex G-200 was equilibrated with 0.01 m PO4 buffer, 0.15 m
NaCl, pH 7.3. Samples of 4-5 ml were applied and the column run by upward flow at 10 ml/hr.
5-ml fractions were collected.
Quaternary Aminoethyl (QAE) Sephadex Chromatography.—A 5 X 30 cm column of QAE
Sephadex was equilibrated with 0.01 m PO4 buffer, pH 7.8. 30-ml samples dialyzed in 0.01 m
PO4 buffer, pH 7.8, were applied to the column. The column was washed with 500 ml of
equilibrating buffer and a linear salt gradient of 2 liters of equilibrating buffer and 2 liters of
equilibrating buffer containing 0.3 m NaCl was applied. The column was run at 60 ml/hr and
12-ml fractions were collected.
Sulfoethyl (SE) Sephadex Chromatography.—A 5 X 30 cm column of SE Sephadex was
equilibrated with 0.01 m PO4 buffer, pH 6.0. 30-ml samples dialyzed in 0.01 m PO4 buffer,
pH 6.0, were applied. The column was washed with 500 ml of equilibrating buffer and a linear
salt gradient of 2 liters of equilibrating buffer and 2 liters of equilibrating buffer containing
0.5 m NaCl was applied. The columns were run at 60 ml/hr and 12-ml fractions were collected.
Isoelectric Focusing in Gels.—Isoelectric focusing in 4% polyacrylamide gels containing from
pH 7 to 10 ampholytes was performed as described by Righetti and Drysdale (7). Samples of
200 jiil were each electrofocused in a series of gels; the ampholytes of one gel were removed by
electrophoresis and the gel was stained with Coomassie blue in 20% ethanol and 7% acetic
acid. The others were cut in 5-mm slices and eluted in 0.2 ml of distilled water overnight at
4°C. The pH of each slice was then measured and the eluates assayed.
chemotactic factor of anaphylaxis; PTA, plasma thromboplastin antecedent; PTC, plasma
thromboplastin component; QAE, quaternary aminoethyl; SE, sulfoethyl; TLCK, tosyl-L-
lysine chloromethyl ketone.
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Preparation and Assay of Components of the Bradykinin-Forming System.—Activated
Hageman factor was prepared by sequential fractionation of plasma on QAE Sephadex,
Sephadex G-100, CM-cellulose,and elution from disc gels after electrophoresis at pH 9.3 as
previously described (5, 8). The prealbumin Hageman factor fragments were prepared by
sequential chromatography of serum on DEAE-cellulose, Sephadex G-100, CM-cellulose, and
elution from disc gels after electrophoresis at pH 9.3 as previously described (5, 8). Preparation
of prekallikrein and kallikrein are described in the Results section.
Bradykinin was routinely determined by bioassay utilizing the isolated guinea pig ileum (9)
or by radioimmunoassay (10). Kallikrein, prekallikrein, and the prealbumin Hageman factor
fragments were determined as previously described (4). Heat-inactivated plasma utilized as a
source of the substrate kininogen was prepared as described by Jonasson and Becker (11).
The shortening of the partial thromboplastin time of PTA-deficient plasma was used as an
assay for PTA. Activated PTA was determined by incubating 0.05 ml of PTA source with 0.05
ml cephalin reagent (12) and 0.05 ml of PTA-deficient plasma for 2 min at 37°C. 0.05 ml of
0.05 m CaCh was added and the clotting time determined at room temperature. The tubes
were tilted each minute and the end point defined as the time interval required for the clot to
adhere to the glass tube. Unactivated PTA was determined by incubation of 0.025 ml of PTA
source with 0.025 ml purified activated Hageman factor for 5 min at 37°C. 0.05 ml cephalin-
kaolin reagent and 0.05 ml of PTA-deficient plasma were then added and the mixture further
incubated at 37°C for 2 min. 0.05 ml 0.05 M CaCh was added and the clotting time determined.
Measurement of Chemotaxis.—Chemotaxis of human leukocytes was assayed by a modifica¬
tion of the Millipore technique of Boyden as previously described (13). Blood was drawn into
plastic syringes and transferred to plastic tubes containing 50 units of heparin/ml of blood.
The red blood cells were allowed to settle for 90 min at 37°C, after which the leukocytes were
removed and centrifuged for 5 min at 100 g. The cells were washed once in Hanks' solution and
resuspended in Hanks' solution containing 0.5% ovalbumin at pH 7.3. The cell count was
adjusted to 1.5 X 106 leukocytes/ml. Chemotactic experiments were performed using a 3.0 p
pore size; except where stated otherwise, donors of peripheral blood leukocytes were normal
volunteers. The 0.5% ovalbumin solution used as a suspending medium in the chemotactic
chambers did not contain active kallikrein or a substrate for kallikrein.
An anaphylactic diffusate from passively sensitized human lung challenged with ragweed
antigen E containing histamine, slow reacting substance of anaphylaxis (SRS-A), and an
eosinophil chemotactic factor of anaphylaxis (ECF-A) was prepared as described (14). In
experiments comparing the selective chemotactic activity of kallikrein and ECF-A, Tyrode's
solution in 0.5% ovalbumin was used as suspending medium both in the test and cell compart¬
ments. Most preparations of kallikrein were dialyzed at 4°C for 6-12 hr against Hanks'
solution. Some kallikrein preparations, contained in Tris HC1 buffer, were assayed directly, the
molarity of the solution in the test compartment being adjusted to that of Hanks' solution.
RESULTS
Chemotactic Activity Associated with Plasma Kallikrein.—Human serum
clotted in glass so as to activate Hageman factor is known to possess chemo¬
tactic activity (15, 16). In order to assess whether any of the chemotactic
activity so obtained was associated with the appearance of serum kalli¬
krein, 5 ml of human serum were fractionated by Sephadex G-200 gel filtration
as shown in Fig. 1. Three major peaks of chemotactic activity were observed,
the first located between the IgM and IgG peaks, the second along the descend¬
ing limb of the IgG peak, and the third with low molecular weight moieties
eluting subsequent to albumin. Assay of the column for kallikrein activity
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indicated a peak which was superimposable upon the second major peak of
chemotactic activity. A more highly purified preparation of kallikrein was
therefore prepared in order to further assess this association.
Human serum was dialyzed against 0.01 m P04 buffer, pH 7.8, and applied
to a column of DEAE-cellulose. The effluent is known to contain IgG (17),
kallikrein (18, 19), and activated PTA (20). Further fractionation by Sephadex
G-150 gel filtration permitted partial separation of these three proteins and the
fractions so obtained were assessed for chemotactic activity (Fig. 2). The
single peak of optical density at 280 mju represented primarily IgG as assessed
by Immunoelectrophoresis using anti-whole human serum. The peak of acti-
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Fig. 1. Chromatography of human serum on Sephadex G-200. After a preliminary assess¬
ment for kallikrein activity, the negative fractions were pooled into 100-ml lots, concentrated
to 5 ml, and assayed for kinin-generating activity while the positive region extending from
tubes No. 165 to 190 was divided into four portions, each concentrated to 5 ml and assayed
for bradykinin-generating activity as indicated. Mean cell count refers to the average of the
cell counts in five high power fields.
vated PTA was found in the ascending limb of the IgG peak and had an esti¬
mated mol wt of 170,000-175,000. The peak of kallikrein activity clearly
followed the IgG peak and had an estimated mol wt of 130,000. For chemo¬
tactic studies, the column fractions were pooled as follows: 1-40, 41-80, 81-120,
121-150, 151-157, 158-190, 191-220, 221-245, 246-300 and concentrated to
10 ml each so that the peak of activated PTA would be essentially free of
kallikrein. The chemotactic activity was found to overlap the peak of kallikrein
activity.
When the kallikrein-rich concentrate (Fig. 2) was assessed by disc gel electro¬
phoresis, the Coomassie blue stain revealed a single broad band in the 7-globulin
region (Fig. 3). An unstained gel was sliced in 2-mm sections, eluted in 0.5 ml
of 0.15 m NaCl, dialyzed against Hanks' solution, and assayed for kallikrein
activity and for chemotactic activity; both were located in the first two slices
as shown in Fig. 3. In addition, some chemotactic activity was found in slice 7.
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The majority of the cells which migrated in response to the various kallikrein
preparations in the experiments described above were neutrophils, only an
occasional eosinophil being noted. The chemotactic activity of kallikrein for
neutrophils was further investigated using peripheral blood leukocytes obtained
from a patient who had an eosinophilia of 70% in association with seropositive
rheumatoid arthritis. The chemotactic response to kallikrein was compared to
that obtained with the anaphylactic diffusate containing ECF-A. As shown in
Fig. 4, a dose response was obtained with each chemotactic factor; however
while ECF-A attracted primarily eosinophils, the kallikrein preparation
attracted only the patient's neutrophils. Bradykinin in concentrations of 1.0,


















Fig. 2. Sephadex G-150 superfine gel filtration of the DEAE-cellulose effluent obtained
with 0.01 m POj buffer, pH 7.8.
Chemotactic Activity Resulting from the Activation of Prekallikrein.—
Preparation and Properties of Human Prekallikrein.—30 ml of dialyzed
plasma containing hexadimethrine were applied to a column of QAE Sephadex.
The effluent contained IgG, as assessed by immunoelectrophoresis, had no
detectable active kallikrein and had only trace quantities of activated PTA.
When 5 /d of the effluent were incubated with 10 ytil of the purified Hageman
factor fragments and then assayed for bradykinin-generating activity after
incubation with 0.2 ml of heat-inactivated plasma, 100 ng of bradykinin were
generated, indicating that the preparation contained prekallikrein. Incuba¬
tion of 25 /d of the QAE Sephadex effluent with 25 /id of activated
Hageman factor shortened the partial thromboplastin time of PTA-deficient
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Fig. 3. Disc gel electrophoresis of the kallikrein-rich concentrate obtained from Sephadex
G-150. An unstained gel run simultaneously was sliced as indicated into IS equal sections,
eluted, and assayed for kallikrein and for chemotactic activity.
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VOLUME OF LUNG DIFFUSATE or KALLIKREIN PREPARATION, ml
Fig. 4. Comparative chemotactic assay of kallikrein and ECF-A utilizing the peripheral
blood leukocytes of a patient who had a 70% eosinophilia.
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effluent. The addition of activated Hageman factor alone to the PTA-deficient
plasma shortened the partial thromboplastin time from the control time of 28
min to 16 min. Addition of the effluent plus activated Hageman factor mixture
in the same amounts as noted above to PTC-deficient plasma gave no shortening
of the partial thromboplastin time.
The QAE Sephadex effluent containing IgG, prekallikrein, and unactivated
PTA was then subjected to chromatography on SE Sephadex as shown in Fig. 5,
resulting in separation of prekallikrein from the majority of IgG and from
unactivated PTA. Prekallikrein eluted between 0.17 and 0.19 m NaCl and was
(•) (°)
i /
40 80 120 160 200 240
TUBE NUMBER
Fig. 5. SE Sephadex chromatography of the QAE Sephadex effluent obtained with 0.01 m
PO4 buffer, pH 7.8.
activated by incubation with the Hageman factor fragments. The prekallikrein
peak was then pooled, concentrated, and further fractionated by Sephadex
G-150 gel filtration as shown in Fig. 6. When the prekallikrein peak was
pooled and concentrated, neither unactivated PTA nor activated PTA was
detectable. IgG, however, was still detectable by gel diffusion using anti-IgG or
anti-x chain antisera. This preparation was then examined by disc gel electro¬
phoresis and isoelectric focusing in gels. Analysis of the preparation by disc gel
electrophoresis revealed a faint broad band in the 7-globulin region. When an
unstained disc gel run simultaneously was sliced in 2-mm slices, eluted, and
assayed for prekallikrein, the activity was found only in the first two slices at
the top of the gel. When the same preparation was assessed by isoelectric
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focusing in polyacrylamide gels, a faint broad band was recognized extending
from pH 7.5 to 8.9, shown in Fig. 7. No other discrete bands were visible.
When an unstained gel run simultaneously was sliced, eluted, and assayed for
prekallikrein, prekallikrein was found between slices 5 and 9, which cor¬
responded to an isoelectric point ranging from pH 8.5 to 8.9, the peak being at
PH 8.7 (Fig. 7).
Chemotactic Activity.—500 pi of the Hageman factor fragments were incubated
with 250 pi of prekallikrein obtained at the SE Sephadex step (Fig. 5) for 5 min
at 37°C, diluted to 1 ml with Hanks' solution, and dialyzed against Hanks'
solution for 12 hr. 100 pi of the mixture incubated with 200 pi of heat-inac-
20 40 60 80 100 120 140 160 180 200 220
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Fig. 6. Sephadex G-150 gel filtration of prekallikrein obtained from SE Sephadex (Fig. 5).
tivated plasma generated 200 ng of bradykinin indicating conversion of the
prekallikrein to kallikrein. The same mixture was chemotactic for human
neutrophils as shown in Table I, Experiment 1. Controls consisting of 250 pi of
prekallikrein incubated with 500 pi of normal saline and 500 pi of the Hageman
factor fragments incubated with 250 pi of normal saline, processed identically,
did not generate bradykinin from heat-inactivated plasma and had no sig¬
nificant chemotactic activity. Experiment 2 shows a similar result utilizing
prekallikrein obtained from the Sephadex G-150 gel filtration step (Fig. 6).
Inhibition of Chemotactic Activity of Kallikrein.—The generation of bradykinin
by human kallikrein is dependent upon an enzymatic site which is inhibitable
by DFP (19, 21) through the action of this agent upon the hydroxyl group of a
serine residue. The effect of DFP as well as an active site histidine inhibitor,
TLCK, upon the chemotactic activity and the bradykinin-generating activity
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of kallikrein was examined. 300 /xl of kallikrein were made 10~3 m in DFP or
10~3 M in TLCK, the mixture incubated for 15 min at 37°C and dialyzed three
times against 500 ml of Hanks' solution for 12 hr. 700 /xl of Hanks' solution
were then added to each sample and the samples assayed for chemotactic and
kinin-generating activity. As a control, an equal quantity of DFP and TLCK
l_l I L J I I I L I I I I
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Fig. 7. Isoelectric focusing in 4% polyacrylamide gels of the prekallikrein-rich concen¬
trate obtained from Sephadex G-150 gel filtration (Fig. 6). An unstained gel run simultaneously
was sliced into 21 equal sections of 5 mm each and assayed for pH and prekallikrein.
were each added to 100 ^il of 0.02 m Tris CI, pH 7.6, the buffer in which the
kallikrein preparation was stored, and dialyzed three times against 500 ml of
Hanks' solution for 12 hr. 300 fx\ of kallikrein were then added, incubated for
15 min at 37°C, the volume brought to 1.0 ml with Hanks' solution, and as¬
sayed for chemotactic and kinin-generating activity. As shown in Fig. 8, DFP
treatment of kallikrein abolished both kinin-generating and chemotactic
activity (B), while removal of DFP from the buffer by dialysis before the
introduction of kallikrein had no effect upon these two functions (D). No effect
was seen with 10~3 m TLCK (C).
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A dose response experiment for inhibition of chemotaxis and bradykinin
generation by TLCK and DFP is shown in Fig. 9. The experiment was per¬
formed as described above except the incubation time of kallikrein with each
TABLE I


























* Prekallikrein obtained from SE Sephadex step,






Fig. 8. Effect of 10-3 m DFP and 10-3 m TLCK upon the chemotactic and bradykinin-
generating activity of kallikrein. hi) Kallikrein control. (B) Kallikrein made 10-3 M in DFP.
(C) Kallikrein made 10-3 m in TLCK. (D) Kallikrein added to dialyzed DFP solution. (E)
Kallikrein added to dialyzed TLCK solution.
inhibitor was 30 min. Longer incubation at this temperature resulted in non¬
specific loss of both kallikrein functions. No inhibition of either activity is
obtained with TLCK until a 10~2 m concentration is used. A dose response
inhibition of both activities was obtained with DFP between 0.25 X 10-4 m
and 1.0 X 10-3 m.
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In order to determine whether the inhibition of DFP is related to the active
site of kallikrein, an experiment was performed in which the action of DFP
upon prekallikrein and kallikrein was compared. 1 ml of prekallikrein obtained
from plasma by QAE Sephadex, SE Sephadex, and Sephadex G-150 chromatog-
MOLAR/TY DFP
Fig. 9. Dose response inhibition of both chemotactic and bradykinin-generating activity of
kallikrein utilizing TLCK and DFP.
raphy was incubated with 100 /d of Hageman factor fragments for 20 min at
37°C. The mixture was then divided in half, one portion was made 10~8 m in
DFP and both were further incubated at 37°C for 15 min, brought to 1 ml
volume with Hanks' solution, and dialyzed three times against 500 ml of
Hanks' solution for 12 hr. Two 500 aliquots of prekallikrein were first made
10-3 m in DFP, incubated at 37°C for 15 min, and dialyzed three times against
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500 ml of Hanks' solution for 12 hr. One portion was then activated by addition
of 50 yul of the Hageman factor fragments, the mixture incubated for 20 min at
37°C, and both aliquots were then brought to 1 ml volume with Hanks' solu¬
tion. Controls consisting of prekallikrein or the Hageman factor fragments
alone, each brought to the same final concentrations utilized above by the
addition of normal saline, were subjected to each incubation and dialysis step.
Each preparation was then assayed for bradykinin-generating and chemotactic
activity. As shown in Fig. 10, the prekallikrein preparation (A), the Hageman
factor fragments (B), and the mixture of prekallikrein and the Hageman factor
fragments which was then exposed to 10-3 m DFP (D) generated no bradykinin
□
A B C D E
Fig. 10. Comparison of the effect of DFP upon kallikrein and prekallikrein. (,4) Prekal¬
likrein preparation. (B) Hageman factor fragments. (C) Prekallikrein activated with the
Hageman factor fragments. (D) Prekallikrein activated with the Hageman factor fragments
and made 10~3 m in DFP. (E) Prekallikrein made 10—3 m in DFP, dialyzed, then activated
with the Hageman factor fragments.
from heat-inactivated plasma and possessed no chemotactic activity. Exposure
of prekallikrein alone to 10~3 m DFP generated no bradykinin from heat-
inactivated plasma and possessed no chemotactic activity. Exposure of pre¬
kallikrein to ICE3 m DFP followed by dialysis to remove the DFP and sub¬
sequent conversion to kallikrein by incubation with the Hageman factor
fragments (E) revealed 80% of the kinin-generating activity and 50% of the
chemotactic activity of prekallikrein which was activated without prior
exposure to DFP (C).
discussion
When human blood is clotted in glass, thereby activating Hageman factor,
the serum obtained has been shown to possess chemotactic activity (15). This
activity is partially destroyed by heating for 30 min at 56°C. Since activation
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of Hageman factor not only initiates the intrinsic pathway of blood coagulation
(22, 23) and the fibrinolytic system (24, 25) but also the kinin-forming sequence,
it seemed appropriate to evaluate the components of the kinin-forming system
as possible contributors to the chemotactic activity of normal serum. Fractiona¬
tion of normal serum on Sephadex G-200 revealed several peaks of chemotactic
activity of which one coincided with the peak of kallikrein (Fig. 1), the most
heat-labile component of the kinin-forming system (26).
The evidence that kallikrein is chemotactic for human neutrophils includes
the superposition of kinin-generating and chemotactic activity when partially
purified kallikrein is further fractionated by Sephadex G-150 gel filtration
(Fig. 2) and by electrophoresis in alkaline disc gels (Fig. 3). Further evidence
that chemotactic activity is a function of active kallikrein is provided by the
finding that conversion of prekallikrein to kallikrein by the Hageman factor
fragments is associated with the appearance of chemotactic activity whereas
neither prekallikrein nor the Hageman factor fragments alone exhibited such a
property (Figs. 5, 6, Table I). Although it seemed possible that the chemotactic
activity observed might be due to a small fragment formed during conversion
of prekallikrein to kallikrein, attempts to dissociate such a fragment from
kallikrein by rechromatography on G-75 at pH 3.5 failed to reveal chemotactic
activity except in association with the kallikrein peak. Furthermore, the
capacity of DFP to inhibit both chemotaxis and kinin generation (Figs. 8, 9)
is consistent with chemotaxis being an intrinsic function of the kallikrein
molecule itself.
Lewis has shown that intradermal injections of relatively high concentrations
of bradykinin (1-100 jug/ml) in the rabbit promotes the migration of leukocytes
(27). Of the components of the kinin-forming system thus far examined, the
Hageman factor fragments, prekallikrein, kallikrein, and bradykinin, only
kallikrein was chemotactic. Furthermore, kallikrein attracted neutrophils but
not eosinophils from a mixed leukocyte population, even when the suspension
contained 70% eosinophils (Fig. 4). In contrast, an eosinophil chemotactic
factor released from human lung sensitized with IgE and challenged with
specific antigen attracted eosinophils but not neutrophils under the same
experimental conditions (14) (Fig. 4).
The activation of Hageman factor by a variety of biologic materials such as
collagen (28, 29), sodium urate crystals (30), pyrophosphate crystals (30), l-
homocystine crystals (31), and human articular cartilage (32), and the capacity
of activated Hageman factor to convert prekallikrein to kallikrein either
directly or through its prealbumin fragments (5) offers a nonimmunologic,
readily activatable mechanism for the generation of a chemotactic principle
independent of the complement system. It is noteworthy that kallikrein is not
only chemotactic for human neutrophils but also leads to the generation of the
permeability factor bradykinin; two other chemotactic factors, fragments from
the third and fifth components of complement both promote leukocyte migra-
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tion in vitro (33, 34) and also increase vascular permeability by virtue of their
anaphylatoxic activity (35, 36). It may be that a change in vascular perme¬
ability plays a role in determining whether or not a chemotactic principle can
express this capability in an in vivo situation.
A series of esterases present in rabbit neutrophils, which play an essential
role in the chemotactic response, have been described (37-39). That the active
site of kallikrein is required for the expression of its chemotactic activity could
be explicable either by direct activation of one of these esterases or through a
substitution which bypasses an activation step utilized by nonenzymatic
chemotactic factors. The relatively high concentration of DFP utilized in the
inhibition experiments was necessitated by the requirement to inactivate
kallikrein at 37°C within a 15 min period; incubation of kallikrein beyond this
interval was associated with a loss in activity which reached 100% in 2 hr.
The histidine inhibitor TLCK, however, was inactive at the same concentra¬
tion and conditions (Fig. 9). The findings that the precursor form of the en¬
zyme, prekallikrein, tolerated a dose of DFP which completely inactivated
kallikrein (Fig. 10) is consistent with studies of other serine esterases in which
the precursor enzyme was resistant to inactivation (40, 41). Since both the
Hageman factor fragments and kallikrein are sensitive to inactivation by DFP
(19, 21, 42), the partial loss of activity experienced by the prekallikrein could
be attributed to residual DFP despite the extensive dialysis.
SUMMARY
Human plasma kallikrein has been shown to directly and selectively attract
human neutrophils from a mixed leukocyte population. The capacity of plasma
kallikrein to be chemotactic and to generate the nonapeptide bradykinin
was maintained during progressive purification. While neither highly purified
prekallikrein nor the prealbumin Hageman factor fragments were chemotactic
alone, their interaction so as to convert prekallikrein to kallikrein yielded both
chemotactic and kinin-generating activity. Both functions of kallikrein were
inhibited by treatment with diisopropyl fluorophosphate, indicating an es¬
sential role for the active site of the enzyme in the expression of its chemotactic
activity.
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Generation of Chemotactic Activity
for Leukocytes by the Action of
Thrombin on Human Fibrinogen
The formation of the fibrin gel during the final stages of blood
coagulation results from the action of thrombin on fibrinogen.
Thrombin is a limited protease, which cleaves several small
peptides from fibrinogen. These fibrinopeptides have been
designated A, AP, AY and B, and are recognized on the basis
of their electrophoretic mobility1.
When human blood is clotted on glass so as to activate
Hageman factor the serum possesses chemotactic activity for
human peripheral blood leukocytes2. Following passage of
the serum through a column of 'Sephadex G-200' several peaks
of chemotactic activity were observed, one of which was
subsequently identified as the enzyme kallikrein. Material of
low molecular weight accounted for a substantial part of the
1 1 1 1 i
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Clot supernatant (ml.)
Fig. 1 Chemotaxis of human leukocytes towards a clot super¬
natant prepared from thrombin and fibrinogen. Thrombin and
fibrinogen at equivalent concentrations gave no chemotactic
activity.
chemotactic activity of normal serum which we considered
may be a consequence, in part, of the release of fibrinopeptides
(molecular weights approximately 2,000 each). We therefore
prepared clot supernatants by incubating fibrinogen with
thrombin and examined their capacity to attract human
peripheral blood leukocytes in vitro.
Lyophilized human fibrinogen (Kabi, Stockholm) containing
95% of clottable protein was reconstituted in water to a concen¬
tration of 14 mg ml.-1 of protein and dialysed against phos¬
phate buffered saline (PBS). Bovine thrombin (Parke-Davis,
Michigan) was purified by 'Sephadex G-200' chromatography.
It eluted as a single peak and was assayed by its ability to clot
human plasma in the presence of calcium. One part of
thrombin was added to 24 parts of fibrinogen and the concen¬
tration of thrombin was adjusted to give a clotting time of
.approximately 45 s. The clot was left for 5 h at room tempera¬
ture or overnight at + 4° C. The fibrin gel was broken up with
scalpel blades and centrifuged at 15,000#- for 45 min. The
supernatant was either assayed immediately or kept frozen at
— 20° C. Chemotaxis of human leukocytes was assayed by the
modification of the 'Millipore' technique of Boyden3.
Fibrinogen and thrombin, when tested alone, did not attract
leukocytes, but the clot supernatant possessed chemotactic
activity which was demonstrable in a dose-response fashion
(Fig. 1). Most of the migrating cells were neutrophils although
occasional eosinophils and monocytes were seen. The activity
present in the clot supernatant was unaffected by heating at
60° C for 30 min or 100° C for 5 min. By ultrafiltration with
membranes which retain molecules of a certain size and with
Fig. 2 Chemotactic activity generated by the action of contor-
trix enzyme on fibrinogen.
chromatography on 'Sephadex G-200' we showed that the
activity was associated with low molecular weight material.
The supernatants were desalted by passage through a column
of 'Sephadex G-25' in 0.1 M pyridine and the material, recon¬
stituted in water, was still active in chemotaxis. By high voltage
electrophoresis using conditions previously described4 the same
preparation was shown to contain fibrinopeptides A, AP and B.
Further evidence that the activity was generated by limited
proteolysis of fibrinogen was obtained with snake venoms which
selectively cleave fibrinopeptides A or B. A purified enzyme
from Agkistrodon rhodostoma (Arvin, Twyford Laboratories)
releases peptides AP, AY and A from fibrinogen and leads to
clot formation4. When a clot supernatant from fibrinogen
treated with 'Arvin' was assayed, no chemotaxis was found.
This was not due to an inhibitory effect of the 'Arvin' super¬
natant as it did not affect the activity of a supernatant prepared
from thrombin. When the purified procoagulant enzyme from
Ancistrodon contortrix contortrix (Sigma, Surrey) was incubated
with fibrinogen, chemotactic activity could be demonstrated.
Contortrix enzyme selectively cleaves fibrinopeptide B from
fibrinogen5. The contortrix venom was purified free of
fibrinolytic enzymes and their activators by 'Sephadex G-75'
chromatography, and its concentration adjusted so that when
0.2 ml. was added to 10 ml. of fibrinogen it gave a clotting time
of between 4 and 20 h. At intervals 1.2 ml. of the mixture
was removed, heated at 100° C for 5 min to precipitate the
fibrinogen and centrifuged to remove particulate matter. The
material obtained at 4 h was shown by high voltage paper
electrophoresis to contain fibrinopeptide B; other fibrino¬
peptides were not detected. Duplicate volumes of 0.5 ml. were
tested for chemotaxis. The time course of release of chemo¬
tactic activity is shown in the experiment depicted in Fig. 2.
Synthetic fibrinopeptide A (Schwarz/Mann, Orangeburg, New
York) was inactive whereas fibrinopeptide B was chemotactic
in a linear dose-response from 25 pg to 200 pg.
Further purification of the clot supernatant is required to
confirm the nature of the activity generated from fibrinogen.
Further, the contribution of other chemotactic agents released
into the clot supernatant under the conditions cited above is
still to be determined. Chemotactic activity for human
leukocytes can be generated by the action of thrombin or
contortrix enzyme on human fibrinogen, however, but not by
'Arvin'. In addition synthetic fibrinopeptide B but not
fibrinopeptide A attracts human leukocytes in vitro.
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The Identification of Fibrinopeptide B as a Chemotactic
Agent Derived from Human Fibrinogen
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Chemotactic activity for human peripheral blood leucocytes was generated by the
action of thrombin on human fibrinogen, a reaction known to release low molecular
weight fibrinopeptides. Following gel filtration of the clot supernatant most of the
activity eluted at the same Kd as synthetic fibrinopeptides. Fibrinopeptides present in
the clot supernatant were then identified and separated by high voltage electrophor¬
esis in two dimensions. Chemotactic activity was a property of fibrinopeptide B and
not of fibrinopeptides A, AP or AY. Supernatants prepared with contortrix venom,
which cleaves the B peptide, were also chemotactic whereas no activity was present
in supcrnatants prepared from Arvin venom which cleaves peptides A, AP and AY.
Synthetic fibrinopeptide B and a B analogue, i-glutamic acid, were found to be
chemotactic but not synthetic fibrinopeptide A. Thus chemotaxis of human
leucocytes represents a further biological activity of fibrinopeptide B.
In a preliminary study we found that clot supernatants, prepared by the action of thrombin
on human fibrinogen, were chemotactic for human peripheral blood leucocytes (Kay et al,
x973)- This reaction is known to generate the release of low molecular weight (approxi¬
mately 1500) fibrinopeptides A, AP, AY and B which are recognized on the basis of their
electrophoretic mobilities (Blomback et al, 1966). Evidence was provided that low molecular
weight material present in the clot supernatant contributed to its chemotactic property
(Kay et al, 1973).
In the present study we have identified fibrinopeptide B as a chemotactic agent by isolating
the peptide from a thrombin clot supernatant using electrophoresis in two dimensions. In
addition details are given of studies using snake venoms which cleave selectively either
fibrinopeptides A, AP and AY or B. We have also compared the abilities ofsynthetic fibrino¬
peptides A, B and a B analogue to attract human peripheral blood leucocytes.
MATERIALS AND METHODS
Preparation ofReagents
Thrombin. Approximately 5000 units of lyophilized bovine thrombin (Parke-Davis,
Correspondence: Dr A. B. Kay, Department of Respiratory Diseases, City Hospital, Greenbank Drive,
Edinburgh EH 10 5SB.
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Detroit, Michigan) were dissolved in 1 ml of distilled water and centrifuged at 10 000 g
for 30 min. The material was applied to a column ofSephadcx G-200 (95 x 2.5 cm) previously
equilibrated with phosphate buffered saline (PBS), pH 7.35, and 2 ml fractions collected.
Alternate tubes were assayed for thrombin activity by measuring the clotting time when
0.1 ml of the sample was added to 0.3 ml of human plasma in the presence of calcium.
Clotting activity eluted as a single peak corresponding to a molecular size of between
30 000 and 40 000.
Procoagulant enzyme from Ancistrodon contortrix contortrix. One hundred mg of Ancistrodon
contortrix contortrix venom (Sigma, Kingston, Surrey) were dissolved in 5 ml ofborate buffered
saline, pH 8.6, and applied to a column of Sephadex G-75 (100x2.5 cm) equilibrated in
the same buffer. Fractions of 5 ml were collected and each tube assayed for procoagulant and
fibrinolytic activity using an automated clot-lysis timer (Medicon (U.K.) Ltd). Procoagulant
activity eluted at V„ and at Kd = 0.3. The material eluting at V0 had no fibrinolytic activity
and was pooled and concentrated by ultrafiltration using a UM-10 membrane (Amicon
Corp., Lexington, Mass.).
Preparation of Supematants following Enzymatic Treatments ofHuman Fibrinogen
Thrombin supernatants. Method 1—Human fibrinogen (Kabi, Stockholm, Sweden) was
dissolved in distilled water to a concentration of 1% and dialysed against PBS at 4°C over¬
night. One part of diluted thrombin was added to 24 parts of fibrinogen giving a clotting
time of 45 s. The clot was stored for 5 hr at room temperature or overnight at +4°C. The
fibrinogen gel was broken up with scalpel blades and centrifuged at 15 000 g for 45 min.
Supernatants were either assayed for chemotaxis immediately or frozen at — 20°C.
Method 2—To prepare larger quantities for electrophorctic isolation of fibrinopeptides,
10 g of human fibrinogen, prepared by the method of Blomback & Blomback (1956), was
dissolved in 0.3 m ammonium acetate to a concentration of 2%. After dialysis against this
same buffer, an equal volume ofwater was added and the solution clotted as above. The clot
supernatant was rotary-evaporated to dryness and lyophilized overnight. To remove residual
buffer salts, the sample was heated in vacuo for 1-2 hr at 40°C. The residue was washed
repeatedly with 20 ml volumes of 0.05 m pyridine until the pH of the extract remained
above 5.6 (Blomback et al, 1966). To the pooled and concentrated extracts was added 1/5
vol of 30% TCA. After centrifugation the supernatant was extracted with water-saturated
ether until the pH was greater than 4. Pyridine was then added to raise the pH to 6 and the
solution concentrated for desalting on a G-25 column in 0.05 m pyridine. The Folin positive
peak eluting before the salt peak was concentrated by rotary evaporation. This material
containing the fibrinopeptides was then suitable for electrophoresis as described below.
Arvin supernatants. Arvin (Agkistrodon rhodostoma venom, Twyford Laboratories, London)
was diluted in PBS to give a clotting time of 10 min when added to 24 parts of 1% fibrinogen
(prepared by Method 1).
Contortrix supernatants. The contortrix venom was diluted in PBS so that 1 vol when added
to 24 vol of 1% fibrinogen (prepared by Method 1) released fibrinopeptide B within 2 hr
(as detected by electrophoresis) but gave no coagulation at 4 hr.
Gel-filtration ofclot supernatants. Ten to 15 ml of fibrinogen clot supernatants were desalted
on Sephadex G-25 as described above. Samples of 1-2 ml were applied to a 104x2.5 cm
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column of Sephadex G-75 equilibrated with 0.05 M pyridine. From alternate 8 ml fractions
1 ml was taken, lyophilized and redissolved in 2 ml of PBS. These solutions were tested for
chemotaxis either undiluted or diluted 1 in 4.
Electrophoresis. Vertical electrophoresis was performed as described by Ambler (1963)
using a pyridine-acetic acid-water buffer (25 :i :22s by vol for pH 6.5 and 1 :10: 89 for
pH 3.5). The coolants used were toluene for pH 6.5 and white spirit for pH 3.5. Salt-free
samples prepared as above, were applied to Whatman No. 3MM paper (57 cm x 45 cm) and a
potential gradient of 60 V/cm applied. Synthetic fibrinopeptides A and B and amino acids
were used as markers (Milstein & Milstein, 1968). After separation in the first dimension for
1.5 hr at pH 6.5, strips were cut from either side of the paper and sprayed with Sakaguchi
reagent (Leggett-Bailey, 1967). Sakaguchi positive spots were marked and the strips immersed
in 0.2% ninhydrin (in acetone) and dried at 6o°C. Paper containing fibrinopeptides located
by these methods was cut and sewn onto a second sheet ofpaper and separated in the second
dimension for 2.5 hr at pH 3.5. The fibrinopeptides were again located by Sakaguchi and
ninhydrin reagents by cutting strips from cither side of the paper. Fibrinopeptides AP and
AY were located as Sakaguchi and ninhydrin positive spots migrating in positions compatible
with their known structure (Blomback et al, 1966; Herzig et al, 1970). Each fibrinopeptide
was eluted in 0.1 N ammonia and individually passed through columns of Sephadex G-25
in 0.05 M pyridine. The peak of Folin positive material from each column run was pooled,
lyophilized and the residue dissolved in PBS. Each peptide was quantitatcd by the Sakaguchi
reaction (Shainoff & Page, i960) using an arginine-standard curve, diluted with PBS and
tested for chemotaxis.
Measurement ofchemotaxis. Chemotaxis ofhuman leucocytes was assayed by a modification
of the Millipore technique ofBoyden as previously described (Kay, 1970). The principle of
the technique is as follows. Two compartments are divided by a Milliporc filter. In the upper
or cell compartment a suspension ofcells rich in human peripheral blood leucocytes is placed.
In the lower, or test compartment, the agent being tested for chemotaxis is introduced. The
chcmotactic agent creates a gradient between the cell and test compartments thereby enabling
the cells to migrate through the thickness of the filter. Following an incubation period the
filter is removed, fixed and stained and the number of cells which have migrated through
the entire thickness of the filter are counted. The results are expressed as the mean cell count
of five high power (x 40) microscopic fields. The leucocyte-rich preparation was prepared
as follows. Blood from normal human volunteers was drawn into plastic syringes and trans¬
ferred to plastic tubes containing 20 units of heparin and 0.1 ml of 6% Dextran per ml of
blood. The red blood cells were allowed to settle at 37°C for 30 min after which the leucocyte
plasma was removed and centrifuged for 3 min at 100 g. The cells were washed once in
Flanks' solution and resuspended in Hanks' solution containing 0.5% ovalbumin at pH 7.2.
The cell count was adjusted to 2 x io6 leucocytes per ml. Chemotactic experiments were
performed using an 8.0 /im pore size and a 90 min incubation period.
RESULTS
Chemotactic Activity Generated by the Action of Thrombin on Fibrinogen
Supernatants prepared by centrifugation of the clot formed by the action of thrombin on
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Table I. The generation of chemotactic activity for human leucocytes
by the action of thrombin on human fibrinogen. In experiments 1-4 and
experiment 5 the dilutions of clot supernatants with Tyrode's solution
were 4:1 and 2:3 respectively.
Experiment
Chemotaxis (mean cell count)






human fibrinogen were found to be chemotactic for human peripheral blood leucocytes
(Table I). This was demonstrable in a dose-response fashion (Fig 1). Fibrinogen and thrombin
when tested alone were inactive (Table I). When clot supernatants were heated at 56°C for
30 min there was a slight loss of chemotactic activity (Fig 1).
In order to determine the nature of the chemotactic substance(s) generated by the inter¬
action of thrombin with fibrinogen, a concentrated clot supernatant was applied to a column
of Sephadex G-75. The major peak of chemotactic activity eluted at a distribution coefficient
(Kd) of 0.72. This peak was concentrated and re-applied to the same column and alternate
fractions tested for chemotaxis at two doses. Chemotactic activity eluted in the same position
and was demonstrable in a dose-response fashion. When synthetic fibrinopeptides were
applied to the column, they clutcd with the same Kd as the major chemotactic peak.
Volume of clot supernatant (^.l)
Fig 1. Chemotaxis of heated (o) and unheated (•) clot supernatants prepared by the action of
thrombin on human fibrinogen.
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The clot supernatant was then prepared for high voltage electrophoresis. The material
applied to paper was active in chcmotaxis indicating that the chemotactic agent(s) was
soluble in TCA. Fibrinopeptide A was identified by comparing its mobility with a synthetic
marker and by its positive reactivity with Sakaguchi and ninhydrin reagents (Fig 2). The A
peptide was inactive in chernotaxis at all doses (Fig 3). Fibrinopeptide B gives a negative
ninhydrin reaction but like the A peptide can be located with Sakaguchi reagent. Its mobility
was also determined with a synthetic marker (Fig 2). Chemotaxis or fibrinopeptide B was




















(1) Electrophoresis at pH 6 5
Fig 2. The separation of fibrinopeptides (FP) by high voltage electrophoresis in two dimensions. The
origin represents the point where the uncharged marker, taurine, migrated at the pHs indicated. A,
Gly, Val, e-DNP lys, B, Glu, XCFF and B (along the axes) indicate respectively the positions reached
by synthetic fibrinopeptide A, glycine, valine, epsilon-dinitro-phenol lysine, synthetic fibrinopeptide
B, glutamic acid, and xylene cyanol FF.
The peptides AP and AY were present in smaller and variable amounts. There was 110
evidence that they had chemotactic activity. Both neutrophils and eosinophils migrated
towards fibrinopeptide B in similar proportions to those present in the cell compartment
prior to migration.
Chemotactic Activity Generated by the Action of Snake Venoms on Fibrinogen
Further evidence that fibrinopeptide B is chemotactic was obtained using purified snake






Concentration of fibrinopeptides (^tmoL/mL)
0-3
Fig 3. Chcmotaxis of fibrinopeptide A (•) and fibrinopeptide B (a) separated by high voltage
electrophoresis prepared as in Fig 2. The points represent the mean result of five experiments.
80r
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Fig 4. Chemotaxis of clot supernatants prepared by the action of contortrix (•), thrombin (o) or
Arvin (a) on fibrinogen.
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venoms which selectively cleave either fibrinopeptides A, AP and AY or fibrinopeptide B
from fibrinogen. Arvin cleaves the A peptides and contortrix the B peptide.
Five ml volumes of 1% fibrinogen in PBS were incubated at time intervals from 15 min
to 4 hr with thrombin, Arvin and the procoagulant enzyme from contortrix. The reactions
were terminated by heating the mixtures at 85°C for 5 min, and the insoluble material
removed by centrifugation. In these experiments the dose of thrombin was adjusted to give
the same coagulation time as Arvin (10 min). No coagulation was observed with contortrix
at the termination of the experiment indicating that the A peptide was not released. Leuco¬
cytes migrated towards the supernatants prepared with contortrix and thrombin but not with
Arvin (Fig 4). When treated in a similar fashion alone, neither fibrinogen, contortrix, Arvin
or thrombin evoked chemotaxis. Arvin had no inhibitory effect 011 the chemotactic activity
of supcrnatants prepared from the action of thrombin 011 fibrinogen. Electrophoresis was
used to identify the fibrinopeptides released by each enzyme in the supernatants tested for
chemotaxis. With Arvin only the A peptides were identified, and with contortrix only
fibrinopeptide B. Electrophoresis of the supernatant obtained with thrombin indicated that
both fibrinopeptide A and B were released.
The Cheinotactic Activity of Synthetic Fibrinopeptides
Synthetic fibrinopeptides were tested for their capacity to attract human peripheral blood
leucocytes. Fibrinopeptides A, B and the [i-Glu] B analogue were tested at concentrations
between 0.015 /tmol/ml and 0.12 /tmol/ml. Chemotaxis was observed in a dose-response
fashion with fibrinopeptides B and [x-Glu] B but not with fibrinopeptide A (Fig 5).
<
A
0 015 0-03 0-06 0-12
Concentration of synthetic fibrinopeptides (^moL/mL)
Fig 5. Chemotaxis of synthetic fibrinopeptides B (•), [i-Glu] B (o) and A (a).
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DISCUSSION
Chemotactic activity for human leucocytes was generated by the action of thrombin on
human fibrinogen (Table I). The activity present in the clot supernatant was relatively
resistant to heat at 56°C and was demonstrable in a dose-response fashion (Fig 1). Following
gel-filtration of this material, a major peak of chemotaxis was observed with the same Kd
as synthetic fibrinopeptide markers indicating that this activity was associated with material
ofmolecular size approximately 1500. Fibrinopeptides were separated and identified by high
voltage electrophoresis in two dimensions (Fig 2). Only fibrinopeptide B possessed chemo¬
tactic activity for human peripheral blood leucocytes, no activity being observed with
fibrinopeptides A, AP or AY (Fig 3). In two experiments fibrinopeptide B gave weak or
negligible chemotaxis. This has been attributed to variations in the response ofthe target cells.
In these experiments low chemotactic counts with fibrinopeptide B were accompanied by
a low response to the normal serum control.
When the purified procoagulant enzyme from contortrix was incubated with fibrinogen,
chemotactic activity could be demonstrated in a dose-response fashion (Fig 4). Contortrix
enzyme selectively cleaves fibrinopeptide B from fibrinogen (Flerzig et al, 1970). Purified
Arvin releases, AP, AY and A from fibrinogen and leads to clot formation (Ewart et al,
1970). The clot supernatant from Arvin was inactive in chemotaxis (Fig 4).
Further evidence that fibrinopeptide B and not fibrinopeptide A was chemotactic was
obtained using synthetic human fibrinopeptides (Fig 5). Synthetic B was chcmotactic in a
dose—response fashion.
Chemotaxis, therefore, joins other biological activities associated with fibrinopeptide B
such as the potentiation of bradykinin-induced contraction of the isolated oestrous rat
uterus (Gladner et al, 1968) and prolonged rhythmic vaso-constriction (Colman et al, 1967).
It is probable that the biological activity associated with fibrinopeptide B is located at its
C-terminus since this part of the molecule is exposed following the action of thrombin and
other enzymes which cleave B from the (S polypeptide chain of fibrinogen. The parent mole¬
cule, with the N terminus exposed, was inactive in chemotaxis. Furthermore, in experiments
using a synthetic fibrinopeptide B analogue in which glutamic acid was substituted for
pyrrolidone carboxylic acid at the N terminus, there was no effect 011 the chemotactic activity
(Fig 5). It would be of interest to determine the species specificity of the chemotactic activity
of fibrinopeptides since these differ markedly in their amino-acid composition (Blomback
et al, 1965a).
The biological significance of the chemotactic activity of fibrinopeptide B is unknown but
it may play a part in the initial accumulation of leucocytes in vivo around the fibrin clot.
Fibrinopeptide B is released more slowly than the A peptide following the action of thrombin
on fibrinogen (Blomback & Vestermark, 1957) a situation which may favour a chemotactic
gradient.
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ABSTRACT Chemotactic activity for human peripheral blood leukocytes was
generated by the action of plasmin on human fibrinogen. When
plasmin digestion was stopped at time intervals up to 24 hours,
a small amount of activity was present at 15 and 30 min. corresponding
to the transient appearance of fragment Y. The activity contained
in the 24-hour digest was considerably higher and eluted from
Sephadex G-75 with molecules of approximately 30,000 daltons.
When purified X, Y, D and E were assayed individually for chemotaxis
only fragment Y was active but in relatively high concentrations.
Thus the chemotactic activity generated by the action of plasmin on
fibrinogen was mainly associated with one or more lower molecular
weight polypeptides and to a lesser extent with the Y fragment.
INTRODUCTION
A number of studies have shown that plasmic degradation of human
fibrinogen yields four major fragments designated X, Y, D and E in addition to
smaller peptide material (l,2,3). Fibrin/fibrinogen degradation products (FDP)
appear in body fluids in association with various clinical states (4,5)6,7) and
have a number of biological activities (8,9)10,11). In a previous report we
have shown that chemotactic activity can be generated by the action of thrombin
on human fibrinogen (12). This was subsequently identified as a property of
fibrinopeptide B (13). In the present study we have examined the capacity of
plasmin digestion products1of fibrinogen to attract human peripheral blood
leukocytes.
MATERIALS AND METHODS
Plasmin Digestion of Human Fibrinogen. One gm of human fibrinogen (KABI,
1
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Grade L) was dissolved in 100 ml of water and dialysed for 18 hours at 4°C
against phosphate buffered saline (PBS), pH 7-2, containing 50 units of
penicillin and 5 pg of streptomycin per ml. To 100 ml of fibrinogen diluted
to a concentration of 5 mg/ml was added 0.25 ml of streptokinase (Streptase,
Behring, 10,000 units/ml) and 2 ml of plasminogen (KABI, 5 CU/ml). The
reaction was stopped at time intervals by the addition of one volume of Trasylol
(Bayer, 10,000 units/ml) to 40 volumes of the reaction mixture. The preparation
was assayed for chemotaxis immediately or following storage at -80°C. Control
mixtures of fibrinogen alone, and plasminogen and streptokinase alone were
prepared in the same way with the addition of Trasylol at zero time and 24 hours.
The digests were analysed by polyacryamide disc gel electrophoresis (14). For
trichloracetic acid (TCA) precipitation one fifth of the volume of 30% TCA was
added to the digest. After centrifugation the supernatant was extracted with
ether, concentrated and desalted on a Sephadex G-25 column in 0.05 M pyridine
as previously described (13)-
Gel Filtration. One millilitre of a 10 times concentrated 24-hour plasmin
digest of fibrinogen was applied to a column of Sephadex G-75 (100 x 2.5 cm)
equilibrated in PBS with streptomycin and penicillin. The separation was
performed at 4°C and 5 ml fractions collected. Markers with the following
molecular weight were also filtered on the column - Blue Dextran, 200,000;
ovalbumin, 45,000; vitamin ^'357, and sodium chloride, 58.
Preparation of Purified Fibrinogen Digestion Products. Fragments X, Y, D
and E were prepared by Sephadex G-200 and ion exchange chromatography on CM-52
(Whatman) (3)» The preparations were concentrated by ultrafiltration on a
UM-10 membrane (Amicon) and dialysed against PBS with added antibiotics as
described above. The fragments gave single bands on disc gel electrophoresis
which using the appropriate markers also corresponded to their previously
described monomeric molecular weights (3)«
Measurement of Chemotaxis. Chemotaxis was assayed by a modification of the
Millipore technique of Boyden (13). The number of cells migrating through an
8.0 yaa filter were counted and the results expressed as the mean cell count of
five high power (x 40) fields or as the percentage of a normal human serum pool
used as the chemotactic control (15).
RESULTS
A 24-hour plasmin digest of human fibrinogen was found to be chemotactic
for peripheral blood leukocytes in a dose-dependent fashion (Fig. l).
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FIG. 1
Cheraotaxis of a 24-hour plasmin/fibrinogen digest. The volume of
digest was made up to 0.8 ml with PBS.
No activity was detected with fibrinogen or plasmin alone incubated under
the same conditions. Trasylol was also devoid of chemotactic activity and did
not inhibit or potentiate the activity of normal human serum used as the
positive chemotactic control. Following precipitation of a 24-hour fibrinogen/
plasmin digest with TCA, little activity was found in the desalted supernatant,
suggesting that the activity was not associated with small peptides.
In Fig. 2 three experiments are depicted in which fibrinogen was digested
with plasmin for time intervals up to 24 hours and the chemotactic activity and
patterns on disc gel electrophoresis compared at intervals. In two out of
three studies a small peak of activity was seen at 15 and 30 min. corresponding
to the transient appearance of fragment Y. The major chemotactic activity,
however, was in the 24-hour digest.
When a preparation of a 24-hour fibrinogen digest was passed over a column
of Sephadex G-75, the major peak of activity eluted with material of an apparent
molecular size of approximately 30,000 daltons (Fig. 3)
The chemotactic activity of purified fragments X, Y, D and E are shown in
Fig. 4. Significant activity was detected only with fragment Y and was
demonstrable at concentrations of 0.5 mg and 1.0 mg per ml.




Disc gel electrophoresis and chemotaxis of plasmin/fibrinogen digests at
various time intervals. The chemotactic results of three experiments
are depicted along with the positions of fibrinogen and fragments X, Y,
D and E on the disc gels.
Chemotaxis Blue Dex.
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FIG. 3
Sephadex G-75 chromatography of a 24-hour plasmin/fibrinogen digest. The
optical density (•—•)of fractions was measured at 280 nm. Chemotaxis is
indicated by vertical bars and the elution of molecular weight markers is
indicated by arrows. Molecular markers are Blue Dextran (Blue Dex.),
ovalbumin (OA), vitamin B, (Vit. B_ ) and sodium chloride (NaCl).
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FIG. 4
Cheraotaxis of purified fragments X, Y, D and E.
DISCUSSION
Chemotactic activity for human leukocytes was generated by plasmin
digestion of fibrinogen (Fig. l). When the reaction was stopped after 15 or
30 minutes, some activity was found in these digests (Fig. 2). A chemotactic
stimulus in these preparations was probably fragment Y since in separate
experiments this fragment was isolated in a pure form and shown to be active
at the concentration estimated for the 15 or 30 minute digests (Fig. 4).
At 24 hours, when Y was no longer detectable, there was considerably more
chemotactic activity. When a sample of the 24-hour digest was applied to a
column of Sephadex G-75 the major peak of chemotactic activity eluted with
molecules having an apparent molecular weight of approximately 30,000 daltons.
The nature of this material is unknown but the activity was clearly generated
by the action of plasmin on fibrinogen whereas neither of these agents alone
were chemotactic. It is possible that the activity rests in unidentified
band(s) which appeared during the plasmin digest. Thus on disc gel several
bands were observed which migrated further than fragment E (ca. 50,000 molecular
weight). These bands first appeared at 30 min. (Fig. 2) and may have contained
the later chemotactic material. The failure to demonstrate greater activity
with the earlier digests may have been a result of inhibition of leukocyte
migration by the larger fragments or possibly a requirement for further
digestion. Furlan and Beck described three polypeptide fragments in addition
to D and E which survive prolonged plasmin digestion (3)- These have disc gel
electrophoretic mobilities corresponding to molecular sizes of 25,000, 14,000
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and 11,000. Whether these contain the chemotactic property described herein
is unknown.
Though fibrinopeptide B is cleaved from the ^-chain of fibrinogen in the
latter stages of plasmin digestion (l7)t little activity was found in the
Sephadex G-75 column fractions corresponding to the molecular weight of this
peptide (ca. 1,500). However it was estimated that the amount of B peptide
in the fibrinogen digest applied to the column was approximately 0.3 pnol/ml if
100% of this peptide was cleaved by plasmin. Thus the concentrations in the
fraction would be less than the minimum concentration previously reported to
stimulate leukocyte migration (0.1 ^umol/ml) (13)-
Barnhart reported that fragment D evoked migration of canine granulocytes
in vivo using a skin window technique (l8). Under the conditions described in
this report fragment D was not chemotactic (Fig. 4). There are difficulties in
attributing chemotactic properties to agents which cause cell migration following
contact with abraded skin as this may lead to the activation of Hageman factor
and subsequent generation of a number of recognised chemotactic factors (13,15)•
Our results suggest that the main chemotactic effect of plasmin digestion
lies in one or more small peptides produced after 24 hours digestion. Using
rabbit leukocytes, Stecher and Sorkin found only weak chemotactic activity in a
24-hour human plasmin/fibrinogen digest (17)- In the present investigation
human leukocytes were used as target cells; the use of a homologous system may
thus explain this apparent discrepancy.
Other biological activity associated with fibrin/fibrinogen digestion products
include anticoagulant activity (8,9) and ability to alter platelet function (9),
potentiation of smooth muscle contraction (10) and increased capillary permeability
(ll). These biological activities together with the capacity of plasmin digestion
products to attract human leukocytes may be of significance in a variety of
pathological conditions such as disseminated intravascular coagulation (4),
pulmonary embolism (5)j transplantation rejection (6) and glomerulonephritis (7)
in which high levels of FDP's have been detected in the blood and urine.
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Chemotaxis for Human Monocytes by Fibrinogen-derived
D. L. Richardson, D. S. Pepper and A. B. Kay
South-East Scotland Regional Blood Transfusion Service, Royal Infirmary ofEdinburgh, and
University Department ofRespiratory Diseases, City Hospital, Edinburgh
Summary. Chemotactic activity for human peripheral blood monocytes was
generated by the action of thrombin on human fibrinogen, a reaction known to
release low molecular fibrinopeptides. Supernatants prepared by incubating Con-
tortrix venom with fibrinogen, which cleaves the B peptide, were also chemotactic,
whereas no activity was present in supernatants from Arvin venom, which cleaves
peptides A, AP and AY. Thus fibrinopeptide B was chemotactic for the monocyte
in addition to the neutrophil, as previously reported.
Monocyte chemotactic activity was also generated by the action of plasmin on
human fibrinogen and shown to be associated with the D and E fragments but not
with a mixture of fragments X and Y. When plasmin digestion was stopped at
time intervals up to 24 h, monocyte chemotactic activity corresponded with the
appearance of the D and E fragments. The monocyte chemotactic activity, con¬
tained in a 24 h digest, eluted from Sephadex G-75 at V0, corresponding to the
expected position of the D and E fragments whereas neutrophil chemotactic activity
eluted with molecules of molecular size of approximately 30 000 daltons. Thus
fragments D and E derived from plasmin digestion of fibrinogen attract the mono¬
cyte whereas only the small uncharacterized peptides were chemotactic for the
neutrophil. These different profiles of chemotactic activity for the neutrophil and
the monocyte in terms of plasmin digestion products of fibrinogen may be of
significance in the events leading to the accumulation of these cells in vivo during
fibrin deposition.
We have recently shown that a number ofpeptides derived from fibrinogen are chemotactic
for human peripheral blood neutrophils. These include fibrinopeptide (FP) B, released from
fibrinogen together with FPs A, AP and AY following the action of thrombin (Kay et al,
1974), and fragment Y and uncharacterized lower molecular weight polypeptides (LWP)
cleaved from fibrinogen during plasmin digestion (McKenzie et al, 1975).
During inflammatory reactions associated with fibrin deposition, such as various types of
glomerulonephritis and clot formation, the initial accumulation ofneutrophils is followed by
the appearance of mononuclear cells. In the present study we report on the capacity of
fibrinogen-derived peptides to attract human monocytes in chemotaxis and have shown a
Correspondence: Dr A. B. Kay, South-East Scotland Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh EH3 9HB.
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difference in the chemotactic properties of these peptides in terms of their capacity to attract
either the monocyte or the neutrophil.
MATERIALS AND METHODS
Plasniiti Digestion ofHuman Fibrinogen
One gram of human fibrinogen (KABI Grade L) was dissolved in 100 ml of water and
dialysed for 18 h at 4°C against phosphate buffered saline (PBS), pH 7.0. To 100 ml of
fibrinogen diluted to a concentration of 5 mg/ml was added 0.25 ml of streptokinase (Strep-
tase, Behring, 10 000 units/ml) and 2 ml of human plasminogen (KABI, 5 CU/ml). The
reaction was stopped at time intervals by the addition of one volume ofTrasylol (Aprotinin,
Bayer, 10 000 units/ml) to 40 volumes of the reaction mixture. The preparation was assayed
for chemotaxis immediately or following storage at — 40°C. Control mixtures of fibrinogen
alone, and plasminogen and streptokinase alone were prepared in the same way with the
addition ofTrasylol at zero time and 24 h. The digests were analysed by polyacrylamide disc
gel electrophoresis (Weber & Osborn, 1969).
Clot Supernatants
Supernatants prepared by the action of purified bovine thrombin, Arvin [Agkistrodon
rhodostoma venom) and Contortrix [Ancistrodon contortrix contortrix) on fibrinogen were pre¬
pared as previously described (Kay et al, 1974) and quantitated by the Sakaguchi reaction
(Shainoff& Page, i960) using an arginine-standard curve.
Gel Filtration
Two millilitres of a 10 times concentrated 24 h plasmin digest of fibrinogen was applied to
a column of Sephadex G-75 (100 x 2.5 cm) equilibrated in PBS. The separation was per¬
formed at 4°C and 7 ml fractions collected. Markers with the following molecular weight
were also filtered on the column: Blue Dextran, 200 000; ovalbumin, 45 000; vitamin B! 2,
1357, and glucose 58.
Preparation ofPurified Fibrinogen Digestion Products
Fragments X+ Y, D and E were prepared by Sephadex G-200 and ion exchange chroma¬
tography on CM-52 (Whatman) (Furlan& Beck, 1972). The preparations were concentrated
by ultrafiltration on a UM-10 membrane (Amicon) and dialysed against PBS. The D and E
fragments gave single bands on disc gel electrophoresis which, using the appropriate markers,
corresponded to their previously described monomeric molecular weights (Furlan & Beck,
1972). The X and Y fragments were not clearly separated and were tested together in
chemotaxis.
Measurement ofChemotaxis
(i) Human monocytes. Human mononuclear cells, free of granulocytes, were prepared by
layering whole heparinized blood onto a Ficol-hypaque gradient as described (Boyum, 1968).
The separated mononuclear cells were washed twice in PBS, pH 7.0, and resuspended in
Hanks' solution, pH 7.0, to a concentration of 1.5 x io6 monocytes per millilitre. Monocyte
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chemotaxis was assayed by measuring the distance that the migrating front of cells had
travelled into Millipore filters of 8.0 /rm pore size following a 90 min incubation period
(Zigmond & Hirsh, 1973). Results are expressed as an average of five high power fields, each
test being done in either duplicate or triplicate.
(ii) Human neutrophils. Chemotaxis was assayed by a modification of the Millipore tech¬
nique of Boyden (Kay, 1970; Kay et al, 1974). The number of cells migrating through an
8.0 pm filter was counted and the results expressed as the mean cell count of five high power
(x 40) fields.
RESULTS
Supernatants prepared by centrifugation ofmixtures of thrombin, Contortrix or Arvin with
fibrinogen were tested for monocyte chemotactic activity as shown in Fig 1. The reactions
were terminated at time intervals by heating the mixtures at 85°C for 5 min and removing
the insoluble material by centrifugation. The dose of thrombin was adjusted to give the same
Time (min)
Fig i. Time course of the appearance of monocyte chemotaxis of clot supernatants prepared by the
action ofContortrix (•), thrombin (o) or Arvin (a) on fibrinogen.
coagulation time as Arvin (10 min). No coagulation was observed with Contortrix at the end
of the experiment, indicating that fibrinopeptide A was not released. Monocytes migrated
towards the supernatant prepared with Contortrix and thrombin but not with Arvin. When
treated in a similar fashion alone, neither fibrinogen, Contortrix, Arvin nor thrombin evoked
monocyte or neutrophil chemotaxis. These experiments were repeated three times and gave
essentially similar results. Electrophoresis was used to identify the peptides released by each
enzyme in the heated supernatants tested for chemotaxis (Kay et al, 1974). With Arvin only
the A peptides (A, AY and AP) were identified whereas only fibrinopeptide B was cleaved by
the action of Contortrix on fibrinogen. Electrophoresis of the supernatant obtained with
thrombin indicated that fibrinopeptides A, AP, AY and B were released.
The Contortrix and thrombin supernatants taken after 60 min incubation (Fig 1) were then
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Fig 2. Monocyte chemotaxis of Contortrix (o) and thrombin (•) clot supernatants prepared from 6o
min incubation times as shown in Fig i.
tested for monocyte chemotactic activity which was demonstrable in a dose-response fashion
as shown in Fig 2. These same supernatants (Contortrix and thrombin) were also chemotactic
for neutrophils (thus confirming our previous report: Kay et al, 1974) whereas the Arvin
supernatant was inactive. Therefore fibrinopeptide B was chemotactic for both the monocyte
and the neutrophil whereas FPs A, AP and AY did not chemoattract these cell types (Table I).
Monocyte chemotaxis by the products of plasmin digestion of fibrinogen is shown in
Fig 3. Both the D and E fragments were chemotactic, whereas no activity could be demon¬
strated with a mixture of the X and Y peptides. Neither the D, E nor X + Y fragments were
chemotactic for human neutrophils using the same concentrations as shown in Fig 3.
When fibrinogen was digested with plasmin for time intervals up to 24 h, monocyte
chemotactic activity corresponded to the appearance of the D and E fragments and was






























Fig 3. Monocyte chemotaxis ofpurified fragments D and E and the mixture ofX and Y. The results
represent the mean values of four experiments.
clearly demonstrable at 15 min and increased to a maximum by 60 min when the distance in
migration was maintained for the duration of the experiment (Fig 4). This experiment was
repeated twice with essentially similar results.
When a 24 h plasmin digest of fibrinogen was applied to a column of G-75, chemotactic
activity for monocytes eluted with the void volume which would be compatible for the
elution profile of fragments D and E. In contrast, neutrophil chemotactic activity eluted with
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Fig 4. Disc gel electrophoresis and monocyte chemotaxis of plasmin/fibrinogen digestions at various
time intervals.
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this cell-type was associated with the uncharacterized low molecular weight peptides (LWP).
The capacity of the peptides derived from the action of thrombin and snake venoms on
fibrinogen (the fibrinopeptides), and plasmin digestion of fibrinogen (FDPs), to attract either
the monocyte or the neutrophil is summarized in Table I.
DISCUSSION
Chemotactic activity for human monocytes was generated by the action of thrombin and
Contortrix on fibrinogen (Fig i). Thrombin cleaves fibrinopeptides A, AY, AP and B (Blorn-
back et al, 1966) whereas Contortrix selectively cleaves the B peptide (Herzig et al, 1970). In
contrast, Arvin releases FPs A, AP and AY (Ewart et al, 1970) and clot supernatants prepared
from this enzyme had no chemotactic activity. These experiments suggest that the B peptide
is chemotactic for blood monocytes as well as the neutrophil as previously reported (Kay et al,
1974)-
Evidence is provided that plasmin digestion products of fibrinogen are also chemotactic for























Fig 5. Sephadex G-75 chromatography of a 24 h plasmin/fibrinogen digest showing the peaks of
monocyte and neutrophil chemotactic activities. Chemotaxis is indicated by vertical bars and the
elution of molecular weight markers by the arrows. Molecular markers were Blue Dextran, oval¬
bumin (OA), vitamin B12 (Vit. B12) and glucose.
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and 4). In a previous report (McKenzie et al, 1975) we showed that the D and E fragments did
not attract the neutrophil and the preparations ofD and E prepared for this study were also
inactive in this respect. In that same report (McKenzie et al, 1975) we were able to separate the
X andY fragments and demonstrated that the Y fragment was chemotactic for the neutrophil,
but only at verv high concentrations (> 1 mg/ml). In the present study, using the same pro¬
cedures (Sephadex G-200 and CM 52) and further separation techniques such as recycling on
Sephadex G-200 and heparin agarose chromatography, it was not possible to separate fully
the X and Y fragments. The reasons for this are not clear but are probably related to variations
in the batches of fibrinogen. It was apparent, however, that a mixture ofX and Y on a milli¬
gram basis had no activity for monocytes or neutrophils whereas the D and E fragments
attracted the monocyte at comparable concentrations.
In contrast to the neutrophil, the lower molecular weight unidentified polypeptides
(LWP) produced by the action of plasmin on fibrinogen had no activity for human mono¬
cytes (Fig 5).
A characteristic feature of clot formation in vivo is the initial accumulation of neutrophils.
During resolution of the clot, cells of the monocyte/macrophage series predominate. The
difference in in vitro activity of plasmin digestion products of fibrinogen for neutrophils and
monocytes may be ofsignificance in the changing cellular response during clot formation and
resolution. The observations reported here may also be of importance in the understanding of
tissue damage mediated by the neutrophil and possibly the macrophage.
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Neutrophil Accumulation in Vivo following the
Administration of Chemotactic Factors
D. G. Jones, D. L. Richardson and A. B. Kay
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Summary. Intravenously administered 51Cr-labelled homologous neutrophils
accumulated at guinea-pig skin sites prepared by intradermal injection of factors
derived from complement-activated serum, possessing in vitro chemotactic activity.
There was a strong correlation between the in vitro potency of Sephadex G-100
fractions of the activated serum and their ability to evoke neutrophil accumulation
in vivo. These experiments suggest that agents which are chemotactic for neutrophils
in vitro also induce the localization of this cell in vivo.
Chemotaxis may be defined as unidirectional migration of cells towards a concentration
gradient of a chemical stimulus. The term is usually reserved for in vitro studies, in particular
the technique ofBoyden in which cells traverse through a micropore filter towards a chemo¬
tactic stimulus (Boyden, 1962). It is thought that the capacity ofcells to respond in chemotaxis
is an essential prerequisite for the defence against certain micro-organisms and conditions
have been described in man in which a defect of chemotaxis in vitro is associated with
recurrent infections (Miller et al, 1971). There is no direct evidence that chemotaxis as
defined above occurs in vivo, although the specific accumulation ofradiolabelled homologous
leucocytes at carageenin-induced inflammatory sites in the rat has recently been demonstrated
(Perper et al, 1974a). Subsequently the same workers demonstrated the drastic effect of
complement depletion on cellular infiltration in the same model (Perper et al, 1974b). In the
present study we provide evidence that intradermal injection of factors derived from
complement-activated serum, which are chemotactic for neutrophils in vitro, evoke the local
accumulation of the same cell in guinea-pig skin.
MATERIALS AND METHODS
Preparation oj Labelled Neutrophils
Albino Dunkin-Hartley strain guinea-pigs, 300-400 g, of either sex, were injected
intraperitoneally with 20 ml of 0.9% w/v saline containing 20 mg of glycogen (ex oyster
pure AR, Koch Light Laboratories, Colnbrook, Bucks., England). 3-4 h later peritoneal
leucocytes were harvested by lavage with a further 20 ml of saline. At that time 93-98%
of the leucocytes were neutrophils. Contaminating erythrocytes were removed by briefly
Correspondence: Dr A. B. Kay, South-East Scotland Regional Blood Transfusion Service, Royal Infirmary,
Edinburgh.
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suspending the cells in 0.5% trisodium citrate. After washing twice in saline the white cells
were resuspended to a concentration of 2-3 x io7/ml. To each millilitre of this suspension
was added 100 /iCi [51Cr]sodium chromate (1 mCi/ml, 100-400 mCi/mg, Radiochemical
Centre, Amersham, England) and the mixture incubated at 37°C for 45 min. The cells were
then washed in 10 ml volumes of saline until the total radioactivity associated with the
supernatant was less than 10% of that associated with the neutrophil-rich pellet. The
leucocytes were finally resuspended to a concentration of 2.5 x io7 cells/ml. The viability of
the white cells, as judged by trypan blue dye exclusion, was 95-99%.
Chemotactic Factors
Complement-activated serum was prepared by incubating fresh normal guinea-pig serum
with 20 mg/ml ofparticulate inulin (Schwarz-Mann, Orangeburg, N.Y.) at 37°C for 30 min,
with frequent inversion to allow mixing. The inulin was removed by centrifugation and the
serum heated at 56°C for 30 min. The heated serum (CAS) was stored in 1 ml portions at
— 85°C until use. Control serum (CS) was prepared in an identical fashion but in the absence
of inulin.
Fractionation ofCAS
Two ml amounts of CAS were fractionated by gel filtration on a 90 x 1 cm column of
Sephadex G-100, in phosphate buffered saline, pH 7.2. Alternate fractions were tested for
chemotaxis by the micropore technique. Fractions were then pooled (Fig 3), concentrated
approximately four times using a Diaflo UM-05 ultrafilter (Amicon, Lexington, Massa¬
chusetts) and o. 1 ml amounts of the pooled concentrates tested for neutrophil accumulation
in vivo.
Neutrophil Accumulation in Vivo
51Cr-labelled leucocytes were administered intravenously in 0.75 ml volumes, into the
ear of guinea-pigs. 5 min later eight dorsal skin sites, previously shaved and marked to a
diameter of 15 mm, were injected intradermally with 0.1 ml volumes of test solutions. At
time intervals the animals were killed, skin sites removed, dissected free of subcutaneous
tissue, placed in 2 ml plastic tubes, and assayed directly for radioactivity using a standard
y-counter (Tracerlabs Gamma/Guard 150).
The radioactivity in peripheral blood samples was measured as follows. 10 ml of hepa-
rinized blood were centrifuged at 400g for 5 min. 0.5 ml ofsupernatant plasma was removed
for counting and the remainder discarded. The cell pellet was resuspended to a volume of
10 ml in 0.5% trisodium citrate for 2-3 min, and then recentrifuged. 0.5 ml of red cell
lysate was retained for counting and the remainder again discarded. The white cell pellet
was resuspended to a volume of 10 ml and 0.5 ml of this suspension counted.
Measurement ofChemotaxis
Chemotaxis was measured by a modification of the micropore technique of Boyden as
previously described (Kay, 1970). Filters of 8 /an pore size (Millipore Corporation, Bedford,
Massachusetts) and an incubation time of 2 h at 37°C were used throughout. Cell counts
were expressed as the mean of five high-power (x 40) fields.
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RESULTS
The radioactivity present in skin sites excised 18 h after the intradermal injection of various
doses of either CAS, CS or saline is shown in Fig i. 51Cr accumulated at sites pretreated
with CAS in a dose-dependent manner. Low levels of activity were present in the saline-
treated sites, but these were below the amount found in any of the sites pretreated with CAS.
At dilutions of i :4 and i :8 the amount of radioactivity in the CS-treated sites was similar to
that in saline treated sites. Higher levels were present in sites treated with undiluted CS.
The experiment was repeated three times with essentially identical results.
CS also evoked neutrophil chemotaxis in vitro but it was approximately nine times less
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Fig 1. 5ICr in guinea-pig skin sites 18 h after the intradermal administration of CAS (•), CS (o)
and saline (■). Each point represents the mean results from three animals pretreated intravenously
with the same 51Cr-neutrophil preparation (2 x 107 cells; 1-2 x io6 counts/2 min/107 cells) ± SEM.
Table I. Distribution of 51Cr in peripheral blood elements after
the intravenous administration of a radiolabelled neutrophil pre¬
paration (2 x io7 cells; 1.2 x io6 counts per 2 min/107 cells).
Sample
°/0 Total countsl2 mini0.5 ml
1 2 3 Mean
Whole blood 100 100 100 100
Plasma 24 8 6 13
Red cell lysate 7 8 IO 8
White cell pellet 69 84 84 79
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In order to show that the label remained principally with the leucocytes the distribution
of 51Cr between blood elements was determined 18 h after injection (Table I). Relatively
little activity was present in the plasma or red cell lysates, the majority being present in the
white cell pellet.
The time course ofaccumulation of 51Cr in skin sites treated with undiluted CAS or saline
following the intravenous injection of 51Cr-labelled neutrophils is shown in Fig 2. In CAS-
treated sites maximal accumulation of 51Cr occurred at 8 h, the levels decreasing thereafter.
Since CS contained chemotactic properties and evoked some cell accumulation in vivo
(Fig 3) saline was used as the control in this experiment. The activity in the saline treated
sites was relatively high after 1 h but decreased thereafter. This closely paralleled the dis¬
appearance of 51Cr from the peripheral blood as shown in Fig 2.
Hours after injection
Fig 2. Time course of the appearance of 51Cr in guinea-pig skin sites injected intradermally with
CAS (•) or saline (a). Each point represents the mean of four CAS-treated and four saline-treated
sites in two animals pretreated intravenously with the same 51Cr-neutrophil preparation (2.5 x io7
cells; 0.8 x 106 counts/2 min/107 cells) + SEM. The mean levels of 51Cr in 0.1 ml peripheral blood
samples from the same animals are also shown (■).
The relationship between the in vitro chemotactic activity of Sephadex G-100 fractions of
CAS and their capacity to evoke the accumulation of radiolabeled cells following intra¬
dermal injection is shown in Fig 3. The major peaks of activity were in pools 1 and 4 as
assessed by the micropore technique. The same pools were associated with 51Cr-neutrophil
accumulation in vivo. Pools 2, 3 and 5 had relatively little chemotactic activity in vitro or
neutrophil-accumulating properties in vivo. Thus there was a strong association between in
vivo 51Cr accumulation following intradermal injections of G-100 fractions of CAS and
the chemotactic activity of these fractions in vitro.
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Fig 3. The in vitro and in vivo chemotactic activity of fractions ofCAS obtained by gel filtration on
Sephadex G-ioo.
DISCUSSION
These experiments indicate that the in vivo administration of preparations chemotactic in
vitro leads to cell accumulation at the site of injection. Preparations which were not chemo¬
tactic in the micropore technique evoked relatively little in vivo cell accumulation. Therefore
it is probable that agents chemotactic in vitro play a part in the recruitment of cells but
whether they do this by a direct action or by increasing the 'stickiness' of the vasculature or
other mechanisms is yet to be determined.
The use, in this study, of radiolabeled cells had considerable advantages over histological
techniques, both in terms ofsimplicity and accuracy. It was important to determine, however,
that the label remained with the leucocyte fraction and this is shown in Table I. Thus in three
animals a mean of 80% of the total radioactivity was associated with the leucocyte fraction,
only small amounts being recovered in the plasma or red cell lystates.
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In both the in vitro an in vivo systems, control serum (CS) possessed some neutrophilotactic
activity. Normal serum clotted on glass is known to possess a number of chemotactic agents
due to the initiation of Hageman factor (Xll)-dependent pathways (Kay & Kaplan, 1975).
This activity was enhanced in inulin-activated serum (CAS) due presumably to the additional
presence of complement-derived chemotactic factors (Fig 1). For establishing the baseline
parameters of the in vivo technique and for comparing the relative abilities of agents which
stimulate neutrophil chemotaxis in vitro to evoke the accumulation of the same cell in vivo
the more active CAS was used in further experiments (Figs 2 and 3).
In time course studies maximal labelling of CAS-treated sites was observed at 8 h, the
levels decreasing thereafter (Fig 2). The appearance and disappearance of radioactivity in
saline-treated sites paralleled the levels present in the peripheral blood.
Following the passage of CAS through a column of Sephadex G-100 two major peaks of
chemotactic activity were observed (Fig 3) as previously described (Kay, 1970). The higher
molecular weight material is as yet unidentified whereas the material with an apparent
molecular weight ofapproximately 13 000 daltons has been identified as C5a (Kay et al, 1973).
The similar in vivo accumulation and in vitro chemotactic patterns of Sephadex G-100
fractions of CAS suggest that directional migration of neutrophils towards complement
derived factors may be operative in the mechanisms by which this cell accumulates at tissue
sites in vivo. This has also been suggested by the recent observations of Perper et al (1974a,
b) on the migration of 51Cr-labelled leucocytes to sites of carageenin-induced inflammation
in the rat, and its inhibition following complement depletion with cobra venom factor.
We suggest that the technique described represents a simple, reproducible, quantitative
model for measuring cell accumulation in vivo, and may therefore be a potentially useful
tool for studying the mechanisms of cell kinetics in inflammatory sites. It may also provide
further insight into the role of chemotaxis in vivo.
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Summary.—Chemotaxis of blood monocytes was measured in 31 patients with
bronchial carcinoma and 19 cigarette smokers. Thirteen patients with metastatic
bronchial carcinoma had significantly less (P < 0 005) chemotactic response than
matched controls. Those with disease confined to the chest, or with recurrent or
operable bronchial carcinoma, had no significant depression ofmonocyte chemotaxis.
There was also no significant difference in monocyte chemotaxis between cigarette
smokers and matched controls. These results support the concept that in human
cancer there is a defect in monocyte chemotaxis, but in bronchial carcinoma signi¬
ficant depression was only apparent in those with advanced disease.
The role of cells of the mononuclear
phagocytic series in immune surveillance
has been suggested by a number of
workers (Hibbs, Lambert and Remington,
1972; Alexander, 1976). For example,anin-
hibitorofmacrophage chemotaxisproduced
by various transplanted tumours in mice
has been described (Snvderman and Pike,
1976) and in man the capacity of peri¬
pheral blood monocytes to respond by
chemotaxis in vitro was depressed in
patients with genito-urinary neoplasms
(Hausman et al., 1975), malignant mela¬
noma (Rubin, Cosimi and Goetzl, 1976)
and other human cancers (Boetcher and
Leonard, 1974). We have studiedmonocyte
chemotaxis from 31 patients with bron¬
chial carcinoma at various clinical stages,
and also the monocyte chemotactic
response of cigarette smokers who are
known to be at risk for developing
bronchial neoplasms.
patients and controls
Patients with bronchial carcinoma were
classified according to the stage of their
disease. Those with small tumours deemed
suitable for surgical resection were termed
operable. Disease which reappeared locally at
the site of a surgical resection was termed
recurrent. Disease confined to the chest had
spread locally from the primary site in the
bronchus to involve surrounding lung, local
lymph nodes and chest wall. The metastatic
group had deposits of tumour outside the
chest, commonly in liver or bone, as demon¬
strated clinically, or by radionuclide scan¬
ning.
Controls for the cancer groups were all
convalescent, hospitalized patients who had
sustained either myocardial infarctions or
respiratory infections and in whom there was
no evidence of malignant disease. Controls for
cigarette smokers were all healthy, non¬
smoking volunteers.
materials and methods
Human peripheral-blood monocytes were
separated on a Ficoll-Triosil gradient as
previously described (Boyum, 1968). Chemo¬
taxis was quantified either by the "leading
front" method using Millipore filters (Milli-
pore Co., Wembley) of 8 pm pore size
(Zigmond and Hirsch, 1973) or by the method
of Snyderman et al., (1972) employing
Correspondence: Dr A. B. Kay, Department of Pathology, University of Edinburgh, Medical School,
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Nucleopore filters and polycarbonate "Boyden
chambers" Neuroprobe, Bethesda, Maryland,
U.S.A.). The only modification was that the
suspending medium for monocytes and for
dilutions of chemoattractant was Medium 199
containing 30 mM Hepes buffer. The chemo¬
attractant was either human serum in which
the complement system had been activated
with purified cobra venom factor (CVF)
(Ballow and Cochrane, 1969) or solutions of
casein (British Drug Houses). Casein was
used in the early part of the study, but its
chemoattracting properties often deteriorated
after a few days, even under a variety of
storage conditions. The experiments with
casein reported here are with freshly prepared
material. In contrast, serum activated with
CVF was divided into portions after pre¬
paration and stored at — 80°C until use.
The chemotactic responses from patients
with bronchial carcinoma or cigarette smokers
were compared with age- and sex-matched
controls and each pair was performed on the
same day under the same experimental
conditions. A three-point dose-response of
chemoattractant was performed for each
experiment. Optimal monocyte migration of
cells, either from patients or smokers, was
achieved with 0-5 mg/ml of fresh casein or
2-5% CVF-activated serum. Each assay was
performed in duplicate, and measurements
from each filter were the pooled results from
10 random high-power fields. The test and
control samples were analysed by the
Wilcoxon test of paired differences. The
variation between duplicate filters was ±15%
as previously described (Turnbull and Kay,
1976; Turnbull, Evans and Kay, 1977).
results
Bronchial carcinoma
The clinical staging and histology of the
31 patients with bronchial carcinoma are
shown in Table I. Apart from one indi¬
vidual, all patients were male, and were
matched with controls within 10 years of
their age. The monocyte chemotactic
response of patients with metastatic
disease, and their respective controls, are
shown in Table I, together with the
histology and the treatment being received
either at the time of sampling or before
the chemotactic assay. There was a
significantly greater depression in the
Table I.—Clinical Staging and, Predomi¬













monocyte chemotactic response in the
metastatic group (P < 0-005) than in
their respective controls. No statistical
difference was observed with patients with
disease confined to the chest, recurrent
cancer or operable disease (Table III, Fig.).
It is unlikely that the observed effect with
the metastatic group was a result of
medication. Three of the 13 were receiving
antibiotics and one had treatment with
prednisolone, but most of the patients
were receiving no treatment at the time
of the chemotactic test. The two patients
receiving prednisolone in the group with
disease confined to the chest had higher
chemotactic responses than the control,
whereas the one in the metastatic
group having corticosteroids had a lower
chemotactic response.
In the Fig. the results are expressed as
the percent migration of each patient's
monocytes as compared to their respective
matched contol. With the patients as a
whole there was a wide scatter; however,
the metastatic group responded signifi¬
cantly less in monocyte chemotaxis. The
one patient who gave a high response had
a pulmonary infection with a white-cell
count of 17,000/p,l. There was no signi¬
ficant difference between patients and
controls in the other groups, although with
operable and recurrent cancer the numbers
were very small.
Cigarette smolcers
The monocyte chemotactic response of

































Fig.—The monocyte chemotactic response of patients with various clinical stages of bronchial
carcinoma, and cigarette smokers, expressed as the percent migration of each patient's monocytes
compared to its matched control. NS = not significant.
Table II.—The Histology, Treatment and Monocyte Chemotactic Response of Patientswith
Metastatic Bronchial Carcinoma. Controls were Matched for Age and Sex
Monocyte chemotaxis
Age Prior treatment
(Years) (interval between end
( a— of treatment Medication at
(distance migrated
in [im)
Pt. No. Pt. Control Histology anrl chemotaxis test time of tost Pt. Control
1 67 69 Unknown — — 19-7 26-8
2 02 61 Anaplastic — ■— 35 • 9 17-2
3 55 59 Oat cell PR (22 months) Prednisolone 7-6 13-3
4 66 61 Unknown Ampicillin 2-0 160
5 54 60 Unknown — — 8-0 17-0
6 85 75 Unknown — — 2-0 18-0
7 73 73 Unknown — Ampicillin 0-5 17-0
8 78 71 Unknown PR (3 years) — 8-3 23-7
9 56 55 Oat cell — — 26-4 33-5
10 61 55 Oat cell — —. 13-4 33-5
11 53 53 Anaplastic PR (1 clay) ■—■ 53-6 59 0
12 69 65 Squamous — Ampicillin 15-0 17-6
13 65 65 Squamous — — 46-4 49-7
PR = palliative radiotherapy. The chemoattractant was complement-activated serum (2-5%) in Patients
1 to 10 and casein (0-5 mg/ml) in Patients 11 to 13.
non-smoking controls, is shown in Table
IV and the Fig. There was no significant
difference between the two groups as a
whole, nor when the smokers were divided
into those who smoked more or less than
20 g per day.
discussion
Our results support previous findings on
depressed monocyte chemotactic responses
in various human cancers (Hausman et al.,
1975; Rubin et al., 1976; Boetcher and
Leonard, 1974). In the present study on
bronchial carcinoma, only those patients
with metastatic disease showed a signifi¬
cant depression (Table II, Fig.). Although
this may have been a non-specific effect
due to general debilitation it was unlikely
to be the result of treatment. Many of the
patients were receiving no medication at
the time of sampling and had not received
prior chemotherapy or radiotherapy
464 A. B. KAY AND J. G. McVIE
Table III.—The Histology, Treatment and Monocyte Chemotactic Response ofPatients with
Bronchial Carcinoma that ivas Confined to the Chest, Recurrent or Operable. Controls
were Matched for Age and Sex
Monocyte chemotaxis
Age Prior treatment (distance
(years) (interval since end of migrated in /um)
Pt. < * treatment until chemotaxisj Medication at r- A
No. Pt. Control Histology test) time of test Pt. Control
Confined to chest
1 61 69 Anaplastic PR (20 weeks) Ampicillin, 24-0 12-7
Prednisolone
2 68 65 Squamous — Oxytetracycline 13-9 18-4
3 62 66 Anaplastic — Ampicillin 140 50-2
4 61 63 Squamous — — 16-1 17-2
5 60 62 Anaplastic PR (24 weeks) — 171 48-1
6 64 65 Unknown — Prednisolone 20-7 12-9
7 51 51 Oat cell — — 211 15-2
8? 54 55 Adenocarcinoma — — 25-9 33-5
9 67 58 Oat cell — — 33 • 0 23-6
10 80 80 Squamous PR (23 days) — 37-8 59-8
11 68 65 Unknown Chemotherapy (16 weeks) — 36-4 46-9
12 57 57 Squamous Chemotherapy (6 weeks) — 58-6 50-2
Recurrent
13 82 81 Unknown — Oxytotracycline 42-5 30-6
14 53 55 Squamous — — 20 0 18-4
Operable
15 65 61 Squamous — — 18-8 17-2
16 50 48 Squamous — — 8-0 11-0
17 57 54 Anaplastic Post-surgery (3 weeks) Ampicillin 28-0 310
18 68 65 Squamous — Ampicillin 28-8 12-3
PR = palliative radiotherapy. The chemoattractant was casein (0-5 mg/ml) in Patients and controls 9 to 12
and 18. In the others it was complement-activated serum (2-5%).
Table IV.—The Monocyte Chemotactic Response of 19 Male
Cigarette Smokers Compared with Non-smoking Male Controls
Age Monocyte chemotaxis
(years) Tobacco No. of years (mean cell count)
smoked/day smoking Ar \ f
Smoker Control (g) Smoker Control
56 63 60 41 49 76
62 51 60 45 45 53
49 42 53 31 65 61
42 33 40 17 76 53
40 55 36 19 66 74
52 64 30 38 116 90
49 31 30 35 17 38
58 44 26 40 *46 31
64 60 23 47 57 48
27 22 21 8 82 81
35 34 20 16 43 70
48 54 20 35 76 95
32 28 20 14 37 28
25 27 20 8 84 76
47 34 20 23 84 66
28 23 16 10 134 72
54 55 15 36 65 100
29 29 29 5 75 91
53 49 14 28 50 59
The chemoattractant was 2-5% CVF-activated serum, with the exception of the pair indicated (*) in which
the concentration was 1*25%.
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(Tables II and III). In a similar study on
malignant melanoma (Rubin et al., 1976),
only patients with advanced disease had a
monocyte defect.
The inhibitor ofmacrophage chemotaxis
produced by various transplanted neo¬
plasms in the peritoneal cavity of mice
was partially identified as a protein of
mol. wt. 6000-10,000 (Snyderman and
Pike, 1976). A similar inhibitor is possibly
elaborated from human neoplasms and if
it is related to tumour mass this may
account for the effect observed in the
metastatic group in the present study.
A recent leading article in the Lancet
(1976), discussing the possible role of
macrophages in tumour surveillance,
emphasized the present difficulties in
relating in vitro data from man and
experimental animals to the clinical situa¬
tion. Nevertheless, if tumour-derived
material with inhibitory effects on mono¬
cyte function can be demonstrated, this
may provide some additional evidence to
support the concept that tumour products
overcome possible tumoricidal effects of
mononuclear phagocytes. Experiments
currently in progress suggest that extracts
of human tumours may inhibit the
chemotactic response of normal blood
monocytes (Abell, C. and Kay, A. B.,
unpublished).
Cigarette smokers showed no difference
from controls in their monocyte migratory
capacity, indicating that monocyte chemo¬
taxis will not be useful in detecting
individuals at risk for developing bronchial
carcinoma (Table IV). Studies with human
alveolar macrophages obtained from
smoking and non-smoking volunteers
demonstrated both an increase in the
number of cells recovered by bronchial
lavage and of the chemotactic response of
these cells from smokers when compared to
controls (Warr and Martin, 1974). This
suggests that cigarette smoke probably
has an initial non-specific "macrophage-
activating effect" analogous to the influx
of macrophages into tissues treated with
various irritants such as mineral oil and
glycogen.
The chemotactic activity of human
serum activated with cobra venom factor
is due almost entirely to the fragment
cleaved from the 5th component of
complement (C5a) liberated as a result of
activation of the alternate pathway. When
CVF-activated serum is placed on either
side of the micropore chamber, migration
is either minimal or absent, suggesting
that this agent evokes chemotaxis, (i.e.
directional migration) rather than random
migration (Kay, unpublished).
There are difficulties in employing the
chemotactic assay for clinical studies.
The reasons include possible deterioration
of the chemoattractant during storage,
variations in an individual's cell response
with time, and failure to reproduce this
biological assay exactly on each occasion.
In the present study these difficulties were
largely overcome by matching each patient
or smoker with a control individual for
age and sex, withdrawing blood from each
pair at the same time and performing the
test under identical conditions. Compari¬
son of these matched pairs by theWilcoxon
test of paired differences allowed stati¬
stical analysis.
Thus the present study suggests that
defects in monocyte chemotaxis are only
apparent at advanced stages of bronchial
carcinoma, and not in those with rela¬
tively confined disease or in those indi¬
viduals who are at risk for developing
bronchial neoplasms.
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Annotation
CHEMOTAXIS AND HAEMOSTASIS
The micropore technique ofBoyden is a sensitive and reproducible in vitro model for studying
chemotaxis. It has been used for the identification of chemotactic factors and the response of
the target cells both in health and disease (Boyden, 1962; Baum, 1975). The Boyden chambers
consist essentially of two compartments divided by a micropore filter. A suspension of
leucocytes is placed in the upper compartment and the chemotactic agent is introduced into
the lower part of the chamber. Following an incubation period the filter is removed, fixed
and stained and chemotaxis is 'quantitated' either by counting the number of cells which have
traversed the entire thickness of the micropore or by measuring the distance the 'leading
front' of cells has migrated from the origin (Zigmond & Hirsch, 1973). Further refinements
to the technique include a method in which leucocytes are labelled with 51 chromium and
chemotaxis is expressed in terms of radioactivity of a second filter placed on the side to which
the cells are migrating (Gallin et al, 1973).
The majority of early studies which employed this technique related almost exclusively to
complement-derived chemotactic factors. Those identified included fragments cleaved from
the third and fifth components (03a, 05a) and the trimolecular complex of the fifth, sixth
and seventh component (C567) (Ward, 1967; Ward & Newman, 1969; Ward et al, 1966;
Lachmann et al, 1970).
It was apparent, however, that a certain amount of activity was invariably present in nor¬
mal serum which had not undergone prior complement activation. Thus normal serum,
under the appropriate conditions, was chemotactic for the neutrophil (Kay, 1969), the mono¬
cyte (Wilkinson et al, 1969) and to a lesser extent the eosinophil (Kay, 1970).
Initial investigations on the chemotactic activity of normal human serum indicated that
many factors were involved since multiple peaks of chemotactic activity could be demon¬
strated following chromatography on Sephadex G-200 (Kaplan et al, 1972). One of these
peaks superimposed the position in which the enzymes kallikrein (mol wt 108 000) and a
plasminogen activator (mol wt 90 000) eluted. Although these molecules have a similar
molecular size it was possible, by further purification and separation, to show that chemotac¬
tic activity was associated with both enzymes (Kaplan et al, 1973). Thus kallikrein, in addition
to cleaving bradykinin from its substrate kininogen, was a chemo-attractant as was this
plasminogen activator.
It should be emphasized that a number of fibrinolytic pathways have been described with
presumed plasminogen activator activity. The activity referred to in this annotation relates
exclusively to Hagcman factor (factor XII)-dependent plasminogen-converting activity. It
would therefore appear to be distinct from the Hageman factor-independent fibrinolytic
pathway present in whole plasma which has a requirement for C3 (Schreiber & Austen,
1974), and from the plasminogen activator derived from human vascular endothelium which
has an estimated molecular size of 65 000 daltons (Aoki & von Kaulla, 1971).




More direct evidence of the chemotactic properties of these enzymes was obtained by
incubating highly purified Hageman factor (HF) fragments with their respective proenzymes.
Thus a mixture of purified HF fragments and prekallikrein led to the elaboration of both
chemotactic activity and cleavage of bradykinin from kininogen. Similarly, plasminogen-
converting and chemotactic activity were generated by the action of activated HF on the
plasminogen proactivator. Of particular interest was the fact that both the enzymatic and
chemotactic principle of the plasminogen activator and kallikrein were inhibited by the serine
esterase inhibitor diisopropyl fluorophosphate (DFP). The activity of these enzymes was
therefore dependent upon the integrity of their active sites since neither enzyme in its pre¬
cursor form was DFP sensitive.
Fibr inopeptides
a, ap, ay, [b]
Fig i. Hageman factor-dependent pathways and chemotaxis. The chemotactic factors associated with
the haemostatic mechanisms are depicted by the 'closed boxes'.
Further insight into the chemotactic properties ofkallikrein and plasminogen activator was
provided by studies on prekallikrein (Fletcher factor) deficient plasma (Weiss et al, 1974).
Plasma from these individuals have defects in coagulation, fibrinolysis, kinin-generation and
chemotaxis all of which can be corrected by the addition of purified prekallikrein. The
correction of these defects by prekallikrein is attributed to a further property of kallikrein,
namely its capacity to activate HF so providing a positive feedback for HF-dependent path¬
ways (Cochrane et al, 1972). These pathways are activated by the action of HF on its three
known substrates, factor XI, prekallikrein and the plasminogen proactivator (Fig 1). Using
kaolin as the HF activator, restoration of chemotactic activity in Fletcher factor deficient
plasma could be achieved by activated HF as well as prekallikrein. This suggested that the
contribution of kallikrein to the chemotactic activity of kaolin-activated serum was small
and that under these conditions the plasminogen activator and other unidentified HF-
dependent chemotactic factors were probably providing the majority of the activity.
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These studies on the chemotactic activity of kallikrein and the plasminogen activator used
unseparated human peripheral blood leucocytes as target cells. Whereas unseparated cell
populations are acceptable for measuring the chemotactic response of the neutrophil, eosino¬
phil and the basophil, study ofmonocyte chemotaxis requires prior separation of the mono¬
nuclear cells. This can be conveniently achieved by layering a leucocyte mixture onto
Hypaque-Ficoll. Following centrifugation, the less dense mononuclear cells can be separated
in a viable form. These cells also responded in chemotaxis to kallikrein and plasminogen
activator and there was a similar inhibition of the active site by DFP (Gallin & Kaplan, 1974).
a2-Macroglobulin inhibited both the enzymatic effect ofkallikrein and plasminogen activator
in terms of their actions on kininogen and plasminogen and also the ability of these enzymes
to respond in monocyte chemotaxis. The Ci inhibitor prevented both the enzymatic action
of kallikrein on kininogen and its chemotatic principle but had no effect on the expression
of the plasminogen activator either as a chemotactic agent or its action on plasminogen.
Therefore these naturally occurring protein inhibitors (a2-macroglobulin and Ci inhibitor)
affect the enzymatic principle in a similar fashion to their chemotactic activity.
Using unseparated leucocytes, neutrophil migration alone was observed when a mixture of
the plasminogen activator and kallikrein was the chemo-attractant. However; these enzymes
attracted the basophil when the cell source were blood leucocytes from individuals with
basophilic leukaemia (Kay & Austen, 1972). In contrast, the eosinophil did not respond in
chemotaxis to these agentswhen leucocytes from patientswith a peripheral blood eosinophilia
were used as target cells (Kay & Austen, 1971).
The action of Hageman factor on factor XI (plasma thromboplastin antecedent—PTA)
leads to the formation of thrombin via the intrinsic coagulation pathway. Clot supernatants
prepared by the action of purified thrombin on fibrinogen are chemotactic for neutrophils,
and to a lesser extent for eosinophils, while neither thrombin nor fibrinogen alone possesses
this activity (Kay et al, 1973). Thrombin is known to be a limited protease which cleaves
several small peptides from fibrinogen. These fibrinopeptides have been designated A, AP,
AY and B and are recognized on the basis of their electrophoretic mobility (Blomback et al,
1966). Evidence has been provided that the chemotactic activity is a property of fibrino-
peptide B and not of fibrinopeptides A, AP or AY (Kay et al, 1974). This was shown by
progressive purification of thrombin-induced clot supernatants using high voltage electro¬
phoresis in two dimensions. Supernatants prepared by the action of the snake venom Con-
tortrix which cleaves the B peptide, were also chemotactic whereas no activity was present
in supernatants prepared from the Arvin venom which cleaves peptides A, AP and AY.
Furthermore, synthetic fibrinopeptide B and a B analogue, i-glutatamic acid, were chemo¬
tactic but not synthetic fibrinopeptide A. Thus chemotaxis joins other biological activities
associated with fibrinopeptide B such as the potentiation of bradykinin-induced constriction
of the isolated oestrous rat uterus (Gladner et al, 1968) and prolonged rhythmic vasocon¬
striction (Colman et al, 1967). It is probable that the biological activity associated with
fibrinopeptide B is located at its C-terminus since this part of the molecule is exposed follow¬
ing the action of thrombin and other enzymes which cleave B from the /? polypeptide chain
of fibrinogen.
Other peptides derived from fibrinogen have been examined for possible chemotactic
activity since fibrin/fibrinogen degradation products (FDP) appear in body fluids in associa-
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tion with various clinical states and have a number of biological activities. Chemotactic
activity for human neutrophils and to a lesser extent eosinophils could be generated by the
action of plasmin on human fibrinogen (McKenzie et al, 1975). Previous studies have shown
that plasmin degradation of human fibrinogen yields four major fragments designated
X, Y, D and E in addition to smaller peptide material (Furlan & Beck, 1972). When plasmin
digestion was stopped at time intervals up to 24 h, a small amount of activity was apparent
at 15 and 30 min corresponding to the transient appearance of fragment Y. Considerably
more chemotactic activity was present in the 24 h digest and by gel-filtration this was shown
to be associated with relatively small molecules having a molecular size of approximately
30 000 daltons. When purified X, Y, D and E were assayed individually for chemotaxis
fragment Y was active but only at relatively high concentrations. Therefore the chemotactic
activity generated by the action of plasmin on fibrinogen was mainly associated with one or
more lower molecular weight polypeptides and to a lesser extent with the Y fragment.
Recent studies have shown that plasmin digestion products of fibrinogen and fibrinopeptide
B have chemotactic activity for human monocytes but the active FDP fragment(s) are yet to
be identified (Richardson & Kay, unpublished observations). The response of these various
cell types to the chemotactic agents is shown in Table I.
Table I. The response of various cell types to chemotactic factors associated with
haemostasis
Neutrophils Monocytes Eosinophils Basophils
Fibrinopeptide B Yes Yes Yes ?
Products of plasmin
digestion of fibrinogen Yes Yes (Yes) ?
Kallikrein Yes Yes No Yes
Plasminogen activator Yes Yes
Thus there is a formidable list of chemotactic factors associated with coagulation, kinin
formation and fibrinolysis (Fig 1). The biological significance of these observations is un¬
known but the accumulation ofvarious cell types in inflammatory conditions associated with
HF-dependent pathways is well recognized. Thus, following the formation of fibrin there
is an initial accumulation ofneutrophils whereas during the resolution the mononuclear cell
predominates. These factors may also act together since synergism between chemotactic
factors has been shown for neutrophils (Wilkinson et al, 1969), monocytes and eosinophils
(Kay et al, 1973). The association of the kinins and related peptides to various disease states
is also appreciated. For instance, the accumulation of neutrophils in the joint fluids of gout
arthritis may in part be mediated by kallikrein formed as a consequence of uric acid crystal-
induced HF activation (Kellermeyer & Breckenridge, 1965).
Many chemotactic agents possess other biological activities. C3a and C5a are anaphyla-
toxins (Cochrane & Miiller-Eberhard, 1968), C567 act in the phenomenon of'reactive lysis'
(Thompson & Lachmann, 1970) and various activities have been attributed to fibrinopeptide
B (see above). It is clear that the full complexity of these cascade-enzyme systems is still to be
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appreciated. However, a consideration of the relationship between the leucocyte, coagula¬
tion, kinin-formation and fibrinolysis may help our understanding of the significance of these
biochemical pathways in health and disease.
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_ Levels of circulating IgE, total haemo-
lytic complement, and components
Clq, C4, C3, C3PA, C6, and C7 were measured in
controls and in 93 asthmatics. In selected patients C2
assays were also performed. C4 levels were signifi¬
cantly higher than normal in child asthmatics but
significantly, lower in adults with asthma. IgE was
significantly higher in both adults and children with
asthma, and C7 was raised in adult asthmatics. When
patients developing the disease in adult life were com¬
pared with those whose asthma started in childhood,
the levels in the adult group were similar, whatever
the duration of the disease. In the childhood group,
levels were initially high with short duration of
disease but fell to that of the adult-onset group
as the duration of asthma increased. This effect
was not found with IgE levels or complement com¬
ponents other than C4. When the levels were
compared with various clinical features associated
with asthma, significant differences were found only
in the levels of C4 and IgE. High C4 levels were
found in association with the symptoms of " allergic
disease " whereas low C4 levels were associated with
features of " non-allergic disease". A similar but
far less conclusive pattern was found with IgE
levels. When 6 asthmatics having all the chosen
clinical features of allergic disease were compared
with 18 having all the features of non-allergic asthma,
the allergic group had significantly higher levels of C4
than the non-allergic patients, whereas the levels of
C2 and IgE were not significantly different. These
2
results suggest that measurements of C4 may be of
use in the classification of asthma since they correlated
better with the clinical features studied than did levels
of circulating IgE. Since C4 is extremely sensitive
to the action of activated CI, these findings also raise
the possibility that there is sequential activation of
the classical complement pathway in non-allergic
disease, possibly due to recurrent infection, even
though levels of Clq and C2 were not significantly
different from the allergic group.
Introduction
The IgE-mediated release of pharmacological
mediators from human lung, which in turn constrict
bronchial smooth muscle, is generally accepted as a
major mechanism in the pathogenesis of " allergic
asthma However, many asthmatics either have an
inconclusive history of allergy or have no evidence of
allergen-induced bronchospasm.
Studies with in-vitro laboratory models have demon¬
strated a mechanism independent of IgE which leads
to the elaboration of biologically active peptides and
subsequent histamine release from mast cells1 and
human leucocytes.2 These effector molecules, or
anaphylatoxins, are fragments derived from the third
and fifth components of complement (C3a and C5a).
Several workers have suggested that the complement
system may participate in the pathogenesis of asthma.
Deposition of C3 on the bronchial basement mem¬
brane was found at necropsy in three of eighteen
asthmatics,3 and decreased arteriovenous levels of
whole complement have been recorded after antigen
infusion in a sensitive patient.4 There is also evidence
of a requirement for complement components in the
antigen-induced release of histamine from passively
sensitised lung.5 Some asthmatics have been found
to have tissue-sensitising antibody of the IgG class 6
which may have required complement components
in the expression of its action.
We have looked for altered serum-complement
profiles in the various forms of asthma and for changes
in profiles with the duration of the disease. Levels
of complement components and IgE were analysed
in relation to the presence of " asthma-associated "
clinical features. Recognition of altered complement
profiles in asthma, especially of the fourth component,
may be of value both in the classification and patho¬




93 asthmatics (70 adults and 23 children) have been
investigated, together with age and sex matched adults and
children as controls. Blood from childhood controls was
taken for clinical purposes during convalescence from virus
meningitis (1 case), tonsillitis (3 cases), or otitis media (1
case), or from inpatients subsequently found to have
enuresis for which no organic cause was found (8 cases),
hydrocephalus (1 case), dermatitis herpetiformis (1 case),
epilepsy (2 cases), ingestion of 10 ml. of ' Tedral' suspen¬
sion (1 case), " non-accidental" injury (1 case), congenital
pulmonary-valve stenosis (1 case), and urinary-tract infec¬
tion (3 cases). None of the child controls had asthma or
other respiratory diseases or a history of other allergies.
The age range in asthmatics and controls was from 2 to
72 years. The asthmatics had generalised airway obstruc¬
tion which reversed by 20% or more of the initial forced
expiratory volume either spontaneously or in response to
therapy. None of the adult controls had an " allergic
history" or were on long-term medication. Sera were
collected at outpatient clinics, divided into portions, and
stored at —70°C or in liquid nitrogen.
Clinical Features
Individual clinical features were assessed before the
laboratory results were known. The pattern of wheeze was
taken from the history, and graded as either " episodic " or
" chronic " in character. Similarly the association of infec¬
tion with exacerbations of asthma was assessed as being
" usual" or " infrequent ". Patients were judged to have
" allergen-induced bronchospasm" if they gave both a
clear history of symptoms associated with exposure to an
inhalant or ingestant and reacted to the appropriate allergen
with a positive skin-prick test. Patients with " other
allergies " had a history of either allergic rhinitis, atopic
or infantile eczema, or urticaria that was clearly antigen
induced. All patients were skin tested to a wide variety
of allergens which included extracts of mixed grass pollens,
the mite Dermatophagoides pteronyssinus, Aspergillus
fumigatus, and house dust. All asthmatics on treatment
with corticosteroids had received their medication for
6 weeks or more. Patients who could not be confidently
graded in terms of the above clinical features were excluded
from the relevant analysis.
Measurement of IgE
Levels of IgE were measured by solid-phase radio¬
immunoassay using the ' Phadebas' kit (Pharmacia) in
which the anti-IgE was raised in the rabbit. The IgE of
the standard sera in the kit was checked against W.H.O.
standard 68/341 and both had virtually identical values.
Twenty of the sera giving high values were measured by
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radial immunodiffusion (Meloy). Both methods gave
similar results.
Measurement of Serum-complement Component Levels
The hemolytic complement (CH50) was measured by the
method of Mayer.7 Levels of complement components
Clq, C4, C3, and the C3 proactivator (C3PA) were
measured by single radial diffusion using monospecific
antisera raised in the rabbit. Anti Clq, C4, and C3 were
prepared as described8; anti-C3PA was purchased from
Beringwerke. Serum levels of C6 were measured using
C6-deficient rabbit serum and C7 by the reactive lysis
method.9 Levels of haemolytically active C2 were measured
by effective molecular titrations.10
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Fig. 1—Serum-complement levels in children and adults with
asthma and controls.
The values are expressed as units per ml. for the CH60 and
% n.p.s. for the individual components. The bars represent the
mean and 1 -96 standard errors about the mean. The number of













Fig. 2—Levels of circulating C4 in asthmatic adults and children
and controls.
Bars represent the mean and 1-96 standard errors about the
mean.
Statistical Analyses
The P values were calculated either by Student's t test
(where the variances were found to be equal) or by the
the difference of the means . , . ,
equation d= — -—= ;— m which Pthe sum of the standard errors
was calculated from the normal distribution curve (where
the variances were not equal).
Results
Adult and Childhood Asthma
There was no significant difference between the
levels of circulating Clq, C3, C3PA, C6, and C7 when
adult and child asthmatics were compared with
their respective normal groups (fig. 1). Adult
asthmatics had a higher CH50 than adult controls
(p<0 002), but differences between child asthmatics
and their controls were not significant (p<0T0).
The levels of C4 were significantly higher in child
asthmatics than in controls (p<005) or adult asth¬
matics (p<0-001) (fig. 2). In controls there was
no significant change in C4 levels with age. In adults
there was a small but significant difference (p<0-01)
in the range of C4 levels between asthmatics and
controls, the asthmatics (in contradistinction to
asthmatic children) having lower levels (figs. 1 and 2).
Only a few adult asthmatics had values which ex¬
tended into the range of childhood diseases (fig. 2).
It was not possible to exclude the effect of treatment
with corticosteroids on the slightly low C4 levels in
adult asthmatics since the C4 level of the 28 adult
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Fig. 3—Circulating IgE levels in asthmatic children and adults
compared with their controls.
The bars represent the mean and 1-96 standard errors about
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Fig. 4—Effect of duration of disease on the levels of C4 and IgE
between child and adult onset asthma.
The bars represent the mean and 1-96 standard errors about
the mean as described in figs. 2 and 3.
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asthmatics not on treatment with corticosteroids was
not significantly below the normal adult mean
(p>0-10). There are other reasons, however, to
believe that this is not a corticosteroid effect (see
below).
The mean C7 level was approximately 20% higher
in asthmatic adults than in adult controls (pCO-OOl);
14% had C7 levels above the highest values of normal
individuals (fig. 1). These effects were not attributable
to treatment with corticosteroids since those not on
steroids also had high levels. There was no significant
difference in the C7 levels between normal and
asthmatic children.
Most asthmatics had IgE levels within the normal
range, although some had very high levels (fig. 3).
The distribution of IgE levels was different between
asthmatic children and adults in that fewer asthmatic
children had low values. Differences in IgE levels
were not associated with any particular form of treat¬
ment.
There was no significant difference in the levels of
the CH50 and of the individual circulating comple¬
ment components or of IgE levels between male and
female controls, or between asthmatic males and
females.
Duration of Disease
Differences in the levels of circulating C4 and IgE
between child and adult onset asthmatics with dura¬
tion of disease are shown in fig. 4. In the short-duration
group (asthma less than 5 years) child-onset asthmatics
had considerably higher mean C4 levels than did
adult-onset asthmatics (p<0001). In adult-onset
asthma the C4 levels were lower than normal adults,
and these values were depressed throughout the dura¬
tion of the disease. When the same analyses were
applied to patients not on corticosteroids a similar
significant difference was found. With CH50 and C3
levels there was a similar changing pattern in terms
of the mean values but the differences were not signi¬
ficant. No changing patterns were found with levels
of Clq, C3PA, C6, and C7. When the same analysis
was made for levels of IgE (fig. 4) there were no
significant differences between childhood and adult
onset asthmatics and the levels remain virtually un¬
changed whatever the duration of the disease.
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Association with Clinical Features
The associations between various clinical features
and levels of C4 and IgE are shown in fig. 5. The
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Fig. 5—The levels of C4 and IgE compared la terms of individual
clinical features.
The bar represents the mean and 1-96 standard errors about
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Fig. 6—Comparison of levels of C4, C2, and IgE between 6
asthmatics with all the features of allergic (A) disease and 18
with all the features of non-allergic asthma (NA).
The bars represent the mean and 1-96 standard errors about
the mean on a linear distribution for C4 and C2 and log distri¬
bution for IgE.
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wheeze pattern as compared with an episodic wheeze
pattern (p<0-01), lower in those who had no other
allergies (p<001) and lower in patients with negative
skin tests (p<0-05). There were also differences in
C4 levels when the association of attacks with infec¬
tion and a history of allergen-induced bronchospasm
was compared, but these were not significant. In
contrast, the association between IgE levels and
clinical features was far less striking. Although
higher mean values of IgE were associated with an
episodic wheeze pattern, allergen-induced broncho¬
spasm, a history of other allergies and skin test posi-
tivity, the differences, with the exception of skin tests,
were not significant. There was no association
between the clinical features studied and changes in
the levels of the CH^,, Clq, C3, C3PA, C6, and C7.
Of the 93 asthmatics, only 6 had all the chosen
features of allergic disease, and 18 had all the features
of non-allergic asthma (fig. 5). There was no signi¬
ficant difference between these two selected groups in
terms of the levels of the CH50, Clq, C3, C3PA, C6,
and C7. However, as shown in fig. 6 the allergic
group had a significantly higher mean C4 than the
non-allergic asthmatics (p<0-05), but there were no
significant differences between the levels of C2 and
IgE. Thus in these selected groups the levels of C4
also showed greater differences than IgE. It was not
possible to provide evidence that the low C4 in non-
allergic asthmatics was associated with activation of
the classical pathway of complement activation since,
although the mean C2 levels were lower in those
asthmatics, they were not significantly different from
the allergic group.
Discussion
Bronchial asthma is very difficult to define. The
classification into intrinsic (non-allergic) and extrinsic
(allergic) is of limited value since most patients have
features associated with both groups. Although early
reports on raised levels of IgE in some patients with
bronchial asthma have been confirmed,11'12 we have
been unable to show that circulating levels of this
immunoglobulin distinguish between the various
forms of the disease.11 Thus for the reasons stated
we have measured complement components in addi¬
tion to IgE and in the first analyses have compared
the values in childhood and adult asthmatics with
their respective controls (fig. 1). Low levels of C4
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were observed in adult asthmatics. Although this
might have been associated with treatment with
corticosteroids, it is relevant that in laboratory
animals Cortisol at a dose of 5 mg. per kg. per day
significantly increased the level of C4 and other com¬
ponents, depressed levels being found only with much
larger doses. Moreover, when the asthma had begun
in childhood C4 concentrations fell progressively with
duration of disease (fig. 4); this also happened in those
not receiving corticosteroids, although the numbers
were smaller. In contrast, raised levels of C4 were
found in childhood asthma, but none of these patients
were on steroid treatment. The significance of or
reasons for the high levels of C4 is unknown. It is
presumably a result of increased synthesis and/or
decreased metabolism.
C7 was raised in adult asthmatics but the signifi¬
cance is yet to be determined. This has also been
found in chronic liver disease, and it has been
suggested that C7 is secreted by connective-tissue cells
during fibrosis and repair.14
The raised CH50 in adult asthmatics is of little
clinical significance as levels of whole complement are
high in a variety of disease states.15
A further limitation on the value of the terms
" extrinsic " and " intrinsic " asthma is suggested by
our findings 16 that adults whose disease originated in
childhood showed a changing pattern in terms of
allergy-associated clinical features. Thus, as the dura¬
tion of the disease increased, the wheeze pattern
tended to change from episodic to chronic in nature
and the features studied became less clearly associated
with allergy.
When individual clinical features associated with
allergic or non-allergic asthma were correlated with
complement components and IgE, the only significant
differences were found in the levels of C4. Thus
raised levels of C4 were more consistently found with
allergic features than were raised IgE values. Con¬
versely, low levels of C4 were usually associated with
the features of non-allergic disease whereas many of
these patients had raised levels of IgE.
To provide evidence that the lower C4 levels in
non-allergic asthma were a result of sequential activa¬
tion of the complement pathway, effective molecular
titrations of C2 were performed in two groups of
patients with all the selected features of allergic or
non-allergic disease. Although the differences in C2
were not significant it does not exclude an activation
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mechanism. In contrast to C2, C4 is exquisitely
sensitive to the action of a few molecules of activated
CI.17 A striking change in C4 can occur with com¬
paratively little alteration in the levels of CI and C2.
If CI activation did occur this may be attributable
to natural antibodies combining with infective agents,
although levels of C4 in a number of patients with
recurrent respiratory infection were normal.18
Natural antibodies against Corynebacterium parvum
have been demonstrated in normal human serum and
the resultant complexes have been shown to activate
the classical complement pathway.19 Further evidence
of complement activation in chronic asthma is being
sought by measuring levels of the CI inhibitor, the
anaphylatoxin inactivator, and the presence of circu¬
lating immune complexes.
The reduced C4 levels in non-allergic asthma could
also be a result of decreased synthesis. C4 synthesis
by cells of the macrophage/monocyte series has been
described although the source of macrophages was
from the peritoneal cavity.20 Whether alveolar macro¬
phages can synthesise C4 is yet to be determined.
Thus, although the mechanism of alterations in the
levels of C4 in asthmatics with allergic and non-allergic
associated disease has yet to be determined, measure¬
ments of this component in the circulation may prove
to be relevant to the pathogenesis of the disease and
perhaps of some value in its classification.
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Complement components and IgE in patients
with asthma and aspirin idiosyncrasy
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Delaney, J. C. and Kay, A. B. (1976). Thorax, 31, 425-427. Complement components and
IgE in patients with asthma and aspirin idiosyncrasy. Levels of circulating IgE, total
haemolytic complement, and components C4 and C3 were measured in 16 asthmatics
with aspirin idiosyncrasy and in control subjects. IgE levels were mostly within normal
limits. No differences were found between the complement profiles—in particular the
C4 levels—in the two groups. As low levels of C4 have been found in patients with
intrinsic asthma, these results would suggest a fundamental difference between asthmatics
with aspirin idiosyncrasy and others with intrinsic asthma.
The development of increased airways obstruction
soon after aspirin ingestion is a well recognized
clinical entity (Samter and Beers, 1967). It is seen
more commonly in females and typically it is
associated with the presence of vasomotor
rhinitis and nasal polyposis. The same effect may
be produced by other simple analgesics, eg, para¬
cetamol (Smith, 1971). The underlying patho¬
genetic mechanism is unknown. The sharp
increase in airways obstruction soon after in¬
gestion suggests an allergic reaction. Extensive
studies, however, have failed to find an immuno¬
logical mechanism (Giraldo, Blumenthal, and
Spinks, 1969; Girard, Hildenbrandt, and Favre,
1969), and IgE levels have been within normal
limits (Henderson, Swedlund et al., 1971).
Asthmatics with aspirin idiosyncrasy are con¬
sidered to form a subgroup of intrinsic asthma.
It has been suggested that the complement sys¬
tem may be activated directly by aspirin in sensi¬
tive subjects (Yurchak, Wicher, and Arbesman,
1970) and that this may lead to the elaboration of
anaphylatoxins which in turn release histamine
and other mediators of the allergic response by a
mechanism independent of IgE.
Measurements of complement components in
asthma have recently revealed high levels of C4
in the serum of allergic asthmatics and low levels
in the serum of non-allergic asthmatics (Kay et al.,
1974).
In the present study, serum IgE measurements
were undertaken to confirm that, in general,
normal levels occur in asthmatics with aspirin
idiosyncrasy. Measurements of serum complement
components were undertaken to determine if there
was any alteration in the complement profile,
especially C4, in this condition. Absence of an
altered profile would distinguish this subgroup of
asthma from others in the intrinsic group.
patients and methods
patients Sixteen patients with asthma and
aspirin idiosyncrasy were investigated. The diag¬
nosis of aspirin idiosyncrasy had been suggested
by the history and was confirmed by oral challenge
with paracetamol and small doses of soluble
aspirin. The clinical features of those patients are
outlined in the Table. Nasal speculum examina¬
tion revealed the presence of polyps in all the
patients. Skin testing by the prick-method re¬
vealed four patients with positive reactions to one
or more common allergens.
Age- and sex-matched adults attending the
general medical clinic were used as controls. None
of these patients had allergic disease, asthma or
other respiratory disorders. The age-range in
asthmatics was 21 to 67 years (mean 46-6 years)
and in the controls it was 25 to 67 years (mean
47 5 years). Sera were collected at outpatient
clinics, randomly numbered, and stored at — 70°C.
Measurements of IgE and complement com¬
ponents were made by one of us (ABK) without
knowledge of the origin of the samples.
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TABLE
CLINICAL FEATURES OF PATIENTS WITH ASTHMA AND ASPIRIN IDIOSYNCRASY
Nasal
Patient Age Sex Skin Tests Polypectomy Asthma Steroid Therapy
(No.) (years) (daily dose)
MB 63 F Positive DP A 4 9 Nil
SM 39 F Positive DP A 3 16 Pred 5 mg
BP 40 M Positive DP 7 34 Nil
PR 51 F Positive DP 0 3 Pred 7*5 mg
PC 32 F Negative 4 14 Becotide
LT 63 F Negative 8 30 Pred 5 mg
DJ 54 F Negative 6 29 Pred 5 mg
JS 50 F Negative 5 16 Nil
JD 64 M Negative 1 2 Pred 10 mg
LT 61 F Negative 3 20 Pred 5 mg
SA 35 F Negative 0 4 Pred 5 mg +Bextasol
HC 50 F Negative 3 4 Pred 5 mg
JA 36 M Negative 13 22 Nil
SR 44 F Negative 3 10 Pred 2-5 mg
SK 21 M Negative 3 4 Pred 5 mg
LK 43 F Negative 1 12 Pred 5 mg




methods The total haemolytic complement
(CH50) was measured by the method of Mayer
(1961). Sheep cells were optimally sensitized by
antisera prepared in the rabbit. Increasing dilu¬
tions of serum were added to constant volumes of
sheep cells and the degree of haemolysis (Y) was
measured by spectrometry at OD 414. The total
haemolytic complement giving 50% haemolysis
(CH50) was calculated as 1-1/y.
Levels of C3 and C4 were measured by radial
immunodiffusion using monospecific antisera
raised in the rabbit (Lachmann, Hobart, and
Aston, 1973).
Levels of IgE were measured by solid phase
radioimmunoassay using the Phadebas Kit (Phar¬
macia) in which the anti IgE was raised in the
rabbit. The IgE of the standard sera in the kit was
checked against WHO standard 68/341 and both
had virtually identical values.
results
The complement profiles and IgE values for the
groups with aspirin idiosyncrasy and for the
control groups are outlined in the Figure.
The mean complement components for the two
groups were as follows:
Asthmatics: CH50= 132, C4=119, C3= 136
Controls: CH50=148, C4= 125, C3= 129
(The values are expressed as a percentage of
the normal pooled serum.)
There was no significant difference in the com¬
plement profiles between the two groups.
The IgE levels were mostly in the lower range
in both groups. The mean IgE in the asthmatic
groups was 281 IU per ml and in the controls it
was 150 IU per ml. The two asthmatic patients
with raised IgE levels had positive skin tests.
discussion
Asthmatic patients with aspirin idiosyncrasy form
a subgroup of chronic (intrinsic) asthma.
Recently, chronic asthmatics have been shown to
have lower levels of circulating C4 than episodic
(extrinsic) patients. In the present study, how¬
ever, there was no significant difference in the
levels of complement components between
asthmatic patients with aspirin idiosyncrasy and
controls. Apart from the two atopic patients the
finding of normal IgE values is in agreement with
previous reports. Measurements of complement
components have not previously been recorded in
this condition. The normal profile does not ex¬
clude direct activation of the complement system
by aspirin and, in this respect, measurements of
complement levels during acute episodes provoked
by aspirin would be helpful.
The absence of an altered complement profile
in asthmatics with aspirin idiosyncrasy would sup¬
port the belief that patients with this syndrome
form a subgroup quite separate from others in
the intrinsic asthma group.
Part of this work was supported by the Scottish Home
and Health Department. We are grateful to Mr.
Roger Dunmow for technical assistance.
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figure Complement and IgE levels in patients with asthma and aspirin idiosyncrasy
(#) and age- and sex-matched controls (O). The bars represent the mean values. There
was no statistical difference between patients and controls as assessed by the Student t
test. NHP=normal human pool (serum).
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COMPLEMENT AND BRONCHIAL ASTHMA
IN CHILDHOOD AND ADULTS
A. B. KAY
Department of Pathology (Experimental Pathology), University of Edinburgh,
Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland, U.K.
Summary :
To differentiate the various clinical forms of bronchial asthma, the level of circulating
IgE and of some components of the complement were measured in the patients serum :
adults and children. A significant difference is observed—in patients as compared to healthy
subjects—in the C4 component : in children the level is increased, on the contrary in
adults it is decreased. Some clinical aspects which enable the distinction between extrinsic
and intrinsic asthma, correlate better with the C4 level than with the IgE level for which
no significant difference has been shown in the various forms of the disease.
Key words : C4; Bronchial asthma; IgE; Allergy; Complement.
Resume : Complement et asthme bronchique de I'enfant et de I'adulte
Attn de differencier les diverses formes cliniques de l'asthme bronchique, le taux d'lgE
circulante et de certains composants du complement ont ete mesures dans le serum de
malades : enfants et adultes. Une difference significative est observee, chez les malades par
rapport aux sujets normaux, pour le compose C4 : chez les enfants le taux est augmente,
par contre pour les adultes ce taux est diminue. Certains aspects cliniques qui permettent de
distinguer entre 1'asthme extrinseque et intrinseque correlent mieux avec le taux de C4
qu'avec le taux d'lgE, pour lequel aucune difference significative n'a pu etre mise en evi¬
dence dans les diverses formes de la maladie.
Mots cles : C4; Asthme bronchique; IgE; Allergie; Complement.
INTRODUCTION
Inhalation of specific allergen is widely accepted as the initiating factor which
leads to bronchoconstriction in allergic asthmatics. Pharmacological agents such as
histamine and slow reacting substance are thought to be released from lung mast cells
sensitized by IgE and these in turn constrict bronchial smooth muscle. However many
asthmatics, including children, often have either an inconclusive history of allergy or
no evidence of allergen-induced bronchospasm. Studies in vitro have shown that
peptides derived from sequential activation of the complement system evoke histamine
release from mast cells [1] or human leucocytes [2], These effector molecules (or
anaphylatoxins) are fragments derived from the third and fifth components of
complement and they are referred to as C3a and C5a. Their action does not require
prior sensitization of mast cells by IgE or equivalent tissue-sensitizing antibody.
Several workers have suggested that the complement system may participate in the
pathogenesis of asthma. For example, deposition of C3 on the bronchial basement
membrane was found at autopsy in three of eighteen asthmatics [3], and decreased
arteriovenous levels of whole complement have been recorded after antigen infusion
in a sensitive patient [4], One in vitro system has been described which apparently
Tires a part : Dr A. B. Kay, a l'adresse ci-dessus.
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required complement components for the antigen-induced release of histamine from
passively sensitized lung [5], In addition, some asthmatics have been found to have
a tissue sensitizing antibody of the IgG class [6] which may exert its effect through
complement components for the full expression of its action.
In order to extend these studies we have measured the serum complement profiles
in various forms of bronchial asthma. We have also determined whether alterations
in serum complement levels could be related to the duration of disease, a number of
« asthma-associated » clinical features and concentrations of IgE [7].
PATIENTS STUDIED AND RESULTS
Ninety-three asthmatics were investigated; 70 adults and 23 below the age of 15.
All measurements were compared with age and sex matched controls.
There was no significant difference between the levels of circulating Clq, C3,
C3PA, C6 and C7 when adult and child asthmatics were compared with their respective
normal groups (Table I). Adult asthmatics had a higher CH50 than adult controls
Table I. — Serum-complement levels in children and adults with asthma and controls.
The values are expressed as units per ml for the CHm and percent normal pooled
serum (N.P.S.) for the individual components. The mean values and 1.96 standard
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+ 20 NS 102
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(p < 0.002), but differences between child asthmatics and their controls were not
significant (p < 0.10). The levels of C4 were significantly higher in child asthmatics
than in controls (p < 0.05) or adult asthmatics (p < 0.001). In controls there was
no significant change in C4 levels with age. In adults there was a small but significant
difference (p < 0.01) in the range of C4 levels between asthmatics and controls, the
asthmatics (in contradistinction to asthmatic children) having lower levels. Only a few
adult asthmatics had values which extended into the range of childhood diseases. It was
not possible to exclude the effect of treatment with corticosteroids on the slightly
low C4 levels in adult asthmatics since the C4 level of the 28 adult asthmatics not on
treatment with corticosteroids was not significantly below the normal adult mean
(p > 0.10). There are other reasons, however, to believe that this is not a corticosteroid
effect (see below). The mean C7 level was approximatively 20 % higher in asthmatic
adults than in adult controls (p < 0.001) ; 14 % had C7 levels above the highest
values of normal individuals (Table I). These effects were not attributable to treatment
with corticosteroids since those not on steroids also had high levels. There was no
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significant difference in the C7 levels between normal and asthmatic children. Most
asthmatics had IgE levels within the normal range, although some had very high
levels. The distribution of IgE levels was different between asthmatic children and
adults in that fewer asthmatic children had low values. Differences in IgE levels were
not associated with any particular form of treatment. There was no significant difference
in the levels of the CH30 and of the individual circulating complement components
or of IgE levels between male and female controls, or between asthmatic males and
females. Differences in the levels of circulating C4 and IgE between child and adult
onset asthmatics with duration of disease are shown in Tables II and III. In the
short-duration group (asthma less than 5 years) child-onset asthmatics had considerably
Table II. — Levels of C4 (% NPS) in patients whose symptoms of bronchial asthma began
either in childhood or adult life compared with the years before the onset of symptoms.
The mean and 1.96 standard error are given.
Years
Since Onset Onset in Childhood Adult Onset
of Symptoms (No. of Patients) (No. of Patients)
150 + 26 (4) 52 + 8 (16)
140





23 (10) 57 + 23 (5)
70




+ 8 (18) 61
+ 7 (3)
Table III. — Levels of IgE (I.U per ml) in patients whose symptoms of bronchial asthma
began either in childhood or adult life compared with the number of years before the
onset of symptoms. The numbers of patients is the same as in table II. The range
represents 1.96 standard errors on a logarithmic distribution.
Years
Since Onset Onset in Childhood Adult Onset
of Symptoms Mean IgE Value (Range) Mean IgE Value (Range)
0-5 600 (75-3,600) 100 (40-180)
6-10 550 (200-1,050) 100 (20-950)
11-20 750 (400-1,800) 100 (40-420)
21-30 600 (200-2,000) 50 (10-60)
>30 400 (200-600) 400 (20-3,300)
higher mean C4 levels than did adult-onset asthmatics (p < 0.001). In adult-onset
asthma the C4 levels were lower than normal adults, and these values were depressed
throughout the duration of the disease. When the same analyses were applied to
patients not on corticosteroids, a similar significant difference was found. With CH5(,
and C3 levels there was a similar changing pattern in terms of the mean values but the
differences were not significant. No changing patterns were found with levels of Clq,
C3PA, C6 and CI. When the same analysis was made for levels of IgE (Table III)
there were no significant differences between childhood and adult-onset asthmatics
and the levels remain virtually unchanged whatever the duration of the disease.
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The association between various clinical features and levels of C4 and IgE are
shown in Table IV. The levels of C4 were lower in asthmatics with a chronic wheeze
pattern as compared with an episodic wheeze pattern (p < 0.01), lower in those who
had no other allergies (p < 0.01) and lower in patients with negative skin tests
(p < 0.05). There were also differences in C4 levels when the association of attacks
Table IV. — The levels of C4, IgE, eosinophil numbers, |3-glucuronidase and sputum hista¬
mine when compared to asthma associated clinical features. The mean and 1.96 standard
errors are given (NS : not significant; p : values were calculated by the student's
t test).
Clinical Manifestations


































































































with infection and a history of allergen-induced bronchospasm was compared, but
these were not significant. In contrast, the association between IgE levels and clinical
features was far less striking. Although higher mean values of IgE were associated
with an episodic wheeze pattern, allergen-induced bronchospasm, a history of other
allergies and skin test ipositivity, the differences, with the exception of skin tests,
were not significant. There was no association between the clinical features studied
and changes in the levels of the CHgo, Clq, C3, C3PA and C7.
Levels of circulating eosinophils and concentrations of serum (3-glucuronidase and
sputum histamine were also related to clinical features. No significant differences were
found when the same analyses were applied (Table IV).
GENERAL DISCUSSION
Bronchial asthma is very difficult to define. The classification into intrinsic (non-
allergic) and extrinsic (allergic) is of limited value since most patients have features
associated with both groups. Although early reports on raised levels of IgE in some
patients with bronchial asthma have been confirmed [8, 9], we have been unable to
show that circulating levels of this immunoglobulin distinguish between the various
forms of the disease [8]. Thus for the reasons stated we have measured complement
components in addition to IgE and in the first analyses have compared the values in
childhood and adult asthmatics with their respective controls (Table I). Low levels
of C4 were observed in adult asthmatics. Although this might have been associated
with treatment with corticosteroids, it is relevant that in laboratory animals Cortisol at
a dose of 5 mg per kg per day significantly increased the level of C4 and other
components, depressed levels being found only with much larger doses [10]. Moreover,
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when the asthma had begun in childhood, C4 concentrations fell progressively with
duration of disease (Table II); this also happened in those not receiving corticosteroids,
although the numbers were smaller. In contrast, raised levels of C4 were found in
childhood asthma, but none of these patients were on steroid treatment. The
significance of, or reasons for, the high levels of C4 is unknown. It is presumably
a result of increased synthesis and/or decreased metabolism. C7 was raised in adult
asthmatics but the significance is yet to be determined. This has also been found
in chronic liver disease, and it has been suggested that C7 is secreted by connective-
tissue cells during fibrosis and repair [11]. The raised CHr,0 in adult asthmatics is of
little clinical significance as levels of whole complement are high in a variety of disease
states [12], A further limitation on the value of the terms « extrinsic » and « intrinsic »
asthma is suggested by our findings that adults whose disease originated in childhood
showed a changing pattern in terms of allergy-associated clinical features. Thus, as
the duration of the disease increased, the wheeze pattern tended to change from
episodic to chronic in nature and the features studied became less clearly associated
with allergy. When individual clinical features associated with allergic or non-allergic
asthma were correlated with complement components and IgE, the only significant
differences were found in the levels of C4. Thus raised levels of C4 were more
consistently found with allergic features than were raised IgE values. Conversely,
low levels of C4 were usually associated with the features of non-allergic disease
whereas many of these patients had raised levels of IgE. To provide evidence that
the lower C4 levels in non-allergic asthma were a result of sequential activation of
the complement pathway, effective molecular titrations of C2 were performed in
two groups of patients with all the selected features of allergic or non-allergic disease.
Although the differences in C2 were not significant it does not exclude an activation
mechanism. In contrast to C2, C4 is exquisitely sensitive to the action of a few
molecules of activated CI [13]. A striking change in C4 can occur with comparatively
little alteration in the levels of CI and C2. If CI activation did occur, this may be
attributable to natural antibodies combining with infective agents, although levels
of C4 in a number of patients with recurrent respiratory infection were normal.
Natural antibodies against Corynebacterium parvum have been demonstrated in
normal human serum and the resultant complexes have been shown to activate the
classical complement pathway [14]. The reduced C4 levels in non-allergic asthma
could also be a result of decreased synthesis. C4 synthesis by cells of the macrophage/
monocyte series has been described although the source of macrophages was from the
peritoneal cavity [15]. Whether alveolar macrophages can synthesise C4 is yet to be
determined.
Thus, although the mechanism of alterations in the levels of C4 in asthmatics
with allergic and non-allergic associated disease has yet to be determined, measurements
of this component in the circulation may prove to be relevant to the pathogenesis of
the disease and perhaps of some value in its classification.
CONCLUDING COMMENTS
1. C4 levels were higher in childhood asthma than controls.
2. C4 was slightly but statistically significantly lower in adult asthma than controls.
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3. Some of the clinical features which distinguish « extrinsic » from « intrinsic »
asthma seemed to correlate better with C4 than either IgE concentrations, eosinophil
counts, (3-glucuronidase levels or the amounts of sputum histamine.
4. With asthmatics who develop their disease in childhood, C4 levels are initially
high but with duration of the disease the concentrations become similar to those with
chronic or intrinsic asthma.
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Immunoglobulins and complement in pleural
effusions associated with bronchogenic carcinoma
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synopsis Levels of IgG, IgA, IgM, the total haemolytic complement (CH50), and the individual
components Clq, C3, C4, C6, and C7 were measured in 29 pleural effusions. Of these, 18 were
associated with carcinoma of the bronchus and 11 were non-malignant elfusions including empye¬
mas.
The level of IgG was significantly lower in the malignant group when compared with non-
malignant effusions. The usefulness of measurements of IgG with respect to malignant effusions
associated with carcinoma of the bronchus requires an expanded study to show whether it has any
real diagnostic value. There were no significant differences in other immunoglobulins, the CH50,
and individual complement components between the two groups.
The identification of total haemolytic activity in the majority of effusions in both groups indicates
that all nine components of the classical pathway of complement, including macromolecules such
as CI, can be present in pleural fluids.
There have been relatively few reports on measure¬
ments of immunoglobulins and complement in
pleural fluid. Hunder et al (1972) found that the
total haemolytic complement (CH50), C4, and C3
concentrations were lower in the pleural fluids from
patients with rheumatoid arthritis and systemic
lupus erythematosus than in fluids from patients
with malignant and other diseases. Hirsch et al
(1971) reported the presence of immunoglobulins
IgG, IgA, and IgM in nine pleural fluids in amounts
comparable to those concentrations present in the
serum.
Since there have been a number of reports which
suggest that cancer patients have circulating antigen-
antibody complexes which in turn may lead to
activation of complement, we have measured immu¬
noglobulins and individual complement components
in 18 malignant pleural fluids and compared these




Samples were centrifuged at 1500 g to remove parti-
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culate matter, divided into portions, and kept at
— 80°C. The effusions were processed and stored on
the same day as the pleural aspiration and were
thawed only once before each assay.
TOTAL PROTEIN
This was measured by a standard AutoAnalyzer
(Technicon Instruments Corporation Ltd, Basing¬
stoke) method (N14b) which uses the biuret reaction.
The between-batch precision (± 1 SD) was 1-0 g/1.
IgG, IgA, AND IgM
These were measured by an automated nephelo¬
metric procedure on an AutoAnalyzer II (method
no. 12). The method incorporates 4% polyethylene
glycol in the antiserum diluent. Samples were pre-
diluted manually (1:50 for IgA and IgM, and
1:200 for IgG) rather than on the AutoAnalyzer.
The between-batch precision (±1 SD) in the range
up to 300 IU/ml was 8 0 IU/ml for IgG, 12-6 IU/ml
for IgA, and 7 0 IU/ml for IgM.
COMPLEMENT
The haemolytic complement (CH50) was measured
by the method of Mayer (1961). Levels of comple¬
ment components Clq and C3 were measured by
single radial diffusion using monospecific antisera
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raised in the rabbit. Levels of C4 and C6 were
measured using C4-deficient guinea-pig and C6-
deficient rabbit sera respectively (Lachmann et al,
1973), and C7 was measured by the reactive lysis
method (Thompson and Lachmann, 1970). Immu¬
noelectrophoresis was performed as described
(Scheidegger, 1955) using a rabbit antiserum to
human plasma proteins purchased from Wellcome
Reagents Ltd.
Results
When the electrophoretic pattern of malignant and
non-malignant pleural effusion, including empyemas,
was compared to the pattern of normal serum there
were no major differences in the number of positions
of the principal protein bands.
The amount of Ig Gper milligram total protein in
the malignant effusions was significantly (p < 0 01)
lower than the IgG content of the nonmalignant
group (fig 1). The differences in IgA and IgM per
milligram of total protein and in total protein con¬
centration itself between the two groups were not
significant.
Total haemolytic complement was measurable in
the majority of pleural effusions but there was no
significant difference in levels between the malig¬
nant and nonmalignant fluids (fig 2). The individual
components Clq, C4, C3, C6, and C7 were also
detectable in the majority of effusions but no sig¬
nificant differences were found between the two
groups (fig 2).
Discussion
In the report by Hirsch et al (1971), three out of the























Fig 1 Immunoglobulins and total protein in malignant
and nonmalignant pleural effusions. Malignant effusions
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ill
,ft
Fig 2 Total haemolytic complement (CH-Q) and the
individual complement components Clq, C4, C3, C6,
and C7 in malignant and nonmalignant pleural effusions.
Malignant effusions (#), empyema (O), tuberculosis
(■), pneumonia (□), pulmonary infarction (A).
I
carcinoma of the lung, but in this small series the
levels of IgG, IgA, and IgM were not markedly
depressed when compared with nine nonmalignant
fluids. Our findings show that the amount of IgG
per milligram of total protein in malignant effusions
was significantly lower than the IgG content of the
nonmalignant fluids, but there was considerable
overlap between the two groups (fig 1). This observa¬
tion may, however, have relevance when very low
IgG concentrations are present although further
studies are necessary to evaluate the real diagnostic
value of these findings. Immunoelectrophoresis
alone does not appear to have diagnostic value as
the patterns were similar with each disease state.
The reasons for the lower concentration of IgG
in themalignant group is unknown. One explanation
is that IgG is an inadvertent substrate for plasmin
as a result of local fibrin formation and activation of
the fibrinolytic pathway. Disseminated intravascular
coagulation (DIG) in association with disseminated
carcinoma is well recognized. Although DIC was
not a complication in any of the patients studied
here it is possible that there was low-grade conver¬
sion of plasminogen by a plasminogen activator in
the pleural space of the patients with carcinoma.
Levels of fibrin degradation products were higher in
pleural fluids from patients with carcinoma than in
nonmalignant fluids (J. D. Cash, personal communi¬
cation).
Although we did not have the opportunity to
measure plasma concentrations of immunoglobulins
at the time of pleural aspirations, it is unlikely that
our findings merely reflect low circulating IgG
levels. In a report by Hughes (1971) IgG levels in
cancer patients, including those with bronchogenic
carcinoma, were significantly increased when com¬
pared with those in matched controls.
Measurements of the CH50 and individual com¬
ponents in body fluids other than plasma have
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been of value diagnostically. The complement levels
in joint effusions in systemic lupus erythematosus
(SLE) and rheumatoid arthritis (RA) have been
found to be lower than in 'non-rheumatoid' arthritis
fluids from patients with osteoarthritis or gout
(Pekin and Zvaifler, 1964; Franco and Schur, 1971).
Similarly, the CH50, Clq, C3, and C4 were lower in
pleural fluids secondary to SLE and RA than in
malignant pleural effusions (Hunder et al, 1972).
These findings are thought to be a consequence of
complement activation by antigen-antibody com¬
plexes. Since there is evidence in both man and
experimental animals for the presence of immune
complexes in cancer (Baldwin et al, 1974), in this
study we have measured complement in malignant
effusions and have included the terminal components
C6 and CI. We have compared our malignant group
with exudates associated with pneumonia, tuber¬
culosis, and pulmonary infarction and with empye¬
mas. Although we found no significant difference
between our two groups in terms of complement
measurements (fig 2), the observation that many of
these components were present adds to knowledge
of the composition of pleural fluids.
The mechanism by which fluid accumulates within
the pleural cavity is incompletely understood.
Leckie and Tothill (1965) found that radiolabelled
albumin can diffuse freely out of the pleural space,
and it seems likely that most proteins in pleural
effusions derive from the circulation as a result of
the inflammatory process rather than from local
production. It is reasonable to suppose that macro-
molecules, such as Cl (molecular size 900 000), can
diffuse into the pleura. The majority of fluids from
the malignant and nonmalignant groups had total
complement activity (the CH50) which requires Cl
and the other components of the 'classical pathway'.
We are grateful to Dr Margaret Calder, Bacteriology
Laboratories, City Hospital, Edinburgh, for supply¬
ing us with pleural fluids, and to the numerous
clinicians who agreed to provide specimens. Part
of this work was supported by a grant from the
Scottish Home and Health Department.
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Summary Mediators of immediate-type hyper¬
sensitivity were studied in the sputum of
patients with chronic bronchitis. The same mediators
were also measured in early-onset, skin-test-positive
asthmatics, in late-onset, skin-test-negative asthmatics,
and in patients with bronchial carcinoma, bronchiec¬
tasis, and pneumonia. Sputum eosinophilia was a fea¬
ture of bronchitics and asthmatics, whereas raised blood
eosinophil levels were found only in the early-onset,
skin-test-positive asthmatics. Histamine and IgE were
present in considerable amounts in the sputum of bron¬
chitics and early-onset, skin-test-positive asthmatics.
Smaller amounts were found in the other groups. The
sputum in all the groups contained material giving an
"s.r.s (slow-reacting substance) like" induced contrac¬
tion of the guineapig ileum. "Classical" s.r.s.-a., deter¬
mined by arylsulphatase iib susceptibility, was present
only in bronchitics and both types of asthmatics. Since
the bronchitics were, in general, skin-test negative and
had normal concentrations of circulating IgE and
eosinophils, it is suggested that the findings in the spu¬
tum indicate an element of local immediate-type (type i)
hypersensitivity in bronchitis although its significance
for pathogenesis is not known.
Introduction
During a study of the aetiology of exacerbations in pa¬
tients with "chronic bronchitis" a common finding was
intermittent eosinophilia in the sputum. This feature
suggested that these patients might have an element of
local, rather than general, immediate-type (type i)
hypersensitivity, because most of them were skin-test
negative to a variety of common allergens and had no
blood eosinophilia. We therefore measured the concen¬
trations in the sputum of a number of agents associated
with type-i hypersensitivity—histamine, slow-reacting
substance of anaphylaxis (s.r.s.-a.), and IgE. We com¬
pared the results with those for sputum of patients with
asthma and other pulmonary diseases.
Patients
Chronic Bronchitis
These 26 patients had the following features: (1) persistent
cough and sputum for at least 3 months in at least 2 consecu¬
tive years, (2) at least one period of illness which had kept the
patient from normal activities for at least 3 weeks in 2 succes¬
sive years, (3) reversibility of airways obstruction of not
greater than 20% of the initial forced expiratory volume in
1 s (f.e.v.j) after one or two inhalations of salbutamol, (4) no
evidence of pulmonary tuberculosis, bronchiectasis, or bron¬
chial carcinoma. They had been or were heavy smokers and
were skin ("prick") test negative, with 2 exceptions, to com¬
mon allergens.
10 of the 26 were given prednisolone (20 mg a day for 2
weeks) with no improvement in the peak expiratory-flow rate.
9 of these 10 patients underwent the tests shown in the table.
The values obtained were consistent with the diagnosis of
chronic bronchitis (except for patient no. 7, who had no air¬
ways obstruction but had the other characteristics described
above).
BronchialAsthma
All had generalised airways obstruction which was rever¬
sible spontaneously or as a result of treatment, with an in¬
crease of 30% or more of the initial f.e.v.,. 18 of the 26 had
never smoked.
The asthmatics were divided into two groups. One group
was skin-test positive and all had had symptoms before the age
of 35. The patients in the other group were skin-test negative
and in all of them the first symptoms had started after the age
of 35. (In the figures the patient's age is also recorded as
greater or less than 35 years, but this refers to the time of sam¬
pling.) All except 4 of the 15 asthmatics who were more than
35 years old at the time of sampling (whether skin-test positive
or negative) were receiving oral corticosteroids.
Bronchial Carcinoma
The diagnosis in all these patients had been proved histolo¬
gically. They had no history of chronic bronchitis and at the
time ofsampling had no clinical infection.
Bronchiectasis
The diagnosis was made either by bronchography or on the
presence of persistent localised coarse crepitations on at least
3 occasions during a period of at least 2 years. All the patients
had produced copious amounts of purulent sputum for a
number ofyears.
Pneumonia
The patients with pneumonia had had a typical acute infec¬
tive episode with no history ofprevious respiratory disease.
Materials and Methods
Eosinophil-counts in sputum were expressed as a percentage
of the first 400 intact cells counted in a smear. Glass beads
were then added to the sputum and the sample shaken vigor¬
ously for 5-10 min, centrifuged, divided and stored at —80°C.
Histamine and slow-reacting substance (s.R.s.-A.)were mea¬
sured on the isolated guineapig ileum1,2 and arylsulphatase
digestion was carried out.2
IgE was measured with a 'Phadebas' kit (Pharmacia) and
the levels of IgG, IgA, and IgM were estimated by the Mancini
technique, monospecific antisera being used. To relate sputum
IgE to protein content values were expressed as international
units (i.u.) per g of total immunoglobulin protein per g of spu¬
tum.
Because of the size of the samples all the measurements
could not be made in all the patients.
The P values were calculated by the equation
. the difference of the means
d=
the sum of the standard errors
in which p was calculated from the normal distribution curve.
Results
4 out of 23 patients with chronic bronchitis had a spu¬




































Fig. 1—Eosinophils in sputum and blood of patients with chronic
bronchitis, asthma, and other pulmonary diseases.
Values given in parentheses are the highest recorded in those bron-
chitics studied monthlv for one year.
monthly counts and the highest recorded percentage is
also shown. Over a period of 12 months all had values
more than 10% in at least one of the specimens; in 12
it was over 40%, though the number of specimens con¬
taining eosinophils varied from patient to patient and
many were negative. The blood eosinophil-count at the
time of sampling was normal (i.e., less than 640x10'
cells/1). In the skin-test-positive asthmatics, on the other
hand, most of the patients tested had raised sputum and
blood eosinophil counts. 3 out of the 6 skin-test-negative
asthmatics also had a sputum eosinophilia. Blood counts
could be done only on 2, but 4 of the 6 patients were on
long-term corticosteroid therapy. In general, sputum
and blood eosinophil-counts in the patients with bron¬
chial carcinoma, bronchiectasis, and pneumonia were
low.
The sputum histamine values are shown in fig. 2.
Only patients with chronic bronchitis (11 out of 26) and
the skin-test-positive asthmatics (12 out of 20) had




















Fig. 2—Histamine concentrations in sputum of patients with
chronic bronchitis, asthma, and other pulmonary diseases.
nificant difference in the sputum histamine values
between the chronic bronchitics and the skin-test-posi¬
tive asthmatics. But when these groups were each com¬
pared with skin-test-negative asthmatics and patients
with bronchial carcinoma, bronchiectasis, and pneu¬
monia, the differences were highly significant (p<0 002
to <0 005).
Nearly all the samples tested showed some "s.R.s.-
like" activity and there was no apparent difference
between any of the groups (fig. 3). To establish whether
the ileal-contracting activity was associated with "classi¬
cal" s.r.s.-a., samples from each of the 6 groups were
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Fig. 3—"S.R.S.-like" activity in sputum of patients with chronic
bronchitis, asthma, and other pulmonary diseases.
turn samples from patients with bronchial carcinoma,
bronchiectasis, and pneumonia were unaffected by this
treatment, indicating that the substance was not "classi¬
cal" s.r.s.-a. On the other hand, samples from chronic
bronchitics and asthmatics were all susceptible to treat¬
ment by this enzyme, indicating "classical" s.r.s.-a.
Activity was completely destroyed in all but 5 samples
and even in these there was partial inactivation. Unlike
the other bronchitics and asthmatics these 5 patients
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Fig. 4—Percentage reduction in S.r.S.-like activity after incu¬
bation of sputum samples witji arylsulphatase iib.
IgE was measured in the serum and sputum (fig. 5).
Serum-lgE concentrations were greatly raised in 5 of the
18 skin-test-positive asthmatics and in 1 of the 6 skin-
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Fig. 5—IgE in sputum and blood of patients with chronic bron¬
chitis, asthma and other pulmonary diseases.
test-negative asthmatics, but in none of the other pa¬
tients. In contrast, appreciable amounts of IgE were
detected in the sputum from 7 of the 22 chronic bron-
chitics and from 7 of the 15 skin-test-positive asthmatics.
Apart from 1 skin-test-negative asthmatic, the values for
the other groups were low.
In general, the younger skin-test-positive asthmatics
(below 35 y) tended to have higher blood eosinophil
values (fig. 1), sputum histamine concentrations (fig. 2),
and serum-IgE (fig. 5) than those in the older age-group;
this difference did not hold for the other measurements.
Discussion
The bronchitics were carefully selected to exclude
those with asthmatic features. They fulfilled the Medical
Research Council criteria,3 were heavy smokers, and
those assessed were unresponsive to corticosteroids. The
presence of sputum mediators, accompanied by normal
blood eosinophil and IgE values, and the negative skin-
tests suggest a local type-i reaction in at least some
chronic bronchitics for at least some of the time. The
significance of these findings for pathogenesis is un¬
known, as is the nature of the allergen, although the H,
antigen ofHamophilus influenza has been suggested.4
The detection of s.r.s.-a. is of particular interest
because it is primarily associated with type-i reactions
and may have other actions besides its effect on smooth
muscle.5,6 The "s.r.s.-like", but arylsulphatase resis¬
tant, activity in sputum from the other patient groups
may be due to to prostaglandins.7
The findings in the asthmatics support the view that
mediators of hypersensitivity may participate in "extrin¬
sic" disease and that in "intrinsic" asthma s.r.s.-a. may
be released by an IgE-independent mechanism, though
the numbers in the "intrinsic" group were too small for
firm conclusions to be drawn.
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Campbell, I. A., Middleton, W. G., McHardy, G. J. R., Shotter, Margaret V., McKenzie, R.,
and Kay, A. B. (1977). Thorax, 32, 424-428. Interaction between isoprenaline and aminophylline
in asthma. Using a factorially designed study, 38 patients with bronchial asthma received a
single dose of either isoprenaline by inhalation (9), aminophylline intravenously (10),
isoprenaline and aminophylline (11), or placebo (8). The maximum expiratory flow (V max),
the maximum expiratory flow at 50% of vital capacity (V max50), and the concentrations of
plasma cyclic AMP were measured at time intervals up to two hours. The combination of
isoprenaline and aminophylline acted synergistically in terms of the percent increase in V max50.
However, this was statistically significant only at 20 minutes. Plasma cyclic AMP concentration
rose with a similar time course of response to the changes in small airways. The elevations in
plasma cyclic AMP observed with the drug combination were higher than those for the
individual drugs at 10, 20, 30, and 60 minutes but these differences were not statistically
significant. These observations support the concept that changes in bronchial smooth muscle
tone are mediated by concentrations of cyclic nucleotides and that combinations of
isoprenaline and aminophylline, rather than the administration of each drug separately, may
have therapeutic advantages in the treatment of bronchial asthma.
It is common practice to use beta-adrenergic
stimulants and methyl xanthines in the treatment
of bronchial asthma. The studies of Robison et al.
(1971) suggest that the beta-adrenergic effects of
catecholamines are mediated through 3'5' cyclic
adenosine monophosphate (cyclic AMP), the
intracellular 'second messenger'. Methyl xanthines
inhibit phosphodiesterase, the enzyme which in¬
activates cyclic AMP (Butcher and Sutherland,
1962), and it is proposed (Leading article, 1970)
that methyl xanthines and beta-adrenergic agents
may produce bronchodilatation by increasing the
level of cyclic AMP in bronchial and bronchiolar
smooth muscle.
Drugs which individually act at different points
in the metabolic pathway of a compound in such
a way as to increase the amount of that compound
may, when used together, produce an increase
greater than the sum of the increases produced
1Present address: Respiratory Department, Bristol Royal Infirmary
aUniversity Department of Pathology, Edinburgh
by each drug alone, that is, they may interact
synergistically (Yeldstra, 1956). There is evidence
in vitro for synergy between beta-adrenergic
agents and methyl xanthines (Rail and West,
1963; Lichtenstein and Margolis, 1968; Kaliner
et al., 1971). The present study was designed to
establish whether such interaction could be
demonstrated in vivo in man. We studied the
effects of inhaled isoprenaline and intravenous
aminophylline on the airways and on heart rate.
The level of cyclic AMP in plasma was also
measured as it has been described as a convenient
index of effects of drugs on tissue levels of cyclic
AMP (Ball et al., 1972; Karlberg et al., 1974;
Wehman et al., 1974).
Patients and methods
Thirty-eight patients were studied. All patients
had airways obstruction and, at some time in
the past, had shown a 20% or more increase in
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FEVj after inhaled isoprenaline or salbutamol. At
the time of study they were symptomatically well
and were therefore considered to be in a stable
state. Informed consent was obtained from each
patient, and the protocol was approved by the
Ethical Committee of the City Hospital, Edin¬
burgh.
design and dosage
A factorial design permitting the detection of drug
interaction (Armitage, 1971) was used. Patients
were allocated in random order to one of four
treatments:
1 Placebo inhaler plus placebo injection (P),
8 patients;
2 Isoprenaline inhaler plus placebo injection
(I), 9 patients;
3 Placebo inhaler plus aminophylline injection
(A), 10 patients;
or
4 Isoprenaline inhaler plus aminophylline in¬
jection (I+A), 11 patients.
The placebo inhaler delivered inactive propel-
lant only and the placebo injection consisted of
10 ml of normal saline. The inhalers and ampoules
were prepared by the hospital pharmacist in such
a way that active and placebo preparations were
indistinguishable. Two 'puffs' were taken from
the isoprenaline inhaler (016-0'18 mg ex valve)
and the intravenous dose of aminophylline was
250 mg in 10 ml. The treatments were given in a
double-blind fashion.
methods
Maximum expiratory flow volume (MEFV) curves
were recorded at the mouth with a Fleisch
pneumotachograph and an integrator, displayed
on a storage oscilloscope (Tektronix 5100), and
photographed on Polaroid film. The system was
calibrated for volume with a Gaensler spiro¬
meter, which had previously been calibrated
by water displacement, and for flow using a
rotameter and vacuum cleaner. Calibration was
performed before, during, and at the end of
each experiment. The maximum expiratory
flow rate (V max) and the maximum expiratory
flow rate at 50% of forced vital capacity (V max30)
were measured from two acceptable records of
the MEFV curve and the greater value of each
index was used for analysis. Obvious differences
in the forced vital capacity or distortion by cough¬
ing were the usual reasons for considering the
records unacceptable. Heart rate was measured
from lead II of the electrocardiogram (ECG) re¬
corded for 30 seconds on a Sharp MT23 machine.
Plasma cyclic AMP was measured by the com¬
petitive protein binding assay of Gilman (1970)
using the materials supplied by the Radiochemical
Centre, Amersham. Blood was drawn into ethyl-
enediaminetetracetate (EDTA) to a final concen¬
tration of 0 005 m and the plasma was separated
and stored at —80° C. The samples were thawed
once and the proteinaceous material removed by
precipitation with 67% ethanol. In order to show
that the drugs or their metabolites did not influ¬
ence the assay 8 picomoles of cyclic AMP
were added to 1 ml aliquots of the seven plasma
samples from a patient who received the com¬
bination of isoprenaline and aminophylline.
Values obtained gave the expected increase above
aliquots to which no cyclic AMP had been added.
procedure
The patients were instructed not to use any bron-
chodilator preparations for at least six hours
before the investigation. A Medicut cannula was
inserted into a forearm vein. The patient remained
at rest in an armchair for at least 15 minutes and
then the ECG was recorded for 30 seconds. Five
millilitres of blood were drawn and two MEFV
curves recorded with the patient in the sitting
position. Two puffs of isoprenaline or of a placebo
inhaler were then taken by the patient during the
first half minute of a five-minute infusion of either
aminophylline or saline. During the last 30 seconds
of the infusion the ECG was recorded. Blood was
taken immediately after the end of infusion, that
is, at time five minutes, and two MEFV curves
were recorded. Measurements and samples were
repeated 10, 20, 30, 60, and 120 minutes from the
start of the infusion.
One patient in the placebo group, one in the A
group, and two in the I+A group fainted during
or immediately after the injection. All four in¬
sisted on continuing the investigation and their
results are included in the analysis.
statistical analysis
The data obtained were subjected to an analysis
of variance for a factorial experiment (Armitage,
1971). This analysis provided an assessment of the
effects of isoprenaline, aminophylline, and of the
combination of the two drugs. An interaction
term was derived at each time and its standard
error was calculated. If the interaction term was
larger than twice its own standard error (that is,
was significantly different from zero), the drugs
had interacted synergistically.
Results
The mean pre-treatment values of V max50,
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Table Mean pre-treatment values (-SE) of V max, VmaxM, heart rate, and plasma cyclic AMP
Isoprenaline
Placebo Isoprenaline Atninophylline arninophylline
No. of patients 8 9 10 11
V max50 (1/sec) 1 32 (±0-25) 102(±0-27) l-53(±022) 113 (±011)
V max (1/sec) 4-36 (±0-63) 3-82 (±0 52) 4-42 (±0-45) 3-85 (±0-2)
Heart rate per min 75 (±4) 80 (±3) 83 (±5) 71 (±4)
Cyclic AMP (nanomoles/1) 11 8 (±2 15) 11 -3 (±15) 11-7 (±1-7) 9-7 (±18)
V max, heart rate, and plasma cyclic AMP for
each group are shown in the Table. The differ¬
ences between groups were not statistically
significant.
The means of the percentage increases in
V max50 produced by each treatment are shown
in Figure 1. The placebo group remained much
the same over the two hours. The combination
I+A produced increases which were larger than
those produced by either drug alone, but at 60
minutes and 120 minutes the differences between
A and I+A were not significant at the 5% level.
Although I+A was significantly different from
the other three groups at all other times, it was
only at 20 minutes that the interaction term was
greater than twice its standard error. At 5, 10,
<U
|30-
and 30 minutes the suggestion that the combina¬
tion was synergistic was not significant at the 5%
level.
The same trend towards a synergistic effect on
V max was apparent up to 30 minutes after treat¬
ment (Fig. 2), but this trend did not achieve statis¬
tical significance. At 60 and 120 minutes the
effects of I+A were greater than those of I alone
(p<0 05) but were much the same as A alone.
Fig. 2 Mean percent change in Vmax
The effects on heart rate are shown in Figure 3.
Neither synergy nor addition occurred. I, A, and
I+A produced increases which were not statistic¬
ally distinguishable from each other. At five
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minutes A and I+A were different from placebo
(p<005) but the changes resulting from I alone
were at no time significantly different from
placebo.
I, A, and I +A produced similar changes in
plasma cyclic AMP (Fig. 4), and these changes
paralleled the time course of the changes in the
airways. At 10, 20, 30, and 60 minutes the com¬
bination I+A produced changes greater than
those produced by each drug alone but the differ¬
ences were not statistically significant.
cyclic AMP in plasma.
Discussion
Synergy between two drugs is said to occur if the
effect produced when they are given together is
greater than the sum of their effects when given
individually. It is generally accepted that a dis¬
placement to the left of the dose-response curve of
one drug by another drug indicates synergistic
interaction. To be conclusive this shift should be
significantly greater than the response to the
second drug alone. An alternative method for
investigating interaction, which avoids the neces¬
sity of establishing dose response curves, is to use
single, fixed doses of the drugs in a factorially
designed experiment (Armitage, 1971; Pearson
et al., 1976), and we have used this latter method.
Hume and Rhys Jones (1961) observed an addi¬
tive effect of isoprenaline and aminophylline on
FEVj in six patients. Pihlajamaki et al. (1972)
examined the effects of glyphylline and isoprena¬
line singly and in combination, and Cohen and
Elizabeth (1974) studied ephedrine and theophyl¬
line, but none of these studies was designed in a
way which would allow the observed effects to be
analysed quantitatively for synergy. Using a
factorial design, we have now shown a synergistic
bronchodilator effect between isoprenaline and
aminophylline on V max50 but not on V max.
While it is possible that reducing variation by
studying larger numbers of patients or by using a
within-patient comparison of the drugs might have
resulted in the demonstration of synergistic inter¬
action on V max it is also possible that the differ¬
ent findings for V max and V maxM represent a
true difference of the effects of the drugs at differ¬
ent sites in the airways, because it has been argued
that changes in maximum expiratory flow rate at
50% forced vital capacity reflect changes in calibre
of the smaller airways (McFadden and Linden,
1972).
It would seem that plasma levels of cyclic AMP
reflect only broadly changes occurring at tissue
level for although the time courses of the plasma
cyclic AMP changes were similar to those of the
airways we have found no difference between the
effect of I, A, and I+A on plasma cyclic AMP.
This is not entirely surprising when one considers
that the level of plasma cyclic AMP is only 1% of
the level in tissues (Karlberg et al., 1974) and that
the plasma concentration of cyclic AMP is
thought to be the result of a leakage of cyclic
AMP from cells into the extracellular space
(Broadus et al., 1971). Nevertheless the marked
response in plasma cyclic AMP 10 minutes after
the administration of drugs used in treating acute
asthma may have important therapeutic implica¬
tions. In status asthmaticus the response to beta-
adrenergic stimulants is sometimes impaired or
absent, and it has been suggested that alpha-
adrenergic blocking drugs can restore beta-
responsiveness (Palmer et al., 1974; Patel and
Kerr, 1975). Furthermore, some patients with
chronic asthma appear to have lost their ability
to respond to beta-adrenergic stimulants, and
Ellul-Micallef and Fenech (1975) have shown that
this responsiveness can be restored by administer¬
ing corticosteroids. The measurement of the
responses of plasma cyclic AMP to beta-adrenergic
stimulants might therefore provide an objective
means of deciding when beta-responsiveness is no
longer present in a clinical situation in which tests
of ventilatory function are either too insensitive
or too impractical to be a useful index of response.
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Neither synergy nor addition was found in the
action of the drugs on heart rate. At rest heart
rate is controlled predominantly by the parasym¬
pathetic nervous system (Robinson et al., 1953;
Robinson et al., 1966) and reflex parasympathetic
changes might be expected to redress changes in¬
duced by isoprenaline and aminophylline, thereby
making it difficult to show interaction of these
drugs on heart rate. However, both A and I+A
produced a significant rise in heart rate five
minutes after treatment. In status asthmaticus
such a rise might be unacceptable unless oxygen
was available to counteract the possible worsening
of hypoxaemia that might result.
Our demonstration of the synergistic interac¬
tion between a beta-adrenergic stimulant and a
methyl xanthine on the airways of man in vivo
supports the concept that cyclic AMP may par¬
ticipate in the events leading to bronchodilatation
and provides a rationale for their combined use in
the treatment of asthma.
We thank Miss S. Merchant and Mr. G. Goode-
nough for expert technical assistance, Professor
J. W. Crofton and Dr. A. C. Douglas for permis¬
sion to study patients under their care, and Riker
Laboratories for financial assistance.
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Summary. A case of chronic benign neutropenia is described in association with
circulating leucoagglutinins. IgG and IgM leucoagglutinins demonstrated by
Sephadex G-200 chromatography agglutinated neutrophils and monocyte enriched
leucocyte preparations. Total IgG, IgA, IgM and IgE, total haemolytic complement,
C3 and C4 complement components were all within normal limits. Lymphocyte
populations and transformation were normal apart from a relative increase in the
number of B lymphocytes. In vitro studies showed that the patient's monocytes
responded in chemotaxis, phagocytosis and intracellular killing of S. aureus in a com¬
parable fashion to that of control neutrophils. Although the patient's serum also
agglutinated monocytes these findings do not exclude the possibility that leuco¬
agglutinins may have aetiological significance in this disease. The study also empha¬
sizes the versatility of the monocyte in benign neutropenia.
There have been several reports in the literature of a chronic benign form of neutropenia in
infants and Stahlie (1956), reviewing the features of 16 cases, found leucoagglutinins to be
absent from three sera examined. A similar benign syndrome has been described in adults
and termed 'chronic idiopathic neutropenia' (Kyle & Linman, 1968).
We describe a further case of benign neutropenia in infancy associated with circulating
leucocyte antibodies. Immunological investigations suggested that monocytes compensated
for the lack of neutrophils.
CASE REPORT
The patient, born in October 1973, was the only child of first cousin Pakistani parents. The
mother was receiving phenobarbitone for grand mal seizures associated with her first preg¬
nancy. The child had a normal, full term delivery and was of normal height and weight. In
March 1974 she was investigated for diarrhoea thought to be associated with feeding prob¬
lems and at this time the neutropenia was noted at a routine blood examination. Apart from
three transient respiratory infections which responded to antibiotics the child has remained
clinically well.
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MATERIALS AND METHODS
Leucoagglutination. Leucoagglutination was performed as essentially described by Kissmeyer
Nielsen & Thorsby (1970). Leucocytes were prepared from defibrinated blood by sedi¬
mentation of the red blood cells with 'Plasmagel' (Roger Bcllon, Paris). Two microlitres
of the serum under investigation were incubated with 3000-6000 leucocytes for 1 h after
which the white cells were stained with toluidine blue prior to microscopic evaluation of
agglutination.
For the investigation of monocyte agglutination the same technique was used but a
monocyte enriched cell population (purity 40%) was prepared using a modification of the
method of Boyum (1968).
Sephadex G-200. Half a millilitre of the patient's serum taken on day 40 (Fig 1) was applied
to a column of Sephadex G-200 (95 x 3.5 cm) equilibrated in phosphate buffered saline. The
separation was performed at 4°C and 2 ml fractions collected. The fractions were pooled as
indicated (Fig 2) and concentrated to 2 ml by ultrafiltration on a UM10 (Amicon) membrane.
Fractions were tested for leucoagglutination and for their contents of IgG or IgM.
Skin window technique. This was performed according to the method ofRebuck & Crowley
(I955)-
Chemotaxis. Chemotaxis was assayed by measuring the distance, in microns, that the
migrating front of cells had travelled into Millipore filters of 3.0 /im pore size following a 90
min incubation period (Zigmond & Hirsch, 1973). The results were expressed as the average
distance migrated in five fields examined.
Phagocytosis and bactericidal activities. Phagocytosis and bacterial killing of S. aureus was
measured as described (McCrae & Raeburn, 1972) using three times washed separated leuco¬
cytes and 10% AB serum as a source of opsonin.
Immunoglobulins. IgG, IgA and IgM estimations were performed by single radial immuno¬
diffusion on plates purchased from Hyland, Thetford. IgE was measured by solid-phase
radioimmunoassay using the 'Phadebas' kit (Pharmacia, London).
Complement. The total haemolytic complement (CH50) was measured by the method of
Mayer (1961). The third and fourth components of complement (C3 and C4) were measured
by single radial immunodiffusion using monospecific antibody prepared in the rabbit.
Lymphocyte studies. Populations of T cells were estimated by the rosette technique using
sheep erythrocytes (Er) (Jondal et al, 1972) and B cells by complement coated sheep cells
(EACr) according to the method of Bianco et al (1970).
Lymphocyte transformation following stimulation by optimal doses of phytohaemagglu-
tinin (1.5 jug/ml), Concanavalin A (16/rg/ml) or pooled mitomycin treated allogeneic cells
(800 000/ml) was estimated by the following method. Lymphocytes were separated from
defibrinated blood using a Ficoll-Triosil gradient (Boyum, 1968). The separated cells were
washed twice and suspended at 2 x io5/ml in the final culture medium TC199 containing
bicarbonate (0.2%), penicillin (100 units/ml) and streptomycin (100/ig/ml), 30 mM Hepes
and 20% pooled heat inactivated human serum. Tritiated thymidine (TRA306, Amersham)
was added to give 1 juCi/ml. After thorough mixing, 4 ml aliquots were taken into culture
tubes (Nunclon 1410.1), the mitogens added and then triplicate 1 ml cultures set up for each
treatment. Incubation was at 37°C in a 5% C02/air humidified atmosphere, the mitogen
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cultures being processed at 72 h and those containing allogeneic cells being terminated at
120 h.
RESULTS
Total and differential leucocyte counts for a 4 month period are shown in Fig 1 and Table I.
A transient increase in the neutrophil count occurred between days 80 and 85. The relative
lymphocyte counts were persistently elevated but the monocyte numbers were generally
within normal limits. Platelets were present in plentiful numbers on all occasions. The bone
marrow showed normal cellularity and erythropoiesis. Megakaryocytes were present. There
was a marked increase in the numbers of promyelocytes and myelocytes but few cells de¬
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+ + + + + +Leucoagglutination +
Fig i. Patient's total and differential WBC. (+), Leukoagglutination test days (all samples positive).
The child was group O Rhesus positive and her serum agglutinated the leucocytes of 12
normal O Rhesus positive individuals. Leucoagglutinins were detected on every sample tested
as indicated in Fig 1 and were positive even during the small transient rise in the neutrophil
count between days 80 and 85. A homologous and an autologous control serum was negative
on each occasion. The agglutinating titrcs were variable depending on the source of target
cells; they were usually 1 in 2 but sometimes 1 in 40. No cytolysis of the agglutinated cells
was observed following the addition of sources of complement from humans, guinea-pig and
the rabbit. The leucoagglutinating activity in the serum was unchanged following heating at
56°C for 30 min. When the child's serum was passed over a column of Sephadex G-200
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Table I. Total and differential white cell counts (x io9/l.) on selected study
days
Day Total Differential WBC
WBC ■ —
Neutrophils Eosinophils Monocytes Lymphocytes
5 6.9 0.207 0.069 0.207 6.42
55 5-5 0.0 0.055 0.495 4-95
85 9.8 0.980 0.098 0.294 8-43
105 11.5 0.460 0.115 0.920 10.00
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Fig 2. Sephadex G-200 chromatography of patient's serum showing IgM (peak 1) and IgG (peak 3)
and the capacity of these antibodies to agglutinate whole leucocytes and monocyte enriched prepara¬
tions.
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leucoagglutinin activity was associated with both the IgM (peak 1) and IgG (peak 3) fractions
(Fig 2). By microscopy it could be seen that most of the agglutinating leucocytes were
neutrophils. However, when separated blood monocytes containing lymphocytes but virtu¬
ally free of neutrophils were used as target cells these were also agglutinated by the IgM and
IgG fractions. The sera did not agglutinate lymphocytes from normal donors.






(% at 30 mitt)
Bactericidal
index
Patient F if 68 and 80 84 10.5 and 6.0
Controls M 2 — 99 7-2
F 4 — 97 2.4
M 4 — 97 10.0
M 6 — 90 8.1
F 8 — 98 6.3
F 10 — 97 15.6
Controls M 4 91 — —
M 7 94 — —
F 11 93 — —
M 2 85 — —




Serum IgG 12 4.0 -14.0
immunoglobulins IgA 1.10 0.2 - 1.2
(g/1-) IgM 1-54 0.3 - 1-5
IgE 0.041* 0.024- 0-12




t Complement values are expressed as the percentage of a
pool of 50 samples of normal human serum (NHP). The
normal range was obtained by comparing the values of the
50 individual samples to the NHP and is expressed as ±2
SD.
With the skin window technique neither neutrophils nor monocytes were seen following
adequate abrasion at time intervals up to 24 h. However, in chemotaxis, in vitro, the child's
monocytes migrated as well as neutrophils from a control at a time when the patient had
virtually no neutrophils. The migration distance (in microns) of the patient's unseparated
leucocytes to doses of 0.5 and 1.0 mg/ml of casein was 74 and 90 respectively. The migrating
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cells were all monocytes. In contrast, unseparated leucocytes from a matched control migrated
distances of 51 and 80 pm to the same doses of casein but these cells were virtually all
neutrophils.
Measurements of phagocytosis and intracellular killing of Staphylococcus aureus by the
patient's cells are shown in Table II. The patient's per cent phagocytosis of S. aureus in 15 min
was 68 and 80 on two separate occasions (mean in four healthy child controls: 91). The
patient's value after 30 min phagocytosis was 84 (mean in six healthy child controls: 96). The
bactericidal indices of 10.5 and 6.0 were comparable to the controls.
The level of IgM was slightly elevated whereas levels of IgG, IgA, IgE, the CH50, C3 and
C4 were all within the normal ranges (Table III).
Table IV. Subpopulations and transformation of the patient's lymphocytes; nor¬
mal adult values shown in parentheses
Lymphocyte populations
T cells (Er) 1858 mm3 (700-3000), 50% ($4-86)
B cells (EACr) 1152 mm3 (200-400), 31% (5—25)
Transformation (cpm of 3H-thymidine/io6 cells)
(dose) (time)
PHA 1.5 Ag/ml 72 h 927158 (255000-580000)
Con A 16 /tg/ml 72 h 154075 (70000-350000)
Frozen mitomycin 800 ooo/ml 120 h 8 005 (6000-30 000)
treated pooled
allogeneic cells
When compared to normal adult ranges the per cent ofT cells was slightly low although
when expressed as the absolute counts they fell within the normal range. The number of B
cells was markedly elevated. The response to PHA was above the normal adult value whereas
normal counts were obtained following stimulation by Con A or pooled mitomycin treated
allogeneic cells (Table IV).
The sera from the mother or father contained no leucoagglutinins and they both had
normal white cell and differential counts. The probably HL-A genotypes of the family were,
mother, HL-A 11, 12/W32, 'X'; father, HL-A 1, W15/'X', HL-A5 and the patient, HL-A 11,
HL-A 12/'X', HL-A 5 ('X' being an unidentified antigen(s)).
DISCUSSION
The association of circulating neutrophil and monocyte antibodies in a patient with benign
neutropenia and maturation arrest of the granulocyte series is described. Although antibodies
were directed against monocytes in addition to neutrophils, these observations did not exclude
the possibility that leucoagglutinins had a causal significance. It is extremely difficult to
obtain a preparation of leucocytes entirely free of neutrophils. The observed agglutination
with the monocyte rich preparation may have been due to small numbers of contaminating
neutrophils which, following agglutination, led to non-specific clumping of monocytes.
Another possibility is that the antigen is present on both these cell types but is expressed
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relatively weakly by the monocyte. Therefore a monocytopenia would only be seen in the
presence of relatively high amounts of circulating agglutinins.
The patient had other unique features in that although neutrophils were virtually absent
she appeared to compensate for this lack as assessed by in vitro chemotaxis, phagocytosis and
bacterial killing. The poor cellular response in both neutrophils and monocytes in the skin
window technique emphasizes the differences between chemotaxis in vitro and in vivo. It has
been suggested that an initial neutrophil infiltration into an inflammatory site is a prerequisite
for subsequent monocyte infiltration (Ward, 1968). Therefore although monocytes from this
patient could pass through micropore filters in vitro the full expression of their migratory
properties in the skin may require the presence of neutrophils.
The slightly raised level of IgM and increased numbers of B lymphocytes were possibly
related to the production of lcucoagglutinins. Although we were only able to give normal
adult values in the lymphocyte studies it is unlikely that the B cell count was in the normal
range for a child of this age.
There is no explanation for the presence of the leucoagglutinins; they are presumably
antibodies of either the IgM and IgG class (Fig 2). It was thought that this abnormal finding
may have been related to the consanguinity of the parents. However, the mother's and the
father's HL-A genotypes were distinct. This does not preclude them, however, for being
histocompatible at the LD loci.
The capacity of this patient's monocytes to respond in chemotaxis, phagocytosis and intra¬
cellular killing point to the versatility of the monocyte in benign neutropenia and may help
explain the remarkable resistance to bacterial infection characteristic of this condition
(Zuelzer & Bajoghli, 1964). This is further supported by our patient who remains well
and fits the diagnostic criteria of chronic benign neutropenia of infancy.
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Summary. Chronic mucocutaneous candidiasis with hypoparathyroidism in a 6-
year-old boy is described. In addition to defects of in vivo and in vitro correlates
of delayed-type hypersensitivity to Candida albicans the child also had abnormalities
of neutrophil function in terms of their capacity to respond by chemotaxis to a
known attractant and to kill suspensions of C. albicans. Dialysable transfer factor
was given on six occasions at intervals of between 26 and 45 days. Neutrophil
chemotaxis (optimal conditions) was restored following each of the six injections,
neutrophil chemotaxis (sub-optimal conditions) following five of the six injections
and candidicidal capacity following four of the six injections. The effects of transfer
factor were transient requiring repeated injections. The Candida delayed-type
hypersensitivity skin test was restored to normal but lymphocyte transformation
to Candida extract was not consistently positive following treatment. There was a
slight clinical improvement following therapy. These abnormalities of neutrophil
and lymphocyte function point to the complexity of chronic mucocutaneous
candidiasis. The improvement in neutrophil chemotaxis and candidicidal capacity
following treatment suggests that transfer factor may be a heterogeneous group
ofmolecules, some ofwhich affect granulocytes and restore defects in their function.
Idiopathic chronic mucocutaneous candidiasis (CMC) is a disorder characterized by recurrent
or persistent infections of the skin, nails and mucous membranes with Candida albicans
(Kirkpatrick et al, 1971). The onset is usually in infancy or early childhood and the extent
of infection is variable but only rarely systemic. Approximately one third to one half of the
patients have an associated defect in endocrine function which may not appear until many
years later (Kirkpatrick et al, 1971; Kirkpatrick & Smith, 1974).
There is a heterogeneous pattern of defects in cell mediated immunity (CMI) as shown by
skin tests and in vitro assays of lymphocyte function (Valdimarsson et al, 1973). Two cases of
CMC have been described in association with defects in chemotaxis. In one patient the mono¬
cyte response was impaired and this was corrected by the administration of transfer factor
(Snyderman et al, 1973). In another case an impairment of neutrophil chemotaxis was found
Correspondence: Dr A. B. Kay, South-East Scotland Regional Blood Transfusion Service, Royal Infirmary,
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but the patient's neutrophils were normal in terms of their capacity to kill Staph, aureus and
E. coli (Clark et al, 1973).
In this report we describe a case ofCMC in association with defects of neutrophil chemo-
taxis and Candida killing, both ofwhich were corrected by transfer factor.
CASE REPORT
K.H., born in August 1968, developed at the age of 10 months a C. albicans infection of the
mouth, scalp, toenails and fingernails with intermittent involvement of the interdigital skin.
Investigations at 4 years showed a normal blood picture, a serum iron of 14.3 /zmol/1. (normal
range 14.3-36 /rmol/l.) and a positive delayed-type hypersensitivity skin reaction to Candida
extract. His neutrophils could reduce nitroblue tetrazolium (NBT). At this time the serum
calcium and phosphate concentrations were normal. A course oforal iron was given without
apparent improvement in his clinical condition.
At 4f years of age he became hypocalcaemic at which time the serum calcium was 1.44
mmol/1.,phosphate 3.1 mmol/1. and alkaline phosphatase 100 units/1. The Ellsworth-Howard
parathormone stimulation test supported the diagnosis ofhypoparathyroidism. There were no
clinical signs of hypocalcaemia and no corneal or lenticular abnormalities were found. A
skeletal survey was normal. Laboratory tests of other endocrine functions were normal.
Vitamin D therapy (calciferol 1.25 mg daily) corrected the biochemical defect (present serum
calcium 2.4mmol/1., phosphate 2.0mmol/1.) and oral nystatin resulted in a slight improvement
of his mouth lesions.
Measles at the age of 6 months and mumps and chickenpox at the age of 4 years were
without complications. The patient had had a number of staphylococcal skin infections
requiring incision but he did not suffer from systemic pyogenic infections.
In 1974, at the age of 6 years, his immunological function was fully investigated. Therapy
with dialysable transfer factor (TF) was begun in 1975 and was administered subcutaneously
at intervals ofapproximately 4 weeks. The first dose was 1 unit, the second to fifth doses were
2 units and the sixth dose 5 units (total 14 units). Since commencing TF therapy the oral
lesions have improved and the nail lesions are slowly regressing.
METHODS
Lymphocyte Studies
Peripheral blood T lymphocytes were estimated by the rosette technique using sheep
erythrocytes (Kaplan & Clark, 1974) and B cells by rosette formation with complement
coated sheep cells (Kaplan & Clark, 1974; Jondal et al, 1972). Lymphocyte transformation in
response to optimal concentrations of the mitogens phytohaemagglutinin (PHA) and
Concanavalin A (Con A), Candida antigen and pooled mitomycin-C treated allogeneic cells
(MLR) were determined by the incorporation of [3H] thymidine into DNA as previously
described (Kay et al, 1976). Preservative-free Candida extract was obtained from HAL-
Allergenen, Haarlem, Holland, and fromDr D. W. R. McKenzie, London School ofHygiene
and Tropical Medicine. Lymphocytes from a donor responsive to Candida were cultured
with the patient's serum to detect any serum inhibitor to transformation.
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Skin Tests
Delayed-type hypersensitivity skin tests were performed using streptokinase-streptodornase
(SKSD) (5 units, Varidase Lederle), mumps antigen (1 complement fixing unit Eli Lilly Ltd)
and Candida extract (0.02 ml 1% extract, Allergenen).
Neutrophil Function
Neutrophil enzymatic activity was assessed by the leucocyte alkaline phosphatase (LAP)
score, NBT test (Gordon et al, 1973), and myeloperoxidase (MPO) stain (Quaglino &
Flemans, 1958). Neutrophil phagocytosis and killing of Staph, aureus (Type 42b) was per¬
formed as previously described (Raeburn, 1972). Neutrophil candidicidal activity was assessed
essentially as described by Lehrer & Cline (1969), as modified by Goldman & Th'ng (1973).
Stained smears of the incubation mixtures were examined to count the percentage of neutro¬
phils containing Candida (% phagocytosis) and the mean number oforganisms per neutrophil
(phagocytic index).
Neutrophil chemotaxis in vitro was assayed by the leading front method using Millipore
filters of 3 /i pore size and a solution of casein (0.5 mg/ml, sub-optimal dose; 1.0 mg/ml,
optimal dose) as the chemoattractant (Wilkinson, 1974).
Immunoglobulins and Complement
IgG, IgA and IgM estimations were performed by single radial immunodiffusion on plates
purchased from Hyland, Thetford. IgE was measured by solid phase radioimmunoassay
using the 'Phadebas' kit (Pharmacia, London). Total haemolytic complement was measured
by the method ofMayer (1961). The individual complement components C3 and C4 were
measured by single radial immunodiffusion using monospecific antibody prepared in the
rabbit (Lachmann et al, 1973).
Preparation of Transfer Factor (TF)
Material was prepared from donors highly sensitive to Candida extract (>30 mm delayed-
type skin reaction). Buffy coat cells were obtained by leucapheresis, contaminating red cells
being removed by hydroxyethyl starch sedimentation at 37° C. The leucocyte supernatant
was washed in sterile pyrogen free saline and submitted to 10 cycles of freezing and thawing.
The leucocyte extract was vacuum dialysed against distilled water. The dialysate was freeze-
dried, reconstituted in saline, filtered through a 0.22 fi Millipore filter and stored at — 40°C.
One unit was defined as the amount ofmaterial prepared from 1 x io9 leucocytes.
RESULTS
Lymphocyte Function
Peripheral blood T and B lymphocyte subpopulations and lymphocyte transformation to
PHA, Con A and allogeneic cells were assessed on several occasions before and after treatment,
and were consistently normal, with no changes noted in relation to TF therapy. There was
no response to Candida extract initially, but a slight response was observed after the first dose
of TF; the response was unequivocally positive 4 d after the fourth dose of TF but has not
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been consistently positive thereafter (Fig i). No specific inhibition of lymphocyte stimulation
by Candida extract could be detected when the patient's pre-treatment serum was incubated
with normal responsive lymphocytes.
Skin Tests
Delayed-type hypersensitivity reactions to Candida, mumps antigen and SKSD were all
negative initially. The reaction to Candida extract was positive 3 d after the third dose of
TF (7 mm induration) and has since remained positive (Fig 1).
Candida lymphocyte transformation
+ -- _ _ + ± _ -a
Candida delayed -type skin test
Fig 1. Effect of transfer factor on Candida killing by neutrophils, lymphocyte transformation by
Candida and Candida delayed-type skin test. Hatched area represents normal range for neutrophil
candidicidal activity. TF = injection of transfer factor.
Neutrophil Function
Peripheral blood neutrophils were normal in number and morphology. The neutrophil
LAP score, MPO stain, and spontaneous and stimulated NBT tests were normal. Neutrophil
phagocytosis and killing of Staph, aureus was normal and phagocytosis ofCandida by neutro¬
phils was also repeatedly normal. The results ofneutrophil candidicidal capacity and chemo-
taxis are summarized in Figs 1 and 2. Prior to TF therapy, candidicidal capacity was low
(17.1% and 11.5%; normal range 21-38%). The capacity of neutrophils to kill Candida was
restored to the normal range after four of the six treatments with TF but this effect was
transient.
Neutrophil chemotaxis was also impaired prior to TF therapy both with the optimal dose
of casein (40 /im migration; normal range 41-75 /an) and the sub-optimal dose (9 pm migra¬
tion; normal range 27-59 /im). These impairments were corrected following TF therapy but
the effect was short-lived since chemotaxis was abnormal 2-3 weeks after the third and fourth
doses. The candidicidal defect in the patient's neutrophils was not corrected by incubation
with normal plasma suggesting that there was probably an intrinsic neutrophil defect.
Immunoglobulins and Complement
Serum levels of IgG, IgA, IgM and IgE were essentially normal. Serum total haemolytic
complement (CH50), C4 and C3 were also within normal limits.




Fig 2. Effect of transfer factor on neutrophil chemotactic response to optimal and sub-optimal doses
of chemoattractant (casein). Normal ranges shown by hatched areas. TF = injection of transfer
factor.
DISCUSSION
Other authors have demonstrated that the clinical response ofCMC to TF therapy is usually
transient, lasting a few weeks or months and necessitating repeated doses of TF to maintain
improvement (Pabst & Swanson, 1972; Grob et al, 1975). In our patient optimal neutrophil
chemotaxis was restored on six occasions, sub-optimal chemotaxis on five of six occasions,
and candidicidal capacity on four of six occasions. These effects were not permanent and
repeated injections ofTF were required. When TF did not fully restore neutrophil function
the preparation may not have been fully active. This emphasizes the necessity for a reliable
in vitro assay of the potency of TF prior to its in vivo use.
Dermal reactivity and lymphocyte in vitro transformation to Candida antigen were observed
after the third and fourth treatments respectively. Skin conversion was permanent but lym¬
phocyte transformation was not consistently restored. There is no correlation between the
pattern ofskin reactivity or lymphocyte transformation to Candida albicans and the restoration
ofneutrophil function by TF, emphasizing the complexity of the underlying defect in CMC
and demonstrating the imperfect correlation between the in vivo skin test and in vitro lympho¬
cyte transformation to the same antigen.
Our findings suggest that TF therapy can transiently affect neutrophil function in addition
to the known effects on lymphocytes. It is generally assumed that TF is derived from blood
lymphocytes or monocytes and that a single family of informational molecules (RNA-
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oligopeptide) is responsible for the transfer of reactivity (Grob et al, 1975; Lawrence, 1969).
However, no critical studies have been published which demonstrate conclusively the cell
type from which TF is derived. It is possible, therefore, that dialysable TF is a mixture of
factors, some ofwhich may be derived from granulocytes and which are capable of affecting
granulocyte function in the recipient.
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INTRODUCTION
The deposition of fibrin and its consequent lysis are complex
biological events. Not only are numerous factors and
co-factors involved but the haemostatic mechanism is also
intimately involved with other cascade-enzyme systems such as
complement and kinin formation. In addition, the generation
of fibrin and its removal i3 associated with the elaboration
of various biologically active peptides such as chemotactic
factors and agents which potentiate the effect of other
vaso-active principles. Some of these inter-relationships
will be described and their possible in vivo significance
discussed. ■
The Initiation of the Intrinsic Coa/pilation Pathway
Hageman factor (HE -.factor XII) is a remarkable protein.
It is an enzyme which can be activated by contact with a
variety of negatively charged materials such as gla33 and
collagen. In its activated form (Xlla) HF lias at least
three major substrates (Kaplan & Austen, 1972; Kaplan &
Austen, 197b). One is factor XI, which is converted to
XIa, proceeding to thrombin formation via the intrinsic
coagulation pathway (Fig. 1). Hageman factor can al30
convert a circulating plasminogen proactivator to its active
form (which in turn converts plasminogen to plasmin) and
prekallikrein to kallikrein which cleaves bradykinin from
its substrate kininogen. In addition to charged surfaces,
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FibrinopepUdea
A, AP, AY, [B]
(Reproduced by permission of the British Journal of
Haematology)
Figure 1. Hageman factor-dependent pathways and chemotaxis
for human neutrophils. The neutrophil chemotactic factors
associated with the haemostatic mechanisms.are depicted by
the "closed boxes". Differences between neutrophil and
monocyte chemotaxis in relation to these peptides is shown
in Tab]e 1.
the formation of activated Hageman factor is also dependent
on, and accelerated by kallikrein (Cochrane et al, 1972)
suggesting that in coagulation, as in other cascade-enzyme
systems such as complement, there are positive feedback
mechanisms at various stages during the enzymatic sequence.
Thus the initiation of the intrinsic coagu]ation pathway is
intimately involved with two other major protein systems,
plasmin generation and kinin formation. Their associated
biological properties are discussed below.
lie
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Figure 2. Diagrammatic representation of the various
plasminogen activator systems. (1) Hageman factor-dependent
(Kaplan & Austen, 1972). (2) Hageman factor-independent,
C3~dependent (Sehreiber & Austen, 1974). (3) Platelets, IgM,
thrombin and complement (Taylor & Mtlller-Eberhard, 1970).
(4) Endothelial cell-derived (Aoki & von Kaulla, 1971 ) -
Plasmin Generation and Its Substrates
A number of pathways have been described which convert
plasminogen to plasmin in vitro (Fig. 2). The substance or
substances involved are referred to as "plasminogen
activators". There- are probably several and which i3 of
greatest in vivo significance is yet to be determined. The
Hageman factor-dependent plasminogen activation pathway has
been mentioned above. In addition, a Hageman factor-
independent fibrinolytic system hao been described with an
apparent requirement for the third component of complement
(C3) (Schreibcr & Austen, 1974). Plasma deficient in C3
could not sustain fibrinolysis under the experimental
conditions described. Furthermore, a particularly complex
system has been reported which involves the platelet,
thrombin, IgM and the terminal complement components, in
particular 08 (Taylor Sr. Mffl I er-Eborhard , 1070). These
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Figure 3. Correlation between plasma 03 concentrations,
expressed as a per cent of a normal human pool (NUT) and the
plasminogen activator activity in the euglobulin portion of
plasma, measured on fibrin plates and expressed as the per
cent-of a standard of urokinase. (r = 0.60)
PlasmaC3
(%NHP)
25 50 75 100
Plasminogen activator in euglobulin (%urokinase standard)
workers suggested that a plasminogen activator is generated on
the surface of the platelet following the action of all these
agents. Finally a plasminogen activator derived from human
vascular endothelium has been identified which differs both
in molecular size and stability to other putative plasminogen
activators (Aoki & von Kaulla, 1971).
Preliminary work has been undertaken'in an attempt to
determine the importance of complement in fibrinolysis by
determining whether there was a correlation between
circulating plasminogen activator levels and C3 (Kay, A.B. -
unpublished observation). The concentration of C3 was plotted
against the plasminogen activator activity in the euglobulin
fraction of plasma from a number of patients and a






Figure 4. Various substrates of plasmin.
The possibility that C3 may be an inadvertent substrate for
plasmin was considered. This would appear unlikely from
previous studies in which it was shown that patients on
fibrinolytic therapy did not show changes in total hacinolytic
complement or concentrations of C3 (Tomar Sc Kolohins, 1972).
Like Hageman factor, plasmin is known to have a number
of substrates. These include fibrin, fibrinogen, activated
Hageman factor, C1 and C3 (Fig. 4). Plasmin digestion of
fibrin (and fibrinogen) leads to the generation of various
"fibrin/fibrinogen degradation products" (FDP) many of which
have biological activity (see below). The action of plasmin
on Xlla leads to the formation of Hageman factor fragments
of low molecular weight. The low molecular weight fragments
are far more efficient at converting prekullikrein to
kallikrein and the Hageman factoi'-dependent plasminogen
proactivator to its active form. In contrast, activated
Hageman factor, which has not been acted on by plasmin, has
greater activity for factor XI (Kaplan Sc Austen, 1970).
Plasmin is also said to activate the first component of
complement (Ratnoff & Naff, 1967) whose natural substrates
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are C4 and C2. Some doubt has been cast on the
significance of this form of "triggering" of the classical
complement pathway. A fragment can be cieaved from C3 by
plasmin which has chemotactic activity for a number of cell
types including neutrophils, eosinophils and monocytes
(Ward, 1907).
Biological Activities of Coagulation-Associated Peptides
Of the "non-coagulation" biological activities associated
with haemostasia, chemotaxi3 ha3 probably received the most
attention (reviewed by Kay & Kaplan, 1975) (Fig. 1).
Initial investigations on the chemotactic activity of
normal human serum indicated that many factors were involved
since multiple peak3 of chcmotactic activity could be
demonstrated following chromatography on Sephadex G-200
(Kaplan et al, 1972). One of these peaks superimposed the
position in which the enzymes kallikrein (mol. wt. 108,000)
and the liageman factor-dependent plasminogen activator (mol.
wt. 90,000) clutcd. Although these molecules have a similar
molecular size it was possible, by further purification and
separation, to show that chemotactic activity was associated
with both enzymes. Thus kallikrein, in addition to cleaving
bradykinin from its substrate kininogen, was a chemoattractant
as was this plasminogen activator. More direct evidence of
the chemotactic properties of these enzymes was obtained by
incubating highly purified HF fragments with their respective
proenzymes. Thus a mixture of purified HF fragments and
prekallikrein led to the .elaboration of both chcmotactic
activity and cleavage of bradykinin from kininogen.
Similarly plasminogen-converting chemotactic activity was
generated by the action of activated Hageman factor on the
plasminogen proactivator. Of particular interest was the
fact that both the enzymatic and chemotactic principle of
the plasminogen activator and kallikrein were inhibited by
the serine esterase inhibitor, diisopropyl fluorophosphate
(DFP). The activity of these enzymes was therefore
dependent upon the integrity of their active sites since
neither enzyme in its precursor form was DFP sensitive.
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Further insight into the chemotactic properties of
kallikrein und plasminogen activator was provided by studies
on prekallikrein (Fletcher factor) deficient plasma (Weiss
et ul, 1974). riasina from these individuals have defects
in coagulation, fibrinolysis, kinin-generation and chemotaxi
all of which can be corrected by the addition of purified
prekallikrein. The correction of these defects by
prekallikrein is attributed to a further property of
kallikrein, namely its capacity to activate HF so providing
a positive feedback for HF-dependent pathways (Cochrane et
al, 1972). These pathways are activated by the action of
HF on its three known substrates, factor XI, prekallikrein
and the plasminogen proactivator (Fig. 1). Using kaolin as
the UF activator, restoration of chemotactic activity in
Fletcher factor deficient plasma could be achieved by
activated HF as well as prekallikrein. This suggested that
the contribution of kallikrein to the chcmotactic activity
of kaolin-activated serum was small and that under these
conditions the plasminogen activator and other unidentified
HF-dependent chcmotactic factors were probably providing
most of the activity.
These studies 011 the chemotactic activity of kallikrein
and the plasminogen activator used unscparated human
peripheral blood leucocytes as target cells. Whereas
unseparated cell populations are acceptable for measuring
the chemotactic response of the neutrophil, study of monocyte
chemotaxis requires prior separation of the mononuclear
cells. This can be conveniently achieved by layering a
leucocyte mixture onto Hypaque-Ficoll. Following
centrifugation, the less dense mononuclear cells can be
separated in a viable form. These cells also responded in
chemotaxis to kallikrein and plasminogen activator and there
was a similar inhibition of the active site by DFF (Gallin &
Kaplan, 1974). Alpha-2-macroglobulin inhibited both the
enzymatic effect of kallikrein and plasminogen activator in
terms of their actions on kininogen and plasminogen and also
the ability of these enzymes to respond in monocyte chemotaxis
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The C1 inhibitor prevented both the enzymatic action of
ka]3ikroin on kininogen and ito ohemotuctic principle but
had no effect on the expression of the plasminogen activator
either as a chetnotactic agent or its action on plasminogen.
Therefore these naturally occurring protein inhibitors
(alpha-2-inacroglobulin and C1 inhibitor) affect the enzymatic
principle in a similar fashion to their chemotactic activity.
The action of Hageman factor on factor XI (plasma
thromboplastin antecedent - PTA) leads to the formation of
thrombin via the intrinsic coagulation pathway. Clot
supernatants prepared by the action of purified thrombin on
fibrinogen are chemotactic for neutrophils, and to a lesser
extent for eosinophils, while neither thrombin nor fibrinogen
alone possesses this activity (Kay et al, 1973). Thrombin
is known to be a limited protease which cleaves several
small peptides from fibrinogen. Those fibrinopeptides have
been designated A, AP, AY and D and are recognised on the
basis of their electrophoretic mobility (Dlomb^ck et al,
1966). Evidence has been provided that the chemotactic
activity is a property of fibrinopeptide B and not of
fibrinopeptides A, AP, or AY (Kay et al, 1974). This was
shown by progressive purification of thrombin-induced clot
supornatuntu using high voltage electrophoresis in two
dimensions. Supernat;mts prepared by the action of the
snake venom Contortrix which cleaves the B peptide, were
also chemotactic whereas no activity was present in
supernatants prepared from the Arvin venom which cleaves
peptides A, AP and AY. Furthermore, synthetic fibrino¬
peptide B and a B analogue, 1-glutamic acid, were chemotactic
but not synthetic fibrinopeptide A. More recent studies
have shown that fibrinopeptide B lias chemotactic activity
for human monocytes (Kiehurdoon et al, 1976).
Other biological activities are associated with
fibrinopeptide B. These include potentiation of bradykinin-
induced constriction of the isolated oestrous rat uterus
(Gladncr et al, 1968) and prolonged rhythmic vaso¬
constriction (Colmon et al, 1967). It i3 probable that the
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biological activity associated with fibrinopeptide D is
located at its G-terminua since this part of the molecule is
exposed following the action of thrombin and other enzymes
which cleave 13 from the ft polypeptide chain of fibrinogen.
Other peptides derived from fibrinogen have been
examined for possible chemotactic activity since fibrin/
fibrinogen degradation products (FDP) appear in body fluids
in association with various clinical states and have a number
of biological activities. Chemotactic activity for human
neutrophils and to a lesser extent eosinophils could be
generated by the action of plasmin 011 human fibrinogen
(McKenzie et al, 1975). .Previous studies have shown that
plasmin degradation of human fibrinogen yields four ma.jor
fragments designated X, Y, D and E in addition to smaller
peptide material (Furlan & Beck, 1977). When plasmin
digestion was stopped at time intervals up to 24 hours, a
small amount of. activity was apparent at 15 and 30 minutes
corresponding to the transient appearance of fragment Y.
Considerably more chemotactic activity was present in the
24 hour digest and by gel-filtration this was shown to be
associated with relatively small molecules having a molecular
size of approximately 30,000 daltons. When purified X, Y,
D and E were assayed individually for eheinotaxis, fragment Y
was active but only at relatively high concentrations.
Therefore the chemotactic activity generated by the action
of plasmin on fibrinogen was mainly associated with one or
more lower molecular-weight polypeptides and to a lesser,
extent with the Y fragment.
Monocyte chemotactie activity was also generated by the
action of plasmin on human fibrinogen and shown to be
associated with the 13 and E fragments but not with a mixture
of fragments X and Y (Richardson et al, 197b). When plasmin
digestion was stopped at time intervals up to 24 hours,
monocyte chemotactic activity corresponded with the appearance
of the 1) and E fragments. The monocyte chemotactic activity
contained in a 24 hour digest, eluted from Sephadex G-75 at
VQ corresponding to the expected position of the D and E
fragments whereas neutrophil cheinotuctic activity eluted with
molecules of molecular si ze of approximately 30,000 dultons.
Thus fragments D and E derived from plusmin digestion of
fibrinogen attract the monocyte whereas only the small
uncharacterised peptides were ehemotactic for the neutrophil.
These different profiles of ehemotactic activity for the
neutrophil and the monocyte in terms of plasmin digestion
products of fibrinogen'may be of significance in the events
leading to tlie accumulation of these cells in vivo during
fibrin deposition.
Tims there is a formidable list of chemotuctic factors
associated with coagulation, kinin formation and fibrinolysis
(Table'1). The biological significance of- these observations
Table 1. The chcmotaetic activities of leucocytes for
fibrinogen-derived peptides and Hageman factor-dependent enzymes
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1,1100















activator 90,000 + +
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isj unknown but the accumulation of various coll types in
inflammatory conditions associated with HF-dependent
pathways is well recognised. For instance, following the
formation of fibrin there is an initial accumulation of
neutrophils whereas during the resolution the mononuclear
cell predominates. These factors may also act together
since synergism between chemotactic factors has been shown
for neutrophils (Wilkinson et al, 1969), monocytes and
eosinophils (Kay et al, 1973)• The association of the
kinins and related peptides to various disease states is also
appreciated. For instance, the accumulation of neutrophils
in .the joint fluids of gout arthritis may in part be mediated
by kallikrein formed as a consequence of uric acid crystal-
induced HF activation (Kellermeyer & Breckenridge, 1969).
Many chemotactic agents possess other biological
activities. C3a and C5a are anaphylatoxins (Cochrane &
Mflller-Eberhard, 1968), C'jb7 act in the phenomenon of
"reactive lysis" (Thompson & Lachmann, 1970) and various
activities have been attributed to fibrinopeptide 13 (see
above). It is clear that the full complexity of these
cascade-enzyme systems is still to be appreciated. However,
a consideration of the relationship between the leucocyte,
coagulation, kinin-formation and fibrinolysis may help our
understandihg of the significance of these biochemical
pathways in health and disease.
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Human transfer factor (TF) was prepared by a variety of methods including dialysis
using cellophane tubing, ultrafiltration through a membrane of known pore size, Sepha-
dex G-25 chromatography or combinations of some of these methods. In general the
various preparations when injected locally into human skin gave greater delayed-type
responses than antigen (PPD or Candida) alone. The combination of either vacuum dia¬
lysis, or ultrafiltration, with G-25 chromatography gave as good or better TF activity
when compared with unchromatographed materials. Since ultrafiltration and concentra¬
tion is a rapid procedure and eliminates the need for freeze-drying, in contrast to vacuum
dialysis against water, these results indicate that ultrafiltration and G-25 chromatography
provide a convenient method for preparing large batches of relatively pure TF from leuco¬
cyte extracts.
INTRODUCTION
Human transfer factor (TF) for both experimental work and clinical use
is usually prepared using cellophane dialysis (Visking) tubing. Transfer fac¬
tor can also be prepared by ultrafiltration or gel filtration, but a critical com¬
parison of biological activity prepared by the three different methods is dif¬
ficult due largely to the lack of a suitable in vitro assay. Furthermore, this
lack of a simple and reliable in vitro assay is a major hindrance to proper
characterisation and standardisation of TF for clinical trials. A number of
laboratories have found the lymphocyte transformation assay, described by
Ascher et al. (1974) to be unreliable mainly because of inconsistencies in
reproducibility (Arala-Chaves et al., 1974; Ahern, 1975; Neidhart and
LoBuglio, 1975; Sanderson, 1975).
The local transfer of intradermal sensitivity by TF was first described by
Lawrence and Zweiman (1968) and was applied more recently to the char¬
acterisation of TF, from a PPD-positive donor, prepared by Sephadex G-25
chromatography (Neidhart et al., 1973).
In the present report the local transfer of skin sensitivity has been used
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as the assay for comparing the activity of human TF prepared by cello¬
phane tubing dialysis alone, ultrafiltration and G-25 gel chromatography.
MATERIALS AND METHODS
Selection of leucocyte donors
Two volunteers, one highly skin-test sensitive to PPD and the other to
Candida extract were selected as leucocyte donors for the preparation of
TF. Both were negative for HBsAg by haemagglutination inhibition.
Preparation of transfer factor
Four hundred ml of blood were drawn into a double plasmapheresis pack
(Fenwal, Thetford, Norfold) containing 75 ml acid—citrate—dextrose and
centrifuged at 2000g for 2 min at 22°C. The buffy-coat was slightly dis¬
turbed to ensure a maximal leucocyte yield and the leucocyte-rich plasma
together with a minimal amount of red cells was expressed into the transfer
pack. The red cells were reinfused and the process repeated. Both packs of
leucocyte-rich plasma were then concentrated by centrifugation at 3,500 £
for 10 min at 22° C following which the supernatant plasma was removed.
The buffy-coat concentrates were allowed to stand for 1 h at 37° C to allow
disaggregation of cells. The concentrates were pooled and mixed with 6%
Dextran 70 (30% by volume) and allowed to stand for 45 min at 37° C to
sediment red blood cells. The leucocytes were removed, centrifuged at
400£ for 10 min at 22°C, washed once in heparin/saline (Fenwal 'saline'
with 10 units of preservative-free heparin (Evans Medical, Liverpool) per
ml) and resuspended in the same buffer and total white cells counted. The
leucocytes were then finally centrifuged at 1,500 g for 10 min and resus¬
pended in 0.01 M NH4H C03. A leucocyte extract was prepared by freezing
and thawing from —70°C to 37° C, the procedure being repeated 10 times.
No DNase was added. The extract was divided into three aliquots for the
preparation of TF by three methods (fig. 1). One 'unit' of TF was arbitrarily
defined as the material prepared from 109 leucocytes.
Dialysis by vacuum
One portion of leucocyte extract (B, fig. 1) was placed in 8/32 inch Vis-
king dialysis tubing (previously boiled). The tubing was then placed in a
500 ml Btichner flask containing 200 ml of pyrogen-free distilled water. One
end of the tubing was fitted over a plastic tube ('biotip') which in turn was
connected to a syringe barrel and covered with a sterile pad as shown in
fig. 2. The vacuum was then applied (22 inches of Hg) for 20 h at 4°C, the
tubing removed and the dialysate 'shell-frozen' in liquid nitrogen and freeze-
dried. The material was reconstituted in 20 ml of saline (Fenwal) and divided
into two portions. One was used directly for in vivo tests (sample 5, fig. 1)
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Freeze/Thawed leucocytes (in 0.01M NH^HCO^)
Centrifugation 20,000g
Vacuum dialysis











Fig. 1. The preparation of freeze/thawed leucocytes (aliquots A, B and C) for the produc¬
tion of transfer factor by three different methods.
and the other applied to a column of G-25 under the conditions described
below.
Dialysis by ultra filtration
The second aliquot (C, fig. 1) was passed through a PMIO membrane in
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an Amicon Cell 50 at a pressure of 25 pounds per cm2. The ultrafiltrate was
then concentrated in the same cell using a UM05 membrane. The concen¬
trate was divided into two. One portion was freeze-dried, reconstituted in
saline (sample 8, fig. 1) as described above and tested for in vivo activity.
The second was applied to a column of Sephadex G-25 as described below.
PPD TRANSFER FACTOR
30 40 50 60 70 80
TUBE NUMBER
Fig. 3. Sephadex G-25 chromatography of leucocyte extracts prepared by three different
methods (fig. 1) from PPD sensitive donors. Unfractionated (crude) material is indicated




















Prior to application to columns of G-25 Sephadex all samples where neces¬
sary were centrifuged to remove particulate matter. Two ml of the various
samples were applied to 2.5 X 100 cm columns of Sephadex G-25 in 0.01 M
NH4HCO3, pH 7.75 and 7.5 ml fraction volumes collected. Glucose was
added to the sample, and detected using 'Clinistix', to estimate the bed
volume (Vs). Material eluted after this point was identified by estimation of
CANDIDA TRANSFER FACTOR
TUBE NUMBER
Fig. 4. Sephadex G-25 chromatography of leucocyte extracts prepared by three different
methods (fig. 1) from Candida-sensitive donors. Unfractionated (crude) material is indi¬
cated on the right hand side of the histograms for samples B and C respectively.
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the absorbance at 260 and 280 nm according to the method of Neidhart
et al. (1973) and Zuckermann et al. (1974). The two peaks of activity at OD
260 nm, eluting after Vs, were pooled as shown in figs. 3 and 4.
Sample A (fig. 1) was applied directly to the column after centrifugation
to remove particulate matter. The vacuum dialysed (VD-TF) and ultrafil-
tered (PM10-TF) preparations were also subjected to G-25 gel filtration and
the peaks appearing after Vs were designated pool 1 and pool 2 (figs. 3 and
4). Thus the two peaks (pool 1 and pool 2) for aliquot A are referred to as
samples 1 and 2; and the G-25 peaks from B and C as samples 3 and 4, and
samples 6 and 7 respectively (fig. 1). All the G-25 pools and the crude Vd-TF
were concentrated by freeze drying and reconstitution in saline (Fenwal).
The G-25 pools were reconstituted to the same volume as the original
starting material for skin testing: i.e. 1 unit of crude TF was diluted to a vol¬
ume of 50 ml and a G-25 pool derived from 1 unit was reconstituted to a
volume of 50 ml.
All preparations were sterilised by filtration through Millipore filters
(0.22 p pore size) and stored at —40°C.
Local transfer of intradermal hypersensitivity
The method of Lawrence and Zweiman (1968) was modified as follows.
0.05 ml of 10~3 units of TF in saline were injected intradermally into the
ventral surface of the forearm. Twenty-four h later the test antigen was
injected intradermally at the same site. Antigen doses were 5 TU of PPD
(Evans) or 0.02 ml of Candida extract (Allergenen). Delayed hypersensitivity
skin reactions were read at 24 and 48 h. Results were assessed by two inde¬
pendent observers. The diameter of induration in 2 directions was measured
and the results averaged. Erythema without induration or swelling was not
considered to be significant. All test sites were on one forearm and the con¬
trol site (saline followed by antigen) was on the other forearm.
The measurement of TF activity was the increase in skin reaction above
the control, expressed in mm.
Intradermal injection of TF alone caused no reaction, either immediate or
delayed.
RESULTS
The elution profiles of the various G-25 columns are shown in fig. 3 (PPD-
sensitive donor) and fig. 4 (Candida-sensitive donor). The local skin reactions
above control values for selected responders (see below) are indicated for the
various pools. Individual data are given in table 1 and table 2 (for Candida).
Local transfer of PPD sensitivity
Eight preparations were tested in 7 subjects of whom 4 were found to give
a substantial response. Since the increment of increased skin reaction above
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control was similar at 24 h and 48 h only the 24 h data are given (table 1).
The results in two responsive recipients (P.F. & J.L.) were averaged as
shown in fig. 3 and are illustrated against the corresponding chromatograms.
In general activity could be demonstrated with all preparations but some
recipients (G. McN and S.W.) gave minimal or no increase in induration
(table 1). However, these two individuals gave vigorous skin responses to
PPD alone. VD-TF Pool 1 (Sample 3) and PM10-TF Pools 1 and 2 (Samples
6 and 7) were in general more active than the corresponding crude prepara¬
tions (which had not been subjected to G-25 chromatography). In general
all samples gave similar increments in skin reactivity with the exception of
Samples 2 and 8 although the latter are the mean results of two good
responders.
Local transfer of Candida sensitivity
The eight preparations were tested in 5 subjects of whom 3 were found to
be reasonably good responders. As with PPD, only the 24 h results are shown
(table 2, fig. 4). The results in three responsive recipients (S.W, M.M. & J.M.)
were averaged as shown in fig. 4. The increase in skin reactions conferred by
Candida/TF is noticeably less than that conferred by PPD/TF. In general the
mean increments with all samples were essentially similar. However, the good
responders (S.W, M.M. and J.M.) gave higher increments (fig. 4).
Again the TF prepared by G-25 gel infiltration alone showed more activity
in pool 1 than in pool 2.
These data and those from preliminary tests on other subjects showed that
6/13 were 'responders' in the PPD system and 5/11 were 'responders' in the
Candida system.
DISCUSSION
When the mean skin test increments of all the samples (1—8) in all volun¬
teers are compared, little difference in activity is apparent (as shown by the
mean increments, tables 1 and 2). However, when the results in the best
responders (P.F. and J.L. for PPD: S.W, M.M, and J.H. for Candida) are
averaged and compared, in general the peaks from the G-25 columns gave
greater activity than the starting material (aliquots B and C, figs. 3 and 4).
This might indicate the presence of inhibitor(s) in the crude unfractionated
preparations as had previously been suggested by Neidhart et al. (1973).
When crude leucocyte extract was subjected only to G-25 filtration,
Pool 1 was slightly more active than Pool 2 thus agreeing with the results of
Neidhart et al. (1973) who also used the local transfer of skin reactivity as
the assay.
The molecular nature of TF remains unknown although there is some evi¬
dence that it may be an oligopeptide-oligonucleotide, perhaps an antigen
fragment linked to RNA (Gottlieb and Schwartz, 1972).
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It has been previously demonstrated that when human TF is eluted from
G-25 with low ionic strength (0.01 M) phosphate buffer the major biological
activity resides in the peak immediately following Vs (Neidhart et al., 1973)
i.e. the active material is adsorbed and therefore the ionic strength of the
buffer is probably of critical importance in determining the pattern of elu-
tion. Thus the G-25 Sephadex procedure probably functions by ion
exchange and not gel filtration in this application.
Crude leucocyte extract would contain a variety of membrane-associated
antigens. Most of these are probably eliminated by dialysis or ultrafiltra¬
tion and therefore G-25 chromatography alone is probably unsatisfactory
because there is no means of ensuring that all antigenic material is eluted
before Vs.
An important limitation of our results is that significant TF activity may
have been eluted in the peaks appearing before Vs, which were not tested.
However, the need to test all preparations simultaneously in one volunteer
limited the number of fractions that could be assayed.
PM-10 filtration and VM-05 concentration is the quickest and most
convenient of the three 'single-stage' methods of preparing human TF. Ultra¬
filtration followed by G-25 chromatography yields active fractions which are
at least as active as ultrafiltered material. Therefore, this may be the method
of choice for preparing batches of partially purified human TF for clinical
use.
Although local transfer of intradermal sensitivity by TF is simple and
reflects in vivo activity, there is still a need for a simple, reliable and sensitive
in vitro assay. In evaluating this technique we made the following observa¬
tions:
a) About 50% of the suitable volunteer recipients were responders to TF
in the local transfer test: 4/6 responded with an increased skin reaction to
PPD and 3/5 responded with an increased skin reaction to Candida extract.
However, even in these individuals the increment obtained with some of the
preparations was slight. Hence it is necessary to test a batch of TF in at
least five, and preferably more, suitable recipients.
b) Each skin test was painful — usually more painful than a venepuncture
— despite the use of isotonic solutions and preservative-free test antigens.
c) Neither the injection of a small volume intradermally nor the reading
of the delayed hypersensitivity skin reaction can be performed with great
accuracy — thus the need to average results from a group of subjects and to
have more than one observer.
d) Local transfer of PPD sensitivity was in general a more sensitive system
than transfer of Candida sensitivity, although this may well have been a func¬
tion of the particular combinations of donors and recipients in our study.
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47.2 Application of immunological methods
This chapter is concerned with the investigations
required for assessment of the nature and extent of
defects of immunity. In most cases the nature of the
illness is self-evident and only the extent of immuno¬
deficiency needs to be defined, together with an
assessment as to whether the defects are primary or
secondary.
Before embarking on time-consuming laboratory
investigations it is important to be satisfied that
'non-immunological' causes have been ruled out.
Immunological investigations are most likely to be
helpful in cases of unusual or recurrent infections.
The cardinal feature of T lymphocyte dysfunction
is the occurrence of severe infection with viral
pathogens or 'unusual' organisms. For instance,
measles, chiekenpox, and candidiasis may take an
unusually sescre course and uncommon pathogens
such as cytomegalovirus and Pneumocystis carinii
may also be involved. In addition severe illness may
follow routine vaccination with live viruses. T cell
deficiency may be associated with failure to thrive,
chronic diarrhoea, chronic candidiasis, and graft-
versus-host disease following blood transfusion.
Failure of B lymphocyte function with low or
absent immunoglobulins (and antibodies) results in
repeated infections with the more common bacterial
pathogens. These include staphylococci, strepto¬
cocci, pneumococci and haemophilus. The most
common sites of infection arc the lung, middle car,
sinuses and meninges. In contrast to T cell deficiency,
B cell deficient individuals tolerate viral infections,
including vaccination.
Neutropenia or deficiency of granulocyte function
also results in repeated bacterial infections. Deficient
phagocyte function as in splenic agenesis or splenec¬
tomy in childhood may be associated with over¬
whelming septicaemia with organisms such as
pneumococci or meningococci. Adults with splenec¬
tomy also have an increased incidence of septicaemia.
Deficiency of complement components arc rare
but may result in either repeated bacterial infections
or a lupus-like syndrome, or no apparent ill health
depending on which factor(s) is involved.
GENERAL. INVESTIGATIONS
Simple laboratory investigations such as full blood
counts and chest X-rays may give valuable informa¬
tion. For instance, lymphopacnia is common in
primary immunodeficiency although a normal
lymphocyte count docs not exclude the diagnosis. In
contrast, a very high lymphocyte count, or abnormal
type (as in the lymphoproliferative disorders) often
results in secondary immunodeficiency. Neutrophil
numbers may be unusually low in the presence of
pyogenic infections and apart from obvious causes
such as cytotoxic drug therapy or agranulocytosis
following drug sensitization, may be the result of
antibodies to neutrophils. Examination of neutrophil
numbers over a period of time is necessary for the
diagnosis of cyclical neutropenia. Morphologically
abnormal granulocytes may be found, e.g. in the
giant lysosomal granules of the Chcdiak-Higashi
syndrome.
A lateral chest X-ray of the mediastinum in infants
or neonates may indicate the absence of the thymus
gland and with an abdominal X-ray the absence of
a splenic shadow may indicate agenesis of that organ.
Histopathology of lymphoid tissue is also a useful
adjunct to the diagnosis of immunodeficiency. Bone
marrow, rectal mucosa and lymph nodes are the
most accessible tissues for study. Lymph node biopsy
will reveal absent lymphoid follicles and germinal
centres in B cell deficiency diseases whereas there
will be a paucity of lymphocytes in the para-cortical
areas in T cell deficiency. Guidelines for morpho¬
logical assessment have been suggested by the
W.H.O. [I]. Lymph node biopsy is not to be under¬
taken lightly as a matter of routine in the diagnosis
of immunodeficiencies as the information obtained
is somewhat limited and there is serious risk of
subsequent infection.
Where there is a poor response to apparently
adequate chemotherapy it is important to determine
the antibiotic sensitivities of the suspected organ¬
ism. Unusual organisms requiring specialized
sampling and culture techniques may be involved.
GENERAL TECHNICAL
CONSIDERATIONS
Many tests for evaluation of the immune system arc
complex and time-consuming. There will inevitably
be a compromise between desirability and practical¬
ity. Tests must therefore be informative, discrimina¬
tory and clinically relevant. In the remaining sections
of this chapter we will outline the currently available
technology with emphasis on its clinical relevance.
Many of the serological techniques have been well
established in other specialities for diagnosing and
assessing disease, e.g. antistrcptolysin-O titre, organ
specific autoantibodies, viral antibody levels. Their
use in clinical immunology is one of different
emphasis and they will not be considered in any detail.
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It is most important that the sample collection,
cell separation and culture methods are standardized
and that normal values are obtained by each labora¬
tory by their own technology. Because of the com¬
plexity of many tests, it is necessary to include a
normal control with each batch of test samples so
that negative results due to methodological errors
are minimized. A single abnormal in vitro result must
not be considered in isolation. If there is a discrep¬
ancy between the in vitro and in vivo test results then
the former must be interpreted with caution and, if
necessary, repeated. There arc always occasions
when it is impossible to interpret the results obtained
in the light of the clinical findings and one must
accept the limitations of present day technology.
Where there is genuine doubt one should be guided
primarily by the patient's clinical condition and not
by an abnormal laboratory result.
The investigation of the immune system may be
conveniently considered as follows:
(a) investigation of T lymphocyte function;
(b) investigation of B lymphocyte function;
(c) investigation of phagocyte function;
(d) investigation of the complement system.
INVESTIGATION OF T LYMPHOCYTE
FUNCTION
Full investigation requires both a numerical and
functional assessment. The enumeration of T lym¬
phocytes is usually performed with peripheral blood
samples, although some additional information may
be obtained from studies on other human material
such as lymph nodes, spleen, thoracic duct lymph
and synovial fluid. Surface marker methods are used
to identify circulating T and B lymphocytes since
they are morphologically indistinguishable. The
functional assessment of T lymphocytes in vitro is
complex and technically demanding, involving tissue
culture, and the interpretation of results is often
difficult. Some of the tests in current use require
large volumes of blood and there is a need for
reliable micromcthods; this is especially important
in the assessment of children and those patients w ith
lymphopaenia. There are limitations in testing only
one 'compartment' of the immune system, however
convenient, and the absence of circulating T cells
may indicate sequestration elsewhere and not an
absolute deficiency.
The in vivo assessment of T cell function is tech¬
nically undemanding. However, tests such as delayed
hypersensitivity (DM) skin tests reflect many aspects
of cell mediated immunity, and even non-immuno-
logic effector systems. Thus the interpretation of
abnormal results may be difficult.
Quantitation of T lymphocytes
The spontaneous sheep red cell rosette (E rosette)
and anti-T cell sera are the most common methods
used for identifying T cells. The E-rosette method is
technically simple and consistent results may be
obtained by any one laboratory. However, widely
differing normal ranges have been reported by slight
variations in technology [2, 3]. Approximately 70
per cent of blood lymphocytes are identified as T
cells by this method. With certain technical modi¬
fications a subpopulation of T cells may be identified
which arc thought to have 'high affinity' receptors
for sheep red cells [4],
Antiscra specific for T cells have been produced
by a number of workers [3, 5] and their use requires
a cytotoxic assay or a fluorescent method. Even so,
different results may be obtained with the same anti¬
serum using both of these methods. For this reason
enumeration of T cells using specific antiscra has had
limited application in routine clinical work.
It is essential that lymphocyte subpopulations are
reported not only as a percentage of circulating
lymphocytes but also in absolute numbers. In this
way, variations in total lymphocyte numbers arc
accounted for. It should be appreciated that separa¬
tion methods may result in selective losses of certain
sub-populations [6, 7], The use of T and B cell
markers has been shown to be of value in the classi¬
fication of a number of lympho-prolifcrative diseases
and immunodeficiencies [8, 9]. Thus, T cells may be
virtually absent from the circulation of patients with
chronic lymphatic leukaemia [10] whereas in acute
leukaemia, cells may be devoid of surface markers
or identified as T cell derived [II], Patients with
immunodeficiencies have variable findings and it is
important to correlate assessment of T cell function
with T ceil numbers since discrepancies may indicate
blocking or inhibitory factors. Many diseases in
which there is evidence of depressed cell mediated
immunity (CMI) by functional analysis, e.g. lepro-
matous leprosy, certain cancers, can also be shown
to have low circulating T cell numbers [4, 12],
Much of this information cannot be translated
clinically in terms of prognosis and better treatment
and the value of many of the tests must await
clarification.
47.4 Application of immunological methods
Method for estimation of T lymphocytes by 'E'
rosettes (after Kaplan & Clark) [13J*
Principle
Lymphocytes which have surface receptors for sheep
red cells arc believed to be thymus-dependent (T
cells). Lymphocytes with these receptors will bind a
cluster of sheep red cells, forming an erythrocyte
rosette (Er). Normally the binding of sheep red
cells (Li) to T lymphocytes is relatively weak, treat¬
ment of E with AET stabilizes the binding, giving a
more reproducible test with maximal identification
of T cells (per cent E(*i.T)r + pcr cent EACr approxi¬
mate to 100 per cent). Similar reproducibility and
maximization can be achieved using papain-trcated
sheep red cells [14).
Materials
(1) Sheep red cells (approximately 50 per cent
solution in Alsevcr's).
(2) AET solution (0 402 g of S2-aminocthyliso-
thiouroniuni-hydrobromide in 10 ml of distilled
water, adjusted to pH 9 0 with 4 n sodium hydroxide).
(3) Fetal calf serum, heat-inactivated (Wellcome,
Dcckcnham, Kent, U.K.).
(4) Medium 199 (Gibeo-Biocult Ltd., Paisley,
Scotland).
(5) Latex suspension (1/100 dilution, size 1011 //
(Dow-Latex, Serva, Heidelberg, W. Germany).
(6) May-Grunwald and Giemsa stains.
(7) Liquid cover glass (Trycolac, Aerosol Market¬
ing & Chemical Co. Ltd., London).
Procedure
Preparation ofAET treated sheep cells
(1) Two millilitres of the sheep red cell suspension
is washed three times in 10 ml of saline.
(2) To 1 volume of washed packed sheep red cells
(approximately 1 ml) add 4 volumes of AET solu¬
tion.
(3) Mix and incubate at 37" C for 15 min with
repeated mixing.
(4) Wash three times in saline and once in medium
199 and resuspend in 80 per cent medium 199 (7 ml)/
20 per cent fetal calf serum (2 ml) to give a 10 per
cent suspension of E<aht>; store at 4° C. The suspen¬
sion can be used for up to 1 week.
* A recent publication indicates that it may be possible
to estimate T lymphocytes on smears using a modification
of the non-specific esterase stain (Kulenkampfe J.,
Janossy G. & Greaves M.F. (1977) Acid esterase in
human lymphoid cells and leukacmic blasts. A marker
for T lymphocytes. Brit. J. Haemal. 36, 231).
Lymphocyte preparation
(1) Mononuclear cells are prepared as for lympho¬
cyte transformation (sec p. 47.5).
(2) Phagocytic cells arc identified by incubation
of the cell suspension with latex particles. Usually 3
to 4 drops of 1/100 latex suspension is added to I ml
at approximately 2-4 million mononuclear cells per
ml. The mixture is incubated tit 37" C" for 30 min
with frequent mixing and then washed in medium
199 and adjusted to give 2 million cells per ml.
Rosetting procedure
(1) To 0 5 ml of lymphocyte suspension (2x 10"/
ml) 0-25 ml of fetal calf scrum is added and 6-8 drops
of E(AtT) to give a minimum ratio of 8 red cells to
1 lymphocyte and mix thoroughly.
(2) Centrifuge gently at 25 g for 5 min.
(3) Incubate overnight at 4' C for maximal rosette
formation.
(4) The cell pellet is rcsuspended by gentle
aspiration with a Pasteur pipette.
(5) Slides arc prepared immediately after rcsus-
pension as follows. Capillarity is used to draw the
cell suspension into the Pasteur pipette, from which
the cell suspension is deposited on a glass slide by
surface tension; an area of about three-quarters of
the slide surface is covered. The slide is air-dried with
a fan and then fixed in methanol for a minimum of
2 min. Staining is done with May-Grunwald-Giemsa
in the usual way (see NBT test, p. 47.18) and the
slides may be preserved by spraying with liquid
cover-glass (Trycolac) after drying, which aids
resolution.
Examination
Lymphocytes having three or more red cells bound
arc counted as rosettes. All non-rosctting lympho¬
cytes are identified and counted. Contaminating cells
should be excluded from the count and are identified
morphologically mainly as polymorphonuclear cells
and monocytes, most of which have phagocytosed
latex particles.
Lymphocyte transformation
The stimulation of lymphocytes by certain agents
results in a sequence of events called lymphocyte
transformation with the production of blast-like cells
which synthesize DNA de novo. The extent of trans¬
formation can be quantified either morphologically
or by assessing the incorporation of radioactive
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DNA precursors into the cells. Stimulating sub¬
stances can be divided into three main groups:
(1) Polyclonal mitogens, e.g. phytohacmagglu-
tinin (PHA), Concanavalin A (Con A), poke-weed
mitogen (PWM);
(2) Antigen specific stimulation, e.g. purified
protein derivative (PPD) from M. tuberculosis,
Candida antigen, streptokinase-strcplodornasc (SK-
.50);
(3) Stimulation by allogeneic lymphocyte mixed
lymphocyte reaction (MLR).
The major responding cells in the above systems are
T lymphocytes and in vitro lymphocyte transformation
is thought to reflect T cell function and CMI [15, 16].
'Non-specific' transformation by mitogens can be
used as an indicator of overall T cell function since
a high percentage of cells are 'triggered' normally
and a low level of transformation usually correlates
well with depressed CMI. A significant degree of
transformation (i.e. at least three times greater than
the spontaneous incorporation) to a given antigen
usually indicates prior sensitivity to that antigen.
Transformation tests arc technically demanding
and arc subject to many variables. It is essential to
include a normal control or even better a 'reference
pool of respondcrs' (see below) with each experiment.
If responses arc significantly different from control
values serial tests are necessary for confirmation.
Some patients (e.g. cancer-bearing subjects) may
have inhibitors present in their scrum which will be
detected if cultures are done w ith autologous as well
as with 'standard' sera. Conversely, if cultures arc
always performed in autologous scrum some nega¬
tive results may be due to the presence of inhibitors
and not to depression of CMI per se [17, 18].
Method for lymphocyte transformation (microculturc
technique) (sec also Chapter 26)
Principle
This micro-culture technique provides a standard¬
ized test system for measuring lymphocyte responses
in vitro to polyclonal mitogens, antigens and in the
mixed lymphocyte reactions (MLR). Low numbers
of lymphocytes arc required, and all stimulants, with
the exception of allogeneic lymphocytes for the
MLR reaction, may be pre-dispensed on the plates
and stored in liquid nitrogen vapour." Lymphocyte
transformation is assessed by triliatcd thymidine
incorporation during the final 18 hours of culture.
A pool of normal lymphocytes, stored in liquid
nitrogen vapour, is used as an internal control for
technical reproducibility of responses, and mito-
myein-treatcd pooled lymphocytes arc stored in
liquid nitrogen vapour for use as MLR stimulators.
Materials
(1) Ficoll/Triosil mixture (specific gravity 1077),
(2) TC medium 199 (Ciibco-Biocult, 25 mmol/l
HEPES-buflcrcd, single strength), containing 100
units penicillin and 100 //g of streptomycin per ml
(Difco, Detroit, Michigan, USA).
(3) Pooled human serum (from ten untransfused
healthy males), heat-inactivated and filter sterilized.
(4) Tissue culture plates (LINBRO—flat-bottom,
Flow Labs., Irvine, Ayrshire, Scotland, cat. no.
77-020-62).
(5) Plate scalers (Mylar) and roller (Flow Labs.,
cat. nos. 77-021-02 and 77-021-10).
(6) Phytohacmagglutinin (PflA-P, Wellcome).
(7) Concanavalin A (Con A, 3x recryslallizcd.
Miles Laboratories Ltd., Slough, Berks., UK).
(8) Candida antigen (10 per cent Candida albicans
antigen suspension, preservative-free, HAL-allcr-
genen, Haarlem, Holland).
(9) PPD (frcezc-dried. Central Vet. Labs., Wcy-
bridgc, Surrey, UK).
(10) Pooled human lymphocytes: (a) untreated
(pooled rcspondcrs); (b) mitomycin-treatcd (pooled
stimulators).
(11) Tritiatcd thymidine (TRA 306, specific
activity 2 Ci/mM, Radiochemical Centre, Amcrsham,
Bucks., UK).
(12) Mitomycin C (Kyowa Co., Japan),
(13) Plastic straws and accessories for freezing
lymphocytes (Instruments dc Medecine Veterinaire,
Socicte Anonymc, L'Aiglc, France).
(14) Dimcthylsulphoxide (DMSO).
(15) Scintillation fluid (NE233, Nuclear Enter¬
prises Ltd., Edinburgh, Scotland).
(16) Scintillation vials (Packard, Caversham,
Berks., UK).
(17) Heparin (preservative free) (Evans Medical,
Liverpool, UK).
Procedure
(I) Separation of lymphocytes (sec also Chapter 23)
Lymphocytes arc separated from heparinized venous
blood samples by layering the blood over Ficoll/Trio¬
sil mixture in sterile centrifuge tubes and centrifuging
at 400-500 g for 20 min as described [19], The band
of mononuclear cells is recovered from the Ficoll/
Triosil-plasma interface and washed three times in
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TC 199 (approximately 100 g to remove platelets),
rcsusperuled in TC 199 and the lymphocytes counted.
(2) Preparation of lymphocyte pools
Lymphocyte pools are prepared by combining, in
equal proportions, the lymphocytes obtained from
ten healthy individuals. When used as a control
responding population, the response of the pool to a
stimulant is equal to the mean response of the
individuals within the pool to that stimulant. When
used as a stimulator of MLR, the pool presents a
diversity of antigenic determinants to the responding
population. Both pooled rcspondcr and pooled
stimulator cells may be prepared in advance by
freezing at a controlled rate in liquid nitrogen
vapour.
To block DNA-synthcsis in pooled stimulators,
lymphocyte suspensions in TC 199 are incubated
with mitomycin C (25 /'g/ml) at 37° C for 30 min.
The lymphocytes arc then ccnlrifugcd, washed three
times in TC 199, resuspended and counted.
(3) Lymphocyte freezing
Lymphocytes arc suspended in tissue culture medium
containing 10 per cent dimethyl sulphoxide and 10
per cent autologous or 'pooled' serum. Cells at any
concentration up to approximately I x l07/ml arc
dispensed into plastic straws and sealed w ith plastic
balls or polyvinyl alcohol powder.
Freezing is carried out in a controlled manner,
usually 5 C° per min to the cutectic point, then 1 C°
per min until -25° C, 5 C° per min until -50" C,
5-10 C" per min until -100" C, and then rapidly to
-196° C. Final storage is in liquid nitrogen vapour
at a temperature of at least - 130" C.
When required the straws are thawed rapidly by
dilution of their contents in 10 ml of TC 199 at
37° C, followed by two washes in TC 199 at 400 g
to remove all the cryoprotective agent (DMSO is
toxic above freezing temperature). The cells can then
be suspended at the right concentration in the
appropriate TC medium for use.
(4) Tissue culture medium
Tissue culture medium is made up by supplementing
TC 199 with penicillin and streptomycin and pooled
human serum (20 per cent v/v).
(5) Preparation ofmicroplates
The 96 wells in the microplates arc arranged in 8
rows (A-H) of 12 wells. Lymphocyte cultures are
performed in triplicates: thus four triplicates (four
different responding lymphocyte populations) can
be applied per row, and different stimulants can be
added to the different rows. Final culture volumes
are 0 25 ml, and stimulants and lymphocytes arc
each added in 0 125 ml volumes of tissue culture
medium at twice their final concentration. All
operations are carried out in a laminar flow hood.
When plates are prepared for storage in liquid
nitrogen vapour, pooled stimulating lymphocytes
(mitomycin-trcatcd) are not added. These should be
added when the plates have been thawed out before
adding the responding cells. In our hands, techniques
for freezing cells in microplates have not proved
satisfactory largely because of the problems of









































Lymphocyte suspensions (3 ml at 0 5 x IO"/ml) arc
added to rows A-G in 0 125 ml aliquots. Three
different individuals' lymphocytes (wells 1-3, 4-6
and 7-9) and pooled responding lymphocytes (wells
10-12) may be added to each plate. The plates arc
then sealed (Mylar) and incubated in a humidified
atmosphere of 5 per cent C02 in air at 37° C. At
18 hours before harvesting of cultures, I //Ci of
tritiatcd thymidine is added in 4 //I volumes (diluted
TRA 306, 1/4 in sterile saline) to each well to be
harvested. It is convenient to deliver the isotope
through the seal directly into each well using a 50 //I
Hamilton syringe fitted with a I //I automatic
dispenser.
Rows A-C arc harvested after three days, and the
remaining rows after 5 days, at the times when these
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cultures reach their peak DNA-synlhesis. Tire seal
can be removed from rows A-C by cutting the seal¬
ing sheet between rows C and D using a scalpel.
Cultures are harvested using an automatic culture
processor (e.g. Sam 21a, Cryotech, Abingdon, Oxon.,
U.K.). The lymphocytes from each culture arc
trapped in filter paper discs and washed free of
isotope which has not been incorporated. The filters
are then dried at 50° C, placed in scintillation vials
with 10 ml of scintillation fluid and the amount ol
tritium-labelled DNA in each sample is determined
by counting for 1 min each in a scintillation counter.
Results are expressed as mean counts per minute
(cpm) per triplicate.
Comments
When applying this culture system to the investiga¬
tion of patients' lymphocyte responses, a normal
range of responses for healthy individuals should be
established. It should be noted that the responses of
healthy individuals may show a wide range of values,
and the responses of an individual can vary from day
to day [20],
Plates should be stored in liquid nitrogen vapour
to prevent the stimulants losing their activity. Aseptic
techniques should be observed for all operations to
prevent contamination of cultures. When adding cell
suspensions these should be well mixed to ensure
even cell dispersion for good triplicate reproduci¬
bility. Accurate dilution of lymphocyte suspensions
to the required cell number is essential, as responses
are related to total cell numbers. Equally, stimulant
concentrations may be highly dosc-dcpcndcnt and
stimulants must be dispensed accurately.
Eymphokine production
As an integral part of the lymphocyte transformation
response, a variety of soluble factors are produced
which are thought to have important short-range
effects in amplifying the response to antigens. These
soluble lymphocyte-derived mediators are sometimes
referred to as iymphokines (see Chapter 27). Assess¬
ment of the effects of lymphokincs can be used as a
correlate of cell mediated immunity [21], One of the
factors released from sensitized lymphocytes chal¬
lenged with specific antigen inhibits the migration of
macrophages from capillary tubes and is termed
macrophage-migration inhibitory factor (MIF).
The elaboration of MIF has been widely used to
indicate sensitization to a variety of antigens [22],
The most reliable system involves the use of a two-
stage culture—firstly, lymphocytes/leucocytes arc
incubated in the presence of the antigen under test
and secondly, cell-free supernatants are assayed
using guinea-pig macrophages as target cells. MIF
tests arc technically difficult with associated problems
of reproducibility. The test has been shown to work
best with particulate rather than soluble antigens. As
with antigen transformation tests, MIF production
can be used as a test of sensitization to a number of
antigens such as thyroglobulin and tumour antigens,
or as a test of competence of CM I where prior
sensitization is assumed or known.
Analysis of MIF and lymphocyte transformation
to Candida antigens in patients with chronic muco¬
cutaneous candidiasis has revealed that some are
unable to transform to the antigen and others can
transform but are unable to synthesize or release
Mil' [2.1]. Overall T cell immunity in many of these
patients as assessed by PHA or MLR responses
shows no impairment and these patients appear to
have only the one defect in C'MI.
Many other lymphokincs have been described
including a factor selectively chcmotactic for mono¬
cytes. It is still not clear whether the various lympho¬
kincs are chemically distinct or a family of closely
related glycoproteins. In practical terms, however,
we find measurement of lymphocyte derived mono¬
cyte chcmotactic factor to be a convenient method of
assessing lymphokine production.
Method for production and assay of lymphocyte
derived monocyte chcmotactic factor (LD-MCF)
(after Snydcrman <•/ ai. [24])
Principle
LD-MCF has a specific effect on cells of the mono¬
cyte/macrophage scries, and is released in vitro by
lymphocytes when stimulated either by specific
antigen or following mitogen stimulation. The assay
may be used to detect either defective lymphocyte or
monocyte function.
Materials
(See Lymphocyte transformation, p. 47.5 and
Chcmotaxis, p. 47.20)
(1) Sterile tissue culture tubes (Nunclon, Roskilde,
Denmark, Cat. No. 1410-1).
Procedure
Production of LD-MCF
(I) Lymphocytes are separated as described for
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lymphocyte transformation (see p. 47.5) and resus-
pended in TC 199 (Gibco-Biocull) (N.B. do not add
serum) containing penicillin and streptomycin to a
concentration of 3 x 10" lymphocytes per ml.
(2) For each stimulant used (mitogen or antigen)
two sets of triplicate I ml cell suspensions are
prepared in sterile tissue culture tubes.
(3) The stimulant is added at the optimal concen¬
tration (see Lymphocyte transformation, p. 47.7) to
one set, while the second serves as the unstimulated
control.
(4) The cultures arc incubated at 37° C in a
humidified atmosphere of 5 per cent C02 in air for
the appropriate time (3 days for mitogens, 4-5 days
for antigens).
(5) An identical amount of the stimulant is then
added to the unstimulated controls before all the
cultures are scdimenled (400 g for 25 niin).
(6) The supernatants arc removed to Tck lab.
tubes (Med. Lab. Ltd., Sacriston, Co. Durham,
U.K.) to be tested for chemotactic activity (below).
If necessary, the supcrnatants may be stored at 4° C
for up to 5 days.
Monocyte chcmotaxis to l.D-MCF
In the LD-MCF assay lymphocyte culture super¬
natants (10 ml) arc placed in Tck lab. tubes in
triplicate. Negative controls (TC 199 alone or with
lymphocyte stimulant) and positive controls (casein,
10 mg/ml in TC 199) may be included. However,
stimulation of LD-MCF production is measured by
the difference between migration of a monocyte
suspension towards supernatants from stimulated
lymphocyte cultures and supcrnatants from un¬
stimulated lymphocyte cultures. Details of the
monocyte chemotactic assay are described elsewhere
(p. 47.21).
Comments
Unstimulated lymphocyte culture supcrnatants al¬
ways show a greater level of chemotactic activity for
monocytes than TC 199 alone. Distances migrated
by monocytes in LD-MCF assays arc much less than
distances migrated towards casein (a known mono¬
cyte chemoattractant) and it may be necessary to
increase incubation times to 90 min to amplify
differences between unstimulated and stimulated
supernatants.
T lymphocyte induced cytotoxicity
Antigen sensitized T lymphocytes have been
shown to kill antigen-bearing target cells in vitro.
Target cells of various sources have been used,
including tumour cells and allogeneic lymphocytes
and it would appear that the mechanism of cell
damage is analogous to that seen in graft rejection
[25], Whereas the quantitation of lymphocyte
transformation gives an indication of the recognition
phase of cell mediated immunity, T cell cytotoxicity
estimates the efficiency of one aspect of the effector
stage. As yet, this technique has been used mainly as
a research tool and details of the methodology will
not be given herein. T lymphocytes transformed
by PHA show similar cytotoxic activity [26J. A
number of laboratories have used this test to assess
one particular aspect of cell mediated immunity. The
clinical significance of these tests remains uncertain
and Chapter 36 discusses the scope and limitations
of the methods.
Deluycd hypersensitivity skin test
This is one of the oldest and simplest tests of CM1
and probably detects pre-existing cellular immune
function. The reaction to a 'panel' of antigens such
as tuberculin, mumps antigen, Candida, tricho¬
phyton, or SK-SD is assessed 48 hours after intra¬
dermal injection at a convenient site, usually the
volar surface of the forearm [8], In cases of absent
CM! all responses are negative. In young children,
however, the interpretation is less satisfactory since
it presupposes prior antigenic exposure. Furthermore
there may be poor skin expression of the inflamma¬
tory response in this age group. Negative results arc
difficult to interpret. For example, the antigenic
material may be inactive or administered incorrectly,
the patient may be overwhelmed by infection and
unable to respond, or may not have had prior
exposure to the antigen.
The skin test response to antigen is complex and
may involve many aspects of the immune response
including antigen recognition as well as T cell
activation. Thus a negative test can mean that a
defect exists at one of several levels, as is seen in the
disease complex of chronic mucocutaneous candidi¬
asis [23],
In some circumstances active sensitization by
agents such as dinitrochlorobenzene (DNCB) which
results in primary sensitization in over 90 per cent
of normal individuals may be of value. Evidence of
sensitization is obtained by measuring the response
to a second application of the chemical approxi¬
mately 21 days later. This test has the advantage that
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it is independent of other antigen exposure but has
the drawback of giving, in some individuals, rather
vigorous and painful responses.
An older method of assessing CM I which is not
now generally used is skin graft rejection. Normally
skin from an unrelated donor is rejected between
12-20 days. One of the dangers of this type of
investigation is that the individual becomes sensitized
to the donor histocompatibility antigens which may
thus prejudice future treatment by materials such
as transfer factor and bone marrow.
Method for delayed hypersensitivity skin tests
Principle
The test is based on recall of T lymphocyte immuno¬
logic memory and thus overall T lymphocyte func¬
tion is assessed. The postulated sequence of events
leading to the appearance of the delayed hyper¬
sensitivity type skin test is that circulating T lympho¬
cytes come into contact with antigen (mainly held by
skin macrophages) and pre-sensitized cells present
are stimulated to lymphokinc production and blast
cell transformation. The lymphokincs encourage the
'trapping' of circulating mononuclear cells at the site
of antigen and the activation of non-sensitized
'bystander' cells into the reaction. A cascade effect is
produced with increasing localization of mononu¬
clear cells which is clinically manifest as induration.
Local persistence of antigen favours the production
of a more vigorous response and vice versa. Thus,
subcutaneous (instead of intradermal) injection of
antigen results in its rapid removal before a local
response is apparent. The presence of oedema of the
skin will result in false negative results due to




(3) Sterile gauze swabs.
(4) Skin pencil or ballpoint pen.
(5) Sterile disposable tuberculin-type syringes
with 0 01 ml graduations.
(6) Sterile disposable needles (26 gauge) (Plastipak
no. 5625, Tuberculin syringes already have 26 gauge
needle attached) (Uecton Dickinson Ltd., Wembley,
Middlesex, UK).
(7) 'Control' intradermal solution (Bencard,
Brentford, Middlesex, UK).
(8) Sterile antigen solutions. The antigens used
depend on the choice available and the expected
exposure of the population to be tested. Commonly
used antigens include:
(a) Streptokinase-streptodornasc ('Varidasc',
Lcdcrlc Labs., Gosport, Hants, UK);
(b) Candida extract (I per cent preservative-free;
HAL-Allergencn, Haarlem, Holland, or Hollister-
Sticr, USA);
(c) Mumps (Eli- Lilly, Indianapolis, USA);
(d) PPD (various sources available);
(c) Trichophyton extract (1 per cent prcserva-
tive-frcc; HAL-Allergcncn or Hollistcr—Sticr).
Histoplasmin and coccidioidin may also be used
in the appropriate geographical areas.
Dosage used:
it is conventional to use 0 1 ml volumes for injec¬
tion, but this is not critical provided the same
volume is used on all occasions. Some antigen
solutions, e.g. Candida, trichophyton, arc rather
painful and 0 05 ml is a convenient volume to use
especially in children. It is our practice to use 0 05
ml volumes of the following materials:
(1) 'Control' intradermal solution (Bencard).
(2) 1 per cent Candida extract, preservative-free
(HAL-AI lergencn).
(3) Strcptokinase-strcptodornase (100 u/ml/25
u/ml) (Varidase).
(4) Mumps skin test antigen (Eli-Lilly).
(5) PPD 1/100 (1000 u/ml).
(6) 1 per cent Trichophyton (preservative-free)
(HAL-Allcrgencn).
The 'control' solution is antigen-free and may
become 'positive' in individuals with dermograph¬
ism.
Method
The volar aspect of the forearm is the most conveni¬
ent site for testing.
(1) Prepare the arm by shaving and cleaning with
isopropyl alcohol, finally drying thoroughly with a
sterile swab.
(2) Mark out the area to be tested with the code
numbers of the antigens to be tested with a skin
pencil or suitable non-washable marker (e.g. ball¬
point pen).
(3) Inject the appropriate antigen solution using
a disposable syringe. The skin is stretched taut with
the free hand and then, with the needle of the syringe
at a very shallow angle with the bevel uppermost, the
needle is introduced intradermally. Care should be
taken not to inject subcutancously causing bleeding,
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or not to penetrate enough resulting in an exit
puncture and leakage of antigen solution over the
skin. Once the needle is in place the solution is
gently injected and the skin should blanch and a
small bleb is raised. Some of the antigen solutions
are painful on injection and the subject should be
warned in advance to obviate inadvertent move¬
ments of the arm. When the needle is withdrawn,
ideally there should be no bleeding at the site of
injection indicating that dermal vessels have not been
punctured. There may occasionally be very .slight
blood leakage with good technique but persistent
oozing suggests that the injection has been subcu¬
taneous and not intradermal; a false negative result
may thus be obtained.
(4) The test sites are examined 48 hours later. If
problems arc expected in distinguishing Arthus
reactions, the tests can be read at 6 and 24 hours.
(5) Both erythema and induration are measured
in mm. The response is not always symmetrical and
irregular induration can be measured in two direc¬
tions at right angles and the result averaged. A
positive response is conventionally assessed as one
giving >5 mm induration. Responses can be graded
with 3-4 mm = ±; 5-8 mm = +; 9-11 mm =
+ + ; 12 mm or more ■= + + + .
Comnwnts
There arc no normal values as such available for
skin test responses and there is very little information
as to the percentage of normal population responding
to the various antigens. It is for this reason that a
'battery' of antigens is used with the expectation that
at least one positive result indicates normal cell
mediated immunity.
It is conventional to measure a positive response
as one with 5 mm or more of induration, although
again information is lacking as to the normal range
of induration in those giving a positive response.
INVESTIGATION OF B LYMPHOCYTE
FUNCTION
Quantitation of B lymphocytes
Plasma cells are immunoglobulin secreting cells
derived from B lymphocytes and can be identified
morphologically. The majority reside in lymphoid
organs but accurate quantitation of these cells in
tissue sections is difficult. B lymphocytes are opera¬
tionally defined by the detection of surface immuno¬
globulin [3], Surface immunoglobulins arc synthe¬
sized by the cells carrying them and must be
distinguished from adsorbed immunoglobulin [27],
B lymphocytes (or a significant sub-population of
them) may also be detected by the presence of Fc
receptors [28] and a receptor for the third component
of complement (C3) [29], Between 10 and 25 per cent
of circulating lymphocytes have such surface
markers. Some information is available on other
lymphoid tissues such as spleen, lymph nodes and
tonsils [2, 5, 10, 27].
There are considerable technical problems with all
of the marker methods currently used. Surface
membrane immunoglobulin (Slg), although the most
specific, is technically most exacting, since complexes
and aggregates in the test antiscra bind to Fc
receptors giving false positive results [27]. It is
possible to use broad spectrum antiscra to enumerate
the total number of B cells, and specific antiscra to
identify the various immunoglobulin classes. Oc¬
casionally, cells may carry more than one Slg, e.g.
some 'double myelomas' giving rise to discrepancies.
Anti-lymphocyte antibodies or immune complexes in
scrum may also be adsorbed on to lymphocytes so
giving 'false' high results as sometimes seen in
systemic lupus erythematosus [27]. Trypsinization
will remove some of the surface layers of the cells,
including immune complexes and adsorbed material,
enabling endogenous immunoglobulins rcsynthesized
by the 'true' B cells in vitro to be recognized. The
lymphocytes may also Ire allowed to 'cap' and endo-
cytosc complexes. These manoeuvres should be
considered where abnormally high values for Slg are
obtained. Such problems are particularly liable to
occur where an indirect technique is used employing
two or more antisera [27].
Lymphocyte Fc and C3 receptors may be detected
by rosctting methods with appropriately treated red
blood cells. However, this is also a characteristic of
the monocyte. Therefore it is necessary to identify
the monocytes cither by their capacity to phagocytose
latex particles, or to remove them prior to testing
by carbonyl iron or plastic/nylon adherence. Neither
of these methods is entirely satisfactory since not all
monocytes may be phagocytic under the conditions
used and some B cells may be removed by the
adherence methods [3], Some of the earlier results in
the literature enumerating B cells in various diseases
may have been erroneous due to insufficient attention
to such details.
Even in health, it is apparent that not all B cells
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possess all three markers (i.e. Slg, C3 and Fc) and
single marker bearing cells or double marker bearing
cells can sometimes be identified. In some diseases
these discrepancies may be even more noticeable and
are possibly important to the disease pathogenesis.
For instance, some agammaglobulinemia patients
with no Slg bearing cells have relatively normal
levels of Fc or C3 bearing cells [2, 5, 10].
The percentage of B lymphocytes bearing Slg of
different classes in normal people bears little relation
to the serum immunoglobulin levels of the same class
(although the relative proportions of these lympho¬
cytes arc remarkably constant) since presumably Slg
bearing cells are not actively secreting immuno¬
globulin in any quantity. In Bruton-typc agamma¬
globulinemia Slg bearing cells arc generally very
low in numbers, or entirely absent. However some
patients with the 'common variable' form of hypo¬
gammaglobulinemia have normal numbers of
circulating Slg bearing cells but abnormally low
scrum immunoglobulin. The converse has also been
demonstrated. Most patients with isolated IgA
deficiency have normal populations of circulating
lymphocytes with IgA [2, 5, 10, 27],
Such information gives interesting insight into the
immunobiology of B cells and their defects and pro¬
vides a rational basis for classification of immuno¬
deficiency diseases. However, clinically this is of
rather limited practical importance at the present
time.
As with T cells it is important that B cells be
enumerated both as percentages and as absolute
numbers.
Method for determination of B cell numbers
Principle
B lymphocytes have membrane receptors for C3.
The technique depends on the capacity of the B
lymphocytes to form rosettes with complement-
coated red cell intermediates. The indicator cells are
sheep red blood cells (E) treated with erythrocyte
antibody (A) and human complement (C). Alterna¬
tively B lymphocytes can be identified by the demon¬
stration of immunoglobulin on their surface mem¬
brane, usually shown by a fluorescent-labelled anti-
human immunoglobulin serum (direct) or by an
indirect (sandwich) technique using an unlabclled
anti-human immunoglobulin scrum raised in a
particular animal species followed by a fluorescent-
labelled anti-species serum.
ft lymphocytes hv rosettes (I.AC) (After Bianco et oi
[29])
Materiuls
(1) Sheep red blood cells (50 per cent solution in
Alscvcr's).
(2) IgM anti-sheep red blood cell scrum.
(3) I'resh frozen human AB scrum.
(4) May-Grunwald-Gicmsa stain.
Procedure
Preparation of indicator cells (EAC)
(1) 0 5 ml of sheep red blood cells arc washed
three times with 10 ml of saline and finally suspended
in 5 ml of saline.
(2) 0 1 ml of rabbit IgM anti-sheep red blood cell
scrum is added (sub-hacmagglutinating dose) and
the mixture is incubated at 37° C for 20 mill with
mixing.
(3) Wash three times in saline and resuspend in
10 ml of saline.
(4) Add 0-3 ml of fresh fro/en human AB serum
(as a source of complement) and incubate for 20 min
at 37° C with frequent mixing.
(5) Wash three times in saline and rcsuspend in
5 ml of saline (FAC suspension). The suspension
must be freshly prepared on the day of the test. Wash
once more in saline if more than an hour has elapsed
between preparing the suspension and its use.
Lymphocyte preparation
(1) Mononuclear cells arc prepared as for lympho¬
cyte transformation (see p. 47.5).
(2) Phagocytic cells arc identified as outlined
under T lymphocytes (see p. 47.4).
Resetting procedure
(1) To 0 5 ml of latex-treated lymphocyte suspen¬
sion (approximately 2 x l06/ml) add 8-10 drops of
the EAG suspension (8:1 ratio).
(2) Mix the suspension and sediment by gentle
ccntrifugation at about 25 g for 5 min. Incubate at
37" C for 40 min.
(3) Rcsuspend by aspiration until no clumps arc
apparent.
(4) Slides arc prepared and fixed as for T lympho¬
cyte enumeration (see p. 47.4).
Examination of rosettes
Essentially this is the same as for E rosettes but it
should be noted that polymorphs and monocytes can
also form EAC rosettes. However, B cell EAC
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rosettes are small with a single layer of adherent red
blood cells. The use of an IgM fraction of the anti-
erythrocytc serum excludes rosette formation due to
Fc receptors.
B lymphocytes by surface immunoglobulin [27]
Materials
(1) Goat anti-human immunoglobulin (polyvalent
for immunoglobulins G, A, M and D).
(2) Rabbit anti-goat immunoglobulin, fluorescein
isothiocyanate (F1TC) labelled.
(3) Cold fluorescent antibody (FA) buffer (Difco)
with 0-2 per cent azide.
(4) FA mounting medium (buffered glycerol)
(Difco).
(5) Clean glass microscope slides and coverslips.
(6) Clear cosmetic nail varnish.
(7) 1 per cent buffered paraformaldehyde.
Procedure
Staining
(1) 5-10x10" latex-treated lymphocytes (sec
detection of T lymphocytes p. 47.4) are washed at
4° C with FA buffer containing 0-2 per cent azidc.
(2) Remove the supernatant thoroughly and add
5-7 drops of a 1/6 dilution of goat anti-human
immunoglobulin and resuspend. Incubate at 4° C
for 30 mill.
(3) Wash three times with 10 ml of cold FA buffer
with azidc and remove the supernatant thoroughly.
(4) Add 5-7 drops of a 1/6 dilution of FITC
rabbit anti-goat immunoglobulin serum, rcsuspend
and incubate for 30 min at 4" C.
(5) Wash three times in 10 ml of cold FA buffer
with azide and discard the supernatant.
(6) Rcsuspend the cells in 2-3 drops of FA
mounting medium. Alternatively fixation can be
carried out here by adding 200//I of I percent para¬
formaldehyde to the cell pellet for 5 min at room
temperature. The cells arc then washed twiec and
mounted in FA mounting medium.
(7) Seal the edges of the covcrslip with clear nail
varnish (prepare duplicate slides).
Slides can be examined immediately or stored in
the dark at 4" C.
Examination and counting
(1) Examine with a phase-contrast/fluoresccnce
microscope with a high-power oil-immersion objec¬
tive. Count the number of lymphocytes in the field
by phase-contrast, eliminating red cells and phago¬
cytes (latex particles ingested) from the count.
(2) Examine the same field under incident ultra¬
violet illumination and count the number of fluores¬
cing lymphocytes.
(3) At least 200 lymphocytes arc counted per
duplicate slide.
Comment
Phagocytes often show fluorescence due to surface-
adsorbed immunoglobulins and should be excluded
by identification under phase-contrast illumination.
Since antiscra vary in strength, optimal dilutions
should be determined by each laboratory.
Immunoglobulin estimation
It is technically easier, and in some respects more
clinically meaningful, to measure the product of B
cells, i.e. immunoglobulins (or antibodies), than to
estimate the numbers of B cells in the circulation,
although both measurements give complementary
information.
Simple electrophoresis of serum proteins is of very
limited value although it has some use as a screening
test to indicate very low or high levels of gamma¬
globulins. A variety of changes in the relative propor¬
tions of the various bands seen on electrophoresis
is seen in a number of disease states, but these
changes are in no way diagnostic.
Immunoelectrophoresis with specific or polyvalent
antisera gives qualitative information on the main
serum immunoglobulin classes, IgG, IgA and IgM,
and a single immunoglobulin class deficiency may
be identified, e.g. IgA deficiency; excess immuno¬
globulin production, or production of abnormal
immunoglobulins, as in myelomas, can also be
identified. This test can therefore also have limited
use as a preliminary screen.
Of far more practical value is the measurement of
concentrations of scrum immunoglobulins. Methods
for quantitating immunoglobulins require the use of
specific antiscra and the test material is compared
with a standard of known concentration (standards
which arc now available from the W.H.O. may be
used to prepare local laboratory standards). Methods
such as single radial diffusion (e.g. Mancini tech¬
nique [30]) may be used. These arc technically simple
and commercial kits are available. False results will
be obtained if the immunoglobulins arc aggregated
or dissociated, and appropriate standards must be
used on all occasions. There are a variety of other
methods available which have the advantage of
Tests of immune function 47.13
sensitivity such as immunoclcctrodiffusion (Laurcll
rocket technique), radioimmunoassay or ncphcl-
ometry, but these tests arc technically more complex
(see Chapter 19). Immunoglobulin levels in scrum
vary both with age, environment and sex and also
in the same individual over a period of time. Values
must be interpreted accordingly [8], Measurements
of lgG in neonates must take into account the
placental passage of maternal IgG. This may delay
the clinical presentation of an agammaglobinacmic
child. A 'physiological' hypogammaglobulinemia
may also be seen between 3 and 5 months of age
■ before the infant's own IgG production increases as
maternal IgG is being lost. IgA and IgM of fetal
origin are usually present in low levels at birth. High
levels of either may be an indication of intrauterine
infection. Failure to produce salivary IgA by 6-8
weeks should suggest a defect. Serum IgA in normal
infants may still be low at this time. The concentra¬
tion of serum immunoglobulins cannot be used as
the sole criterion for the diagnosis of primary im¬
munodeficiency since selective deficiency of a single
Ig class, e.g. IgA, can occur occasionally in appar¬
ently healthy individuals [8], Low levels may also be
seen in protein losing conditions or in hypcrcatabol-
ism since the serum level of a protein reflects the sum
of synthesis, distribution, breakdown and loss.
Estimation of scrum IgD is in general of little clinical
value except in the identification of IgD-mycloma.
Syndrome classification solely on the basis of the
pattern of immunoglobulin levels has, so far, been of
limited value [31 ].
Absent or very low levels of serum immuno¬
globulins usually indicate a deficiency of the B cell
compartment either alone, or in combination with
T cell deficiency as in severe combined immuno¬
deficiency. X-linked agammaglobulinemia is charac¬
terized by very low concentrations of all five im¬
munoglobulin classes. IgM may be low in Wiskott-
Aldrich syndrome and IgA is commonly low in
ataxia telangiectasia. However, abnormal immuno¬
globulin levels alone do not necessarily distinguish
between the different forms of immunodeficiency [8],
Measurements of immunoglobulin concentrations
in other body fluids such as saliva, tears, colostrum
and cerebrospinal fluid may occasionally be of
clinical value. Patients with scrum IgA deficiency
may have mucosal IgA synthesizing plasma cells as
determined by rectal or jejunal biopsy.
Quantitation of serum immunoglobulin is of value
in the diagnosis of certain lymphoproliferativc dis¬
orders which result in secondary immunodeficiencies,
e.g. myeloma, Waldenstrom's macroglobulinaemia
and lymphomas. Monoclonal bands usually correlate
with increased B cell numbers of the appropriate
immunoglobulin class. Bone marrow or lymph node
biopsies may reveal plasma cells containing intra¬
cellular immunoglobulin of the same class as that in
the scrum. Quantitation of serum immunoglobulins
in these patients may be a useful monitor for therapy
and there is some evidence that the immunoglobulin
class or subclass may give an indication of the
ultimate prognosis and the response to treatment.
Patients with normal or high levels of immuno¬
globulins or with isolated immunoglobulin deficien¬
cies may fail to respond to one or more antigens.
Responses to antigenic stimulation arc needed if
immunodeficiency is suspected but immunoglobulin
concentrations are normal [8].
Method for determination of immunoglobulin concen¬
tration
Commercially available kits can be used for deter¬
mination of immunoglobulins (and C3 and C4) by
the conventional Mancini technique [30],
Alternatively 'home made' plates and antisera can
easily be produced and if large numbers of assays arc
to be done then they may be economically justified.
The only modifications that we have found
necessary when using commercial kits tire to dispense
the test serum into the wells using a microsyringe as
an alternative to the capillary pipette and to incubate
at a standard temperature rather than 'room
temperature".
Assay for IgE
This may be performed using a commercially
available radioimmunoassay kit such as 'Phadcbas'
(Pharmacia, London. UK). It is usually possible to
render such kits more 'economical' by adjusting the
volumes of reagents used. For example a 1/2 scale
method will give twice the number of tests.
More recently an immunodiffusion plate has been
produced for measurement of IgF but would appear
to be only suitable for those patients with consider¬
ably elevated levels.
Salivary immunoglobulins
On occasions it may be necessary to measure the
immunoglobulins in other body fluids, e.g. saliva.
The method utilizes conventional commercial
plates as for scrum immunoglobulins and differs only
in the method of sample preparation. Samples
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should be processed as soon as possible afler
collection.
Materials
(1) Sterile plastic Universal containers.
(2) Glass beads of 2-3 mm in diameter.
Procedure
(1) At least 1-2 nil of saliva is produced into a
sterile Universal container.
(2) Glass beads of 2-3 mm diameter are added to
the specimen and shaken vigorously for 5 min.
(3) The homogenized saliva is transferred to a
clean polycarbonate centrifuge tube and spun at
25 000 g for 30 min at 4° C.
(4) The supernatant is removed and stored at
— 80° C until the immunoglobulin levels are assessed,
usuully on commercial low or ultra low level plates.
Specific antibodies
Measurement of antibody levels is an indication of
the capacity of B lymphocytes to produce functional
immunoglobulins. liven with normal T cell function,
failure to detect antibodies following an appropriate
antigenic challenge docs not necessarily indicate B
cell dysfunction as certain individuals may be non-
respondcrs to one antigen whereas the response to
other antigens is normal. Antibody responses may
be assessed by measuring antibody levels to (a) anti¬
gens to which the population is commonly exposed,
and (b) antigens used in active immunization.
Live vaccines (smallpox, polio, measles, rubella and
mumps) should never be given in suspected immuno¬
deficiency disease since severe complications or even
death may occur.
lsohaemagglutinins against blood groups A and/or
B give an indication of IgM antibody production in
those having the appropriate blood group and these
are usually detectable by 3-6 months of age. By late
childhood they attain a level which is maintained
with very little variation throughout life, tending to
decrease again in old age. Maternal IgG anti-A or
anti-B, if present, can cross the placenta and so give
false positive results during the first few months
following delivery. Heteroagglutinins (mainly IgM)
may occur as 'natural' antibodies (heterophil anti¬
body against sheep red cells) in many individuals and
therefore their measurement may provide a simple
screening test. Antibodies to the O antigen of com¬
mensal E. coli are seen in the sera of most normal
children and remain detectable throughout adult
life. The specificity of the E. coli antibody responses
depends on the serotypes prevalent in the community
and pooled appropriate antigens can be used to
identify IgG and IgM antibodies both in adults and
children [32]. This test is not satisfactory in the very
young. A search for appropriate bacterial or viral
antibodies can be undertaken with the knowledge
of the appropriate exposure to infections. Therefore
measurements of antistreptolysin-O, antistaphylo-
coccal antibodies, antibodies to respiratory syncy¬
tial virus, influenza virus, rubella, measles, chicken-
pox and mumps, etc. may give additional informa¬
tion. A clear history of exposure with failure to
produce the appropriate antibody is suggestive of a
defect. However, these studies should be interpreted
with caution since a virus may be isolated in culture
without it necessarily being the pathogenic agent.
Viral antibody levels arc of limited value because of
the variability of responses in normal individuals and
the difficulty in defining normal ranges.
Method for determination of isohaemagglntinins
Principle
Antibodies to blood group substances A and B arc
invariably found in the scrum of healthy normal
individuals of the appropriate ABO blood group.
They arc described as isohacmagglutinins because of
their ability to sensitize and agglutinate suspensions
of human red cells containing the relevant antigen.
Group O individuals have anti-A and anti-B in
their scrum.
Group A* individuals have anti-B in their scrum.
Group B individuals have anti-A in their scrum.
Group AB* individuals have neither anti-A nor
anti-B in their serum.
(* Subgroups A, and AjB may form anti-A,
which reacts with the more common A, subgroup.)
The principle of the test is that serum containing
or suspected to contain isohacmagglutinins is
incubated with red cells of known ABO type. The
presence of such antibodies results in sensitization
and agglutination of the appropriate red cells. A
semi-quantitative result is obtained by recording the
agglutination end-point of a series of doubling
dilutions of scrum.
The ABO group of the patient is also required for
correct interpretation of the results.
IgM antibodies may be differentiated from IgG
and IgA antibodies by preincubation of sera with
dithiothrcitol (DTT) which dissociates the IgM
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antibodies into subunits, resulting in loss of agglu¬
tinating ability.
Materials
(1) Clotted whole blood (test sample).
(2) 5 per cent suspension in 0-9 per cent saline of
standard group A,, A2, 'A mix' (A, + A2), B and O
red cells.
(3) Complete anti-A standard serum.
(4) Complete anti-B standard serum.
(5) Complete anti-A + B (group O scrum). •
Any of the above reagents are obtainable from
Ortho Diagnostics (Raritan, New Jersey, USA).
Procedure
(1) Centrifuge sample to obtain scrum and remove
to a clean glass tube.
(2) Prepare a 5 per cent red cell suspension from
test sample in 0 9 per cent saline.
(3) Identify ABO group of test cells:
(a) Set up six glass tubes (60 mm x 8 mm).
(b) To the first three are added 1 vol of 5 per
cent test red cells.
(c) To the last three are added 2 vols (e.g. 2
drops with Pasteur pipette) of test serum.
(d) Standard reagents are then added as follows:
Tube 1—add I vol A mix cells.
2—add 1 vol B cells.
3—add 1 vol O cells.
4—add I vol complete anti-A.
5—add 1 vol complete anti-B.
6—add 1 vol complete anti-A+ B.
Incubate at room temperature (15—18° C) for 1
hour and read the results macroscopically,




ample mix B O Ami Ami Ami of
cells cells cells A 1) A+B sample
(1) + + — — — — O
(2) — + — + — + A
(3) + — — — + + n
(4) — — — + + + AU
Any other pattern indicates that further tests arc
required (see Comments).
(4) Isohaemagglutinin titration:
(a) Prepare a master titrc on the separated test
serum in 0 9 per cent saline, the dilutions being as
follows: neat, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128,
1/256, 1/512.
(b) Place 1 vol of each dilution into four glass
tubes (1 drop with Pasteur pipette is usually
sufficiently accurate for most purposes provided
that the same pipette is used throughout).
(c) To one set of dilutions add 1 vol of standard
group A i cells per tube, to the second set of
dilutions add 1 vol of group A2 cells, to the third
set group B cells and to the fourth set group O
cells. Shake to mix and incubate at room tem¬
perature (15-18° C) for 1 hour.
(d) Read for agglutination. The end point is
determined microscopically, when an even distri¬
bution of clumps of three or more red cells is
evidence of agglutination.
(c) The titrc of isoagglutinin is expressed as the
reciprocal of the greatest dilution causing aggluti¬
nation.
(5) Identification of lgM/IgG agglutinin [33]:
(a) Prepare 0 01 mol/l dithiothreitol in 0 9 per
cent sodium chloride or PBS (see p. 47.16).
(b) Add equal volumes of test scrum and DTT
to a clean glass tube and incubate at 37° C for
I hour.
(c) Control consists of equal volumes of test
scrum plus dilution buffer (without DTT) treated
in an identical manner.
(d) Proceed with preparation of master dilu¬
tions as above, starting at 1/2 to allow for initial
dilution.
(c) Determine isoagglutinin titre as above.
Activity due to IgM isoagglutinin will be abolished
resulting in complete loss of agglutination, or a
marked reduction in titrc.
Comments
These techniques are performed on a routine basis
by blood banks and transfusion centres anil it may
be convenient to refer samples directly for testing.
Mood grouping. There may be apparent discrepan¬
cies due to subgroups of A or B, and false positive
results due to autoantibodies, cold agglutinins,
rouleaux formation, and other less common red cell
antibodies present in the test sample. The group O
cells arc added as a screening check for cold agglu¬
tinins outwith the ABO system which may give false
positive results. If this test is positive, expert advice
should be sought for the interpretation of the results.
Isoagglutinin titre. Even in normal individuals the
anti-A litres arc usually greater than the anti-B
titrcs. Furthermore, group O individuals tend to
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have higher values than group A or B for the
respective isoagglutinins.
Method for determination of Escherichia coli an I ibody
levels (after Webster et al.) [32]
Principle
E.coli antigens, prepared by boiling a suspension of
bacteria, arc coated on to human group O rhesus
negative erythrocytes, which are then used todetcct
specific antibody by direct haemagglutination.
Samples are titrated before and after treatment
with dithiothrcitol to determine the relative activity
of specific anli-£. coli lgM and IgG [33] (see p. 47.15).
Materials
(1) L. coli antigen—a bacterial suspension is boiled
(water bath) for 2 hours, then ccntrifugcd at 5000 g
for 30 min. The supernatant is removed, adjusted to
optimal concentration as determined by optical
density measurements, aliquoted and frozen at
-20° C.
(2) Fresh human group O rhesus negative blood—
up to one week old in anticoagulant (3 8 per cent
tri-sodium citrate).
(3) Dithiothrcitol—(BDH) (British Drug Houses
Ltd., Poole, Dorset, UK) stored as powder at
-20" C and prepared immediately before use.




(1) Human O negative erythrocytes are washed
three times in saline, and 0 1 ml of packed cells
incubated with 5 ml of antigen solution for 30 min
at 37" C. The cells arc then adjusted to a I per cent
suspension in saline.
Test procedure
(1) Sera under test arc inactivated at 56" C for 30
min and divided into two aliquots. One is heated
with dithiothreitol whilst the other is heated with an
equal volume of phosphate buffered saline.
(2) Two-fold dilutions of test sera are made in
microtitre haemagglutination trays (25 /il volumes).
(3) An equal volume of antigen coated red cells is
added to each well and the trays incubated at 37" C
for 3 hours before reading, followed by an overnight
incubation at 4° C and rechcck before discarding.
Comments
Best results are obtained if cells are coated with
antigen on the day of testing. Evidence accumulated
so far with this technique suggests a definite correla¬
tion between scrum anli-ZT. coli litre, scrum immuno¬
globulin levels and a diagnosis of immunodeficiency.
False positives may occur due to the presence of
'atypical' red cell antibodies (see isoagglutinin
methodology p. 47.15).
Immunization
In a previously immunized person antibodies to
diphtheria (DT) or tetanus toxoid (TT) may be
detectable. A better assessment of the secondary
response can be made if a booster injection of DT
or DT plus IT is given for subsequent antibody
determination. In ubimmunized children commercial
DT or TT may be given at standard doses (0-5 ml
intramuscularly). A complete schedule of three to
four injections at 4-6 week intervals should be given
before concluding a failure to respond. Antibody
levels should be determined 7, 14, and 21 days
following the last injection. Killed polio virus can
also be given intramuscularly (instead of the usual
oral route) in three doses 2 weeks apart and the
neutralizing antibody assessed. Measurement of the
IgM and IgG antibodies following the above
immunizations may be useful in defining an inade¬
quate primary or secondary response, but normal
ranges and responses are not known.
Bacteriophage <r>AT74 has been shown to be a
potent, safe, useful and discriminating antigen and
techniques have been developed which allow
measurement of antigen clearance, and of the prim¬
ary and secondary immune response [34], The
secondary responses of normal individuals to this
antigen have been shown to be remarkably uniform
and consistent. The special facilities required for
these determinations have probably limited the
potential widespread use of such a useful antigen.
Method for determination of tetanus antibody levels
(after Nelson [35])
Principle
Tetanus vaccine is coupled to glutaraldchydc-fixcd
human group O rhesus negative erythrocytes using
chromic chloride. These 'antigen carriers' arc capable
of detecting specific antibody in a direct hacmag¬
glutination assay. Sera found or suspected to contain
specific anti-tetanus activity are titrated in parallel
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with a standard of known unitage, and the units/ml
of the test sample calculated.
Materials
(1) Human group O rhesus negative erythrocytes
—up to 7 days old.
(2) Glutaraldehydc solution—1 per cent in phos¬
phate buffered saline pH 8 0.
(3) Tetanus vaccine—40 LF units/ml in simple
solution (Wellcome).
(4) Chromic chloride solution—-freshly made by
dissolving 1 g chromic chloride in 100 ml saline,
dilute 1/2 in saline just before use to give a final con¬
centration of 0-5 per cent.
(5) Phosphate buffered saline pll 8 0 (PUS):
1 vol NajHP04, 0 15 mol/l
9 vols NaCl, 0 15 mol/l
5 vols sterile distilled water (SOW)
Adjust pH to 8 0 with HCI
(6) Diluting fluid—10 ml 1/800 tetanus vaccine in
saline.
83-4 ml saline.
6-6 ml 30 per cent bovine scrum albumin.
(7) 0-9 per cent normal saline—36 g NaCl in
4000 ml SOW.
(8) Positive controls—high litre antibody, either
scrum or immunoglobulin of known unitage, e.g.
Humotet (Wellcome) containing 250 international
units per ml of anti-tetanus activity.
(9) Haemagglutination plates—microtitre, U-bot-
tomcd, disposable.
Procedure
Gluiaraldeliyde fixing of cells
(1) Human group O negative erythrocytes are
washed three times in saline .and the packed cell
volume established by ccntrifugation at 1(X)0 g for
5 min.
(2) A 2 per cent suspension of cells in 1 per cent
glutaraldehydc is incubated at 4° C for 30 min, with
frequent mixing.
(3) The cells are then washed three times in saline
and three times in SDW and stored as a 10 per cent
suspension in SDW containing I mg/ml sodium
azide.
Coating of cells
(1) Glutaraldehyde fixed cells are washed three
times in saline and the packed cell volume established
as above.
(2) I ml of tetanus vaccine is mixed with 3-5 ml
saline and I ml of packed cells added. This is
followed by the addition of 0 5 ml of 0 5 per cent
chromic chloride, and the mixture incubated at 25" C
for 6 min.
(3) The cells are washed three times in saline and
stored as a 20 per cent suspension in saline at 4" C
for at least one week before use.
Hacmagglutillation assay
(1) Test sera are initially diluted 1/40 in diluting
fluid with subsequent doubling dilutions in a
haemagglutination plate. A positive control (serial
dilutions of anti-tetanus standard) and a negative
control (diluting fluid) are set up in each plate.
(2) One drop (25 nil) of test scrum dilution is
mixed with 1 drop of a 0 6 per cent suspension of
'coated cells', the plate covered and left at room
temperature (25" C) for li 2 hours before reading.
(3) The plates arc also read after overnight
incubation before discarding.
(4) The test sample titrc is converted into inter¬
national units of anti-tetanus activity as follows:
jy (',rc ,cst x known units of standard
titrc of standard
Comments
The hacmagglutination test described is simple to
perform, easy to read, very sensitive and specific
(specificity may be checked by inhibition with anti¬
gen), and reagents may be stored for at least 6 months
at 4' C without affecting sensitivity, provided azide
is present to prevent microbial contamination.
INVESTIGATION OF PHAGOCYTE
FUNCTION
Quantitation of neutrophils and monocytes
Alterations in the percentage or absolute number of
circulating neutrophils or monocytes will often be
the earliest indication of immune deficiency. The
results must be interpreted with caution. For instance
neutropenia in infancy can either be uniformly lethal
as in congenital neutropenia (Kostman disease) [36]
or compatible with good health as in chronic benign
neutropenia of infancy [37], Rare disorders such as
cyclical neutropenia require regular white cell counts
as the oscillations in the numbers of circulating cells
are sometimes as short as 14 or as long as 35 days. It
is important to differentiate the primary neutropenias
from the many causes of secondary neutropenias
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found in association with infections, the administra¬
tion of drugs, megaloblastic anaemia, hypersplcnism,
lcuco-erythroblastic anaemia, acute leukaemia,
aplastic anaemia, paroxysmal nocturnal haemo-
globinuria, ionizing radiation, cytotoxic drugs and a
number of miscellaneous conditions such as systemic
lupus erythematosus (SLE). Maternal-derived leuco¬
cyte-agglutinating antibodies may be found in
neonatal neutropenia and these should be sought
where appropriate. Neutropenia following trans¬
fusions has also been reported in association with
anti-neutrophil antibodies. Leucocyte autoantibodies
in SLE may also result in low neutrophil counts and
these antibodies should be sought in cases of unex¬
plained persistent neutropenia.
Method for detection of leucoagglutinating antibodies
[38]
Principle
When leucocytes are mixed with a serum containing
leucocyte antibodies, the cells and scrum interact to
form clumps or agglutinates.
Materials
(1) Dextran 150 in 5 per cent dextrose (Dcxtraven
150, Fisons Ltd., Loughborough, Lcics., UK).
(2) Toluidine blue 0-2 per cent in distilled water.
(3) Glass tissue typing trays (Searlc Laboratories,
High Wycombe, Bucks., UK).
(4) Mineral oil (Shell Ondina 33, Shcll-BP,
Grangemouth, Scotland, UK).
(5) Phosphate buffered saline 1-8 per cent.
Procedure
(1) 2 p\ of the serum under investigation, previ¬
ously heat inactivated at 56° C for 30 min, is dis¬
pensed using a micro-syringe into the wells of a tissue
typing tray containing mineral oil.
A known positive and negative control scrum is
included on each tray and the plate can be stored at
-20° C until required.
(2) 7 ml of defibrinated blood is mixed with 3 ml
of Dextran 150 (or other red cell sedimcnting agent)
and incubated at 37° C for 30-45 min. Usually a
panel of 5-10 donors are used to cover a variety of
leucocyte antigens.
(3) The supernatant, usually containing between
3000 6000 leucocytes/mm3 is removed into a clean
tube and the cell count standardized to 3000-6000/
mm3.
(4) 1 p\ of the cell suspension is added to the test
plate with a microsyringc and incubated for 1 hour
at 37° C.
(5) After incubation the plates are 'rotated' on an
orbital bench rotator at a speed sufficient to 'button'
the test mixture.
(6) A volume of 0-2 per cent toluidine blue in
distilled water is mixed with an equal volume of 1-8
per cent buffered saline and centrifugcd. 1 //I of the
stain is then added to each well on the plate.
(7) Examine after a period of 5 min at a magni¬
fication of x 100 with bright light. Agglutinates when
present are easily observed and should be compared
with positive and negative controls for scoring
purposes.
Comments
Leucocytes and test sera must be ABO compatible.
For convenience group O cell donors may be used.
Morphology and staining methods
Abnormal morphology of neutrophils can often aid
the diagnosis of a number of primary and secondary
immune deficiencies. Giant lysosomal granules are
found in Chediak-Higashi disease. The presence of
large numbers of immature granulocytes in the
peripheral blood is suggestive of chronic granulocytic
leukaemia.
A number of simple staining procedures are of
value for screening certain primary immune deficien¬
cies. Leucocytes from patients with chronic granulo¬
matous disease are unable to reduce the dye nitroblue
tctrazolium (NBT). Myeloperoxidase deficiency
should be considered in individuals susceptible to
systemic infections with Candida albicans. Myelo¬
peroxidase staining of peripheral blood leucocytes
should probably be undertaken in all cases where a
defect in phagocytic cells is considered.
Method for nitrobluc tctrazolium (NBT) test (after
Park et al. [39])
Principle
Ingesting phagocytes convert the yellow soluble dye
(NBT) to an insoluble dark blue precipitate (forma-
zan) in the phagocytic vacuoles. The process is
dependent on an intact nucleotide oxidase within the
cell, the NBT substituting for oxygen in the oxidase
reaction or being reduced by the superoxide radical.
In patients with systemic bacterial infection there
is an increase in NBT reduction in contrast to
Tests of immune function 47.19
patients with chronic granulomatous disease when
90+ per cent arc unable to reduce the dye.
Comparisons are normally made between un¬
stimulated NBT reduction and cells that arc actively
phagocytosing. The estimation of reduction is deter¬
mined by counting all cells containing a deposit of
formazan.
Materials
(1) Nitro blue tetrazolium-Ficoll solution: 2 g
of Ficoll are added slowly to 10 ml of phosphate
buffered saline pH 7-2 (Oxoid tablets, Oxoid Ltd.,
London, UK) until all the Ficoll is dissolved. 10 mg
of nitro blue tctrazolium (BDH) are then dissolved
in this solution. The solution is filtered through a
Millex 0-22 n filter (Millipore S.A., 78530 Buc-
Francc) and used at room temperature.
(2) Stimulating agent: Escherichia coli endotoxin
(Difco E. coli I2(>B) at a concentration of 0 2 mg per
ml in phosphate buffered saline.
(3) Stain: May-Grunwald (50 per cent stock in
buffered distilled water pM 6-8). Giemsa (10 per cent
stock in buffer distilled water pH 6-8).
Procedure
(1) 2-5 ml of venous blood is taken in to a potas¬
sium F.DTA tube.
(2) 0-5 ml of blood is aliquotcd into two tubes.
0 05 ml of phosphate buffered saline is added to one
tube (unstimulated) 0 05 ml of stimulating agent
added to the other tube (stimulated). The tubes are
left at 20° C for 15 min.
(3) 01 ml aliquots-arc taken into the wells of a
Boerner tray (Clay Adams cat. no. 5419—Parsip-
pany, N.J., U.S.A.) with both unstimulated and
stimulated mixtures being duplicated.
(4) 01 ml of the NBT-Ficoll solution is added to
each well, mixed, and the slide incubated in the
humidified box for 30 min at 37° C, followed by a
further incubation at 20° C for 15 min.
(5) At the end of incubation the wells arc gently
mixed with a Pasteur pipette and a drop of the
reaction mixture placed on a clean glass slide and a
smear prepared.
(6) The slide is air dried and fixed in methanol for
2 min.
(7) Stain the slide in May-Grunwald for 3 min.
(8) Transfer directly to Giemsa for a further 3
min.
(9) The excess stain is rinsed with a wash bottle
containing distilled water buffered at pll 6-8.
(10) Differentiate for approximately 1 min with
distilled water buffered at pH 6-8 checking visually
at intervals with a low power objective on the
microscope.
(11) Observe wet at a magnification of x400 or
the slide can be air dried and observed with an oil
immersion objective at x 1000.
(12) 100 cells and two fields arc counted on each
slide and the number of formazan containing cells
scored.
Comment
F.DTA used as an anticoagulant prevents cell
clumping. The sensitivity of the test and cell mem¬
brane integrity arc maintained by adding Ficoll (a
sucrose polymer) to the test system.
Method for myeloperoxidase staining (after Kurstak
&. Kurstak [40])
Principle
The peroxidase reaction depends upon the presence
of peroxidases within the cytoplasm of granulocytes
and to a lesser extent, of monocytes. The peroxidase
of neutrophils is generally termed myeloperoxidase.
Peroxidase activity is indicated after appropriate
staining by discrete blue granules in the cytoplasm
of granulocytes and monocytes.
Materials
(1) Nadi reagent is prepared by dissolving 15 mg
a-naphthol and 22 mg p-phcnylcnc diamine in 20 ml
0 07 mol/l P04 buffer, pll 7 2 containing 0 17 mol/l
NaC'l (i.e. in phosphate buffered saline pll 7 2).
Prepare fresh reagent several hours before use and
filter. Store in dark bottle at 4° C.
(2) Formal-cthanol fixative (10 ml 37 per cent
formaldehyde + 90 ml absolute cthanol).
(3) Safranin (0 2 per cent in buffer pll 6 8).
(4) 0-2 per cent methyl green or Giemsa stain.
Procedure
(1) Use fresh smears of blood. Heparin, oxalate
and FDTA arc not inhibitory as anticoagulants, but
l-DTA reduces the tendency of leucocytes to clump.
(2) Fix slides for I min at room temperature in
10 per cent formal cthanol.
(3) Wash for 15-30 sec with gently running tap-
water. Shake olf excess water.
(4) Apply 2 3 drops of Natli reagent to smears.
Leave for 5 niin or until stain develops.
(5) Wash briefly (5 10 sec) in running tap-water.
(6) Countcrstain with safranin for 1 min.
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(7) Recountcrstain with (0-2 per cent) methyl
green or Giemsa stain if greater nuclear detail is
required.
Comments
The peroxidase reaction occurs at once in the pre¬
sence of HjOj and the sites of peroxidase activity
appear in the form of blue coloured spots.
Examine microscopically under x400 magnifica¬
tion.
Chcniotaxis and random migration
It is sometimes convenient to consider increased
susceptibility to infection, especially by pyogenic
organisms, in terms of the various biological events
which result in microbial killing. Thus the cells must
have the capacity to respond in chemotaxis and
random migration; the individual must generate the
appropriate chcmoattractants; the particles must be
opsonized by antibody and complement; the phago¬
cytic cell must adhere to the particle (immune
adherence); there must be a functional phagocytic
mechanism and the cell must have the appropriate
biochemical pathways to kill the micro-organisms.
The micropore technique of Boydcn is a sensitive
and reproducible in vitro model for studying chcnio¬
taxis and random mobility [41], It has been used for
the identification of chemotactic factors and the
response of target cells both in health and disease
[42], The Boyden chambers consist essentially of two
compartments divided by a micropore filter. A
suspension of leucocytes is placed in the upper com¬
partment and the chcmotaetic agent is introduced
into the lower part of the chamber. Following an
incubation period the filter is removed, fixed and
stained and chemotaxis quantified cither by counting
the number of cells which have traversed the entire
thickness of the membrane or by measuring the
distance the 'leading front' of cells has migrated from
the origin [43], Further refinements to the technique
include a method in which leucocytes arc labelled
with "chromium and chemotaxis is expressed in
terms of radioactivity of a second filter placed on the
side to which the cells are migrating [44],
A number of patients have been described with
intrinsic defects of leucocyte movement although
these in general are rare conditions and poorly
classified. Two groups of disorders, the lazy leuco¬
cyte syndrome and familial chemotactic defects, both
show diminished chemotaxis in vitro although in the
latter random migration was normal [45J. In general
these patients have normal phagocytic and bacteri¬
cidal activities. Chemotactic response is also im¬
paired in the Chediak-Higashi syndrome but this is
presumably due to slow migration as a result of large
lysosomal granules. A number of patients with
chronic mucocutaneous candidiasis have defects of
both monocyte and neutrophil chemotaxis, some
of which can be corrected by the administration of
transfer factor [46, 47]. There arc also a number of
conditions in which a defect in neutrophil chemo¬
taxis is associated with markedly raised levels of
immunoglobulin E, atopic dermatitis and recurrent
infection [45]. The reason for these associations is
unclear. Defects in chemotaxis arc also found in
association with a number of disease states such as
tumours, diabetes and rheumatoid arthritis [42],
The skin-window (Rebuck) technique may also be
of value as an ancillary investigation [48] although
in general a diminished skin-window response is
always reflected by impairment in chemotaxis in
vitro. The main value of this test is its simplicity as
there are no requirements for special apparatus. It
is a satisfactory primary screen when a chcmotactic
defect is suspected, but difficult to quantitate. The
early response (2-4 hours) consists of neutrophils but
by 24 hours these are replaced by monocytes. By
changing coverslips at appropriate times the chemo¬
tactic response of both cell types can be assessed.
Method for measurement of chemotaxis (after
Zigmond & Hirsch [43])
Principle
This in vitro technique measures the ability of
leucocytes to migrate towards a chcmotactic stimu¬
lant. A leucocyte suspension is separated from a
chemotactic agent by a filter through which neutro¬
phils or monocytes can migrate. Either the distance
of migration into the filter (leading front) or the
number of cells migrating to the underside of the
filter arc measured.
Materials
(1) Chemotaxis chambers (see Procedure) made
from I ml plastic syringe barrels; Millipore filters
nos. SSWPO 13(H) 3 n or SCWPO 13(H) 8 //; UHU
adhesive.
(2) Tek lab. tubes.
(3) Materials for neutrophil preparation (sec p.
47.24).
(4) Medium 199 (Gibco-Biocult, HEPES-buf-
fered).
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(5) Ficoll/Triosil solution (specific gravity 1076)
(see Lymphocyte transformation, p. 47.5).
(6) Materials for differential cell count (sec NBT
test, p. 47.18).
(7) Casein, Hammerstein (BDH).
(8) Ethanol, Harris hacmatoxylin (Scarlc), buta-
nol, xylene, DPX.
Procedure
Preparation of chemota.xis chambers
(1) Chemotaxis chambers are prepared from cut¬
off upper parts of 1 ml syringe barrels retaining the
flanges. The length of the chamber is such that there
is no difference in hydrostatic pressure between the
contents of the chamber and the chemotactic solu¬
tion in which it is suspended.
(2) The chambers are prepared by gluing Milliporc
filters to the end of the barrel with bill) adhesive,
taking care to ensure a good seal without blocking
the end of the chambers. When dry, the excess filter
is trimmed away. For neutrophil chemotaxis the 3 p
filter (Milliporc SSWPO 1300) is used and for mono¬
cytes an 8 // filter (Milliporc SCWPO 1300) is used.
Great care should be taken in preparation to avoid
damage and contamination of the fillers.
Preparation ofneutrophils
(1) Neutrophils are prepared as outlined for the
phagocytic and Candida killing assays (sec p. 47.24).
(2) The cell suspension is made up in HEPES-
bufl'cred medium 199 (Gibco-Biocult) containing 100
units per ml of penicillin/Streptomycin solution and
a cell concentration of 1 x 107ml.
Preparation ofmonocytes
(1) 10 ml of heparinized venous'blood is diluted
with 10 ml of sterile saline and layered on to a mixture
of Ficoll/Triosil (specific gravity 1 076) after Boyum
[19] (see Lymphocyte transformation, p. 47.5).
(2) Centrifuge at 150 g for 25 min then remove
the cell band from the interface and wash three times
in medium 199. The cells are suspended in 5 ml of
medium prior to counting in a haemocylomctcr.
(3) The suspension is diluted in medium 199 to
give 3 x 10" mononuclear cells per ml (monocytes
approximately 30 per cent). A differential count may
be performed as a check.
Preparation of chemotactic agent
(1) 2 g of casein (Hammerstcin, BDH) is dissolved
in 180 ml of sterile distilled water adjusted to pH II
with sodium hydroxide solution.
(2) 20 ml of ten times concentrated 199 solution
(Difco) is added and the pH adjusted to 7-2 with
phosphoric acid.
(3) The final solution containing 10 mg of casein
per ml in medium 199 is dispensed into 5 ml aliquots
and stored at -40" C.
Chemotaxis
For neutrophils and monocytes the test systems are
identical except that 3 /; or 8 // filters arc used
respectively.
(1) Test chcmotactic solutions are made up by
diluting casein stock solution in medium 199 (Gibco-
Biocult) to give: 0 mg, 0-5 mg and I 0 mg casein per
ml. 1 ml of each test solution is placed in Tek lab.
tubes, in triplicates, for each cell suspension to be
tested.
(2) 0 2 ml of cell suspension is placed into the
chemotaxis chambers which arc then suspended by
the flanges in the Tek lab. tubes containing the test
solutions of chcmotactic agent. A suspension of cells
from a healthy individual, possibly age/sex matched,
is included in each assay as a control.
(3) The system is incubated for 75 min at 37" C
in a humidified air atmosphere.
(4) The chambers arc then removed, the remaining
cells ejected, and triplicate chambers arc immersed
in beakers of cthanol. The ethanol fixes the reaction
and dissolves the glue, permitting the filters to detach
from the chambers. The following sequence is used
for staining and mounting the filters (minimum
times):
Rehydration: distilled water, 2 min
Staining: Harris hacmatoxylin, 2 min
Wash: distilled water, 3 min
Blueing: alkaline water, until blue (^10
min)
Dehydration: cthanol 96 per cent, 5 min
ethanol 96 per cent, It) min
cthanol/bulanol (80/20), 15 min
xylene, 15 min
The filters arc then mounted origin side uppermost
(using the rough texture and convcx-upwards shape
as a guide) on a glass slide in DPX, care being taken
to express air bubbles trapped under the filters.
(5) The filters arc examined under x4(X) magni¬
fication with a microscope equipped with micro¬
meter scale fine adjustment. Note the micrometer
reading when the origin is in focus (N.B. top of the
filter, not cells) and then measure the distance to
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where the furthest migrating front of cells arc found
by focusing down using the fine adjustment. Five
random readings are taken on each filter and the
readings averaged for the triplicate. The results are
given as the migration distance in microns.
Comments
Sources of error:
(1) False negatives are usually due to torn or
poorly scaled filters.
(2) All apparatus should be thoroughly washed
and rinsed free of detergents.
(3) Poor triplicates are usually the result of excess
glue, inconsistent 'reader' definition of the leading
front or reading areas of the filter close to the
extremities of the migration area.
Method for determination of in vivo leucocyte migra¬
tion by the 'Rebuck skin window' (after Rebuck &
Crowley [48])
Principle
This is an in vivo assessment of the complex sequence
of events involved in leucocyte migration to a site of
induced inflammation. Only the end-stage of these
events is measured, i.e. appearance of cells in the
inflammatory exudate. The method is simple to
perform and allows visualization of cellular events,
but docs not permit accurate quantitation of the
cellular inflammatory response; furthermore it may
represent a model of foreign body reaction rather
than one depicting the early phase of neutrophil host
defence.
The stimulus to cell migration is a skin abrasion
which should not be deeper than the dermal-epi¬
dermal junction otherwise severed blood vessels may
result in direct 'leak' of cells in the exudate. The
abrasion is covered with a glass covcrslip to which
migrating cells adhere and the cell types can be
identified by conventional staining techniques. The
predominant cell over the first 6-8 hours is the
neutrophil and this cell is gradually replaced by
monocytes until at 24 hours these predominate.
Materials
(1) Razor.
(2) Sterile gauze swabs.
(3) Isopropyl alcohol.
(4) Adhesive tape (micropore).
(5) Circular glass coverslips (15 mm diameter).
(6) Sterile disposable scalpel (or high speed
lapidary drill with sterilized interchangeable cylindri¬
cal grinder heads (e.g. Expo (Drills) Ltd., 62 Ncal
Street, London WC2H 9PA, UK).
(7) Haematological fixatives and stains.
Procedure
The most convenient site for the procedure is the
volar aspect of the forearm, but other sites, e.g.
anterior aspect of the thigh, can also be used pro¬
vided they can be protected from accidental blows.
(1) Shave the area to be used, together with the
surrounding area of the skin.
(2) Cleanse the skin with isopropyl alcohol and
dry with a sterile swab.
(3) The area to be abraded is stretched taut whilst
the abrasion is made.
(a) Using a sterile disposable scalpel held vertical
to the skin surface the epithelium is gradually
scraped away over an area of approximately 0 5
cm1. The depth of the lesion is critical. The
correct level is reached when a 'smarting' discom¬
fort is felt on scraping and fine capillary loop
bleeding points are visible. If abrasion is continued,
excessive bleeding will be produced giving an
unsatisfactory site.
(b) An alternative method of abrasion is to slide
a grinding cylinder rotating at high speed over the
taut skin, resulting in a rectangular abrasion of
appropriate size in a matter of seconds. Operator
experience is required to produce a lesion of the
correct depth and the risk of going too deep is
greater than with the scalpel method. It is, how¬
ever, much quicker. The grinder heads should be
sterilized by autoclaving after each patient to
prevent accidental transmission of disease, e.g.
scrum hepatitis or syphilis.
(4) The abrasion is then immediately covered with
a cleansed sterile glass covcrslip, followed by a
square of sterile gauze and secured with adhesive
tape (micropore tape is the most convenient). A
circular covcrslip is slightly less susceptible to
accidental breakage in situ, than a square one.
(5) The covcrslip is changed at intervals (depend¬
ing on the requirements), e.g. 2 hours, 6 hours, 12
hours and 24 hours and replaced by a fresh sterile
coverslip.
(6) The coverslips are air dried, fixed in methanol
and stained with May-Grunwald-Giemsa.
(7) After staining, slips may be mounted on
microscope slides giving permanent records.
(8) The wound should finally be covered with a
sterile dressing until a dry scab is formed. In some
patients with a neutrophil defect infection may be
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produced at the site of abrasion and this will require
treatment in the usual manner with sterile dressings
and appropriate topical antibiotics.
Opsonization
it is generally agreed that the third component of
complement is an essential prerequisite for the
preparation of micro-organisms for ingestion by
phagocytic cells. Cells are coated with C3 following
interaction cither with specific antibody and the
classical complement pathway components CI, C4
and C2 or via the components of the alternate
pathway. Other cofactors are probably required for
the full expression of opsonic activity but in clinical
practice defective opsonization is unusual in the
presence of normal levels of immunoglobulins and
complement (see below). The sera from patients with
hypogammaglobulinemia and the rare deficiencies
in the third component of complement arc relatively
ineffective in preparing particles for optimal phago¬
cytosis [49].
Phagocytosis and microbial killing (see also Chapter
32)
A defect in the rate of ingestion of particles alone,
that is in the absence of other phagocytic defects
such as chemotaxis and microbial killing, is rare. A
patient has been described with deficient poly¬
merization of G-actin who suffered from recurrent
bacterial infections [50], This individual's neutro¬
phils did not respond in chemotaxis and ingested
particles at a very slow rate.
Patients with neutropenia, by and large, have a
poor rate of ingestion when compared, on an equal
cell to cell ratio, with normal leucocytes. Similarly
patients with hyposplenism have been reported to
have a poor phagocytic response.
There is considerable variation between labora¬
tories as to the choice of tests for phagocytic function
on a clinical basis. Such procedures usually incorpor¬
ate both measurements of the rate of phagocytosis
and microbial killing capacity. f:or example, proce¬
dures which measure the rate of ingestion and killing
of organisms such as Staphylococcus aureus, Escheri¬
chia coli and Candida albicans are commonly
employed. The tests involving 'plating-out' proce¬
dures are laborious and time-consuming. We find
the Candida-killing test to be, in general, the more
convenient [51]. Culture techniques arc not necessary
with the Candida-killing assay as viability can be
quantified by exclusion of methylene blue. It should
be noted that there have been reports of cases,
largely anecdotal, in which selective defects have
been reported in terms of an inability to kill only
certain micro-organisms. If a patient is susceptible to
infections with one particular micro-organism it
would seem prudent to assess the capacity of the
individual's leucocytes to ingest and kill the same
organism in vitro. The elegant assay described by
Stossel [49] which measures the rale of phagocytosis
of opsonized lipopolysaccharide coated oil red O
particles (which can be combined with a quantitative
NBT test) has been found in our experience to be
largely impracticable for routine clinical work.
However, this test and others of oxygen consumption
and glucose oxidation, such as the generation of the
superoxide radical and hexosc monophosphate shunt
activity, may be required in special circumstances
such as the detection of carrier states in chronic
granulomatous disease [52, 53], In these situations as
much information as possible is required in relation
to phagocytic function for informed genetic coun¬
selling.
Method for estimation of Candida killing and phago¬
cytosis (after Lehrer & Cline [51])
Principle
A quantitative method for measuring the phagocytic
and Candidacidal activity of human leucocytes based
on the uptake of methylene blue by non-viable
Candida albicans.
A laterials
(1) Candida albicans suspension.
(2) Sabouraud glucose agar. Sabouraud liquid
broth.
(3) 001 per cent methylene blue in distilled
water.
(4) 6 per cent Dextran 70.
(5) Red cell lysing solution (0-8 per cent NH*C1/
CDTA/KCOj pll 7 4).
(6) Hanks's balanced salt solution (HBSS) pH 7-4.





Preparation of Candida suspension
(1) Candida albicans is inoculated into Sabouraud
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liquid broth from a stock culture maintained on a
Sabouraud agar slope and left overnight at 37° C.
(2) The culture is centrifuged at 400 g for 10 min
and the supernatant discarded prior to resuspension
in 2 ml of 0 9 per cent sterile saline and shaken
vigorously to give a single cell suspension. A 01 ml
aliquot is suspended in 5 ml of saline and counted
in a hacmoeytomcter and the concentration in
millions/ml calculated.
(3) The viability of the Candida is checked by dye
exclusion. An equal volume of suspension is mixed
with an equal volume of 0 01 percent methylene blue
and left for 5 min at room temperature before
checking microscopically for dead cells. The Candida
suspension may be left on ice to prevent further
growth prior to use.
Neutrophil suspension
(1) 7-5 ml of heparinized (preservative free) blood
is mixed with 3-75 ml of 6 per cent Dcxtran 70 and
the erythrocytes scdimcnted at 37° C for 30 -40 min in
a container inclined at 45°.
(2) The leucocyte rich plasma is removed and
centrifuged at 100 g for 10 min.
(3) The cells are washed twice more at 100 g for
10 min with Hanks's balanced salt solution and sus¬
pended in 5 ml of HBBS prior to counting and adjust¬
ing to a concentration of 7 x 10"/ml.
Phagocytosis of Candida
(1) The following combinations are prepared in
Eppcndorf plastic centrifuge tubes using a ratio of
1:4 (neutrophil v. Candida at 7 x 10" and 28 x 10"/m!
respectively).
Volume
0.062 ml AH scrum, autologous scrum or con¬
trol serum.
0 062 ml HBSS.
0 062 ml Leucocytes (7 x 10"/ml).
0 062 ml Candida (28 x 10"/ml).
All reactions are carried out in duplicate and a
blank is incorporated with no neutrophils as well as
comparing all reactions with an age/sex matched
control where possible.
(2) The tubes are incubated for 1 hour at 37° C
with continuous slow mixing and then slide smears
are made of all the suspensions and also of a centri¬
fuged pellet.
(3) The slides arc air dried, fixed in methanol and
stained with May-Grunwald-Gicmsa in the usual way
(see NBT, p. 47.18).
(4) One hundred cells are examined microscopi¬
cally from each culture and the percent phagocytosis
and the phagocytic index calculated.
Candida killing
(1) The following reaction mixtures arc prepared
in Eppendorf plastic centrifuge tubes.
Volume
0 062 ml AH or autologous scrum or control
scrum.
0 062 ml HBSS.
0 062 ml Leucocyte suspension (7 x 10"/ml).
0 062 ml Candida suspension (7 x 10"/ml).
All reactions arc carried out in duplicate with an
appropriate blank and an age/sex matched control
where possible.
(2) The tubes arc incubated at 37" C for 1 hour
with continuous mixing.
(3) A slide smear is made of each culture after 30
min to check that phagocytosis is taking place.
(4) After 60 min incubation 0 062 ml of sodium
dcoxycholate (pH 8-7) is added to each culture to
lysc the neutrophils and then I ml of ice-cold 0 01
per cent methylene blue is added to each tube prior
to centrifuging at 400 g for 5-10 min.
(5) The supernatant is removed and the cells
suspended in the remaining volume and mixed
thoroughly. The tubes may be left on ice for up to
2 hours, until examination.
(6) The suspension is examined on a hacmoeyto-
meter and 300 Candida cells counted and the per¬
centage killed (blue) scored.
Method for quantitative phagocytic and NBT assay
(after Stosscl [49])
Principle
A technique for assaying the rate of ingestion by
phagocytes from human peripheral blood. Isolated
phagocytic cells ingest F.. coli lipopolysaccharidc-
coatcd para (Tin oil droplets containing oil red O. The
pre-ingested particles are opsonized with fresh human
scrum. After incubation, the undigested oil particles
are separated from the cells containing ingested
particles by centrifugation. Oil red O is extracted
from the washed cell pellets with dioxanc and
measured spectrophotometrically. A simultaneous
quantitative determination of nitrobluc tetrazolium
reduction (NBT) can also be included.
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Materials
(1) Oil red O from Gurr Chemicals (Searlc
Diagnostics Ltd.).
(2) Paraffin oil from BDH Chemicals.
(3) p-Dioxane from BDH Chemicals.
(4) Hanks's buffered salt solution pH 7 4 (HBSS).
(5) E. coli lipopolysaccharide (026: B6 Difco) 10
mg/ml in HBSS.
(6) Nitroblue tctrazolium (BDH) 2 mg/ml filtered
solution in HBSS. Stored at 4" C in the dark.
(7) n-Ethylmaleimide (Koch Light Laboratories
Ltd., Colnbrook, Bucks., UK).
(8) Fresh human serum.
Procedure
Granulocyte isolation
Granulocytes are prepared as outlined under Super¬
oxide radical (see p. 47.26).
Cells are resuspended at a concentration of 10 x
107ml.
Preparation of oil red O in para/Jin oil
Method (7)
2 g oil red O is added to 50 ml heavy paraffin oil
(density 0-89) in a mortar and ground carefully. The
saturated suspension is ccntrifuged hard in an MSE
centrifuge to remove undissolved dye (re-usable).
The dye-containing oil can be stored indefinitely at
room temperature.
Method (2)
Using di-iso-decyl phthalate instead of heavy paraffin
oil. Prepare as for method (1)—a more viscous
solution which does not pack so well.
To permit normalization and comparison of results
a factor conversion for optical density (O.D.) of dye
to mg paraffin oil is calculated. 10 //I oil red O is
added to 10 ml p-dioxane and O.D. read at 525 nm,
K: conversion factor (mg/O.D.)
K = '
O.D./mg x 0 89
« - 0'89 (density of oil)
O.D. actual reading at 525 nm
Preparation ofparticles
3 ml of 10 mg/ml E. coli lipopolysaccharide solution
is dispersed by brief sonication (5 sec). 1 ml of oil
red O oil is layered over the aqueous solution and
sonicated for 45-90 sec (the probe being just below
the oil-aqueous interface).
Preparations can be frozen at -20° C and thawed
and sonicated before use.
Standardization ofNBT solution (2 nig/ml)
To permit standardization and obtain a conversion
factor from O.D. to //g formazan, a known weight
of NBT was reduced to formazan (blue precipitate)
and the O.D. measured at 580 nm.
Conversion factor from O.D. to //g formazan is
14 4 per 1 cm of light path in p-dioxane at 25° C.
Opsonization ofparticles before ingestion
An equal volume of fresh scrum is added to the
prepared emulsion and incubated at 37" C for 25-30
min to give optimal C3 deposition.
Assay
Using siliconized glass tubes for incubation proce¬
dure:
(I) The following reaction mixtures arc prepared.
1 2 3 4
Opsonized particles 0-2 0-2 0-2 0-2 ml
Cells (lOx 107ml) 0-4 0-4 0-4 0-4
HBSS pll 7-4 0 4 — 0-4 —
NBT (2 mg/ml) — 0-4 — 0.4
Total re;action volume = 1 ml
Tube I measures rate of ingestion
2—measures rate of NBT reduction
3—measures rale of ingestion (control on ice)
4— measures rate of NBT reduction (control on ice)
(2) Start reaction by adding cells to other prc-
warmcd (37° C) premised reagents.
(3) After 5 min incubation in a shaking water bath
at 37° C, stop reaction by adding 6 ml ice-cold 1
mmol/l A'-cthylmalcimide in 015 mol/l NaCI to
each tube. Centrifuge at 1500 rpm for 15 min.
(4) Carefully discard the rim of oil red O and
undigested cells by shaking tube vertically and pour
off" supernatant. Rcsuspcnd pellet and repeat A'-
cthylmalcimide wash.
(5) Drain pellets and wipe sides of tubes with
dioxanc soaked tissue to remove any undigested dye.
(6) Add 1-5 ml dioxane to cell pellet to solubilizc
the oil red O.
(7) To complete dissolution of any precipitated
forniazan in tube 2 or 4, place tubes in a boiling
water bath for 15 min.
47.26 Application of immunological methods
(8) Centrifuge to remove cell debris and measure
O.D. of the supernatants.
Measure O.D. for tubes 1 and 3 at 525 nm.
Measure O.D. for tubes 2 and 4 at 580 nm.
Calculation of results
Tubes 1 and 3:
Initial rate of ingestion =
O.D. (525 nm) x K (conversion factor)
time of incubation x no. of phagocytic cells x'101
= mg parallin oil ingcstcd/107 cclls/min.
Tubes 2 and 4:
* Rate of NBT reduction =
(O.D.(580nm)tubc2) -(O.D.(580nm)tubc 1) x 1414
time of incubation x no. phagocytic cells x 101
<= //g formazan/101 cclls/min.
Comments
Since oil red O itself does absorb at 580 nm, then
the O.D. (580 nm) of extracts containing oil red O
alone are subtracted from those containing oil red O
and NBT (see calculation above *).
Method for determination of superoxide radical pro¬
duction (after Weening et al. [52])
Principle
The superoxide radical (Oi) is a highly reactive
intermediate produced in biological systems by the
one-electron reduction of oxygen and is generated by
phagocytes during the 'metabolic burst'. It has been
shown that O; is an intermediate in the formation of
H202 and may participate in bacterial killing. Detec¬
tion of Or is based on its ability to reduce cyto¬
chrome C when incubated with isolated granulo¬
cytes. This reaction is inhibited by superoxide dis-
mutase, an enzyme which destroys Oj activity.
Materials
(1) Horsc-hcart cytochrome C and superoxide
dismutase from bovine blood are obtained from
Miles Laboratories.
(2) Dow-latex (10 per cent solution) from Serva.
Used as a 1 per cent solution.
(3) Washing medium (a phosphatc-bulTercd saline
solution at pH 7-4) with 5 5 mmol/l glucose.
(4) Incubation medium (as for washing medium
with 0-5 per cent albumin (or 0 5 per cent pooled
AB serum) and 5 5 mmol/l glucose).
(5) 6 per cent Dcxtran 70.
(6) Solution for lysing red cells—0-8 per cent
NLLCI, 10 mmol/l KCOj, 0 1 mol/l EDTA, pH 7 4
at 0° C.
(7) Scrum treated zymosan (10 mg/ml). Scrum is
added to zymosan A (Sigma) and homogenized with
ice-cold Potter-homogenizer. Incubate mixture for
20 min at 37° C, mixing frequently. Wash twice with
0-9 per cent NaCI. Rcsuspend to appropriate volume.
Procedure
Preparation ofgranulocytes
(1) Approximately 15 ml blood is adequate for
one assay. Hcparinized blood is mixed with half its
volume of 6 per cent Dextran 70 in 0-9 per cent
NaCI and the erythrocytes allowed to sediment at
37° C for 30-40 min at an angle of 45°.
(2) Remove supernatant plasma containing granu¬
locytes. Centrifuge at 100 g for 10 min.
(3) Rcsuspend cell button in ice-cold lysing solu¬
tion and leave on ice for 5-10 min with frequent
mixing. This lyscs any remaining erythrocytes.
(4) Centrifuge at 100 g for 10 min. Wash cells
twice in washing medium and resuspend cell button
in 5 ml. Count granulocytes and rcsuspend to final
concentration of 2 x 10"/ml in incubation medium.
Incubation procedure
(I) The following reaction mixtures arc prepared:
1 3
Cells (2x IO*/ml) 0-85 0-85 0-85 0-85 ml
STZ (10 nig/ml) — 01 — 01
or Latex particles
0-9 per cent NaCI 012 0 02 01 —
1 niM Cyt. C 0 05 0 05 0 05 0 05
S.D. (43 //M) — — 0 02 0 02
Total reaction volume = 102 ml
Tube 1—resting value
2—phagocytosis of scrum treated zymosan/
latex
3—superoxide dismutasc inhibition ofOf pro¬
duction (resting)
4 —superoxide dismutase inhibition ofOf pro¬
duction (stimulated)
(2) Incubate for 1 hour in a shaking water bath
(180 cyclcs/min) at 37° C.
(3) Terminate reaction by transferring samples to
ice-cold F.ppcndorf centrifuge tubes and centrifuge
for 6 min.
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(4) Store supcmatants in Eppendorf tubes in
liquid Na vapour.
Determination of Oi
Using Pye Unicam SP 800 Recording Spectrophoto¬
meter.
(1) The absorbcnce of cytochrome C in the
samples is measured from 540-560 nm.
(2) To determine the amount of reduced cyto¬
chrome C, one grain of potassium ferricyanide was
added to the sample in the cuvette and the decrease
in absorbence followed at 550 nm (i.e. oxidation of
cytochrome C).
(3) Some grains of sodium dithionite are added
to show total amount of cytochrome C in the
incubation mixtures and the increase followed from
540-560 nm.
Absorbence coefficient of (red-ox.) cytochrome C
is 211 mmol/1" 1 cm" '. The results of Ot determina¬
tion arc expressed as // moles cyt.C reduced/1010
cells/hour.
Comments
Identical control reaction mixtures can be kept on
ice as reference blanks. These samples would have
the same amount of reduced cytochrome C as those
containing superoxide dismutasc.
Method for determination of hexose monophosphate
shunt activity (after Pachman et al. [53])
Principle
The respiratory burst following phagocytosis is
accompanied by an increase in oxygen consumption
and glucose oxidation through the hexose monophos¬
phate shunt pathway (11 MP). Stimulation of the
11 MP is determined by measuring the amount of
l-14C-glucosc converted to ,4C02.
Materials
(1) Dow latex (10 per cent solution) from Scrva.
(2) Zymosan A (Sigma). Scrum treated (see
Superoxide radical, p. 47.26).
(3) D-(1-'*C) glucose from Radiochemical Centre,
Amcrsham, Bucks., UK, diluted to concentration
of 20 /iCi/ml with 0-9 per cent NaCl.
(4) Hyamine hydroxide from Nuclear Enterprises
Ltd.
(5) Sodium azide (NaNj) from BDH Chemicals.
(6) Washing medium (phosphate buffered saline
pll 7-4 with 5 5 mmol/1 glucose).
(7) Incubation medium (phosphate buffered saline
pH 7-4 with 0 5 per cent albumin or 0-5 per cent
pooled AB and 5 5 mmol/1 glucose).
(8) NE 260 scintillation fluid from Nuclear
Enterprises Ltd.
Procedure
Isolation of granulocytes is as for (>j determination
(see p. 47.26).
The granulocytes are used at a final concentration
of 4xl06/ml in phosphate buffered medium (pH
74) with 5-5 mmol/1 glucose and 0 5 per cent human
pooled AB scrum.
Incubation assay
(1) The following reaction mixtures arc prepared:
12 3 4
Cells (4 x lC/ml) 0 X5 0 X5 0-85 0 X5 ml
C 1-,4C(0 4//Ci) 0 002 0 002 0 002 0002
STZ/latcx — 01 — 0 1
0 9 per cent NaCl 0 128 0 028 0128 0 028
100 niM NaNj 0 02 0 02 0 02 0 02
Total reaction volume = 1 ml
Tube 1—resting value
2 phagocytosis of scrum treated zymosan (STZ) or
latex
3 -control for resting value \ on j
4—control for phagocytosis J
(2) Tubes I and 2 arc stoppered and incubated at
37° C for 1 hour in a shaking water bath. The COa
is trapped in 0-5 ml hyaminc hydroxide in a separate
vial attached to the stopper of the incubation tube.
(3) The reaction is stopped by injecting 1 ml 2N
HC1 through the rubber stopper. Incubation for a
further 30 min at 37" C ensures maximum COj
absorption.
(4) The hyaminc hydroxide is dissolved in 9 5 ml
of scintillation fluid and the radioactivity counted in
a liquid scintillation counter. Results are expressed
as counts per minute.
Comments
Addition of the metabolic inhibitors NaN , or KC'N
(inhibiting catalasc or myeloperoxidase activity)
ensures there is added stimulation of HMP activity.
INVESTIGATION OF THE COMPLE¬
MENT SYSTEM (see also Chapter 5)
Defects of the complement system in association
with primary immune deficiencies are extremely rare.
47.28 Application of immunological methods
Genetically determined deficiencies of C3 have been
reported [54] as well as an extensively investigated
patient with an absence of the naturally occurring
C3b inactivator [55]. Certain families have been
described with unusual skin conditions and bacterial
infections who responded to treatment with infusions
of fresh plasma. These patients are said to have a
functional abnormality of C5 as assessed by defective
opsonic activity and generation of chemotactic
factors [56], However, in these individuals C5 was
antigenically and hacmolytically intact. Further¬
more, an individual with complete absence of C5 has
been reported who docs not have these defects.
In general measurement of the total haemolytic
complement (CHjo) and the individual components
C3 and C4 is a satisfactory 'complement screen'.
Thus normal levels of C3 and C4 with an absent
CHso are suggestive of a congenital defect of one of
the individual components required to complete the
hacmolytic sequence. Such deficiencies arc, by and
large, unassociated with recurrent infections al¬
though various connective tissue disease-like slates
have been described in individuals with absence of
C2 or the subunits of CI [57], A low C4 suggests
activation of the classical components by immune
complexes whereas a low C3 with a normal C'4
indicates alternate pathway activation such as found
in association with certain forms of mcsangiocapil-
lary glomerulonephritis and certain types of partial
lipodystrophy [58]. Many of these conditions cannot
be considered as primary immune defects although
the inclusion of a 'complement screen' should be
included in the general immune profile especially as
this is a rapidly developing field in terms of the
association of complement defects with disease. It
should be noted that complement components like
other plasma proteins can be antigenically intact but
functionally inactive. An example is genetic variants
of CI esterase inhibitor deficiency. If complement
defects arc recognized then an extended complement
profile is required in terms of measurements of other
individual components of the classical and alternate
pathways as well as measurements of terminal
complement components.
Estimation of the concentrations of C'3 and C'4 can
be measured by the Mancini technique (sec p. 47.13).
Method for determination of the total haemolytic
complement (CII5o) (after Fischer [59])
Principle
The haemolysis of sensitized sheep cells is followed
with a continuous recording spectrophotometer and
the time for 50 per cent lysis of the indicator sheep
cells (CI 1 so) is a function of total complement activity.
Materials
(1) 0 15 mol/l sodium chloride.
(2) 0 01 mol/l F.DTA gelatin Veronal buffer com¬
posed of:
5 x Veronal 200 ml
10 per cent gelatin 10 ml
Distilled water to 1 litre
The gelatin Veronal buffer is used to dilute a stock
solution of EDTA (e.g. 1 mol/l) to a molarity of 0 01
mol/l.
(3) Dextrose gelatin Veronal buffer made up fresh
each day by mixing equal volumes of (i) and (ii).
(i) Composed of:
5 x Veronal 200 ml
10 per cent gelatin, 10 ml
0 03 mol/l calcium chloride, 5 ml
01 mol/l magnesium chloride, 5 ml
Distilled water to I litre
(ii) Composed of:
Dextrose 50 g
0 03 mol/l calcium chloride, 5 ml
01 mol/l magnesium chloride, 5 ml
Distilled water to 1 litre
Solutions (i) and (ii) are made up fresh every day and
stored at 4° C.
(4) Sheep cells (E) in Alscver's solution stored at
4° C. Usable for up to one month.
(5) Sheep erythrocyte antibody (A). Prepared in
rabbits by repeated injections of autoclaved sheep
erythrocyte stroma. The antiscra arc heat treated at
56" C for 30 min. The optimum concentration of the
antibody to use is obtained by titration against sheep
cells in a known source of complement.
(6) Disposable 1 cm plastic cuvettes (cat. no.
45/1010, Sarstcdt, Leicester, UK).
Procedure
Preparation of sensitized sliecp cells (PA)
(1) 50 ml (optimal) of sheep cells in Alscver's arc
washed twice in 0 15 mol/l NaCI and then once in 0 01
mol/l EDTA in gelatin Veronal buffer. The cells arc
adjusted to a concentration of 1 x lO* cells/ml using
cither the spectrophotometer or a hacmocytomctcr.
(2) Antibody is added to the sheep cells at the
optimal concentration. For example, 01 ml of anti¬
body with a tit re 1/300 is added to 30 ml of sheep
cells.
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(3) The mixture is incubated at 37" C for 30 min
in a shaking water bath followed by incubation at
0° C for a further 30 min.
(4) The cells arc washed once in EDTA gelatin
Veronal buffer and then twice in dextrose gelatin
buffer with added magnesium and calcium. They can
be stored in the latter for up to 2 weeks at 4" C
providing the buffer is changed daily.
Estimation of haemolytic complement (CH»o)
(I) The sensitized sheep cells (I:A) prepared as
outlined above are washed three times in dextrose
gelatin Veronal buffer with added magnesium and
calcium and adjusted to 5x10" cells/ml using a
spectrophotometer. This suspension is diluted
approximately 1:26 to give an optical density of 0 9
in a 1 cm cuvette using transmitted light at 545 m//.
These figures may vary somewhat from instrument
to instrument.
(2) For an assay the following is added to each
cuvette—01 ml of the serum under test, 0-5 ml of
dextrose gelatin Veronal buffer with magnesium and
calcium and 2-4 ml of FA solution at 37° C. The
latter is added fiercely to ensure mixing and then
recording started immediately. A continuous record¬
ing spectrophotometer with a carrier holding four
cuvettes and a chart recorder is used. Controls
necessary are a cuvette containing 3 0 ml of the
dextrose gelatin Veronal buffer with added calcium
and magnesium (blank) and a pooled scrum control
for comparison with the test scrum.
(3) The results are calculated using the mean
height of the peak and base. From this a time for
50 per cent haemolysis can be estimated. This figure
is then expressed as a percentage of the normal
human pool, e.g.
Normal human pool time in seconds x 100
Test scrum time in seconds
S U M M A R Y
It must be emphasized that the technology and
approach to the investigation of immune deficiencies
is a rapidly developing field and therefore it is not
possible to give a comprehensive list of investigations
for use as standard practice. Many of the tests
described are laborious, expensive and require con¬
siderable technical skills. Furthermore, the number
of patients where these laboratory investigations arc
of value in the diagnosis, management and treatment
is relatively small. Most laboratories will inevitably
Tahii: 47.1. Laboratory investigations in immuno¬
deficiency
Primary Screen
White cell count and differential
Immunoglobulins (IgO, IgA, IgM and fgH)
Antibodies (isohaemugglulinins, anti-viral antibodies, E.
coli antibodies)
Complement screen (Clljo. C3 and C4)
Delaycd-typc skin tests (PPD, Candida, SK-SD and
mumps)
Skin window (Rcbuck) test
NUT test ami myeloperoxidase slain
Candida killing
Secondary Screen*
T and H lymphocyte estimations
Lymphocyte transformation (mitogens, antigens, allo¬
geneic cells)
Phagocytic function (chcmotaxis, ingestion and killing
of E. coli, S. aureus, etc.)
Anti-lcucocytc antibodies
Extended complement profile
Salivary immunoglobulins (especially IgA)
Response to immunization with tetanus toxoid
Tertiary Screen*
Lymphokinc production
Extended tests of phagocyte function (Stossel assay)
Immunofluorescence of tissue sections (biopsy material)
Antigen transformation to any relevant antigen not
included in initial screen
* Done where indicated by results of primary screen
have to make compropiiscs and it is our practice to
have a threc-tiercd screen along the lines indicated in
Table 47.1. For instance, extensive tests of lympho¬
cyte function arc not usually helpful in the presence
of positive delaycd-typc skin tests to the common
antigens. Similarly, if the white cell and differential
counts arc normal and the patient responds in the
skin-window lest, reduces NBT and has a positive
myeloperoxidase stain it is in general unlikely that
further investigations of phagocyte function will
yield additional information. However, as has already
been emphasized, a careful clinical history will be
the main guide as to what emphasis should be placed
in terms of the various laboratory investigations.
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